,id,ticker,title,category,content,date,provider,url,article_id
128357,349872,BIIB,Why Biogen Could Become the King of Alzheimer s Disease Treatment,news,"If there is one group that can produce stock gains regardless of the daily market activities  that would be biotechnology and emerging pharmaceuticals  Coming up with a new approach or new way to treat cancers and other major diseases probably doesn t need a strong stock market to produce major interest  Alzheimer s disease is one of the most debilitating diseases of the modern era  and currently there are no cures to chase   no real approved drugs on the market that make a difference on the progression of Alzheimer s Biogen Inc   NASDAQ  BIIB  has an on again off again history with its efforts to treat Alzheimer s  The biotech giant is set to report earnings this week  and the view of the company s Alzheimer s study may be only a portion of the consideration for the coming week and the weeks ahead According to Canaccord Genuity  Biogen may be the best current bet of any major company that has at least a chance of getting further toward an FDA approval around Alzheimer s  Monday s top analyst upgrades and downgrades included Biogen  with Canaccord Genuity upgrading it to Buy from Hold and raising its target price to  360 from  305 div connatix margin bottom  1 5em   div connatix img  margin  unset  While Sumant Kulkarni sees Biogen s aducanumab facing a regulatory saga with much public skepticism  he also sees much potential upside heading into that process  The analyst was surprised by Biogen s sudden revival of aducanumab last October  and he retains a healthy degree of skepticism around the trial data that were presented in December  Despite that skepticism  there is still believed to be a  decent short at FDA approval  for aducanumab  Kulkarni believes that any approval is not baked into the shares now The report comes with some potential pitfalls  including early patent challenges in other drugs  but the potential fear of missing out on the part of investors chasing an Alzheimer s approval is massive  Biogen is also only valued at roughly nine times the expected 2020 earnings  Biogen is also said to have approximately  50 billion of  financial flexibility through 2024  that would allow the company to make acquisitions or have other efforts  And Kulkarni believes that investors are now undervaluing the company s core pipeline outside of aducanumab The largest driver of the target hike and upgrade comes from the chances of aducanumab getting FDA approval now at 50 m up from a prior chance of just 20   Kulkarni s view is that 2020 will see many events around the filing of and the acceptance of the filing  or not  for aducanumab by the FDA  That would then come with Advisory Committee meetings  votes and an ultimate FDA action date With a projected cost of roughly  8 700 per year in the United States and a later launch at a 20  discount in European Union and Japan  the analyst s view is that aducanumab could see as much as  9 9 billion in revenues per year by 2030  That said  other companies  both large and small  are also still chasing their own ambitions of coming up with an approvable treatment for such a debilitating disease like Alzheimer s  That means any approvals or related news from any of those programs could also cause volatility for Biogen shares Again  this analyst upgrade is not a prediction about Biogen s upcoming earnings  Investors should also never just use any single analyst report as a sole basis to buy or sell a stock  Remember that many biotech companies and many of the world s top pharmaceutical companies have bet and lost countless billions of dollars with nothing to show after failing in their quest to treat Alzheimer s disease Biogen shares opened flat at  278 14  but after a lack of news around the coronavirus hurting stocks  its shares were last seen up 0 85  at  280 50 with just over two hours left in Monday s trading session  Biogen has a 52 week range of  215 78 to  338 87  and its consensus analyst target price from Refinitiv was  304 57  Biogen s market cap is currently just above  50 billion  and its annualized revenues are around  14 billion Any drug approval to treat Alzheimer s  even a less than universal approval  would be in line for the blockbuster status of more than  1 billion in annual sales  even if it only is able to delay or minimize the onset stages of the disease According to Alzheimer s News Today  Alzheimer s is growing  and only around one in four people with the disease even get diagnosed  The group estimates that approximately 44 million people worldwide are living with Alzheimer s disease  or related form of dementia  and roughly 5 5 million people in the United States alone have the disease  
By Jon C  Ogg",2020-01-27,247wallst,https://invst.ly/pnj9c,2068713
128358,349873,BIIB,Biogen  2  premarket on Q4 beat,news,"Biogen  BIIB  Q4 results  Revenues   3 671 3M   4 1   
Net Income   1 439 7M   52 1    EPS   8 08   70 8    non GAAP Net Income   1 485 6M   6 1    non GAAP EPS   8 34   19 3    CF Ops   7 079M 
Spinraza sales   543M   16    below estimates of   555M and down from  547M in Q3 
Key product sales  Tecfidera   1 161M   5    Tysabri   473M   2    Avonex   411M   15    Rituxan Gazyva   395M   3    Ocrevus royalties   205M   35   
Biogen acquired commercialization rights to biosimilars of Lucentis and Eylea in the U S  and other major markets 
2020 Guidance  Revenue    14 0B   14 3B vs  Yahoo Finance consensus of  14 1B  GAAP EPS   29 50    31 50  non GAAP EPS   31 50   33 50 vs  Yahoo Finance consensus of  33 03 
Shares are up 2  premarket 
Previously  Biogen EPS beats by  0 28  beats on revenue  Jan  30 ",2020-01-30,Seeking Alpha,https://invst.ly/pox9h,2071637
128359,349874,BIIB,Biogen s Earnings Per Share Jumped 19  in Fourth Quarter,news,"Biogen  NASDAQ BIIB  delivered its fourth quarter earnings report on Thursday  showing revenue up 4  year over year to  3 67 billion  Adjusted income of  1 49 billion was up 6  year over year  but on a per share basis  the growth was 19  because the biotech repurchased 23 6 million shares worth  5 87 billion over the course of 2019 
Sales of Biogen s top selling multiple sclerosis drug  Tecfidera  increased 5  year over year in the fourth quarter  while revenues from Tysabri  another multiple sclerosis drug  rose 2   Sales of its older interferon drugs for multiple sclerosis continued their decline of the last few years  falling 14  
Rounding out its major drugs  spinal muscular atrophy drug Spinraza was the top grower of the quarter with sales up 16   But its growth rate is decelerating    for the year  Spinraza sales were up 22     now that the drug must compete with Novartis  gene therapy Zolgensma  In addition  sales growth outside the U S  has as slowed as the initial momentum from its launch has waned 

For 2020  management expects revenue in a range of  14 0 billion to  14 3 billion  lower than the  14 38 billion Biogen brought in last year  Adjusted earnings per share are expected to fall between  31 50 and  33 50  again slightly lower than the  33 57 per share the drugmaker earned last year 
Biogen is currently in a fight over the patent for Tecfidera  and its guidance assumes no generics for it will be launched in 2020  The guidance also accounts for additional costs associated with the potential launch of its Alzheimer s disease drug aducanumab  assuming it gets approved by the Food and Drug Administration ",2020-01-30,The Motley Fool,https://invst.ly/pp2v6,2072150
128363,349878,BIIB,Biogen Inc  BIIB  Q4 2019 Earnings Call Transcript,news,"Biogen Inc  NASDAQ BIIB Q4 2019 Earnings CallJan 30  2020  8 00 a m  ETContents 

Prepared Remarks
Questions and Answers
Call Participants

Prepared Remarks 
OperatorGood morning  My name is Carmen  and I will be your conference operator today  At this time  I would like to welcome everyone to the Biogen Fourth Quarter and Full Year 2019 Financial Results and Business Update   Operator Instructions Thank you  I would now like to turn the conference over to Mr  Joe Mara  Vice President  Investor Relations  You may begin Joe Mara    Vice President  Investor RelationsGood morning  and welcome to Biogen s fourth quarter 2019 earnings call  Before we begin  I encourage everyone to go to the Investors section of the biogen com to find the earnings release and related financial tables  including a reconciliation of the GAAP to non GAAP financial measures that we will discuss today  Our GAAP financials are provided in Tables 1 and 2  and Table 3 includes a reconciliation of our GAAP to non GAAP financial results  We believe non GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally  We have also posted our slides on our website that follow the discussions related to this call I would like to point out that we will be making forward looking statements  which are based on our current expectations and beliefs  These statements are subject to certain risks and uncertainties and our actual results may differ materially  I encourage you to consult the risk factors discussed in our SEC filings for additional detail On today s call  I am joined by our Chief Executive Officer  Michel Vounatsos  Dr  Al Sandrock  EVP  Research and Development  and our CFO  Jeff Capello  Now  I will turn the call over to Michel Michel Vounatsos    Chief Executive OfficerGood morning  everyone  and thank you for joining us  First  let me start with some financial highlights  Biogen closed 2019 with quarterly revenues of  3 7 billion  an increase of 4  compared to the same period a year ago  For the full year 2019  Biogen generated  14 4 billion in revenues  representing growth of 7  year over year Full year 2019 GAAP earnings were  31 42 a share  a 46  increase versus full year 2018  Full year 2019 non GAAP earnings were  33 57 a share  a 28  increase versus full year 2018  We are pleased with the strong year over year growth  as we continue to execute on our strategy for long term leadership in neuroscience Now  let me review the year  First  full year MS revenue  including OCREVUS royalties  were  9 2 billion  an increase of 2  versus the prior year  The number of patients on our MS products globally increased 3  versus the prior year  driven by strong patients growth in emerging markets  as well as all of the large mature European markets  and our business demonstrated resilience in the US  Our team has executed well  demonstrating our ability to compete in an increasingly crowded market  We launched VUMERITY in the US as an important new oral treatment option  It remains early in the launch  but so far  we are pleased with the level of interest from patients and physicians Second  SPINRAZA generated full year global revenues of  2 1 billion  a 22  increase versus the prior year  This blockbuster performance was driven by strong year over year revenue growth in the US and even greater revenue growth outside the US  Including the expanded access program and clinical trials  over 10 000 patients are now being treated with SPINRAZA Third  full year biosimilars revenue was  738 million  which represents 35  growth year over year  driven primarily by IMRALDI  We estimate that our biosimilars generated approximately EUR1 8 billion of savings to the European healthcare systems in 2019  which we expect will continue to increase in 2020  This is critical as we work to create financial headroom for innovation and contribute to the long term sustainability of the healthcare system We also bolstered our biosimilars business this quarter with a new transaction with Samsung Bioepis  This provides us access to two new potential biosimilars in ophthalmology with a significant market opportunity in major markets worldwide  including  for the first time  in the US  as well as commercialization rights to our anti TNFs biosimilars in China Fourth  this was an historic year for R D organization  We are inspired by what the positive implications of the aducanumab data may mean for patients  physicians and the broader scientific community  who have been waiting decades for a therapy that can reduce the clinical decline of Alzheimer s disease  We are actively engaging with the FDA as well as regulators in Europe and Japan  and we look forward to completing a regulatory filing in the US as soon as possible  In addition  there has been important progress related to the redosing study  as we have successfully submitted the protocol to the FDA  and we are currently working with the sites and ethics committees toward study initiation Fifth  beyond aducanumab  we continue to expand and progress our pipeline with approval for VUMERITY in the US  a positive data readout for BIIB059 in lupus  and adding seven new clinical program in MS  ALS  Parkinson s disease  ophthalmology and brain contusion  2019 was one of our most productive years in R D  and we believe we have multiple opportunities for near term value creation  as we prepare for multiple potential launches in the early 2020 Sixth  our cash flow generation remains strong and continue to provide us with significant optionality and flexibility to allocate capital  In 2019  we generated approximately  7 1 billion in cash flow from operations  an increase of approximately 14  versus the prior year  Throughout the year  we repurchased approximately 24 million shares for a total value of approximately  5 9 billion  As we have stated previously  we view share repurchase as an important element of thoughtful and value creating capital allocation  At the same time  we have the financial flexibility and capacity to continue to evaluate potential external business development and M A opportunities  Over the past three  Phonetic  years  we have executed 15 business development transactions  which have contributed to the significant expansion of our pipeline  We executed four deals over the past three months alone  including our proposed transaction with Pfizer for a potential symptomatic therapy with potential application in both Alzheimer s disease and Parkinson s disease As we have demonstrated in the past  we are committed to maximizing returns to our shareholders  while continuing to bring innovative therapies to patients  something that demands a thoughtful approach toward all our investment over both the short and the long term In summary  2019 was a very productive and successful year for Biogen as we executed on our strategy and continued to deliver noticeable progress  Our core MS business continued to demonstrate resilience with growth in both patients and revenues  and we are excited to be launching VUMERITY  SPINRAZA continued to grow in the US and even more so outside of the US  as we continue to expand into new geographies  With over 10 000 patients on therapy and the largest body of clinical data in SMA  SPINRAZA remains a foundation of care in SMA We grew our biosimilars business  and we expanded our portfolio and geographic presence  We are preparing to lead in the fight against Alzheimer s disease as we plan for a US filing for aducanumab  Beyond aducanumab  we expanded and progressed our pipeline with seven new clinical programs and a positive data readout in lupus  And we generated ample cash flow as we focus on strategically allocating capital to maximize shareholder return over the long term I will now turn the call over to Al for a more detailed update on our recent progress in R D Alfred Sandrock  Jr     Executive Vice President  Research   Development and Chief Medical OfficerThank you  Michel  and good morning  everyone  Before I begin  I would like to welcome back Dr  Maha Radhakrishnan as the new Chief Medical Officer at Biogen  Maha brings more than 16 years of experience across multiple geographies in a broad range of therapeutic areas  She previously worked with us here at Biogen as Vice President  Europe and Canada Medical  and Vice President  US Medical  and subsequently held senior positions in medical affairs at Bioverativ and Sanofi  Maha s extensive background will be crucial as we prepare for future pipeline launches  including the potential launch of aducanumab As Michel discussed  2019 was a historic year for Biogen  In addition to announcing positive results on aducanumab  we made significant progress on building a multi franchise portfolio by receiving approval for VUMERITY  adding seven clinical programs and advancing two programs to Phase III  Reflecting our modality agnostic approach  our neuroscience pipeline now includes small molecules  antibodies  other advanced biologics  antisense oligonucleotides and gene therapy Let me now turn to the advances we made in the fourth quarter  starting with Alzheimer s disease and dementia  At the Clinical Trials on Alzheimer s Disease  or CTAD  annual meeting held last month in San Diego  we presented top line results from the Phase III studies of aducanumab in early Alzheimer s disease  Final analysis of these data showed that EMERGE was a positive study with a high dose regimen of aducanumab achieving statistical significance on both the pre specified primary endpoint of CDR Sum of Boxes  as well as on all three pre specified secondary endpoints On the other hand  data from the ENGAGE study did not meet the primary endpoint  although we do believe that data from patients who achieved sufficient exposure to high dose aducanumab in ENGAGE support the findings of EMERGE  Please note that we do not expect to present additional data on aducanumab prior to a regulatory decision by the FDA As Michel said  with the support of the FDA  we are working to initiate the open label Aducanumab redosing study as soon as possible  We have successfully submitted the protocol to the FDA  and we are currently working with the sites and ethics committees toward study initiation  In this study  eligible patients previously enrolled in our clinical studies  including patients previously treated with either aducanumab or placebo  will be titrated to 10 milligrams per kilogram aducanumab infusions every four weeks In addition to aducanumab  we continue to advance a broad Alzheimer s disease portfolio  including the Phase III study of BAN2401  BIIB080  a tau targeted antisense oligonucleotide in Phase I  BIIB076  an anti tau antibody in Phase I  and gosuranemab  a distinct anti tau antibody in Phase II for which we expect data next year As we continue to develop our Alzheimer s portfolio  we aim to expand into even earlier patient populations to potentially prevent the clinical onset of the disease  To that end  our collaboration partner Eisai  along with the Alzheimer s Clinical Trials Consortium  plans to initiate the AHEAD 345  Phonetic   AHEAD 345 is comprised of two studies termed A3 and A45  The A3 study will evaluate low dose BAN2401 versus placebo in cognitively normal individuals who are currently below the threshold for amyloid positivity but are at high risk for further amyloid accumulation  The A45 study will evaluate high dose BAN2401 versus placebo in individuals who are amyloid positive but show little to no cognitive impairment  Together  these studies will evaluate whether administration of BAN2401 can slow amyloid accumulation or cognitive decline in the very early stages of Alzheimer s disease Turning to MS and neuroimmunology  this quarter  we were pleased to announce that VUMERITY  a novel oral fumarate  was approved by the FDA for the treatment of relapsing forms of MS  Detailed results from the Phase II EVOLVE MS 2 study  which directly compared patient reported GI tolerability of VUMERITY and TECFIDERA  were presented at the annual meeting of the European Charcot Foundation in November and published in the journal  CNS Drugs  earlier this month Specifically  on the primary endpoint  these data showed that patients treated with VUMERITY self reported 46  fewer days with intensity scores of at least 2 on the IndividualGastrointestinal Symptom and Impact Scale compared to TECFIDERA  This result was highly statistically significant with a p value of 0 0003  Consistent with these data  the proportionate patients who discontinued the study due to GI adverse events was 0 8  for VUMERITY and 4 8  for TECFIDERA  Together  these data indicate that VUMERITY offers a clinically meaningful improvement in GI tolerability compared with TECFIDERA Across our MS portfolio  we continue to advance BIIB091  an oral BTK inhibitor in Phase I  BIIB061  an oral remyelinating agent in Phase I  and opicinumab  a Phase II anti LINGO antibody for which we expect data in the middle of this year Moving to our progress in immunology  there remains a tremendous unmet medical need for people living with lupus  including both cutaneous and systemic forms  Treatment options for lupus are limited  and new medicines are needed to manage this difficult to treat and chronic disease  Our work in lupus builds on a long history that Biogen has in immunology  including both home grown assets and collaborations We were very excited to report positive data this quarter from the Phase II LILAC study of BIIB059  a potential first in class anti BDCA2 antibody discovered and developed by Biogen  in two forms of lupus that affect a total of approximately 800 000 individuals in the G7  This two part study evaluated BIIB059 versus placebo in individuals with active cutaneous lupusErythematosus  or CLE  with or without systemic manifestations  and in individuals with systemic lupus erythematosus  or SLE  with active joint and skin manifestations  With a p value of less than 0 001  the CLE part of the study met its primary endpoint by demonstrating a statistically significant response of BIIB059 on the percentage change from baseline in the CLASI A score at week 16  The SLE part of the study also met its primary endpoint of reducing disease activity as measured by change from baseline in the total number of tender or swollen joints at week 24 In this study  patients treated with 450 milligrams of BIIB059 experienced a statistically significant reduction of 3 4 total active joint counts compared to placebo  In addition  improvements in skin disease and overall disease activity were consistently observed across multiple secondary endpoints  The safety and tolerability of BIIB059 support its continued development  and we are planning to move forward to Phase III We believe that the BIIB059 program exemplifies important elements of our broader approach to R D at Biogen  For example  by implementing biomarkers of target engagement and a measure of clinical efficacy early in clinical development  we were able to generate compelling proof of biology data and preliminary proof of concept data in Phase I  which were subsequently confirmed in a well controlled Phase II study  We believe that such de risking strategies may serve to increase the probability of success of other programs across our portfolio In neuromuscular disorders  last month  at the International Symposium on ALS Motor Neuron Disease  Biogen  Ionis Pharmaceuticals and our collaborators were awarded the Healey Center International Prize for Innovation in ALS  Presented by the ALS Center at Massachusetts General Hospital  this award recognized our contributions to the discovery and development of tofersen  our antisense oligonucleotide for SOD1 ALS  At this meeting  we were pleased to present the final data from the Phase I II study of tofersen  which demonstrated a statistically significant decrease in CSF SOD1 protein levels and trends toward slowing of clinical decline as assessed by three independent measures compared to placebo Furthermore  treatment with tofersen reduced levels of neurofilament in both plasma and CSF  We are encouraged by the concordance across data sets generated in the study  including target engagement  clinical and neurofilament data  and the broad potential of antisense oligonucleotides to target genetic drivers of neurodegenerative disease  We expect data from the Phase III VALOR study of tofersen next year In addition  we continue to advance the Phase I studies of BIIB078  an ASO for C9orf72 mediated ALS  and BIIB100  a small molecule inhibitor of XPO1 for sporadic ALS Turning to ophthalmology  this quarter  we completed enrollment in the Phase III STAR study of BIIB111 in choroideremia  a rare X linked inherited retinal disorder that inevitably leads to blindness and currently has no approved treatments  Choroideremia affects approximately 15 000 individuals in the G7 and is caused by loss of function mutations in the gene encoding Rab escort protein 1  or REP1  BIIB111 is a gene therapy aimed to address the underlying cause of this disease by expressing an AAV2 packaged REP1 transgene In Phase I II studies  patients treated with BIIB111 demonstrated a higher rate of maintained vision compared to natural history  In addition  a subset of patients treated with BIIB111 in Phase I II studies demonstrated a meaningful improvement in visual activity  as defined    sorry  in visual acuity  as defined by a gain of at least 15 letters corresponding to three lines on the eye chart  Specifically  21  of patients treated with BIIB111 demonstrated an improvement of at least 15 letters at one year  as compared to only 1  observed in the natural history study The Phase I II studies also demonstrated that BIIB111 was generally well tolerated with an acceptable safety profile  We are encouraged by these early signs of efficacy and safety and look forward to data from the Phase III study of BIIB111 toward the end of this year  We are also advancing the Phase II III study of BIIB112 in XLRP with data expected in the middle of next year In stroke  we continue to advance the Phase III study of BIIB093  or IV glibenclamide  for cerebral edema caused by large hemispheric infarction  or LHI  In a Phase II study  treatment with BIIB093 was associated with a 46  reduction in midline shift  an imaging measure of cerebral edema  and reduced mortality by over 50   We look forward to data from the Phase III study of BIIB093 in LHI by the end of next year In addition  the Phase II study of TMS 007 continues to progress  TMS 007 is a small molecule modulator of plasminogen that has the potential to become a best in class thrombolytic drug candidate for patients following an acute ischemic stroke  Data from this study are expected by the end of this year Within movement disorders  we continue to advance cinpanemab  or BIIB054  an anti alpha synuclein antibody for Parkinson s disease  with Phase II data expected in the second half of this year  as well as the Phase I study for BIIB094  an antisense oligonucleotide targeting LRRK2 Last month  we reported top line results from the Phase II PASSPORT study of gosuranemab for PSP  The primary endpoint was not met  and we therefore discontinued the development of gosuranemab for PSP and other primary tauopathies  While we were disappointed in this result  we chose to continue the Phase II study of gosuranemab in early Alzheimer s disease  given the potentially significant differences in disease pathophysiology And in neurocognitive disorders  we continue to advance a Phase II study of BIIB104  an AMPA receptor potentiator for cognitive impairment associated with schizophrenia  We now expect data from this study in the second half of this year    of next year Finally  we had a productive quarter on the business development front  Building further depth in ophthalmology  last month  we entered into an agreement with Catalyst Biosciences to develop and commercialize pegylated CB 2782 for the potential treatment of geographic atrophy  or GA  GA is an advanced form of dry age related macular degeneration  or AMD  that leads to blindness  has no approved therapies and affects approximately 1 million individuals in the US alone  This molecule is a novel protease that selectively cleaves C3  a genetically validated target in AMD  And we are encouraged by preclinical data demonstrating that a single intravitreal injection of this protease eliminated over 99  of C3 from the vitreous humor for at least 28 days In addition  this quarter  we initiated a collaboration with CAMP4 Therapeutics to leverage their Gene Circuitry Platform to potentially identify a suite of druggable targets in microglial signaling pathways already known to play a causal role in neurological disease And most recently  we announced an agreement to acquire a novel CNS penetrant small molecule inhibitor of casein kinase 1  or CK1  from Pfizer  CK1 is a key regulator of circadian rhythms  which can become dysregulated and contribute to irregular sleep wake rhythm disorder  or ISWRD  in Parkinson s disease  as well as sundowning in Alzheimer s disease  ISWRD is a non motor symptom of Parkinson s disease  characterized by fragmented sleep  severe fatigue and difficulties with activities of daily living  Sundowning affects approximately 20  of AD patients and causes patients to become confused  anxious and agitated later in the day  In a Phase I study    Phase Ia study  this molecule demonstrated an acceptable safety profile and proof of mechanism  Specifically  there was a statistically significant and dose related increase in salivary melatonin concentration  a marker of circadian phase modulation  We believe this may represent an innovative symptomatic treatment for both AD and PD  and we expect to initiate a Phase Ib study by the end of this year  This transaction is subject to customary closing conditions  and we expect it to close in the first quarter of 2020 Overall  Biogen R D delivered significant progress in 2019  We believe we are in a strong position today with 27 clinical programs  including six programs in Phase III  12 in Phase II and nine in Phase I  with a deep preclinical pipeline across multiple modalities  With our plan to file aducanumab in the US and multiple additional near term opportunities ahead of us  we believe that no other company is as well positioned to develop potentially breakthrough medicines for patients living with devastating neurological diseases I ll now pass the call over to Jeff Jeffrey Capello    Executive Vice President and Chief Financial OfficerThanks Al  Good morning  everyone  Let me now provide more detail on our financial performance for 2019 and share with you our guidance for 2020  Let s start with revenues As Michel mentioned earlier  we had a very strong performance in Q4 2019 across all of our core business areas  Total revenues for the fourth quarter grew 4  year over year to approximately  3 7 billion and grew 7  for the full year to  14 4 billion Overall  our MS business delivered revenues of  2 4 billion in the fourth quarter of 2019  including OCREVUS royalties of approximately  205 million  MS revenues in Q4 2019 decreased 1  versus prior year without OCREVUS royalties and increased 2  including OCREVUS royalties  US MS revenues in the fourth quarter of 2019 benefited from an increase in channel inventory of approximately  135 million compared to an increase of approximately  105 million in Q4 2018  Based on historical results  we typically see a decrease in channel inventory in the first quarter  following year end build of inventory Full year MS revenues were  9 2 billion  including OCREVUS royalties of approximately  688 million  Full year MS revenues decreased 1  versus the prior year without OCREVUS royalties and increased 2  versus the prior year including OCREVUS royalties Global fourth quarter TECFIDERA revenues were  1 2 billion  a 5  increase versus the prior year  This included revenues of  877 million in the US  an increase of 2  versus Q4 2018  and  284 million outside the US  an increase of 12  versus the fourth quarter of 2018  TECFIDERA benefited from an increase in channel inventory in the US of approximately  100 million in the fourth quarter of 2019 compared to an increase of approximately  60 million in Q4 2018  Throughout 2019  we were pleased to see four consecutive quarters of relative stability in our share of total prescriptions for TECFIDERA in the US In addition to strong performance from TECFIDERA  we launched VUMERITY in late Q4 in the US and recorded  5 million of revenue  all of which we attribute to channel loading  Outside the US  TECFIDERA again performed very well in the fourth quarter with strong patient growth in all major European markets and approximately 50  patient growth in Asia Pacific and Latin America versus the prior year For the full year  worldwide TECFIDERA revenues were  4 4 billion  an increase of 4  versus the prior year  This included  3 3 billion in the US and  1 1 billion in sales outside the US Interferon revenues  including both AVONEX and PLEGRIDY  were  516 million during the fourth quarter  a decrease of 14  versus Q4 2018 due to a continued shift from the injectable platforms to oral or high efficacy therapies  This included  359 million in the US and  157 million in sales outside the US  Interferon revenues outside the US were negatively impacted by channel dynamics and timing of shipments  Within the US  AVONEX and PLEGRIDY benefited from an increase in channel inventory of approximately  30 million compared to an increase of approximately  35 million in Q4 2018 For the full year  worldwide interferon revenues decreased 11  to  2 1 billion  consisting of  1 4 billion in the US and  675 million in sales outside the US TYSABRI worldwide revenues were  473 million this quarter  an increase of 2  versus the fourth quarter of 2018  This included  270 million in US and  203 million outside the US  In the US  revenues increased 5  versus the prior year  representing the fourth consecutive quarter of improved performance on a year over year basis  Within the US  inventory levels for TYSABRI were relatively stable compared to an increase of approximately  10 million in the fourth quarter of 2018 Throughout 2019  we were pleased to see relative stability in TYSABRI s share of both new and total prescriptions in the US  Outside the US  TYSABRI revenues decreased 2  versus the prior year as revenues were negatively impacted by channel dynamics and timing of shipments  For the full year  worldwide TYSABRI revenues were approximately  1 9 billion  an increase of 2  versus prior year  We recorded US revenues of  1 billion and  850 million internationally Overall  we were very pleased with the performance of our MS business in 2019 and are focused on maintaining the resilience of this franchise in light of new competition entering the market Let me now move on to SPINRAZA  Global fourth quarter SPINRAZA revenues were  543 million  a 16  increase versus the prior year and relatively flat versus the third quarter  In the US  SPINRAZA revenues for the fourth quarter of 2019 were  243 million  an increase of 3  versus both Q4 2018 and Q3 2019 The number of patients on therapy in US increased 2  as compared to the end of the third quarter of 2019  with growth coming from both the pediatric and adult patient segments  We continue to make strong progress with adults  as more than 50  of the new starts in Q4 were adults  And growth in adults exceeded our overall patient growth  As a reminder  the adult population is the largest segment of the market  We have continued to see an impact from gene therapy within the infant population  which represents approximately 5  of the total SMA market Outside the US  SPINRAZA revenues in the fourth quarter of 2019 were  300 million  an increase of 28  versus the prior year and a decrease of 3  versus the prior quarter  Outside the US  we saw strong growth in patients across all regions  with broad growth from both existing and newly launched countries  The number of commercial SPINRAZA patients increased approximately 10  versus the third quarter of 2019  Despite strong overall patient growth  fourth quarter ex US SPINRAZA revenues decreased slightly versus the third quarter of this year due to a combination of loading dose dynamics  country mix  the timing of shipments in certain markets and pricing dynamics Overall  we were very pleased with SPINRAZA s performance again this quarter  as we saw continued patient growth across the large mature markets and strong uptake in the emerging markets  Additionally  more than 50  of our revenue came from outside the US  and there remains significant opportunity to reach additional patients  particularly outside the US For the full year  worldwide SPINRAZA revenues increased 22  to  2 1 billion  driven by 9  growth in the US to  933 million and 30  growth outside the US to  1 2 billion Let me now move on to our biosimilars business  which generated revenues of  196 million this quarter  growing 25  versus the prior year  We estimate that we have more than 200 000 patients receiving treatments with our three anti TNF biosimilars  which is a significant increase of approximately 70  versus the prior year BENEPALI is the leading ENBREL biosimilar in Germany  the UK and Italy  FLIXABI is the most prescribed Remicade biosimilar in Italy  And IMRALDI is the leading HUMIRA biosimilar in major markets such as Germany and the UK  For the full year  biosimilars revenues grew 35  to  738 million Turning to our anti CD20 revenues  we recorded  601 million for the fourth quarter  an increase of 12  versus the prior year  primarily driven by OCREVUS royalties  Full year anti CD20 revenues were  2 3 billion  a 16  increase versus 2018  In the fourth quarter  we saw the first entry of a RITUXAN biosimilar  We expect additional biosimilar entrants in 2020  which we expect will put further pressure on RITUXAN revenues  Also as a reminder  our royalty rate on US sales of OCREVUS resets every calendar year Total other revenues were  146 million in the fourth quarter  a decrease of 12  versus the prior year due to the timing of shipments  Other revenues were  708 million for the full year  an increase of 21  versus 2018  As a reminder  other revenues in the first quarter of 2019 benefited from a large one time shipment to Bioverativ  In addition  note that other revenues are variable and difficult to predict Let me now turn to gross margin performance  Q4 2019 gross margin was 88  of revenues versus approximately 86  in the fourth quarter of 2018  The improvement in gross margin was due to slightly lower royalties  as well as lower cost related to our other revenues  Gross margins for the full year 2019 were approximately 86   relatively flat compared to full year 2018 Q4 GAAP and non GAAP R D expense was 19  of revenue or  692 million  Q4 R D expense includes  63 million related to the transaction with Samsung Bioepis  the  45 million opt in payment we made to Ionis related to BIIB080  and  30 million related to our collaboration agreements with CAMP4 Therapeutics and Catalyst Biosciences  Full year GAAP and non GAAP R D expense was 16  of revenue or  2 3 billion Q4 GAAP SG A expense was 18  of revenue or  665 million  Q4 non GAAP SG A expense was 18  of revenue or  662 million  Both GAAP and non GAAP SG A increased versus the prior quarter  primarily due to increased commercial and medical investments  as well as the timing of spend on G A  Full year GAAP SG A was 17  of sales or  2 4 billion  Full year non GAAP SG A was 16  of sales or  2 3 billion GAAP other expense  which includes interest  was  49 million in the fourth quarter  and GAAP other income was  83 million for the full year  Non GAAP other expense was  50 million in the fourth quarter and  110 million for the full year  The difference between these GAAP and non GAAP results is driven primarily by gains on strategic investments  which we classify as GAAP only In the 4th quarter and the full year  our GAAP and non GAAP tax rate was approximately 16   Compared to the prior year  GAAP and non GAAP tax rates for both the full year and the fourth quarter of 2019 benefited from a non recurring change in the Company s tax profile in 2019 and the sale of the remaining portion of higher tax inventory in 2018 due to inter Company effects  Furthermore  the GAAP rate also benefited from the unfavorable prior year effect of US tax reform in 2018 Our weighted average diluted share count was approximately 178 million for the fourth quarter and 187 million for the full year  Throughout 2019  we repurchased approximately 24 million shares at an average price of approximately  249 for a total value of approximately  5 9 billion  including approximately 7 7 million shares in the fourth quarter for a total value of approximately  2 1 billion  As of the end of the year  we had a total of approximately  6 3 billion in share repurchase authorization outstanding  including the new  5 billion plan approved by the Board in December 2019  which now brings us to our diluted earnings per share In the fourth quarter  we booked GAAP EPS of  8 08  an increase of 71  versus the fourth quarter of 2018  and non GAAP earnings per share of  8 34  a 19  increase versus the prior year  For the full year  GAAP EPS was  31 42  a 46  increase versus 2018  and non GAAP EPS was  33 57  a 28  increase versus 2018 We generated approximately  2 billion in net cash flows from operations in Q4 and approximately  7 1 billion for the full year  marking the final year where cash flows are impacted by payments to Fumapharm  We ended the quarter with approximately  5 9 billion in cash and marketable securities and  6 billion in debt Let me now turn to our full year guidance for 2020  We expect revenues of approximately  14 billion to  14 3 billion  We anticipate GAAP and non GAAP R D expense to be between 15  and 16  of revenues  We expect GAAP and non GAAP SG A expense to be approximately 19 5  to 20 5  of revenues  We anticipate our GAAP and non GAAP tax rates for 2020 to be between 18  to 19   And we anticipate full year 2020 GAAP diluted earnings per share results of  29 50 to  31 50 and non GAAP diluted earnings per share to be between  31 50 to  33 50 It s important to note that this guidance does not include any impact from potential acquisitions or large business development transactions  as both are hard to predict  This guidance does assume our proposed transaction with Pfizer closes  Our guidance also assumes a stable share count off the fourth quarter of 2019 and no change to foreign exchange rates  Importantly  our guidance also assumes no generic competition in the US for TECFIDERA in 2020 and assumes additional commercial and R D expenses related to aducanumab  This guidance reflects our best assumptions as of now  And as a reminder  we will provide an update mid year on our second quarter earnings call I ll now turn the call back over to Michel for his closing comments Michel Vounatsos    Chief Executive OfficerThank you  Jeff  We delivered strong performance in 2019 with growth across all of our core business areas  double digit earnings growth versus a year ago and strong execution across each pillar of our strategy  For 2020  we aim to continue our momentum by executing well on our strategic priorities across MS  SMA  biosimilars and our pipeline  with a priority on aducanumab We are actively preparing for the potential launch of aducanumab with an initial focus on the US  This includes implementing a thorough go to market model  hiring the sales force  building out our medical teams and preparing for market access  In addition  we are actively engaging with regulators outside of the US  including Europe and Japan Beyond aducanumab  our pipeline is maturing  We now have six programs in Phase III and 27 clinical programs overall  an increase from 17 just three years ago  We have multiple near term opportunities for value creation  including in Alzheimer s disease  ALS  stroke  lupus  ophthalmology and biosimilars  as we aim to build a multi franchise portfolio  Between now and the end of 2021  we expect 11 mid to late stage data readouts  including Phase III readouts for tofersen in ALS  BIIB111 in choroideremia and BIIB093 in large hemispheric infarction  and eight Phase II readouts across MS  Alzheimer s disease  Parkinson s disease  ophthalmology  schizophrenia  acute neurology and neuropathic pain As the leader in neuroscience  with asymmetric  Phonetic  core capabilities  we believe that no other company is better positioned to continue to deliver breakthrough therapies for diseases of the nervous system to address a significant and growing unmet medical need  We ll continue to execute on our core strategy to build a multi franchise portfolio across our core and emerging growth areas  I want to reiterate our commitment to maximizing returns to our shareholders and bringing innovative therapies to patients over the long term  This demands that we continue to look at capital efficiently  effectively and appropriately  As we have demonstrated in the past  we will always strive to have an optimal capital structure  as well as aim for superior returns from the investment we make I d like to take a moment to discuss how we brought the purpose as an organization as we aim to pioneer science for the betterment of humanity  This includes doing the right thing for patients  our employees  the environment and the community  all of which we believe contributes to a long term sustainable shareholder value  I am proud of what Biogen stands for  and I believe this approach positions us well to be a sustainable organization over the long term  as we remain focused on being the leader in neuroscience to address the tremendous societal needs in this space Finally  I would like to thank our employees around the world  who are dedicated to making a positive impact on patients  lives  and all of the physician  caregivers and participants in our clinical development programs  Our past and future achievements could not be realized without their passion and commitment We will now open the call for questions Questions and Answers Operator Operator Instructions  Your first question comes from the line of Geoff Porges with SVB Leerink  Please go ahead Geoffrey Porges    SVB Leerink    AnalystThank you very much  and congratulations on the quarter and the results and all the progress  Just a couple of questions  Jeff  on the guidance  Could you talk about what assumptions are built into your guidance about the effect of the risdiplam imminent launch on SPINRAZA  And also just have you incorporated the full launch costs for aducanumab  Your sales force and everything you mentioned that  but is it fully budgeted in that guidance  Thanks Jeffrey Capello    Executive Vice President and Chief Financial OfficerSo thanks for the questions  Geoff  So with regard to risdiplam  we are assuming that that product does launch  And so we re anticipating  as everyone else is  to kind of see the data and kind of what it means  We d just remind people that we have 10 000 people on therapy today doing very  very well with a very low discontinuation rate  So we ll see kind of what happens on the data and how that product is received  But certainly  there s a lot of growth opportunity for us ahead With regard to aducanumab  we re not going to give specific perspective on numbers in terms of the launch  but I would just point you back to looking at the SG A guidance  which is up quite a bit from a percentage perspective  and you get a sense of the amount we re spending year over year relative to that that we spent last year  And that is I think the prudent thing to do  given the significant opportunity ahead of us  which we re quite excited about OperatorYour next question comes from the line of Terence Flynn with Goldman Sachs Terence Flynn    Goldman Sachs    AnalystGreat  thanks for taking the question  Maybe just two for me  Just wondering if you can give us any more detail on what s gating to the aducanumab filing  And then  are you expecting a priority review  And then the outlook in terms of the ex US regulatory filings there  do you have a similar level of confidence in filing in both Europe in Japan as you do in the US  Thank you Alfred Sandrock  Jr     Executive Vice President  Research   Development and Chief Medical OfficerHi  Terence  this is Al  It s basically a matter of putting together documentation  the electronic Common Technical Document  It s an electronic document with hyperlinks  etc  It s a matter of assembling all that and submitting that to the FDA And in terms of the engagement  we ve been engaged with them since last    the first Type C meeting last June  and it s been very constructive  I ve never    this is a unique situation to me  It s pretty unusual  I think  across the industry  But I ll say that it s been    there has been a high level of constructive engagement ever since last June And with respect to the other regions  we have started our engagement with them  but it s still early days  But we do anticipate that we will be filing at some point in those other regions as well at some point OperatorYour next question comes from the line of Ronny Gal with Bernstein  Please go ahead Ronny Gal    Bernstein    AnalystGood morning  Congratulations on the results  and thank you for taking the questions  You mentioned you re beginning to    the redosing trial  I wonder if you can just tell us a little bit about what you re trying to achieve with that trial  Essentially  now that you ve got the protocol  what are the endpoints and when    what is the data that we should see from that And then second on VUMERITY  can you describe a little bit the launch plans here  I guess it didn t really make commercial step yet  Can you talk a little bit about whether you intend to give it the same kind of parity business model to TECFIDERA  Or would there be some things you do with VUMERITY that    in terms of access  support and so forth  that will be better or worse than TECFIDERA Alfred Sandrock  Jr     Executive Vice President  Research   Development and Chief Medical OfficerHi Ronny  it s Al  The main reason for the redosing study were humanitarian reasons  We had all these patients who had volunteered to be in our clinical studies  They helped us develop aducanumab  We felt we owed something to them  Many of them had expressed a desire to the investigators that they wanted the drug  So that s the primary reason  As I said in my notes that    in my script that it s a single arm study  Basically  every patient gets titrated up to 10 milligrams per kilogram aducanumab  and all patients who were in prior studies  including placebo patients  are eligible  In a single arm study  the main thing you can really look at is safety and tolerability  And we had always envisioned doing a long term extension study  In fact  we had one in place to evaluate long term safety and tolerability  And so that s the primary endpoint of the study In addition  of course  we ll answer    we ll take a look at efficacy as best you can in a single arm study because we would be interested in continued    if there s durable effect  obviously  we ll be looking at amyloid and other biomarkers  and we ll also see whether or not a treatment gap had any effect on these kinds of markers Michel Vounatsos    Chief Executive OfficerSo  Ronny  concerning the second part of your question  with a superior to take  Indecipherable  we have the opportunity with VUMERITY to strengthen the overall fumarate portfolio  But TECFIDERA remains front and center in our promotion  You see the performance  We continue to support  And again  a key metric will be to increase the share of fumarate down the road  We are pleased with the access to date that is superior to what we have seen from competition a few months after launch  and for some competitors  12 months after launch  So we are pleased with the access  We monitor very closely the Start Forms and the grads  Phonetic   We are pleased to see so far that there is more Start Forms being issued ex tech than tech  So this is a    but it s still the beginning  It s a bit too early  We ll come back with more color when we have more data OperatorYour next question is from the line of Phil Nadeau with Cowen and Company  Please go ahead Phil Nadeau    Cowen and Company    AnalystGood morning  Thanks for taking my question  It s actually on TECFIDERA and the IP  I believe  we are going to get a decision on the IPR next week  Can you remind us in the case where the IP were to fall  what would be the next steps  what is the appeal process there  And then secondarily  what is the status of the court case  Can you give us an update on the timelines there  should the IPR actually go your way next week  Thanks Jeffrey Capello    Executive Vice President and Chief Financial OfficerYeah  so it s Jeff  So there is a    expect a decision  from the IPR perspective  no later than the end of the first week of February  So that will be the first of the three decisions  Depending on how that goes    if it goes in our favor  that s great  If it doesn t  we plan to appeal  and the appeal process typically takes 12 to 18 months Two other cases  West Virginia and Delaware  are expected to read out some point mid year  plus or minus a month or two  Depending on how those go those go    if those go our way  that s great  If not  we plan to appeal those  and the appeal period  again  tends to take 12 to 18 months  So we obviously await kind of the results of that  We do believe we have valid patents  Nonetheless  these outcomes are difficult to predict  There s a number of considerations need to be weighed  There s obviously multiple decisions that we just talked about  There s the appeal periods and then there s handicapping whether or not people    if we re unsuccessful  we ll launch at risk  So it s difficult to predict in the short term  So we ll keep people apprised of kind of the developments as we move our way through the year OperatorYour next question is from the line of Umer Raffat with Evercore  Please go ahead Umer Raffat    Evercore ISI    AnalystHi  thanks so much for taking my questions  Al  I just wanted to focus on Alzheimer s for a minute  if I may  And it s very clear that FDA has a long history of approving CNS drugs  which have failed and or negative trials in the past  However  every time FDA goes down that direction  I find that they pool results across every single thing  So my question is  if you pool results across ENGAGE  EMERGE and Phase Ib  what does that look like  That will be very helpful to understand  And also  how many post hoc analysis were done before you guys arrived at the Protocol Version 4 population  I mostly ask because I m trying to understand how we should think about what should be the p value  given all the splits that theoretically should be thought about before we arrived at the PV4 Alfred Sandrock  Jr     Executive Vice President  Research   Development and Chief Medical OfficerSo Umer  this is Al Sandrock  We haven t disclosed the results of any other kinds of analyses  including pooling or subsets  So we re not going to do that this morning  But I would say that I would not assume that    I mean  when you look back in the history of approved drugs  I wouldn t say it s always the case that pooling is done  I think that there is    there are exceptions to that  And so I would not assume that here  and let s see Your question    the other question was how many post hoc analyses  We did say it was post hoc  but I don t remember how many there were OperatorYour next question is from the line of Geoff Meacham with Bank of America  Please go ahead Geoff Meacham    Bank of America Merrill Lynch    AnalystHi  good morning  guys  Thanks for the question  I just have a few  On SMA  in clinical development  patients on ZOLGENSMA switched back to SPINRAZA  Just curious if you guys have seen evidence that this is occurring in the real world And then Al  bigger picture question on Alzheimer s  So if I assume that A beta antibody is an anchor therapy  when we look down the road at combination approaches  is there sort of a fast path to derisk  In other words  do you feel like FDA    you can look at surrogate markers such as a PET imaging initially  and then down the road  look at cognition  Just wanted to get a sense for looking at post aducanumab  Thanks Alfred Sandrock  Jr     Executive Vice President  Research   Development and Chief Medical OfficerYeah  So we    your first question was about SMA and ZOLGENSMA  I don t really consider that as switch back  if you will  because if they ve had ZOLGENSMA  arguably that    they re still on it  if you will  They re getting the effect of the gene therapy  So in some ways  it s like a combination of adding SPINRAZA  We have heard about that  It does happen in the real world  And you might want to    you might wonder why people are doing that  I think it s because parents and the physicians feel like there might be more room to improve  and so that s what I hear from    in the real world  And in terms of data from that  we are starting to collect that data  But we have    we don t have any conclusions at this point  But we are    because it s happening in the real world  And since we re very interested in real world evidence  we are starting to collect that data In terms of Alzheimer s and combination  one of the reasons why we built the pipeline the way we did was that we had always envisioned combination therapy  And the first obvious thing to combine aducanumab or BAN2401 with would be an anti tau or a tau ASO  something that affects tau  We were actually pleasantly surprised that aducanumab already affects tau  though  So we ll have to keep that in mind  But nevertheless  I think the most obvious thing to do would be to combine with tau as the next step  and then maybe that there are certain stages of the disease that need the combination more than other stages And in terms of a fast track  yeah  we will employ biomarkers  not only of the toxic proteins that we re trying to reduce  A beta and tau  but also potentially other kinds of biomarkers that look at additive effects in a more expedient way  But ultimately  I anticipate we will need to show some effect of the combination on reducing clinical decline further  I think that will still be important  Unless you can do it  in other words  if you re in an early stage of Alzheimer s where there is no cognitive impairment  you may not be able to do it where biomarkers alone may be the only approach OperatorYour next question is from the line of Michael Yee with Jefferies  Please go ahead Michael Yee    Jefferies    AnalystThanks for the question  You had made some comments around preparation for aducanumab  including SG A  Could you just put a little more color around  I guess  the work being done in terms of timing of when you actually expect the sales force to be on  And maybe some comments around what you re hearing from payers and what they would    how they are putting in perspective this type of drug and what type of actions that type of drug would get And then just a quick one also for Al  there is a DIAN TU study reading out  I m sure people will try to make read throughs into what this means for the beta amyloid about    this is maybe just a comment on anything to know or your perspective on that study  I appreciate it Michel Vounatsos    Chief Executive OfficerSo Michael  if I can get started with the launch readiness  actually  the work started more than two years ago with an understanding of the patient journey from origination to diagnosis  the referral dynamics that change from market to market  and even within the US  which is different  understand the different types of markets within the US  it s    the different segments  We have finalized the go to market for the US  This has been approved  and this is funded in our budget  as discussed  And hiring has started  first with the medical affairs  obviously  Engagement with scientific leaders also at the community level is important  And also the biomanufacturing needs to be stepped up and be ready for eventually a large demand with the functional support  OK  to support the increased engagement and team In terms of price  it s still early  even if we are making progress  We engage with stakeholders  because as you can imagine  there is almost no drug cost today  So we engage with patient association  pharmacoeconomics  through leaders and all the customers  mostly in the US and beyond the US  Beyond the price  it s all about the access condition and the affordability  We know that the more we wait  the more transition    that people will transition to full blown assistance and loss of dependence  which costs so much to the society  So basically  we start engaging  and hopefully  we ll have all the incentives in that field in order to further invest in R D  This is our belief  So good progress  step by step  but we engage broadly and we ask for advice and we listen Alfred Sandrock  Jr     Executive Vice President  Research   Development and Chief Medical OfficerHi Michael  it s Al  DIAN TU    so DIAN is the Dominantly Inherited Alzheimer Network  So obviously  in these patients  amyloid is likely to be causal because most of the dominantly inherited mutations that lead to ultimately  Phonetic  Alzheimer s disease are patients either in APP  the amyloid precursor protein  or enzymes that process it  And so I think that these are very interesting studies  My understanding is that solanizumab and gantenerumab are being tested  If the results are positive  I think that that would lend further support to the amyloid hypothesis  If the results are negative  I d want to see that there is evidence of target engagement and biological changes in the brain before I make any conclusions OperatorYour next question is from the line of Cory Kasimov with J P  Morgan  Please go ahead Cory Kasimov    J P  Morgan    AnalystGreat  Good morning  guys  Thanks for taking my question  I wanted to ask on capital allocation  and given the Company s current portfolio and pipeline  considering prevailing market dynamics  how do you look at the relative attractiveness between continued share repurchases  considering the 6 plus billion in dry powder you have there  and business development opportunities  I guess  do you have enough bandwidth to do both in a meaningful way  And do you    and how much of an appetite do you have on the acquisition front at this time  Thanks Jeffrey Capello    Executive Vice President and Chief Financial OfficerSo Cory  it s Jeff  Thanks for the question  So we re in a good position from that perspective  We have no net debt as of the end of the year  In 2019  we generated  7 billion of cash flow and we expect that we ll have a strong cash flow year again in 2020  So we ve got the financial flexibility to do both  and we have been doing both  Over the last three years  we ve done 15 M A BD type transactions  spending  3 5 billion  And in the last year alone  we bought back 24 million shares for almost  6 billion So our interest is strong in terms of building the pipeline  We ve taken the pipeline from 17 clinical assets to 27  significant increase  And then  of those 27  there s 11 that have important readouts in the next two years  five of which could have a meaningful impact on the Company  So we feel good about that  We d like to continue to add to those assets and build the pipeline  But at the same point  we have  6 3 billion of authorized share repurchase capability as well  So we ll continue to make good decisions that are in the best interest long term of the shareholders and we ll have the capacity to do both OperatorYour next question is from the line of Matthew Harrison with Morgan Stanley  Please go ahead Matthew Harrison    Morgan Stanley    AnalystHey  good morning  Thanks for taking the question  I had one for Al on two pipeline program  Al  can you just comment why a LRRK2 ASO could be differentiated from the kinase inhibitors that we see in development  And then maybe just share your views on anti LINGO in MS  Has that changed since you initiated that study or any updated views there  Thanks Alfred Sandrock  Jr     Executive Vice President  Research   Development and Chief Medical OfficerSo LRRK2 is a wonderful target  we believe  for Parkinson s disease  not only for the patients with familial PD due to LRRK2 mutations  but also potentially even for sporadic Parkinson s disease  And the ASO  it s another approach to    instead of inhibiting the enzyme with a small molecule  you reduce the levels of LRRK2  and it remains to be seen  One thing I ll say about the ASO is that it s CNS  Because we give it intrathecally  it s only going to affect LRRK2 in the central nervous system  whereas a small molecule may have affects on the enzyme in other places  But I would say other than that  it s kind of early days for whether or not these drugs will be effective And in terms of anti LINGO  the Phase II study that we re doing now is different from the first Phase II study in the sense that we selected patients based on advanced imaging to be sure that they actually had demyelination based on MTR and actually had intact exons based on DTI  We also chose the dose that looked the most promising  based on the first Phase II study  And we re combining it with multiple different kinds of immunomodulators  In the first trial  we only combined it with interferon  but now we re combining it with TECFIDERA  TYSABRI as well as interferon to see whether or not the level of inflammatory disease in the brain affects remyelination  And perhaps when you have less inflammation  the oligodendrocyte precursor cells may be able to remyelinate better  So that s the difference  And we ll find out soon whether or not the second trial is positive OperatorYour next question is from the line of Jay Olson with Oppenheimer  Please go ahead Jay Olson    Oppenheimer    AnalystHi  congrats on a successful 2019  and thanks for taking the question  Could you elaborate on the rationale for studying BAN2401 in patients whose amyloid levels fall below the threshold of positivity  And is the goal here to create a complementary positioning for BAN2401 in patient segments that would be distinct from aducanumab Alfred Sandrock  Jr     Executive Vice President  Research   Development and Chief Medical OfficerWell  we do view this    we do view the two drugs as part of a multi drug franchise  and we will use the drugs where they naturally fit the best  and we ll need data for that  Just because they re not positive based on a visual read  that doesn t mean there s no amyloid accumulation  So I think that s the distinction  And in some ways  A345 study looks at    between the two studies  looks at both Stage 1 and Stage 2  both of the    both stages as defined by the FDA guidance document that came out last year on the various stages of Alzheimer s disease  So I would say that those two studies evaluate both Stage 1 and Stage 2  and both are important to study  I believe Joe Mara    Vice President  Investor RelationsThere s probably time for two more questions OperatorYour next question will come from the line of Evan Seigerman with Credit Suisse  Please go ahead with your question Evan Seigerman    Credit Suisse    AnalystHi  guys  Thank you for taking my questions and congrats on the quarter  I m just looking toward next week with the potential results from the IPR  If they were to not go your way  would you consider reprioritizing your business development priorities versus share repurchases  Or would you have to wait until you kind of see the results of the court cases mid year Michel Vounatsos    Chief Executive OfficerSo thanks for the good question  And we see business development M A opportunities as being independent from what happens next week or what happened six months ago  in March  We continue to remain    we are very engaged on BD opportunities  and the team continue to look at the opportunities to create value for the shareholders  and this will be independent from any event Jeffrey Capello    Executive Vice President and Chief Financial OfficerYeah  and just as a reminder  we ended the year with no net debt  And in 2019  we generated  7 billion in operating cash flow  So we ve got the capacity to do both OperatorThe final question will come from the line of Robyn Karnauskas with SunTrust  Please go ahead with your question Robyn Karnauskas    SunTrust Robinson Humphrey    AnalystHi  thanks for the question  Just to give us some comfort  as the investors and we think about Alzheimer s  should it be approved  given that you ve  Phonetic  a huge amount of antibody  can you give us any comfort around cost of goods and margins that it wouldn t be too harmful  I know you guys have very good manufacturing capacity  but that s still a lot of antibodies  So when would we learn this  And can you give us any comfort that the dollar amount to make this drug isn t extremely high that it would overburden the system  Thanks Jeffrey Capello    Executive Vice President and Chief Financial OfficerYeah  So thanks for the question  So it s obviously something we ve been looking at for a while  And I ll say    I don t want to get into too much specifics with regard to that at this point in time  but we re comfortable that given the nature of the substance that we ll produce  it will be a fair margin and that it will do well economically Joe Mara    Vice President  Investor RelationsSo I m going to turn it back over to Michel for his closing comments Michel Vounatsos    Chief Executive OfficerSo thank you all for being on the call  We turned the page of a very strong 2019  and now  the team at Biogen is ready for a very material 2020 and  obviously  with a priority for a potential aducanumab  Thank you for your attention Joe Mara    Vice President  Investor RelationsThank you  End the call Operator Operator Closing Remarks Duration  68 minutesCall participants Joe Mara    Vice President  Investor RelationsMichel Vounatsos    Chief Executive OfficerAlfred Sandrock  Jr     Executive Vice President  Research   Development and Chief Medical OfficerJeffrey Capello    Executive Vice President and Chief Financial OfficerGeoffrey Porges    SVB Leerink    AnalystTerence Flynn    Goldman Sachs    AnalystRonny Gal    Bernstein    AnalystPhil Nadeau    Cowen and Company    AnalystUmer Raffat    Evercore ISI    AnalystGeoff Meacham    Bank of America Merrill Lynch    AnalystMichael Yee    Jefferies    AnalystCory Kasimov    J P  Morgan    AnalystMatthew Harrison    Morgan Stanley    AnalystJay Olson    Oppenheimer    AnalystEvan Seigerman    Credit Suisse    AnalystRobyn Karnauskas    SunTrust Robinson Humphrey    Analyst
More BIIB analysis
All earnings call transcripts",2020-01-30,The Motley Fool,https://invst.ly/pp40u,2072256
128366,349881,BIIB,Top Analyst Upgrades and Downgrades  Aimmune  Amgen  Biogen  Chevron  CRISPR  Exxon  Nike  Snap  Uber  Ulta  Verizon and More,news,"Friday s 600 point sell off in the Dow Jones industrials actually knocked out the 2020 gains  but just two weeks ago the market was at all time highs  China s stock market is back open after the Lunar New Year  and the market was down handily with concerns over the coronavirus still pressing  U S  futures were indicated to open higher on Monday  and many investors have yet to make any major changes to their holdings after the incredible gains from 2019  This is an election year  and the Iowa caucus count is imminent  with much at stake  Strategists are by and large calling for single digit percentage gains in 2020 
24 7 Wall St  reviews dozens of analyst research reports each day of the week with a goal of finding new ideas for traders and long term investors alike  Some of the daily analyst calls cover stocks to buy  while some calls cover stocks to sell or to avoid div connatix margin bottom  1 5em   div connatix img  margin  unset  
We have provided these analyst calls in a quick hit summary for easy reading  and additional comments and trading data have been added on many of the calls  The consensus analyst price targets and other valuation metrics are from the Refinitiv sell side research service 
These are the top analyst upgrades  downgrades and initiations from Monday  February 3  2020 
Aimmune Therapeutics Inc   NASDAQ  AIMT  was down 2 9  at  31 05 on Friday  but after the close the FDA approved its peanut allergy drug  The shares were last seen up about 16  at  36 00  versus a prior consensus target price of  47 82  Cantor Fitzgerald reiterated it as Overweight and raised its target price to  64 from  55 

Amgen Inc   NASDAQ  AMGN  closed down 4 5  at  216 05 on Friday  with a prior consensus target price of  246 41  SunTrust Robinson Humphrey reiterated it as Buy and raised its target price to  265 from  254 
Applied Materials Inc   NASDAQ  AMAT  was raised to Buy from Hold and the target price was raised to  72 from  60 at Deutsche Bank  Shares closed down 3 75  at  57 99 on Friday  with a prior consensus target price of  68 74 
Biogen Inc   NASDAQ  BIIB  closed down 3 1  at  268 85 on Friday  with a prior consensus target price of  309 56  SunTrust Robinson Humphrey reiterated its Buy rating and raised its target price to  360 from  335 
Bluebird Bio Inc   NASDAQ  BLUE  was upgraded to Outperform from In Line and its target was raised to  100 from  86  versus a  79 96 prior close  after a 3 1  drop  at Evercore ISI 
Carrols Restaurant Group Inc   NASDAQ  TAST  was reiterated as Buy with a  12 target price  versus a  4 54 close  at SunTrust Robinson Humphrey  The stock was down 3 6  on Friday  and its consensus target price was  10 50 
Charter Communications Inc   NASDAQ  CHTR  was up almost 5  at  517 46 on Friday after earnings  Raymond James reiterated the shares as a Strong Buy and raised its target price to  600 from  525  Credit Suisse upgraded it to Outperform from Neutral and raised its target price to  600 from  520 
Chevron Corp   NYSE  CVX  was down 3 8  at  107 14 on Friday with the market sell off and after earnings  Credit Suisse maintained its Outperform rating but cut the target price to  128 from  135 
CRISPR Therapeutics A G   NASDAQ  CRSP  was downgraded to In Line from Outperform and its target price was lowered to  52 from  85  versus a  51 95 close  at Evercore ISI  The prior consensus target price was  77 50 
Danaher Corp   NYSE  DHR  was reiterated as Buy and its target price was raised to  187 from  167  versus a  160 87 close  at Needham  It had a  173 19 consensus target price 
Electronic Arts Inc   NASDAQ  EA  was downgraded to Market Perform from Outperform and its target price was lowered to  110 from  130 at BMO Capital Markets 
Exxon Mobil Corp   NYSE  XOM  closed down 4 1  at  62 12 on Friday with the market and after earnings disappointed  Goldman Sachs downgraded it to Sell from Neutral and lowered its target price to  59 from  72  Credit Suisse maintained its Neutral rating but lowered its  70 target to  65 



				ALSO READ  10 Big Stocks That Should Keep Avoiding the Coronavirus Stock Market Panic",2020-02-03,247wallst,https://invst.ly/pqf5i,2074424
128382,349897,BIIB,3 Pharma   Biotech Pipeline Areas To Keep An Eye On In 2020,opinion,In 2019  the FDA granted approval to 48 novel drugs  As in the past years  several approvals were for cancer drugs  These apart  the agency s approvals included treatment options for patients living with cystic fibrosis  sickle cell disease and rare muscular disorders  Important approvals of non cancer drugs were for Caplyta for schizophrenia  Nourianz for Parkinson s disease patients experiencing  off  episodes  Vyondys 53 to treat some patients with Duchenne muscular dystrophy and Oxbryta for sickle cell disease  among others The last year clearly proved that the FDA is increasingly giving green signal to innovative new products in various therapeutic areas  Though cancer will always be a key area for R D research  here we take a look at three non cancer therapeutic areas that we think will garner a lot of interest in 2020  These areas are marked by extensive research  innovative technologies  and the promise of transforming the way diseases are treated Alzheimer s DiseaseAlzheimer s disease is an area where many companies have tried their luck but with minimal success  Over the last several years  big players like Merck   NYSE MRK    AstraZeneca   NYSE AZN    Lilly   NYSE LLY    Pfizer   NYSE PFE   and J J   NYSE JNJ   have faced setbacks in their quest to find a treatment for Alzheimer s While Pfizer sports a Zacks Rank  1  Strong Buy   Lilly   J J have a Zacks Rank of 2  Buy   You can see  Companies that are currently working on Alzheimer s disease treatments include players like Biogen  NASDAQ BIIB   Lilly  Novartis and Eisai Biogen s aducanumab is a leading candidate for AD  In October last year  Biogen and partner Eisai announced their intention to seek U S  approval for aducanumab  a few months after it halted two late stage studies on the same drug  following a futility analysis  Biogen s decision was based on positive results of a new analysis of larger dataset  which became available after the discontinuation of the studies  The candidate  if approved by the FDA  will become the first medicine to treat Alzheimer s disease A group of analysts believe that the promising new data from two failed studies on aducanumab have revived hopes for approval of this almost written off experimental Alzheimer s therapy  However  another group believes that the FDA may not approve aducanumab  particularly with mixed outcome results across the two studies  Also  the FDA may require additional studies to be conducted to confirm the candidate s benefits  Biogen also has another AD candidate in its portfolio  BAN2401which is in late stage development Although Alzheimer s has historically been a very challenging therapeutic area with quite a few companies stumbling in their efforts to find a treatment  the market is highly lucrative  This is because more than five million Americans are living with Alzheimer s disease with the numbers expected to triple by 2050  Data  Alzheimer s Association   The market has immense commercial potential and companies coming out with new treatments could rake in billions of dollars in sales  As a result  several companies continue to invest heavily in developing Alzheimer s disease treatments Medical MarijuanaAnother segment of the pharma and biotech industry that will be in the limelight this year is medical marijuana  Canada has become the first major economy to legalize recreational pot  with quite a number of U S  states giving green signal to cannabis in some capacity last year The only FDA approved cannabidiol drug  Epidolex  marketed by GW Pharma  has shown strong uptake in sales and new patient enrollments since its launch in November 2018 in the United States  Epidiolex was approved in Europe in September 2019 Epidiolex oral solution is approved to treat seizures associated with Lennox Gastaut syndrome  LGS  or Dravet syndrome  A new drug application seeking approval of Epidiolex for a new indication   tuberous sclerosis complex   is expected to be filed in early 2020  A late stage study on Rett Syndrome is ongoing  Epidiolex represents blockbuster potential  GW Pharma has several new formulations of CBD in development including modified oral solution  capsule and intravenous formulationThe industry is expected to grow rapidly with legislators allowing or looking to allow more legal uses of marijuana and marijuana related products  especially in the medical and life sciences industry Zynerba Pharmaceuticals is developing its CBD candidate  Zygel  in pediatric patients with autism spectrum disorder  Several Canada based companies like Tilray  Aurora Cannabis  Cronos Group and Canopy Growth Corporation are involved in cultivating  producing and commercial distribution of recreational and medical marijuana We note that there is huge untapped market opportunity for cannabis based products  which can create the next booming industry  We expect legalization of marijuana at the federal level to attract several big pharma companies into development of marijuana based drugs  which can boost sales of cannabis based drugs  Moreover  this will likely create new treatment options for patients if the unsubstantiated claims are proved in clinical studies Rare DiseasesA rare disease is a condition affecting less than 200 000 people in the United States  There are around 7 000 known rare diseases  Though each such disease affects only a few people  25 30 million Americans are living with such diseases  There are numerous types of rare diseases including infectious diseases  CNS disorders  birth defects  and cancers  Though significant progress has been made to diagnose  treat  and even prevent a variety of rare diseases  mainly rare genetic diseases  there are still many such diseases for which no treatments are available  Also  the FDA supports development of drugs for these diseases and there are incentives for drug companies to develop treatments for rare diseases  which also explain increased interest of drug companies in this field  Also  advances in technology  such as gene editing technologies  and improvements in gene therapies  have drawn increased commercial interest to the realm of rare disorders Alexion   NASDAQ ALXN    BioMarin  Sanofi   NASDAQ SNY   and Pfizer are some of the bigger companies making rare disease drugs  Meanwhile  mostly smaller companies have rare disease drugs in their pipelines  which also make them attractive buyout targets for their larger counterparts The Hottest Tech Mega Trend of All                 Last year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2020-01-08,Zacks Investment Research,https://www.investing.com/analysis/3-pharma--biotech-pipeline-areas-to-keep-an-eye-on-in-2020-200497168,200497168
128383,349898,BIIB,Biogen Acquires Early Stage CNS Drug From Pfizer For  75M,opinion,"Biogen Inc    NASDAQ BIIB   announced that it has signed an agreement with Pfizer   NYSE PFE   to acquire the latter s CNS penetrant small molecule inhibitor  PF 05251749  The early stage candidate has exhibited potential as treatment of behavioral and neurological symptoms across various psychiatric and neurological diseases in early stage studies Per the terms of the agreement  Biogen will pay  75 in upfront payment to Pfizer along with potential additional development and commercialization milestone payments of up to  635 million  Pfizer is also eligible to receive tiered royalties in high single digits to sub teens  The transaction is expected to be completed in the first quarter of 2020 Biogen s shares have declined 11  in the past year compared with the  s decrease of 1 2  Biogen plans to develop PF 05251749 as potential therapy to treat certain symptoms disorders of Alzheimer s disease   AD   and Parkinson s disease   PD    It plans to develop PF 05251749 as a treatment for Sundowning symptom in patients with AD and Irregular Sleep Wake Rhythm Disorder  ISWRD  in patients with PD  The company is planning to initiate a phase Ib study in the fourth quarter of 2020 The acquisition of PF 05251749 is in line with Biogen s strategic priority to build potential therapies for neurological conditions  Moreover  Biogen regularly in licenses assets to build its pipeline with several candidates having transformative potential  The company  collaboration deals with two private biotechs early last year to discover and develop novel treatment options for treating neurological conditions  such as Alzheimer s disease and Parkinson s disease Biogen has a diversified pipeline with several promising candidates in different stages of clinical development targeting AD and PD The company s aducanumab is a leading candidate for AD  In October last year  Biogen and partner Eisai announced their intention to seek U S  approval of aducanumab  a few months after it halted two late stage studies on the same drug  following a futility analysis  Biogen s decision was based on positive results of a new analysis of larger dataset  which became available after the discontinuation of the studies  The candidate  if approved by the FDA  will become the first medicine to treat Alzheimer s disease  BAN2401 is another candidate for AD which is currently in late stage development The company is evaluating BIIB054 in a phase II study for treating PD  Important data readouts are expected across clinical programs in multiple sclerosis  epilepsy  Parkinson s disease and others in 2020 The drugs presently available just to treat the symptoms of the disease and new treatment options have faced many setbacks and failures  Several large pharma companies  including Biogen  Roche   OTC RHHBY    Amgen   NASDAQ AMGN    Novartis  Merck  Pfizer  Lilly and AstraZeneca stopped development of their AD candidates in 2019 2018 either due to low possibility of success or safety concerns Despite the setbacks  companies continue to invest heavily in developing AD treatments  given the high commercial potential in this market  Success in this area means huge returns  This is because more than 5 million Americans are living with AD with the numbers expected to triple by 2050  Data  Alzheimer s Association   The market has immense commercial potential and companies coming out with new treatments could rake in billions of dollars in sales Biogen Inc  Price
    Zacks RankBiogen currently carries a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ",2020-01-13,Zacks Investment Research,https://www.investing.com/analysis/biogen-acquires-earlystage-cns-drug-from-pfizer-for-75m-200498659,200498659
128384,349899,BIIB,Roche s Risdiplam Meets Primary Endpoint In Infants Study,opinion,Roche Holdings   OTC RHHBY   announced positive top line results on pipeline candidate  risdiplam  for the treatment of spinal muscular atrophy  SMA  from part 2 of the FIREFISH study The study is evaluating risdiplam in infants aged one to seven months with type 1 SMA  Risdiplam is an investigational survival motor neuron 2  SMN2  splicing modifier  designed to increase and sustain SMN protein levels throughout the central nervous system and in peripheral tissues The primary outcome measure of the study was the proportion of infants sitting without support for at least five seconds at month 12 of treatment  assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler Development Third Edition  BSID III  Risdiplam met the primary endpoint by demonstrating statistically significant and medically meaningful motor milestone improvement in infants with Type 1 SMA FIREFISH is a two part  open label  pivotal study in infants aged one to seven months with type 1 SMA  Part 1  n 21  assessed the safety profile of the drug and determined the dose for Part 2  Part 2  n 41  assessed efficacy as measured by the proportion of infants sitting without support after 12 months of treatment or longer We remind investors that Roche leads the clinical development of risdiplam as part of a collaboration with the SMA Foundation and PTC Therapeutics   NASDAQ PTCT   The drug is being evaluated in a broad clinical trial program in newborn babies to 60 year olds with SMA  The study also includes patients previously treated with SMA targeting therapies Apart from FIREFISH  the company has three ongoing studies   SUNFISH  JEWELFISH and RAINBOWFISH In November 2019  Roche announced positive results from Part 2 of SUNFISH  evaluating the efficacy and safety of risdiplam in patients aged two to 25 years with Type 2 or 3 SMA In the same month  the FDA granted priority review to the drug  A decision for approval is expected by May 24  2020 The successful development of risdiplam will significantly benefit Roche  However  competition is stiff in the SMA market from the likes of Biogen s   NASDAQ BIIB   Spinraza and Novartis    NYSE NVS   gene therapy  Zolgensma Roche s shares have gained 32 8  in the past year compared with the  s 17 3  growth  The company s efforts to develop its portfolio beyond oncology are encouraging  The company has more than a dozen investigational medicines in clinical development for diseases like multiple sclerosis  SMA  neuromyelitis optica spectrum disorder  Alzheimer s disease  Huntington s disease  Parkinson s disease  Duchenne muscular dystrophy and autism The stock currently carries a Zacks Rank  2  Buy   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2020-01-22,Zacks Investment Research,https://www.investing.com/analysis/roches-risdiplam-meets-primary-endpoint-in-infants-study-200500911,200500911
128385,349900,BIIB,Can Biogen  BIIB  Keep The Earnings Streak Alive In Q4 ,opinion,"We expect Biogen Inc    NASDAQ BIIB    to beat expectations when it reports fourth quarter and full  year 2019 results on Jan 30  before market open In the last reported quarter  the company delivered a positive earnings surprise of 10 88  Biogen s shares have declined 15 7  in the past year compared with the  s decrease of 4 7  in the same time frame Biogen s earnings performance has been strong as it delivered a positive surprise in each of the four trailing quarters with the average being 9 30  Biogen Inc  Price and EPS Surprise
    Let s see how things have shaped up for this announcement Factors to ConsiderBiogen s third quarter MS revenues  excluding Ocrevus royalties  were almost flat over year and we expect fourth quarter performance to have been similar  Biogen receives royalties on U S  sales of Roche s   OTC RHHBY   newly launched MS drug  Ocrevus which is likely to have contributed significantly to the top line  The Zacks Consensus Estimate for Ocrevus royalties is  192 million Among the MS drugs  Tecfidera s U S  revenues are likely to have been supported by patient growth  Meanwhile  ex U S  Tecfidera revenues are likely to have benefited from volumes increases in Europe and Japan in the fourth quarter  which might have offset the impact of ongoing price decreases in certain European countries  U S  sales of another MS drug  Tysabri may have been hurt by Ocrevus launch The Zacks Consensus Estimate for sales of Tecfidera in the fourth quarter is pegged at  1 13 billion while that for Tysabri is  466 million Meanwhile  combined interferon revenues  Avonex and Plegridy  are likely to have declined due to transition of patients to other oral or high efficacy MS therapies as well as higher discounts and allowance Spinraza sales are likely to have been driven by continued patient growth in U S  markets across both mature and new markets and strong performance in established markets such as EU and Japan in ex U S  segment  The Zacks Consensus Estimate for sales of Spinraza is  549 million On the third quarter conference call  Biogen had said that it witnessed some negative impact of Novartis  new SMA treatment  Zolgensma s launch on Spinraza s U S  sales in this segment  Zolgensma is approved to treat children under two years old  which represents about 5  of the prevalent market  An update is expected on the fourth quarter conference call Interestingly  biosimilars contributed significantly to Biogen s top line in the first three quarters of 2019 driven mainly by Imraldi s launch  a trend that most likely continued in the fourth quarter  The Zacks Consensus Estimate for sales of biosimilars is  201 million Importantly  in October  Biogen revealed controversial plans to pursue U S  regulatory approval of aducanumab based on positive results of a new analysis of larger dataset from the discontinued ENGAGE and EMERGE studies  which became available after the studies were ceased In March  Biogen and Eisai had discontinued ENGAGE and EMERGE following a futility analysis  which relied on an earlier and smaller dataset  Biogen  in October  had said that a new analysis of the larger dataset showed a different outcome than the one predicted at the time of the futility analysis  In October  Biogen said it plans to submit a biologics license application  BLA  seeking approval of aducanumab to the FDA in early 2020 Numerous investor questions are expected on Biogen s timeline for filing the regulatory application for aducanumab on the call Earnings WhispersOur proven model predicts an earnings beat for Biogen in the soon to be reported quarter because it has the right combination of two key ingredients  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for a likely positive surprise Earnings ESP  Biogens Earnings ESP is  3 95  as the Zacks Consensus Estimate of  7 95 is lower than the Most Accurate Estimate of  8 27  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Biogen has a Zacks Rank  3 Other Stocks to ConsiderHere are some other large biotech stocks that also have the right combination of elements to beat on earnings this time around Gilead Sciences   NASDAQ GILD   with an Earnings ESP of  4 45  and a Zacks Rank  3  The company is scheduled to release results on Feb 4  You can see  Alexion   NASDAQ ALXN   has an Earnings ESP of  5 97  and a Zacks Rank  1  The company is scheduled to release results on Jan 30 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained and impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ",2020-01-26,Zacks Investment Research,https://www.investing.com/analysis/can-biogen-biib-keep-the-earnings-streak-alive-in-q4-200501745,200501745
128386,349901,BIIB,Biogen  BIIB  Q4 Earnings   Sales Beat Estimates,opinion,Cambridge  MA based Biogen Inc    NASDAQ BIIB   holds a strong position in the multiple sclerosis   MS   market with a wide range of products including Tysabri and Tecfidera  However  as competition in the MS market intensifies  Biogen is trying to diversify beyond MS to other areas like Alzheimer s  Parkinson s  stroke  among others Biogen s earnings performance has been strong as it delivered a positive surprise in each of the four trailing quarters with the average being 9 3  Currently  Biogen has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  Biogen s fourth quarter 2019 earnings beat expectations  The company posted earnings of  8 34 per share while our consensus called for EPS of  8 00 Revenues Beat  Biogen posted revenues of  3 67 billion  beating the consensus estimate of  3 54 billion  Revenue increased 5  year over year Key Statistics  Revenue growth was principally driven by higher sales of its key multiple sclerosis  MS  drugs  continued global growth of spinal muscular atrophy  SMA  drug  Spinraza  and expansion of biosimilar business Tecfidera sales rose 5  year over year to  1 16 billion  Sales of Spinraza increased 16  year over year to  543 million 2019 Results  Biogen posted full year revenues of  14 4 billion  representing a year over year growth of 7   Earnings per share were up 28  year over year at  33 57 2020 Guidance  Biogen expects full year revenues in 2020 to be in the range of  14  14 3 billion and earnings per share to lie between  31 50 and  33 50 Pre Market Trading  Shares were up 0 6  in pre market trading Check back later for our full write up on this BIIB earnings report later Biogen Inc  Price and Consensus   Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ,2020-01-29,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-q4-earnings--sales-beat-estimates-200503036,200503036
128387,349902,BIIB,Biogen  BIIB  Surpasses Q4 Earnings And Sales Estimates,opinion,"Biogen Inc    NASDAQ BIIB   reported fourth quarter 2019 earnings per share of  8 34  which comprehensively beat the Zacks Consensus Estimate of  8 00  Earnings rose 19  year over year  backed by higher revenues and lower operating expenses Sales of this neuroscience focused biotech came in at  3 67 billion  up 4  from the year ago quarter  Sales also beat the Zacks Consensus Estimate of  3 54 billion Revenue growth was principally driven by higher sales of its key multiple sclerosis   MS   drugs  continued global growth of spinal muscular atrophy   SMA   drug  Spinraza  and expansion of its biosimilar business Quarter in DetailProduct sales in the quarter were  2 9 billion  up 4  year over year  Royalties on sales of Roche s   OTC RHHBY   MS drug  Ocrevus were  205 million in the quarter  up 35  year over year  Though Ocrevus poses strong competition to Biogen s MS drugs  the company receives royalties on U S  sales of Ocrevus from Roche  Revenues from Biogen s share of Rituxan and Gazyva operating profits increased 3  from the year ago period to  395 million  Other revenues declined 12  in the quarter to  146 million Biogen s MS revenues of  2 39 billion in the reporter quarter  including Ocrevus royalties  rose 2  year over year as well as sequentially Tecfidera sales rose 5  year over year to  1 16 billion driven by global revenue growth  Tecfidera global sales were up 3  sequentially  U S  sales in the quarter were  877 million  up 2 4  year over year while ex U S  sales were  284 3 million  up 11 9  Tysabri sales rose 2  year over year but declined 2  sequentially to  473 million  Tysabri U S  sales rose 4 9  to  269 5 million in the quarter  International revenues declined 2  to  203 4 million Combined interferon revenues  Avonex and Plegridy  in the quarter were  516 million  down 14  year over year  Avonex revenues declined 15  from the year ago quarter to  411 million  Plegridy contributed  106 million to revenues  down 9  year over year Sales of Spinraza increased 16  year over year driven by higher sales in the United States as well as ex U S  markets but declined 1  sequentially to  543 0 million Spinraza U S  sales were  243 million in the quarter  up 2 8  year over year  In ex U S  markets  Spinraza sales rose 28 5  year over year to  300 million The number of patients on Spinraza grew approximately 2  in the United States and 10  outside the United States sequentially Samsung  KS 005930  Bioepis  the joint venture between Biogen and Samsung BioLogics  markets three anti TNF biosimilars in the EU   Flixabi  a biosimilar referencing J J   NYSE JNJ   Merck s Remicade   Benepali  a biosimilar referencing Amgen Pfizer s Enbrel  and Imraldi  a biosimilar referencing AbbVie s    NYSE ABBV    Humira   Imraldi generated sales of  52 million in the fourth quarter compared with  49 million in the third quarter  Benepali recorded sales of  126 million in the quarter  up 1  year over year  Flixabi sales of  18 million rose 29  year over year  During the quarter  the company acquired commercialization rights to biosimilars referencing two eye drugs   Roche s Lucentis and Regeneron s Eylea Research and development  R D  expenses declined 15  year over year to  692 million  Selling  general and administrative  SG A  expenses were down 12  year over year to  662 million Full Year ResultsThe company reported 2019 earnings per share of  33 57  which beat the Zacks Consensus Estimate of  33 20  Earnings rose 28  year over year  backed by higher revenues  lower tax rate and lower operating expenses Revenues came in at  14 38 billion  which increased 7  year over year and exceeded the Zacks Consensus Estimate of  14 24 billion 2020 GuidanceBiogen expects revenues of  14  14 3 billion  Earnings per share are expected between  31 50 and  33 50 The Zacks Consensus Estimate for revenues and earnings currently stands at  14 1 billion and  32 98 per share  respectively Our TakeBiogen beat estimates for both earnings and sales in the fourth quarter  However  guidance for 2020 suggests a year over year decline in revenues as well as earnings  In the past year  Biogen s shares have declined 15 4  compared with the  s decrease of 5 6  in the same time frame  We like Biogen s efforts to regularly in license assets to build its pipeline  Several of these assets have transformative potential  The company expanded its pipeline to include seven new candidates targeting multiple indications  In October 2019  the company received approval for a new MS Drug  Vumerity  Moreover  its plans to file regulatory application for Alzheimer s disease candidate  aducanumab  looks promising However  Biogen is heavily reliant on sales of its drugs for MS  which is a highly competitive disease space  Also  potential competition to Spinraza from Novartis  oral gene therapy for SMA Type 1  Zolgensma  which was approved by the FDA for use in children less than 2 years old in May 2019  is a concern Biogen Inc  Price  Consensus and EPS Surprise
    Zacks RankBiogen currently carries a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ",2020-01-29,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-surpasses-q4-earnings-and-sales-estimates-200503230,200503230
128388,349903,BIIB,Biotech Stock Roundup  Earnings Updates From VRTX  AMGN  GILD  AIMT Gains FDA Nod ,opinion,"It was a busy week for the biotech sector as many big biotechs came out with their fourth quarter results  While Vertex Pharmaceuticals   NASDAQ VRTX   and Biogen   NASDAQ BIIB   reported impressive results  Gilead Sciences   NASDAQ GILD   missed on earnings yet again  Meanwhile  Aimmune   NASDAQ AIMT   surged on the FDA approval of its allergy drug Recap of the Week s Most Important Stories Earnings Updates From Bigwigs  Quite a few big biotech players came out with fourth quarter results  and came out with strong numbers for the fourth quarter  beating both sales and earnings expectations  However  both companies issued a disappointing 2020 outlook Vertex Pharmaceuticals Inc  also  on both metrics and provided an encouraging outlook for the next quarter  Strong cystic fibrosis product revenues led to higher earnings in the reported quarter  Biogen both earnings and sales estimates in the fourth quarter  driven by higher sales of key multiple sclerosis drugs  continued global growth of spinal muscular atrophy drug  Spinraza  and the expansion of its biosimilar business  Gilead reported mixed results  beating sales estimates on a strong HIV franchise  However  it missed on earnings and the outlook for 2020 was disappointing as well Vertex currently carries a Zacks Rank  2  Buy   You can see  United Therapeutics Announces Disappointing Data  United Therapeutics   NASDAQ UTHR   announced disappointing top line results from the phase II III DISTINCT study  evaluating Unituxin  dinutuximab  injection added to irinotecan compared to irinotecan or topotecan alone in patients with relapsed or refractory small cell lung cancer  SCLC   The study did not meet its primary efficacy objective of extending the overall survival with Unituxin and irinotecan versus irinotecan alone  The company is also seeking a label expansion for Unituxin in combination with irinotecan and temozolomide for the treatment of pediatric patients with relapsed or refractory neuroblastoma  United Therapeutics plans to meet with the FDA to discuss the proposed label expansion in the first half of 2020 and file a supplemental BLA shortly thereafter Aimmune s Peanut Allergy Drug Approved  Aimmune Therapeutics announced that the FDA approved its oral immunotherapy Palforzia  for the treatment of patients with peanut allergy  Palforzia is designed to reduce the incidence and severity of allergic reactions  including anaphylaxis  which may occur due to an accidental exposure to peanut  The drug is to be administered in conjunction with a peanut avoidant diet and only in patients with a confirmed diagnosis of peanut allergy  Per the company  initial dose escalation may be administered to patients aged from four to 17 years and up dosing and maintenance may be continued in patients aged four years and above Regeneron Expands Collaboration for New Coronavirus  Regeneron Pharmaceuticals  Inc    NASDAQ REGN   announced an expanded agreement with the U S  Department of Health and Human Services  HHS  to develop new treatments combating the novel coronavirus  2019 nCoV   The company has several active collaborations with HHS s Biomedical Advanced Research and Development Authority  The HHS and Regeneron Other Transaction Agreement is mainly focused on the discovery  research  development and manufacturing of a portfolio of antibodies targeting up to 10 pathogens that pose significant risk to public health  This now includes the Influenza virus and 2019 nCoV Performance    Medical   Biomedical and Genetics Industry 5YR   Return
 The Nasdaq Biotechnology index gained 1 03  in the last five trading sessions  Among the biotech giants  Gilead gained 4 72  in the period  Over the past six months  shares of Vertex have gained 36 51    See the last biotech stock roundup here     What s Next in Biotech Stay tuned for more earnings updates Biggest Tech Breakthrough in a GenerationBe among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity  Current technology will soon be outdated and replaced by these new devices  In the process  it s expected to create 22 million jobs and generate  12 3 trillion in activity A select few stocks could skyrocket the most as rollout accelerates for this new tech  Early investors could see gains similar to buying Microsoft  NASDAQ MSFT  in the 1990s  Zacks  just released special report reveals 8 stocks to watch  The report is only available for a limited time ",2020-02-05,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-earnings-updates-from-vrtx-amgn-gild-aimt-gains-fda-nod-200504863,200504863
128389,349904,BIIB,Better Buy  Gilead Sciences vs  Biogen,news,"Gilead Sciences  NASDAQ GILD  and Biogen  NASDAQ BIIB  are two cheap stocks for healthcare investors to consider today  Neither stock has performed particularly well over the past few years  and both have significant question marks  They re risky buys  but if they perform well in 2020  their share prices could take off  Let s take a look at which one is the better buy for not just this year  but for the long term as well 
Will Gilead s pipeline be enough to save the crashing stock 
In five years  Gilead s share price has fallen by more than 35   and over the past 12 months its returns have been flat  In contrast  the Health Care Select Sector SPDR Fund has risen by 45  in five years and increased by 22  in the last year  Gilead s been an underperformer for years  as not only have its sales been shrinking from  32 6 billion in 2015 to just  22 1 billion in 2018  but profitability has also fallen from  18 1 billion to  5 5 billion during that time 
While HIV product sales of  14 6 billion in fiscal 2018 rose by 12  from the prior year and are up 25  in two years  there s been a more profound decline in the sale of Harvoni during that time  Harvoni treats patients who have Hepatitis C  and in 2016 its product sales totaled  9 1 billion  The drug then declined to just  1 2 billion in 2018  decreasing more than 86  in only two years  The change in Gilead s product mix is also likely the reason for the change in its product gross margin  which in 2016 was 86  and is now at 78   Falling sales along with a declining gross margin only make it more difficult for the company to cover rising expenses 

The company needs new products to help turn around its numbers and inject some growth into its financials  The problem is that although it has many products it is working on with more than 100 active clinical studies  it s too early to tell if any one of those will be able to generate the sales needed to make Gilead an attractive buy  Outside of its HIV products  only two    Harvoni and Epclusa    had sales of more than  1 billion in fiscal 2018  New products are great for growth  but finding a winner is easier said than done 
Is Biogen too dependent on the success of one drug 
Biogen is another stock that s struggled in recent years  but its decline has been more modest than Gilead s  falling 14  in five years and just 4  over the past 12 months  However  the stock dropped  100 last March when the company scrapped trials relating to its key Alzheimer s drug  aducanumab  which did not have encouraging results  The company did not believe it was likely to pass late stage trials  Biogen s stock dropped from  320 to below  220 in just two days 
However  in October  the company flipped the script and said it was going to seek approval for the drug in the U S  after additional data showed that one of the trials was successful  While the reversal did not entirely make up for the losses the stock incurred in March  it did help rally the share price  which closed 2019 just short of  300 
The problem for Biogen investors is that they need good news from aducanumab or the stock could be headed back down in a hurry  Over the past nine months  the company s sales have grown by just 4 9  from the same prior year period  While multiple sclerosis product sales during the past nine months of  6 3 billion continue to make up the bulk  75   of the company s sales  they re also down from the prior year when sales were  6 4 billion  Spinal muscular atrophy drug sales of  1 6 billion from Spinraza represent the only other segment that has more than  1 billion in revenue  While sales from the segment have risen an encouraging 24  in one year  Biogen needs more than that to stimulate its long term growth 
Gilead s diversification makes it the better stock
Both of these healthcare stocks pose risks for investors today  Valuation multiples can change rapidly for either company depending on how their new drugs do  and that s why Biogen trading at less than 11 times earnings compared to Gilead trading at 31 times shouldn t be the only metric that investors consider today  
Biogen has more overall risk and dependency on aducanumab  which makes it hard to justify buying the stock today  While a good trial result will certainly help improve the company s prospects  it s proven to be too volatile with respect to the success of just one drug  That s why Gilead  despite trading at a higher earnings multiple and being the more expensive stock of the two  may be a better long term buy since all of its hopes aren t in just one basket ",2020-01-05,The Motley Fool,https://invst.ly/pduoe,2052555
128390,349905,BIIB,Better Buy  AbbVie vs  Biogen,news,"AbbVie  NYSE ABBV  and Biogen  NASDAQ BIIB  are two pharma stocks that haven t performed well lately  Over the last 12 months  AbbVie s shares are down by 2   while Biogen s stock is down by 10   By contrast  the pharmaceutical industry    as measured by the SPDR S P Pharmaceuticals Index    is up by 14  over the same period 
However  2020 could be very different for both companies  as AbbVie is hoping its acquisition of Allergan  NYSE AGN  pays off  while Biogen is putting its hopes on its potential drug for Alzheimer s disease  AD   aducanumab  With that in mind  let s see which of these two companies is the better buy today  
AbbVie isn t dead in the water yet
Humira remains AbbVie s top selling drug  However  Humira has been facing stiff competition from biosimilars in Europe  and the international sales of the drug have declined as a result  Beyond Humira  the company can count on such products as cancer drugs Venclexta and Imbruvica  as well as Skyrizi  a medicine for moderate to severe plaque psoriasis 

AbbVie s revenue growth has been crawling in recent quarters  During the third quarter  the company reported net revenue of  8 5 billion  a meager 3 5  increase year over year  Humira s net revenue was  4 9 billion  a 3 7  decrease compared to the prior year quarter  This was because Humira s international revenue declined by 33 5  year over year 
And while sales of Imbruvica increased by 29 3  year over year  and sales of Venclexta grew by 130   revenue from these products is unlikely to be enough to offset Humira s decreasing sales  This is precisely why AbbVie is acquiring Allergan in an all cash transaction valued at  63 billion  Once this transaction closes    which is expected to happen in early 2020    AbbVie will become a leader in the medical aesthetics market 
AbbVie CEO Richard Gonzalez said  

With the planned acquisition of Allergan  we will be adding highly valuable on market assets with leadership positions across additional and attractive growth segments including significant new growth platforms in medical aesthetics and CNS  Central Nervous System  

Gonzalez also touted the value of the most important asset the company will be acquiring in this transaction  namely Botox    B ased on the uniqueness of this particular molecule  we have come to the conclusion that it would be extremely difficult to create a biosimilar version of Botox and I would tell you  we looked at this very extensively with a lot of outside expertise and we feel very confident that that s the case   In other words  AbbVie s future after Humira may not look so bleak after all  
Biogen s hopes rest on aducanumab
Biogen s current top selling product is multiple sclerosis  MS  drug Tecfidera  The company s lineup also includes MS drug Tysabri  a treatment for spinal muscular atrophy  and Flixabi  a biosimilar for rheumatoid arthritis 
Much like AbbVie  Biogen s financial results haven t been particularly impressive recently  During the third quarter  the company s revenue was  3 6 billion  a mediocre 5  increase compared to the year ago period  Most notably  sales of Tecfidera only increased by 3  year over year  Biogen s bright spot during the quarter was Spinraza  whose sales increased by 17  compared to the prior year quarter  But Biogen s MS segment    its largest medical segment by revenue    continues to struggle to generate stellar top line growth  and the company is looking elsewhere for a boost  
That s where aducanumab comes in  Before investors place their hopes in this potential blockbuster drug for AD  though  it is essential to review its history  Biogen first announced it was abandoning the development of aducanumab in March because monthly doses of the AD drug failed to prove their efficacy in a pivotal late stage trial  But in October  Biogen argued that a few more monthly doses of aducanumab were shown to be effective in treating AD after all  and the company decided to bring aducanumab back from the dead 
Biogen is hoping to send aducanumab to the U S  Food and Drug Administration for approval sometime this year  and if all goes well  the company will receive approval for this potential blockbuster medicine later in the year  However  whether things will work out as planned for Biogen is far from being a foregone conclusion 
Which stock is the better buy 
Both AbbVie and Biogen are attractively valued  Biogen s forward price to earnings  PE  ratio is 8 87  and its price to earnings to growth  PEG  ratio is 1 72  AbbVie  with its  forward PE of 9 10 and its PEG of 2 74  is slightly less attractive   
However  AbbVie is a more attractive dividend stock  The company currently offers a juicy 5 3  dividend yield  and AbbVie has raised its quarterly dividend payouts by 141  over the past five years  By contrast  Biogen currently does not return cash to its shareholders by way of dividends 
With that said  I think AbbVie looks like the better option right now  While the company s sales of Humira will continue to decline  Humira alone generated more revenue than Biogen s entire lineup during the last quarter   4 9 billion versus  3 6 billion   Further  AbbVie s acquisition of Allergan will bring more diversification to its revenue stream  By contrast  Biogen s future is hanging on aducanumab  and if the FDA does not approve the AD drug  the company s shares will likely come crashing down  again   and its future will look bleak ",2020-01-08,The Motley Fool,https://invst.ly/pfdht,2054802
128391,349906,BIIB,Biogen to acquire neurological disease candidate from Pfizer,news,"Biogen  NASDAQ BIIB  has agreed to acquire Pfizer s  NYSE PFE  PF 05251749  a novel CNS penetrant small molecule casein kinase 1  CK1  inhibitor  for the potential treatment of behavioral and neurological symptoms associated with a range of psychiatric and neurological disorders 
It plans to develop the asset for the treatment of sundowning  late day confusion  in Alzheimer s disease and irregular sleep wake rhythm disorder in Parkinson s disease  A Phase 1b trial should launch in Q4 
Under the terms of the agreement  Biogen will pay Pfizer  75M upfront  up to  635M in milestones and tiered high single digit to sub teen royalties on net sales 
Biogen expects to close the transaction later this quarter 
BIIB is down 1  premarket while PFE is up a fraction ",2020-01-13,Seeking Alpha,https://invst.ly/phc80,2057900
128392,349907,BIIB,Biogen Buys Azheimer s and Parkinson s Drug From Pfizer,news,"Biogen  NASDAQ BIIB  announced it has reached an agreement with Pfizer  NYSE PFE  to buy a drug in early development that is designed to treat debilitating symptoms related to the disruption of daily rhythms in patients with Alzheimer s and Parkinson s disease  The pipeline drug  PF 05251749  is for the treatment of Sundowning  a condition affecting 20  of Alzheimer s patients that causes confusion and anxiety late in the day  and Irregular Sleep Wake Rhythm Disorder  which causes fragmented nighttime sleep in Parkinson s sufferers 
Biogen will pay  75 million up front for rights to the drug  up to  635 million in additional milestone payments as it develops and commercializes it  and tiered royalties on sales from high single digits to the low teens 

Pfizer spun off its drug candidates for central nervous system  CNS  disorders in 2018 to create Cerevel Therapeutics  jointly owned with Bain Capital  but PF 05251749 apparently didn t make the cut and was put up for sale at a low price  The drug was evaluated before the spin off in two Phase 1A clinical trials that yielded positive safety results but no data on efficacy 
Biogen intends to initiate a phase 2B study of PF 05251749 in the fourth quarter of 2020 as part of its effort to grow its assets in CNS drugs  In October  Biogen stunned investors when it reversed itself on Alzheimer s drug aducanumab  saying it will file for approval of the drug with the U S  Food and Drug Administration in early 2020 after having given up on it earlier in 2019  The biotech company also has another Alzheimer s drug  BAN2401  in late stage testing that uses an approach similar to that of aducanumab ",2020-01-13,The Motley Fool,https://invst.ly/phj5x,2058393
128393,349908,BIIB,Why Biogen Stock Slumped Last Year,news,"What happened
Biotech heavyweight Biogen  NASDAQ BIIB  failed to follow the broader industry higher last year  Despite biotech stocks at large posting market beating gains in 2019  Biogen s shares actually lost 1 4  of their value last year  according to data from S P Global Market Intelligence  
So what
Biogen s stock lost ground for three key reasons in 2019 

The company s core multiple sclerosis franchise essentially flatlined from a revenue generation standpoint  
Although Biogen did reel off a handful of important business development deals in 2019  the company didn t pursue a bolt on acquisition that would immediately change its near term outlook  
Biogen s decision to pursue a regulatory approval for its controversial Alzheimer s disease drug candidate  aducanumab  failed to win over the whole of the investing community  Most industry insiders  in fact  think that the Food and Drug Administration will ultimately reject the drug  


Now what
Even though Biogen hasn t even filed for aducanumab s approval  the biotech is reportedly already gearing up for the drug s potential launch  That s a rather surprising move  given that aducanumab faces an uphill battle on the regulatory front 
The key takeaway  though  seems to be that management probably won t pull the trigger on a major acquisition in 2020  Avoiding the numerous pitfalls associated with costly merger and acquisition deals could turn out to be a stroke of genius    that is  if regulators unexpectedly give the thumbs up to aducanumab 
But the flip side is that Biogen will be behind the eight ball in terms of business development in the event that aducanumab turns out to be a dead end  Therefore  investors may want to take a wait and see approach with this large cap biotech stock this year ",2020-01-16,The Motley Fool,https://invst.ly/pivx-,2061160
128394,349909,BIIB,2 Reasons to be Optimistic About Biogen s Alzheimer s Drug,news,"Biogen  NASDAQ BIIB  shocked investors last year when it said it would submit its investigational Alzheimer s drug to the Food and Drug Administration for approval    months after halting studies that showed the drug didn t work 
The biotech company explained its decision to file in early 2020 for regulatory approval  saying a look at broader data renewed its belief in aducanumab  The drug acts by binding to and eliminating beta amyloid  a protein that clings to neurons in the brains of Alzheimer s patients 

Biogen said the earlier data  which didn t meet endpoints and resulted in halting trials  involved giving the drug at lower doses  In patients with a gene variant that increases a side effect risk  researchers started with lower doses  then later increased them when it was deemed safe to do so 
Therefore  that study  called Engage  had fewer participants getting high doses for the full treatment period compared with Emerge  the second study  In Emerge  the high dose of aducanumab reduced clinical decline  while in Engage  only the subset of patients given high doses showed the same result 
Though this newer data left doubts among some scientists and investors  there are two reasons to be optimistic about a possible FDA approval 
1  The FDA has been approving more and more drugs
In 2019  the FDA approved 48 novel drugs  While down from the total of 59 approved in 2018  it still is well above the 10 year average of about 38 
The number of approvals has more than doubled since 2010  and with the exception of a couple of dips  the approval numbers have been on an upward trajectory for most of the decade 
Why is the FDA approving so many drugs  The answer to that question leads us to the second reason to be optimistic about Biogen s aducanumab 
2  The Alzheimer s drug is a treatment for an unmet need
The FDA faces the dilemma of whether to approve a much needed drug based on weaker data due to market need  or wait until clinical outcomes are met 
Often  the FDA bases a decision on  surrogate  endpoints  which measure quicker to establish elements like tumor shrinkage in the case of cancer drugs  rather than clinical outcomes like survival or disease free status 
Clinical outcomes take more time to meet  which has the result of denying an entire patient population access to a drug that could be life changing or lifesaving   The FDA has increasingly accepted less data and more surrogate measures  and has shortened its review times   according to a recent paper in The Journal of the American Medical Association 
Biogen s aducanumab  if approved  would be the first drug on the market to reduce clinical decline in Alzheimer s disease 
According to the Alzheimer s Association  5 8 million Americans are living with the disease  In trials  the Biogen drug showed benefits in areas of memory  orientation  language  and daily activities 
But some analysts and physicians argue that the data falls short of meeting the FDA s requirement of  substantial evidence  of effectiveness 
Evaluate s Vantage 2020 report  which says the FDA s accommodating position on approvals is likely to last  predicts the aducanumab decision could confirm exactly how flexible the FDA will continue to be in future cases 
The Vantage report said a nod from regulators might be seen as  a Sarepta  NASDAQ SRPT  2 0 and a further demise in standards of evidenced based medicine   The FDA drew criticism in 2016 when it approved Exondys 51  Sarepta s first drug for Duchenne muscular dystrophy  even though an advisory committee said the drug didn t provide enough proof of efficacy 
The example of Sarepta s drug isn t alone  Last year  the FDA approved Karyopharm Therapeutics s  NASDAQ KPTI  Xpovio for multiple myeloma even though the advisory committee favored waiting for further trial data and recommended postponing an approval  In these cases  as in the case of Biogen s Alzheimer s drug  patients  treatment options are limited    and an FDA refusal could draw ire from patient groups 
What does this mean for investors 
The FDA s decisions and flexibility are indeed reasons to be optimistic about aducanumab  but it still is too early for Biogen and its investors to proclaim victory 
Once Biogen submits aducanumab to the FDA  investors should be on the lookout for the advisory committee s opinion  Though  the FDA doesn t always follow the direction of this panel of experts  the regulatory agency does seriously consider its opinion  A positive opinion from the panel is likely to boost Biogen shares and mitigate the risk of buying the stock 
Conversely  a negative message from the panel is likely to weigh on the shares and shake investor confidence  For the long term investor  Biogen s pipeline makes it a valuable investment  but in the coming months  the aducanumab story may translate into some ups and downs for the shares ",2020-01-21,The Motley Fool,https://invst.ly/pkz9a,2064214
128395,349910,BIIB,Is Biogen Stock a Buy ,news,"Investors who bought shares of Biogen  NASDAQ BIIB  in 2010 or earlier and held onto them have plenty of reason to smile  Biogen has gained more than 390  since 2010  Last year  its portfolio of more than 10 drugs  including partnered therapies  generated  13 5 billion in total revenue 
Investors who are newer to the Biogen story  though  might not be as happy  The stock is down 40  from the high it reached in March 2015  and it finished last year 1 4  lower after the company scrapped development of its Alzheimer s drug aducanumab  but then reinstated the program 

After Biogen s great gains earlier in the last decade and somewhat less impressive performance over the past year or so  investors might wonder about future potential  Are Biogen s biggest stock gains in the past  Not necessarily  Earnings  products  and valuation are three reasons why investors can be optimistic about the shares as a longer term investment 
This year  however  the stock seems set for more volatility as investors bet on whether the Food and Drug Administration will approve aducanumab  Another looming uncertainty is whether the U S  patent office will vote for or against a patent protecting Biogen s billion dollar multiple sclerosis  MS  drug  Tecfidera  in the next few weeks 
Aducanumab driving stock performance
Aducanumab has pretty much taken over Biogen s stock performance since last March  when the company said the Alzheimer s treatment didn t work  ending clinical trials  The shares tumbled 33  on the news and only began to recover when Biogen reversed its decision in October  The company shocked investors when it reinstated the aducanumab program and said it would submit the drug to the FDA for approval in early 2020  Biogen brought the drug back after examining data from a broader set of patients who had access to a higher dose of the product  Higher doses reduced clinical decline  meaning it stemmed the worsening of the disease   the company said  Since that news  the stock has climbed 30  
Once Biogen submits the drug to the FDA  the next catalyst will be when the advisory committee to the regulatory agency offers its opinion on the drug  The FDA doesn t always follow the expert panel s advice but does seriously consider it  Lastly  the final FDA decision will be the ultimate catalyst 
With all eyes focused on aducanumab  the biggest risks for Biogen are a negative opinion from the advisory committee and a rejection from the FDA  The stakes are high  considering the absence of a competitor and size of the market  Currently  there isn t an FDA approved treatment that reduces clinical decline in Alzheimer s disease  which affects 5 8 million Americans  According to Zion Market Research  the global Alzheimer s drug market is expected to generate revenue of  5 7 billion by the end of 2024 
Patent office decision
As for Tecfidera and the patent office decision in the coming days that will either favor Biogen or Mylan  the drugmaker that hopes to bring a generic to market  the stakes are surprisingly not too high  Though SVB Leerink analyst Geoffrey Porges expects Biogen to win  he noted that impact on the shares should be limited  with much of the risk linked to the case priced in at the current level  He predicts shares would gain 5  if Biogen wins and fall 12  if the company loses the review and an appeal 
Setting aside the aducanumab case and the upcoming Tecfidera decision  let s turn to earnings  Though growth has slowed for Biogen s MS drugs as the company faces competition from European rivals Novartis  Sanofi  and Roche  MS drugs represented  2 3 billion in third quarter revenue  a 2  increase year over year  The company surpassed analysts  earnings estimates in the past four quarters and most products are posting sales growth  Spinraza  a treatment for spinal muscular atrophy  gained 17  to  547 million in the quarter  while Biogen s biosimilar portfolio grew sales 36  to  184 million  The pipeline is reason to be positive about future drugs that may eventually compensate for declining revenue from older drugs  Including aducanumab  Biogen has five drugs in phase 3 trials and about 20 in earlier stage trials 
Another plus for Biogen is its valuation  Biogen trades at 10 times earnings  and its price to book value    or the company s market value in relation to the actual value of the business    is 3 7  Both measures are close to the lowest ever for the company  Wall Street analysts advise buying the stock  and considering the average price estimate  Biogen s shares have at least 6 7  upside 
Is Biogen s stock a buy 
From a valuation  earnings  and pipeline perspective  Biogen is a buy    for investors who are either very short term or who are in this for the long haul  Here s why  There will be bumps along the road until the FDA issues a decision on aducanumab  Biogen expects to submit the drug early this year  then approval could take about six to 10 months  Investors who buy and sell on a day to day basis could benefit from fluctuations  and investors who believe in the Biogen story and hope to hold onto the shares well past the aducanumab decision likely will reap rewards from the company s sales growth over the long term    with or without the Alzheimer s drug  But investors who want to buy shares now with the idea of selling in a few months may face a lot more risk ",2020-01-25,The Motley Fool,https://invst.ly/pms85,2067754
128398,349913,BIIB,Canaccord likes Biogen in premarket analyst action,news,"Relmada Therapeutics  NASDAQ RLMD  initiated with Buy rating and  75  73  upside  price target at Jefferies 
Biogen  NASDAQ BIIB  upgraded to Buy with a  360  29  upside  price target at Canaccord Genuity citing the potential FDA nod for aducanumab in Alzheimer s  Shares down 1  premarket 
Denali Therapeutics  NASDAQ DNLI  upgraded to Buy with a  37  50  upside  price target at Goldman Sachs  Shares up 1  premarket 
Intuitive Surgical  NASDAQ ISRG  downgraded to Hold at Deutsche Bank  Shares down 3  premarket 
Medpace Holdings  NASDAQ MEDP  downgraded to Hold with an  87  1  downside risk  price target at SunTrust 
Mylan N V   NASDAQ MYL  downgraded to Market Perform with a  24  10  upside  price target at SVB Leerink  Shares down 4  premarket 
Tivity Health  NASDAQ TVTY  downgraded to Neutral at Piper Sandler ",2020-01-27,Seeking Alpha,https://invst.ly/pne7j,2068371
128416,349931,BIIB,Biotech Stock Roundup  AMRN Stock Up  Pipeline Updates From GILD  BIIB  AMGN   More,opinion,"Quite a few biotech companies came out with pipeline and regulatory updates this week  While Amarin   NASDAQ AMRN   gained on a label expansion for its key drug  Amgen   NASDAQ AMGN   won approval for its osteoporosis drug in Europe  Both Gilead Sciences  Inc    NASDAQ GILD   and Biogen   NASDAQ BIIB   came out with pipeline updates 
Recap of the Week s Most Important Stories 
Gilead Announces Top Line Results From NASH Study  Gilead announced mixed top line results from the mid stage study on combination and monotherapy of investigational treatments for advanced fibrosis  F3 F4  due to nonalcoholic steatohepatitis  NASH  
The 48 week  phase II ATLAS randomized  double blind  placebo controlled study evaluated the safety and efficacy of monotherapy and dual combination regimens of the nonsteroidal farnesoid X receptor  FXR  agonist cilofexor 30 mg  the acetyl CoA carboxylase  ACC  inhibitor firsocostat 20 mg and selonsertib 18 mg in patients with advanced fibrosis  F3 F4  due to NASH 
The results showed that the investigational regimens did not lead to a statistically significant increase in the proportion of patients who achieved the primary efficacy endpoint of a  1 stage improvement in fibrosis without worsening of NASH 
Earlier  Gilead s Kite and Kiniksa Pharmaceuticals  Ltd    NASDAQ KNSA   entered a clinical collaboration to conduct a phase II  multicenter study on pipeline candidate mavrilimumab in combination with CAR T cell therapy Yescarta  The objective of the study is to determine the effect of mavrilimumab on the safety of Yescarta 
Concurrently  Kite submitted a Biologics License Application  BLA  to the FDA for the investigational CAR T cell therapy  KTE X19  for the treatment of adult patients with relapsed or refractory mantle cell lymphoma  MCL  
Biogen s Gosuranemab Fails in Phase II Brain Disorder Study  Biogen announced that its phase II study   PASSPORT   evaluating pipeline candidate  gosuranemab  BIIB092   in patients with progressive supranuclear palsy  PSP  failed to meet its primary endpoint   Data from the study showed that improvement in PSP patients treated with gosuranemab as measured by PSP rating scale at week 52 was not statistically significant 
Moreover  the candidate failed to demonstrate efficacy in patients on key clinical secondary endpoints  Based on these data  the company has decided to discontinue further development of the candidate for PSP and other primary tauopathies 
However  Biogen stated that it will continue the development of gosuranemab for treating mild cognitive impairment due to Alzheimer s disease  Currently  the candidate is being evaluated in the phase II TANGO study for this indication 
Amarin Up on FDA Approval of Vascepa Label Expansion  Shares of Amarin Corporation gained after the company announced that the FDA approved a label expansion of Vascepa  Vascepa is now approved as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction  stroke  coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride  TG  levels   150 mg dL  and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease 
The label expansion should significantly boost sales as  per estimates  millions of high risk patients in the United States could benefit from this one of a kind prescription therapy  Vascepa will be a new FDA approved treatment option to reduce the persistent cardiovascular risk faced by many patients despite the use of statins with other contemporary standard of care therapies 
Amgen s Evenity Gets Approval in Europe  Amgen and partner UCB announced that the European Commission  EC  has granted marketing authorization to Evenity  romosozumab  for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture  The approval was supported by the positive opinion given by the Committee for Medicinal Products for Human Use  CHMP  in October 
The drug is expected to be launched in Europe in the first half of 2020  Evenity was approved in April by the FDA  It is the first and only approved drug for osteoporosis to increase bone mineral density   BMD   and reduce the risk of fracture 
Alexion Exercises Option for Two Additional RNAi Programs  Alexion   NASDAQ ALXN   announced that it has exercised its option for exclusive rights to two additional targets within the complement pathway for the discovery and development of GalXC RNAi molecules under its collaboration with Dicerna Pharmaceuticals  As a result  Alexion will pay Dicerna a total of  20 million  or  10 million in option exercise fees per additional target 
Both companies collaborated in October 2018 for the discovery and development of subcutaneously delivered GalXC RNAi molecules directed to a total of four complement pathway targets for the treatment of complement mediated diseases  Dicerna is leading the joint discovery and research efforts through the preclinical stage  while Alexion will lead development efforts beginning the phase I studies 
Alexion currently carries a Zacks Rank  2  Buy   You can see  
PerformanceMedical   Biomedical and Genetics Industry 5YR   Return
 

 
The Nasdaq Biotechnology index inched up 0 64  in the last five trading sessions  Among the biotech giants  Amgen gained 3 85  in the period  Over the past six months  shares of Amgen have gained 38    See the last biotech stock roundup here  See the last biotech stock roundup here   

 
What s Next in Biotech 
Stay tuned for more pipeline updates 
7 Best Stocks for the Next 30 Days
Just released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  
Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ",2019-12-18,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-amrn-stock-up-pipeline-updates-from-gild-biib-amgn--more-200493589,200493589
128417,349932,BIIB,The Zacks Analyst Blog Highlights  Amarin  Amgen  Gilead Sciences  Biogen And Kiniksa Pharmaceuticals,opinion,For Immediate ReleaseChicago  IL   December 19  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Amarin   NASDAQ AMRN    Amgen   NASDAQ AMGN    Gilead Sciences  Inc    NASDAQ GILD    Biogen   NASDAQ BIIB   and Kiniksa Pharmaceuticals  Ltd    NASDAQ KNSA   Here are highlights from Wednesday s Analyst Blog  Biotech Stock Roundup  AMRN  GILD  BIIB and MoreQuite a few biotech companies came out with pipeline and regulatory updates this week  While Amarin gained on a label expansion for its key drug  Amgen won approval for its osteoporosis drug in Europe  Both Gilead Sciences  Inc  and Biogen came out with pipeline updates Recap of the Week s Most Important Stories Gilead Announces Top Line Results From NASH Study  Gilead announced mixed top line results from the mid stage study on combination and monotherapy of investigational treatments for advanced fibrosis  F3 F4  due to nonalcoholic steatohepatitis  NASH  The 48 week  phase II ATLAS randomized  double blind  placebo controlled study evaluated the safety and efficacy of monotherapy and dual combination regimens of the nonsteroidal farnesoid X receptor  FXR  agonist cilofexor 30 mg  the acetyl CoA carboxylase  ACC  inhibitor firsocostat 20 mg and selonsertib 18 mg in patients with advanced fibrosis  F3 F4  due to NASH The results showed that the investigational regimens did not lead to a statistically significant increase in the proportion of patients who achieved the primary efficacy endpoint of a  1 stage improvement in fibrosis without worsening of NASH Earlier  Gilead s Kite and Kiniksa Pharmaceuticals  Ltd  entered a clinical collaboration to conduct a phase II  multicenter study on pipeline candidate mavrilimumab in combination with CAR T cell therapy Yescarta  The objective of the study is to determine the effect of mavrilimumab on the safety of Yescarta Concurrently  Kite submitted a Biologics License Application  BLA  to the FDA for the investigational CAR T cell therapy  KTE X19  for the treatment of adult patients with relapsed or refractory mantle cell lymphoma  MCL  Biogen s Gosuranemab Fails in Phase II Brain Disorder Study  Biogen announced that its phase II study   PASSPORT   evaluating pipeline candidate  gosuranemab  BIIB092   in patients with progressive supranuclear palsy  PSP  failed to meet its primary endpoint   Data from the study showed that improvement in PSP patients treated with gosuranemab as measured by PSP rating scale at week 52 was not statistically significant Moreover  the candidate failed to demonstrate efficacy in patients on key clinical secondary endpoints  Based on these data  the company has decided to discontinue further development of the candidate for PSP and other primary tauopathies However  Biogen stated that it will continue the development of gosuranemab for treating mild cognitive impairment due to Alzheimer s disease  Currently  the candidate is being evaluated in the phase II TANGO study for this indication Amarin Up on FDA Approval of Vascepa Label Expansion Shares of Amarin Corporation gained after the company announced that the FDA approved a label expansion of Vascepa  Vascepa is now approved as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction  stroke  coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride  TG  levels   150 mg dL  and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease The label expansion should significantly boost sales as  per estimates  millions of high risk patients in the United States could benefit from this one of a kind prescription therapy  Vascepa will be a new FDA approved treatment option to reduce the persistent cardiovascular risk faced by many patients despite the use of statins with other contemporary standard of care therapies Amgen s Evenity Gets Approval in Europe  Amgen and partner UCB announced that the European Commission  EC  has granted marketing authorization to Evenity  romosozumab  for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture  The approval was supported by the positive opinion given by the Committee for Medicinal Products for Human Use  CHMP  in October The drug is expected to be launched in Europe in the first half of 2020  Evenity was approved in April by the FDA  It is the first and only approved drug for osteoporosis to increase bone mineral density   BMD   and reduce the risk of fracture PerformanceMedical   Biomedical and Genetics Industry 5YR   ReturnThe Nasdaq Biotechnology index inched up 0 64  in the last five trading sessions  Among the biotech giants  Amgen gained 3 85  in the period  Over the past six months  shares of Amgen have gained 38    See the last biotech stock roundup here  See the last biotech stock roundup here  Biotech Stock Roundup  ASH Data in Focus  Amgen Gets FDA Nod to Remicade Biosimilar What s Next in Biotech Stay tuned for more pipeline updates 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention See 7 handpicked stocks now   Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-12-18,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-amarin-amgen-gilead-sciences-biogen-and-kiniksa-pharmaceuticals-200493834,200493834
128423,349938,BIIB,Biogen s secret campaign to bring its Alzheimer s drug back from the ashes,news,"By Julie Steenhuysen
CHICAGO  Reuters    Biogen Inc s  O BIIB  shock decision this week to bring its experimental Alzheimer s drug back from the scrap heap was born out of  top secret  meetings  non disclosure agreements and six months of hashing over trial data with scientists  regulators and statisticians  researchers told Reuters 
Biogen had announced in March that it would terminate two large clinical trials of aducanumab because they were likely to fail  Within weeks  a group of company researchers set out to understand what went wrong 
As they studied data from a larger pool of patients who received the drug  they began to question that conclusion 
In the months that followed  Biogen kept its own trial investigators and committee overseeing the trial in the dark about the possibility that some patients had benefited from high doses of the therapy  researchers told Reuters 
The company said it brought in outside Alzheimer s experts and statisticians to help it parse the new findings  and sought feedback from U S  regulators on whether it could be considered for approval 
The result  made public on Tuesday  was an astounding reversal  Biogen will seek U S  approval for the therapy early next year  once again raising hopes for patients suffering from the brain wasting disease  Biogen shares gained 27  on investor hopes for a multibillion dollar blockbuster 
The risks for Biogen remain high  Wall Street analysts cast doubt on whether Biogen s analysis would pass muster with the U S  Food and Drug Administration without an additional years long trial to confirm the findings 
Several Alzheimer s researchers questioned why one trial appeared to succeed  while another with the same design failed 
Many experts say they are reserving judgment until Biogen presents more detailed data in December 
Company executives are reluctant to characterize their interactions with the FDA  but said they worked closely with the agency until they were confident in the findings 
Biogen was only willing to move forward with seeking approval for aducanumab after meeting twice with FDA  The final decision was made immediately after the second of those meetings  which took place on Monday  Biogen officials said 
For the FDA  to say it s reasonable to file an application after two extensive discussions with them  formal meetings as well as a number of informal discussions  I think it s significant   Biogen research chief Al Sandrock said in an interview 
A NAIL IN THE COFFIN
Biogen s earlier decision to terminate the trials was viewed as the final nail in the coffin for the so called  amyloid hypothesis    the theory that removing a protein associated with Alzheimer s could stave off this fatal form of dementia  Many similar drugs had previously failed 
Globally  131 million people are expected to be diagnosed with Alzheimer s by 2050  up from 50 million today  Any successful treatment could be worth  10 billion or more in annual sales  industry analysts say 
The March announcement also raised concerns about a second therapy  BAN2401  that works in a similar way  Biogen is partnering with Japan s Eisai on both drugs 
Ivan Cheung  Eisai s chief executive  said in an interview that he expects aducanumab s revival will energize enrollment in a late stage study of BAN2401  with results expected in 2022  Patients taking the highest dose of BAN2401 showed some encouraging results in a midstage trial last year 
 That s why in the Phase III trial  we are only studying the highest dose   Cheung said 
The two aducanumab trials   Engage and Emerge   started a month apart in 2015  Each had about 1 640 patients  As they progressed  the company made changes in the trial that expanded the number of patients who received a higher dose 
As part of a planned  futility analysis   outside monitors reviewed half of the data as of December 2018 to determine whether the drug had a reasonable chance of success 
 So many of us felt that this might be the drug that would cross the finish line   said Dr  Sharon Cohen  director of the Toronto Memory program  who led one of the studies  In March  she received the answer  the therapy looked like a dud 
However  patients continued to receive treatment in the interim  Cohen believes the fact that some patients got a higher dose for longer helped swing results in the Emerge study  which ultimately showed a benefit 
A CONTRADICTION
A month after announcing the failure  Biogen began analyzing results from both trials  including additional data from patients who later completed treatment 
By the time Biogen had its first FDA meeting in mid June  the company knew that one of the studies had succeeded  and understood that dose was important  said Samantha Budd Haeberlein  who runs Biogen s Alzheimer s program 
 We did a great deal of analysis in close contact with the FDA to really understand what occurred in these trials   Haeberlein said   It took several months to work through that  
During that entire stretch  Cohen said she and fellow investigators were waiting to hear why the drug had failed  They expected a presentation in July during the Alzheimer s Association annual meeting  but none came 
 I was completely unaware of what had been discovered until last Sunday   said Dr  Anton Porsteinsson  a principal investigator for the trials from the University of Rochester School of Medicine and Dentistry  Porsteinsson said Biogen asked him to sign a non disclosure agreement before sharing the new analysis 
Cohen said she first reviewed the new data on Monday in what she called a  top secret  meeting  She said the company wanted a few investigators to hear the findings ahead of Tuesday s announcement  but had concerns about insider trading 
Many still question why only one trial succeeded 
 The signal from the positive trial was kind of convincing   said Mayo Clinic Alzheimer s expert Dr  Ronald Petersen  who has been a paid adviser for Biogen  It showed a 23  reduction in a key measure of cognitive decline 
 But the other study  which was meant to be identical  didn t show it   he said   That s the challenge there  ",2019-10-25,Reuters,https://www.investing.com/news/stock-market-news/biogens-secret-campaign-to-bring-its-alzheimers-drug-back-from-the-ashes-2004238,2004238
128424,349939,BIIB,Charity to pay  4 million to resolve U S  pharma kickback probe,news,"By Nate Raymond
BOSTON  Reuters    A Florida based charity will pay  4 million to resolve claims that it acted as a conduit for companies including Biogen Inc  O BIIB  and  Novartis  AG  S NOVN  to pay kickbacks to Medicare patients using their high priced multiple sclerosis drugs  the U S  Justice Department said on Wednesday 
The settlement with the patient assistance charity The Assistance Fund marked the third so far with a foundation linked to an industry wide probe that has resulted in  850 million in settlements with drugmakers and charities 
TAF like the other foundations provide assistance to patients seeking to pay out of pocket costs for medications and says that since 2009 it has provided assistance to 78 000 people 
TAF did not admit wrongdoing  It said it fully cooperated with the investigators and is committed to operating in full compliance with federal guidelines governing how charities like it can provide assistance to Medicare patients 
Biogen  Novartis and Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA   which the department said also provided the charity money  did not respond to requests for comment or declined to comment 
Drug companies are prohibited from subsidizing co payments for patients enrolled in the government s Medicare healthcare program for those aged 65 and older  Companies may donate to non profits providing co pay assistance as long as they are independent 
But the government has alleged that various drugmakers have used charities like Orlando  Florida based TAF as means to improperly pay the co pay obligations of Medicare patients using their drugs  in violation of the Anti Kickback Statute 
The investigation  led by the U S  Attorney s Office in Boston  came amid growing attention to soaring U S  drug prices  Co pays are partly meant to serve as a check on healthcare expenses by exposing patients to some of a medicine s cost 
The settlement with TAF centered on payments it received from three MS drug manufacturers  Teva  which sells Copaxone  Biogen  which sells Tysabri and Avonex  and Novartis  which sells Gilenya 
The government alleged that TAF engaged in practices that allowed it to coordinate with Teva  Biogen and Novartis from 2011 to 2014 ensure that it used the companies  money to support patients using their respective MS drugs instead of rival ones 
The department said that TAF also solicited and received payments from Teva for the years 2011 to 2015 that correlated with the charity s spending on patients using Copaxone ",2019-11-20,Reuters,https://www.investing.com/news/stock-market-news/charity-to-pay-4-million-to-resolve-us-pharma-kickback-probe-2024780,2024780
128425,349940,BIIB,Wild Biotech Day Sparks  7 6 Billion Shuffle for Neurology Trio,news," Bloomberg     Thursday marked another wild day for biotechnology firms as a highly anticipated presentation from Biogen Inc  NASDAQ BIIB   took the spotlight and results from neurology focused peers triggered huge stock swings amid a flurry of reports 
When the dust settled in afternoon trading  the presentation from Biogen  combined with key study data from Sage Therapeutics Inc  and Acadia Pharmaceuticals Inc   resulted in a combined  7 6 billion shift in value for the three companies  The huge moves were yet another reminder of how biotechnology investing    and  more specifically  betting on drug development for diseases affecting the brain    can often resemble a roulette wheel 
Biogen s standing room only presentation of detailed results for its Alzheimer s disease drug at a California medical meeting initially sank its shares by 5   The stock later rallied to add about  2 billion to the company s market value  Despite Biogen s advance  some analysts on Wall Street were skeptical  including Mizuho s Salim Syed  who called the data  not that impressive  and added that  old questions remain  new ones raised  
For Sage  Thursday s trading action was a day to forget  The Cambridge  Massachusetts based company saw its shares plummet about 60   That was worth a whopping  4 6 billion as some investors quickly pointed out that sales of the company s lone drug on the market are projected to top out at less than  500 million annually  Bloomberg data show 
Acadia  a company focused on developing drugs to address unmet medical needs in central nervous system disorders  was among the day s big winners after data drew praise across Wall Street  The company added a cool  1 billion to its value after presenting better than anticipated data at a conference Wednesday night for patients with dementia 
Small cap drug developer Aurinia Pharmaceuticals Inc   while not focused on neurological diseases  briefly doubled Thursday after promising data ",2019-12-05,Bloomberg,https://www.investing.com/news/stock-market-news/wild-biotech-day-sparks-76-billion-shuffle-for-neurology-trio-2035125,2035125
128426,349941,BIIB,More drugmakers hike U S  prices as new year begins,news,"By Michael Erman NEW YORK  Reuters    Drugmakers including Bristol Myers Squibb Co  N BMY    Gilead Sciences Inc   O GILD   and Biogen Inc  O BIIB  hiked U S  list prices on more than 50 drugs on Wednesday  bringing total New Year s Day drug price increases to more than 250  according to data analyzed by healthcare research firm 3 Axis Advisors  Reuters reported on Tuesday that drugmakers including  Pfizer  Inc  N PFE   GlaxoSmithKline PLC  L GSK  and Sanofi SA  PA SASY  were planning to increase prices on more than 200 drugs in the United States on Jan  1   Nearly all of the price increases are below 10  and the median price increase is around 5   according to 3 Axis  More early year price increases could still be announced  Soaring U S  prescription drug prices are expected to again be a central issue in the presidential election  President Donald Trump  who made bringing them down a core pledge of his 2016 campaign  is running for re election in 2020  Many branded drugmakers have pledged to keep their U S  list price increases below 10  a year  under pressure from politicians and patients  The United States  which leaves drug pricing to market competition  has higher prices than in other countries where governments directly or indirectly control the costs  making it the world s most lucrative market for manufacturers  Drugmakers often negotiate rebates on their list prices in exchange for favorable treatment from healthcare payers  As a result  health insurers and patients rarely pay the full list price of a drug  Bristol Myers said in a statement it will not raise list prices on its drugs by more than 6  this year   The drugmaker raised the price on 10 drugs on Wednesday  including 1 5  price hikes on cancer immunotherapies Opdivo and Yervoy and a 6  increase on its blood thinner Eliquis  all of which bring in billions of dollars in revenue annually  It also raised the price on Celgene s flagship multiple myeloma drug  Revlimid  6   Bristol acquired rival Celgene  NASDAQ CELG  in a  74 billion deal last year  Gilead raised prices on more than 15 drugs including HIV treatments Biktarvy and Truvada less than 5   according to 3 Axis   Biogen price increases included a 6  price hike on multiple sclerosis treatment Tecfidera  according to 3 Axis  Gilead and Biogen could not be immediately reached for comment  
3 Axis advises pharmacy industry groups on identifying inefficiencies in the U S  drug supply chain and has provided consulting work to hedge fund billionaire John Arnold  a prominent critic of high drug prices ",2020-01-01,Reuters,https://www.investing.com/news/stock-market-news/more-drugmakers-hike-us-prices-as-new-year-begins-2050803,2050803
128448,349963,BIIB,Biotech Stock Roundup  CBAY Falls  CCXI Gains  Amgen Acquires Otezla   More,opinion,"It was a busy week for the biotech sector with updates from quite a few companies  While Intercept Pharmaceuticals   NASDAQ ICPT   obtained Priority Review for its New Drug Application  NDA  for NASH drug  CymaBay   NASDAQ CBAY   plunged on termination of NASH study  Amgen   NASDAQ AMGN   upped its guidance after buying Otezla whereas Global Blood Therapeutics   NASDAQ GBT   obtained FDA approval for its SCD drug   Meanwhile  ChemoCentryx   NASDAQ CCXI   soared after it announced positive data from a late stage study on its rare disease candidate Recap of the Week s Most Important Stories Intercept NDA for NASK Drug Gets Priority Review   Intercept Pharmaceuticals  that the FDA has accepted its New Drug Application  NDA  for obeticholic acid  OCA  seeking accelerated nod for the treatment of fibrosis due to nonalcoholic steatohepatitis  NASH   The agency also granted a Priority Review to the same  Notably  the regulatory authority generally grants priority review to drugs with potential to treat a serious condition and if approved  would provide a significant improvement in safety or effectiveness  The FDA set a Prescription Drug User Fee Act  PDUFA  target action date of Mar 26  2020  for the NDA  The agency indicated that it currently plans to hold an advisory committee meeting to discuss the application  However  the date for the meet has not been finalized and the timeline for the NDA review is subject to change CymaBay Plunges on Termination of NASH Study  Shares of CymaBay plummeted significantly after the company announced that it was terminating its phase IIb study of seladelpar in patients with NASH and its recently initiated phase II study of the drug in patients with primary sclerosing cholangitis  PSC   Moreover  it is putting a hold on all studies of seladelpar in patients with primary biliary cholangitis  PBC   The decision to terminate these studies was based on initial histological findings observed in the phase IIb study of seladelpar for NASH after data showed some patients experiencing some liver damage  These planned  blinded  histological assessments of the first tranche of liver biopsies in the study showed atypical histological findings including histology characterized as an interface hepatitis presentation with or without biliary injury Alexion Gets Label Expansion Nod for Soliris in Japan   Alexion Pharmaceuticals    NASDAQ ALXN   Soliris Japan s Ministry of Health  Labour and Welfare s  MHLW  approval for a label expansion  The drug is now approved for neuromyelitis optica spectrum disorder  NMOSD  in adult patients  who are anti aquaporin 4  AQP4  antibody positive  Soliris is the first and the only approved medication for this indication in Japan  The nod was based on comprehensive results from the phase III  randomized  double blind  placebo controlled PREVENT study  Soliris was approved for the treatment of NMOSD in adult patients  who are anti AQP4 antibody positive  by the FDA in June 2019 and the European Commission  EC  in August  Alexion currently carries a Zacks Rank  2  Buy   You can see  Amgen Buys Otezla  Lifts Outlook  Amgen that it has completed the previously declared acquisition of Celgene s blockbuster psoriasis drug Otezla  which the latter had to divest in order to complete its merger with Bristol Myers   Amgen had to pay Celgene  NASDAQ CELG   13 4 billion in cash or approximately  11 2 billion net of anticipated future cash tax benefits for Otezla and certain related assets and liabilities  Otezla is approved to treat psoriasis  psoriatic arthritis and oral ulcers associated with Beh et s diseaseFollowing this buyout  the company raised its overall guidance for 2019  Amgen now expects total revenues in the range of  23 1  23 3 billion  previously expected within  22 8  23 0 billion  Adjusted EPS is expected in the band of  14 5   14 7 compared with the previous range of  14 20 14 45 Biogen Completes Enrollment in Retinal Disorder Study  Biogen   NASDAQ BIIB   announced that it has completed enrollment in the global phase III STAR study on its gene therapy  timrepigene emparvovec  currently being developed to treat choroideremia  CHM   CHM is a rare  inherited retinal disorder that causes progressive loss of vision due to degeneration of the choroid and retina  This mainly affects males  Timrepigene emparvovec  previously BIIB111  was added to Biogen s portfolio in June as part of its acquisition of Nightstar Therapeutics  The STAR study enrolled 170 adult males with CHM  The primary endpoint of the study is the proportion of patients who will experience an improvement of at least 15 letters from baseline in best corrected visual acuity  BCVA  at 12 months post the treatment  as measured by the Early Treatment Diabetic Retinopathy Study  ETDRS  visual acuity protocol Global Blood Gets FDA Approval for SCD Drug   Global Blood Therapeutics that the FDA has approved its lead product candidate Oxbryta  voxelotor  as an oral  once daily treatment for sickle cell disease  SCD  in patients aged 12 years and above  The approval comes almost three months ahead of the scheduled action date of Feb 26  2020   SCD is a chronic  inherited blood disorder that affects hemoglobin levels  Following this nod  Oxbryta became the first approved therapy that directly inhibits sickle hemoglobin polymerization  a major cause for SCD ChemoCentryx Gains on Study Results  ChemoCentryx surged significantly after it announced encouraging top line data from the phase III study ADVOCATE evaluating its orally administered selective complement 5a receptor inhibitor  avacopan  The pivotal study evaluated avacopan in patients with anti neutrophil cytoplasmic antibody associated vasculitis  ANCA vasculitis   a rare disease affecting small blood vessels  Data from the study showed that patients in the study treated with avacopan achieved both primary endpoints of clinical remission at weeks 26 and 52   Clinical remission was statistically superior in the avacopan arm compared to SOC at 52 weeks  The company is planning to file a regulatory application seeking approval for avacopan to treat ANCA vasculitis in the United States and Europe next year Performance    Medical   Biomedical and Genetics Industry 5YR   Return
 The Nasdaq Biotechnology index gained 4 44  in the past five trading sessions  Among the biotech giants  Biogen gained 6 15  in the period  Over the past six months  shares of Amgen have gained 38 73  whereas the Alexion stock has declined 10 61    See the last biotech stock roundup here  See the last biotech stock roundup here   What s Next in Biotech Stay tuned for more pipeline updates Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-11-26,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-cbay-falls-ccxi-gains-amgen-acquires-otezla--more-200488351,200488351
128449,349964,BIIB,3 Best Performing Biotech Funds So Far In 2019,opinion,The biotechnology industry has surpassed the S P 500 so far this year  turning up as one of the best performers this year  The better than average performance of the industry has been mainly driven by mergers and acquisitions  initial public offerings  IPOs   introduction of biosimilars  collaborative operations  rising use of AI and new job opportunities In fact  the major biotech ETFs and indexes have performed impressively so far this year  The SPDR S P Biotech ETF  NYSE XBI  has gained 26 7  year to date  while the ProShares Ultra Nasdaq Biotechnology  BIB  added 38 4  Biotechnology mutual funds are good investment options regardless of how the financial markets are performing  Investors who wish to make the best of the biotechnology industry s gains could consider investing in mutual funds focused on biotechnology companies M As  IPOs   Tie Ups Keep Biotech in the LimelightThe biotechnology sector has been in news since the beginning of 2019  A significant number of companies participated in mergers and acquisitions  In January alone  two major deals were signed  First  Bristol Myers Squibb Company  NYSE BMY  announced that it will acquire Celgene Corporation  NASDAQ CELG   The acquisition was finally completed in November 2019 Takeda Pharmaceutical Company Limited completed the acquisition of Shire in January  In the very next month  Eli Lilly and Company  NYSE LLY  acquired Loxo Oncology  This acquisition extended the scope of the former s oncology portfolio into precision medicines via the addition of an array of highly selective potential medicines for patients that suffer from genomically defined cancers  There were many other such deals announced during the period The number of IPOs has also been vast in 2019  In fact  the numbers have been rising steadily over the last couple of years This is because biotechnology firms call for much financing  particularly when they advance in their research  Going public not only makes it easier to take care of the financing they need but also gives them more visibility in the industry  This may open up opportunities for acquisitions and collaborations later on  thus helping the company The industry was also in news because of a number of collaborations this year  In October  Amgen  NASDAQ AMGN  announced a strategic collaboration with BeiGene to help the former expand its oncology presence in China Earlier this year  Biogen  NASDAQ BIIB  and C4 Therapeutics announced a collaboration to evaluate the use of the latter s novel protein degradation platform  The companies plan to discover and develop treatments for patients with neurological conditions The Future of Biotechnology ShinesAccording to   the size of the biotechnology market was valued at  399 4 billion in 2017  The market is expected to see a compound annual growth rate of 9 9  from 2018 to 2024 Apart from the factors mentioned above  rise in chronic ailments such as cancer  asthma  arthritis and diabetes  healthcare s expanding reach in remote areas  and evolving research and development are instrumental in boosting the biotechnology sector Our ChoicesWe have  therefore  selected three mutual funds that invest in biotechnology companies  All of these funds carry a Zacks Mutual Fund Rank  1  Strong Buy  or 2  Buy   Moreover  these funds have encouraging year to date returns  In addition  the minimum initial investment is within  5 000 We expect these funds to outperform peers in the future  Remember  the goal of the Zacks Mutual Fund Rank is to guide investors to identify potential winners and losers  Unlike most of the fund rating systems  the Zacks Mutual Fund Rank is not just focused on past performance but also on the likely future success of the fund The question here is why should investors consider mutual funds  Reduced transaction costs and diversification of portfolio without several commission charges that are associated with stock purchases are primarily why one should be parking money in mutual funds  read more    Fidelity Select Biotechnology Portfolio  fund aims for capital growth  The fund invests majority of its assets insecurities of companies primarily engaged in the research  development  manufacture and distribution of biotechnological products and services  etc  These companies also gain considerably from scientific and technological advances in biotechnology This Zacks sector   Health product has a history of positive total returns for more than 10 years  To see how this fund performed compared to its category  and other 1 and 2 Ranked Mutual Funds   FBIOX carries a Zacks Rank  1 and has an annual expense ratio of 0 72   which is below the category average of 1 27   It has returned 15 4  on a year to date basis  FBIOX has no minimum initial investment T  Rowe Price Health Sciences Fund  aims for capital appreciation  The fund invests majority of its assets in common stocks of companies that pursue research  development  production or distribution of products or services related to health care  medicine or the life sciences  PRHSX is a non diversified fund This Zacks sector   Health product has a history of positive total returns for more than 10 years  To see how this fund performed compared to its category  and other 1 and 2 Ranked Mutual Funds   PRHSX carries a Zacks Rank  1 and has an annual expense ratio of 0 77   which is below the category average of 1 26   It has returned 15 6  on a year to date basis  PRHSX has a minimum initial investment of  2500 Janus Henderson Global Life Sciences Fund Class A  aims for long term capital growth  The fund invests majority of its assets in securities of companies that the portfolio managers consider to have a life science orientation This Zacks sector   Health product has a history of positive total returns for more than 10 years  To see how this fund performed compared to its category  and other 1 and 2 Ranked Mutual Funds   JFNAX carries a Zacks Rank  2 and has an annual expense ratio of 0 99   which is below the category average of 1 27   It has returned 14 3  on a year to date basis  JFNAX has a minimum initial investment of  2500 Want key mutual fund info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ,2019-12-02,Zacks Investment Research,https://www.investing.com/analysis/3-best-performing-biotech-funds-so-far-in-2019-200489704,200489704
128450,349965,BIIB,Biogen s Shares Down On Rating Downgrade By Baird Analyst,opinion,"Biogen Inc    NASDAQ BIIB   shares declined almost 2 5  on Dec 2  following rating downgrade by an analyst at Robert W  Baird  per a Bloomberg   The analyst downgraded the company from  Neutral  to  Sell  with a target price of  250  reportedly on concerns related to approval of Alzheimer s disease   AD   candidate  aducanumab  a human monoclonal antibody  The company s stock closed at  292 39 on Dec 2 Please note that in October  Biogen  its intention to seek U S  approval of Alzheimer s treatment  aducanumab  a few months after it  late stage studies   ENGAGE and EMERGE   on the same candidate  following a futility analysis Biogen s decision was based on results from a new analysis of a larger dataset of the discontinued ENGAGE and EMERGE phase III studies on aducanumab in patients with early Alzheimer s disease  This analysis was conducted in consultation with the FDA  Biogen  back then  had said that it plans to submit a biologics license application seeking approval of aducanumab to the FDA in early 2020 The company is scheduled to present additional data from ENGAGE and EMERGE studies at the Clinical Trials on Alzheimer s Disease meeting on Dec 5  The analyst at Baird expects the data to be presented to be disappointing  There are also doubts about aducanumab receiving FDA approval as a treatment for AD  The analyst stated that the standard for FDA s approval is substantial evidence of efficacy but mixed outcome results across the two studieson the candidate falls short of this standard Meanwhile  there is no treatment available for AD  Aducanumab is the first candidate  which is being pursued for FDA approval  A potential approval to the candidate is likely to generate billions of dollars for Biogen Shares of Biogen have decreased 2 9  so far this year against the  s rise of 5 4   Alzheimer s  a fatal condition that causes progressive decline in memory  has always been a highly challenging area and not much progress has been made despite significant investments  both funds and resources   Several companies have failed to develop safe and effective treatment options for this deadly brain disease In September 2019  Biogen  two late stage studies evaluating its oral BACE inhibitor  elenbecestat  as a treatment for mild cognitive impairment or mild AD  collectively known as early AD  The studies were discontinued due to unfavorable risk benefit ratio In July 2019  Amgen   NASDAQ AMGN   and Novartis   NYSE NVS    two pivotal phase II III studies evaluating their BACE1 inhibitor  CNP520  to prevent or delay the symptoms of AD in a high risk population  In January 2019  Roche   OTC RHHBY   discontinued two late stage studies evaluating its humanized monoclonal antibody  crenezumab in AD patients as it was unlikely to meet primary endpoints of the studies  Several large pharma companies  including Merck  Pfizer  NYSE PFE  and Lilly AstraZeneca have stopped development of their AD candidates either due to low possibility of success or safety concerns in the past few years Biogen Inc  Price
    Zacks RankBiogen currently carries a Zacks Rank  3  Hold   You can see  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ",2019-12-02,Zacks Investment Research,https://www.investing.com/analysis/biogens-shares-down-on-rating-downgrade-by-baird-analyst-200489671,200489671
128451,349966,BIIB,Biogen Up On New Data On Alzheimer s Candidate Aducanumab,opinion,Biogen Inc    NASDAQ BIIB   and its Japan based partner Eisai presented mixed new data from the ENGAGE and EMERGE phase III studies on its Alzheimer s candidate  aducanumab at the Clinical Trials on Alzheimer s Disease  CTAD  conference in San DiegoBiogen s shares were up 3 4  on Thursday after the news was announced  However  Biogen s shares have declined 0 5  this year so far against the  s increase of 6 2  in the same time frame   In October  Biogen revealed controversial plans to pursue U S  regulatory approval of aducanumab based on positive results of a new analysis of larger dataset from the discontinued ENGAGE and EMERGE studies  which became available after the studies were ceased In March  Biogen and Eisai had discontinued ENGAGE and EMERGE following a futility analysis  which relied on an earlier and smaller dataset  Biogen in October said that a new analysis of the larger dataset showed a different outcome than the one predicted at the time of the futility analysis The EMERGE study met the primary endpoint  showing that patients treated with high dose  10mg kg  of aducanumab experienced a statistically significant reduction in clinical decline of Alzheimer s disease  At the CTAI  detailed data from EMERGE showed that the higher of the two tested doses   10mg kg and 6mg kg  led to 22  less cognitive decline in patients with early Alzheimer s disease after 78 weeks than placebo based on a standard scale called the Clinical Dementia Rating Sum of Boxes  CDR SB   Also  key secondary endpoints were met  which demonstrated improvements in cognition and function The ENGAGE study  however  did not meet the primary endpoint  However  Biogen said that data from a post hoc analysis  from a subset of patients in the ENGAGE study who received higher dose of aducanumab  support the findings from EMERGE study  Biogen is confident that the totality of these data supports a regulatory filing  Biogen plans to submit a biologics license application  BLA  seeking approval of aducanumab to the FDA in early 2020 A group of analysts believe that the promising new data from two failed studies on aducanumab have revived hopes for approval of this almost written off experimental Alzheimer s therapy  However  another group believes that the FDA may not approve aducanumab  particularly with mixed outcome results across the two studies  Also  the FDA may require additional studies to be conducted to confirm the candidate s benefits Alzheimer s  a fatal condition that causes progressive decline in memory  has always been a highly challenging area  and not much progress has been made despite significant investments  both funds and resources   The drugs presently available just treat the symptoms of the disease  Several companies have failed to develop safe and effective treatment options to treat this deadly brain disease  Other than Biogen  several large pharma companies  including Roche   OTC RHHBY    Amgen   NASDAQ AMGN    Novartis   NYSE NVS    Merck  Pfizer  NYSE PFE   Lilly and AstraZeneca stopped development of their AD candidates in 2019 2018 either due to low possibility of success or safety concerns Despite the setbacks  companies continue to invest heavily in developing AD treatments  given the high commercial potential in this market  Success in this area means huge returns  This is because more than 5 million Americans are living with AD with the numbers expected to triple by 2050  Data  Alzheimer s Association   The market has immense commercial potential and companies coming out with new treatments could rake in billions of dollars in sales No doubt  Biogen is leaving no stone unturned to resurrect aducanumab because if it is approved by the FDA it will become the first medicine to treat Alzheimer s disease Biogen currently carries a Zacks Rank  3  Hold   You can see Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ,2019-12-05,Zacks Investment Research,https://www.investing.com/analysis/biogen-up-on-new-data-on-alzheimers-candidate-aducanumab-200490678,200490678
128452,349967,BIIB,J J Presents Data On CAR T Therapy Drug And Imbruvica At ASH,opinion,"Johnson   Johnson   NYSE JNJ   announced initial data from a phase Ib II CARTITUDE 1 study evaluating its CAR T therapy candidate  JNJ 68284528  The B cell maturation antigen directed CAR T therapy is being developed by Janssen  a subsidiary of J J  as a potential treatment for relapsed or refractory multiple myeloma  r rMM  The study is evaluating the CAR T therapy candidate in multiple myeloma patients who have received at least three prior lines of therapies and their disease has progressed on or within 12 months of their last line of therapy  Data from the study showed that JNJ 68284528 achieved a response in 100  of patients who have received a median of five prior treatment regimens at a median six month follow up  The complete response rate was 69  and 86  of patients achieved a very good partial response A partial response was achieved in 14  of the patients  Moreover  all the patients in the study achieved early minimal residual disease negative disease status  Most of the patients  27 of 29  were progression free at six month follow up  Based on the data from the study  0 75x10 6 CAR  viable T cells kg was chosen as the recommended dose for phase II study on JNJ 68284528  The data will be presented at the American Society of Hematology   ASH   annual meeting  schedule on Dec 9 J J also announced that the FDA granted Breakthrough Therapy designation to JNJ 68284528 for treating r rMM based on the positive initial data from the CARTITUDE 1 study J J s shares have gained 8 8  so far this year compared with the  s increase of 7 2   At ASH  J J also presented long term data from separate clinical studies evaluating its key cancer drug  Imbruvica  in previously untreated patients with chronic lymphocytic leukemia   CLL   Follow up data of up to six years from two phase III studies   RESONATE and RESONATE 2   showed that Imbruvica monotherapy improved progression free survival   PFS    overall survival   OS   and response rates in previously untreated patients with CLL  Please note that J J develops and commercializes Imbruvica in partnership with AbbVie   NYSE ABBV    The drug is approved in 10 different settings in six cancer indications  including first line CLL Meanwhile  data from a 48 month follow up analysis of another phase III study  E1912  showed that Imbruvica in combination with Roche   OTC RHHBY   Biogen s   NASDAQ BIIB   Rituxan  rituximab  achieved a statistically significant difference in PFS and OS in first line treatment of CLL compared to a standard chemoimmunotherapy regimen Data from a phase II CAPTIVATE study evaluating Imbruvica in combination with Roche AbbVie s Venclexta  venetoclax  achieved high rates of undetectable minimal residual disease   MRD   in previously untreated patients with CLL for time limited  MRD guided combination regimen Last week  J J announced a definitive agreement with privately held XBiotech Inc  to acquire all rights to the latter s pipeline candidate  bermekimab  for  750 million  XBiotech is developing bermekimab in mid stage study as a potential treatment for skin disorders namely atopic dermatitis and hidradenitis suppurativa Johnson   Johnson Price
    Zacks RankJ J currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-12-08,Zacks Investment Research,https://www.investing.com/analysis/jj-presents-data-on-cart-therapy-drug-and-imbruvica-at-ash-200491239,200491239
128458,349973,BIIB,FDA says some data testing Novartis   2 million gene therapy was manipulated,news,"By Michael Erman NEW YORK  Reuters    The U S  Food and Drug Administration said on Tuesday that some data from early testing of Novartis   S NOVN  more than  2 million gene therapy Zolgensma was manipulated  but the agency believes the treatment should remain on the market  The FDA said it is carefully assessing the situation   The manipulated data was used to illustrate comparability between an early version of Zolgensma and the later version of the treatment  which was manufactured using a different process  The FDA does not believe that the manipulation impacts the safety or testing surrounding the version of the drug  which treats spinal muscular atrophy  SMA   the leading genetic cause of death in infants  Novartis  Avexis unit informed the FDA of the data manipulation on June 28  the regulator said    Novartis  acquired the therapy s maker in 2018  and the drugmaker was aware of the manipulation as early as March   more than two months before the treatment s approval  the FDA said  The regulator plans to take action against the company including possible civil or criminal penalties   In a statement on Tuesday  Novartis said it is  fully confident  in the safety  quality and efficacy of Zolgensma  The issue is not expected to impact the timing of its ongoing Zolgensma regulatory filings and development programs  the drugmaker added    The data in question were a small portion of our overall submission and are limited to an older process no longer in use   Zolgensma   the world s most expensive drug   was approved as a one time treatment for SMA in late May  The disease often leads to paralysis  breathing difficulty and death within months for babies born with the most serious Type I form  SMA affects about one in every 10 000 live births  with 50  to 70  having Type I disease  The FDA said its concerns were currently limited to a small portion of product testing data included in the marketing application for the therapy  According to an inspection note released by the agency  there were discrepancies in some of its mouse survival data results  The manipulated data does not change the FDA s positive assessment of information from human clinical trials  it said  The agency said it will continue to evaluate the integrity of the product testing data used in the development of Zolgensma s manufacturing process  
U S  listed shares of Swiss drugmaker Novartis closed down 2 8  at  88 20 on Tuesday  Shares of Biogen Inc  O BIIB   which makes rival SMA treatment Spinraza  closed up 2 1  at  240 17 and shares of PTC Therapeutics Inc  O PTCT   which is also developing an SMA treatment  closed 4 9  higher at  44 75 ",2019-08-06,Reuters,https://www.investing.com/news/stock-market-news/fda-says-some-data-testing-novartis-2-million-gene-therapy-was-manipulated-1946908,1946908
128459,349974,BIIB,SoftBank backed Vir Biotechnology s shares tumble in market debut,news," Reuters    Shares of SoftBank backed  Vir Biotechnology Inc   O VIR  fell as much as 28  in one of the worst market debuts in recent months  adding to the gloom in the IPO market after WeWork s failed attempt to list its stock 
Vir s disastrous IPO deals another blow to Japan s SoftBank  T 9984   which is still smarting from the botched initial public offering of WeWork last month following increased investor skepticism regarding the office sharing startup s path to profitability 
SoftBank s  T 9984   100 billion Vision Fund owns 19 8  of Vir after the offering  a slight decrease from its pre IPO stake of 21 2    https    Investors and experts tracking recent IPOs believe companies thinking of going public in the next 12 18 months would be extremely wary of the recent backlash against loss making firms 
Vir posted revenue of  10 7 million for 2018  a nearly four fold jump from a year earlier  but its losses also ballooned by 66  to roughly  116 million in the same period 
Shares of the San Francisco based infectious disease researcher opened at  16 15 after its initial public offering was priced at the low end of its  20 to  22 per share price range  It raised  142 9 million from the offering 
At the day s low of  14 17  the company was valued at slightly over  1 5 billion 
Vir researches new therapies for infectious diseases such as hepatitis  tuberculosis and HIV  and counts some of the most high profile investors in the industry among its backers 
Co founded by Arch Venture Partners  Robert Nelsen  both SoftBank s Vision Fund and the Bill   Melinda Gates Foundation are among its biggest backers  Biogen Inc s  O BIIB  former Chief Executive Officer George Scangos is its CEO 
JP Morgan  Goldman Sachs  NYSE GS   Cowen and  Barclays   LON BARC  are among the lead underwriters for Vir s IPO ",2019-10-11,Reuters,https://www.investing.com/news/technology-news/softbankbacked-vir-biotechnologys-shares-tumble-in-market-debut-1995291,1995291
128478,349993,BIIB,Healthcare ETF  RYH  Hits New 52 Week High,opinion,"For investors looking for momentum  Invesco S P 500 Equal Weight Health Care ETF    is probably a suitable pick  The fund just hit a 52 week high   up roughly 28 9  from its 52 week low of   165 66 share 
Does it have more gains in store  Let s take a look at the fund and its near term outlook to gain an insight into where it might be headed 
RYH in Focus
The underlying S P 500 Equal Weight Health Care Index equally weights stocks in the health care sector of the S P 500 Index  The fund charges 40 bps in fees  see  here 
Why the Move 
A host of positive news has been driving the healthcare sector higher with the most recent being The Medicines Company s   NASDAQ MDCO   innovative approach to   Before this  Biogen   NASDAQ BIIB   spread optimism in the healthcare sector following its Alzheimer s treatment report  The sector has been hitting headlines this year due to mergers and acquisitions  Valuation is also compelling 
More Gains Ahead 
The fund also has a   which gives cues of further rally 
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2019-11-20,Zacks Investment Research,https://www.investing.com/analysis/healthcare-etf-ryh-hits-new-52week-high-200486605,200486605
128479,349994,BIIB,AstraZeneca Gets FDA Nod For Calquence Line Extension In CLL,opinion,"AstraZeneca   NYSE AZN   announced that the FDA approved the label expansion of its BTK inhibitor  Calquence  acalabrutinib   as a treatment for adult patients with chronic lymphocytic leukemia   CLL   or small lymphocytic lymphoma   SLL    The approval was based on positive data from two phase III studies   ELEVATE TN and ASCEND   wherein Calquence demonstrated superior progression free survival  PFS  in both first line and relapsed or refractory CLL Calquence is presently marketed for the treatment of relapsed or refractory mantle cell lymphoma  The company has plans to submit regulatory applications seeking a label expansion of the same to include CLL patients in Europe and Japan in the first half of 2020 Shares of AstraZeneca have rallied 25 3  so far this year compared with the  s growth of 4 1  The ELEVATE TN study evaluated Calquence monotherapy or in combination with Roche s   OTC RHHBY   Gazyva  obinutuzumab  in first line CLL patients  Data from the study showed that treatment with the drug alone or in combination has reduced the risk of disease progression or death by 80  and 90   respectively  compared to chemotherapy  chlorambucil  in combination with Gazyva  standard of care medicines   The median time to disease progression in patients has not been reached yet for both monotherapy and the combo regimen versus 22 6 months for standard of care The ASCEND study compared Calquence monotherapy to a combination regimen of Roche Biogen s   NASDAQ BIIB   CD 20 antibody  Rituxan  rituximab   plus Gilead s   NASDAQ GILD   Zydelig  idelalisib  or Teva s Treanda  bendamustine  in previously treated CLL patients  Previously announced data showed that Calquence reduced the risk of disease progression by 69  compared to the Rituxan combination therapy after a median follow up of 16 1 months  The median PFS for the drug is yet to be reached  while the same for the Rituxan combo is 16 5 months  Meanwhile  88  of patients treated with Calquence did not show any disease progression at 12 months compared to 68  for the control arm The safety and tolerability profile for Calquence was consistent with its established profile in both clinical studies Calquence generated  108 million in the first nine months of 2019  With the approval for this much larger indication  AstraZeneca can gain access to a broader patient population and boost sales of this promising drug AstraZeneca has built a strong oncology portfolio  which includes Tagrisso  Imfinzi  Lynparza  Iressa  Calquence and other legacy drugs  Sales of this segment were 37  of the company s total sales in the first nine months of 2019  Oncology sales were up 50  year over year in that period AstraZeneca PLC Price
    Zacks RankAstraZeneca currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-11-21,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca-gets-fda-nod-for-calquence-line-extension-in-cll-200487355,200487355
128480,349995,BIIB,Alkermes  ALKS  Up 3  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Alkermes  ALKS   Shares have added about 3  in that time frame  underperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Alkermes due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Alkermes Earnings and Sales Beat Estimates in Q3Alkermes reported adjusted loss of 4 cents per share in the third quarter of 2019 in contrast to earnings of 7 cents in the year ago quarter  However  the reported loss was narrower than the Zacks Consensus Estimate of a loss of 21 cents The company s revenues of  255 2 million in the quarter increased 2 6  from the year ago quarter  The top line beat the Zacks Consensus Estimate of  250 98 million  The company s proprietary products  especially Aristada  drove revenues  However  this was offset by declining sales of Ampyra  following the entry of generics into the market in 2018 Factors Impacting Q3Manufacturing and royalty revenues from Risperdal Consta  InvegaSustenna Xeplion and InvegaTrinza Trevicta were  76 7 million  down 0 6  year over year  The same from Ampyra Fampyra were down 62 1  year over year to  7 7 million due to generic competition  Research and development revenues  primarily from the collaboration with Biogen  NASDAQ BIIB  for Vumerity  diroximel fumarate  were  12 7 million  down 22 1  year over year Vivitrol sales improved about 6 6  year over year to  85 2 million Aristada sales came in at  53 6 million  up 48 5  year over year Research and development  R D  expenses were  107 7 million  down 6 3  year over year Selling  general and administrative  SG A  expenses were  148 7 million  up 15 5  year over year 2019 GuidanceAlkermes maintained its total revenue guidance for 2019 in the range of  1 14  1 19 billion  The expected range includes milestone payment of  150 million  which will be triggered following final FDA approval for multiple sclerosis   MS   candidate  Vumerity  The Zacks Consensus Estimate for 2019 revenues is  1 18 billion The company now expects Aristada net sales for 2019 to be  185  190 million  down from its previous expectation of  200  210 million The company narrowed its guidance for Vivitrol sales to the range of  330  340 million from its previous range of  330  350 million  It anticipates R D expenses to be  430  450 million compared with the previous range of  450  480 million  Alkermes  guidance for SG A expenses stands at  590  610 million  previously  590  620 million  The company raised its profit guidance  It expects earnings per share to be 44 57 cents  compared with 25 43 cents expected previously  The Zacks Consensus Estimate for 2019 earnings is pegged at 36 cents Pipeline UpdateThe company stated that the FDA has tentatively approved Vumerity for treating relapsing form of MS  However  the final approval is pending and is expected by the end of 2019  Meanwhile  it intends to submit a new drug application for ALKS 3831 in both schizophrenia and bipolar I disorder and the first efficacy data for early stage immuno oncology candidate   ALKS 4230 before year end 
How Have Estimates Been Moving Since Then 
It turns out  estimates review have trended downward during the past month 
VGM Scores
Currently  Alkermes has an average Growth Score of C  a grade with the same score on the momentum front  Charting a somewhat similar path  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Alkermes has a Zacks Rank  1  Strong Buy   We expect an above average return from the stock in the next few months ",2019-11-21,Zacks Investment Research,https://www.investing.com/analysis/alkermes-alks-up-3-since-last-earnings-report-can-it-continue-200487822,200487822
128481,349996,BIIB,Roche s NDA For SMA Drug Risdiplam Gets Priority Review,opinion,"Roche Holding  SIX ROG  AG   OTC RHHBY   announced that the FDA has accepted the new drug application  NDA  for its investigational agent risdiplam  The company is seeking approval of the candidate for the treatment of patients with spinal muscular atrophy  SMA  
Risdiplam is an investigational  orally administered liquid survival motor neuron 2  SMN 2  splicing modifier for SMA 
With the FDA granting a priority review to the NDA  a decision from the regulatory body is expected on May 24  2020  If approved  risdiplam will become the first at home administered medicine for people with SMA 
We note that a Priority Review designation is granted to drugs with potential to provide significant improvements in the safety and effectiveness of the treatment plus prevention or diagnosis of a serious disease 
The NDA was based on 12 month data from the pivotal FIREFISH and SUNFISH studies  which evaluated risdiplam across a broad patient population suffering type 1  2 or 3 SMA 
In November  Roche announced  from the part 2 of the SUNFISH study on risdiplam  The study met its primary endpoint of change from baseline in the MFM 32 scale after one year regimen with risdiplam compared to placebo  as data showed statistically significant improvements in the overall study population with type 2 or 3 SMA 
Moreover  no treatment related safety findings causing study withdrawal have been seen in any risdiplam study to date 
Shares of Roche have rallied 22 5  so far this year compared with the  increase of 5 1  

 
We remind investors that Roche leads the clinical development of risdiplam in collaboration with the SMA Foundation and PTC Therapeutics   NASDAQ PTCT   
Risdiplam is also being evaluated in a broad clinical program for SMA in patients ranging from newborns to 60 year olds  It includes those who are previously treated with SMA targeting therapies  Additionally  the company has two ongoing studies  namely JEWELFISH and RAINBOWFISH 
Successful development of risdiplam will boost Roche s growth prospects  However  competition is stiff in the SMA market from the likes of Biogen s   NASDAQ BIIB   Spinraza and Novartis    NYSE NVS   gene therapy Zolgensma 
Zacks Rank
Roche currently carries a Zacks Rank  2  Buy   You can see  
Today s Best Stocks from Zacks
Would you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0  and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ",2019-11-25,Zacks Investment Research,https://www.investing.com/analysis/roches-nda-for-sma-drug-risdiplam-gets-priority-review-200487893,200487893
128487,350002,BIIB,Lagging U S  healthcare stocks could see short term boost but clouds linger,news,"By Lewis Krauskopf NEW YORK  Reuters    Second quarter strength in U S  healthcare stocks is almost as reliable for Americans as warming weather and the start of baseball season  This year  however  the already lagging sector may struggle to sustain any kind of rally  Healthcare shares are suffering from a broad market rotation favoring other groups  market watchers say  as well as from policy related uncertainty  although positive earnings reports in the coming weeks could provide temporary relief  Federal government pressure to lower the cost of healthcare  and in particular prescription drug prices  for consumers continues  And as the 2020 U S  presidential election campaign heats up  that focus is likely to intensify with numerous Democratic candidates keeping it front and center  which could heighten volatility for the group s shares  That could upend a traditional second quarter trend  The overall market tends to be more rocky starting in the period  so investors become more defensive with their portfolios  benefiting groups such as healthcare that are seen as safer bets  according to CFRA strategists  To some degree  healthcare is suffering from its own success  Healthcare was the best performing major S P 500 sector last year  when the overall stock market stumbled  As the market rebounded this year  fueled by the Federal Reserve signal that it was not inclined to raise interest rates  optimism regarding global trade tensions and better than feared economic data  investors piled into laggards  That favored sectors such as technology and industrials  while healthcare s strength last year stemmed partly from its allure as a more defensive bet   When the Fed shifted their stance in early January  it totally changed the backdrop   said Walter Todd  chief investment officer at Greenwood Capital in South Carolina  Investors sold healthcare stocks and  started buying the most beat up names   he said  Earnings could provide a boost  starting on Tuesday  Results are due from diversified healthcare manufacturer Johnson   Johnson  NYSE JNJ  and insurer UnitedHealth Group Inc  NYSE UNH   the biggest and third biggest U S  healthcare companies by market value  respectively  Healthcare companies in aggregate are expected to increase first quarter earnings by 4 4  from a year earlier  according to IBES data from Refinitiv  That is the second biggest rise expected of the 11 major sectors and a stand out as earnings for the overall S P 500 are expected to drop 2 1    If the healthcare companies are reporting good earnings and the stocks continue to underperform  then you start to get some valuation support   said James Ragan  director of wealth management research at D A  Davidson  The healthcare sector has climbed 72  of the time during the second quarter  according to CFRA  which looked at 30 years of data  That compares to 62  for the overall S P 500  and is a higher rate than the other sectors  The healthcare sector on average has gained 3 6  in the second quarter  compared to 2 2  for the S P 500  according to CFRA  But the clouds that have rained on healthcare s performance so far in 2019 are not expected to dissipate soon  The S P 500 healthcare sector has climbed 4  year to date  well below the nearly 16  gain for the overall S P 500  as the benchmark index nears record highs   A BAD WEEK   Uncertainty over policy is particularly punishing shares of health insurers and other services companies  investors say  That includes proposals to change the drug rebate system under which drugmakers refund money to insurers and pharmacy benefit managers  and the prominence of Senator Bernie Sanders and other left leaning presidential candidates who support  Medicare for All  government run healthcare  Last week alone  the S P 1500 managed healthcare care index tumbled 10   including steep drops for insurers Anthem  NYSE ANTM  Inc and UnitedHealth   It s a bad week where all these things have kind of combined and people just want out   Jeff Jonas  a healthcare portfolio manager with Gabelli Funds  said on Friday  Shares of many large pharmaceutical and biotech companies   which comprise about half the sector   have struggled this year  Biogen Inc  NASDAQ BIIB  shares tumbled after the company s closely watched experimental Alzheimer s disease medicine failed in clinical trials  the kind of event that analysts say scare off investors from drugmaker shares broadly  Those stocks have largely avoided the pain doled out to services shares from drug pricing and other policy concerns  but that could change   I am not sure if we are done with the news flow regarding that topic   said Thrivent Financial healthcare analyst David Heupel   Shares of life science tool and healthcare equipment companies  viewed as relatively immune from policy concerns  have outperformed their healthcare brethren this year  But they also now trade at expensive valuations compared to their five year averages  After selling off to end 2018  many small  and mid cap biotech stocks have rebounded this year  making valuations less cheap than they were   I d love to say that healthcare is going to claw back a lot of this underperformance   said Jeffrey Schulze  investment strategist at ClearBridge Investments   
But  he adds  political risk and his expectation that other market groups will lead  when it s clear that global growth is going to come  may weigh on the sector s prospects  ",2019-04-15,Reuters,https://www.investing.com/news/stock-market-news/lagging-us-healthcare-stocks-could-see-shortterm-boost-but-clouds-linger-1836626,1836626
128488,350003,BIIB,Biogen Earnings  Revenue Beat in Q1,news,"Investing com   Biogen  NASDAQ BIIB  reported first quarter earnings  that Beat analysts  expectations on Wednesday and revenue that topped forecasts 
The firm reported earnings per share of  6 98 on revenue of  3 49B  Analysts polled by Investing com anticipated EPS of  6 83 on revenue of  3 38B  That compared to EPS of  6 05 on revenue of  3 13B in the same period a year earlier  The company had reported EPS of  6 99 on revenue of  3 53B in the previous quarter 

Biogen follows other major Healthcare sector earnings this month
 On April 16  J J reported first quarter EPS of  2 1 on revenue of  20 02B  compared to forecasts of EPS of  2 04 on revenue of  19 61B 
Novartis ADR earnings Beat analysts  expectations on Wednesday  with first quarter EPS of  1 21 on revenue of  11 11B  Investing com analysts expected EPS of  1 1 on revenue of  11 4B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-04-24,Investing.com,https://www.investing.com/news/stock-market-news/biogen-earnings-revenue-beat-in-q1-1844100,1844100
128489,350004,BIIB,Biogen beats first quarter profit estimates on Spinraza strength,news," Reuters    Drugmaker Biogen Inc  NASDAQ BIIB  beat analysts  estimates for first quarter profit on Wednesday  boosted by higher sales of its growth driver Spinraza  even as its top selling multiple sclerosis drug faces intensifying competition  The company s shares rose 2 1 pct to  235 01 in pre market trading  Spinal muscular atrophy treatment Spinraza brought in  518 million in the quarter  beating Refinitiv IBES estimates of  486 4 million  Biogen s multiple sclerosis drug Tecfidera  which brought in  999 million in the quarter  missed estimates  and faces several challenges to its intellectual property  which is key to shielding the blockbuster drug from generic competition  The company suffered an  18 billion drop in market value when the drugmaker and its partner Eisai Co Ltd last month ended two late stage trials of their experimental Alzheimer s treatment aducanumab  Biogen said it expects a nearly  125 million reduction in operating expenses during the year related to the discontinuation of aducanumab  with net savings of about  80 million  Net income attributable to the company rose 20 percent to  1 41 billion  in the quarter ended March 31   https    
On an adjusted basis  the company earned  6 98 per share on revenue of  3 49 billion  Analysts had expected the company to earn  6 87 per share on revenue of  3 39 billion ",2019-04-24,Reuters,https://www.investing.com/news/stock-market-news/biogen-firstquarter-profit-rises-20-percent-on-spinraza-strength-1844137,1844137
128490,350005,BIIB,Cognizant Nears Dubious Milestone With Flurry of Downgrades,news," Bloomberg     Cognizant Technology Solutions  NASDAQ CTSH  Corp  neared a dubious milestone on Friday after a disappointing forecast led at least nine analysts to cut their ratings on the stock  approaching the most downgrades in a single day this century 
The professional services company blamed the shortfall on continued softness in business from  a few of our largest banking clients  and a slowdown in its health care segment  Cognizant now sees full year revenue up 3 6 percent to 5 1 percent  down from a prior view of 7 percent to 9 percent  Its adjusted earnings per share view was lowered to a range of  3 87 to  3 95  down from a February projection of  at least  4 40  
Wall Street bulls were quick to throw in the towel as eight buy rated analysts trimmed their ratings to neutral  including  Deutsche Bank   DE DBKGn   which wrote that it was  still confused on what happened during the qtr so suddenly   JPMorgan  NYSE JPM  cut its rating to underweight from neutral  saying  execution likely played a role  in the company s first quarter revenue miss as new Chief Executive Brian Humphries took the reins after the period ended 
With at least 33 analysts covering the stock on Wall Street  there could be more downgrades still to come for Cognizant  Ten would match the number of cuts Biogen Inc  NASDAQ BIIB   received in March after a failed Alzheimer s drug study cost the shares almost a third of their value  That was the biggest one day reduction in sell side projections for any S P 500 company since 2000  according to data compiled by Bloomberg 
Cognizant sank 10 percent at 9 47 a m  in New York  adding to a 7 7 percent decline late in Thursday s session after the earnings report was released on the company s website  The stock is trading at its lowest levels since late December ",2019-05-03,Bloomberg,https://www.investing.com/news/stock-market-news/cognizant-nears-dubious-milestone-with-flurry-of-downgrades-1855830,1855830
128491,350006,BIIB,For Anderson family  an early bet on SMA gene therapy,news,By Caroline Humer NEW YORK  Reuters    When Malachi Anderson was diagnosed with a rare and often deadly disease called spinal muscular atrophy  SMA  as an infant nearly four years ago  his parents Tina and Torence had a decision to make  In years past  many of the babies born with the most severe form of SMA  like Malachi  died before their second birthday  Those who survived longer would likely not walk  eat or breathe on their own  By 2015  drugmakers were testing two experimental therapies in clinical trials  a one time gene therapy treatment that is now owned by Novartis AG and Spinraza  a Biogen Inc  NASDAQ BIIB  drug which is given through spinal infusion every four months  indefinitely  On Friday  U S  regulators approved the gene therapy  called Zolgensma  for children under age 2 with all types of the disease  The company set the price at  2 125 million  the highest price yet for a new medicine  saying that it was comparable over a five year period to the cost of Spinraza  already approved in late 2016   After Malachi missed development milestones and was diagnosed  the Andersons researched possible treatments online  the couple said in an interview arranged by Novartis  They were connected to a family whose daughter had been treated with the gene therapy and were encouraged by the progress she had made   The Spinraza trial was underway in Chicago  several hours from their home in Mansfield  Ohio  Participating would have separated Tina and baby Malachi from his family  including his father and five siblings  to undergo treatments  Tina Anderson said   In addition  some patients in the trial were receiving a placebo as a comparison  a risk she didn t want to take   I didn t want to have to depart from our family   she said   Was it worth me going if he didn t get the drug   A Biogen spokeswoman said that more than 7 500 people with SMA have been helped by Spinraza  and that it is the only treatment available for a broad age range of patients  It has more than 300 patients who have been followed for up to six years  An hour from their home  Nationwide Children s Hospital in Columbus  Ohio had enrolled just over a dozen patients in the first SMA gene therapy trial   If this worked  our son would have a chance at a life   she recounted  After passing several screenings  Malachi was chosen as patient number 14  making him one of the last to enter that trial  Within weeks  he received the treatment  an hour long infusion  cradled in his mother s arms  Tina said she was confident of the choice they had made that day  despite the many unknowns of an experimental treatment   I don t think we had much fear going into it  We had prayed about it   she said  The next day reality hit  Tina described shaking and vomiting  overwhelmed with the idea that  we just got something really huge  in a therapy so new   Malachi will turn four this summer  He cannot walk or crawl but can propel himself in a wheelchair and has learned other maneuvers  such as climbing down off the couch  Torence Anderson said  He enjoys going to school and sharing meals with his family  including his favorite food  cheeseburgers  The Andersons say he is gaining strength in regular PT sessions and are hopeful he will be even more mobile  So far they are not looking for treatment beyond Zolgensma  but are paying attention to the new drugs in development for SMA   There s not a whole lot of definitive information on this is what we should be doing  this is what needs to happen   Torence said   We are hoping the decisions that we are making are the right decisions    HIGH COST FOR FAMILIES  As part of a clinical trial  the Andersons received Zolgensma at no cost  It is unclear how much patients will now pay for the therapy under their insurance plans or if they do not have insurance   Ahead of the approval  some payers had told Reuters that they were concerned about being able to afford a new generation of million dollar treatments like Zolgensma  Gene therapies are also being tested to treat hemophilia and Duchenne muscular dystrophy  another rare disorder  On Friday  Novartis said it had signed a deal with Cigna  NYSE CI  Corp s specialty pharmacy and distribution units  The agreement will allow small insurers and employers the ability to pay over five years  Cigna Chief Clinical Officer Steve Miller said in an interview  They are also working on a payment structure that would enable payers to be compensated if patients receiving the treatment do not meet agreed upon thresholds  Miller said  Dave Lennon  head of Novartis  AveXis unit which developed Zolgensma  said that the largest health insurers  such as  Aetna Inc   NYSE AET   UnitedHealth Group  NYSE UNH  and Anthem  NYSE ANTM  Inc  are likely to cover the therapy in one payment  Smaller regional insurers and employers would likely be interested in pay over time deals  Lennon said in an interview  Miller said the employers who hire Cigna to manage prescription drug benefits for their workers are worried about gene therapy costs  On the other hand  he said  the treatment has saved the lives of children   I believe there is enough money in the healthcare system to make it work   Miller said ,2019-05-24,Reuters,https://www.investing.com/news/stock-market-news/for-anderson-family-an-early-bet-on-sma-gene-therapy-1878738,1878738
128492,350007,BIIB,Biogen Earnings  Revenue Beat in Q2,news,"Investing com   Biogen  NASDAQ BIIB  reported second quarter earnings  that beat analysts  expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  9 15 on revenue of  3 62B  Analysts polled by Investing com anticipated EPS of  7 53 on revenue of  3 48B  That compared to EPS of  5 8 on revenue of  3 36B in the same period a year earlier  The company had reported EPS of  6 98 on revenue of  3 49B in the previous quarter 

Biogen follows other major Healthcare sector earnings this month
 On July 16  J J reported second quarter EPS of  2 58 on revenue of  20 56B  compared to forecasts of EPS of  2 46 on revenue of  20 29B 
Novartis ADR earnings beat analysts  expectations on Thursday  with second quarter EPS of  1 34 on revenue of  11 76B  Investing com analysts expected EPS of  1 21 on revenue of  11 49B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-07-23,Investing.com,https://www.investing.com/news/stock-market-news/biogen-earnings-revenue-beat-in-q2-1931277,1931277
128493,350008,BIIB,Biogen profit rises 72  on multiple sclerosis therapy sales,news," Reuters    Biogen Inc  O BIIB  posted a 72  rise in quarterly profit and lifted its 2019 earnings forecast on Tuesday  boosted by higher sales of its top selling multiple sclerosis therapy Tecfidera 
Shares of the company rose 5 4  to  244 99 before the bell  as the U S  biotechnology company raised its 2019 adjusted earnings forecast to between  31 50 and  32 30 per share from the prior range of  28 to  29 
Analysts were expecting earnings of  29 70 per share  according to IBES data from Refinitiv 
Tecfidera brought in  1 15 billion in second quarter sales  beating estimates of  1 05 billion 
On the other hand  sales of spinal muscular atrophy treatment Spinraza  the company s most closely watched growth driver  came in at  488 million  missing estimates of  535 1 million 
Net income attributable to the company rose to  1 49 billion  or  7 85 per share  in the quarter ended June 30  from  866 6 million  or  4 18 per share  a year earlier   https    Excluding items  Biogen earned  9 15 per share 
Total revenue rose to  3 62 billion from  3 36 billion ",2019-07-23,Reuters,https://www.investing.com/news/stock-market-news/biogen-profit-rises-72-on-multiple-sclerosis-therapy-sales-1931319,1931319
128521,350036,BIIB,Pharma Sector Tops In October  Best ETFs   Stocks ,opinion,"Almost every corner of the broader healthcare sector has been on a tear since October  Among the all industries  Pharmaceuticals gained the most in October itself  adding 8 7   Pharma was followed by Biotechnology  up 6 9    Health Care Services  up 3 8   and Healthcare Equipment  up 1 1   
Inside the Rally 
Per the  issued on Nov 6  2019  total earnings of 91 6  of the entire healthcare market capitalization that has reported so far are up 7 0  on revenue growth of 7 8   The earnings growth rate seems to be the fifth highest among the 16 Zacks classified sectors  Revenue growth rate was the third highest  Blended beat ratio was 69 6   which was the third highest 
Medical   Drugs belongs to a top ranked Zacks industry  top 23    Shares of the industry can be availed at 17 53x forward earnings or less against the S P 500 ETF IVV s P E multiple of 19 04x  Though low P E does not indicate future stock performance  cheaper valuation is always lucrative amid a spate of good news  The projected ESP growth rate of the sector was 9 49  versus 5 68  of IVV  Debt to equity ratio of the industry  0 2x  is much lower than that of 0 72x 
Large Cap Pharmaceuticals also belongs to a top ranked Zacks industry  top 36    The industry has a forward P E ratio of 14 63x  which ensures its undervalued status  Debt to equity ratio of the industry  0 71x  is in line with that of the S P 500 
There was positive news in the industry  Biogen   NASDAQ BIIB   spread optimism into the broad healthcare sector following its Alzheimer s treatment report  The biotech company decided to go ahead with the approval of aducanumab  a treatment for early Alzheimer s diseases  after the drug met the primary endpoint of a Phase 3 Emerge study  read    
Hepion Pharmaceuticals also led the sector higher following data that showed potential for its CRV431 as a drug candidate for liver disease treatment  Alexion Pharmaceuticals   NASDAQ ALXN   agreed to acquire a clinical stage biopharmaceutical company Achillion Pharmaceuticals   NASDAQ ACHN    All these positive developments fueled the rally in the pharma and biotech sectors in October 
Below we highlight top performing ETFs and stocks from the sector in the past four week period  as of Nov 6  2019   see  here  
Top Stocks
GlycoMimetics Inc     NASDAQ GLYC      Up 31 6   Zacks Rank  2  Buy 
Rigel Pharmaceuticals Inc    NASDAQ RIGL     Up 31 1   Zacks Rank  2
Ironwood Pharmaceuticals Inc     NASDAQ IRWD      Up 28 3   Zacks Rank  1 Strong Buy 
Dermira Inc     NASDAQ DERM      Up 23 5   Zacks Rank  1
Top ETFs
SPDR S P Pharmaceuticals  NYSE XPH  ETF    HN XPH      Up 9 6   Zacks Rank  3  Hold 
Invesco Dynamic Pharmaceuticals ETF    WA PJP      Up 6 3   Zacks Rank  3
VanEck Vectors Pharmaceutical ETF    ASX PPH      Up 6 1   Zacks Rank  3
First Trust Nasdaq Pharmaceuticals ETF      Up 5 2   Zacks Rank  3
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2019-11-07,Zacks Investment Research,https://www.investing.com/analysis/pharma-sector-tops-in-october-best-etfs--stocks-200483840,200483840
128522,350037,BIIB,Roche s SMA Drug Meets Primary Endpoint In Pivotal Study,opinion,Roche   OTC RHHBY   announced positive data from the part 2 of the SUNFISH study on pipeline candidate  risdiplam  in patients with spinal muscular atrophy  SMA  Risdiplam is an investigational  orally administered liquid survival motor neuron 2  SMN 2  splicing modifier for SMA SUNFISH is a two part  double blind  placebo controlled pivotal study in people aged 2 25 years with types 2 or 3 SMA  Part 1  n 51  determined the dose for the confirmatory Part 2  Part 2  n 180  evaluated the motor function  using total score of Motor Function Measure 32  MFM 32  at 12 months The study met its primary endpoint of change from baseline in the MFM 32 scale after one year of treatment with risdiplam compared to placebo  as data showed statistically significant improvements in the overall study population with type 2 or 3 SMA Moreover  no treatment related safety findings leading to study withdrawal have been seen in any risdiplam trial to date We remind investors that Roche leads the clinical development of risdiplam as part of a collaboration with the SMA Foundation and PTC Therapeutics   NASDAQ PTCT   The drug is being evaluated in a broad clinical trial program in SMA in newborn babies to 60 year olds and includes patients previously treated with SMA targeting therapies  Additionally  the company has three ongoing studies   FIREFISH  JEWELFISH and RAINBOWFISH The successful development of risdiplam will bode well for Roche  However  competition is stiff in the SMA market from the likes of Biogen s   NASDAQ BIIB   Spinraza and Novartis    NYSE NVS   gene therapy Zolgensma Roche s efforts to develop its portfolio beyond oncology is encouraging  The company has more than a dozen investigational medicines in clinical development for diseases like multiple sclerosis  spinal muscular atrophy  neuromyelitis optica spectrum disorder  Alzheimer s disease  Huntington s disease  Parkinson s disease  Duchenne muscular dystrophy and autism Roche s shares have gained 21 6  in the year so far compared with the  s 0 5  growth  Additionally  Roche announced data from the phase II NOBILITY study  investigating the safety and efficacy of lymphoma drug Gazyva  obinutuzumab  in adults with proliferative lupus nephritis  Data showed that 40  of patients treated with Gazyva plus standard of care achieved complete renal response at week 76 compared to 18  of patients treated with placebo plus standard of care Roche currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-11-11,Zacks Investment Research,https://www.investing.com/analysis/roches-sma-drug-meets-primary-endpoint-in-pivotal-study-200484611,200484611
128523,350038,BIIB,Biotech Stock Roundup  SLDB Plunges  CELG Gets FDA Nod For Reblozyl   Other Updates,opinion,"It was a busy week for the biotech sector with updates from quite a few companies  Solid Biosciences   NASDAQ SLDB   plummeted after the FDA placed a clinical hold on its gene therapy candidate  while Amarin   NASDAQ AMRN   gained ahead of an FDA committee meeting on the label expansion of its approved drug Vascepa  Meanwhile  Celgene Corp    NASDAQ CELG   and partner Acceleron   NASDAQ XLRN   obtain FDA approval of Reblozyl for the treatment of anemia in adult patients with beta thalassemia 
Recap of the Week s Most Important Stories 
Solid Biosciences Plunges As FDA Places Clinical Hold   Shares of Solid Biosciences plunged after the FDA notified it that a clinical hold has been placed on IGNITE DMD  its phase I II study of lead candidate SGT 001  after a patient dosed in one of the cohorts experienced a serious clinical event  SAE  
Six patients have been dosed with SGT 001  the company s gene transfer candidate under investigation for Duchenne muscular dystrophy  DMD   This includes three patients in the first cohort at a 5E13 vg kg dose  who continue to do well and are being followed per the study protocol  Three patients were subsequently dosed in the second cohort at a 2E14 vg kg dose 
However  the third patient in the 2E14 vg kg cohort  dosed in late October  experienced an SAE deemed related to the study drug that was characterized by complement activation  thrombocytopenia  a decrease in red blood cell count  acute kidney injury  and cardio pulmonary insufficiency  Thereafter  Solid Biosciences reported the event to the FDA and the study Data Safety Monitoring Board  DSMB   The hold comes as a setback for the company  which plans to report additional biomarker data from the study before the year end 
Celgene   Acceleron Get FDA Nod for Rare Blood Disorder Drug  Celgene Corporation and partner Acceleron Pharma Inc  announced that the FDA has approved pipeline candidate Reblozyl  luspatercept aamt  for the treatment of anemia in adult patients with beta thalassemia  who require regular red blood cell  RBC  transfusions  Per the company  Reblozyl is the first and only FDA approved erythroid maturation agent  representing a new class of therapy for these patients  The approval comes ahead of the target action date of Dec 4 
The approval of the drug for beta thalassemia was based on encouraging results from the pivotal  phase III  randomized  double blind  placebo controlled  multicenter BELIEVE study  Meanwhile  the FDA is also evaluating luspatercept aamt for the treatment of anemia in adults with very low  to intermediate risk myelodysplastic syndromes  MDS   who have ring sideroblasts and require RBC transfusions  The agency has set a target action date of Apr 4  2020  for the same 
Celgene currently carries a Zacks Rank  2  Buy   You can see  
Gilead Presents Data on HIV Therapy  Gilead Sciences   NASDAQ GILD   announced encouraging data on pipeline candidate GS 6207 at the 17th European AIDS Conference  EACS  in Basel  Switzerland  GS 6207 is an investigational  novel  selective  first in class inhibitor of HIV 1 capsid function  New data from two phase I studies demonstrated that GS 6207 has potent antiviral activity and a potential dosing interval of up to every six months 
GS 6207 was generally well tolerated and no serious adverse events were reported in both clinical studies  Additionally  the vitro virology study results suggested that GS 6207 can potentially be used in a broad range of HIV patients regardless of their treatment history 
Amarin Up Ahead of FDA Committee Meet  Shares of Amarin gained 23 8  ahead of the Endocrinologic and Metabolic Drugs Advisory Committee  EMDAC  meeting scheduled for Nov 14  The committee will decide on the label expansion of Amarin s lead drug  Vascepa  which is indicated as an adjunct to diet to reduce triglyceride  TG  levels in adult patients with severe   500 mg dL  hypertriglyceridemia  Amarin is seeking a label expansion of the drug to include cardiovascular risk reduction in statin treated patients with only moderately increased triglyceride 
Biogen to Expand Biosimilars Portfolio  Biogen   NASDAQ BIIB   announced a new collaboration with Samsung  KS 005930  Bioepis Co   Ltd  to secure the exclusive rights to commercialize two new ophthalmology biosimilars  SB11  biosimilar of Lucentis  and SB15  biosimilar of Eylea   in major markets worldwide  including the United States  Canada  Europe  Japan and Australia  Additionally  the company will acquire exclusive commercialization rights for its anti TNF portfolio  including Benepali  etanercept   Flixabi  infliximab  and Imraldi  adalimumab   in China 
Moreover  Biogen will acquire an option to extend its existing commercial agreement with Samsung Bioepis for this anti TNF portfolio in Europe  Per the terms  Biogen will make a  100 million upfront payment to Samsung Bioepis  Additionally  the company may pay Samsung Bioepis up to  210 million in milestone payments 
Performance    Medical   Biomedical and Genetics Industry 5YR   Return
 

The Nasdaq Biotechnology index gained 0 93  in the last five trading sessions  Among the biotech giants  Amgen  NASDAQ AMGN  gained 20 83  in the period  Over the past six months  shares of Biogen have gained 29 13   whereas the Alexion  NASDAQ ALXN  stock has declined 13 09    See the last biotech stock roundup here   

What s Next in Biotech 
Stay tuned for more pipeline updates 
Breakout Biotech Stocks with Triple Digit Profit Potential
The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases 
Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-11-13,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-sldb-plunges-celg-gets-fda-nod-for-reblozyl--other-updates-200485103,200485103
128524,350039,BIIB,Top   Flop ETFs Halfway Through Q4,opinion,The fourth quarter brings strong gains for Wall Street buoyed by easing U S  China trade worries  stronger than expected corporate earnings and Fed s third rate cut  The S P 500 breached the 3 100 level for the first time ever last week and rallied for the sixth consecutive week  its longest winning streak since November 2017  Meanwhile  the Dow Jones topped the 28 000 milestone  read    The fixed income world  which saw astounding strength due to trade issues  started to falter with risk on sentiments and rise in yields  The bullish backdrop has also diminished the safe haven appeal  pushing precious metals down  in particular gold and silver Given this  many corners of the market have seen smooth trading while a few are still lagging  Below we have highlighted ETFs from the best and worst zones at the halfway mark in Q4 Best ZonesHealthcareThe healthcare sector is outperforming this quarter driven by a slew of positive news flow  including trial results and deal activities  and better than expected corporate earnings  In particular  Biogen   NASDAQ BIIB   spread optimism following its Alzheimer s treatment report  While most of the ETFs in the healthcare space have been surging  iShares U S  Healthcare Providers ETF  tops the list  having gained nearly 18  so far this quarter This ETF follows the Dow Jones U S  Select Healthcare Providers Index with exposure to companies that provide health insurance  diagnostics and specialized treatment  In total  the fund holds 49 securities in its basket with each making up for no more than 22 71  of assets  The fund has amassed  839 4 million in its asset base  while volume is moderate at about 67 000 shares per day on average  It charges 43 bps in annual fees and has a Zacks ETF Rank  3  Hold  with a Medium risk outlook  read    SemiconductorThe trade deal optimism is leading to a surge in the semiconductor corner of the broad technology sector given its significant exposure to China  Additionally  strong earnings from some of the well known players in the industry are driving the sector higher  First Trust Nasdaq Semiconductor ETF  spiked 14   It offers exposure to the 29 most liquid U S  semiconductor securities based on volatility  value and growth by tracking the Nasdaq US Smart Semiconductor Index  It has accumulated  39 5 million in AUM and trades in average daily volume of 14 000 shares  It charges 0 60  in expense ratio and has a Zacks ETF Rank  3  read    Inverse BondThe yield curve  which had inverted earlier  is now back to its normal shape  The Fed began buying short term Treasury debt last month as it tries to keep the money markets functioning smoothly  Further  optimism regarding trade talks sent the yields higher  As such  Barclays  LON BARC  Inverse US Treasury Composite ETN  is the star performer in the bond space  having risen about 12   It provides investors a unique strategy to benefit from rising U S  interest rates by tracking the Barclays Inverse US Treasury Futures Composite Index  This benchmark employs a strategy  which follows the sum of the returns of the periodically rebalanced short positions in equal face values of each of the 2 year  5 year  10 year  long bond and ultra long U S  Treasury futures contracts  The ETN has accumulated  7 9 million in AUM and trades in light volume of about 2 000 shares per day on average  It charges 43 bps in annual fees  read    Worst ZonesMarijuanaThe hype regarding marijuana stocks has faded with many of them losing two third or more of their value in a few months  Then  a wave of disappointing earnings added to the chaos  While all the marijuana ETFs declined  Global X Cannabis ETF   BO POTX   led the way higher  losing 28 5   This ETF  which seeks to invest in companies across the cannabis industry  tracks the Cannabis Index and holds 26 stocks in its basket with none accounting for more than 8 31  of assets  It has accumulated  3 million in its asset base within two months of debut and trades in average daily volume of 11 000 shares  Expense ratio comes in at 0 50  CurrencyAfter skyrocketing in the first nine months  the overlooked Market Vectors Indian Rupee USD ETN   ASX INR   has shed more than 28  so far this quarter  The decline stemmed from several rate cuts  Reserve Bank of India cut repo rate five times this year with the last reduction being enacted in early October  The product tracks the performance of the S P Indian Rupee Total Return Index and has accumulated  1 million in its asset base  The ETN charges 55 bps in annual fees and has a Zacks ETF Rank  3 with a High risk outlook VolatilityVolatility has taken the back seat this quarter on bullishness in the stock market  As such  volatility products are the losers with iPath Series B S P 500 VIX Short Term Futures ETN  stealing the show and shedding 26 7   This is a popular option providing exposure to volatility that sees a truly impressive average volume of about 31 8 million shares a day  The note has amassed  963 2 million in AUM and charges 89 bps in fees per year  The ETN focuses on the S P 500 VIX Short Term Futures Index  which reflects implied volatility in the S P 500 Index at various points along the volatility forward curve  It provides investors with exposure to a daily rolling long position in the first and second months of VIX futures contracts  read    Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-11-17,Zacks Investment Research,https://www.investing.com/analysis/top--flop-etfs-halfway-through-q4-200486060,200486060
128529,350044,BIIB,Biogen scraps two Alzheimer drug trials  wipes  18 billion from market value,news,By Julie Steenhuysen and Takashi Umekawa CHICAGO TOKYO  Reuters    Biogen Inc  NASDAQ BIIB  and partner Eisai Co Ltd are ending two late stage trials of their experimental Alzheimer s disease drug aducanumab  a major setback in the quest to find a treatment for the mind wasting disease and a blow to Biogen  which lost more than  18 billion of its value on Thursday  Experts had seen aducanumab as one of the last tests of the hypothesis that removing sticky deposits of amyloid from the brain of patients in earlier stages of the lethal disease could stave off its ravages  which include loss of memory and the ability to care for oneself  Biogen shares fell nearly 30 percent to  225 70  its largest drop since February 2005  when they fell nearly 43 percent to close at  38 65 on Nasdaq  The decision was based on a so called futility analysis of aducanumab data by an independent monitoring committee that determined the trials had little hope of succeeding  Markets in Japan were closed for a national holiday so the impact of the news on Eisai will be delayed  Eisai in July had touted promising but confusing 18 month results from another Alzheimer s drug  BAN2401  being co developed with Biogen  That drug failed in a 12 month analysis   TRANSFORMATIVE FAILURE  Investors had been cautiously optimistic about aducanumab following early promising data  Without potential future revenue from Alzheimer s  Biogen has poor growth prospects as it faces patent issues over its big selling multiple sclerosis drug Tecfidera and possible competition to spinal muscular atrophy drug Spinraza  Wall Street analysts said   We view this as a transformative failure for Biogen s pipeline   RBC Capital Markets analyst Brian Abrahams wrote in a research note  Abrahams  who reduced his Biogen price target to  240 per share  said further declines were likely given that  investors owned Biogen to not miss out on what could have been one of the biggest blockbuster products in the pipeline of large biopharma   Any successful treatment for Alzheimer s  which affects about 5 7 million Americans  is virtually guaranteed to become one of the world s top selling drugs  But efforts so far have had a dismal track record  with more than 100 failures   The two halted trials were in the final stages of testing aducanumab in patients with mild cognitive impairment due to Alzheimer s and mild Alzheimer s disease dementia  Detailed results will be presented at a future medical meeting   This disappointing news confirms the complexity of treating Alzheimer s disease and the need to further advance knowledge in neuroscience   Biogen Chief Executive Officer Michel Vounatsos said   Eisai and Biogen said they would continue to work on other Alzheimer s treatments  including BAN2401  Guggenheim analyst Yatin Suneja said Biogen instead should be looking to build its pipeline through acquisitions   They need to stop wasting or stop investing money in Alzheimer s now   Suneja said  Suneja said Biogen has about  42 billion in financing capacity and identified potential acquisition targets such as Sage Therapeutics Inc   GW Pharmaceuticals  O GWPH  and Zogenix Inc that are  very interesting companies that should be considered now  more seriously   WHAT S NEXT  Major drugmakers  including Eli Lilly  NYSE LLY  and Co  AstraZeneca Plc  Roche Holding  SIX ROG  AG   Pfizer  Inc  NYSE PFE   Merck   Co and Johnson   Johnson  NYSE JNJ   have abandoned Alzheimer s drugs targeting amyloid because of lack of efficacy or safety issues  Roche is still testing an amyloid targeting drug  gantenerumab  at a higher dose after it failed in a trial in early stage disease   Dr  Ronald Petersen of the Mayo Clinic  who has consulted for Eisai and Biogen  said amyloid is clearly linked with Alzheimer s because it shows up in the brains of people with the disease  But removing it did not appear to help   Should we abandon amyloid  I m not completely there yet  but you d certainly like to see some kind of positive response   Many companies including Biogen  Eisai  Lilly and AbbVie  NYSE ABBV   are pursuing alternative approaches  such as focusing on tau  another Alzheimer s protein that is more closely linked with the onset of symptoms  Others are pursuing targets aimed at reducing inflammation  which is believed to play a role in the very early formation of the disease  Dr  Howard Fillit of the Alzheimer s Drug Discovery Foundation said research must identify biomarkers and diagnostics to help  weed out ineffective drugs earlier   before they are tested in large  expensive trials  Fillit said aducanumab hit its target and removed amyloid but still did not help patients  which makes him  very pessimistic that the amyloid approach will work clinically   He said BAN2401 is not that different from aducanumab   If they want one more shot on goal  I would think that would be a business decision rather than a strong scientific decision  ,2019-03-21,Reuters,https://www.investing.com/news/stock-market-news/biogen-scraps-alzheimers-trial-shares-skid-1814229,1814229
128530,350045,BIIB,Eisai starts phase 3 trials for second Alzheimer s drug after first s failure,news,"By Takashi Umekawa TOKYO  Reuters    Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer s treatment BAN2401  a day after the Japanese drugmaker and U S  partner Biogen Inc  NASDAQ BIIB  scrapped trials for another Alzheimer s drug  aducanumab  The aducanumab announcement knocked  18 billion of Biogen s stock value  On Friday  Eisai was untraded  flooded with sell orders at 7 565 yen  almost 17 percent lower than its previous close  The demise of aducanumab came after independent experts determined the trials had little hope of succeeding  marking the latest setback in the quest to treat a mind wasting disease that affects 5 7 million people in the United States alone  Eisai and Biogen were jointly developing three experimental drugs for Alzheimer s  aducanumab  BAN2401 and elenbecestat  all designed to target the brain destroying protein beta amyloid   As we have believed aducanumab was the best hope for treating Alzheimer s  ending its trials is big negative surprise   said analyst Motoya Kohtani at Nomura Securities  BAN2401 has been met with scepticism since the partners reported promising but confusing 18 month results in July  Yet Eisai remains confident in its continued development   We still believe that amyloid beta hypothesis is potentially the right approach for the treatment of Alzheimer s disease   an Eisai spokesman told Reuters  Eisai will conduct phase 3 trials of BAN2401 involving 1 566 patients with mild cognitive impairment or mild Alzheimer s disease dementia with confirmed amyloid accumulation  Alzheimer s treatments are known as being particularly difficult to develop  as both diagnosis and the recruitment of appropriate trial participants are challenging  From 1998 through 2017  only four treatments have been approved with another 146 attempts resulting in failure  according to the Adis R D Insight database  
Alzheimer s is the most common form of dementia  In Japan  the government estimates there will be 7 million dementia sufferers in 2025  from 4 6 million in 2012 ",2019-03-22,Reuters,https://www.investing.com/news/stock-market-news/shares-of-japans-eisai-swamped-with-sell-orders-after-ending-alzheimer-trials-1814939,1814939
128531,350046,BIIB,Biogen announces  5 billion buyback days after shelving Alzheimer s trials,news," Reuters    Biogen Inc  NASDAQ BIIB  said on Monday it would buy back shares worth  5 billion  days after its stock slumped on the drugmaker s announcement to end two Alzheimer s disease trials  Biogen had lost more than  18 billion of its value last week after the company and partner Eisai Co Ltd ended two late stage trials of their experimental Alzheimer s disease treatment  aducanumab  Biogen shares  which lost 32 4 percent of their value since the company s announcement on Thursday to scrap the trials  were up 1 5 percent before the opening bell on Monday  
The share buyback is in addition to the approximately  1 7 billion remaining under the stock repurchase program authorized by its board in August 2018  the company said in a regulatory filing https   ",2019-03-25,Reuters,https://www.investing.com/news/stock-market-news/biogen-announces-5-billion-buyback-days-after-shelving-alzheimers-trials-1816947,1816947
128551,350066,BIIB,Drug Biotech Stock Q3 Earnings Due On Oct 29  MRK  PFE   More,opinion,"The third quarter reporting cycle for the  sector is in full swing  The sector comprises pharma biotech and medical device companies The  shows that the sector participants  which reported until Oct 23 and constitute nearly 38 9  of the sector s market capitalization  delivered 9 1  earnings growth and a 8  rise in sales year over year  The beat ratio for earnings was 91 7  and for revenues  83 3   Overall  third quarter earnings and sales growth of this sector is expected to be 1 2  and 5 8   respectively Several big drug biotech companies like Eli Lilly   NYSE LLY    AstraZeneca   NYSE AZN    Alexion   NASDAQ ALXN    Biogen   NASDAQ BIIB   and Gilead Sciences   NASDAQ GILD   reported third quarter results last week AstraZeneca  Alexion and Biogen beat on both counts in the third quarter  Alexion raised its revenue and earnings guidance for 2019  Lilly surpassed on third quarter earnings but missed on sales  Gilead Sciences  earnings missed the mark while sales managed to marginally top the same  The company narrowed its guidance for 2019 Let s analyze the four pharma biotech companies that are set to report third quarter 2019 results on Oct 29 What the Model SuggestsThe proven Zacks model predicts an earnings beat for the stock with a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   This combination increases the chances of a likely positive surprise  You can uncover the best stocks to buy or sell before they re reported with our  Merck   Co   Inc    NYSE MRK  Merck  which is scheduled to release earnings before the market opens  delivered a positive earnings surprise of 12 07  in the last reported quarter  The company beat on earnings in each of the last four quarters  the average being 7 96  For the quarter to be reported  Merck has an Earnings ESP of  0 16  and a Zacks Rank  3  The Zacks Consensus Estimate stands at  1 25 per share 
Merck s new products like cancer drug Keytruda  Gardasil vaccine and Bridion injection are likely to have driven the top line in the to be reported quarter on the back of strong demand trends  However  the top line is expected to reflect the impact of loss of exclusivity  LOE  for some products as well as currency headwinds   Read more   
Merck   Co   Inc  Price and EPS Surprise   Pfizer Inc    NYSE PFE  Pfizer  which is scheduled to release earnings before the opening bell  delivered a positive earnings surprise of 3 90  in the last reported quarter  The company beat on earnings in each of the preceding four quarters  the average being 4 63  For the to be reported quarter  Pfizer has an Earnings ESP of  0 67  and a Zacks Rank of 3  The Zacks Consensus Estimate is pegged at a loss of 63 cents per share Higher sales of Pfizer s key brands Eliquis and Ibrance in the Biopharma segment  biosimilars and strong sales in the emerging markets are likely to have compensated lower sales in the Upjohn group   Read more   Pfizer Inc  Price and EPS Surprise   Amgen Inc    NASDAQ AMGN  Amgen is scheduled to release earnings  after the market closes  The company delivered a positive earnings surprise of 10 89  in the last reported quarter  Amgen s performance has been impressive with the company delivering a positive surprise in each of the trailing four quarters  the average being 6 72  For the quarter to be reported  Amgen has an Earnings ESP of  0 04  and a Zacks Rank of 3  The Zacks Consensus Estimate stands at  3 51 per share Higher sales of products like Prolia  Xgeva  Kyprolis and Blincyto are expected to have made up for weak sales of Amgen s mature drugs  namely Enbrel  Aranesp  Epogen  Neupogen  Neulasta and Sensipar that face an array of branded and generic competitors   Read more   Amgen Inc  Price and EPS Surprise   Incyte Corporation   NASDAQ INCY  Incyte is scheduled to report third quarter 2019 results on Oct 29  before market open  In the last reported quarter  the company beat on earnings by a whopping 53 06   Its earnings surpassed expectations twice over the last four quarters  the average positive surprise being 25 01  For the to be reported quarter  Incyte has an Earnings ESP of  1 15  and a Zacks Rank of 1 which suggest an earnings beat  The Zacks Consensus Estimate is pegged at 65 cents per share  You can see  Incyte s lead drug Jakafi drove second quarter results  a trend that most likely continued in the third quarter  Notably  Jakafi sales and royalties are key catalysts for the company s revenue growth  while Iclusig sales and Olumiant royalties also contribute to the top line  These are therefore expected to have contributed significantly to the company s revenues in the third quarter   Read more   Incyte Corporation Price and EPS Surprise   Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-10-27,Zacks Investment Research,https://www.investing.com/analysis/drugbiotech-stock-q3-earnings-due-on-oct-29-mrk-pfe--more-200479101,200479101
128552,350067,BIIB,Biotech Stock Roundup  Q3 Earnings Beat At ALXN   AMGN  Pipeline Updates   More,opinion,"It was a busy week for the biotech sector with updates from most bigwigs  Alexion   NASDAQ ALXN   and Amgen   NASDAQ AMGN   both topped earnings estimates in the third quarter  while Gilead   NASDAQ GILD   reported mixed results  Meanwhile  the FDA advisory committee voted on AMAG s   NASDAQ AMAG   Makena Recap of the Week s Most Important Stories Alexion   Amgen Impress in Q3   Alexion s earnings and sales beat estimates in the third quarter of 2019 on sustained growth of its blockbuster drug  Soliris  and solid uptake of Ultomiris Amgen too beat on earnings and sales in the third quarter  The company slightly raised its sales guidance  while increasing the earnings range significantly However  Gilead reported mixed results for the third quarter as earnings missed expectations but sales managed to marginally surpass the same Amgen currently carries a Zacks Rank  2  Buy   You can see  Gilead Collaborates With Glympse Bio   Gilead Sciences Inc announced that it had entered a collaboration with Glympse Bio for advancing its nonalcoholic steatohepatitis clinical development  The financial terms of the agreement were not disclosed  Glympse Bio s proprietary synthetic biomarkers are bioengineered to identify the stage and progression of the disease as well as early detection of treatment response  Gilead will use these to determine clinical trial participants  stage of disease at initial screening and their responses to study treatment AMAG s Updates on FDA Committee Meeting for Makena   AMAG Pharmaceuticals announced that the FDA s Bone  Reproductive and Urologic Drugs Advisory Committee has analyzed the data from the PROLONG trial on Makena  The drug is approved to reduce preterm birth in pregnant women  who have had a prior spontaneous preterm birth  Nine of 16 advisory committee members voted to recommend the FDA to pursue the withdrawal of Makena from the market  while the rest voted to keep the product in the market under accelerated approval and request a new confirmatory trial  The agency will consider the advisory committee s recommendation when making its decision but is not bound by the same Regeneron s Dupixent Label Expansion in Europe  Regeneron Pharmaceuticals  Inc   NASDAQ REGN   and partner Sanofi   NASDAQ SNY   announced that the European Commission has approved a label expansion of asthma drug  Dupixent  The drug is indicated as an add on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis  CRSwNP   for whom therapy with systemic corticosteroids and or surgery do not provide adequate disease control  Hence  Dupixent now is approved in the EU for three type 2 inflammatory diseases   severe CRSwNP  severe asthma and moderate to severe atopic dermatitis Amgen to Make Repatha Available at a Lower List Price  Amgen announced that its PCSK9 inhibitor  Repatha  will be available at a 60  lower list price of  5 850 per year  effective Dec 31  2019  The drug is approved for the treatment for patients with high cholesterol and cardiovascular disease to reduce heart attacks and strokes  In October 2018  Amgen slashed the U S  list price of Repatha by 60  PerformanceMedical   Biomedical and Genetics Industry 5YR   Return
 The Nasdaq Biotechnology index gained 2 06  in the last five trading sessions  Among the biotech giants  Alexion gained 8 3  in the period  Over the past six months  shares of Biogen  NASDAQ BIIB  have gained 29 7   whereas Alexion stock has declined 20 5    See the last biotech stock roundup here  Biotech Stock Roundup  Biotech Stock Roundup   What s Next in Biotech Stay tuned for quarterly results from most biotech bigwigs Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-29,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-q3-earnings-beat-at-alxn--amgn-pipeline-updates--more-200480077,200480077
128553,350068,BIIB,The Zacks Analyst Blog Highlights  Alexion  Amgen  Gilead And AMAG,opinion,For Immediate ReleaseChicago  IL  October 31  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Alexion   NASDAQ ALXN    Amgen   NASDAQ AMGN    Gilead   NASDAQ GILD   and AMAG   NASDAQ AMAG   Here are highlights from Wednesday s Analyst Blog Biotech Stock Roundup  ALXN  AMGN  GILD and MoreIt was a busy week for the biotech sector with updates from most bigwigs  Alexion and Amgen both topped earnings estimates in the third quarter  while Gilead reported mixed results  Meanwhile  the FDA advisory committee voted on AMAG s Makena Recap of the Week s Most Important Stories Alexion   Amgen Impress in Q3   Alexion s earnings and sales beat estimates in the third quarter of 2019 on sustained growth of its blockbuster drug  Soliris  and solid uptake of Ultomiris Amgen too beat on earnings and sales in the third quarter  The company slightly raised its sales guidance  while increasing the earnings range significantly However  Gilead reported mixed results for the third quarter as earnings missed expectations but sales managed to marginally surpass the same Amgen currently carries a Zacks Rank  2  Buy   You can see  Gilead Collaborates With Glympse Bio   Gilead Sciences Inc announced that it had entered a collaboration with Glympse Bio for advancing its nonalcoholic steatohepatitis clinical development  The financial terms of the agreement were not disclosed  Glympse Bio s proprietary synthetic biomarkers are bioengineered to identify the stage and progression of the disease as well as early detection of treatment response  Gilead will use these to determine clinical trial participants  stage of disease at initial screening and their responses to study treatment AMAG s Updates on FDA Committee Meeting for Makena   AMAG Pharmaceuticals announced that the FDA s Bone  Reproductive and Urologic Drugs Advisory Committee has analyzed the data from the PROLONG trial on Makena  The drug is approved to reduce preterm birth in pregnant women  who have had a prior spontaneous preterm birth  Nine of 16 advisory committee members voted to recommend the FDA to pursue the withdrawal of Makena from the market  while the rest voted to keep the product in the market under accelerated approval and request a new confirmatory trial  The agency will consider the advisory committee s recommendation when making its decision but is not bound by the same Amgen to Make Repatha Available at a Lower List Price  Amgen announced that its PCSK9 inhibitor  Repatha  will be available at a 60  lower list price of  5 850 per year  effective Dec 31  2019  The drug is approved for the treatment for patients with high cholesterol and cardiovascular disease to reduce heart attacks and strokes  In October 2018  Amgen slashed the U S  list price of Repatha by 60  PerformanceThe Nasdaq Biotechnology index gained 2 06  in the last five trading sessions  Among the biotech giants  Alexion gained 8 3  in the period  Over the past six months  shares of Biogen  NASDAQ BIIB  have gained 29 7   whereas Alexion stock has declined 20 5    See the last biotech stock roundup here  Biotech Stock Roundup  Biotech Stock Roundup   Media ContactZacks Investment Research800 767 3771 ext  9339 Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-10-30,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-alexion-amgen-gilead-and-amag-200480975,200480975
128554,350069,BIIB,Value Biotech ETFs   Stocks To Buy Now,opinion,"This year  biotech stocks have seen their  since 2012  A solid merger and acquisition momentum has been instrumental in this rally  Still  valuation is cheaper for this segment as the Nasdaq Biotechnology Index  which is weighted by market value  is down nearly 20  from the record high set in 2015  per an  
M A Hot in 2019
The announcement of the mega merger deal between Bristol Myers   NYSE BMY   and Celgene   NASDAQ CELG   in the beginning of 2019 has set the space on fire  Also  Eli Lilly and Company   NYSE LLY   announced that it will acquire Loxo Oncology for  8 billion to expand its oncology portfolio to precision medicines or targeted therapies 
The winning momentum for M A started from December 2018  when Glaxo   NYSE GSK   offered to acquire TESARO for almost  5 1 billion  With this deal  Glaxo s objective was to get access to TESARO s PARP inhibitor  Zejula  which is approved for ovarian cancer  There were other announcements like Roche s   OTC RHHBY   acquisition of Spark Therapeutics for  4 8 billion and Merck s   NYSE MRK   acquisition of Immune Design 
Upbeat Clinical Trials   Listing for FDA Approvals
Biogen   NASDAQ BIIB   has spread optimism into the broad healthcare sector following its Alzheimer s treatment report  The biotech company decided to go ahead with the approval of aducanumab  a treatment for early Alzheimer s diseases  after the drug met the primary endpoint of a Phase 3 Emerge study  If approved  Biogen s drug would be the first to slow cognitive decline in Alzheimer s patients  thus opening up huge opportunity for investors  read    
Bristol Myers Squibb also recently announced that its immunotherapy combination of drugs showed strong results in a lung cancer trial  Hepion Pharmaceuticals also led the sector higher following data that showed potential for its CRV431 as a drug candidate for liver disease treatment  read    
Low P E Multiple Rampant in Sector 
Many biotech shares can be availed at 12x forward earnings or less against the S P 500 s 17x  per Wall Street Journal  Though low P E does not indicate the future stock performance  cheaper valuation is always lucrative amid a spate of good news 
This is especially true given that Biomedical and Genetics belongs to the top ranked Zacks industry  top 28    And large cap pharmaceuticals come from a top ranked Zacks industry  top 29   
ETFs in Focus
Below we highlight a few biotech ETFs that have considerably a low P E in the sector and can benefit investors with solid gains   here  
SPDR S P Biotech  NYSE XBI  ETF    P E 15 67x
iShares Genomics Immunology and Healthcare ETF    P E 17 08x
VanEck Vectors Biotech ETF   LON BBH     P E 19 24x
Stocks in Focus 
The below mentioned biotech stocks have a low P E and a decent P E 
AbbVie Inc    NYSE ABBV     P E 9 16x  Zacks Rank  2  Buy   Yield 5 38 
Bristol Myers Squibb Company   NYSE BMY     P E 13 32x  Zacks Rank  2  Yield 2 86 
Amgen Inc    NASDAQ AMGN     P E 15 09x  Zacks Rank  3  Yield 5 28 
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2019-11-04,Zacks Investment Research,https://www.investing.com/analysis/value-biotech-etfs--stocks-to-buy-now-200481943,200481943
128555,350070,BIIB,Biotech ETFs In Focus On Impressive Q3 Earnings Results,opinion,The year 2019 has been pretty decent for the biotechnology market so far  with the returning 13 3   Increasing M A deals  growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market  The sector has been benefitting from a flurry of positive news  including trial results and deal activities  For instance  the mega merger deal between Bristol Myers   NYSE BMY   and Celgene   NASDAQ CELG   that was announced at the beginning of 2019 created quite a stir in the sector  Also  Biogen s progress with the approval of aducanumab  a treatment for early Alzheimer s diseases  after the drug met the primary endpoint of a Phase 3 Emerge study has raised optimism among investors  read    Alexion Pharmaceuticals also joined the M A wave in the pharma biotech sector  The company agreed to acquire a clinical stage biopharmaceutical company Achillion Pharmaceuticals for  930 million in a move to expand its pipeline of rare disease treatments  The transaction is expected to close in the first half of 2020  subject to approvals  even from Achillion shareholders Let s take a look at some big biotechnological earnings releases and see if these will impact ETFs exposed to the space Earnings in FocusOn Oct 29  Amgen   NASDAQ AMGN   reported third quarter 2019 earnings of  3 66 per share  which surpassed the Zacks Consensus Estimate of  3 51  Earnings declined 1  year over year due to lower revenues and operating profits  Total revenues of  5 74 billion in the quarter outpaced the Zacks Consensus Estimate of  5 63 billion  However  total revenues declined 3  year over year The company slightly raised its previously issued sales guidance while lifting the earnings range significantly  Amgen expects revenues in the range of  22 8  23 billion versus  22 4  22 9 billion expected previously  Adjusted earnings per share are anticipated in the range of  14 20  14 45 versus  13 75  14 30 expected previously  The guidance excludes the impact of the Otezla acquisition  Shares rose about 4 3  since the earnings release  as of Nov 1  2019  On Oct 24  Gilead Sciences   NASDAQ GILD   reported mixed results for the third quarter of 2019 as earnings missed expectations while sales managed to surpass the same by a slight margin  The company reported earnings of  1 75 per share in the third quarter  down from  1 84 a year ago and missing the Zacks Consensus Estimate by a penny  Total revenues of  5 60 billion outpaced the Zacks Consensus Estimate by 0 1  and were almost flat year over year  see  here  Gilead now expects sales of  21 8  22 1 billion compared with the previous guidance of  21 6  22 1 billion  Adjusted R D and adjusted SG A expenses are projected to be  3 7  3 8 billion and  4 0 4 1 billion  respectively  Adjusted product gross margin is anticipated to be 85 87   Moreover  the stock has slipped 2  since reporting earnings  as of Nov 1  On Oct 22  Biogen   NASDAQ BIIB   reported third quarter 2019 earnings per share of  9 17  which surpassed the Zacks Consensus Estimate of  8 28  Earnings increased 24  year over year on higher revenues  lower tax rate and a lower share count  Sales of this neuroscience focused biotech came in at  3 6 billion  up 5  from the year ago quarter  Sales also beat the Zacks Consensus Estimate of  3 53 billion  Sales growth was primarily led by higher sales of its key multiple sclerosis drugs and continued global launch of spinal muscular atrophy  SMA  drug  Spinraza  The stock has gained 33 9  since the earnings release on Nov 1 On Oct 23  Alexion Pharmaceuticals   NASDAQ ALXN   posted third quarter 2019 adjusted earnings per share of  2 79  which rose 38  from the year ago quarter s  2 02  Earnings also outpaced the Zacks Consensus Estimate of  2 49  Revenues were up 23  year over year to  1 26 billion and surpassed the Zacks Consensus Estimate of  1 24 billion  Revenues were led by higher sales of Soliris  Strensiq  Kanuma and the uptake of Ultomiris Alexion raised its revenue and earnings view for 2019  The company expects adjusted earnings per share of  10 25  10 40  up from the previous guidance of  9 65  9 85  Alexion projects revenues of  4 86  4 89 billion against the prior outlook of  4 75  4 80 billion  Combined revenues from Soliris and Ultomiris are expected at  4 18  4 20 billion  up from  4 10  4 13 billion guided previously  The stock has gained 10 2  since the earnings release on Nov 1 Biotech ETFs in FocusIn the current scenario  we believe it is prudent to discuss a few ETFs which have a relatively wide exposure to the companies discussed iSharesNasdaq Biotechnology ETF This fund seeks to provide exposure to U S  biotechnology stocks and tracks the NASDAQ Biotechnology Index  It comprises 218 holdings with the above mentioned companies taking about 24  of the fund  It has AUM of  7 04 billion and charges a fee of 47 basis points a year  The fund carries a Zacks ETF Rank  2  Buy  with a High risk outlook  read    VanEck Vectors Biotech ETF   LON BBH  The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production  marketing and sales of drugs based on genetic analysis and diagnostic equipment  It holds about 25 securities in its basket  with the concerned companies having 28  weight in the fund  Its AUM is  343 8 million and expense ratio is 0 35   The fund carries a Zacks ETF Rank  2 with a High risk outlook SPDR S P Biotech  NYSE XBI  ETF The fund seeks daily investment results  before fees and expenses  which match the S P Biotechnology Select Industry Index  It holds about 117 securities in its basket and puts about 7  weight in the in focus companies  Its AUM is  3 85 billion and expense ratio is 0 35   The fund carries a Zacks ETF Rank  2 with a High risk outlook  read    First Trust Amex Biotechnology Index The fund measures the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services  It holds about 31 securities in its basket with the concerned companies having 14 3  weight in the fund  Its AUM is around  1 67 billion and expense ratio is 0 57   The fund carries a Zacks ETF Rank  3  Hold  with a High risk outlook Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-11-04,Zacks Investment Research,https://www.investing.com/analysis/biotech-etfs-in-focus-on-impressive-q3-earnings-results-200481983,200481983
128562,350077,BIIB,Biogen Inc Earnings  Revenue beat in Q4,news,"Investing com   Biogen Inc  NASDAQ BIIB  reported fourth quarter earnings  that beat analysts  expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  6 99 on revenue of  3 53B  Analysts polled by Investing com forecast EPS of  6 73 on revenue of  3 39B  That compared to EPS of  5 26 on revenue of  3 31B in the same period a year earlier  The company had reported EPS of  7 4 on revenue of  3 44B in the previous quarter 

Biogen Inc follows other major Healthcare sector earnings this month
 On January 22  J J reported fourth quarter EPS of  1 97 on revenue of  20 39B  compared to forecasts of EPS of  1 95 on revenue of  20 2B 
Abbott Labs earnings matched analyst s expectations on January 23  with fourth quarter EPS of  0 81 on revenue of  7 77B  Investing com analysts expected EPS of  0 81 on revenue of  7 81B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-01-29,Investing.com,https://www.investing.com/news/stock-market-news/biogen-inc-earnings-revenue-beat-in-q4-1761187,1761187
128563,350078,BIIB,Takeda s dengue vaccine successful in late stage study,news,Results from a Phase 3 clinical trial evaluating Takeda Pharmaceutical s  NYSE TAK  dengue vaccine candidate TAK 003 showed that it was effective in preventing dengue fever caused by any of the four serotypes of the virus  No safety signals were observed The study  called TIDES  is ongoing  Additional data are expected later this year  as are results from other Phase 3 trials Now read ,2019-01-29,Seeking Alpha,https://www.investing.com/news/stock-market-news/takedas-dengue-vaccine-successful-in-latestage-study-1761394,1761394
128564,350079,BIIB,Boehringer Ingelheim teams up with IBM to explore use of blockchain in clinical trials,news,Boehringer Ingelheim will collaborate with  IBM   NYSE IBM  to explore the use of blockchain technology in clinical trials  specifically to determine if blockchain can improve trial quality and patient safety at reduced cost via a decentralized framework enabling data integrity  provenance  transparency  patient empowerment and process automation Financial terms are not disclosed Selected tickers  XLV  XBI  PFE  MRK  BMY  NVS  TEVA  TAK  BHC  OTCQX RHHBY  ABBV  AZN  GSK  BIIB  AMGN  GILD  LLYNow read ,2019-02-12,Seeking Alpha,https://www.investing.com/news/stock-market-news/boehringer-ingelheim-teams-up-with-ibm-to-explore-use-of-blockchain-in-clinical-trials-1777118,1777118
128565,350080,BIIB,Biotech Companies Slump Midday With FDA Chief Set to Leave,news,"Investing com   Biotechnology companies were among the hardest hit midday  as the sector was rocked by news of U S  Food and Drug Administration Commissioner Dr  Scott Gottlieb leaving the agency 
Gottlieb said in a letter addressed to the agency that he is leaving to be with family 
 It s is hard for me to write this note to share with you the news that I ll be leaving my job as the Commissioner of Food and Drugs in the next month  There s perhaps nothing that could pull me away from this role other than the challenge of being apart from my family for these past two years and missing my wife and three young children   he said 
The news  announced on Tuesday  dragged on sector as the future of drug approvals becomes uncertain 
Biogen  NASDAQ BIIB  fell 1 37   while Amgen  NASDAQ AMGN  slipped 2 6  and  Nektar Therapeutics   NASDAQ NKTR  slumped 4 14  
Overall  the Nasdaq Biotechnology index fell 2 3  and the S P 500 health care sector was down 1  ",2019-03-06,Investing.com,https://www.investing.com/news/stock-market-news/biotech-companies-slump-as-fda-chief-leaves-1799556,1799556
128582,350097,BIIB,Biogen  BIIB  Up 40  On Alzheimer s Drug   More,opinion,Tuesday  October 22  2019 A couple of front office shakeups take the headlines this morning  in lieu of new economic data which   outside of new earnings reports   won t be forthcoming until Thursday  are making headlines today  And one S P 500 company is up 40  on pre market earnings  Japanese conglomerate SoftBank has announced it will be taking over WeWork  the company experiencing delays in its IPO launch thus far in 2019  for around  8 billion  This takeover includes nearly  1 7 billion for beleaguered founder Adam Neumann  including  185 million in  consulting fees   and  500 million in extended credit to the WeWork founder  For his part  Neumann will be obliged to sell  1 billion in WeWork stock  Many WeWork employees had been hopeful they would be able to collect from the expected  20 billion IPO  but as it turns out  SoftBank CEO Masa Son appears to be buying out Neumann and perhaps laying off 2000 WeWork employees  Quite a turn of events   we look forward to fleshing out this story as it unfolds  Also  Under Armour   NYSE UAA   CEO Kevin Plank has announced he ll be stepping down from day to day duties at the company he founded in 1996  Plank will retain the title of Executive Chairman but turn over the CEO job to Under Armour COO Patrik Frisk  who came aboard in the summer of 2017 to help with UA distribution  This transition is expected to complete on January 1st  2020  McDonalds   NYSE MCD   has missed earnings estimates in its third consecutive quarter  posting  2 11 per share  9 cents light of the Zacks consensus  Quarterly sales of  5 43 billion was beneath the  5 48 billion expected  While global comps surprised to the upside    5 9  vs   5 6  anticipated   U S  comps missed expectations   4 8  vs   5 2   McDonalds continues to spend on technical acquisitions  which may help explain its earnings shortfall  Biotech giant Biogen   NASDAQ BIIB    on the other hand  has zoomed up 40  on its Q3 earnings report this morning  but even more on its news that its treatment for Alzheimer s disease  aducanumab  shows promise in reducing signs of the disease in a sample of patients  Biogen will now seek clearance from the Food   Drug Administration  FDA   This is about as  game changer  as a drug can get  at least in the early stages  As far as earnings  Biogen posted  9 17 per share vs   8 28 expected  Revenues of  3 6 billion outperformed the  3 53 billion expected  up 5  year over year   Mark VickerySenior Editor  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 50  per year  So be sure to give these hand picked 7 your immediate attention ,2019-10-21,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-up-40-on-alzheimers-drug--more-200476201,200476201
128583,350098,BIIB,Biotech ETFs Surge On A Flurry Of Positive News,opinion,The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities  This is especially true as the ultra popular SPDR S P Biotech  NYSE XBI  ETF  jumped 4 1  over the past week compared to a gain of just 0 04  for the broad market fund   ASX SPY   Inside the NewsThe latest is Biogen   NASDAQ BIIB    which skyrocketed 26  on Oct 22  on the news that its treatment for Alzheimer s disease  aducanumab  shows promise in reducing signs of the disease in a sample of patients  Biogen plans to seek approval for aducanumab in early 2020 and it would continue talks with regulatory authorities in international markets  including Europe and Japan  If approved  Biogen s drug would be the first to slow cognitive decline in Alzheimer s patients  a milestone in long running efforts to find a medicine that can treat the memory robbing disease Aducanumab belongs to a class of drugs that removes plaque in the brain called amyloid  Amyloid is a hallmark of Alzheimer s disease  New analysis from the Emerge and Engage studies show that aducanumab is pharmacologically and clinically active  It not only removed amyloid plaque in the brain  but also slowed clinical decline in patients with early Alzheimer s disease  A solid Q3 earnings report also added to Biogen s strength  see    Hepion Pharmaceuticals   NASDAQ HEPA   soared last week following data that showed potential for its CRV431 as a drug candidate for liver disease treatment  A pan cyclophilin inhibition  CRV431  is well suited to address multiple therapeutic needs that are currently either underserved  or completely absent  It reduces fibrosis and tumor development in chronic liver disease models The last but not the least  Alexion Pharmaceuticals   NASDAQ ALXN    which joined the ongoing M A wave in the pharma biotech sector  added to the strength in the space  The company agreed to acquire a clinical stage biopharmaceutical company Achillion Pharmaceuticals   NASDAQ ACHN   for  930 million in a move to expand its pipeline of rare disease treatments  Under the terms of the deal  Alexion will pay  6 30 for each Achillion share outstanding  which is 73  higher than the Oct 15 closing price  The deal also includes potential for an additional payment for Achillion shares in the form of contingent value rights  CVRs  to be paid if certain clinical and regulatory milestones are achieved  The transaction is expected to close in the first half of 2020  subject to approvals  including Achillion shareholders ETF ImpactAll these developments are fueling growth in the biotech companies  leading to a rally in their share prices and impressive levels of momentum in biotech ETFs  This suggests that a tilt toward biotech is definitely a good idea  Below  we highlight five biotech ETFs that have been leading the way higher over the past week Virtus LifeSci Biotech Clinical Trials ETF   ASX BBC     Up 8 2 This fund has a novel approach to biotechnology investing with exposure to companies that are in the clinical trial stage  This can easily be done by tracking the LifeSci Biotechnology Clinical Trials Index  BBC has amassed  23 1 million in its asset base and charges 79 bps in fees per year from its investors  It trades in a light average daily volume of around 4 000 shares and holds 97 securities in its basket with each accounting for less than 2 7  share  The product has gained 20 6  and carries a Zacks ETF Rank  3  Hold  with a High risk outlook ALPS Medical Breakthroughs ETF   SI SBIO     Up 5 6 This fund provides exposure to companies with one or more drugs in Phase II or Phase III FDA clinical trials by tracking S Network Medical Breakthroughs Index  It holds 78 securities in its basket with none accounting for more than 4 8  share  The product charges 50 basis points in fees per year from investors and trades in a moderate average daily volume of about 34 000 shares  It has AUM of  166 3 million in its asset base and has a Zacks ETF Rank  3 with a High risk outlook  read    Principal Healthcare Innovators Index ETF    Up 4 8 This fund offers access to early phase companies developing treatments for conditions like migraines  Crohn s disease  multiple sclerosis  diabetes  and other illnesses by tracking the Nasdaq Healthcare Innovators Index  It holds 190 stocks in its basket with none making up for more than 4 7  of assets  BTEC charges 42 bps in annual fees  The product has accumulated  51 4 million in its asset base  It has a Zacks ETF Rank  3 iShares Genomics Immunology and Healthcare ETF    Up 4 3 This ETF has newly debuted in the space and follows the NYSE FactSet Global Genomics and Immuno Biopharma Index  which offers exposure to developed and emerging market companies that could benefit from long term growth and innovation in genomics  immunology  and bioengineering  Holding 44 stocks in its basket  it is widely spread across components with none accounting for more than 6 24  of assets  The fund has gathered  22 5 million in AUM since its inception on Jun 11 but trades in paltry average daily volume of 2 000 shares  It charges 47 bps in annual fees  read    Virtus LifeSci Biotech Products ETF   BS BBP     Up 4 2 The ETF follows the LifeSci Biotechnology Products Index  which measures the performance of biotechnology companies with at least one drug therapy approved by the FDA  Holding 41 stocks  the product has moderate concentration across components with each holding less than 4 6  share  The product has accumulated AUM of about  25 9 million and charges 79 bps in fees per year  BBP trades in volume of 3 000 shares a day on average and has a Zacks ETF Rank  3 with a High risk outlook Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-10-22,Zacks Investment Research,https://www.investing.com/analysis/biotech-etfs-surge-on-a-flurry-of-positive-news-200476934,200476934
128584,350099,BIIB,Top Ranked Sector ETFs To Buy For Q4,opinion,"This year has been pretty decent for Wall Street with the S P 500 adding about 20  despite trade tensions between the United States and several other countries  mainly China  slowdown in developed economies  geopolitical woes and Brexit 
However  the fourth quarter draws the maximum investor attention as festivities during this period generate huge business for many industries Chances of more dovishness from the Fed and a likely U S  China trade deal  though partial  could be encouraging developements this fourth quarter 
 Over the past three decades back to 1989  the Dow  4 3    S P  3 6   and Nasdaq  4 7   all show gains in the fourth quarter  according to Kensho  and trade positive 75  80  of the time    
In this light  we highlight a few top ranked sectors and related ETFs 
Aerospace   Rank  1
The Industrial sector has been one of the top performers of the fourth quarter over the last 10 years with   per CNBC  However  given the slowdown in the U S  manufacturing sector  it is better to take a look at the specialized corner of the industrial sector   aerospace and defense   SPDR S P Aerospace   Defense  NYSE XAR  ETF   LON XAR    a Zack Rank  2  Buy  ETF  is a good pick here  read    
Construction   Rank  2
The Construction sector thrives in a low rate environment  Though home sales have not been great of late  the U S  homebuilders sentiment data for  is upbeat  The metric has hit the highest level since  2018  The boost in confidence level in October can be due to a drop in mortgage rates in September  iShares U S  Home Construction ETF   WA ITB    which has a Zacks Rank  3  Hold   can thus be tapped  read    
Medical   Rank  3
The broader healthcare sector gains even if there is an economic slowdown  Plus  its specialized corner   biotech   is high growth in nature  The biotech sector gets benefited from FDA approvals and solid study data  Recently  Biogen  NASDAQ BIIB  said that it is seeking regulatory approval for its Alzheimer s drug  aducanumab  even after it stopped testing the treatment  The news acted as a corner for the entire space  Health Care Select Sector SPDR Fund   a Zacks Rank  2  Buy  ETF  can easily be tapped  read    
Utilities   Rank  4
Low rate environment and utilities go hand in hand  Plus  the U S  utilities sector is thriving on several developments  One of the most significant developments in the space is the    and implementation of the same in residential and commercial buildings and industrial plants   Utilities Select Sector SPDR Fund  is a good buy in this regard  read    
Retail   Rank  5
Investors should also note that the late October December period embraces the key holiday season  which puts the spotlight on the performance of retailers  As a series of sales boosting events   Halloween  Thanksgiving  Cyber Monday  Black Friday and Christmas   fall in this quartile  the sector generally sees a sales boost  Deloitte expects sales to increase between  from a year ago  SPDR S P Retail  NYSE XRT  ETF  has a Zacks ETF Rank  2  read    
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2019-10-23,Zacks Investment Research,https://www.investing.com/analysis/topranked-sector-etfs-to-buy-for-q4-200476908,200476908
128587,350102,BIIB,Cellectis misses by  0 01  misses on revenue,news,"Cellectis   NASDAQ CLLS   Q3 GAAP EPS of   0 54 misses by  0 01 
Revenue of  2 2M   69 9  Y Y  misses by  6 26M 
Press Release
Now read ",2018-11-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/cellectis-misses-by-001-misses-on-revenue-1687025,1687025
128610,350125,BIIB,Biotech Stock Roundup  Pipeline Updates From REGN  BIIB  AMGN And More,opinion,The biotech sector saw updates from a few bigwigs last week  Both Regeneron   NASDAQ REGN   and Biogen   NASDAQ BIIB   obtained positive opinions on their drugs from the CHMP  Meanwhile  Amgen   NASDAQ AMGN   reported positive data on its leukemia drug from late stage studies Recap of the Week s Most Important Stories Positive CHMP Opinion for Regeneron s Dupixent   Regeneron and partner Sanofi  PA SASY   that the European Medicines Agency s Committee for Medicinal Products for Human Use  CHMP  has adopted a positive opinion for the label expansion of asthma drug  Dupixent  in a third indication  The CHMP recommended the approval of the drug as add on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis  CRSwNP   for whom therapy with systemic corticosteroids and or surgery do not provide adequate disease control  The positive opinion of the committee was based on two pivotal phase III trials   the 24 week SINUS 24 and 52 week SINUS 52   which evaluated Dupixent 300 mg every two weeks plus standard of care intranasal corticosteroids compared to placebo plus intranasal corticosteroids Biogen s MS Drugs Get CHMP Nod for Use in Pregnancy  Biogen  that the CHMP has given a positive opinion recommending the use of its interferon beta treatments  including Plegridy and Avonex  during pregnancy and breastfeeding in women with relapsing multiple sclerosis  MS   The committee has recommended removing pregnancy contraindications from labels of these drugs  The recommendation was based on data from real world pregnancy outcomes  which showed that exposure to interferon beta  before conception and or during the first trimester  did not lead to an increase in risk of major congenital anomalies Additionally  the company  that it has initiated a phase II III study on its spinal muscular atrophy  SMA  drug  Spinraza  nusinersen   The DEVOTE study will evaluate a higher dose of the drug to see whether it can provide greater efficacy for the treatment of SMA  Based on the long term safety profile and proven efficacy of Spinraza  the DEVOTE study will also evaluate the safety and tolerability of the drug when administered at a higher dose  Moreover  long term data from the SHINE study showed that treatment with Spinraza demonstrated improvements in or stabilization of motor function in patients as old as 21 years  who are treated for up to almost six years Amgen Announces Positive Results From Leukemia Studies  Amgen announced positive results from late stage studies on Blincyto  The 20120215 study evaluated the efficacy  safety and tolerability of the drug compared to conventional consolidation chemotherapy in pediatric patients with high risk  B cell acute lymphoblastic leukemia  ALL  at first relapse  The pre specified interim analysis of the open label phase III study showed that the primary endpoint of event free survival was met  Based on a recommendation from the Independent Data Monitoring Committee  DMC   enrollment was terminated early due to encouraging efficacy in the Blincyto arm  Meanwhile  follow up will continue as prescribed per protocol Additionally  a randomized  phase III study  AALL1331  conducted by the Children s Oncology Group  COG   using Blincyto in pediatric B cell ALL patients at first relapse  has closed to accrual for the high risk and intermediate risk arm based on the recommendation of the COG DMC   This study was also stopped early due to treatment benefit of Blincyto over chemotherapy Amgen currently carries a Zacks Rank  2  Buy    You can see  Zealand Jumps on Positive Results From Late Stage Study  Shares of Zealand Pharma A S   NASDAQ ZEAL   jumped after it announced positive results in the pediatric phase III trial with dasiglucagon for severe hypoglycemia in diabetes  Dasiglucagon is a potential first in class soluble glucagon analog  which is being developed in the ready to use HypoPal rescue pen  The dasiglucagon HypoPal rescue pen is being developed as an easy to use  fast and effective rescue treatment for diabetes patients having a severe hypoglycemic event  The trial compared the glycemic response observed after induction of hypoglycemia and administration of dasiglucagon  0 6 mg  with that of placebo and GlucaGen  1 mg   a currently marketed glucagon in powder form for reconstitution prior to injection  The primary endpoint was time to plasma glucose recovery  which was defined as the first increase in plasma glucose of greater than equal to 20 mg dL  1 1 mmol L  from baseline without administration of rescue intravenous glucose  All primary and key secondary endpoints were met Clovis Gains Rights to Pre Clinical Cancer Program   Clovis Oncology   NASDAQ CLVS   a global licensing and collaboration agreement with privately held  Germany based biotech  3B Pharmaceuticals GmbH  The deal grants Clovis the global rights  excluding Europe  to fibroblast activation protein alpha  FAP  targeted radiopharmaceutical program  3B Pharmaceuticals retains rights in Europe related to the FAP program Performance Medical   Biomedical and Genetics Industry 5YR   ReturnThe Nasdaq Biotechnology index lost 2 71  in the last five trading sessions  Among the biotech giants  Alexion  NASDAQ ALXN  lost 6 96  in the period  Over the past six months  shares of Celgene  NASDAQ CELG  have gained 12 17   whereas the Regeneron stock has slumped 26 66    See the last biotech stock roundup here   What s Next in Biotech Stay tuned for more pipeline updates 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-09-24,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-pipeline-updates-from-regn-biib-amgn-and-more-200467984,200467984
128611,350126,BIIB,Formycon  H119 Results   FYB201 FDA Filing Imminent,opinion,"Formycon AG   DE FYB  partner Bioeq IP  Bioeq  plans to file FYB201  a Lucentis biosimilar candidate  to treat neovascular age related macular degeneration  nAMD  with the FDA imminently in Q419  The US launch could be in 2021 and the EU in 2022  H119 revenues were  17 2m from partners for product development services  There are three main projects  Bioeq is the partner on FYB201  Santo on FYB203  an Eylea biosimilar candidate  and a joint venture with Aristo Pharma on FYB202  a Stelara biosimilar candidate   FYB202 is due to enter a Phase I trial soon  Formycon guides for FY19 revenues of about  35m  formerly  34m  End June cash was  7 5m  effectively  19 8m including the final  12 3m of proceeds from the  17 3m private placing in March 2019 
FYB201 and FYB203 target the major nAMD markets
Formycon has two biosimilar projects targeting the nAMD market  Based on positive 2018 data  the global exclusive partner  Bioeq  plans to make regulatory filings in Q419 in the US and in the EU in Q120  A deal with a US marketing partner is expected to be agreed to enable a launch in 2021  The EU launch is possible in 2022  Global 2018 Lucentis sales rose 9  to  3 7bn  Formycon s preclinical Eylea biosimilar candidate  FYB203  also for nAMD  is licensed to Santo in a deal worth over  100m according to management  Global sales of Eylea were  6 7bn in 2018  core patents expire in 2023  US  and 2025  EU   Formycon assumes strong biosimilar demand due to healthcare cost pressures 
A stellar opportunity through a JV
Formycon has made significant progress on FYB202  a Stelara biosimilar for Crohn s disease  psoriasis and  EU only  ulcerative colitis  through a joint venture with Aristo Pharma  Formycon owns 24 9   Stelara  2018 sales  5 2bn  has a different mode of action to anti TNF agents  lead product Humira   19 9bn in 2018  so should be protected from the fierce competition developing in the anti TNF area  The project is now guided to start imminently in Q419  formerly mid 2019  Formycon needs to fund its share of the costs   4 7m in H1  but shares the profits so this could be very lucrative  Stelara patents expire in 2023  US  and 2024  EU  
Valuation  yet to reflect likely progress from Q4 2019
Formycon s market cap is about  310m with an effective EV of  290m  In Q4  starting the regulatory review of FYB201  initiating clinical development of FYB202 and signing a US FYB201 marketing partner should add value  Including cash  unpaid placing proceeds and trade receivables  June liquid assets were  27 8m 
Consensus estimates




Share price graph




Business description
Formycon is a biotechnology company developing biosimilars  The main lead is FYB201  a Lucentis biosimilar candidate that has completed Phase III and is entering regulatory review  FYB203 is an Eylea candidate biosimilar in preclinical  They are both out licensed  FYB202  a biosimilar candidate of Stelara  is being developed in a joint venture
Financials  H119 results review
Formycon reported H1 revenues of  17 2m as research and development payments from partners vs  24 6m in H118  The operating loss was  0 7m  vs  8m in H118  including non recurring items  
The FYB202 project is run through a joint venture company  FYB202 GmbH   Co KG  with Aristo Pharma  which requires periodic investment depending on its undisclosed financial position  According to Formycon  the projected development cost is estimated at about  130m  which implies a total contribution by Formycon of  32 4m  There was an H1 investment of  4 7m in the joint venture which added to the  15 97m invested in H118 to give a balance sheet asset of  20 7m  Further investment of  12m may be required at some point 
Formycon made a  17 26m placing on 22 March 2019 with Swiss investor M H Equity  M H   The investment was at  29 90 per share for the 577 397 shares  However  M H only part paid the shares to a value of  5m  To resolve the matter on June 26 2019  Wendeln   Cie  KG  an asset management company controlled by the shareholder and Supervisory Board member Peter Wendeln  assumed all rights from the subscription by M H and acquired the 577 397 shares  This increased the combined shareholding of Peter Wendeln and companies affiliated with him from about 18 9  to about 24 6   In the 30 June balance sheet  there remained  12 3m as a creditor 




The H119 profit and loss and cash situation is summarised in Exhibit 1 with a simple projection for H2 based on Edison estimates and management guidance 
After the  17 3m cash raised  less the creditor of  12 3m  cash and cash equivalents was  7 5m  down from  12 3m as of 31 December 2018  Formycon expects H219 revenues of about  18m  Formycon has guided to a small overall reported loss for FY19  If H219 has similar expenses to H1  about  18m  year end cash after settlement of the  12 3m creditor might be about  19m  but this will vary depending on underlying development costs and unknown working capital movement and H2 JV investment  The historic financial position is shown in Exhibit 2 
A marketing partner for FYB201 in the US might be agreed  according to Formycon  in Q419  This will allow a 2021 US launch assuming an FDA approval  In Europe  regulatory review is expected from Q120 with potential launch in 2022 on European patent expiry 




Three key projects for global markets
The lead project is FYB201  a biosimilar candidate to Lucentis now entering regulatory review  The project on the Stelara biosimilar candidate has completed a pilot phase and is due to enter Phase I soon in Q419 and the Eylea biosimilar candidate  FYB203  is preclinical  Formycon estimates that it may enter clinical development in mid 2020  A further project is currently undisclosed 
Although we cite the reference product sales for each project  the in market biosimilar price will be typically lower by c 15 20  initially and possibly 30 50  if competition is tough  One element in these markets is that switching rates from established reference products to slightly cheaper  but not necessarily identical biosimilars has often been slow  For approval  a biosimilar must show comparable safety  efficacy and immunogenicity to the original  reference  products so  technically  there is no reason for prescribers not to switch  In May 2019 the FDA set out guidelines to establish full interchangeability with reference products  This might enhance US uptake of biosimilars 
A new set of EU rules were approved on 20 May 2019 and allow potential competitors to manufacture biosimilars in Europe from six months before the patent and any supplementary protection expires  Formycon does not expect this  in practice  to accelerate the launch of FYB201  but it may enable more rapid launches for other products  for example FYB202 
FYB201  viewing a competitive space
Lucentis  ranibizumab  Roche  US  Novartis  EU   had 2018 sales of  3 7bn  Ranibizumab is a humanised monoclonal antibody fragment produced in Escherichia coli cells by recombinant DNA technology  it binds vascular endothelial growth factor A  VEGF A   The later competitor product Eylea  Regeneron  initially took sales and market growth from Lucentis  The position has stabilised and Lucentis sales grew 9  in 2018  Lucentis patents expire in 2020 in the US and 2022 in Europe 
Formycon licensed FYB201 to Bioeq  based in Z rich  Bioeq comprises a joint venture between Polpharma  a Polish pharmaceutical company  and the Str ngmann family s investment company  The clinical studies for FYB201 are run by a Bioeq subsidiary  Bioeq GmbH  based in Germany  A US marketing partner is expected to be agreed  according to Formycon  in Q4 2019 
The Phase III study  COLUMBUS AMD  NCT02611778   reported its primary endpoint in May 2018  which confirmed comparable efficacy between FYB201 and Lucentis in patients with nAMD  included in wet AMD   The clinical primary endpoint measured the change in the best corrected visual acuity after eight weeks  All secondary endpoints were also met  The Phase III is now completed with no observed issues about the safety and immunogenicity of FYB201 
Competitors include 
Samsung  KS 005930  Bioepis  Korea  sales via Biogen  NASDAQ BIIB   with a Phase III  NCT03150589  completing in Q419  the primary endpoint may have completed in January with the safety phase ongoing 
Xbrane  Sweden  is partnered with STADA  a privately owned German based generics and OTC company that sells  some  in licensed biosimilars  The global Phase III  NCT03805100  XPLORE  has a primary endpoint due in May 2020  Xbrane management expect sales from Q122  STADA currently has no US distribution at all and selective EU and Asian coverage 
Roche has a novel antibody  faricimab  in a Phase III  primary data Q321  completion Q422  The excellent Phase II performance was based on one injection every 16 weeks  this might compete in the premium market after 2023  Roche is also trialling a Lucentis medical device delivery system to protect its core franchise  the primary endpoint will be reached in Q1 2021 
Novartis has filed brolucizumab  a scFv antibody fragment against VEGF A  with the FDA  This has a priority review  If approved by the FDA  in mid October  Novartis anticipates launching brolucizumab by the end of 2019  It claims a dosing interval of up to every 12 weeks 
A market complication will be biosimilar versions of Avastin  Avastin has the same mode of action as Lucentis but is a large monoclonal rather than a smaller fragment  Avastin is used off label for nAMD as it is cheaper  generic versions could accentuate this gap  This use is believed to be decreasing because the larger Avastin pack size gives handling and sterility issues 
FYB202  A stellar project
Formycon is developing a biosimilar  FYB202  to Stelara  ustekinumab  Jansen   The product is an antibody that binds interleukin 12  IL 12  and IL 23  These potent cytokines drive the immune response so neutralising them controls autoimmune diseases such as Crohn s disease and psoriasis  In Europe  it was EMA approved in July 2019 for moderate to severe active ulcerative colitis that was unresponsive to other therapies  It is not used for rheumatoid arthritis  a massive market  but is effective for psoriatic arthritis  Veale and Fearon  2015    Stelara has its main US patent expiry in September 2023 in the US and in January 2024 in Europe  Sales were  5 2bn in 2018 driven by the 2017 approval in Crohn s disease 
The general market for these anti inflammatory therapies targeting cytokines such as IL 12 and tumour necrosis factor  TNF  is likely to be competitive with the patent expiries of huge   19 9bn  global franchises such as Humira  adalimumab  an anti TNF monoclonal   mainly used for rheumatoid arthritis  but also Crohn s disease and psoriatic arthritis  Stelara has a different mode of action to anti TNF therapies as it binds a different set of inflammatory messenger proteins  This different approach might be better for some patients 
In Europe  the Humira patent expired in October 2018 and four Humira biosimilars are sold  Amgevita  Amgen  NASDAQ AMGN    Hyrimoz  Sandoz   Hulio  Mylan Fujifilm Kyowa Kirin Biologics  and Imraldi  Biogen Samsung Bioepis   International  mainly European  2018 Humira sales were  6 3bn after a 14 8  Q4 decline due to European patent expiry 
In the US  2018 sales were  13 7bn  up 9   The primary patent expired in 2016 and three biosimilars are already approved  Amjevita  adalimumab atto  Amgen  NASDAQ AMGN    Hyrimoz  adalimumab adaz  Sandoz  and Cyltezo  adalimumab adbm  Boehringer Ingelheim   with Imraldi  Biogen Samsung Bioepis  under FDA review  However  so far patents and agreements with Amgen mean that these biosimilar launches will be delayed and then phased over 2023 
FYB202 has been licensed to privately owned Aristo Pharma through a joint venture vehicle  FYB202 GmbH   Co  KG  Formycon holds 24 9  and will therefore have to fund this proportion of the clinical and development costs  amount undisclosed  but will receive that share of profits  The pilot phase of the project has ended  After FDA meetings  Phase I could now start in early Q4 2019  This implies Phase III starting in 2020 21  There are no clinical trials disclosed  Others such as Icelandic company Alvotech and Australian NeuClone are in preclinical development of Stelara candidate biosimilars  no trials are listed 
FYB203  An eye on the future
FYB203 is a preclinical project to develop an Eylea biosimilar  Regeneron had 2018 Eylea sales of  6 7bn  split  4bn US and  2 7bn international   Eylea is used in a similar way to Lucentis but has a different mode of action as it binds both VEGF A and placental growth factor  Lucentis binds only VEGF A  The Eylea maintenance dose interval is every eight weeks  double that of Lucentis although Formycon notes that in reality clinical surveys show that the use patterns are similar  US Eylea patents start to expire in 2020 but there seem to be patent extensions  Sharma et al   2018  that will prevent biosimilar competition in the US until 2023  European patents expire in 2025  In addition  Eylea formulation patents do not expire until 2027 28  Formycon has filed patents for an alternative formulation that has shown preclinical intraocular bioequivalence 
Formycon has a global licensing deal with Santo Holding and gains sales related royalties  Preclinical work is underway  a Phase I III trial might start in 2020  according to management 
Competitors include a joint development programme between Momenta Pharmaceuticals and Mylan  NASDAQ MYL  NV on the Eylea biosimilar  M710  A Phase III trial  NCT03610646  in 324 patients is underway and due to report primary data in Q120  Alteogen  South Korea  has a preclinical project  ALT L9  so it might be a potential future competitor 
Valuation  Clear pipeline and solid financial position
So far  the biosimilar business has been less aggressive than small molecule generics  This is because the technology is complex and the development and production costs of biologicals are high  which sustains margins  Formycon expects switch rates to increase due to cost pressures on healthcare systems 
Formycon s market cap is about  310m with about  1m of debt liabilities  Adding liabilities and subtracting  19 8m effective cash gives an EV of about  290m  Value progression depends on the likely royalties from FYB201 and FYB203 and the 24 9  profit share from the joint venture on FYB202  Filing for FDA and EMA review and signing a US marketing partner are anticipated short term value points 
Formycon is in a strong position on Lucentis biosimilar development with a completed  positive Phase III and planned early Q419 BLA application to the FDA with EMA submission in Q120  However  Samsung  KS 005930  Bioepis is not far behind in the US and both Samsung Bioepis and Xbrane might be ready for the European patent expiry in 2022  making the market competitive 
The other projects are further behind  but FYB202 could develop quickly through the JV  Formycon s 24 9  share of costs will need funding  this is worthwhile as it gives an increased profit share  The Stelara franchise appears not to be targeted by many developers but the related Humira EU market is a battleground  with the US protected until 2023 and competitors queuing to pile in  Stelara might be a more protected market as not all Crohn s and psoriasis patients will use anti TNF products  which might protect volume and margins  The recent EU ulcerative colitis indication extension should boost the potential market 
It is harder to assess FYB203  An Eylea biosimilar should sell very well but competitors seem  oddly  very limited to date given high sales and relatively close US patent expiry in mid 2023  The Momenta Pharmaceuticals and Mylan  NASDAQ MYL  joint venture is the clear leader so far  We would expect further entrants over the next few years  The market will also be complicated by new  long acting antibody fragment products from Novartis and Roche at premium prices  However  while the new products may be more convenient  if approved  neither of them has shown clinical superiority over Lucentis and Eylea so the biosimilar market will be substantial and very valuable 
Investment case summary
Formycon has a robust financial position with high revenues  cash for investment and a strong product pipeline targeting major global markets  It can now develop its own proprietary pipeline  which should add further value 
Although there are always technical risks and delays in development  these are manageable  more predictable and much lower than in mainstream therapeutic development  The main uncertainties are on exact product launch dates  competition and the ability of partners to market effectively in large  complex global markets  Assuming these aspects are resolved  Formycon should become one of the leading and very profitable biosimilar companies ",2019-10-02,Edison,https://www.investing.com/analysis/formycon-h119-results--fyb201-fda-filing-imminent-200469828,200469828
128612,350127,BIIB,Biogen  BIIB  To Report Q3 Earnings  What s In The Cards ,opinion,Biogen Inc    NASDAQ BIIB   is set to report third quarter 2019 results on Oct 22  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 20 71  Biogen s shares have declined 24 9  this year so far compared with the  s decrease of 6 4  in the same time frame   Biogen s earnings performance has been strong as it delivered a positive surprise in each of the four trailing quarters with the average being 8 79  Biogen Inc  Price and EPS Surprise   Let s see how things are shaping up for this announcement Factors to ConsiderSecond quarter MS revenues  excluding Ocrevus royalties  were flat over year  We do not expect it to have improved much in the third quarter  Biogen is receiving royalties on U S  sales of Roche s   OTC RHHBY   newly launched MS drug  Ocrevus  which is likely to have contributed to the top line in the third quarter Among the MS drugs  Tecfidera s U S  revenues are expected to have increased as the share of new prescriptions is rising  Meanwhile  ex U S  Tecfidera revenues are likely to have benefited from volumes increases in Europe and Japan in the third quarter  which might have offset the impact of ongoing price decreases in certain European countries  U S  sales of another MS drug  Tysabri may have been hurt by Ocrevus launch On the second quarter conference call  management said that launch of Novartis  new drug Mayzent  siponimod  has had a minimal impact on sales of Tysabri and Tecfidera  An update is expected on the upcoming call The Zacks Consensus Estimate for sales of Tecfidera in the third quarter is pegged at  1 12 billion while that for Tysabri  Global In Market sales  is  462 million Meanwhile  combined interferon revenues  Avonex and Plegridy  are likely to have declined due to transition of patients to other oral or high efficacy MS therapies as well as higher discounts and allowance Spinraza sales in the second quarter were supported by continued patient growth in U S  markets  which made up for sequentially lower sales in ex U S  markets due to positive pricing adjustment in France in the first quarter  unfavorable timing of shipments in some markets and continued transition from loading to less intensive maintenance doses in more mature markets  It remains to be seen if ex U S  sales have improved in the third quarter  The Zacks Consensus Estimate for sales of Spinraza is  519 million Interestingly biosimilars contributed significantly to Biogen s top line in the first half driven mainly by Imraldi s launch  a trend that most likely continued in the third quarter In September  Biogen and Eisai discontinued two late stage studies on its Alzheimer s disease  AD  candidate  elenbecestat  The decision was taken following a safety review conducted by the Data Safety Monitoring Board  The board s recommendation to discontinue the studies was due to unfavorable risk benefit ratio  An update on Biogen s plans for its AD program is expected on the third quarter call  especially after failure of two AD candidates this year  In March  Biogen Eisai had discontinued ENGAGE and EMERGE phase III studies on aducanumab in early AD Lower R D costs following the closing of the aducanumab and elenbecestat studies are expected to get reflected in the bottom line number Earnings WhispersOur proven model predicts an earnings beat for Biogen this earnings season because it has the right combination of two key ingredients  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for a likely positive surprise Earnings ESP  Earnings ESP  which represents the difference between the Most Accurate Estimate   8 44 per share  and the Zacks Consensus Estimate   8 26 per share   is  2 18   You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Biogen has a Zacks Rank  3  The combination of Biogen s Zacks Rank  3 and positive ESP makes us reasonably confident of an earnings beat in the upcoming release Sell rated stocks  Zacks Rank  4 or 5  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Other Stocks to ConsiderHere are some other large biotech stocks that also have the right combination of elements to beat on earnings this time around Gilead Sciences  Inc    NASDAQ GILD   with an Earnings ESP of  1 80  and a Zacks Rank  3  The company is scheduled to release results on Oct 24  You can see  Amgen  Inc    NASDAQ AMGN   has an Earnings ESP of  1 44  and a Zacks Rank  3  The company is scheduled to release results on Oct 29 Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-10-15,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-to-report-q3-earnings-whats-in-the-cards-200473960,200473960
128613,350128,BIIB,Biogen  BIIB  Q3 Earnings   Sales Beat Estimates,opinion,"Cambridge  MA based Biogen Inc    NASDAQ BIIB   holds a strong position in the multiple sclerosis   MS   market with a wide range of products including Tysabri and Tecfidera  However  as competition in the MS market intensifies  Biogen is trying to diversify beyond MS to other areas like Alzheimer s  Parkinson s  stroke  among others Biogen s earnings performance has been strong as it delivered a positive surprise in each of the four trailing quarters with the average being 8 79  Currently  Biogen has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  Biogen s third quarter 2019 earnings beat expectations  The company posted earnings of  9 17 per share while our consensus called for EPS of  8 28 Revenues Beat  Biogen posted revenues of  3 6 billion  beating the consensus estimate of  3 53 billion  Revenue increased 5  year over year Key Statistics  Revenue growth was principally driven by higher sales of its key multiple sclerosis  MS  drugs and continued global launch of spinal muscular atrophy  SMA  drug  Spinraza Tecfidera sales rose 3  year over year to  1 12 billion  Sales of Spinraza increased 17  year over year and 12  sequentially to  547 0 million To Pursue FDA Approval of Aducanumab  In a separate press release today  Biogen said it plans to submit a regulatory application seeking approval of its experimental Alzheimer s therapy to the FDA in early 2020  The regulatory application will be based on promising results from a new analysis of a larger dataset of the discontinued ENGAGE and EMERGE phase III studies in patients with early Alzheimer s disease  The new data showed that aducanumab reduced clinical decline of Alzheimer s disease in such patients Pre Market Trading  Shares rose 40  in pre market trading Check back later for our full write up on this BIIB earnings report later  Biogen Inc  Price and Consensus
     
7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 50  per year  So be sure to give these hand picked 7 your immediate attention ",2019-10-21,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-q3-earnings--sales-beat-estimates-200476158,200476158
128614,350129,BIIB,Biogen  BIIB  Beats On Q3 Earnings  Eyes FDA Nod For Aducanumab,opinion,"Biogen Inc    NASDAQ BIIB   reported third quarter 2019 earnings per share of  9 17  which comprehensively beat the Zacks Consensus Estimate of  8 28  Earnings rose 24  year over year  backed by higher revenues  lower tax rate and a lower share Sales of this neuroscience focused biotech came in at  3 6 billion  up 5  from the year ago quarter  Sales also beat the Zacks Consensus Estimate of  3 53 billion Revenue growth was principally driven by higher sales of its key multiple sclerosis  MS  drugs and continued global launch of spinal muscular atrophy  SMA  drug  Spinraza To Pursue FDA Approval for AducanumabIn a separate press release today  Biogen released results from a new analysis of a larger dataset of the discontinued ENGAGE and EMERGE phase III studies on aducanumab in patients with early Alzheimer s disease  This analysis was conducted in consultation with the FDA  We remind investors that in March  Biogen and its Japanese partner Eisai had discontinued ENGAGE and EMERGE studies following a futility analysis The new data showed that aducanumab reduced clinical decline of Alzheimer s disease in such patients as measured by the pre specified primary and secondary endpoints  The data also showed that aducanumab is  pharmacologically and clinically active  as determined by dose dependent effects in reducing accumulation of amyloid  a kind of protein  in the arteries of the brain  Based on this data  Biogen plans to submit a biologics license application  BLA  seeking approval of aducanumab to the FDA in early 2020  This new analysis of a larger dataset includes additional data that became available after the pre specified futility analysis  This includes a subset of patients getting the highest dose of the drug The promising new data from two failed studies on aducanumab have revived hopes for approval of this almost written off experimental Alzheimer s therapy Quarter in DetailProduct sales in the quarter were  2 9 billion  up 4  year over year  Royalties on sales of Roche s   OTC RHHBY   MS drug  Ocrevus were  188 million in the quarter  up 37  year over year  Though Ocrevus poses strong competition to Biogen s MS drugs  the company receives royalties on U S  sales of Ocrevus from Roche  Revenues from Biogen s share of Rituxan and Gazyva operating profits increased 9  from the year ago period to  408 million  Other revenues declined 26  in the quarter to  110 million Biogen s MS revenues of  2 35 billion in the reporter quarter  including Ocrevus royalties  rose 2  year over year but declined 2  sequentially  Tecfidera sales rose 3  year over year to  1 12 billion driven by revenue growth in international markets  However  Tecfidera global sales declined 2  sequentially  U S  sales in the quarter were  842 0 million  flat year over year while ex U S  sales were  280 4 million  up 13 1  Tysabri sales rose 3  year over year and 2  sequentially to  484 million  Tysabri U S  sales rose 3 9  to  263 0 million in the quarter  International revenues rose 1 6  to  220 6 million Combined interferon revenues  Avonex and Plegridy  in the quarter were  530 million  down 10  year over year  Avonex revenues declined 13  from the year ago quarter to  420 million  Plegridy contributed  110 million to revenues  up 2  year over year U S  Interferon revenues have been declining due to transition of patients to other oral or high efficacy MS therapies as well as higher discounts and allowance Sales of Spinraza increased 17  year over year and 12  sequentially to  547 0 million driven by higher sales in the United States as well as ex U S  markets Spinraza U S  sales were  236 7 million in the quarter  up 5 7  year over year driven by continued patient growth  In ex U S  markets  Spinraza sales rose 27 3  year over year to  310 4 million The number of patients on Spinraza grew approximately 3  in the United States and 18  outside the United States in the quarter compared with the end of the second quarter Samsung  KS 005930  Bioepis  the joint venture between Biogen and Samsung BioLogics  markets three anti TNF biosimilars in the EU   Flixabi  a biosimilar referencing J J   NYSE JNJ   Merck s Remicade   Benepali  a biosimilar referencing Amgen Pfizer s Enbrel  and Imraldi  a biosimilar referencing AbbVie s    NYSE ABBV    Humira   In the quarter  biosimilars revenues increased 36 3  year over year to  184 million driven by Imraldi which was launched in mid October last year  It generated sales of  49 million in the third quarter compared with  47 million in the second quarter  Benepali recorded sales of  116 million in the quarter  down 6  year over year  Flixabi sales of  18 million rose 63  year over year Research and development  R D  expenses rose 6  year over year to  540 million  Selling  general and administrative  SG A  expenses rose 11  year over year to  547 million Our TakeBiogen beat estimates for both earnings and sales in the third quarter  However  the results were overshadowed by Biogen s announcement that it will pursue regulatory approval of aducanumab  which pushed its stock up almost 35  in pre market trading  However  this year  till Oct 21   Biogen s shares declined 25 7  compared with the  s decrease of 5 8  in the same time frame   We like Biogen s efforts to regularly in license assets to build its pipeline  Several of these assets have transformative potential  In the third quarter alone  Biogen initiated two new clinical programs targeting Parkinson s disease and brain contusion  Nine important data readouts are expected by the end of 2020 However  Biogen is heavily reliant on sales of its drugs for MS  which is a highly competitive disease space  Also  potential competition to Spinraza from Novartis  oral gene therapy for SMA Type 1  Zolgensma  which was approved by the FDA for use in children less than 2 years old in May 2019  is a concern Biogen currently carries a Zacks Rank  3  Hold   You can see  Biogen Inc  Price  Consensus and EPS Surprise
    
 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 50  per year  So be sure to give these hand picked 7 your immediate attention ",2019-10-21,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-beats-on-q3-earnings-eyes-fda-nod-for-aducanumab-200476229,200476229
128619,350134,BIIB,TrovaGene reports Q2 results,news,TrovaGene  NASDAQ TROV   Q2 EPS of   0 44Revenue of  0 11M   10 0  Y Y Cash   cash equivalents  18 52MShares  1 19 Press ReleaseNow read ,2018-08-03,Seeking Alpha,https://www.investing.com/news/stock-market-news/trovagene-reports-q2-results-1560552,1560552
128620,350135,BIIB,Market Pulse  What s Moving Ahead of Market Close ,news,"Investing com   Wall Street was under pressure into the close Wednesday  but is on course to post a strong quarterly gain following a solid quarterly showing in tech and health care 
The U turn in U S  stocks arrived courtesy of a slump in Facebook  NASDAQ FB  as cyber thieves hacked the social media giant s platform  gaining access to as many as 50 million user accounts 
Elsewhere  Walgreens Boots Alliance  NASDAQ WBA  came under pressure late Friday after confirming it would pay a  34 5 million penalty to settle Securities and Exchange Commission allegations that the company s former chief executive and former chief financial officer failed to provide adequate warning about the risks concerning Walgreens  planned merger with Alliance Boots 
The red hot Cannabis sector continued to smoke out gains  meanwhile  as New Age Beverages  NASDAQ NBEV  soared 30  and Tilray  NASDAQ TLRY  rose nearly 7  
New Age Beverage recently announced that it will unveil its portfolio of cannabidiol  CBD  infused products during next month s North American Convenience Store show 
Healthcare  meanwhile  was on track to post its best quarter in five years  underpinned by strong quarterly gains from Eli Lilly  NYSE LLY   Biogen   NASDAQ BIIB  and  Pfizer   NYSE PFE  
Alexion Pharmaceuticals  NASDAQ ALXN   which has been on a tear in recent sessions  continued to add to gains ",2018-09-28,Investing.com,https://www.investing.com/news/stock-market-news/market-pulse-whats-moving-ahead-of-market-close-1628463,1628463
128621,350136,BIIB,Biogen Inc Earnings  Revenue beat in Q3,news,"Investing com   Biogen  NASDAQ BIIB  Inc reported third quarter earnings  that beat analyst s expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  7 15 on revenue of  3 44B  Analysts polled by Investing com expected EPS of  6 79 on revenue of  3 33B  That compared to EPS of  6 31 on revenue of  3 08B in the same period a year earlier  The company had reported EPS of  5 8 on revenue of  3 36B in the previous quarter 

For the year  Biogen Inc shares are down 1 75   under performing the S P 500 which is up 2 69  year to date 
Biogen Inc follows other major Healthcare sector earnings this month
 On October 16  J J  NYSE JNJ  reported third quarter EPS of  2 05 on revenue of  20 35B  compared to forecasts of EPS of  2 03 on revenue of  20 04B 
Novartis ADR earnings beat analyst s expectations on Thursday  with third quarter EPS of  1 32 on revenue of  12 78B  Investing com analysts expected EPS of  1 31 on revenue of  12 98B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-10-23,Investing.com,https://www.investing.com/news/stock-market-news/biogen-inc-earnings-revenue-beat-in-q3-1655063,1655063
128622,350137,BIIB,Enanta launches mid stage study on RSV candidate EDP 938  shares up 4  premarket,news,Thinly traded Enanta Pharmaceuticals  NASDAQ ENTA  is up 4  premarket on light volume on the heels of its announcement that dosing is underway in a Phase 2a clinical trial evaluating orally administered EDP 938 against respiratory syncytial virus infection in a human challenge study  Topline data should be available in Q3 2019 EDP 938 is an N protein inhibitor that targets RSV replication  The company says its mechanism of action enables it to have a high barrier of resistance against the virus and may be effective in later stages of infection Phase 1 data will be presented on November 1 at the International Respiratory Syncytial Virus Symposium in Asheville  NC  No safety signals were observed  The half life of EDP 938 was 12  9   17 6 hours Now read ,2018-10-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/enanta-launches-midstage-study-on-rsv-candidate-edp938-shares-up-4-premarket-1655509,1655509
128638,350153,BIIB,Biogen Stops Late Stage Studies On Alzheimer s Candidate,opinion,Biogen   NASDAQ BIIB   and its Japan based partner Eisai announced the discontinuation of two late stage studies evaluating their Alzheimer s disease   AD   candidate  elenbecestat  The decision was taken following a safety review conducted by the Data Safety Monitoring Board  The board s recommendation to discontinue the studies was due to unfavorable risk benefit ratio The two phase III studies with identical protocols were evaluating elenbecestat  an oral BACE inhibitor  in patients with mild cognitive impairment or mild AD  collectively known as early AD  Detailed data from these studies will be presented at future medical meetings The companies will also halt the long term extension of the phase II study  Study 202   on elenbecestat  as part of this decision However  the discontinuation was expected by investors  following the failure of another AD candidate    in March  Shares were up almost 1 9  on Sep 13  presumably as investors anticipate lower expenses with termination of another fruitless but costly program  Shares of the company have declined 21 4  so far this year compared with the  s decrease of 1 7 The decision to discontinue aducanumab development was taken following a futility analysis conducted by an independent data monitoring committee   IDMC    The analysis showed that the studies are unlikely to meet their primary endpoints  However  there were no safety concerns We remind investors that in July  Amgen  NASDAQ AMGN  along with partner Novartis   NYSE NVS   had announced the discontinuation of two pivotal phase II III studies evaluating their BACE1 inhibitor    to prevent or delay the symptoms of AD in a high risk population Alzheimer s  a fatal condition that causes progressive decline in memory  has always been a highly challenging area and not much progress has been made despite significant investments  both funds and resources   Several companies have failed to develop safe and effective treatment options for this deadly brain disease In January 2019  Roche   OTC RHHBY   discontinued two late stage studies evaluating its AD candidate  crenezumab as it was unlikely to meet primary endpoints of the studies as assessed by an IDMC In 2018  several large pharma companies  including Merck  Pfizer  NYSE PFE  and Lilly AstraZeneca stopped development of their AD candidates either due to low possibility of success or safety concerns Despite the setbacks  companies continue to invest heavily in developing AD treatments  given the high commercial potential in this market  Success in this area would lead to huge returns  This is because more than 5 million Americans are living with AD with the numbers expected to triple by 2050  per data from Alzheimer s Association  The market has immense commercial potential and companies coming out with new treatments could rake in billions of dollars in sales Biogen continues to develop another AD candidate  BAN2401  in a phase III Clarity AD study  Other companies working on Alzheimer s disease treatments include Novartis  AstraZeneca   NYSE AZN    Eisai  Alector and Amgen Biogen Inc  Price   Zacks RankBiogen currently carries a Zacks Rank  2  Buy   You can see  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2019-09-15,Zacks Investment Research,https://www.investing.com/analysis/biogen-stops-latestage-studies-on-alzheimers-candidate-200464994,200464994
128640,350155,BIIB,Alexion  ALXN  Down On News Of CFO Clancy s Departure In 2019,opinion,Shares of Alexion Pharmaceuticals  Inc    NASDAQ ALXN   were down 4 5  after it announced the departure of its current chief financial officer  Paul Clancy  later this year Shares of the biotech bigwig  have gained 5 7  in the year so far against the  s decline of 1 1   Clancy joined Alexion in July 2017  after serving Biogen  Inc    NASDAQ BIIB    Clancy will be succeeded by Aradhana Sarin  M D   who is currently the chief strategy and business officer of the company The transition will take place after the company reports third quarter results  Meanwhile  Clancy will serve Alexion as a senior advisor through mid 2020 Sarin has been with Alexion since November 2017 and taken on roles with various responsibilities The stock most likely declined due to uncertainties regarding the transition Nevertheless  the company s performance has been steady in the past year  Per Alexion  Sarin had more than 20 years  experience at global financial institutions before joining the company  with extensive knowledge of global healthcare systems and an excellent understanding of the biopharmaceutical sector    She has overseen nine business development deals at Alexion  which have diversified the company s pipeline In 2018  the company acquired Sweden based Wilson Therapeutics and added a late stage candidate  ALXN1840  formerly WTX101   to its pipeline Alexion is looking to diversify its portfolio and reduce dependence on its blockbuster drug  Soliris  In line with this  the company acquired a clinical stage biotechnology company  Syntimmune  in the fourth quarter of 2018  The acquisition added anti FcRn antibody  ALXN1830  formerly SYNT001   to its pipeline  The company has also collaborated with Dicerna Pharmaceuticals to jointly discover and develop up to four subcutaneously delivered GalXC RNA interference  RNAi  candidates The company has also partnered with Complement Pharma to co develop CP010 for neurodegenerative disorders  In January 2019  Alexion entered a collaboration agreement with Caelum Biosciences to develop CAEL 101 for AL amyloidosis  a rare systemic disorder that causes misfolded immunoglobulin light chain protein to build up in and around tissues  resulting in progressive and widespread organ damage  In March 2019  the company announced a partnership with Affibody AB to co develop ABY 039 for rare Immunoglobulin G  IgG  mediated autoimmune diseases  The company is also collaborating with Zealand Pharma A S to discover and develop novel peptide therapies for up to four targets in the complement pathway Alexion recently announced a license agreement with BridgeBio Pharma  Inc  s subsidiary  Eidos Therapeutics  Inc    NASDAQ EIDX   Notably  the company was recently in news on the speculations of a potential buyout by biotech bigwig Amgen   NASDAQ AMGN    However  Amgen recently announced an agreement to purchase Celgene  NASDAQ CELG  Corporation s plaque psoriasis and psoriatic arthritis drug Otezla  thereby quashing the rumors of acquiring Alexion  Consequently  Alexion s stock declined  Nevertheless  it has been considered one of the prime candidates for acquisition from the onset of 2019  after the mega merger announcement of Bristol Myers and Celgene Alexion currently carries a Zacks Rank  2  Buy   You can see  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-09-19,Zacks Investment Research,https://www.investing.com/analysis/alexion-alxn-down-on-news-of-cfo-clancys-departure-in-2019-200466077,200466077
128641,350156,BIIB,6 Small Drug Stocks In Focus Ahead Of World Alzheimer s Day,opinion,Every year World Alzheimer s Day is observed on Sep 21  which is part of World Alzheimer s Month  The theme this year is to raise awareness to counter the common stigma surrounding Alzheimer s related dementia  The World Alzheimer s Month campaign was launched in 2012 A type of dementia  Alzheimer s disease  AD  is a progressive medical condition  The majority of AD patients are aged above 65 years  However  per estimates  approximately 200 000 people below the senior citizen age bracket are suffering from the disease in the United States alone  Most people often think that this disease is normal during one s silver years Drugs Therapies Currently ApprovedWhile there is no cure for the disease yet  there are a few drugs approved by the FDA for Alzheimer s that help control the symptoms  A class of drugs called cholinesterase inhibitors is administered to patients in the early to moderate stages of Alzheimer s  Among these  Exelon  NYSE EXC  patch is a prescription medicine used to treat mild  moderate  and severe memory problems associated with AD  Allergan s Namenda is an N methyl D aspartate  NMDA  receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer s type  Generic versions of Namenda have also been launched Failures Outweigh SuccessesAlzheimer s has always been a highly challenging area with not much progress being made in spite of significant investments  both funds and resources   Several companies have failed to develop safe and effective treatment options for this deadly brain disease  This may be somewhat because the underlying causes of severe neurological ailments like Alzheimer s may not be as clear as diseases like cancer  Also  Alzheimer s progress may go unnoticed for years   By the time  the symptoms of the ailment become evident  significant functions may be already lost  which makes developing drugs to treat this disease difficult According to the Alzheimer s Association  in the 10 years from 2002 2012  244 drugs were tested for Alzheimer s in studies registered with clinicaltrials gov  out of which only one succeeded and went on to gain FDA approval Big shots like Merck  Lilly  Biogen  NASDAQ BIIB   Amgen  NASDAQ AMGN   Novartis and Pfizer  NYSE PFE  have terminated development of candidates for AD due to failure of studies Among more recent failures  in July  Amgen Novartis discontinued two pivotal late stage studies on their BACE1 inhibitor CNP520 to prevent or delay the symptoms of AD in a high risk population as some patients in the studies experienced worsening of cognitive function  Last week  Biogen Eisai discontinued two late stage studies on elenbecestat  following a safety review conducted by the Data Safety Monitoring Board  The board s recommendation to discontinue the studies was due to unfavorable risk benefit ratio  In March  Biogen Eisai discontinued two phase III studies on aducanumab in early AD as a futility analysis showed that the studies were unlikely to meet their primary endpoints  In January  Roche  RHHBY  discontinued two late stage studies evaluating crenezumab as it was unlikely to meet primary endpoints of the studies  Roche is developing crenezumab in partnership with AC Immune   NASDAQ ACIU   Interest Still Alive in the AreaDespite the setbacks  several companies continue to invest heavily in developing AD treatments  given the high commercial potential of this market  estimated value of the U S  market for the disease is around  30 billion  and also due to an increase in the understanding of this disease  Success in this area will lead to huge returns  considering 5 8 million Americans are living with Alzheimer s disease with the numbers expected to more than double by 2050  Data  Alzheimer s Association   It is considered to be one of the biggest burdens of society and is the sixth leading cause of death across all ages in the United States  The market has immense commercial potential and companies coming out with new treatments could rake in billions of dollars in sales In 2018  the FDA proposed new guidelines  which are aimed at lowering the clinical study goals of Alzheimer s disease drugs  aimed to treat earlier stage patients who have not yet displayed functional disability or clinical abnormality  This strategy is part of FDA s ongoing efforts to expand access to safe and effective treatment options for many serious conditions  These efforts by the FDA may also reinvigorate research efforts related to Alzheimer s drugs after repeated failures Stocks in FocusLet us take a look at six small cap companies with promising candidates in their pipeline for AD AC Immune AC Immune has collaborated with Lilly is to research and develop tau aggregation inhibitor small molecules for the potential treatment of AD and other neurodegenerative diseases  In July  AC Immune dosed the first patient in a phase I study of   being developed as part of the collaboration  AC Immune is now developing crenezumab in a phase II preventive study for AD in partnership with Roche  AC Immune has a few other AD candidates in various stages of development Alector   NASDAQ ALEC   Allector  in collaboration with AbbVie  NYSE ABBV   is developing two candidates  AL003 and AL002  in early stage studies  for the treatment of AD Cassava Sciences   NASDAQ SAVA  Cassava Sciences  earlier known as Pain Therapeutics  is evaluating PT 125  a proprietary small molecule drug  in a mid stage study  for the treatment of AD  In 2019  the company expects to complete the mid stage study and announce clinical data  Moreover  it has a diagnostic test for AD  PTI 125DX is a simple blood test to detect or confirm whether a person has Alzheimer s disease  even years before symptoms appear  Its Alzheimer s program has financial support from the National Institutes of Health  NIH  vTv Therapeutics   NASDAQ VTVT   vTv Therapeutics is evaluating azeliragon in a phase II study as a potential treatment of mild Alzheimer s disease in type II diabetes patients  Top line data from the study is expected to be announced in the fourth quarter of 2020 Intra Cellular Therapies   NASDAQ ITCI  Intra Cellular Therapies is developing its lead drug candidate  lumateperone  also known as ITI 007   in phase III studies for the treatment of behavioral disturbances in patients with dementia  including AD INmune Bio   NASDAQ INMB  INmune Bio is developing XPro1595 for the treatment of mild to moderate Alzheimer s disease with biomarkers inflammation  It expects to start patient enrollment in the phase I study this year Alector  Cassava Sciences  vTv Therapeutics  Intra Cellular Therapies and AC Immune all have a Zacks Rank  3  Hold   You can see  ConclusionGiven the unmet need in the AD space and the risks associated with the disease  favorable development of any of these candidates will be a great boost to the concerned companies Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ,2019-09-19,Zacks Investment Research,https://www.investing.com/analysis/6-small-drug-stocks-in-focus-ahead-of-world-alzheimers-day-200466584,200466584
128646,350161,BIIB,AbbVie out licenses Humira patents to Mylan  biosimilar sales five years away in U S ,news,AbbVie  NYSE ABBV  inks agreements with Mylan  NASDAQ MYL  granting it a non exclusive license to market a biosimilar of HUMIRA  adalimumab  in the U S  and other countries at specific dates  Mylan will be able to sell its biosimilar in the U S  beginning on July 31  2023  for example  It will pay AbbVie royalties on net sales Mylan s U S  license will not be accelerated by Amgen s  NASDAQ AMGN  or Samsung  KS 005930  Bioepis   NASDAQ BIIB  entry  expected on January 31  2023 and June 30  2023  respectively Now read ,2018-07-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/abbvie-outlicenses-humira-patents-to-mylan-biosimilar-sales-five-years-away-in-us-1532840,1532840
128647,350162,BIIB,Top 5 Things To Know In The Market On Tuesday  Google  Harley  ATT,news,"Investing com   Here are the top five things you need to know in financial markets on Tuesday  July 24 
1  Alphabet On Track To Open At Record High After Blowout Earnings
Alphabet shares are on track to open at a record high this morning  after second quarter earnings smashed expectations  allaying fears about an immediate impact from Europe s new privacy rules 
The Google parent company reported  3 2 billion in net income for the quarter after Monday s closing bell  which works out to  4 54 a share  after accounting for a record antitrust fine out of Europe related to its Android phone software 
Without the fine  Alphabet would have reported earnings of  11 75 a share  the company said  well higher than analysts  average estimate of  9 66 a share 
Alphabet reported revenue of  26 24 billion after accounting for traffic acquisition costs  higher than the average analyst estimate of  25 58 billion 
Meanwhile  its  other revenues  category  which includes its cloud business and hardware sales and is especially important to investors looking for Google s future beyond ads  hit  4 4 billion  or a 36 5  increase year over year 
Alphabet  NASDAQ GOOGL  stock jumped 3 7  in premarket trade to an all time high of  1 249 80 
2  Harley  Verizon  AT T Highlight Busy Day Of Earnings 
The busiest week of the second quarter earnings season continues today  when 24 members of the S P 500 report results 
Harley Davidson  NYSE HOG   Verizon  NYSE VZ    Lockheed Martin   NYSE LMT   3M  NYSE MMM   United Technologies  NYSE UTX   and Biogen  NASDAQ BIIB  are set to report ahead of the opening bell 
Harley s earnings will be closely watched for any additional commentary on the company s decision last month to move some of its motorcycle manufacturing overseas as a result of tariffs imposed by the EU 
After the close  AT T  NYSE T   Texas Instruments  NASDAQ TXN  and iRobot  NASDAQ IRBT  are the big names on the docket 
AT T s earnings will pique the interest of those looking for updates on its merger with Time Warner  which was approved by regulators in June but quickly appealed by the Justice Department 
3  U S  Stock Futures Point To Higher Open 
U S  stock futures pointed to a higher open  as investors looked ahead to another wave of corporate earnings 
At 5 40AM ET  the blue chip Dow futures were up 95 points  or roughly 0 4   the S P 500 futures tacked on 6 points  or about 0 2   while the tech heavy Nasdaq 100 futures indicated a gain of 13 points  or around 0 2  
Elsewhere  in Europe  most of the region s major bourses were higher  as gains for UBS Group  SIX UBSG  and other banks helped push the market toward its first advance in four sessions 
Earlier  Shanghai shares led Asia higher  after China s cabinet said it would pursue a more vigorous fiscal policy and as traders bet on further easing in monetary conditions 
Shanghai blue chips rose 1 6  to a one month high  government bond yields jumped  and the offshore yuan hit a one year low 
4  Dollar Holds Steady  10 Year Yield Slips To 2 95 
Away from equities  the U S  dollar was little changed  amid expectations the Federal Reserve would persist with its rate hikes this year 
The U S  dollar index  which measures the greenback s strength against a basket of six major currencies  was steady at 94 39 
Elsewhere  in the bond market  U S  Treasury prices edged higher  pushing yields lower across the curve  with the benchmark 10 year yield dipping to around 2 95   while the Fed sensitive 2 year note was near 2 63  
Demand for the greenback remained underpinned despite criticism from President Donald Trump about the impact of the strength of the dollar and Federal Reserve rate hikes on the economy 
On the data front  reports on home prices from the FHFA  manufacturing activity in July from Markit Economics  and the Richmond Fed s latest manufacturing index will be released 
5  Bitcoin Hits  8 000 Again 
Bitcoin prices continued higher  climbing back above the  8 000 level for the first time since mid May  amid a raft of positive regulatory news around the world 
Prices of the world s biggest digital currency were last up around 3 6   or  286  at  8 000 30 on the Bitfinex exchange  a level last seen on May 22 
Meanwhile  Ethereum  the world s second largest cryptocurrency by market cap  was up 1 7  at  471 32 
Elsewhere  Ripple s XRP token was trading at  0 45393  little changed for the day ",2018-07-24,Investing.com,https://www.investing.com/news/economy-news/top-5-things-to-know-in-the-market-on-tuesday-google-harley-att-1542017,1542017
128648,350163,BIIB,Eisai Biogen to advance Alzheimer s drug  provide fresh hope,news,"By Julie Steenhuysen and Deena Beasley  Reuters    Eisai Co Ltd and Biogen  NASDAQ BIIB  Inc will move forward with late stage clinical trials of their Alzheimer s disease drug  BAN2401  and are working with regulators to design the next studies and gain expedited review as a breakthrough therapy  The companies announced this month that despite failing at an earlier stage  the drug slowed Alzheimer s progression at its highest dose  providing renewed hope in a field littered with failures  In interviews with Reuters  Japanese drugmaker Eisai said the treatment also worked at lower doses  Full results will be presented on Wednesday at the Alzheimer s Association International Conference in Chicago   Our plan would be to start more trials   Dr  Lynn Kramer  chief medical officer of Eisai s neurology unit  told Reuters   Whether it be Phase III in the same patient population  or other populations  We are thinking about a number of things   Kramer said the company had already contacted various regulators and plans to pursue accelerated approvals   We are certainly considering  prime  status in Europe   breakthrough  in the United States and  sakigake  in Japan   he said of various paths to potentially swifter approvals  The companies said after 18 months of treatment  patients who received the highest dose of BAN2401 saw a statistically significant improvement in cognitive and biological measures of Alzheimer s versus placebo  That was a welcome surprise as the drug did not appear to be working at the 12 month mark  The news marked a rare success for Alzheimer s research following failure after failure of candidates from companies including  Pfizer   NYSE PFE   Eli Lilly and Merck  NYSE MRK    Co  It also raised hope for aducanumab  another Biogen Eisai drug in final stage testing  Both treatments are antibodies aimed at removing toxic clumps of amyloid from the brain  Any successful Alzheimer s treatment is virtually guaranteed to become a multibillion dollar seller  Alzheimer s  the most common form of dementia  affects nearly 50 million people worldwide and is expected to rise to more than 131 million by 2050  according to Alzheimer s Disease International   All the chips are on the table with these two trials   said Dr  Ronald Petersen  an Alzheimer s expert from Mayo Clinic in Rochester  Minnesota  ALL HAD BRAIN AMYLOID One difference  experts say  is that the Eisai Biogen drugs are among the first to use PET scans to ensure study participants all have amyloid in their brains  Many dementia patients in previous trials later proved not to have the amyloid plaques the experimental drugs targeted  greatly increasing the likelihood of failure  The U S  Food and Drug Administration has said it is open to trials that measure effects on biomarkers  such as beta amyloid  rather than symptoms like memory loss  to allow companies to test treatments much earlier in the disease  The trial of 856 patients with early Alzheimer s tested BAN2401 at five doses against placebo  Participants were evaluated using an Eisai devised tool that drew from three established Alzheimer s assessment scales  Kramer said the custom endpoint was important as prior cognitive scales were developed for people with later stage disease  The trial also used an  adaptive  design that allowed Eisai to place new enrollees into groups receiving what appeared to be the most effective doses  Kramer would not reveal how many patients received the highest dose   We believe that there are plenty of patients at the higher doses  When people see the results  they will think so too   he said  While the news release only mentioned the highest dose  Kramer said other doses were also effective   There is a clear dose response   he said  The companies will likely face some skepticism  The 12 month results used a predictive  Bayesian  statistical method  while the 18 month results used traditional statistical methods to assess the drug  Kramer said the goal at 12 months was to show an 80 percent probability that patients would be 25 percent better off at the end of the trial than those who got a placebo   This was a very complicated trial design  I m not surprised that it didn t work   said Dr  Paul Aisen of the University of Southern California s Alzheimer s Therapeutic Research Institute  Aisen said he wished they had used a more traditional design from the start   Now we re left having to worry about changing the analysis after seeing some of the results and what kind of bias they may have introduced   Any positive data out of these clinical trials  has to be a good thing  even if it s small   said Gareth Howell  an Alzheimer s expert from The Jackson Laboratory in Maine  Dr  Stephen Salloway  a Brown University neurologist and an investigator on the aducanumab trials  said the BAN2401 results provide  consistent evidence that this strategy could be effective   
Kramer said there is no doubt the BAN2401 results are positive for aducanumab s prospects   It has a bigger positive implication for BAN2401   he said ",2018-07-24,Reuters,https://www.investing.com/news/stock-market-news/eisaibiogen-to-advance-alzheimers-drug-provide-fresh-hope-1542021,1542021
128649,350164,BIIB,Citron s Left reiterates belief AbbVie shares will fall sharply,news,NEW YORK  Reuters    Short seller Andrew Left s Citron Research expanded on his prediction that U S  drugmaker AbbVie Inc s  N ABBV  stock would fall to  60 a share  arguing that new regulations to speed biosimilar drugs to the market and reform rebates will hurt revenue from the company s top selling drug  Humira  Left initially tweeted the  60 a share call last Thursday  The shares fell as much as 7 percent that day before closing 4 7 percent lower  AbbVie shares closed up 2 4 percent at  91 54 on Tuesday  In a research note published on Tuesday afternoon  Left detailed his skepticism about AbbVie s prospects   There finally seems to be changes coming to the system   he wrote  AbbVie declined to comment on the report   Other analysts have said that deals AbbVie has signed with rivals such as  Amgen Inc   O AMGN   Biogen Inc  O BIIB  and Mylan NV  O MYL  to prevent them from launching biosimilar competitors to Humira until 2023 will likely protect the company from any of the moves regulators make in the near term  Last week  U S  Food and Drug Administration Commissioner Scott Gottlieb laid out a plan to increase biosimilar competition for biologic drugs  The Trump administration has proposed a rule that would scale back protections currently in place that allow rebates between drug manufacturers and insurers and pharmacy benefits managers  Humira  for rheumatoid arthritis and other autoimmune diseases  is the world s top selling prescription medicine with sales expected to exceed  20 billion this year  according to Thomson Reuters data ,2018-07-24,Reuters,https://www.investing.com/news/stock-market-news/citrons-left-reiterates-belief-abbvie-shares-will-fall-sharply-1543305,1543305
128659,350174,BIIB,Why Is Alkermes  ALKS  Down 3 9  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Alkermes  ALKS   Shares have lost about 3 9  in that time frame  outperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Alkermes due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Alkermes Earnings and Sales Beat Estimates in Q2Alkermes reported earnings of 9 cents per share in the second quarter of 2019  down from earnings of 29 cents in the year ago quarter  However  earnings surpassed the Zacks Consensus Estimate of a loss of 10 cents The company s revenues of  279 9 million in the quarter declined 8 1  from the year ago quarter  The top line  nevertheless  beat the Zacks Consensus Estimate of  254 million  The company s proprietary products   Vivitrol and Aristada   drove revenues  However  this was offset by declining sales of Ampyra  following the entry of generics into the market in 2018 Factors Impacting Q2Manufacturing and royalty revenues from Risperdal Consta  InvegaSustenna Xeplion and InvegaTrinza Trevicta were  91 9 million  up 7 9  year over year  The same from Ampyra Fampyra were down 50 3  year over year to  9 8 million due to generic competition  Research and development revenues  primarily from the collaboration with Biogen  NASDAQ BIIB  for Vumerity  diroximel fumarate   were  14 3 million  down 21 9  year over year Vivitrol sales improved about 15 8  year over year to  88 2 million Aristada sales came in at  48 4 million  up 44 1  year over year Research and development  R D  expenses were  104 4 million  down 2 2  year over year Selling  general and administrative  SG A  expenses were  155 1 million  up 12 2  year over year 2019 OutlookAlkermes now expects Aristada net sales for 2019 to be  200  210 million  down from its previous expectation of  210  230 million  Alkermes anticipates this decline in expectation to be offset by increase in royalty and manufacturing revenues However  the company maintained its total revenue guidance for 2019 along with the guidance for Vivitrol and its profit outlook  The company expects total revenues of  1 14  1 19 billion  The Zacks Consensus Estimate for 2019 revenues is  1 17 billion The company expects Vivitrol sales to be  330  350 million  It anticipates R D expenses to be  450  480 million  Alkermes  guidance for SG A expenses is  590  620 million The company expects earnings per share to be 25 43 cents  The Zacks Consensus Estimate for 2019 earnings is pegged at 34 cents Pipeline UpdateThe company expects a regulatory action from the FDA forVumerity to treat multiple sclerosis  It also intends to submit new drug application  NDA  for ALKS 3831 in both schizophrenia and bipolar I disorder  and the first efficacy data for ALKS 4230  before year end 
How Have Estimates Been Moving Since Then 
Fresh estimates followed a downward path over the past two months  The consensus estimate has shifted  29 94  due to these changes 
VGM Scores
At this time  Alkermes has an average Growth Score of C  however its Momentum Score is doing a bit better with a B  However  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Alkermes has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-08-23,Zacks Investment Research,https://www.investing.com/analysis/why-is-alkermes-alks-down-39-since-last-earnings-report-200458242,200458242
128660,350175,BIIB,Novartis   NVS  MS Drug Achieves Goals In Late Stage Studies ,opinion,"Swiss pharma giant Novartis   NYSE NVS   announced positive results on pipeline candidate ofatumumab  OMB157  from two late stage studies for the treatment of relapsing forms of multiple sclerosis  RMS  The phase III ASCLEPIOS I and II studies investigated the efficacy and safety of monthly subcutaneous ofatumumab 20mg versus once daily oral dose of Sanofi s   NASDAQ SNY   Aubagio 14mg in adults with RMS Data from the head to head studies showed that ofatumumab was superior to Aubagio in MS patients with a favorable safety profile  Both studies met the primary endpoints  Ofatumumab showed a highly significant and clinically meaningful reduction in the number of confirmed relapses  evaluated as annualized relapse rate  ARR   Key secondary endpoints of delaying time to confirmed disability progression were also met  Novartis plans to initiate submissions to health authorities by the end of 2019 Ofatumumab works by binding to the CD20 molecule on the B cell surface and inducing potent B cell lysis and depletion  If approved  ofatumumab has the potential to become a treatment option for a broad RMS population  including early MS  It will also be the first B cell therapy that can be self administered at home Novartis initiated a phase III program on ofatumumab in RMS in August 2016 after obtaining rights from Genmab in all indications  including MS  in December 2015  We note that ofatumumab is marketed by the company for oncology indications as an intravenous infusion under the brand name  Arzerra Novartis  shares have gained 3 8  in the year so far against the  s decline of 1 7  A potential approval will strengthen the company s MS portfolio  which includes approved drugs like Gilenya and Extavia  interferon beta 1b for subcutaneous injection   Earlier this year  Novartis obtained FDA approval for Mayzent  siponimod   a next generation  selective sphingosine 1 phosphate receptor modulator  for the treatment of adults with RMS  The FDA approved the drug for the treatment of secondary progressive multiple sclerosis  SPMS  with active disease  relapsing remitting multiple sclerosis  RRMS  and clinically isolated syndrome  CIS  Novartis  generic division  Sandoz  markets Glatopa  a generic version of Teva Pharmaceuticals    NYSE TEVA   Copaxone  both 20 and 40 mg  However  competition is stiff in the market  We note that Biogen  Inc    NASDAQ BIIB   holds a strong position in the MS market  with a wide range of products  including Avonex  Tysabri  Tecfidera and Plegridy Novartis currently carries a Zacks Rank  2  Buy   You can see  
Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-08-30,Zacks Investment Research,https://www.investing.com/analysis/novartis-nvs-ms-drug-achieves-goals-in-latestage-studies-200460235,200460235
128661,350176,BIIB,Amgen s KRAS Inhibitor Shows Response In Larger NSCLC Group,opinion,Amgen  Inc  s   NASDAQ AMGN   novel investigational KRAS inhibitor for solid tumor  AMG 510  showed anti tumor activity with no dose limiting toxicities in a larger group of lung cancer patients Amgen presented new data from a phase I study evaluating AMG 510 in patients with heavily pretreated KRAS G12C mutated solid tumors at IASLC 2019 World Conference on Lung Cancer  WCLC  Amgen shares have risen 6 7  this year so far compared with 2 4  decrease registered by the during this period   In June  Amgen presented encouraging early clinical data on AMG 510 at the annual meeting of the American Society of Clinical Oncology  ASCO   In the phase I study  AMG 510  when given as a monotherapy  showed encouraging anti tumor activity in patients with locally advanced or metastatic KRASG12C mutant solid tumors like non small cell lung cancer  NSCLC  and colorectal cancer  CRC  The follow up data presented at WCLC was from a larger group of NSCLC patients  The data showed that 54  of the 13 evaluable NSCLC patients  given a high dose of 960 mg once daily  experienced a partial response  Also  46  of the patients achieved stable disease for a disease control rate of 100  at the target dose We remind investors that in July  along with the second quarter results  Amgen said that AMG 510 showed responses in patients with colorectal and appendiceal cancer  Back then  Amgen had said that it is enrolling patients in a NSCLC cohort in combination with a PD 1 inhibitor  It plans to initiate a registration enabling phase II study soon KRAS gene has been a target of active exploration in cancer research and is particularly common in solid tumors  Amgen believes that AMG 510 has the potential to be developed into a successful targeted therapy to treat patients with the KRASG12C mutation due to its high selectivity for this mutation AMG510 enjoys orphan drugs status from the FDA for KRASG12C positive NSCLC and colorectal cancers Another company  Mirati Therapeutics Inc   NASDAQ MRTX   also has a candidate  MRTX849  which targets the KRAS G12C mutation Amgen currently carries a Zacks Rank  2  Buy   You can see  Some other top ranked biotech stocks include Alexion   NASDAQ ALXN   and Biogen   NASDAQ BIIB    Both carry a Zacks Rank  2 Shares of Alexion have risen 6 6  this year so far  Earnings estimates for 2019 and 2020 have risen 4 7  and 2 3   respectively over the past 60 days Earnings estimates for Biogen for 2019 and 2020 have risen 9 1  and 3 6   respectively over the past 60 days Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-09-08,Zacks Investment Research,https://www.investing.com/analysis/amgens-kras-inhibitor-shows-response-in-larger-nsclc-group-200462953,200462953
128666,350181,BIIB,J J s Ponesimod Superior To Aubagio In Relapsing MS Patients,opinion,"Janssen  a subsidiary of Johnson   Johnson   NYSE JNJ    announced that its pipeline candidate  ponesimod demonstrated superior efficacy to Sanofi s   NASDAQ SNY   blockbuster multiple sclerosis   MS   drug  Aubagio  in a phase III study  The head to head late stage OPTIMUM study evaluated 20 mg dose of ponesimod in patients with relapsing MS versus 14 mg dosage of Aubagio Data from the OPTIMUM study showed that ponesimod reduced annualized relapse rate in MS patients by statistically significant 30 5  compared to Aubagio up to 108 weeks following the treatment  The candidate also achieved a 56  reduction in cumulative number of combined unique active lesions compared to Sanofi s drug  Data from the study was presented at the annual conference of The European Committee for Treatment and Research in Multiple Sclerosis held in Stockholm  Sweden J J is planning to file regulatory applications in the United States and Europe for approval of ponesimod for treating relapsing forms of MS Share price of J J has increased 1 6  against the  s decline of 2  year to date   Please note that ponesimod was added to J J s pipeline with the June 2017  30 billion acquisition of Swiss biotech  Actelion However  several companies are developing their candidates or commercializing drugs targeting relapsing MS  Sanofi  PA SASY  itself has another drug  Lemtrada  for treating relapsing MS  Moreover  it is developing Aubagio for pediatric MS patients  However  Aubagio is set to face generic competition  starting 2023 Novartis   NYSE NVS   successfully  two late stage studies evaluating its pipeline candidate  ofatumumab for the treatment of relapsing forms of MS last month  Ofatumumab also demonstrated superiority to Aubagio in clinical studies  Meanwhile  in June  Celgene s   NASDAQ CELG   regulatory applications seeking approval for its MS candidate  ozanimod  were  for review in the United States as well as in Europe  Moreover  Biogen  NASDAQ BIIB  holds a strong position in the MS market with a wide range of products Ponesimod is likely to face competition from currently available therapies and upcoming branded as well generic drugs targeting MS Johnson   Johnson Price
    Zacks RankJ J currently carries a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-09-11,Zacks Investment Research,https://www.investing.com/analysis/jjs-ponesimod-superior-to-aubagio-in-relapsing-ms-patients-200464139,200464139
128672,350187,BIIB,Forward Pharma up 35 ,news,Thinly traded micro cap Forward Pharma A S  FWP  34 5   jumps on more than double normal volume  albeit on turnover of only 228K shares  No particular news accounts for the action A couple of weeks ago  it filed an appeal of a decision by the European Patent Office revoking its EP2801355 patent related to dimethyl fumarate  the active ingredient in Biogen  NASDAQ BIIB  s MS med Tecfidera The appeal process could take as long as three years so Forward s Tecfidera royalties should be safe until then Previously  Forward Pharma loses challenge to European patent covering dimethyl fumarate  Tecfidera royalties at risk  appeal planned  shares down 14   Jan  29 Now read ,2018-05-22,Seeking Alpha,https://www.investing.com/news/stock-market-news/forward-pharma-up-35-1458012,1458012
128673,350188,BIIB,Biogen options stroke candidate for up to  22M,news,Biogen  NASDAQ BIIB  inks an exclusive option agreement with privately held Tokyo based TMS Co   Ltd   for small molecule TMS 007  a plasminogen activator designed to restore blood flow following acute stroke  Its value proposition is an extended treatment window compared to current standard of care Under the terms of the deal  Biogen will pay  4M upfront   18M if it exercises its option  up to  335M in milestones and tiered royalties on net sales Now read ,2018-06-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/biogen-options-stroke-candidate-for-up-to-22m-1484120,1484120
128674,350189,BIIB,Incyte s Jakafi successful in mid stage study in severe form of GvHD,news,A Phase 2 clinical trial  REACH1  evaluating the combination of Incyte s  NASDAQ INCY  Jakafi  ruxolitinib  and corticosteroids in patients with steroid refractory acute graft versus host disease  aGvHD  met the primary endpoint of overall response rate  ORR   Specifically  at day 28  ORR was 55   n 39 71   The proportion of patients achieving a response at any time during the study was 73   n 52 71  The most common treatment emergent adverse events of any grade were anemia  61    thrombocytopenia  61   and neutropenia  56   The company plans to file a U S  marketing application for the Breakthrough Therapy tagged indication next quarter Related ticker   NASDAQ MESO Now read ,2018-06-21,Seeking Alpha,https://www.investing.com/news/stock-market-news/incytes-jakafi-successful-in-midstage-study-in-severe-form-of-gvhd-1501959,1501959
128675,350190,BIIB,Biogen bullishness spreads to AC Immune  up 32 ,news,Thinly traded AC Immune  ACIU  32 4   is up a 16x surge in volume in apparent concert with Biogen s  BIIB  17 9   rally related to positive Phase 2 data on early Alzheimer s candidate BAN2401  a humanized anti amyloid beta protofil monoclonal antibody One of AC Immune s Alzheimer s candidates is crenezumab  in Phase 3 development by licensee Genentech  a humanized monoclonal antibody that binds to all forms of misfolded proteins  including Tau and beta amyloid Previously  Biogen  6  after Alzheimer s drug succeeds in trial  July 5 Previously  Biogen s Alzheimer s candidate BAN2401 flunks mid stage study  Dec  21  2017 Now read ,2018-07-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/biogen-bullishness-spreads-to-ac-immune-up-32-1520200,1520200
128685,350200,BIIB,Should You Invest In The Invesco Dynamic Biotechnology   Genome ETF  PBE  ,opinion,"Designed to provide broad exposure to the Healthcare   Biotech segment of the equity market  the Invesco Dynamic Biotechnology   Genome ETF  PBE  is a passively managed exchange traded fund launched on 06 23 2005 
While an excellent vehicle for long term investors  passively managed ETFs are a popular choice among institutional and retail investors due to their low costs  transparency  flexibility  and tax efficiency 
Investor friendly  sector ETFs provide many options to gain low risk and diversified exposure to a broad group of companies in particular sectors  Healthcare   Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification  It is currently ranked 3  placing it in top 19  
Index Details
The fund is sponsored by Invesco  It has amassed assets over  241 04 M  making it one of the average sized ETFs attempting to match the performance of the Healthcare   Biotech segment of the equity market  PBE seeks to match the performance of the Dynamic Biotechnology   Genome Intellidex Index before fees and expenses 
This is comprised of stocks of 30 U S  biotechnology and genome companies  These are companies that are principally engaged in the research  development  manufacture and marketing and distribution of various biotechnological products  services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research 
Costs
Investors should also pay attention to an ETF s expense ratio  Lower cost products will produce better results than those with a higher cost  assuming all other metrics remain the same 
Annual operating expenses for this ETF are 0 59   making it one of the more expensive products in the space 
Sector Exposure and Top Holdings
While ETFs offer diversified exposure  which minimizes single stock risk  a deep look into a fund s holdings is a valuable exercise  And  most ETFs are very transparent products that disclose their holdings on a daily basis 
This ETF has heaviest allocation in the Healthcare sector  about 100  of the portfolio 
Looking at individual holdings  Bio Techne Corp  TECH  accounts for about 5 14  of total assets  followed by Biogen Inc  NASDAQ BIIB  and Amgen Inc  NASDAQ AMGN  
The top 10 holdings account for about 45 94  of total assets under management 
Performance and Risk
The ETF return is roughly 11 32  and is down about  9 37  so far this year and in the past one year  as of 08 07 2019   respectively  PBE has traded between  43 44 and  60 27 during this last 52 week period 
The ETF has a beta of 1 46 and standard deviation of 23 84  for the trailing three year period  making it a high risk choice in the space  With about 30 holdings  it has more concentrated exposure than peers 
Alternatives
Invesco Dynamic Biotechnology   Genome ETF carries a Zacks ETF Rank of 3  Hold   which is based on expected asset class return  expense ratio  and momentum  among other factors  Thus  PBE is a good option for those seeking exposure to the Health Care ETFs area of the market  Investors might also want to consider some other ETF options in the space 
SPDR S P Biotech ETF  NYSE XBI  tracks S P Biotechnology Select Industry Index and the iShares Nasdaq Biotechnology ETF  IBB  tracks Nasdaq Biotechnology Index  SPDR S P Biotech ETF has  4 B in assets  iShares Nasdaq Biotechnology ETF has  6 95 B  XBI has an expense ratio of 0 35  and IBB charges 0 47  
Bottom Line
To learn more about this product and other ETFs  screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe  please visit Zacks ETF Center ",2019-08-07,Zacks Investment Research,https://www.investing.com/analysis/should-you-invest-in-the-invesco-dynamic-biotechnology-amp-genome-etf-pbe-200452057,200452057
128686,350201,BIIB,Top Ranked Momentum Stocks To Buy For August 12th,opinion,"Here are four stocks with buy rank and strong momentum characteristics for investors to consider today  August 12th ACADIA Pharmaceuticals Inc   ACAD   This biopharmaceutical companyhas a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 6 3  over the last 60 days ACADIA Pharmaceuticals Inc  Price and Consensus   ACADIA s shares gained 12  over the last one month compared to S P 500 s fall of  3 2   The company possesses a  of B 
ACADIA Pharmaceuticals Inc  Price   Biogen Inc  NASDAQ BIIB    BIIB   This developer of innovative therapies for treating serious neurological and neurodegenerative diseases has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 8  over the last 60 days 
Biogen Inc  Price and Consensus   Biogen s shares gained 0 9  over the last one month  The company possesses a Momentum Score of A 
Biogen Inc  Price   AerCap Holdings N V   AER   This aircraft leasing company has a Zacks Rank  1  Strong Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 12 7  over the last 60 days 
Aercap Holdings N V  Price and Consensus   AerCap s shares gained 4 3  over the last one month  The company possesses a Momentum Score of A 
Aercap Holdings N V  Price   Alamos Gold Inc   AGI   This explorer and developer of gold deposits has a Zacks Rank  1  Strong Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 58 3  over the last 60 days 
Alamos Gold Inc  Price and Consensus   Alamos Gold s shares gained 16 2  over the last one month  The company possesses a Momentum Score of A 
Alamos Gold Inc  Price   See the 
Learn more about the  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-08-11,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-momentum-stocks-to-buy-for-august-12th-200454280,200454280
128688,350203,BIIB,Are Investors Undervaluing Biogen  BIIB  Right Now ,opinion,"While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks  we also know that investors tend to develop their own individual strategies  With this in mind  we are always looking at value  growth  and momentum trends to discover great companies 
Looking at the history of these trends  perhaps none is more beloved than value investing  This strategy simply looks to identify companies that are being undervalued by the broader market  Value investors use a variety of methods  including tried and true valuation metrics  to find these stocks 
On top of the Zacks Rank  investors can also look at our innovative Style Scores system to find stocks with specific traits  For example  value investors will want to focus on the  Value  category  Stocks with high Zacks Ranks and  A  grades for Value will be some of the highest quality value stocks on the market today 
One stock to keep an eye on is Biogen  BIIB   BIIB is currently sporting a Zacks Rank of  2  Buy   as well as a Value grade of A 
Another valuation metric that we should highlight is BIIB s P B ratio of 3 29  The P B ratio pits a stock s market value against its book value  which is defined as total assets minus total liabilities  This company s current P B looks solid when compared to its industry s average P B of 3 32  Over the past year  BIIB s P B has been as high as 5 85 and as low as 3 08  with a median of 4 67 
Finally  investors should note that BIIB has a P CF ratio of 7 08  This metric focuses on a firm s operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook  BIIB s P CF compares to its industry s average P CF of 7 54  Over the past 52 weeks  BIIB s P CF has been as high as 20 62 and as low as 7 04  with a median of 12 04 
These are just a handful of the figures considered in Biogen s great Value grade  Still  they help show that the stock is likely being undervalued at the moment  Add this to the strength of its earnings outlook  and we can clearly see that BIIB is an impressive value stock right now ",2019-08-13,Zacks Investment Research,https://www.investing.com/analysis/are-investors-undervaluing-biogen-biib-right-now-200455160,200455160
128691,350206,BIIB,Amgen  AMGN  Soars To 52 Week High  Time To Cash Out ,opinion,"Have you been paying attention to shares of Amgen  AMGN   Shares have been on the move with the stock up 16 1  over the past month  The stock hit a new 52 week high of  211 9 in the previous session  Amgen has gained 5 9  since the start of the year compared to the 3 8  move for the Zacks Medical sector and the  0 5  return for the Zacks Medical   Biomedical and Genetics industry 
What s Driving the Outperformance 
The stock has a great record of positive earnings surprises  as it hasn t missed our earnings consensus estimate in any of the last four quarters  In its last earnings report on July 30  2019  Amgen reported EPS of  3 97 versus consensus estimate of  3 58 while it beat the consensus revenue estimate by 3 43  
For the current fiscal year  Amgen is expected to post earnings of  14 25 per share on  22 79 billion in revenues  This represents a  1 04  change in EPS on a  4 04  change in revenues  For the next fiscal year  the company is expected to earn  14 91 per share on  22 88 billion in revenues  This represents a year over year change of 4 68  and 0 42   respectively 
Valuation Metrics
Amgen may be at a 52 week high right now  but what might the future hold for the stock  A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself 
On this front  we can look at the Zacks Style Scores  as these give investors a variety of ways to comb through stocks  beyond looking at the Zacks Rank of a security   These styles are represented by grades running from A to F in the categories of Value  Growth  and Momentum  while there is a combined VGM Score as well  The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style 
Amgen has a Value Score of B  The stock s Growth and Momentum Scores are D and B  respectively  giving the company a VGM Score of B 
In terms of its value breakdown  the stock currently trades at 14 5X current fiscal year EPS estimates  On a trailing cash flow basis  the stock currently trades at 11 4X versus its peer group s average of 14 2X  Additionally  the stock has a PEG ratio of 2 42  This isn t enough to put the company in the top echelon of all stocks we cover from a value perspective 
Zacks Rank
We also need to consider the stock s Zacks Rank  as this supersedes any trend on the style score front  Fortunately  Amgen currently has a Zacks Rank of  2  Buy  thanks to rising earnings estimates 
Since we recommend that investors select stocks carrying Zacks Rank of 1  Strong Buy  or 2  Buy  and Style Scores of A or B  it looks as if Amgen passes the test  Thus  it seems as though Amgen shares could have a bit more room to run in the near term 
How Does Amgen Stack Up to the Competition 
Shares of Amgen have been moving higher  and the company still appears to be a decent choice  but what about the rest of the industry  Some of its industry peers are also looking good  including Genomic Health  GHDX   Alexion Pharmaceuticals  NASDAQ ALXN   and Biogen  BIIB   all of which currently have a Zacks Rank of at least  2 and a VGM Score of at least B  making them well rounded choices 
The Zacks Industry Rank is in the top 38  of all the industries we have in our universe  so it looks like there are some nice tailwinds for Amgen  even beyond its own solid fundamental situation ",2019-08-13,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-soars-to-52week-high-time-to-cash-out-200455121,200455121
128697,350212,BIIB,AbbVie s JAK Inhibitor Rinvoq Receives FDA Approval For RA,opinion,"Shares of AbbVie Inc    NYSE ABBV   rose 2 3  on Aug 16 after its oral JAK inhibitor  upadacitinib  received FDA approval for the treatment of moderate to severe rheumatoid arthritis   RA   in patients who experience inadequate response or are intolerant to methotrexate  The drug will be marketed with the trade name of Rinvoq  The company is expected to launch the drug later this month The company had filed a new drug application   NDA   for upadacitinib in December 2018  seeking approval for the aforementioned indication  In February  AbbVie used a priority review voucher and the FDA granted priority review to the NDA  expediting the approval process  Meanwhile  a regulatory application for upadacitinib is under review in Europe for a similar indication Meanwhile  shares of AbbVie have declined 30 1  so far this year compared with the  s decrease of 2 4  Submission of the NDA for upadacitinib was based on encouraging data from the phase III SELECT program  which evaluated more than 4000 patients across five phase III studies on RA  In all studies  upadacitinib met every primary and secondary endpoint Data from the studies in the SELECT program showed that treatment with upadacitinib  both as a monotherapy and in combination with conventional synthetic DMARDs  led to improved symptoms of RA  better physical function and inhibited radiographic progression Approval to Rinvoq  upadacitinib  is encouraging as the drug may support long term growth of AbbVie and offset the potential decline in sales of blockbuster RA drug  Humira  following launch of biosimilars  which is scheduled for 2023  in the United States  Biosimilars of Humira have already been launched in Europe  which are severely impacted international sales of the drug  In the EU  several biosimilars have been launched by companies including Amgen   NASDAQ AMGN    Biogen   NASDAQ BIIB   and Novartis    NYSE NVS   generic subsidiary   Sandoz Humira  which is approved for multiple inflammation indications  generates nearly 60  of the company s total sales  The drug generated sales of  9 3 billion in the first half of 2019  reflecting a decrease of 5 8  year over year  The decline was the result of a year over year fall in sales by almost a third in international markets  partially offset by growth in the United States  The drug generated 75  of the sales in the United States  Launch of biosimilars in the United States will likely lead to a steep fall in sales of the drug Notably  AbbVie is developing upadacitinib for multiple indications  Apart from RA  upadacitinib is being evaluated in a mid stage study for giant cell arteritis and late stage analyses for Crohn s disease  psoriatic arthritis  ulcerative colitis and atopic dermatitis  Successful commercialization of Rinvoq in RA and development in additional indications can create a potential Humira replacement AbbVie Inc  Price
    Zacks RankAbbVie currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-08-19,Zacks Investment Research,https://www.investing.com/analysis/abbvies-jak-inhibitor-rinvoq-receives-fda-approval-for-ra-200456271,200456271
128703,350218,BIIB,Biogen boosts investment in neurology with  1 billion Ionis deal,news,By Tamara Mathias  Reuters    Biogen  NASDAQ BIIB  Inc struck a  1 billion neurology drug development deal with Ionis Pharmaceuticals on Friday  expanding a partnership that developed the company s potential blockbuster drug for spinal muscular atrophy  Biogen s shares  however  fell about 2 percent as investors were looking for a larger deal  especially after rival Novartis AG last week said it would buy AveXis Inc for  8 7 billion to gain access to its gene therapy for spinal muscular atrophy   Given the fact that just happened and    here they are a week later not buying that company and doing a  1 billion pre clinical deal  I think the Street remains very nervous and uncertain   Jefferies analyst Michael Yee told Reuters  Biogen  which has a  37 billion war chest  licensed the spinal muscular atrophy treatment Spinraza from Ionis as part of an earlier agreement   The company is now banking on Spinraza  with a list price of  750 000 for the first year  to offset slowing growth of its top selling drug Tecfidera  a treatment for multiple sclerosis  Biogen s new 10 year agreement with Ionis gives the company the option to license and commercialize a range of neurological therapies for conditions including Alzheimer s and dementia   We anticipate advancing up to seven new high potential drug candidates from these collaborations into the clinic in the next two years   Biogen executives said on a conference call  The executives also highlighted strong safety data for treatments Ionis is working on  including a class of medicines called antisense oligonucleotides over gene therapies   Opportunities for antisense technology are by far broader and larger  than gene therapy   and technology is far more validated   Ionis executives said on a conference call  California based Ionis is also eligible to receive milestone based payments  license fees and royalties on net sales of the drugs as per the deal  The agreement  which comes ahead of Biogen s first quarter earnings report on Tuesday  includes a  625 million equity investment in Ionis and a  375 million upfront payment  Ionis  shares rose 4 7 percent in early trading on Friday ,2018-04-20,Reuters,https://www.investing.com/news/stock-market-news/biogen-boosts-investment-in-neurology-with-1-billion-ionis-deal-1405482,1405482
128704,350219,BIIB,Amid drug price worries  earnings to test U S  pharma  biotech shares,news,By Lewis Krauskopf NEW YORK  Reuters    Major U S  pharmaceutical and biotechnology companies  whose shares have been laggards even in a sluggish market  face a litmus test in the corporate earnings season as investors already gun shy over concerns about pressures on drug prices prepare to give a sharp eye for both hits and misses  As a group  pharmaceutical stocks in the S P 500  are down about 4 percent so far this year  while S P biotech stocks  are off about 6 percent  Even in a choppy overall market  biotech and pharma have underperformed the broader S P 500  SPX   which is little changed for 2018  Shares of Biogen Inc  O BIIB    Celgene Corp   O CELG  and Bristol Myers Squibb Co  N BMY  are all down at least 14 percent this year   While various companies have suffered regulatory and other setbacks of their own  taking a toll on their stocks  analysts say worries over prescription drug prices continue to cloud shares of pharma and biotech companies in general   We need something that will breathe excitement in the group   said Kevin Gade  a portfolio analyst who follows pharmaceutical and biotech stocks at Bahl   Gaynor Investment Counsel in Cincinnati  This week  Eli Lilly and Co  N LLY   Biogen and  Amgen Inc   O AMGN  report quarterly results on Tuesday  with  AbbVie Inc   N ABBV  and Bristol Myers due on Thursday  For the 10 largest drug and biotech companies by market value  first quarter earnings per share are expected to rise an average of 8 7 percent  according to an analysis of Thomson Reuters data  ranging from an expected rise of nearly 41 percent for AbbVie to a decline of 25 percent for  Gilead Sciences Inc   O GILD   In the earnings reports  Morningstar analyst Damien Conover will be tracking growth of important drugs  such as Merck   Co Inc s  N MRK  Keytruda and Bristol Myers  rival cancer treatment  Opdivo  Lilly s Trulicity diabetes drug and Taltz psoriasis therapy  and  Pfizer  Inc s  N PFE  Ibrance cancer medicine  Gade said that  given low sentiment  for the stocks  he will be looking for the companies to at least hit analysts  earnings estimates and ideally raise their financial outlooks  Indeed  big biotech and pharmaceutical stocks overall are trading at much steeper discounts to the broad market than they have on average over the past five years  S P 500 biotech companies recently traded at 12 6 times forward earnings  while S P 500 drug companies traded at 14 2 times  compared with 16 4 times for the overall S P 500  according to Thomson Reuters Datastream   The group is extremely cheap historically   Gade said  While pharma and biotech stocks have been laggards this year  two healthcare industries generally seen as more immune from concerns about pricing  medical device companies and makers of life science research tools  are up over 7 percent and 8 percent  respectively  Those healthcare industries have been outperformers since a watershed moment for healthcare investing  when Hillary Clinton as the Democratic presidential candidate tweeted about  price gouging  in the specialty drug market  Since that tweet in September 2015  medical device and life science tool stocks have soared  more than 50 percent and 65 percent  respectively  while pharma stocks are up only about 4 percent and biotech is down 6 percent  Drug pricing was expected to again be in the spotlight on Thursday  with President Donald Trump due to address the topic  But Trump postponed his speech to a date in the near future  the White House said on Sunday   One of the concerns people still have are pricing pressures for drugs  whether or not that will intensify either through the government channels or through  pharmacy benefit managers  Morningstar s Conover said ,2018-04-23,Reuters,https://www.investing.com/news/stock-market-news/amid-drug-price-worries-earnings-to-test-us-pharma-biotech-shares-1409504,1409504
128705,350220,BIIB,Samsung BioLogics  shares slide again  unit s valuation jump questioned,news,"By Joyce Lee and Ju min Park
SEOUL  Reuters    Shares in South Korea s Samsung BioLogics Co Ltd  KS 207940  fell 3 5 percent on Thursday  a day after losing almost  6 billion in market value as the contract biotech drugmaker was hit by a regulatory probe into its accounting rules 
South Korea s financial regulator said earlier this week it had given preliminary notice to BioLogics  an affiliate of tech giant Samsung Electronics  KS 005930   and its auditors of measures it could take concerning breach of accounting rules 
While the regulator did not elaborate  some lawmakers and an activist group have previously said BioLogics breached rules to inflate net profit before its 2016 listing  The drugmaker has denied it breached rules 
According to its stock market filing in 2016  the valuation in its books of loss making drug developing unit Samsung Bioepis jumped by 18 times to 4 8 trillion won   4 5 billion  in 2015 after it switched to valuing the unlisted firm at fair market value instead of at book value 
BioLogics said on Wednesday it treated Bioepis as an affiliate  not a unit  from 2015 and thus switched to fair market valuation  because it could lose control of the unit due to the possibility of the unit s minority investor Biogen Inc  O BIIB  exercising a call option to increase its stake to nearly 50 percent 
In making the switch of the valuation method  BioLogics said it followed accounting rules and recommendations by accounting experts  with the approval of country s three major accounting firms 
The change in the method helped BioLogics swing to a net profit of 1 9 trillion won in 2015 from a loss of 28 billion won a year earlier  bringing criticism that the process  ahead of its  2 billion IPO in 2016  lacked transparency and may have misled investors 
 It s unclear how they came up with the 4 8 trillion won valuation for a loss making firm  and what kind of valuation criteria they used to reach that conclusion   said Kim Eun jung at People s Solidarity for Participatory Democracy  the activist group that reported the case to the regulator last year 
 If the value was inflated  Samsung BioLogics shareholders are the victims here  
Some blamed the regulators 
 Regulators could have caught it earlier when it was being listed  I am more upset at regulators than Samsung  We are the ones damaged without any protection   said an asset manager at a local firm who sold off personal holding of BioLogics shares on Wednesday 
Shares in BioLogics  the world s No 3 biotech contract manufacturer after Lonza Group  S LONN  and Boehringer Ingelheim  have nearly trebled since its listing  The news of the notice on accounting irregularities sent shares in the  24 billion company down nearly 20 percent  its biggest daily drop  on Wednesday  The stock closed at its lowest level since January on Thursday 
Regulators are expected to begin deliberating on the case within a month before making a final decision  If they rule that BioLogics violated accounting rules  South Korea s stock exchange could then debate whether to delist the firm  an exchange official said 
Biogen  which owns approximately 5 percent of Bioepis  has yet to exercise the option  and its CFO said last week on an earnings call that it plans to do that and increase its equity stake 
  1   1 074 2700 won ",2018-05-03,Reuters,https://www.investing.com/news/stock-market-news/samsung-biologics-shares-slide-again-units-valuation-jump-questioned-1428603,1428603
128712,350227,BIIB,3 Reasons Growth Investors Will Love Biogen  BIIB ,opinion,"Growth investors focus on stocks that are seeing above average financial growth  as this feature helps these securities garner the market s attention and deliver solid returns  However  it isn t easy to find a great growth stock 
That s because  these stocks usually carry above average risk and volatility  In fact  betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss 
However  the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects  makes it pretty easy to find cutting edge growth stocks 
Biogen  BIIB  is on the list of such stocks currently recommended by our proprietary system  In addition to a favorable Growth Score  it carries a top Zacks Rank 
Studies have shown that stocks with the best growth features consistently outperform the market  And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy  
Here are three of the most important factors that make the stock of this biotechnology company a great growth pick right now 
Earnings Growth
Arguably nothing is more important than earnings growth  as surging profit levels is what most investors are after  For growth investors  double digit earnings growth is highly preferable  as it is often perceived as an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for Biogen is 16 7   investors should actually focus on the projected growth  The company s EPS is expected to grow 18 7  this year  crushing the industry average  which calls for EPS growth of 9 9  
Impressive Asset Utilization Ratio
Growth investors often overlook asset utilization ratio  also known as sales to total assets  S TA  ratio  but it is an important feature of a real growth stock  This metric shows how efficiently a firm is utilizing its assets to generate sales 
Right now  Biogen has an S TA ratio of 0 54  which means that the company gets  0 54 in sales for each dollar in assets  Comparing this to the industry average of 0 19  it can be said that the company is more efficient 
In addition to efficiency in generating sales  sales growth plays an important role  And Biogen looks attractive from a sales growth perspective as well  The company s sales are expected to grow 4 8  this year versus the industry average of 3 5  
Promising Earnings Estimate Revisions
Beyond the metrics outlined above  investors should consider the trend in earnings estimate revisions  A positive trend is a plus here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
The current year earnings estimates for Biogen have been revising upward  The Zacks Consensus Estimate for the current year has surged 8 2  over the past month 
Bottom Line
Biogen has not only earned a Growth Score of A based on a number of factors  including the ones discussed above  but it also carries a Zacks Rank  2 because of the positive earnings estimate revisions 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination indicates that Biogen is a potential outperformer and a solid choice for growth investors ",2019-07-30,Zacks Investment Research,https://www.investing.com/analysis/3-reasons-growth-investors-will-love-biogen-biib-200447095,200447095
128713,350228,BIIB,Stocks Advance In July Despite Rate Cut Selloff ,opinion,"SPECIAL ALERT  Remember  we need your input to make next week s new Zacks Ultimate Strategy Session episode the best it can be  There are two ways you can participate  1  Zacks Mailbag  In this regular segment  Kevin Matras answers your questions ranging from current market conditions  general investing wisdom  usage of the Zacks Rank or any resources of Zacks com and more  Pretty much anything goes 
	2  Portfolio Makeover  Sheraz Mian and Kevin Cook review a customer portfolio to give feedback for improvement  No need to send us personal information such as dollar value of holdings  Simply email us with all of the tickers you own 
	Just make sure to email your submissions for either one  or both  by Thursday morning  August 1  Email now to mailbag zacks com  The market got the 25 basis point cut that was widely expected on Wednesday  but the major indices still plunged on the uncertainty of future easing 
	The problem really started at Fed Chair Jerome Powell s press conference  when he said that today s action was more like a  mid cycle  policy adjustment 
	In other words  further rate cuts are possible but far from guaranteed 
	That s not what the market wanted to hear  sending the major indices sharply lower before paring some of the losses by the closing bell 
	The Dow still slumped by 1 23   or about 333 points  to 26 864 27  The NASDAQ slipped 1 19   or around 98 points  to 8175 42  while the S P dipped 1 09  to 2980 38 
	With the rate cut being so widely expected  the market wanted more  It would ve loved to hear that we were at the beginning of an easing cycle  And we know how the market can throw a tantrum when it doesn t get what it wants  Even with today s selloff though  the major indices were up for July  The NASDAQ increased more than 2   while the S P gained 1 3  and the Dow advanced 1  
	That s a second consecutive month of gains for stocks 
	In other news  this was Apple s first session since reporting a positive earnings surprise and encouraging outlook after the close yesterday  Shares of the iPhone maker were up a little more than 2  today despite the lower market 
	If you thought that all the drama was done for this week  think again  On Friday  we re getting the government s jobs report for July  It blew past expectations in June by adding 224 000  which had people nervous at the time that the Fed wouldn t cut rates at the July meeting 
	Though not a harbinger of what s coming on Friday  the ADP  NASDAQ ADP  jobs report today showed 156 000 jobs added in July  which was inline with expectations 
	Well  here we go into August  Let s hope for THREE straight months of gains  Today s Portfolio Highlights Large Cap Trader  The portfolio put the rest of its set aside cash equally into the following three stocks with 5  allocations each 
	  Biogen  NASDAQ BIIB    a leading biopharma company
	  CACI International  CACI    a provider of IT and network solutions for defense
	  Logitech Int l  LOGI     a maker of innovative peripherals for the digital world
	All three of these companies are Zacks Rank  2s  Buys  in highly ranked industries  They ve also suffered through pullbacks and have a lot of upside ground to recover  Read John s specifics on all of these new buys in the complete commentary Technology Innovators  You want to know why Brian likes the solar space right now  Take a look at portfolio position Enphase Energy  ENPH   which soared 30  on Wednesday after reporting a strong quarter  The company beat the Zacks Consensus Estimate by more than 38   while revenues of a little over  134 million topped our expectations by more than 10   Needless to say  ENPH was easily the top performer of the day among all ZU portfolios  Surprise Trader  In the past couple of quarters  WillScot  WSC  has beaten the Zacks Consensus Estimate with triple digit surprises  Now  on the eve of its next report  this provider of modular space and portable storage solutions has a positive Earnings ESP of 11 7   This Zacks Rank  2  Buy  reports after the bell tomorrow  Dave sees another low bar for its release  so he added WSC on Wednesday with a 12 5  allocation  To make room  the editor sold Skechers  SKX  for a nice 13 2  return in approximately three weeks  See the full write up for more on today s moves  Insider Trader  When Tracey bought railroad components maker Wabtec  WAB  back in late May  the company had been down more than 30  year to date  And then it suffered a panic sell off stemming from a downgrade  However  the editor remained patient  and today it paid off  The market liked its recent quarterly report  so the editor felt this was a great time to sell WAB and secure a 21 3  return in two months   Healthcare Innovators  Short sellers have begun to attack medical instruments company Penumbra  PEN  after a brokerage saw the potential for a big downside  Kevin was holding onto this name on the possibility of some M A activity  But today s pullback convinced the editor to just sell PEN and bank a nearly 25  return in about 10 months  He ll look to get back into the name once it has moved lower 
	Until Tomorrow 
	Jim Giaquinto 
Recommendations from Zacks  Private Portfolios   Believe it or not  this article is not available on the Zacks com website  The commentary is a partial overview of the daily activity from Zacks  private recommendation services  If you would like to follow our Buy and Sell signals in real time  we ve made a special arrangement for readers of this website  Starting today you can see all the recommendations from all of Zacks  portfolios absolutely free for 7 days  Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises  which we ve predicted with an astonishing 80   accuracy    Click here to  test drive  Zacks Ultimate for FREE   ",2019-07-31,Zacks Investment Research,https://www.investing.com/analysis/stocks-advance-in-july-despite-rate-cut-selloff-200448708,200448708
128716,350231,BIIB,Healthcare leads big rebound,news,A panicky start to the session has reversed big time  with the Nasdaq now up 0 5  and the S P 500 0 1   The Dow is just modestly lower Leading the way today is the healthcare sector  XLV  0 6    in particular the biotechs  IBB  2   Among the movers  JNJ  1   Merck  NYSE MRK   1   Celgene  NASDAQ CELG   2 3   Incyte  3 3   Biogen  NASDAQ BIIB   1 2  Now read ,2018-03-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare-leads-big-rebound-1322713,1322713
128717,350232,BIIB,Top Ranked Momentum Stocks To Buy For August 2nd,opinion,"Here are four stocks with buy rank and strong momentum characteristics for investors to consider today  August 2nd Agnico Eagle Mines Limited  AEM   This explorer and developer of mineral properties has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 47 1  over the last 60 days Agnico Eagle Mines Limited Price and Consensus   Agnico Eagle s shares gained 5 8  over the last one month compared to S P 500 s fall of  1 8   The company possesses a  of A 
Agnico Eagle Mines Limited Price   Biogen Inc  NASDAQ BIIB    BIIB   This developer of innovative therapies for treating serious neurological and neurodegenerative diseases has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7 1  over the last 60 days 
Biogen Inc  Price and Consensus   Biogen s shares gained 2 1  over the last one month  The company possesses a Momentum Score of A 
Biogen Inc  Price   American International Group  NYSE AIG   Inc   AIG   This provider of property casualty  life and retirement  and general insurance services has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0 6  over the last 60 days 
American International Group  Inc  Price and Consensus   American International s shares gained 0 8  over the last one month  The company possesses a Momentum Score of A 
American International Group  Inc  Price   Ally Financial Inc   ALLY   This digital financial services company has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 2 8  over the last 60 days 
Ally Financial Inc  Price and Consensus   Ally s shares gained 2 5  over the last one month  The company possesses a Momentum Score of B 
Ally Financial Inc  Price   See the 
Learn more about the  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-08-02,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-momentum-stocks-to-buy-for-august-2nd-200450245,200450245
128719,350234,BIIB,ObsEva inks  50M stock sale agreement,news,ObsEva  OBSV  0 8   enters into an agreement with Jefferies for the at the market sale of  50M of common stock  Jefferies will earn the standard 3  commision for its efforts Now read ,2018-03-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/obseva-inks-50m-stock-sale-agreement-1348550,1348550
128721,350236,BIIB,In broad healthcare bets  small stocks favored over large,news,"By Lewis Krauskopf NEW YORK  Reuters    When it comes to investing in the U S  healthcare sector  it has paid off big to bet on smaller stocks  So far this year  the healthcare sector within the small cap S P 600  SPSMCA  has gained about 14 percent as investors point to a boost from an expected pick up in deal making  Those gains far outpace the 1 5 percent decline for the healthcare sector within the S P 500  SPXHC   the benchmark for large cap U S  companies  as of Monday s close  While small cap stocks in general have fared better than large caps this year  the edge has been slight   with the overall S P 600  SPCY  up 0 8 percent versus a 0 6 percent dip for the S P 500  SPX    GRAPHIC  Smallcap health stocks in 2018     An expectation for increased acquisitions in healthcare has benefited small stocks  with deal premiums and improved valuations leading to higher share prices  investors say  The anticipation of more consolidation has gained steam as investors began anticipating the federal tax reform package that paves the way for larger companies to bring back money from overseas  Healthcare analysts also point to relatively strong innovation among smaller companies as helping their shares  while some investors cite the potential for smaller stocks to be more immune to concerns about regulatory pressures in healthcare   GRAPHIC  Small cap health stocks  performance over three years      A lot of it is all the M A and consolidation that has been going on  You are seeing it across medical devices  you pretty constantly see it in pharma and biotech  now you are seeing it in large cap deals in the insurance and  pharmacy benefit  side of things   said Jeff Jonas  a portfolio manager focusing on healthcare for Gabelli   Co   That has given the big boost   Over the past three years  small cap healthcare has also beaten large cap   65 percent to 11 5 percent   with small cap outperforming large in the four biggest industries  pharmaceuticals  biotechnology  equipment and supplies  and providers and services  The top small cap healthcare stock gainers this year include diagnostics company Abaxis Inc  O ABAX   biotech Enanta Pharmaceuticals  O ENTA  and HealthEquity Inc  O HQY   which provides health savings accounts  Among large healthcare companies  shares of biotech firms  Celgene Corp   O CELG  and Biogen Inc  O BIIB  have stumbled in 2018 amid product setbacks  along with shares of  Cigna Corp   N CI   following its planned purchase of pharmacy benefit manager Express Scripts  O ESRX    The stock price of the largest healthcare company by market value  Johnson   Johnson  N JNJ   is down about 9 percent in 2018   Big cap healthcare is generally dominated by major pharma  and they have done nothing     Same thing with big biotech   said Les Funtleyder  healthcare portfolio manager at E Squared Capital Management   The interesting science has all happened at the small cap therapeutic level   Money flows suggest a small cap strategy within healthcare gaining favor  The Powershares S P Smallcap Health Care Portfolio ETF  O PSCH  has seen its assets grow to  392 million  more than double than at the end of 2016  according to Lipper data   While more than  3 8 billion has flowed out of healthcare ETFs and mutual funds this year   66 million has flowed into the Powershares smallcap ETF  according to Lipper  Similarly  the SPDR S P Biotech ETF  P XBI   which weights large  mid and small cap biotech stocks relatively equally  has drawn  276 million in net inflows this year  The Ishares Nasdaq Biotechnology ETF  O IBB   which is more heavily weighted to large cap stocks  has had net outflows of  822 million   There s certainly more innovation in the small cap space and I don t think it s any big secret that the pipelines of the larger companies are kind of looking boring at this point      said Terry Smith  director of life sciences research at Emerald Advisers  a small cap investment firm in Leola  Pennsylvania   So they do need to buy innovation   Another factor that could be propelling smaller stocks  including biotechs  is the potential for them to be less in the crosshairs of any concerns over drug pricing  an issue that has clouded the healthcare sector since the run up to the 2016 presidential election  investors said  Smaller biotech companies typically work on fairly innovative therapies or those that address new markets  said David Heupel  a healthcare analyst for Thrivent Investment Management   GRAPHIC  Smallcap healthcare stock graphic  interactive      Typically that is not where we re so worried about price   Heupel said   It s been more in the areas of   I ve got five diabetes drugs that do the same thing  why are we allowing them to price up 6  to 8 percent every year    Greenwood Capital has an overweight position on healthcare in its small cap portfolio  but not in its large cap fund  according to Walter Todd  chief investment officer for the Greenwood  South Carolina  firm   We felt like in healthcare you had a lot of opportunity with much less risk than the large cap space   Todd said  To be sure  betting on individual small cap stocks is still a very risky endeavor  For example  biotech companies banking on one product can see huge share swings on single events  
 It is better to have a basket of them  so if one or two of the pharma or biotech companies fail  it doesn t ruin the entire portfolio   Gabelli s Jonas said ",2018-03-27,Reuters,https://www.investing.com/news/stock-market-news/in-broad-healthcare-bets-small-stocks-favored-over-large-1365371,1365371
128727,350242,BIIB,Samsung C T mulling raising up to  2 8 bln to buy stake in biopharma affiliate  MBC,news,"SEOUL  Reuters    Samsung  KS 005930  C T Corp  de facto holding company of Samsung Group  is considering raising up to 3 trillion won   2 8 billion  to buy a 30 percent stake in sub subsidiary Samsung Bioepis Co Ltd  a South Korean TV channel reported on Monday  Samsung C T has been contacting large financial institutions to raise the money  MBC reported on Monday  citing an unnamed person with knowledge of Samsung s process  Samsung Bioepis is 94 6 percent owned by Samsung BioLogics Co Ltd and 5 4 percent owned by a unit of Biogen  NASDAQ BIIB  Inc as of end 2017  according to a Bioepis filing  However  Biogen has the option to increase its stake in Bioepis to 49 9 percent  according to Biogen presentation material seen by Reuters  Samsung BioLogics has seen its shares rise to an all time high after Samsung Bioepis  which develops biosimilars   or low cost copies of blockbuster biotech drugs   signed a deal with  AbbVie Inc   NYSE ABBV  last week that allows Bioepis to sell its copy of AbbVie s blockbuster drug Humira from October 2018 onwards  Established in 2012  Samsung Bioepis now has five biosimilar drugs approved in Europe  and one approved in the United States so far  according to its website  
Samsung C T  which owns a 43 percent stake in Samsung BioLogics  did not have an immediate comment  A spokesman for Samsung BioLogics could not be reached  Samsung Bioepis said it was not in a position to comment ",2018-04-09,Reuters,https://www.investing.com/news/technology-news/samsung-ct-mulling-raising-up-to-28-bln-to-buy-stake-in-biopharma-affiliate-mbc-1385171,1385171
128734,350249,BIIB,Atara Reports Initial Data For Multiple Sclerosis Candidate,opinion,Atara Biotherapeutics  Inc    NASDAQ ATRA   announced initial ATA188 phase I safety results for patients with progressive multiple sclerosis  MS  at the 5th Congress of the European Academy of Neurology  EAN  in Oslo  Norway  The primary objective of the ongoing ATA188 phase I  dose escalating clinical study is to evaluate safety and tolerability for patients with progressive MS  ATA188 is a T cell immunotherapy targeting Epstein Barr virus  EBV  antigens  believed to be important for the potential treatment of MS   MS is a chronic autoimmune  inflammatory disease that affects axons in the central nervous system  CNS  Shares of the company have plunged 42 2  year to date against the  s growth of 5 7  Initial safety results  as of Apr 8  2019  showed that the first three ATA188 dose cohorts were well tolerated  with no dose limiting toxicities and no  3 grade treatment related  treatment emergent adverse events  The key secondary endpoints of the phase I study include measures of clinical improvement  such as expanded disability status scale  EDSS   MRI imaging and other clinical activity measures  The study is ongoing and aims to identify a recommended phase II dose  RP2D   Further  a phase Ib extension period for this study  using the RP2D  is now planned following the completion of the open label  dose escalation period MS is a crowded market  with many companies already having drugs in their portfolio approved for this indication  Biogen  Inc    NASDAQ BIIB   holds a strong position in this market with a wide range of products  including Avonex  Tysabri  Tecfidera and Plegridy  In March  swiss pharma giant Novartis AG   NYSE NVS   received FDA approval for its pipeline candidate Mayzent  siponimod   a next generation  selective sphingosine 1 phosphate receptor modulator  for the treatment of adults with relapsing forms of MS  Also Celgene s   NASDAQ CELG   ozanimod  being developed for the treatment of people with relapsing forms of MS  is under review in the United States and Europe Zacks RankAtara currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-06-30,Zacks Investment Research,https://www.investing.com/analysis/atara-reports-initial-data-for-multiple-sclerosis-candidate-200436115,200436115
128736,350251,BIIB,Amgen   Novartis  Alzheimer Studies End In Another Failure,opinion,Amgen  Inc   NASDAQ AMGN   and Novartis   NYSE NVS   have announced that they are discontinuing two pivotal phase II III studies evaluating their BACE1 inhibitor CNP520 to prevent or delay the symptoms of Alzheimer s disease  AD  in a high risk population The two studies were being conducted under the Alzheimer s Prevention Initiative Generation Program  and were sponsored by Amgen and Novartis in collaboration with Banner Alzheimer s Institute A review of clinical data from the study showed that some patients in the studies experienced worsening in cognitive function  This led the sponsors of the Generation Program to conclude that the potential benefit for participants in the studies failed to outweigh the risks Amgen s shares were down 2 3  while that of Novartis declined 1 15  on Wednesday in response to the news  So far this year  Amgen shares have declined 9 6  compared with 5 7  decrease registered by the  during this period   Alzheimer s  a fatal condition that causes progressive decline in memory  has always been a highly challenging  and not much progress has been made despite significant investments  both funds and resources   Several companies have failed to develop safe and effective treatment options for this deadly brain disease In March 2019  Biogen   NASDAQ BIIB   Eisai announced the discontinuation of  phase III studies on their pipeline candidate aducanumab in early AD  A futility analysis conducted by an independent data monitoring committee   IDMC   showed that the studies were unlikely to meet their primary endpoints In January 2019  Roche   OTC RHHBY   discontinued two late stage studies evaluating its AD candidate  crenezumab as it was unlikely to meet primary endpoints of the studies as assessed by an IDMC In 2018  several large pharma companies  including Merck  Pfizer  NYSE PFE  and Lilly AstraZeneca stopped development of their AD candidates either due to low possibility of success or safety concerns Despite the setbacks  companies continue to invest heavily in developing AD treatments  given the high commercial potential in this market  Success in this area means huge returns  This is because more than 5 million Americans are living with AD with the numbers expected to triple by 2050  Data  Alzheimer s Association   The market has immense commercial potential and companies coming out with new treatments could rake in billions of dollars in sales Companies that are currently working on AD treatments include Biogen  Novartis  AstraZeneca  Eisai and Amgen Amgen currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2019-07-11,Zacks Investment Research,https://www.investing.com/analysis/amgen--novartis-alzheimer-studies-end-in-another-failure-200439336,200439336
128737,350252,BIIB,Biogen  BIIB  Up On Q2 Earnings   Sales Beat  Raised View,opinion,"Biogen Inc    NASDAQ BIIB   reported second quarter 2019 earnings per share of  9 15 which comprehensively beat the Zacks Consensus Estimate of  7 58  Earnings rose 58  year over year  backed by higher revenues and lower R D costs  Also  a lower share count due to share buybacks in the quarter benefited earnings per share Sales of this neuroscience focused biotech came in at  3 62 billion  up 8  from the year ago quarter  Sales also beat the Zacks Consensus Estimate of  3 48 billion Revenue growth was principally driven by higher sales of its key multiple sclerosis  MS  drug  Tecfidera globally and spinal muscular atrophy  SMA  drug  Spinraza in the United States Quarter in DetailProduct sales in the quarter were  2 88 billion  up 4  year over year  Royalties on sales of Roche s   OTC RHHBY   MS drug  Ocrevus were  183 million in the quarter  up 62  year over year  Though Ocrevus poses strong competition to Biogen s MS drugs  the company receives royalties on U S  sales of Ocrevus from Roche  Revenues from Biogen s share of Rituxan and Gazyva operating profits increased 4  from the year ago period to  394 million  Other revenues rose 47  in the quarter to  160 million Biogen s MS revenues of  2 4 billion in the reporter quarter  including Ocrevus royalties  rose 3  year over year  In the second quarter  increase in channel inventory added approximately  25 million to U S  MS product revenues versus an unfavorable impact of approximately  170 million in the first quarter due to a decrease in channel inventory Tecfidera sales rose 6  year over year and 15  sequentially to  1 15 billion  U S  sales in the quarter were  869 8 million  up 5 3  year over year while ex U S  sales were  280 4 million  up 7 4  Tysabri sales rose 2  year over year and 3  sequentially to  475 million  Tysabri U S  sales were almost flat at  264 3 million in the quarter  International revenues rose 4 6  to  211 0 million Combined interferon revenues  Avonex and Plegridy  in the quarter were  554 million  down 11  year over year  Avonex revenues declined 13  from the year ago quarter to  438 million  Plegridy contributed  117 million to revenues  down 6  year over year U S  Interferon revenues have been declining due to transition of patients to other oral or high efficacy MS therapies as well as higher discounts and allowance Sales of Spinraza increased 15  year over year to  488 0 million  Spinraza sales  however  declined 6  sequentially due to lower sales in ex U S  markets Spinraza U S  sales were  230 6 million in the quarter  up almost 12  year over year  In ex U S  markets  Spinraza sales rose 18 8  year over year to  257 6 millionHowever ex U S  sales declined 12 7  sequentially due to positive pricing adjustment in France in the first quarter  unfavorable timing of shipments and a transition from loading to less intensive maintenance doses in more mature markets The number of patients on Spinraza grew approximately 4  in the United States and 17  outside the United States in the quarter compared with the end of the first quarter Samsung  KS 005930  Bioepis  the joint venture between Biogen and Samsung BioLogics  markets three anti TNF biosimilars in the EU   Flixabi  a biosimilar referencing J J   NYSE JNJ   Merck s Remicade   Benepali  a biosimilar referencing Amgen Pfizer s Enbrel  and Imraldi  a biosimilar referencing AbbVie s    NYSE ABBV    Humira   In the quarter  biosimilars revenues increased 44 9  year over year to  184 million in the quarter driven by Imraldi  The drug was launched in mid October last year  It generated sales of  47 million in the second quarter compared with  35 7 million in the first quarter  Benepali recorded sales of  120 million in the quarter  up 4  year over year  Flixabi sales of  17 million rose 50  year over year Research and development  R D  expenses declined 42  year over year to  477 million  following the closing of the aducanumab studies  In March 2019  Biogen Eisai announced the discontinuation of ENGAGE and EMERGE phase III studies on aducanumab in early Alzheimer s disease  AD   A futility analysis conducted by an independent data monitoring committee showed that the studies were unlikely to meet their primary endpoints  Also  R D costs in the second quarter of 2018 increased by  324 million attributable to an upfront payment made by Biogen to expand its agreement with partner Ionis for the identification of new gene therapies to treat SMA as well as a broad range of neurological diseases Selling  general and administrative  SG A  expenses were up 8  year over year to  553 million 2019 GuidanceThe company raised its full year expectations for revenues and earnings per share while lowering its costs and tax expense guidance The revenue guidance was raised from a range of  13 6  13 8 billion to  14 0  14 2 billion Earnings per share are now expected between  29 60 and  30 40  an increase from the prior guidance range of  26 65 and  27 65 R D costs are expected to be 15 5  to 16 5  of total revenues  less than approximately 16  to 17  expected previously  SG A costs are expected in the range of 15 5  to 16 5  of total revenues  versus the prior guidance range of approximately 16  to 17   Adjusted tax rate guidance was lowered from a range of approximately 18  to 19  to 15 5  to 16 5  Our TakeBiogen beat estimates for both earnings and sales in the second quarter and upped its financial guidance for the year  Shares rose around 2  in pre market trading in response  However  this year so far  Biogen s shares have declined 22 8  this year compared with the  s decrease of 0 2  in the same time frame   We like Biogen s efforts to regularly in license assets to build its pipeline  Several of these assets have transformative potential  In the second quarter alone  Biogen added four new programs to its pipeline including two potentially mid  to late stage clinical assets in inherited retinal disease from the June 2019 acquisition of gene therapy maker Nightstar Therapeutics Several data readouts are expected in 2019 2020 with multiple potential launches in the early 2020s However  its core MS business  excluding Ocrevus royalties  is facing rising competitive pressure  Also  potential competition to Spinraza from competitors  gene therapy programs for SMA is a concern  Though Biogen s CNS pipeline is attractive  it is a high risk area as evident from the recent failure of aducanumab and uncertainty over the future of others likeBAN2401 Biogen currently carries a Zacks Rank  3  Hold   You can see  Biogen Inc  Price  Consensus and EPS Surprise
  
   
Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-07-22,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-up-on-q2-earnings--sales-beat-raised-view-200443310,200443310
128740,350255,BIIB,Biogen  BIIB  Q2 Earnings   Sales Beat Estimates,opinion,"Cambridge  MA based Biogen Inc    NASDAQ BIIB   holds a strong position in the multiple sclerosis   MS   market with a wide range of products including Tysabri and Tecfidera  However  as competition in the MS market intensifies  Biogen is trying to diversify beyond MS to other areas like Alzheimer s  Parkinson s  stroke  among others Biogen s earnings performance has been strong as it delivered a positive surprise in each of the four trailing quarters with the average being 6 39  Currently  Biogen has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  Biogen s second quarter 2019 earnings beat expectations  The company posted earnings of  9 15 per share while our consensus called for EPS of  7 58 Revenues Beat  Biogen posted revenues of  3 62 billion  beating the consensus estimate of  3 48 billion  Revenue increased 8  year over year Key Statistics  Revenue growth was principally driven by higher sales of its key multiple sclerosis drug Tecfidera and spinal muscular atrophy  SMA  drug Spinraza in the United States Tecfidera sales rose 6  year over year and 15  sequentially to  1 15 billion  Sales of Spinraza increased 15  year over year to  488 0 million  Spinraza sales  however  declined 6  sequentially due to lower sales in ex U S  markets Ups 2019 Outlook  The company raised its full year expectations for revenues and earnings per share while lowering its costs and tax expense guidance The revenue guidance was raised from a range of  13 6  13 8 billion to  14 0  14 2 billion Earnings per share are now expected between  29 60 and  30 40  an increase from the prior guidance range of  26 65 and  27 65 The Zacks Consensus Estimate for earnings and sales stood at  29 78 per shares and  13 93 million Pre Market Trading  Shares rose around 1  in pre market trading Check back later for our full write up on this BIIB earnings report later Biogen Inc  Price and Consensus
     
Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-07-23,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-q2-earnings--sales-beat-estimates-200443098,200443098
128751,350266,BIIB,Sanofi set to buy Bioverativ for more than  11 5 billion  WSJ,news," Reuters    Sanofi  PA SASY  SA is close to a deal to take over U S  drug maker Bioverativ Inc for more than  11 5 billion  the Wall Street Journal reported  citing people familiar with the matter  The potential deal  which could be announced as soon as Monday  would value Bioverativ at about  105 a share  the Journal reported     The price represents a 64 percent premium to Bioverativ stock s close on Friday on the Nasdaq  Bioverativ  a hemophilia drug maker  was separated from Biogen  NASDAQ BIIB  Inc early last year   Sanofi has failed to land major deals after losing California based cancer specialist Medivation to  Pfizer  Inc  NYSE PFE  in 2016 and Swiss biotech company Actelion to Johnson   Johnson  NYSE JNJ  last year  Earlier this month  Sanofi said it obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with Alnylam Pharmaceuticals  
Sanofi and Bioverativ were not immediately available for comment outside regular business hours ",2018-01-21,Reuters,https://www.investing.com/news/stock-market-news/sanofi-set-to-buy-bioverativ-for-more-than-115-billion-wsj-1131967,1131967
128752,350267,BIIB,Sanofi digs deep to buy U S  haemophilia group Bioverativ for  11 6 billion,news,"By Sudip Kar Gupta PARIS  Reuters    French healthcare group Sanofi  PA SASY  has agreed to buy U S  haemophilia specialist Bioverativ for  11 6 billion  its biggest deal for seven years  which it said would strengthen its presence in treatments for rare diseases  Sanofi shares fell 3 4 percent by 0920 GMT  making the stock the worst performer on France s benchmark CAC 40 index and several analysts deemed the deal expensive  The move comes at a time of renewed interest by large drugmakers in smaller biotech firms and predictions by some experts that 2018 will see a substantial pick up in mergers and acquisitions   Sanofi has agreed to buy all of the outstanding shares of Bioverativ for  105 per share in cash  marking a premium of 64 percent to Bioverativ s closing price on January 19  Bioverativ  a maker of haemophilia drugs  was separated from Biogen  NASDAQ BIIB  Inc early last year  The agreed transaction marks Sanofi s successful return to deal making after its failure to land major takeovers in recent years  It is its biggest acquisition since the 2011 takeover of U S  biotech company Genzyme for around  20 billion  Sanofi lost out on buying California based cancer specialist Medivation to  Pfizer   NYSE PFE  in 2016  and also missed acquiring Swiss biotech company Actelion  which was bought by Johnson   Johnson  NYSE JNJ  last year   With Bioverativ  we welcome a leader in the growing haemophilia market   Sanofi Chief Executive Olivier Brandicourt said  The market dealing with treatments for haemophilia is an important one that is evolving rapidly as new drugs change the landscape  Further ahead  gene therapy promises to disrupt traditional approaches to tackling the inherited condition  Sanofi said the sector had around  10 billion in annual sales  dealing with 181 000 people affected worldwide  It added that haemophilia represented the largest market for rare diseases and was set to grow by more than 7 percent per year through to 2022   MORE DEALS  Sanofi expects the acquisition to be immediately accretive to its business earnings per share in the full 2018 financial year and up to 5 percent accretive for the following year  However  some analysts questioned the cost   Bioverativ looks a relatively expensive acquisition  It is logical in terms of building around Sanofi s presence and pipeline in rare diseases and haemophilia  though management may have to argue against concerns on competition   analysts with Jefferies wrote in a note to clients   The obvious parallel is Shire s highly unpopular acquisition of Baxalta  but Sanofi s 2011 acquisition of rare disease specialist Genzyme was also unpopular at the time  yet has it turned into a major success story   analysts with Kepler said  Sanofi added it would fund the takeover with a mixture of existing cash resources and a debt issue   We have the means to make further takeovers   added Brandicourt on a conference call  without going into further details  Brandicourt has said in the past he was ready to do deals of a similar size to the  20 billion purchase of Genzyme to help accelerate growth at France s biggest drugmaker  One asset analysts and bankers believe could be of interest is Pfizer s consumer health unit  although competition for this business is likely to be fierce   Sanofi said it expected to achieve a return on its invested capital  ROIC  in excess of the cost of capital within three years  The French group also expects to preserve its strong credit rating  This month Celgene  NASDAQ CELG  agreed to pay up to  7 billion to take over Impact Biomedicines and the U S  company is also said to be circling Juno Therapeutics  In Europe   Novo Nordisk   CO NOVOb  has offered  3 1 billion for Ablynx and Japan s Takeda Pharmaceutical plans to buy TiGenix for  630 million  The spate of deal making follows a relatively subdued 2017 for biotech M A  
Lazard advised Sanofi on the deal  while Guggenheim Securities and J P  Morgan advised Bioverativ ",2018-01-22,Reuters,https://www.investing.com/news/stock-market-news/sanofi-confirms-deal-to-buy-bioverativ-for-116-billion-1132178,1132178
128753,350268,BIIB,Biotech M A takes off as Sanofi and Celgene spend  20 billion,news,"By Ben Hirschler  Sudip Kar Gupta and Michael Erman  Reuters    Biotech deal activity exploded on Monday with French drugmaker Sanofi  PA SASY  and U S  based Celgene  NASDAQ CELG  spending a combined total of more than  20 billion to add new products for hemophilia and cancer to their medicine cabinets  The acquisitions will fuel expectations for a busy year of mergers and acquisitions  M A  as large drugmakers snap up promising assets from smaller rivals to help revive growth  Sanofi agreed to buy U S  hemophilia expert Bioverativ for  11 6 billion  its biggest deal for seven years  while Celgene is paying about  9 billion for the 90 percent of cancer specialist Juno Therapeutics it does not already own  The two cash deals were agreed at a prices of  105 and  87 per share respectively  Shares in Bioverativ leaped 63 percent in early U S  trading and Juno jumped 27 percent  reflecting the offers  while Sanofi fell 4 percent  Celgene was little changed  Other biotech stocks were driven higher by the takeover news  with rivals to Juno including Bluebird Bio   Sangamo Therapeutics and Cellectis each gaining around 10 percent   The signs are good for biotech deal activity in 2018   said Chris Stirling  head of KPMG s global life sciences practice  Big companies are under pressure from declining sales of older treatments and many are struggling to find sufficient high value replacements from within their own laboratories  making buying in products and know how an attractive option   It takes a long time to introduce technology that makes a significant difference  and in the interim CEOs are looking at any way to get their hands on product where they believe they can make a decent return   Stirling said   They ve got to be seen to be doing things  otherwise they really struggle to convince investors   Both Sanofi and Celgene had been seen as likely multibillion dollar acquirers  BUSY START The French group  which faces mounting competition in its key diabetes unit  lost out on buying U S  cancer firm Medivation to  Pfizer   NYSE PFE  in 2016  and also missed acquiring Swiss based Actelion  which was bought by Johnson   Johnson  NYSE JNJ  last year  Celgene  meanwhile  needs to dilute its reliance on cancer drug Revlimid  It had been widely tipped as a buyer for Juno  whose technology is at the cutting edge of cancer treatment  Juno is one of several pioneers of a system to modify immune cells to fight tumors and its JCAR017 product is likely to reach the market in 2019  behind rival approval treatments from Novartis and Gilead  Gilead only recently jumped into the space after acquiring Kite Pharma last year for  12 billion in one of the few standout deals during a relatively subdued year for biotech M A  Despite the late start  Celgene believes JCAR017 could have peak annual sales of  3 billion and it sees the acquisition being  incrementally additive  to net product sales in 2020  Following setbacks at Juno  Celgene is paying less than the  93 a share it stumped up for just under 10 percent of the company in 2015   Sanofi expects Bioverativ  which was spun off from Biogen  NASDAQ BIIB  last year  can deliver commercial success despite rapid changes in the  10 billion hemophilia market posed by a novel drug from Roche and the potential of gene therapy to provide a one time cure  Those changes have spooked some investors but Sanofi is betting that the factor replacement therapies made by Bioverativ will remain the standard of care for many years and it expects the deal to boost earnings immediately  Monday s two big acquisitions build on an already busy start for 2018 biotech M A  with Celgene earlier agreeing to acquire privately held Impact Biomedicines for as much as  7 billion  including  1 1 billion upfront  and  Novo Nordisk   CO NOVOb  bidding  3 1 billion for Belgium s Ablynx  Separate reports this month by consultancy EY and law firm Baker McKenzie both predicted a significant rise in life sciences M A in 2018  helped by U S  tax changes that may lift big companies  appetite for deals  
Lazard advised Sanofi on its deal  while Guggenheim Securities and J P  Morgan worked for Bioverativ  J P  Morgan also worked for Celgene and  Morgan Stanley   NYSE MS  for Juno ",2018-01-22,Reuters,https://www.investing.com/news/stock-market-news/biotech-ma-takes-off-as-sanofi-and-celgene-spend-20-billion-1134112,1134112
128754,350269,BIIB,Biogen misses by  0 19  beats on revenue,news,Biogen  NASDAQ BIIB   Q4 EPS of  5 26 misses by  0 19 Revenue of  3 31B   15 3  Y Y  beats by  230M Shares  0 52  PM Press ReleaseNow read ,2018-01-25,Seeking Alpha,https://www.investing.com/news/stock-market-news/biogen-misses-by-019-beats-on-revenue-1149568,1149568
128755,350270,BIIB,Prometic finalizes design of pivotal trial supporting lead drug PBI 4050,news,Prometic Life Sciences  OTCQX PFSCF  has finalized the design of a pivotal Phase 3 clinical trial assessing lead candidate PBI 4050 in patients with idiopathic pulmonary fibrosis  IPF  Based on FDA guidance  the study will recruit  all comers  with mild to moderate IPF  substantially simplifying the enrollment criteria  The trial will generate efficacy data on PBI 4050 as monotherapy and as an add on to nintedanib  Boehringer Ingelheim s OFEV   The primary endpoint will be the annual rate of decline in forced vital capacity  FVC  over 52 weeks  An interim analysis will be performed at week 26 On Wednesday  January 31  the company will host a meeting of key opinion leaders who will discuss novel treatments for IPF Now read ,2018-01-29,Seeking Alpha,https://www.investing.com/news/stock-market-news/prometic-finalizes-design-of-pivotal-trial-supporting-lead-drug-pbi4050-1164369,1164369
128769,350284,BIIB,The Zacks Analyst Blog Highlights  Incyte  Blueprint Medicines  Verastem And UniQure,opinion,For Immediate ReleaseChicago  IL   June 20  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Incyte   NASDAQ INCY    Blueprint Medicines   NASDAQ BPMC    Verastem   NASDAQ VSTM   and uniQure N V    NASDAQ QURE   Here are highlights from Wednesday s Analyst Blog  Cancer Gene Therapy Biotechs in Focus Post Pfizer Array DealShares of many biotech companies have rallied following the announcement of the Pfizer  NYSE PFE    Array BioPharma deal  Announced earlier this week  the deal has an enterprise value of approximately  11 4 billion  The deal is likely to strengthen Pfizer s oncology portfolio as Array BioPharma is focused on developing targeted small molecule drugs for treating cancer and other high burden diseases  Its first commercial therapy  Braftovi plus Mektovi  approved as a treatment for BRAF mutant melanoma  was approved July last year and has shown encouraging uptake  Cancer has become the area of focus of several pharmaceutical companies due to unmet needs and lucrative market opportunities In a move to bolster their oncology pipelines  several pharmaceuticals companies may acquire or collaborate to gain rights to prospective cancer treatments  Major drug biotech players struggling with organic growth need an infusion of new growth drivers into their pipeline product portfolios   either from internal development or from the purchase of assets  Amgen  NASDAQ AMGN   Biogen  NASDAQ BIIB  and Gilead  NASDAQ GILD  are the forerunners with huge cash pile  These companies are also looking to expand their pipeline to continue on growth path As expected  there has been an accelerated pace of merger and acquisitions  M A  activity in pharma space this year  especially in cancer  We have already seen some major deals this year  In January  Bristol Myers offered to buy Celgene  NASDAQ CELG  for  74 billion  followed by Lilly s acquisition of Loxo Oncology for  8 billion in February Apart from cancer focused stocks  pharmaceuticals companies are also targeting biotechs with transformative  next generation gene therapies in their pipeline  Gene therapies targeting rare diseases are expected to achieve better efficacy  Moreover  rare diseases with high unmet need can also lead to high asking price for these therapies The performance of the Zacks Biomedical and Genetics industry has not been impressive as a whole  However  the industry has gained 4  so far this year  after falling more than 25  in 2018  driven by increased M A activity this year  pipeline successes and frequent new drug approvals  Moreover  certain stocks in the sector with innovative pipelines or commercial drugs with significant sales potential have seen their share price rise  Some of these companies have already been acquired We have chosen four companies among the stocks that surged following the Pfizer Array BioPharma deal and have an encouraging cancer gene therapy pipeline or portfolio of drugs  making them potential acquisition targets IncyteIncyte s strong oncology portfolio makes it a lucrative target for companies like Gilead  Amgen and Bristol Myers  The market cap of Incyte is around  14 billion The primary reason behind Incyte being a strong buyout target is its key marketed product  Jakafi  a JAK inhibitor  It is the first and the only product to be approved for polycythemia vera  PV  and myelofibrosis   MF     two rare blood cancers  Jakafi is seeing strong sales performance driven by strong patient demand for both indications  In order to expand the patient population and increase commercial potential of the drug  the company is working on expanding its label further Another asset of interest to investors is Olumiant  also a JAK inhibitor  marketed in the EU and the United States  only the lower 2 mg dose  for rheumatoid arthritis  RA   Meanwhile  Incyte s pipeline boasts interesting targeted therapies like pemigatinib  itacitinib and capmatinib among others Incyte currently carries a Zacks Rank  3  Hold   The stock is up 32 5  so far this year and up 8 5  so far this week  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Blueprint Medicines Blueprint Medicines  lead pipeline candidate  avapritinib  is being developed for various oncology indications  The candidate has been successful in three pivotal studies  Earlier this month  Blueprint Medicines announced encouraging data from the registration enabling NAVIGATOR study  which evaluated avapritinib for treating patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumors   GIST    The company is planning to file a new drug application later this month  seeking approval for avapritinib as a treatment for the aforementioned indication  The company is also developing avapritinib in combination with Pfizer s Sutent and Bayer s Stivarga for second line and third or fourth line GIST  respectively  in phase III studies The company has other pipeline candidates   BLU 667 and BLU 554   which are being developed for carcinoma and other cancer indications  The company intends to submit an NDA for BLU 667 for the NSCLC indication in the first quarter of 2020 while the NDA for the MTC indication is expected to be filed during the first half of 2020 So far this year  shares of the company are up 81 4  and up 7 8  so far this week  Blueprint Medicines currently carries Zacks Rank  3 Verastem Verastem is a small biotech company  which focuses on developing treatments targeting oncology indications  The company has one commercial drug  Copiktra  and an oncology candidate in its pipeline  Copiktra was approved for relapsed or refractory chronic lymphocytic leukemia small lymphocytic lymphoma and refractory follicular lymphoma in September 2018  The drug targets a patient population with significant unmet need  The company is also developing the drug to support its label expansion in non Hodgkin lymphoma  T cell lymphoma  lung cancer  mesothelioma  ovarian cancer and pancreatic cancer  Data from studies have shown promising efficacy in patients The company s pipeline candidate defactinib is an oral small molecule kinase inhibitor  which is being developed for ovarian cancer  pancreatic cancer  mesothelioma  NSCLC  and other solid tumors  The candidate also enjoys orphan drug designation in ovarian cancer and mesothelioma Meanwhile  shares of Verastem have been on a downtrend in 2019  which makes the price attractive for potential bidders  The stock was however up 30  so far this week for its buyout potential  The company currently carries a Zacks Rank  3 uniQure N V  The company is a promising player in the gene therapy space  It is engaged in creating a pipeline of innovative gene therapies that have been developed both internally and through its collaboration  focused on cardiovascular diseases  with Bristol Myers Squibb The company s lead candidate AMT 061  an experimental AAV5 based gene therapy incorporating the FIX Padua variant  is being evaluated in the phase III HOPE B pivotal study for the treatment of patients with severe and moderately severe hemophilia B  In January 2019  the company received clearance from the FDA to initiate clinical study for AMT 130 for the treatment of Huntington s disease uniQure s stock has surged 170 6  so far this year and up 7 5  so far this week  The company currently carries a Zacks Rank  3 This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month Click here to see these breakthrough stocks now    Media ContactZacks Investment Research800 767 3771 ext  9339    Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-06-19,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-incyte-blueprint-medicines-verastem-and-uniqure-200433288,200433288
128770,350285,BIIB,3 Reasons Why Growth Investors Shouldn t Overlook Biogen  BIIB ,opinion,"Growth stocks are attractive to many investors  as above average financial growth helps these stocks easily grab the market s attention and produce exceptional returns  But finding a growth stock that can live up to its true potential can be a tough task 
In addition to volatility  these stocks carry above average risk by their very nature  Also  one could end up losing from a stock whose growth story is actually over or nearing its end 
However  the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects  makes it pretty easy to find cutting edge growth stocks 
Biogen  BIIB  is on the list of such stocks currently recommended by our proprietary system  In addition to a favorable Growth Score  it carries a top Zacks Rank 
Research shows that stocks carrying the best growth features consistently beat the market  And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy   returns are even better 
Here are three of the most important factors that make the stock of this biotechnology company a great growth pick right now 
Earnings Growth
Arguably nothing is more important than earnings growth  as surging profit levels is what most investors are after  For growth investors  double digit earnings growth is highly preferable  as it is often perceived as an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for Biogen is 17 7   investors should actually focus on the projected growth  The company s EPS is expected to grow 12 9  this year  crushing the industry average  which calls for EPS growth of 9 8  
Impressive Asset Utilization Ratio
Asset utilization ratio    also known as sales to total assets  S TA  ratio    is often overlooked by investors  but it is an important indicator in growth investing  This metric shows how efficiently a firm is utilizing its assets to generate sales 
Right now  Biogen has an S TA ratio of 0 55  which means that the company gets  0 55 in sales for each dollar in assets  Comparing this to the industry average of 0 18  it can be said that the company is more efficient 
In addition to efficiency in generating sales  sales growth plays an important role  And Biogen looks attractive from a sales growth perspective as well  The company s sales are expected to grow 3 2  this year versus the industry average of 1 2  
Promising Earnings Estimate Revisions
Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions  A positive trend is of course favorable here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
There have been upward revisions in current year earnings estimates for Biogen  The Zacks Consensus Estimate for the current year has surged 0 1  over the past month 
Bottom Line
Biogen has not only earned a Growth Score of A based on a number of factors  including the ones discussed above  but it also carries a Zacks Rank  2 because of the positive earnings estimate revisions 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination indicates that Biogen is a potential outperformer and a solid choice for growth investors ",2019-06-25,Zacks Investment Research,https://www.investing.com/analysis/3-reasons-why-growth-investors-shouldnt-overlook-biogen-biib-200434433,200434433
128779,350294,BIIB,Bumper crop of new drugs fails to lift big pharma R D returns,news,"By Ben Hirschler LONDON  Reuters    It is shaping up to be a bumper year for drug approvals  with U S  officials clearing twice as many novel medicines as in 2016  yet returns on research investment at leading pharmaceutical companies are down  In fact  projected returns at 12 of the world s top drugmakers have fallen to an eight year low of only 3 2 percent  consultancy Deloitte said on Thursday  The disconnect reflects the rising cost of developing new drugs  meager peak sales expectations for individual products and the fact that younger biotechnology companies are accounting for a growing proportion of new products  So far this year  the U S  Food and Drug Administration  gatekeeper to the world s biggest drugs market  has approved 41 novel drugs compared with 22 for the whole of 2016      The strong biotech sector is good news for investors like Daniel Koller  head of investment management at Swiss based BB Biotech  which has money tied up in fast growing U S  and European companies   It s been a great year for approvals in 2017 and we assume another very positive year for biotech in 2018   he told Reuters   It is a confirmation of the health of the industry   But for the giants of the pharma world tracked by Deloitte  things are not so rosy  This decade has seen shrinking profitability in their research labs  with the average internal rate of return  IRR  down sharply from 10 1 percent in 2010 to 3 2 percent this year  A separate group of four large biotech companies are projected to enjoy an IRR nearly four times higher at 11 9 percent  The calculations are based on long term sales forecasts   The biotech companies are seeing more success   said Mark Steedman  one of the report s authors  Steedman said biotechs typically had a leaner cost structure  although there were signs of big pharma beginning to streamline R D operations and deploy new technologies in drug discovery  such as artificial intelligence   There are reasons for optimism   he said   It s going to take a little bit of time but we the think the impact could be monumental in terms of increasing productivity    2 BILLION PER DRUG Today  the average cost of bringing a new drug to market at a large company is nearly  2 billion  up from  1 2 billion in 2010  while forecast annual peak sales per drug have fallen from  816 million in 2010 to  465 million  The figures highlight a dilemma as R D resources are shifted from mass market treatments to more specialist therapy areas  This year s haul of new drugs does include some likely blockbusters designed for relatively wide use  such as Roche s multiple sclerosis drug Ocrevus and Novo Nordisk s Ozempic for diabetes  But many new drugs are for rare diseases  including very specific sub types of cancer  A few are truly ground breaking  such as the first gene modified cell therapy against a type of leukemia from Novartis  and next year is expected to see the first U S  approval of a gene therapy for a rare inherited eye condition   Such pioneering drugs come at a huge price  with Novartis  cell therapy Kymriah costing  475 000  while gene therapy could fetch around  1 million per patient   The insights from human genetics and the insights from an understanding of the immune system are finally being translated in medicines  and very new technologies are now starting to pay off   Roche CEO Severin Schwan said in a recent interview  The 12 big drugmakers analyzed in the Deloitte study were  Pfizer   NYSE PFE   Roche  Novartis  Sanofi  PA SASY   GlaxoSmithKline  Johnson   Johnson  NYSE JNJ   AstraZeneca  Merck  NYSE MRK    Co  Eli Lilly  Bristol Myers Squibb  Takeda and Amgen  NASDAQ AMGN   
The four large biotech companies were Biogen  NASDAQ BIIB   Celgene  NASDAQ CELG   Gilead Sciences  NASDAQ GILD  and AbbVie ",2017-12-13,Reuters,https://www.investing.com/news/stock-market-news/bumper-crop-of-new-drugs-fails-to-lift-big-pharma-rd-returns-989961,989961
128780,350295,BIIB,Britain s cost watchdog backs Novartis  MS med Extavia for use by NHS,news,Britain s service quality and cost advisor  the National Institute for Health and Care Excellence  NICE   approves National Health Service funding for Novartis   NYSE NVS  Extavia  interferon beta 1b  for the treatment of relapsing remitting multiple sclerosis or secondary progressive multiple sclerosis with continue relapses NICE did not approve funding for MS drugs glatiramer acetate or other beta interferons  Biogen s Avonex and Plegridy  Bayer  DE BAYGN  s Betaferon  Merck  NYSE MRK  KGaA EMD Serono s Rebif  because none were cost effective Related tickers   NASDAQ BIIB  OTCPK BAYRY  OTCPK MKGAF  OTCPK MKGAY Now read ,2017-12-20,Seeking Alpha,https://www.investing.com/news/stock-market-news/britains-cost-watchdog-backs-novartis-ms-med-extavia-for-use-by-nhs-1013284,1013284
128781,350296,BIIB,Biogen s Alzheimer s candidate BAN2401 flunks mid stage study,news,An Independent Data Monitoring Committee has determined that a Phase 2 clinical trial assessing Biogen s  NASDAQ BIIB  BAN2401  a humanized anti amyloid beta protofil monoclonal antibody  in patients with early or mild Alzheimer s disease  AD  failed to meet the criteria for success at month 12  Final results should be available in H2 2018 Biogen and Eisai  OTCPK ESALF  have been co developing BAN2401 since March 2014 Now read ,2017-12-21,Seeking Alpha,https://www.investing.com/news/stock-market-news/biogens-alzheimers-candidate-ban2401-flunks-midstage-study-1017822,1017822
128782,350297,BIIB,VanEck Vectors Morningstar Wide Moat ETF  MOAT  December Summary,news,December monthly performance was   1 05 AUM of  1 34B52 week performance vs  the S P 500 is   2  0 46 in dividends were paid in DecemberTop 10 Holdings as of 11 30 2017   Polaris Industries  Inc  PII   3 17038   L Brands Inc  LB   3 03496   VF Corp  VFC   2 86814   Twenty First Century Fox Inc Class A  FOXA   2 84391   Amazon com Inc  AMZN   2 81693   Salesforce com Inc  CRM   2 7218   Biogen Inc  BIIB   2 68907    Visa Inc  Class A  V   2 66465   Bristol Myers Squibb Company  BMY   2 62815    Wells Fargo    Co  WFC   2 57962 ,2018-01-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/vaneck-vectors-morningstar-wide-moat-etf-moat-december-summary-1061127,1061127
128783,350298,BIIB,S P keeps New Year s rally alive  Dow eases,news,"By Sinead Carew  Reuters    The S P 500 extended its winning streak for 2018 on Monday although its advance slowed to a crawl as the healthcare and financial sectors weighed and investors awaited the start of the quarterly earnings season  The healthcare sector was the S P s worst performer on Monday  and investors were cautious about pouring money into bank stocks before the companies kick off the fourth quarter earnings season later this week    We had a big move last week and everyone knows earnings is coming up  People don t want to chase too much further when you have a round of fundamental inputs in the next few weeks   said Michael O Rourke  chief market strategist at JonesTrading in Greenwich  Connecticut  The Dow Jones Industrial Average  DJI  fell 12 87 points  or 0 05 percent  to 25 283  the S P 500  SPX  gained 4 56 points  or 0 17 percent  to 2 747 71  and the Nasdaq Composite  IXIC  added 20 83 points  or 0 29 percent  to 7 157 39  The three major indexes kicked off 2018 with their strongest first four trading days in more than a decade  according to Reuters data  The Dow had its strongest start since 2003  and the Nasdaq and S P 500 had their strongest starts since 2006  Historically  the first five trading days of January can be an indicator for the market s direction for the full year  according to the Stock Traders Almanac   The S P 500 s healthcare sector  SPXHC  ended 0 4 percent lower  Last week it rose 3 2 percent   The Nasdaq biotech index  NBI  fell 1 4 percent  on track for its biggest one day percentage decline since mid December  led by a 3 7 percent drop in Biogen Inc  O BIIB  and a 3 3 percent decline in Regeneron Pharmaceuticals Inc  O REGN    A 0 4 percent decline in the bank subsector  pressured the broader financials index  SPSY   which fell 0 1 percent  Investors were waiting for more details about the impact of recent U S  corporate tax cuts in fourth quarter earnings calls when the reporting season begins later in the week   Wells Fargo   N WFC  and  Citigroup   N C  fell more than 1 percent while Goldman Sachs  N GS  declined 1 5 percent  Most big U S  lenders have estimated one off charges to their fourth quarter earnings on account of U S  tax cuts  Utilities  SPLRCU  were the S P s biggest percentage gainers  regaining some ground lost in the previous week along with real estate    Caterpillar   N CAT  closed up 2 5 percent to  166 03  just below a record high set earlier in the day  after JP Morgan upgraded the stock saying the tax overhaul could help North America s construction business cycle extend in 2018  Kohl s Corp  N KSS  rose 4 7 percent after the department store operator posted far stronger same store sales for the holidays than its bigger peers    GoPro Inc   O GPRO  shares ended down 12 8 percent at  6 56 after the company said it would be open to a sale but is not actively pursuing one  Earlier in the day  the shares lost about a third of their value  hitting a record low at  5 04  after GoPro announced preliminary fourth quarter revenue that was well below expectations and said it would exit the drone business  Advancing issues outnumbered declining ones on the NYSE by a 1 40 to 1 ratio  on Nasdaq  a 1 03 to 1 ratio favored advancers  The S P 500 posted 98 new 52 week highs and no new lows  the Nasdaq Composite recorded 124 new highs and 26 new lows  
Volume so far on U S  exchanges was 6 36 billion shares  compared to the 6 28 billion average for the full session over the last 20 trading days ",2018-01-08,Reuters,https://www.investing.com/news/stock-market-news/futures-flat-caterpillar-set-for-a-record-open-1074854,1074854
128793,350308,BIIB,Celgene s Revlimid Rituximab Combo Gets FDA Nod For Lymphoma,opinion,Celgene Corporation   NASDAQ CELG   announced that the FDA approved Revlimid  lenalidomide  in combination with a rituximab product  R   for the treatment of adult patients with previously treated follicular lymphoma  FL  or marginal zone lymphoma  MZL  R2 previously received Priority Review designation from the FDA  With the approval  this combination regimen will be the first treatment option for patients with indolent forms of non Hodgkin lymphoma  NHL  that does not include chemotherapy  Indolent lymphomas  which account for about 40  of all NHL cases  are slow growing forms of the disease  which can often be asymptomatic or have fewer symptoms upon diagnosis  Most patients with indolent forms of NHL will relapse or become refractory to their current treatment  according to Celgene Revlimid  an oral immunomodulatory drug in combination with R2 leads to immune mediated treatment effects and represents a chemotherapy free treatment option that can help patients with previously treated FL and MZL delay disease progression  Celgene s key growth driver  Revlimid  is currently approved for several indications  including multiple myeloma  MM   myelodysplastic syndromes  MDS  and mantle cell lymphoma  MCL   The approval of R2 is based on data from the phase III AUGMENT study  evaluating the safety and efficacy of the combination regimen compared with rituximab plus placebo in patients with previously treated FL and MZL  Per the study  patients treated with R2 showed statistically significant improvement in the primary endpoint of progression free survival  PFS   as evaluated by an independent review committee  compared with rituximab plus placebo Shares of Celgene have surged 48 6  year to date compared with the  s growth of 1 1  A Marketing Authorization Application for R2 is currently under review by the European Medicines Agency for the treatment of relapsed refractory FL and MZL  A supplemental new drug application was also submitted to the Japanese Pharmaceuticals and Medical Devices Agency for an additional indication along with dosage and administration updates for Revlimid in combination with rituximab for the treatment of relapsed refractory indolent B cell NHL Meanwhile  the current focus is on the company s impending merger with Bristol Myers Squibb Company   NYSE BMY    In January  Bristol Myers announced that it will acquire Celgene for approximately  74 billion  on receipt of approval from all the shareholders  Bristol Myers earlier announced that independent proxy advisory firms  Institutional Shareholder Services   ISS   and Glass Lewis   Co    Glass Lewis   recommended that shareholders should vote in favor of the approval of the impending merger with Celgene  The merger is expected to close in the third quarter The acquisition announcement prompted quite a few other deals  Another leading biotech Biogen   NASDAQ BIIB   announced that it will acquire Nightstar Therapeutics  Swiss pharma giant Roche   OTC RHHBY   announced that it will acquire Spark Therapeutics for  5 billion  Celgene Corporation Price     Zacks RankCelgene currently carries a Zacks Rank  2  Buy   You can see  Will you retire a millionaire  One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-05-29,Zacks Investment Research,https://www.investing.com/analysis/celgenes-revlimidrituximab-combo-gets-fda-nod-for-lymphoma-200426091,200426091
128794,350309,BIIB,PDL BioPharma s Royalties Help  Heavy Partner Reliance Hurts,opinion,On May 29  we issued an updated research report on PDL BioPharma  Inc    NASDAQ PDLI   PDL BioPharma is currently focused on acquiring and managing income generating assets and maximizing value for stockholders The company also has royalty agreements with several companies whereby it is entitled to royalty rights on product sales  PDL BioPharma receives royalties from the sales of approved products of these companies  Such royalty agreements comprise the company s revenue stream and help enhance its financial position Shares of PDL BioPharma have inched up 2  so far this year  outperforming the  increase of 0 9  PDL BioPharma has made a strategic shift under which  the company will make equity investments in product focused companies  The company has a majority ownership in Noden Pharma and receives revenues from the sales of Noden products   Tekturna and Tekturna HCT   in the United States  Notably  Noden Pharma closed an asset purchase agreement with Novartis   NYSE NVS   whereby it acquired exclusive global rights to manufacture  market and sell Tekturna Notably  in April 2019  PDL BioPharma invested  30 million in Evofem Biosciences  Inc    NASDAQ EVFM    representing the first tranche of a planned  60 million transaction  The company currently has an approximate 20  ownership in Evofem  This investment is a good strategic fit and will create an attractive value for PDL BioPharma s shareholders Evofem is a biopharmaceutical company  which develops products for women s sexual and reproductive health  Its lead investigational drug product  Amphora  is an on demand  non hormonal gel contraceptive for women However  we remain concerned about PDL BioPharma s revenue stream for the future  The company is heavily dependent on its partners for royalty revenues  The same from Biogen s   NASDAQ BIIB   multiple sclerosis drug  Tysabri  is getting depleted of late due to weak product supplies  On first quarter 2019 conference call  PDL BioPharma stated that it does not expect to report any meaningful Tysabri royalty revenues in the future quarters of 2019 Moreover  in March 2019  the authorized generic version of Tekturna  150 mg 300 mg tablets  was launched in the United States by the privately held company  Prasco LLC  which is hurting PDL BioPharma s revenues from the sales of this authorized generic product Amid such circumstances  PDL BioPharma s royalty revenues could be materially and adversely impacted and have an unfavorable effect on the company s growth prospects PDL BioPharma  Inc  Price and Consensus   Zacks RankPDL BioPharma currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-05-29,Zacks Investment Research,https://www.investing.com/analysis/pdl-biopharmas-royalties-help-heavy-partner-reliance-hurts-200426712,200426712
128795,350310,BIIB,Roche  RHHBY  Up 6 3  YTD On Strong Demand For New Drugs ,opinion,"Shares of Swiss pharma giant  Roche Holdings   OTC RHHBY   have gained 6 3  in the year so far against the  s 1 9  decline  Roche is a leading healthcare company  focused on developing and commercializing innovative diagnostic and therapeutic products and services  which enable early detection and prevention of diseases as well as their treatment and monitoring The company s performance has been strong in the year so far  as growth in demand for new drugs has offset the adverse impact of competition for legacy drugs  The company dominates the breast cancer space with strong demand for its HER2 franchise drugs  The HER2 franchise includes Herceptin  Perjeta and Kadcyla  Label expansion of these drugs  since approval  have kept the momentum in sales alive Apart from its strong breast cancer franchise  Roche has a strong oncology portfolio for various indications  New drug approvals like Alecensa for lung cancer  and Venclexta in combination with Rituxan MabThera for the treatment of patients suffering from chronic lymphocytic leukaemia  CLL  or small lymphocytic lymphoma and acute myeloid leukemia  among others  have boosted the portfolio  Label expansion of these drugs will further enable the company to drive its top line In particular  the FDA approval of Ocrevus for the treatment of two forms of multiple sclerosis  MS    relapsing MS  RMS  and primary progressive MS  PPMS    has been a significant boost for Roche  as the drug has been performing impressively since launch amid stiff competition from the likes of Biogen   NASDAQ BIIB    among others  Hemlibra  emicizumab kxwh  for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors has also taken off well Immuno oncology is a key focus area for Roche  and Tecentriq is its leading immuno oncology drug for multiple indications  The performance of the drug has been strong  even though it faces stiff competition from Merck s   NYSE MRK   Keytruda and Bristol Myers Squibb Company s   NYSE BMY   Opdivo Meanwhile  Roche has been making prudent acquisitions to broaden its portfolio  The company acquired Flatiron Health and Ignyta  Inc in 2018  While Flatiron Health will accelerate development and delivery of breakthrough medicines for oncology patients  Ignyta s lead molecule  entrectinib  targets tumors with one of two genetically defined gene rearrangements   ROS1 fusions in NSCLC  and NTRK fusions across a broad range of solid tumors  In July 2018  Roche acquired Foundation Medicine Inc  to broaden its healthcare portfolio  The company s subsidiary  Genentech  also obtained full rights to Jecure Therapeutics  entire preclinical portfolio of NLRP3 inhibitors  Jecure is focused on the discovery of novel therapeutics for the treatment of non alcoholic steatohepatitis  NASH  and liver fibrosis  The acquisition will enable Roche to foray into the promising NASH space Earlier this year  the company announced that it has entered a definitive agreement to acquire Philadelphia based gene therapy company  Spark Therapeutics  for  4 8 billion Apart from offering therapeutic products and services for diverse medical needs  Roche also focuses on innovative diagnostic solutions for the early detection and treatment of diseases  The company continues to launch innovative diagnostic tests in this segment We expect the momentum to continue in the rest of the year as well Zacks RankRoche currently carries a Zacks Rank  2  Buy   You can see  
This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-05-31,Zacks Investment Research,https://www.investing.com/analysis/roche-rhhby-up-63-ytd-on-strong-demand-for-new-drugs-200427219,200427219
128796,350311,BIIB,Biogen  BIIB  Outpaces Stock Market Gains  What You Should Know,opinion,"Biogen  BIIB  closed at  227 33 in the latest trading session  marking a  1 33  move from the prior day  This move outpaced the S P 500 s daily gain of 1 05   Elsewhere  the Dow gained 1 02   while the tech heavy Nasdaq added 1 66  
Coming into today  shares of the biotechnology company had lost 1 8  in the past month  In that same time  the Medical sector lost 1 73   while the S P 500 lost 2 76  
Wall Street will be looking for positivity from BIIB as it approaches its next earnings report date  In that report  analysts expect BIIB to post earnings of  7 47 per share  This would mark year over year growth of 28 79   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  3 46 billion  up 3 22  from the year ago period 
For the full year  our Zacks Consensus Estimates are projecting earnings of  29 55 per share and revenue of  13 88 billion  which would represent changes of  12 79  and  3 21   respectively  from the prior year 
Any recent changes to analyst estimates for BIIB should also be noted by investors  These recent revisions tend to reflect the evolving nature of short term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Our research shows that these estimate changes are directly correlated with near term stock prices  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Within the past 30 days  our consensus EPS projection has moved 0 11  lower  BIIB currently has a Zacks Rank of  3  Hold  
Digging into valuation  BIIB currently has a Forward P E ratio of 7 59  This valuation marks a discount compared to its industry s average Forward P E of 22 2 
Meanwhile  BIIB s PEG ratio is currently 1 01  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  Medical   Biomedical and Genetics stocks are  on average  holding a PEG ratio of 1 77 based on yesterday s closing prices 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This group has a Zacks Industry Rank of 70  putting it in the top 28  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-06-07,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-outpaces-stock-market-gains-what-you-should-know-200429776,200429776
128797,350312,BIIB,Biogen  BIIB  Gains But Lags Market  What You Should Know,opinion,"In the latest trading session  Biogen  BIIB  closed at  230 86  marking a  0 19  move from the previous day  The stock lagged the S P 500 s daily gain of 0 41   Meanwhile  the Dow gained 0 39   and the Nasdaq  a tech heavy index  added 0 57  
Heading into today  shares of the biotechnology company had lost 0 07  over the past month  lagging the Medical sector s gain of 2 28  and the S P 500 s gain of 0 1  in that time 
Wall Street will be looking for positivity from BIIB as it approaches its next earnings report date  The company is expected to report EPS of  7 47  up 28 79  from the prior year quarter  Meanwhile  our latest consensus estimate is calling for revenue of  3 46 billion  up 3 22  from the prior year quarter 
BIIB s full year Zacks Consensus Estimates are calling for earnings of  29 57 per share and revenue of  13 88 billion  These results would represent year over year changes of  12 86  and  3 21   respectively 
Investors might also notice recent changes to analyst estimates for BIIB  These revisions typically reflect the latest short term business trends  which can change frequently  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Our research shows that these estimate changes are directly correlated with near term stock prices  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 0 04  lower  BIIB currently has a Zacks Rank of  3  Hold  
Valuation is also important  so investors should note that BIIB has a Forward P E ratio of 7 79 right now  This valuation marks a discount compared to its industry s average Forward P E of 22 92 
We can also see that BIIB currently has a PEG ratio of 0 93  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  The Medical   Biomedical and Genetics was holding an average PEG ratio of 1 76 at yesterday s closing price 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This group has a Zacks Industry Rank of 73  putting it in the top 29  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2019-06-13,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-gains-but-lags-market-what-you-should-know-200431464,200431464
128804,350319,BIIB,Biotechs continue slide  XBI down 2 ,news,The selloff in biotechs continues apace  The SPDR S P Biotech  MX XBI  ETF  XBI  2 1   has lost  10  since early October  The retracement is not unexpected considering its 50  run up this year Selected tickers   IBB  1 5   FBT  1 1   BBH  0 8   BIB  2 4   PBE  1 5   BTEC  1 6   CNCR  2 5   BBC  2 1   BIIB  1 4   AMGN  1 7   GILD  2 1   CELG  0 8  Now read ,2017-11-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/biotechs-continue-slide-xbi-down-2-858242,858242
128805,350320,BIIB,VanEck Vectors Morningstar Wide Moat ETF  MOAT  November Summary,news,November monthly performance was   0 41 AUM of  1 3B52 week performance vs  the S P 500 is  0 No dividends were paid in NovemberTop 10 Holdings as of 10 31 2017   Polaris Industries  Inc  PII   3 07855   VF Corp  VFC   2 89284   Amazon com Inc  AMZN   2 7608    Visa Inc  Class A  V   2 75904   Salesforce com Inc  CRM   2 75879   Biogen Inc  BIIB   2 74429   Bristol Myers Squibb Company  BMY   2 66669   TransDigm Group Inc  TDG   2 66595    Wells Fargo    Co  WFC   2 66381   United Technologies Corp  UTX   2 58199 ,2017-12-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/vaneck-vectors-morningstar-wide-moat-etf-moat-november-summary-948138,948138
128806,350321,BIIB,Biotech drug pricing should not get substantially worse next year   Mizuho,news,In an interview with Bloomberg News  Mizuho Securities  Salim Syed says pricing in the biotech sector is  not getting any better  but  will not get substantially worse  in 2018  He says pricing and M A activity will be key areas next year and beyond after a slowdown in deals this year Mr  Syed also says lower taxes for repatriated funds will be a positive  especially for cash rich outfits like Amgen  AMGN  1 6   and Gilead Sciences  GILD  0 3   adding that bringing funds back to the U S  should stoke deals Gilead  BUY  83   A top pick for 2018 on bullish prospects for Yescarta  It could pursue deals but it would be potentially distracting from the Yescarta launch Amgen  BUY  192   A  risky long  with attractive balance sheet and cash for acquisitions  Likes prospects for biosimilars and cholesterol med Repatha Biogen  BIIB  1 7    BUY  400   A top pick for 2018 on bullish prospects for Alzheimer s candidate aducanumab  Sees a 10  boost to share price if it improves its messaging around Spinraza in Duchenne muscular dystrophy Celgene  CELG  0 8    BUY  128   Needs to do deals to reignite share growth Separately  analyst Difei Yang likes  Zogenix   ZGNX  4 4   and ViewRay  VRAY  0 7   adding that ZGNX   Nektar Therapeutics   NKTR  3 1    Aerie Pharmaceuticals  AERI  2 5    Revance Therapeutics  RVNC  2   and Achaogen  AKAO  0 5   are all potential acquisition targets Source  BloombergNow read ,2017-12-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/biotech-drug-pricing-should-not-get-substantially-worse-next-year--mizuho-960925,960925
128815,350330,BIIB,The Zacks Analyst Blog Highlights  Chubb  Las Vegas Sands  Biogen  Dollar General And Canadian Pacific,opinion,"For Immediate Release
Chicago  IL   May 23  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Chubb   NYSE CB    Las Vegas Sands   NYSE LVS    Biogen   NASDAQ BIIB    Dollar General   NYSE DG   and Canadian Pacific   NYSE CP   
Here are highlights from Wednesday s Analyst Blog  
Top Research Reports for Chubb  Las Vegas Sands and Biogen
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Chubb  Las Vegas Sands and Biogen  These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see all of today s research reports here    
Chubb s shares have gained  8 1  in the past year  outperforming the Zacks Property  Casualty and Title industry  which has increased  2 8  over the same period  The Zacks analyst thinks the company benefits from a suite of compelling products as well as services  Its inorganic growth story is impressive  helping it to achieve a higher long term ROE 
Increased scales  efficiencies and a solid balance sheet will lend it a competitive edge  It estimates solid growth in Overseas General operations  which includes both commercial and consumer lines  A strong capital position aids Chubb to boost shareholders  value and invest in strategic initiatives for driving growth 
However  exposure to cat loss remains a concern as it induces volatility in underwriting profitability  Also  mounting expenses weigh on margin expansion  Chubb Limited s first quarter 2019 core operating income of  2 54 per share outpaced the Zacks Consensus Estimate of  2 49 by 2  and also improved 8 5  year over year on the back of robust premium growth and net investment income 
Shares of Buy ranked Las Vegas Sands have gained  15 7  over the past six months  outperforming the Zacks Gaming industry s increase of  11   The Zacks analyst thinks that increased revenues at casino  rooms and mall drove the company s top line in first quarter 2019  It generated solid revenues from Macao operations as well 
In the next couple of years  the company is likely to spend  2 billion in Macao  To strengthen the resort portfolio  Las Vegas Sands is focusing on expanding the Four Seasons Tower Suites Macao  St  Regis Tower Suites Macao and the Londoner Macao  Planned investment in new capital projects in Macao and higher revenues from The Parisian Macao are also likely to drive growth 
Las Vegas Sands  consistent focus on a convention based Integrated Resort business model is an added positive  Nevertheless  high debt and competition are worrisome  Estimates for the current year have witnessed upward revisions in the past 60 days 
Biogen s shares have underperformed the Zacks Biomedical and Genetics industry year to date   22 6  vs   2 2    Biogen beat estimates for earnings and sales in Q1  The Zacks analyst thinks the Biogen has a strong position in the MS market  Efforts to diversify beyond MS to other areas like Alzheimer s  Parkinson s and stroke among others are encouraging 
Meanwhile  its newest drug Spinraza is performing well and has multi billion dollar potential  Biogen s effort to regularly in license assets to build its pipeline is a major positive with several having transformative potential  Several data readouts are expected in 2019 2020 with multiple potential launches in the early 2020s 
However  its core MS business  excluding Ocrevus royalties  has been on a declining trend  Also  potential competition to Spinraza from competitors  gene therapy programs for SMA is a concern  Though Biogen s CNS pipeline is attractive  it is a high risk area 
Other noteworthy reports we are featuring today include Dollar General and Canadian Pacific 
Today s Best Stocks from Zacks
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1  and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year 
See their latest picks free   
Media Contact
Zacks Investment Research
800 767 3771 ext  9339
 
 
Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2019-05-22,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-chubb-las-vegas-sands-biogen-dollar-general-and-canadian-pacific-200424365,200424365
128816,350331,BIIB,Formycon  FY18 Results  FYB201 Launch On Track For 2021,opinion,"Formycon AG  DE FYB  s partner Bioeq IP AG  Bioeq  plans to file FYB201  its Lucentis biosimilar  to treat neovascular age related macular degeneration  nAMD  with the FDA in early Q419  The Phase III met its key primary endpoint  The US launch could be in 2021 and the EU in 2022  FY18 revenues were  43m  which includes  34 5m in payments from partnered projects  Bioeq is the partner on FYB201  Santo on FYB203  an Eylea biosimilar  and there is a joint venture with Aristo Pharma on FYB202  a Stelara biosimilar   FYB202 could enter a Phase I trial in mid 2019  Formycon guides for FY19 revenues of about  34m  Liquid cash at end FY18 was  12 31m  There was a private placing of  17 3m in March 2019  implying Q119 cash of about  29m 
FYB201 and FYB203 target the major nAMD markets
Formycon has two biosimilar projects targeting the nAMD market  In May 2018  the COLUMBUS AMD Phase III study of FYB201 met its primary endpoints  The global exclusive partner  Bioeq  plans to make regulatory filings in the US in early Q419 and in the EU in Q120  Bioeq aims to launch the product in 2021  US  and 2022  EU  and is developing its marketing strategy  Global 2018 Lucentis sales rose 9  to US 3 7bn  Formycon s preclinical Eylea biosimilar FYB203  also for nAMD  is licensed to Santo  Formycon notes that the total payments from development compensation and sales participation should be over  100m  Global sales of Eylea were  6 7bn in 2018  core patents expire in 2023  US  and 2025  EU   One Eylea biosimilar consortium  Momenta plus Mylan is in Phase III  With the cost pressures on healthcare  Formycon assumes a very valuable nAMD market for biosimilars 
A stellar opportunity through a JV
Formycon has made significant progress on FYB202  a Stelara biosimilar for Crohn s disease and psoriasis  through a joint venture deal with Aristo Pharma  Formycon owns 24 9   Stelara  2018 sales  5 2bn  has a different mode of action to anti TNF agents  lead product Humira   19 9bn in 2018  so should be protected from the fierce competitive environment developing in the anti TNF area  The project should enter Phase I in mid 2019 with Phase III possible in 2020 in our estimate  Formycon needs to fund its share of the costs but then shares the profits so this could be very lucrative  Stelara patents expire in 2023  US  and 2025  EU  
Valuation  Starting to reflect clinical progress
Formycon s market cap is about  319m with an EV of  310m  Regulatory review of FYB201 and the clinical progression of FYB202 will be key to adding value in 2019 


Business description
Formycon is a biotechnology company focused on biosimilars  The lead product is FYB201  a Lucentis biosimilar that has completed Phase III  FYB203 is an Eylea biosimilar in preclinical  They are both out licensed  FYB202  a biosimilar candidate of Stelara  is being developed in a joint venture with Aristo Pharma and enters Phase I in mid 2019 
Bull
Leading biosimilars company addressing markets worth  15 6bn in 2018 
Two partnered products plus JV deal 
Potential first to market advantage for FYB201 
Bear
No EMA guidance for intraocular biosimilars 
US biosimilar market still immature 
No apparent Bioeq sales capability yet 
Financials  FY18 results review
Formycon reported revenues of  43 00m in 2018 driven by licensing deals and milestones for out licensed projects  These comprised cash income of  34 5m  vs  29 43m in FY17  plus a non cash recognition of  8 5m from the H118 deal with Aristo Pharma to create a joint venture on FYB202  The company had guided to FY18 cash revenues of  32m  The headline FY18 revenue figure gave an accounting profit of  7 1m  vs a loss of  1 58m in FY17  Exhibit 1   although on cash revenues alone this would have been a loss of about  1 4m 
Investments on the balance sheet rose from  0 25m in FY17 to  15 97m in December 2018 due to the FYB202 JV  The cash outflow after investments was  3 17m so cash reduced to  12 31m in December 2018 from  15 48m in FY17  Formycon had  5 22m in receivables at the year end   10 97m FY17  so effective cash was  17 53m  FY17 26 45m   Formycon made a placing on 22 March 2019 with the strategic Swiss investor M H Equity AG  M H  and Formycon s share capital of  9 4m increased to  10m after issuing 577 397 new shares  The investment was  17 26m at  29 90 per share  Formycon states that the funds will be used for proprietary biosimilar developments 
Management has guided that 2019 revenues will be around  34m  If operating cash flows are similar to 2018  then Formycon will make yearly small loses or a minor profit up to the potential FYB201 2021 US launch 
Bioeq funds the FYB201 project but has no sales operations  so marketing partners will be needed in Europe and  especially in the US  Formycon expects that a commercialisation partner will be agreed during 2019  this could add to overall value 

Three key projects
The lead project is FYB201  a biosimilar to Lucentis and licensed to Bioeq  The project on Stelara has completed a pilot phase and is due to enter Phase I and the Eylea biosimilar  FYB203 is preclinical  Each of these is in a deal or joint venture  Although we cite the reference product sales for each project  the in market biosimilar price will be typically lower by c 15 20  initially and possibly 30 50  if competition is tough  One element is these markets is that switching rates from established reference products to slightly cheaper  but not necessarily identical  biosimilars has often been slow  For approval  a biosimilar must show comparable safety  efficacy and immunogenicity to the original  reference  products so  technically  there is no reason for prescribers not to switch  In May 2019 the FDA set out guidelines to establish full interchangeability with reference products  This might mean further clinical trials are needed but  if followed  it could enable routine switching and so faster penetration to give higher biosimilar shares 
A new set of EU rules  due to start in summer 2019  will allow potential competitors to manufacture biosimilars in Europe from six months before the patent and any supplementary protection expires  Formycon does not expect this  in practice  to accelerate the launch of FYB201  but it may enable more rapid launches for other products  for example FYB202 in 2023 
FYB201  Viewing a competitive space
Lucentis  ranibizumab  Roche  US  Novartis  EU   had 2018 sales of  3 7bn  Ranibizumab is a humanised monoclonal antibody fragment produced in Escherichia coli cells by recombinant DNA technology  it binds vascular endothelial growth factor A  VEGF A   The later competitor product Eylea  Regeneron  initially took sales and market growth from Lucentis due to a longer dosing interval  The position has now stabilised and Lucentis sales grew 9  in 2018  Lucentis patents expire in 2020 in the US and 2022 in Europe 
Formycon licensed FYB201 to Bioeq based in Z rich  Bioeq comprises a joint venture between Polpharma  a Polish pharmaceutical company  and the Str ngmann family s investment company  The clinical studies for FYB201 are run by a Bioeq subsidiary  Bioeq GmbH  based in Germany 
The Phase III study  COLUMBUS AMD  NCT02611778   reported its primary endpoint in May 2018  which confirmed comparable efficacy between FYB201 and Lucentis in patients with nAMD  included in wet AMD   The clinical primary endpoint measured the change in the best corrected visual acuity after eight weeks  All secondary endpoints were also met  The Phase III is now completed with no issues about the safety and immunogenicity of FYB201 observed 
Competitors include 
 
Samsung  KS 005930  Bioepis  Korea  sales via Biogen  NASDAQ BIIB   with a Phase III  NCT03150589  completing in Q419  the primary endpoint may have been reached with the follow up safety phase ongoing 
 
Xbrane  Sweden  is partnered with STADA  a privately owned German based generics and OTC company that sells  some  in licensed biosimilars  The global Phase III  NCT03805100  XPLORE  has a primary endpoint due in May 2020  Xbrane management expect sales from Q122  STADA currently has no US distribution at all and selective EU and Asian coverage 
 
Roche has a novel antibody  faricimab  entering Phase III after excellent Phase II performance with one injection every 16 weeks  this might compete in the premium market after 2023  Roche is also trialling a Lucentis medical device delivery system to protect its core franchise 
 
Novartis has filed brolucizumab  a scFv antibody fragment against VEGF A  with the FDA and this will potentially have an H220 launch  It claims a dosing interval of up to every 12 weeks 
A market complication will be biosimilar versions of Avastin  Avastin has the same mode of action as Lucentis but is a large monoclonal rather than a smaller fragment  Avastin is used off label for nAMD as it is cheaper  generic versions could accentuate this gap  This use is believed to be decreasing because the larger Avastin pack size gives handling and sterility issues 
FYB202  A stellar project
Formycon is developing a biosimilar  FYB202  to Stelara  ustekinumab  Jansen   The product is an antibody that binds interleukin 12  IL 12  and IL 23  These potent cytokines drive the immune response so neutralising them controls autoimmune diseases such as Crohn s and psoriasis  It is not used for rheumatoid arthritis  a massive market  but is effective for psoriatic arthritis  Veale and Fearon  2015    Stelara has its main US patent expiry in September 2023 in the US and in January 2024 in Europe  Sales were  5 2bn in 2018 driven by the 2017 approval in Crohn s disease 
The general market for these anti inflammatory therapies targeting cytokines such as IL 12 and tumour necrosis factor  TNF  is likely to be competitive with the patent expiries of huge   19 9bn  global franchises such as Humira  adalimumab  an anti TNF monoclonal   mainly used for rheumatoid arthritis  but also Crohn s disease and psoriatic arthritis  Stelara has a different mode of action to anti TNF therapies as it binds a different set of inflammatory messenger proteins  This different approach might be better for some patients 
In Europe  the Humira patent expired in October 2018 and four Humira biosimilars are sold  Amgevita  Amgen  NASDAQ AMGN    Hyrimoz  Sandoz   Hulio  Mylan Fujifilm Kyowa Kirin Biologics  and Imraldi  Biogen Samsung Bioepis   International  mainly European  2018 Humira sales were  6 3bn after a 14 8  Q4 decline due to European patent expiry 
In the US  2018 sales were  13 7bn  up 9   The primary patent expired in 2016 and three biosimilars are already approved  Amjevita  adalimumab atto  Amgen   Hyrimoz  adalimumab adaz  Sandoz  and Cyltezo  adalimumab adbm  Boehringer Ingelheim   with Imraldi  Biogen Samsung Bioepis  under FDA review  However  so far patents and agreements with Amgen mean that these biosimilar launches will be delayed and then phased over 2023 
FYB202 has been licensed to privately owned Aristo Pharma through a joint venture vehicle  FYB202 GmbH   co KD  Formycon holds 24 9  and will therefore fund this proportion of the clinical and development costs  amount undisclosed  but receive that share of profits  The pilot phase of the project has ended  After FDA meetings  Phase I is planned to start in mid 2019  This implies Phase III starting in 2020  which Formycon indicates could lead to a 2023 launch  There are no clinical trials disclosed  Others such as Icelandic company Alvotech and Australian Neuclone are in preclinical development of Stelara biosimilars  no trials are listed 
FYB203  An eye on the future
FYB203 is a preclinical project to develop an Eylea biosimilar  Regeneron had 2018 Eylea sales of US 6 7bn  split  4bn US and  2 7bn international   Eylea is used in a similar way to Lucentis but has a different mode of action as it binds both VEGF A and placental growth factor  Lucentis binds only VEGF A  The Eylea maintenance dose interval is every eight weeks  double that of Lucentis although Formycon notes that in reality clinical surveys show that the use patterns are similar  US Eylea patents start to expire in 2020 but there seem to be patent extensions  Sharma et al   2018  that will prevent biosimilar competition in the US until 2023  European patents expire in 2025  In addition  Eylea formulation patents do not expire till 2027 2028  Formycon has filed patents for an alternative formulation which has shown preclinical intraocular bioequivalence 
Formycon has a global licensing deal with Santo Holding and gains sales related royalties  Preclinical work is underway and a Phase I III trial might start in 2020  according to management 
Competitors include a joint development programme between Momenta Pharmaceuticals and Mylan  NASDAQ MYL  NV on the Eylea biosimilar  M710  A Phase III trial  NCT03610646  in 324 patients is underway and due to report primary data in Q120  Alteogen  South Korea  has a preclinical project  ALT L9  so it might be a potential future competitor 
Valuation  Clear pipeline and solid financial position
Formycon s market cap  14 May 2019  is  319m  Adding liabilities and subtracting cash gives an EV of about  310m  The current base value is set by the M H investment at  29 90 per share  Value progression depends on the likely royalties from FYB201 and FYB203 and the 24 9  profit share from the joint venture on FYB202  So far  the biosimilar business has been less aggressive than small molecule generics  This is because the technology is complex and the production costs of biologicals are high  which sustains margins but reduces the incentive to switch unless products are proved interchangeable 
Formycon is in a strong position on Lucentis biosimilar development with a completed  positive Phase III and planned early Q419 BLA application to the FDA with EMA submission in Q120  However  Samsung Bioepis is not far behind in the US and both Samsung Bioepsis and Xbrane might be ready for the European patent expiry in 2022  making the market competitive  Bioeq has no stated plans for marketing  a crucial aspect  However  Formycon expects Bioeq to announce its US and European marketing partners during 2019 to add value to the investment case 
The other projects are further behind but FYB202 could develop quickly through the JV  Formycon s 24 9  share of costs will need funding  this is worthwhile as it gives increased profit share  The Stelara franchise itself appears not to be targeted by many developers but the related Humira EU market is a battleground  with the US protected until 2023 after which competitors are queuing to pile in  Stelara might be a good  more protected market as not all Crohn s and psoriasis patients will use anti TNF products  which might protect volume and margins 
It is harder to assess FYB203  An Eylea biosimilar should sell very well but competitors seem  oddly  very limited to date given high sales and relatively close US patent expiry in mid 2023  The Momenta Pharmaceuticals and Mylan joint venture is the clear leader so far  We would expect further entrants over the next few years  The market will also be complicated by new  long acting antibody fragment products from Novartis and Roche at premium prices  However  while the new products may be more convenient  if approved  neither of them has shown clinical superiority over Lucentis and Eylea so the biosimilar market will be substantial and very valuable 
Investment case summary
Formycon has a robust financial position with high revenues  cash for investment and a strong product pipeline targeting major global markets  It can now develop its own proprietary pipeline  which should add further value 
Although there are always technical risks and delays in development  these are manageable and much lower than mainstream therapeutic development  The main uncertainties are on exact product launch dates  competition and the ability of partners to market effectively in large  complex global markets  Assuming these aspects are resolved  as we expect  Formycon should become a leading and very profitable biosimilar company ",2019-05-23,Edison,https://www.investing.com/analysis/formycon-fy18-results-fyb201-launch-on-track-for-2021-200424177,200424177
128817,350332,BIIB,Biogen  BIIB  Down 0 3  Since Last Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Biogen  BIIB   Shares have lost about 0 3  in that time frame  outperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Biogen due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Biogen Beats on Q1 Earnings  Spinraza Drives SalesBiogen reported first quarter 2019 earnings per share of  6 98  which beat the Zacks Consensus Estimate of  6 84  Earnings rose 15  year over year  backed by higher revenues and a lower share count due to share buybacks in the quarter Sales came in at  3 49 billion  up 11  from the year ago quarter  Sales also beat the Zacks Consensus Estimate of  3 38 billion  Revenue growth was principally driven by higher sales of Spinraza and higher contribution from biosimilars Quarter in DetailProduct sales in the quarter were  2 68 billion  up 6  year over year  Royalties on sales of Ocrevus were  112 million in the quarter  up 46  year over year  Revenues from Biogen s share of Rituxan and Gazyva operating profits increased almost 11  from the year ago period to  405 million  Other revenues rose 78  in the quarter to  292 million primarily due to the sale of approximately  200 million of inventory associated with the Bioverativ spinoff Biogen s multiple sclerosis  MS  revenues of  2 1 billion in the reporter quarter  including Ocrevus royalties  were flat year over year  However  excluding Ocrevus royalties  MS revenues declined 2  year over year In the first quarter  U S  MS product revenues were hurt by approximately  170 million due to a decrease in channel inventory In 2019  Biogen expects the growth rate in core MS revenues  excluding Ocrevus  to be similar to 2018  which means a decline year over year Tecfidera sales rose 1  year over year to  999 million  U S  sales in the quarter were  717 7 million  down 1 5  year over year while ex U S  sales were  281 1 million  up 9   Tecfidera U S  sales were hurt by lower volumes and higher discounts and allowances  Strong ex U S  performance in the quarter was driven by double digit volume increases in Europe and Japan  which offset the impact of ongoing price decreases in certain European countries Tecfidera sales declined 10  sequentially in the quarter due to lower U S  sales  Tecfidera U S  revenues were hurt by a decrease in channel inventory of approximately  110 million against an increase of  60 million in the previous quarter Tysabri sales were flat year over year and fell 1  sequentially to  460 million  Tysabri U S  sales declined 1 9  to  245 0 million in the quarter due to lower channel inventory levels  International revenues rose 1 4  to  215 4 million Combined interferon revenues  Avonex and Plegridy  in the quarter were  500 9 million  down 9  year over year  Avonex revenues declined 12  from the year ago quarter to  397 million  Plegridy contributed  104 million to revenues  up 4  year over year U S  Interferon revenues have been declining due to transition of patients to other oral or high efficacy MS therapies as well as higher discounts and allowance Sales of Spinraza increased 42  year over year to  518 0 million  Spinraza sales rose 10 3  sequentially as strong sales performance in ex U S  markets offset lower sales in the United States Spinraza U S  sales were  223 3 million in the quarter  down 5 5  sequentially hurt by seasonality  In ex U S  markets  Spinraza sales rose 26  sequentially to  295 2 million driven by new country launches and increased penetration across all major geographies The number of patients on Spinraza grew approximately 5  in the United States and 24  outside the United States in the quarter compared with the end of the fourth quarter of 2018 In the United States  the number of adult patients on Spinraza rose approximately 8  in the quarter compared with the last quarter  with the company making strong progress in capturing the under penetrated adult segment  In the first quarter  approximately 50  of the new patient starts in the United States comprised adults Biogen said that approximately 75  of U S  sales in the first quarter were from patients who received less intensive maintenance doses  dosing only once 4 months  versus 65  in the previous quarter  Moreover  the percentage of free doses decreased to 10  versus 15  in prior quarters On the call  the company said that there are around 45 000 SMA patients globally much higher than the company s initial expectation of 20 000  which represents an incremental growth opportunity In 2019  global Spinraza revenues are expected to grow in the mid to high teens range with growth in both the U S  and ex U S In the quarter  biosimilars revenues increased 36 7  year over year to  175 million in the quarter driven by Imraldi s launch  Imraldi  launched in mid October last year  generated sales of  35 7 million in the first quarter  Benepali recorded sales of  124 million in the quarter  up 3  year over year  Flixabi sales of  14 7 million more than doubled from  6 6 million in the year ago quarter In 2019  the company expects biosimilars to record double digit revenue growth  primarily driven by the launch of Imraldi Research and development  R D  expenses increased 13  year over year to  564 million  R D costs included  39 million related to the Skyhawk Therapeutics deal and  45 million closeout costs for aducanumab studies  Selling  general and administrative  SG A  expenses were up 13  year over year to  563 million  However  both R D and SG A costs declined sequentially in the first quarter In the quarter  Biogen repurchased approximately 2 4 million shares worth  656 million  In April 2019 so far  it has repurchased another 2 1 million shares worth approximately  492 million and has approximately  1 0 billion remaining under the share repurchase program authorized in August 2018  In the first quarter of 2019  Biogen s board of directors authorized a new share buyback plan of up to  5 billion Update on Alzheimer s ProgramsOn the conference call  Biogen said that on further analysis of data it has decided not to initiate a phase III secondary prevention study to evaluate whether early use of aducanumab can prevent or delay the clinical onset of Alzheimer s disease  Earlier in March  while announcing the decision to discontinue aducanumab  Biogen had said the decision whether to pursue the prevention study would be taken after further evaluation of data from ENGAGE and EMERGE studies Also  Biogen said that it is analyzing the results from the aducanumab phase III studies and BAN2401 phase II study  Based on the findings from these data  Biogen will inform about the future development plans for BAN2401  However  Biogen remains committed to its anti tau antibody  BIIB092 gosuranemab 2019 Guidance The company did not provide any new update on the earnings and sales guidance issued on the fourth quarter conference callWhile revenues are expected in the range of  13 6  13 8 billion  earnings per share are expected between  28 00 and  29 00  indicating growth of 7  to 11   Gross margin is expected to be 85  to 86  For the remainder of 2019  Biogen expects R D expenses to be reduced by approximately  125 million following the closing of the aducanumab studies  This will result in net savings of  80 million for 2019 adjusting for the  45 million closeout costs incurred in Q1  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates 
VGM Scores
At this time  Biogen has a strong Growth Score of A  though it is lagging a bit on the Momentum Score front with a B  Charting a somewhat similar path  the stock was allocated a grade of A on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending upward for the stock  and the magnitude of these revisions looks promising  Notably  Biogen has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-05-23,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-down-03-since-last-earnings-report-can-it-rebound-200424773,200424773
128818,350333,BIIB,Why Is Alkermes  ALKS  Down 21  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Alkermes  ALKS   Shares have lost about 21  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Alkermes due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Alkermes Reports Narrower Than Expected Loss in Q1Alkermes reported a loss of 17 cents per share in the first quarter of 2019  narrower than the Zacks Consensus Estimate of a loss of 19 cents  The loss was  however  wider than the year ago quarter s loss of 9 cents The company s revenues of  223 1 million in the quarter declined 0 9  from the year ago quarter  The top line  however  beat the Zacks Consensus Estimate of  221 2 million  The company s proprietary products   Vivitrol and Aristada   drove revenues  However  this was offset by declining royalties on Acorda s Ampyra   ALkeremes receives royalties on Ampyra Quarters in DetailVivitrol sales improved about 10  year over year to  69 2 million Aristada sales came in at  30 3 million  up 4  year over year Manufacturing and royalty revenues from Risperdal Consta  InvegaSustenna Xeplion and InvegaTrinza Trevicta were  75 6 million  up 9 9  year over year  The same from Ampyra Fampyra were down 56 9  year over year to  12 2 million as the drug faces generic competition  Research and development revenues from the collaboration with Biogen  NASDAQ BIIB  for diroximel fumarate  BIIB098  were  13 9 million  down 20 6  year over year Research and development  R D  expenses were  102 5 million  down 5 3  year over year Selling  general and administrative  SG A  expenses were  141 2 million  up 19 3  year over year 2019 OutlookAlkermes reiterated its guidance for 2019  The company expects total revenues of  1 14  1 19 billion  driven by anticipated growth of its proprietary products and an expected  150 million milestone payment from Biogen in the fourth quarter of 2019 related to the potential FDA approval of diroximel fumarate  BIIB098  Alkermes expects Vivitrol sales to be  330  350 million  while Aristada sales are anticipated to be  210  230 million  The company expects R D expenses to be  450  480 million  Alkermes  guidance for SG A expenses is  590  620 million The company expects earnings per share to be 25 43 cents 
How Have Estimates Been Moving Since Then 
Fresh estimates followed a flat path over the past two months  The consensus estimate has shifted 7 56  due to these changes 
VGM Scores
Currently  Alkermes has an average Growth Score of C  though it is lagging a bit on the Momentum Score front with a D  Following the exact same course  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Alkermes has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-05-24,Zacks Investment Research,https://www.investing.com/analysis/why-is-alkermes-alks-down-21-since-last-earnings-report-200425103,200425103
128832,350347,BIIB,FDA launches new tool aimed at easier access to adverse event data,news,The FDA introduces a new search tool that it says will be make it much easier for consumers  providers and researchers to access adverse event data through the FDA s Adverse Event Reporting System   FAERS   The new dashboard enables users to search for and organize data by such criteria as drug biologic product  patient age  type of adverse event and the year the event occurred or within a particular timeframe The agency hopes the increased transparency will increase the submission of more detailed and complete reports from consumers  healthcare professionals and others by making it easier for them to see other reports the FDA receives IBB XBI FBT BBH BIB PBE PJP IHE XPH PPH GNRX GILD BIIB AMGN MRK LLY BMY MRK CELG PFE OTCQX RHHBY NVSNow read ,2017-09-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-launches-new-tool-aimed-at-easier-access-to-adverse-event-data-534385,534385
128833,350348,BIIB,Med stocks up early  biotechs lead,news,"Biotech  biopharma and medical device stocks show positive action in early trading  leading the broad market rally 
 IBB  1 5   XBI  1 6   FBT  1 5   BBH  1 1   BIB  2 9   CNCR  2 3   BBC  1 1   PJP  1 5   IHE  1 5   XPH  1 9   GNRX  2   FTXH  GILD  2 2   CELG  0 5   AMGN  0 5   BIIB  1   NVS  0 8   PFE  0 5   LLY  0 9   MRK  0 7   GSK  0 9   OTCQX RHHBY  0 1   JNJ  0 8   ABBV  0 9   ABT  0 1   MDT  0 3  
Now read ",2017-10-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/med-stocks-up-early-biotechs-lead-535473,535473
128834,350349,BIIB,VanEck Vectors Morningstar Wide Moat ETF  MOAT  September Summary,news,September monthly performance was   0 41 AUM of  1 29B52 week performance vs  the S P 500 is   3 No dividends were paid in SeptemberTop 10 Holdings as of 8 31 2017   Gilead Sciences Inc   GILD   3 10975    Guidewire Software Inc   GWRE   2 97895   Biogen Inc  BIIB   2 9496   VF Corp  VFC   2 88204    Visa Inc  Class A  V   2 73694   Bristol Myers Squibb Company  BMY   2 71876   Salesforce com Inc  CRM   2 7005    Polaris Industries  Inc  PII   2 69259    Amgen Inc   AMGN   2 6372   Amazon com Inc  AMZN   2 60426 ,2017-10-03,Seeking Alpha,https://www.investing.com/news/stock-market-news/vaneck-vectors-morningstar-wide-moat-etf-moat-september-summary-535950,535950
128835,350350,BIIB,Soleno nabs U S  patent covering lead candidate diazoxide  shares ahead 5  premarket,news,Thinly traded nano cap Soleno Therapeutics  NASDAQ SLNO  is up 5  premarket on light volume in response its announcement that the USPTO has issued it an new patent  No  9 782 416  covering the use of diazoxide to treat hyperphagia  excessive hunger  in patients with Prader Willi syndrome  PWS  The company expects to launch a Phase 3 clinical trial assessing diazoxide in PWS by year end Now read ,2017-10-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/soleno-nabs-us-patent-covering-lead-candidate-diazoxide-shares-ahead-5-premarket-539959,539959
128836,350351,BIIB,Resverlogix secures  87M private capital raise,news,Resverlogix  OTCPK RVXCF  inks an agreement with shareholder Shenzhen Hepalink Pharmaceutical Co  Ltd  for the direct sale of 60 416 667 units at  1 44 per unit yielding gross proceeds of  87M Each units consists of one share of common stock an 0 082759 of a four year warrant to purchase one share of common at  1 64 Net proceeds will fund the repayment of the company s  68 8M secured term loan that matures in December  R D  working capital and general corporate purposes Now read ,2017-10-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/resverlogix-secures-87m-private-capital-raise-541224,541224
128838,350353,BIIB,Biotech ETFs In Focus On String Of Q1 Earnings Beats,opinion,President Trump s latest move to raise the tariffs to 25  from 10  on  200 billion of Chinese goods might have  trumped  hopes of many investors waiting for a truce between the two largest economies  However  amid this political conundrum  the industry has kept its promise for solid returns so far  The rally in some major biotechnology indexes reflects the same  In this context  the has returned 11 5  year to date Increasing M A deals  growing AI dominance and favorable regulatory tidings continue to boost the biotech market  read    Let s take a look at some big biotechnological earnings releases and see if these can leave an impact on ETFs exposed to the space Earnings in FocusOn Apr 30  Amgen   NASDAQ AMGN   reported first quarter 2019 earnings of  3 56 per share  which beat the Zacks Consensus Estimate of  3 45  Earnings increased 3  year over year helped by a lower share count as sales were weak in the quarter  Total revenues of  5 56 billion in the quarter were almost in line with the Zacks Consensus Estimate and flat year over year The company raised the low end of its previously issued sales and earnings guidance for 2019  The company expects revenues in the range of  22 0  22 9 billion versus  21 8  22 9 billion previously  Adjusted earnings per share are anticipated in the range of  13 25  14 30 versus  13 10  14 30 expected previously  Shares dipped about 1 2  since reporting earnings  as of May 3  2019  On May 2  Gilead Sciences   NASDAQ GILD   reported mixed results for the first quarter of 2019 wherein earnings surpass expectations but revenues missed the same  Gilead delivered earnings of  1 76 per share in the first quarter  up from  1 48 a year ago  The bottom line also beat the Zacks Consensus Estimate of  1 62  Total revenues of  5 28 billion lagged the Zacks Consensus Estimate of  5 31 billion but inched up 3 8  year over year  see  here  Gilead continues to expect net product sales of  21 3  21 8 billion  Adjusted R D and adjusted SG A expenses are projected at  3 6  3 8 billion and  3 9  4 1 billion  respectively  Adjusted product gross margin is anticipated at 85 87   The stock has gained 2 3  since reporting earnings  as of May 3  2019  On Apr 24  Biogen   NASDAQ BIIB   reported first quarter 2019 earnings per share of  6 98  which beat the Zacks Consensus Estimate of  6 84  Earnings rose 15  year over year  backed by higher revenues and a lower share count due to share buybacks in the quarter  Sales came in at  3 49 billion  up 11  from the year ago quarter  Sales also beat the Zacks Consensus Estimate of  3 38 billion  Revenue growth was principally driven by higher sales of Spinraza and increased contribution from biosimilars  The stock has gained 0 4  since reporting earnings  as of May 3  2019  On Apr 25  Alexion Pharmaceuticals   NASDAQ ALXN   posted first quarter 2019 adjusted earnings of  2 39 per share  which increased 42 3  from the year ago quarter s  1 68  Earnings also beat the Zacks Consensus Estimate of  2 19  Strong product revenues drove the bottom line in the quarter  Revenues rose 22 6  year over year to  1 140 billion and exceeded the Zacks Consensus Estimate of  1 112 billion  Revenues were driven by increased sales of Soliris  Strensiq and Kanuma  The company raised its revenue and earnings guidance for 2019  The company expects earnings per share to be  9 25  9 45  up from the previous guidance of  9 10  9 30  Alexion projects revenues of 4 68  4 75 billion  up from the prior outlook of  4 63  4 70 billion  The stock has gained 5 1  since reporting earnings  as of May 3  2019  Biotech ETFs in FocusIn the current scenario  we believe it is prudent to discuss the following ETFs that have relatively high exposure to the companies discussed iSharesNasdaq Biotechnology ETF This fund seeks to provide exposure to U S  biotechnology stocks and tracks the NASDAQ Biotechnology Index  It comprises 222 holdings with the above mentioned companies  taking about 26 3  of the fund  It has AUM of  7 71 billion and charges a fee of 47 basis points a year  The fund carries a Zacks ETF Rank  2  Buy  with a High risk outlook  read    VanEck Vectors Biotech ETF   LON BBH  The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production  marketing and sales of drugs based on genetic analysis and diagnostic equipment  It holds about 25 securities in its basket  with the concerned companies having 23 6  weight in the fund  Its AUM is  392 9 million and expense ratio is 0 35   The fund carries a Zacks ETF Rank  1  Strong Buy  with a High risk outlook  read    ProShares Ultra Nasdaq Biotechnology ETF The ProShares Ultra Nasdaq Biotechnology seeks daily investment results  before fees and expenses  that match twice the daily performance of the NASDAQ Biotechnology Index  It holds about 220 securities in its basket and puts about 25 9  weight in the in focus companies  Its AUM is  261 8 million and expense ratio is 0 95  First Trust Amex Biotechnology Index   LON FBT  The fund measures the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services  It holds about 31 securities in its basket with the concerned companies having 13 5  weight in the fund  Its AUM is around  3 billion and expense ratio is 0 56   The fund carries a Zacks ETF Rank  2 with a High risk outlook  read    Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-05-07,Zacks Investment Research,https://www.investing.com/analysis/biotech-etfs-in-focus-on-string-of-q1-earnings-beats-200418368,200418368
128839,350354,BIIB,Biotech Stock Roundup  FDA Nod For REGN s Eylea In DR  Tie Ups   Other Updates ,opinion,"It s been a pretty ho hum week for the biotech sector with regulatory and other pipeline updates as well as collaborations  While Regeneron s leading ophthalmology drug was approved by the FDA for yet another indication  Celgene s oncology drug was given a Breakthrough Designation for a difficult indication Recap of the Week s Top Stories FDA Approves Label Expansion of Regeneron s Eylea   Regeneron Pharmaceuticals  Inc    NASDAQ REGN   announced that the FDA has approved a label expansion of its lead drug Eylea  The drug has been approved to treat all stages of diabetic retinopathy  DR   thereby reducing the risk of blindness  The approval was based on the results of PANORAMA study  which showed that 20  of untreated patients developed proliferative diabetic eye disease at the end of twelve months and Eylea lowered this risk by 85 88  when administered using an every 16 week or eight week dosing regimen  respectively  DR is the leading cause of blindness among the working age American adults Celgene s Pomalyst Gets Breakthrough Designation  Celgene Corporation   NASDAQ CELG   announced that the FDA has granted Breakthrough Therapy designation to Pomalyst  pomalidomide  for the treatment of patients with human immunodeficiency virus  HIV  positive Kaposi sarcoma  who previously received systemic chemotherapy as well as patients with HIV negative Kaposi s sarcoma  The drug is already approved in combination with dexamethasone for patients with multiple myeloma  who received at least two prior therapies including lenalidomide and a proteasome inhibitor and also demonstrated disease progression in 60 days   The status is intended to expedite the development and review of medicines with an early evidence of potential clinical benefit in serious diseases  Celgene plans to submit a supplemental New Drug Application for Pomalyst pertaining to this indication by the end of 2019 Gilead Collaborates With Goldfinch Bio on Kidney Disease   Gilead Sciences  Inc    NASDAQ GILD   announced an alliance with the biotechnology company Goldfinch Bio to discover  develop and commercialize a pipeline of innovative therapeutics for the diabetic kidney disease  DKD  and certain orphan kidney diseases  Gilead has exclusive options to license the worldwide rights to certain products directed toward targets emerging from Goldfinch s proprietary Kidney Genome Atlas  KGA   Per the terms of the collaborative deal  Goldfinch will receive  55 million in upfront payments  including a  5 million equity investment and an additional  54 million fee to support the development of the KGA platform for DKD  The company is also eligible to receive up to  1 95 billion in potential payments for the first five collaboration programs based on the successful achievement of its research  development  regulatory and commercial milestones and tiered royalties on the sales of potential products originating from this collaboration Myovant Slumps Despite Positive Data for Lead Drug  Shares of Myovant Sciences  Inc    NYSE MYOV   plunged even though the company posted positive data on its lead drug  relugolix  from a late stage study  LIBERTY 1  the first of the two phase III studies on once daily relugolix combination therapy met its primary efficacy endpoint and six key secondary endpoints in women with uterine fibroids  The outcomes show that 73 4  of women receiving once daily oral relugolix combination therapy achieved the responder criteria compared with only 18 9  of them receiving placebo  Relugolix combination therapy maintained bone mineral density at levels comparable to placebo over 24 weeks and was generally well tolerated  The company expects findings from LIBERTY 2  the replicate phase III study evaluating once daily relugolix combination therapy in women with uterine fibroids and heavy menstrual bleeding  Assuming the program to be successful  the company plans to submit a New Drug Application  NDA  to the FDA in fourth quarter 2019 Myovant currently carries a Zacks Rank 2  Buy    You can see  PerformanceMedical   Biomedical and Genetics Industry 5YR   Return The NASDAQ Biotechnology index declined 2 8  in the past five trading sessions  Among the major biotech giants  Regeneron lost 5 51  in the period  Over the past six months  shares of Celgene have surged 35 21  whereas the Biogen  NASDAQ BIIB  stock has lost 26 91    See the last biotech stock roundup here    What s Next in Biotech Stay tuned for pipeline development news Will you retire a millionaire 
One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-05-14,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-fda-nod-for-regns-eylea-in-dr-tieups--other-updates-200421751,200421751
128840,350355,BIIB,5 Low Price to Book Value Stocks For Great Returns ,opinion,Price to earnings  P E  and price to sales  P S  are the first ratios to hit an investor s mind while finding undervalued stocks  However  price to book ratio  P B ratio   though underrated  is also an easy to use valuation tool for identifying low priced stocks with great returns The P B ratio is calculated as below P B ratio   market capitalization book value of equityNow let us understand the concept of book value What is Book Value There are several ways by which book value can be defined  Book value is the total value that would be left over  according to the company s balance sheet  if it goes bankrupt immediately  In other words  this is what shareholders would theoretically receive if a company liquidates all its assets after paying off its liabilities It is calculated by subtracting total liabilities from the total assets of a company  In most cases  this equates to the common stockholders  equity on the balance sheet  However  depending on the company s balance sheet  intangible assets should also be subtracted from the total assets to determine book value Understanding P B RatioBy comparing the book value of equity to its market price  we get an idea of whether a company is under  or overpriced  However  like P E or P S ratio  it is always better to compare P B ratios within industries  A P B ratio less than one means that the stock is trading at less than its book value  or the stock is undervalued and therefore a good buy  Conversely  a stock with a ratio greater than one can be interpreted as being overvalued or relatively expensive For example  a stock with a P B ratio of 2 means that we pay  2 for every  1 of book value  Thus  the higher the P B  the more expensive the stock But there is a caveat  A P B ratio less than one can also mean that the company is earning weak or even negative returns on its assets  or that the assets are overstated  in which case the stock should be shunned because it may be destroying shareholder value  Conversely  the stock s price may be significantly high   thereby pushing the P B ratio to more than one   in the likely case that it has become a takeover target  a good enough reason to own the stock Moreover  the P B ratio isn t without limitations  It is useful for businesses   like finance  investments  insurance and banking or manufacturing companies   with many liquid tangible assets on the books  However  it can be misleading for firms with significant R D expenditure  high debt  service companies or those with negative earnings In any case  the ratio is not particularly relevant as a standalone number  One should analyze other ratios like P E  P S and debt to equity before arriving at a reasonable investment decision Screening ParametersPrice to Book  common Equity  less than X Industry Median  A lower P B compared with the industry average implies that there is enough room for the stock to gain Price to Sales less than X Industry Median  The P S ratio determines how much the market values every dollar of the company s sales revenues   a lower ratio than the industry makes the stock attractive Price to Earnings using F 1  estimate less than X Industry Median  The P E ratio  F1  values a company based on its current share price relative to its estimated earnings per share   a lower ratio than the industry is considered better PEG less than 1  PEG ratio links the P E ratio to the future growth rate of the company  PEG ratio portrays a more complete picture than the P E ratio  A value of less than 1 indicates that the stock is undervalued and investors need to pay less for a stock that has bright earnings growth prospects Current Price greater than or equal to  5  They must all be trading at a minimum of  5 or higher Average 20 Day Volume greater than or equal to 100 000  A substantial trading volume ensures that the stock is easily tradable Zacks Rank less than or equal to  2  Zacks Rank  1  Strong Buy  or 2  Buy  stocks are known to outperform irrespective of the market environment  equal to A or B  Our research shows that stocks with a Value Score of A or B when combined with a Zacks Rank  1 or 2 offer the best opportunities in the value investing space Here are five of the eight stocks that qualified the screening Biogen  Inc    NASDAQ BIIB    a leading pharma company  currently has a Zacks Rank  2 and a Value Score of A  It has a 3 5 year EPS growth rate of 8 53   You can see  DXC Technology Company   NYSE DXC    a leading end to end IT services providing company  currently has a Zacks Rank  2 and a Value Score of A  It has a 3 5 year EPS growth rate of 6 6   SYNNEX Corporation   NYSE SNX    a business process services company  has a Zacks Rank  2 and a Value Score of A  It has a 3 5 year EPS growth rate of 12  Brighthouse Financial  Inc    NASDAQ BHF   is a holding company formed to own the legal entities that historically operated a substantial portion of the former Retail segment of MetLife  NYSE MET   Inc  The company has a projected 3 5 year EPS growth rate of 11 7   It currently has a Zacks Rank  2 and a Value Score of A G III Apparel Group  Ltd    NASDAQ GIII    a leading apparel company  currently has a Zacks Rank  1  It has a 3 5 year EPS growth rate of 15  and a Value Score of A You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at ,2019-05-15,Zacks Investment Research,https://www.investing.com/analysis/5-low-pricetobook-value-stocks-for-great-returns-200421606,200421606
128841,350356,BIIB,Celgene Gets EC Nod For Label Expansion Of Revlimid  Imnovid,opinion,"Celgene Corporation   NASDAQ CELG   announced that the European Commission  EC  has approved the label expansion of IMiD medications  leading oncology drug Revlimid  lenalidomide  and Imnovid 
The EC approved Revlimid in combination with Velcade and dexamethasone  RVd  for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant  The approval for RVd was supported by data from SWOG S0777  a phase III trial evaluating the triplet combination  RVd  in adult patients with previously untreated multiple myeloma 
The commission also approved Imnovid in combination with Velcade and dexamethasone  PVd  for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide 
The approval of PVd was supported by data from OPTIMISMM study  which evaluated the regimen in patients who were previously treated with Revlimid 
An approval was in the cards as the CHMP had recommended approval of the same last month 
The new triplet regimens should improve outcomes for both newly diagnosed patients as well as those who have relapsed or become refractory to first line therapy  Thus  sales should get a boost  Celgene s key growth driver  Revlimid  an oral immunomodulatory drug  is currently approved for several indications  including multiple myeloma  myelodysplastic syndromes and mantle cell lymphoma   Net sales of Revlimid came in at  2 6 billion in the first quarter  reflecting 15  year over year increase 
Celgene s stock has gained 49 1  in the year so far compared with the  s rise of 2 4  

 
Celgene has been in the news for its impending merger with Bristol Myers Squibb Company   NYSE BMY    In January  Bristol Myers had announced that it will acquire Celgene for approximately  74 billion 
The merger is expected to close in the third quarter 
The acquisition announcement prompted quite a few other deals  Another leading biotech  Biogen   NASDAQ BIIB   announced that it will acquire Nightstar Therapeutics  Swiss pharma giant  Roche   OTC RHHBY   announced that it will acquire Spark Therapeutics for  5 billion 
Zacks Rank
Celgene currently carries a Zacks Rank  2  Buy   You can see  
Breakout Biotech Stocks with Triple Digit Profit Potential
The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases 
Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-05-17,Zacks Investment Research,https://www.investing.com/analysis/celgene-gets-ec-nod-for-label-expansion-of-revlimid-imnovid-200422714,200422714
128857,350372,BIIB,House Dems look into MS med prices  seven drug makers contacted,news,Reuters reports that Democrats on the House Committee on Oversight and Government Reform have launched an investigation into price increases for multiple sclerosis  MS  drugs  Seven firms have received letters requesting information Targeted companies  Bayer  DE BAYGN  AG  OTCPK BAYRY   Biogen  BIIB  2 2    Merck  NYSE MRK  KGaA s EMD Serono  OTCPK MKGAY   Roche  OTCQX RHHBY  0 3     Sanofi   PA SASY   SNY  0 2   and Teva Pharmaceutical Industries  TEVA  0 3   Biogen is the only stock underwater reflecting its large exposure to the MS space Now read ,2017-08-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/house-dems-look-into-ms-med-prices-seven-drug-makers-contacted-519782,519782
128858,350373,BIIB,Biogen leads MS drug firms retreat on House Committee s price inquiry  shares down 3 ,news,The market s selloff notwithstanding  Biogen  BIIB  2 9   is taking it on the chin after a U S  House of Representatives committee initiated an investigation into price hikes for drugs to treat multiple sclerosis  MS  Of the seven firms contacted  Biogen has the largest exposure to the MS arena  accounting for more than 88  of its Q2 product sales   2 336M 2 640M  Teva s Copaxone accounted for almost half of its Q2 specialty drug sales   1 023M 2 065M  but less than 18  of its total product sales   1 023M 5 686  Previously  House Dems look into MS med prices  seven drug makers contacted  Aug  17 Now read ,2017-08-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/biogen-leads-ms-drug-firms-retreat-on-house-committees-price-inquiry-shares-down-3-519813,519813
128859,350374,BIIB,House Democrats launch probe into MS drug pricing,news,By Michael Erman NEW YORK  Reuters    U S  House Democrats said on Thursday they were launching an investigation into why prices for Multiple Sclerosis  MS  treatments have nearly quintupled since 2004  and they sent letters requesting information from seven drugmakers   U S  Representatives Elijah Cummings and Peter Welch sent the letters to  Bayer AG   DE BAYGN   Biogen  NASDAQ BIIB  Inc  Merck  NYSE MRK  KGaA s EMD Serono unit  Novartis AG  Roche Holding  SIX ROG  AG  Sanofi  PA SASY  SA  and Teva Pharmaceutical Industries  NYSE TEVA  Inc  The lawmakers on the U S  House Committee on Oversight and Government Reform said in the letters that they were looking to determine whether drug companies were raising prices for MS drugs in lockstep with their competitors  The average annual cost of MS therapy rose to  78 000 in 2016 from  16 000 in 2004  according to the National Multiple Sclerosis Society  Drugmakers have faced a global pushback from regulators and lawmakers about high prices   President Donald Trump has said the companies are  getting away with murder  and has pledged to lower the cost of prescription drugs  He met with Representative Cummings to discuss the issue in March  Previous congressional investigations and hearings into drug pricing practices have had far reaching effects  Mylan  NASDAQ MYL  NV sharply reduced the cost of EpiPen after the Oversight Committee began looking into the increases that drove the list price of the life saving allergy treatment to around  600 a pair   Valeant Pharmaceuticals  NYSE VRX  International and Turing Pharmaceuticals have also faced congressional pressure over high prices  Roche said it plans to work with the lawmakers to address their questions  and said the industry needs to reverse the trend of sharp increases in MS drug prices  It said its treatment Ocrevus is priced around 20 percent below the current average cost of treatment and does not plan to aggressively raise its price  A Bayer spokeswoman said the company had received the letter and planned to reply directly to the congress members  Novartis said it was reviewing the letter to determine how to address the request  Sanofi did not immediately have a comment on the probe  Biogen  EMD Serono  and Teva Pharmaceutical Industries Inc could not immediately be reached for comment ,2017-08-17,Reuters,https://www.investing.com/news/politics-news/house-democrats-launch-probe-into-ms-drug-pricing-519760,519760
128860,350375,BIIB,Biotechs up in early trading,news,"Led by the Gilead s  11B takeover of  Kite Pharma    biotechs are leading market in early trading 
Selected tickers   IBB  1 8   XBI  2 5   BBH  1   FBT  2 5   GILD  2 6   KITE  28 4   JUNO  15 6   AMGN  1 5   BIIB  2 4   CELG  2 1   ALXN  1 6  
Now read ",2017-08-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/biotechs-up-in-early-trading-523031,523031
128861,350376,BIIB,VanEck Vectors Morningstar Wide Moat ETF  MOAT  August Summary,news,August monthly performance was   0 41 AUM of  1 28B52 week performance vs  the S P 500 is   2 No dividends were paid in AugustTop 10 Holdings as of 8 31 2017   Gilead Sciences Inc   GILD   3 10975    Guidewire Software Inc   GWRE   2 97895   Biogen Inc  BIIB   2 9496   VF Corp  VFC   2 88204    Visa Inc  Class A  V   2 73694   Bristol Myers Squibb Company  BMY   2 71876   Salesforce com Inc  CRM   2 7005    Polaris Industries  Inc  PII   2 69259    Amgen Inc   AMGN   2 6372   Amazon com Inc  AMZN   2 60426 ,2017-09-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/vaneck-vectors-morningstar-wide-moat-etf-moat-august-summary-526809,526809
128862,350377,BIIB,Alexion Pharma to lay off 20 percent of workforce,news,By Manas Mishra  Reuters    Alexion Pharmaceuticals Inc  O ALXN  said on Tuesday it would lay off about 20 percent of its workforce and sharpen its focus on its core rare disease drugs business  as it looks to restore investor confidence  Alexion has been roiled in recent months by a sales practices scandal related to Soliris  its pricey rare disease treatment  as well as an exodus of top management  Alexion s chief executive and chief financial officers resigned in December  weeks after the drugmaker said it was investigating allegations related to its sales practices  The company named longtime Biogen Inc  O BIIB  finance chief Paul Clancy as CFO in June  months after appointing former Baxalta executive Ludwig Hantson as CEO  Alexion s restructuring efforts showed the drugmaker was focused on execution and serious about controlling costs  Cowen   Co analyst Eric Schmidt said  Clancy  on a call with analysts  said rebuilding Alexion s pipeline  which includes treatments for rare diseases  was a  critical need   Alexion s growth so far has been fueled by Soliris  which has a U S  list price of about  480 000 per year but faces looming competition   We are optimistic that the process of restoring credibility with investors has begun  and believe that Alexion can soon emerge as one of the cleaner large cap names within biotech   Schmidt said  Alexion  which had about 3 100 employees worldwide as of the end of last year  also said it would close some offices and manufacturing sites  including its Rhode Island facility  The layoffs follow a 7 percent workforce reduction announced by Alexion in March  The drugmaker will also relocate its headquarters to Boston from New Haven  Connecticut by mid 2018  the company said  Alexion expects its restructuring to yield cost savings of  270 million each year by 2019  on a pre tax  adjusted basis  It forecast pre tax expenses of  340 million to  440 million related to the restructuring  Alexion s shares were slightly lower at  142 33 in late morning trading  The stock has gained about 16 percent since the beginning of the year ,2017-09-12,Reuters,https://www.investing.com/news/stock-market-news/drugmaker-alexion-to-cut-20-percent-of-jobs-527815,527815
128863,350378,BIIB,FDA s Woodcock says clinical trials system  broken ,news,In a presentation at a workshop at the National Academies of Sciences  Engineering and Medicine  FDA Center for Drug Evaluation and Research s Janet Woodcock said the current clinical trials system is  broken  and there needs to be new ways to collect and utilize patient data She mentioned master protocols  studies that assess multiple therapies in a single disease or a single treatment in multiple diseases  and the development of clinical trial networks as  the future  Real world evidence  RWE  may also play a much larger role since both the 21st Century Cures Act and new user fee laws expand the agency s use of RWE in certain cases  RWE has been used very little historically in the approval process  but represents a big incentive for industry to prove effectiveness  cautioning that it is much more difficult for RWE to uncover small effects since  so many biases are introduced   One opportunity may be using some RWE with randomization Draft guidance on RWE and a new framework on its use should be released by the FDA before 2021 IBB XBI FBT BBH PJP IHE XPH PPH GILD CELG BIIB AMGN PFE MRK BMY LLY NVS JNJ ABBV GSK OTCQX RHHBYNow read ,2017-09-21,Seeking Alpha,https://www.investing.com/news/stock-market-news/fdas-woodcock-says-clinical-trials-system-broken-531633,531633
128868,350383,BIIB,Biogen  BIIB  To Report Q1 Earnings  What s In The Cards ,opinion,"We expect Biogen Inc    NASDAQ BIIB   to beat estimates when it reports first quarter 2019 results on Apr 24  before market open  Last quarter  the company delivered a positive earnings surprise of 4 02  Biogen s shares have declined 24 8  this year so far against the  s increase of 2 9  in the same time frame   Biogen s earnings performance has been strong as it delivered a positive surprise in each of the last four trailing quarters  with the average being 6 49  Biogen Inc  Price and EPS Surprise
     Let s see how things are shaping up for this announcementFactors to ConsiderOn the fourth quarter conference call  Biogen had said that it expects core MS revenues  excluding royalties on Ocrevus  to be similar to 2018  which implies a year over year decline In the fourth quarter  MS revenues benefited from  115 million in inventory channel build  expected to reverse in the to be reported quarter  Therefore  a potential inventory draw down is expected to hurt revenues in the first quarter of 2019 Among the MS drugs  Tecfidera s U S  revenues were relatively stable in the second half of 2018 against declines seen in the first half  U S  Tecfidera revenues are expected to remain stable in the first quarter of 2019  Meanwhile  ex U S  Tecfidera revenues should continue to benefit from volumes increases in Europe and Japan  which may offset the impact of ongoing price decreases in certain European countries  U S  sales of another MS drug  Tysabri  are expected to be hurt by Ocrevus launch The Zacks Consensus Estimate for sales of Tecfidera in the first quarter is pegged at  1 08 billion while that for Tysabri  Global In Market sales  is  447 million Combined interferon revenues  Avonex and Plegridy  are expected to decline again due to the transition of patients to other oral or high efficacy MS therapies as well as higher discounts and allowance Biogen receives royalties on U S  sales of Roche s  RHHBY  newly launched MS drug  Ocrevus  The Zacks Consensus Estimate for Ocrevus royalties is  148 million for the first quarter of 2019 Biogen s new drug  Spinraza  approved for spinal muscular atrophy  saw strong sales performance in 2018  On the Q4 call  management guided that in 2019  global Spinraza revenues are expected to grow in the mid to high teens range with growth in both the U S  and ex U S  Global Spinraza revenues are expected to be flat sequentially in the first quarter due to seasonality with return to growth beyond first quarter  In ex U S  markets  Spinraza s uptake will be driven by continued patient growth in 2019 although at a more modest rate in more markets  The Zacks Consensus Estimate for Spinraza is  488 million in the first quarter Samsung  KS 005930  Bioepis  the joint venture between Biogen and Samsung BioLogics  markets three anti TNF biosimilars in the EU   Flixabi  a biosimilar referencing Remicade   Benepali  a biosimilar referencing Enbrel  and Imraldi a biosimilar referencing AbbVie s   NYSE ABBV   Humira   Interestingly in 2018  biosimilars contributed significantly to Biogen s top line  Biogen expects biosimilars to record double digit revenue growth through 2019  primarily driven by the launch of Imraldi Key Q1 DevelopmentsLast month  Biogen entered into an agreement to acquire London based clinical stage gene therapy company  Nightstar Therapeutics for approximately  800 million  In January  Biogen announced two strategic collaborations to develop potential therapies for Alzheimer s disease  Parkinson s disease and other devastating neurological diseases  Investor questions are expected on the strategic benefits of the deals and plans to integrate them on the first quarter earnings call Also last month  Biogen and partner Eisai discontinued two phase III studies    ENGAGE and EMERGE    on aducanumab in early Alzheimer s disease  AD   The decision was taken following a futility analysis conducted by an independent data monitoring committee   IDMC    The analysis showed that the studies are unlikely to meet their primary endpoints  Investors are expected to question management on future plans for aducanumab on the investor call Earnings WhispersOur proven model shows that Biogen is likely to beat estimates this quarter because it has the right combination of two key ingredients  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for a likely positive surprise Earnings ESP  Earnings ESP  which represents the difference between the Most Accurate Estimate   6 91 per share  and the Zacks Consensus Estimate   6 86 per share   is  0 73   You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Biogen has a Zacks Rank  3  The combination of Biogen s Zacks Rank  3 and positive ESP makes us confident of an earnings beat in the upcoming release Sell rated stocks  Zacks Rank  4 or 5  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderLarge biotech pharma stocks that have both a positive ESP and a favorable Zacks Rank include Incyte Corporation   NASDAQ INCY   with an Earnings ESP of  14 47  and a Zacks Rank  1  The company is slated to release results on Apr 30  You can see  Pfizer  Inc    NYSE PFE   with an Earnings ESP of  0 65  and a Zacks Rank  3  The company is slated to release results on Apr 30 Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-04-21,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-to-report-q1-earnings-whats-in-the-cards-200409106,200409106
128869,350384,BIIB,Will Bristol Myers  BMY  Disappoint This Earnings Season ,opinion,"Bristol Myers Squibb Company   NYSE BMY   is scheduled to report first quarter 2019 results on Apr 25  before market opens The company s shares have declined 8 5  in the past six months compared with the  s decline of 0 8  Bristol Myers has delivered average positive earnings surprise of 14 3  in the trailing four quarters  In the last reported quarter  the company delivered a positive surprise of 10 6  Let s see how things are shaping up for this quarter Factors to ConsiderBristol Myers  key immuno oncology drug  Opdivo  is expected to be the primary revenue driver in the to be reported quarter  extending its previous performance  The drug  which is approved for multiple indications  generated sales of  1 8 billion in the fourth quarter  increasing 33  year over year  and  6 7 billion in 2018  increasing 36  from 2017  In January  Opdivo Yervoy received approval in Europe for treating patients with intermediate  and poor risk advanced renal cell carcinoma in first line setting Oncology drug  Sprycel  is also maintaining momentum  The FDA approved a label expansion of Sprycel in January to include pediatric patients aged a year or above with newly diagnosed Philadelphia chromosome positive  Ph   acute lymphoblastic leukemia  ALL   in combination with chemotherapy  The European Commission also approved the drug for the same indication in February 2019  We expect the recent label expansion of the drug to boost sales in the quarter Cardiovascular drug  Eliquis  also showed strong performance in 2018  with sales growing 32  from 2017 and 25  in the fourth quarter  The drug is expected to continue its robust sales in the first quarter However  the Hepatitis C and HIV businesses continue to face competitive pressure  Sales for the franchises are expected to decline The Zacks Consensus Estimate for first quarter sales and earnings is pegged at  5 80 billion and  1 05  respectively Key Anticipated Updates
Investors will also focus on further updates on the company s impending acquisition of Celgene Corporation   NASDAQ CELG    The impending acquisition will result in a specialty biopharma company with a strong oncology portfolio and diverse pipeline in the therapeutic areas of inflammatory  immunologic and cardiovascular diseases  While the company s blockbuster drug  Opdivo  is performing well on the back of label expansions  it continues to face pricing pressure and stiff competition in the immuno oncology space  This in turn has led to limited additional market share gains  Bristol Myers recently announced that its shareholders have given a green signal to the acquisition  More than 75  of the shareholders voted in favor of the merger agreement at the Special Meeting of Stockholders  The transaction will close in the third quarter of 2019  subject to the satisfaction of customary closing conditions and regulatory approvals  However  a few shareholders had earlier opposed the deal  expressing multiple concerns related to growth of the company following the acquisition Earnings WhispersOur proven model does not conclusively show that Bristol Myers will beat earnings estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Earnings ESP  The company s Earnings ESP is  2 61   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Bristol Myers has a Zacks Rank  4  Sell  We caution against the stocks with a Zacks Rank  4 or 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revisions Bristol Myers Squibb Company Price  Consensus and EPS Surprise
    Stocks to ConsiderHere are some stocks you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter 
Biogen   NASDAQ BIIB   is scheduled to release results on Apr 24  The company has an Earnings ESP of  0 73  and a Zacks Rank  3  You can see   GlaxoSmithKline plc   NYSE GSK   is scheduled to release results on May 1  The company has an Earnings ESP of  2 63  and a Zacks Rank  3 Is Your Investment Advisor Fumbling Your Financial Future 
See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-04-22,Zacks Investment Research,https://www.investing.com/analysis/will-bristolmyers-bmy-disappoint-this-earnings-season-200409021,200409021
128870,350385,BIIB,Biogen  BIIB  Beats On Q1 Earnings  Spinraza Drives Sales ,opinion,"Biogen Inc    NASDAQ BIIB   reported first quarter 2019 earnings per share of  6 98  which beat the Zacks Consensus Estimate of  6 84  Earnings rose 15  year over year  backed by higher revenues and a lower share count due to share buybacks in the quarter Sales came in at  3 49 billion  up 11  from the year ago quarter  Sales also beat the Zacks Consensus Estimate of  3 38 billion Revenue growth was principally driven by higher sales of Spinraza and higher contribution from biosimilars Biogen s shares have declined 23 5  this year so far against the  s increase of 4 2  in the same time frame Quarter in DetailProduct sales in the quarter were  2 68 billion  up 6  year over year  Royalties on sales of Roche s   OTC RHHBY   MS drug  Ocrevus were  112 million in the quarter  up 46  year over year  Though Ocrevus poses strong competition to Biogen s MS drugs  the company receives royalties on U S  sales of Ocrevus from Roche  Revenues from Biogen s share of Rituxan and Gazyva operating profits increased almost 11  from the year ago period to  405 million  Other revenues rose 78  in the quarter to  292 million Biogen s multiple sclerosis  MS  revenues were  2 1 billion in the reporter quarter  including Ocrevus royalties  MS revenues were flat year over year  However  excluding Ocrevus royalties  MS revenues declined 2  year over year   In the first quarter  U S  MS product revenues were hurt by  175 million of inventory drawdown Tecfidera sales rose 1  year over year to  999 million  However  Tecfidera sales declined 10  sequentially in the quarter due to lower U S  sales  U S  sales in the quarter were  717 7 million  down 1 5  year over year while ex U S  sales were  281 1 million  up 9  Tysabri sales were flat year over year and fell 1  sequentially to  460 million  Tysabri U S  sales declined 1 9  to  245 0 million in the quarter due to lower channel inventory levels  International revenues rose 1 4  to  215 4 million Combined interferon revenues  Avonex and Plegridy  in the quarter were  500 9 million  down 9  year over year  Avonex revenues declined 12  from the year ago quarter to  397 million  Plegridy contributed  104 million to revenues  up 4  year over year U S  Interferon revenues have been declining due to transition of patients to other oral or high efficacy MS therapies as well as higher discounts and allowance Sales of Spinraza  the first drug approved for treating spinal muscular atrophy  increased 42  year over year to  518 0 million  Spinraza sales rose 10 3  sequentially as strong sales performance in ex U S  markets offset lower sales in the United States  Spinraza s sequential sales growth of more than 10  was far ahead of the guidance of flat sequential sales provided back in January Spinraza U S  sales were  223 3 million in the quarter  down 5 5  sequentially  In ex U S  markets  Spinraza sales rose 26  sequentially to  295 2 million  The number of patients on Spinraza grew approximately 5  in the United States and 24  outside the United States in the quarter compared with the end of the fourth quarter of 2018  Spinraza was approved in China in February this year Samsung  KS 005930  Bioepis  the joint venture between Biogen and Samsung BioLogics  markets three anti TNF biosimilars in the EU   Flixabi  a biosimilar referencing J J   NYSE JNJ    Merck s Remicade   Benepali  a biosimilar referencing Amgen Pfizer s Enbrel  and Imraldi  a biosimilar referencing AbbVie s    NYSE ABBV    Humira   Biosimilars revenues increased 36 7  year over year to  175 million in the quarter driven by Imraldi s launch  Imraldi  launched in mid October last year  generated sales of  35 7 million in the first quarter  Benepali recorded sales of  124 million in the quarter  up 3  year over year  Flixabi sales of  14 7 million more than doubled from  6 6 million in the year ago quarter Research and development  R D  expenses increased 13  year over year to  564 million  Selling  general and administrative  SG A  expenses were up 13  year over year to  563 million  However  both R D and SG A costs declined sequentially in the first quarter Key Q1 DevelopmentsLast month  Biogen entered into an agreement to acquire London based clinical stage gene therapy company  Nightstar Therapeutics for approximately  800 million  In January  Biogen announced two strategic collaborations to develop potential therapies for Alzheimer s disease  Parkinson s disease and other devastating neurological diseases Also last month  Biogen and partner Eisai discontinued two phase III studies   ENGAGE and EMERGE   on aducanumab in early Alzheimer s disease  AD   The decision was taken following a futility analysis conducted by an independent data monitoring committee   IDMC    The analysis showed that the studies are unlikely to meet their primary endpoints Our TakeBiogen beat estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its newest drug  Spinraza  which we believe has multi billion dollar potential  We like Biogen s efforts to diversify beyond MS to other areas like Alzheimer s  Parkinson s and stroke  among others and its efforts to regularly in license assets to build its pipeline  Several of these assets have transformative potential Several data readouts are expected in 2019 with multiple potential launches in the early 2020s  However  its core MS business  excluding Ocrevus royalties  has been on a declining trend  Also  potential competition to Spinraza from competitors  gene therapy programs for SMA is a concern  Though Biogen s CNS pipeline is attractive  it is a high risk area as evident from the recent failure of aducanumab Biogen currently carries a Zacks Rank  3  Hold   You can see  Biogen Inc  Price  Consensus and EPS Surprise
    Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-04-23,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-beats-on-q1-earnings-spinraza-drives-sales-200410289,200410289
128871,350386,BIIB,Biogen  BIIB  Q1 Earnings   Sales Beat Estimates,opinion,"Cambridge  MA based Biogen Inc    NASDAQ BIIB   holds a strong position in the multiple sclerosis   MS   market with a wide range of products including Avonex  Tysabri  Tecfidera and Plegridy  However  as competition in the MS market intensifies  Biogen is trying to diversify beyond MS to other areas like Alzheimer s  Parkinson s  stroke  among others Biogen s earnings performance has been strong as it delivered a positive surprise in each of the last four trailing quarters with the average being 6 49  Currently  Biogen has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  Biogen s first quarter 2019 earnings beat expectations  The company posted earnings of  6 98 per share while our consensus called for EPS of  6 84 Revenues Beat  Biogen posted revenues of  3 49 billion  beating the consensus estimate of  3 38 billion  Revenue increased 11  year over year Key Statistics  Tecfidera sales rose 1  year over year to  999 million  However  Tecfidera sales declined 10  sequentially in the quarter due to lower U S  sales  Sales of Spinraza  the first drug approved for treating spinal muscular atrophy  grew 42  year over year to  518 0 million  Spinraza sales rose 10 3  sequentially as strong sales performance in the ex U S  markets offset lower sales in the United States Pre Market Trading  Shares rose more than 1  in pre market trading Biogen Inc  Price and Consensus
    Check back later for our full write up on this BIIB earnings report later Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-04-24,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-q1-earnings--sales-beat-estimates-200410013,200410013
128883,350398,BIIB,S P  Dow hurt by energy  banks  biotech boosts Nasdaq,news,"By Sinead Carew NEW YORK  Reuters    The S P 500 and Dow stock indexes were weighed down by falling energy shares as oil prices fell on Wednesday and added to investor concerns about low inflation  while healthcare and technology stocks helped lift the Nasdaq Composite index  Energy  SPNY  was the weakest S P sector with a 1 6 percent decline after oil prices  LCOc1  reversed course during the morning session and U S  crude  CLc1  touched its lowest point since August despite larger than expected declines in inventories   Continued weakness in oil futures added to investor worries about inflation and as a result hurt cyclicals such as banks and industrials  according to Chris Zaccarelli  Chief Investment Officer at Cornerstone Financial Partners in Huntersville  North Carolina   Because people are seeing oil lower as another harbinger of lower inflation  a lot of other cyclicals  besides energy stocks  aren t doing well   said Zaccarelli  Bank stocks  fell 0 8 percent as investors worried interest rate margins would be hurt by a flattening yield curve  which is also driven by inflation expectations  Industrial stocks  SPLRCI  were also among the biggest decliners with a 0 7 percent drop  Caterpillar s  N CAT  3 3 percent fall weighed on the sector while a 1 6 percent rise in FedEx  N FDX  was its biggest boost   Investors looking for growth opportunities turned to Nasdaq  which contains many technology and biotechnology companies  according to Zaccarelli  Healthcare stocks were helped by reports that U S  President Donald Trump s efforts to rein in drug prices may be friendlier than expected to the industry  according to Brad McMillan  Chief Investment Officer for Commonwealth Financial in Waltham  Mass  In general equity investors are biding their time ahead of quarterly results  which are expected to be good   We re just continuing to bounce around here until second quarter earnings come out   said McMillan   The Dow Jones Industrial Average  DJI  fell 57 11 points  or 0 27 percent  to close at 21 410 03  the S P 500  SPX  lost 1 42 points  or 0 06 percent  dropping to 2 435 61 and the Nasdaq Composite  IXIC  added 45 92 points  or 0 74 percent  rising to 6 233 95  The energy index has fallen 14 9 percent so far this year compared with an 8 9 percent rise for the S P 500  Oil futures have fallen about 21 percent so far this year  The four company telecommunications sector  SPLRCL  was the second weakest with a 1 2 percent drop  with AT T Inc  N T  leading the percentage declines  The Nasdaq biotechnology index  NBI  was up 4 1 percent  on track for its biggest one day gain since the day after Trump s Nov  8 election  Its biggest boosts were Celgene  O CELG   and Regeneron  O REGN  which both rose more than 5 percent and Biogen  O BIIB   which rose 4 7 percent  Republicans were due to release details of a bill aimed at overhauling U S  healthcare law on Thursday and a vote could come as soon as next week  several senators told Reuters  Republicans worked behind closed doors for weeks on the bill  If it passes  some investors see it as a positive sign for Trump s pro business agenda Declining issues outnumbered advancing ones on the NYSE by a 1 70 to 1 ratio  on Nasdaq  a 1 04 to 1 ratio favored decliners  
About 7 16 billion shares changed hands on U S  exchanges compared with a 6 92 billion average for the last 20 sessions ",2017-06-21,Reuters,https://www.investing.com/news/stock-market-news/stock-futures-lower-as-oil-hovers-near-seven-month-lows-497689,497689
128884,350399,BIIB,Insider buys may mean it s time to buy  Biogen  Alexion  and Incyte,news,The team at Cowen looked at insider transactions for the 10 largest biotechs over the last decade  While sales were of little predictive value  buying alongside insiders offered significant outperformance when measured over 30  90  180  or 365 days  Over that one year time frame  the stocks with insider buys outperformed the Nasdaq Biotech Index by a whopping 19 5  And where were insiders buying in Q2  Biogen  NASDAQ BIIB   Alexion  NASDAQ ALXN   and Incyte  NASDAQ INCY   Cowen rates all three Outperform Now read ,2017-06-30,Seeking Alpha,"https://www.investing.com/news/stock-market-news/insider-buys-may-mean-it's-time-to-buy:-biogen,-alexion,-and-incyte-501162",501162
128885,350400,BIIB,Biotechs head higher ahead of Q2 earnings dump,news,Biotechs are on the move after Bernstein expresses confidence on the sector ahead of Q2 earnings The firm predicts earnings beats for Biogen  BIIB  1 7   and  Jazz Pharmaceuticals   JAZZ  0 4   when their numbers are spilled  On a broader look  Bernstein thinks concerns on drug prices are fading a bit Gainers today include Calithera Biosciences  CALA  11 1    Blueprint Medicines  BPMC  8 7    Achillon Pharmaceuticals  ACHN  8 4     ImmunoGen   IMGN  6 9   and Juno Therapeutics  JUNO  6 3   Source  BloombergThe iShares Nasdaq Biotechnology Index  NASDAQ IBB  is up 1 21  Now read ,2017-07-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/biotechs-head-higher-ahead-of-q2-earnings-dump-502391,502391
128886,350401,BIIB,Biogen raises 2017 forecast on Spinraza success,news," Reuters    Biogen  NASDAQ BIIB  Inc s second quarter profit smashed estimates on Tuesday  boosted by strong sales of its spinal muscular atrophy  SMA  drug  Spinraza  which is priced at  750 000 for the first year of therapy  Buoyed by the demand for Spinraza  the U S  drugmaker raised its full year earnings and revenue forecasts  sending shares up 4 1 percent in premarket trading   The U S  Food and Drug Administration last December approved the injection for SMA  a rare disorder and the leading genetic cause of death in infants   The expensive drug  priced at  125 000 per injection in the first year of use  brought in a whopping  203 million  compared with consensus estimates of  70 million  compiled by Evercore ISI  Spinraza s success helped Biogen lift its full year adjusted profit forecast on Tuesday to a range of  20 80 per share to  21 40 per share  and revenue between  11 5 billion to  11 8 billion  It had forecast earnings of  20 45 per share to  21 25 per share and revenue of  11 1 billion to  11 4 billion in January  Spinraza is the latest addition to Biogen s portfolio  but the bulk of the company s revenue comes from its roster of multiple sclerosis  MS  treatments   Sales of Tecfidera  Biogen s leading MS drug  came in at  1 11 billion  just ahead of consensus estimates of  1 02 billion   Revenue from its other MS drugs Avonex and Plegridy came in at  691 million  above consensus estimates of  666 million   Biogen  which spun off its hemophilia business in February  said on Tuesday its MS drug business would continue to be the primary driver of future cash flow even as it the company aimed to develop more neuroscience drugs   The drugmaker said it expected to keep aside up to  400 million a year for research and development by 2019   Excluding items  Biogen earned  5 04 per share  handsomely beating estimates of  4 41 per share  according to Thomson Reuters I B E S estimates   Total revenue rose to 6 4 percent to  3 08 billion in the second quarter ended June 30  ahead of analysts  estimates of  2 81 billion   Net income attributable to the company fell to  862 8 million  or  4 07 per share  compared with  1 05 billion  or  4 79 per share  a year earlier  due to higher costs  
Share of Biogen were trading at  296 40 before the bell on Tuesday ",2017-07-25,Reuters,https://www.investing.com/news/stock-market-news/biogen-revenue-rises-6.4-percent-on-spinraza-demand-509473,509473
128887,350402,BIIB,HCA Q2 top line up 4   earnings flat  cash flow down 2   shares down 5  premarket,news,HCA Healthcare  NYSE HCA  Q2 results   M   Revenues  10 733   4 0   Net Income  657   0 2    EPS  1 75   6 1   CF Ops  6 mo    2 684   2 3   Same facility revenue equivalent admission up 2 0   Same facility admissions up 0 8  2017 Guidance  Revenues   43 0B   44 0B  EPS   7 00   7 30  Non GAAP EBITDA   8 35B   8 50B  Capex    2 9B Shares are down 5  premarket on light volume Previously  HCA Holdings misses by  0 08  misses on revenue  July 25 Now read ,2017-07-25,Seeking Alpha,https://www.investing.com/news/stock-market-news/hca-q2-top-line-up-4;-earnings-flat;-cash-flow-down-2;-shares-down-5-premarket-509593,509593
128892,350407,BIIB,Health Day Checkup Of Medical ETFs  5 Top Picks,opinion,"The biggest healthcare ETF Health Care Select Sector SPDR Fund  has beaten the S P 500 in the one year period and has matched the performance in the two year and five year frame   Though this broader healthcare fund lagged the S P 500 this year  one of its specialized corners   biotech   easily topped it  SPDR S P Biotech  NYSE XBI  ETF  is up 28  this year  trumping the S P 500  up 14 9   
Let s do a health checkup of the sector itself before the World Health Day on Apr 7 
M As
Mergers and acquisitions  M As  are the wind beneath the wings of the sector  The U S  healthcare supply chain is consolidating fast  with  ranging from insurers  pharmacies to drug distributors  Thanks to an uptick in M As  biotech stocks have seen their best ever start to a year since 2012 
The announcement of the mega merger deal between Bristol Myers   NYSE BMY   and Celgene   NASDAQ CELG   at the beginning of 2019 set the space on fire   Also  Eli Lilly and Company   NYSE LLY   has announced that it will acquire Loxo Oncology for  8 billion to expand oncology portfolio  The winning momentum started from December 2018  when Glaxo   NYSE GSK   offered to buy TESARO for almost  5 1 billion 
Roche and Biogen  NASDAQ BIIB  followed suit with the acquisition offers for Spark Therapeutics   NASDAQ ONCE   and Nightstar Therapeutics   NASDAQ NITE    respectively  Also  Pfizer  NYSE PFE  collaborated with the privately held Vivet Therapeutics  Notably  heightened speculation about increasing consolidation in the cancer space is doing rounds  Analysts have predicted a sizable increase in M A activity in both  
Q1 Earnings Growth Picture Positive for Medical
First quarter 2019 earnings growth is expected to turn negative    This would mark the first earnings decline since second quarter 2016  Margin pressure acted as headwind but revenues continued to grow 
There are very few sectors that are expected to witness earnings growth for the first quarter  and Medical has made it to the winners  list with a likely earnings growth rate of 2 7   The sector is likely to witness a revenue growth of 5 9     
Upbeat Zacks Rank
The broader medical sector belongs to a top ranked Zacks sector  top 19   The sector has been creating solid jobs for a few months in a row  It  overall  saw an annual increase of 361 000 jobs in February  read    
The  currently belongs to the top ranked Zacks industry  top 30   while Medical   Products   Instruments is in the top 39   Medical Services also belongs to a top ranked Zacks industry  top 40   while Generic Drugs is in top 41  
Against this backdrop  below we highlight few top ranked ETFs picks   see  here  
VanEck Vectors Biotech ETF   LON BBH     Zacks Rank  1  Strong Buy 
The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production  marketing and sales of drugs based on genetic analysis and diagnostic equipment  read    
Vanguard Health Care ETF   AX VHT     Zacks Rank  1
The underlying MSCI US Investable Market Health Care 25 50 Index is made up of stocks of U S  companies within the health care sector  Pharma  healthcare equipment and biotech take the major share of the fund 
iShares U S  Healthcare ETF    Zacks Rank  1
The underlying Dow Jones U S  Health Care Index measures the performance of the healthcare sector of the U S  equity market  Pharmaceuticals  Health Care Equipment  Biotechnology and Managed Health Care are the top our spots of the fund 
First Trust NYSE Arca Biotechnology Index Fund   LON FBT     Zacks Rank  2  Buy 
The fund measures the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services 
Principal Healthcare Innovators Index ETF    Zacks Rank  2
The underlying Nasdaq U S  Healthcare Innovators Index provides exposure to U S  companies that are early stage healthcare companies 
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2019-04-05,Zacks Investment Research,https://www.investing.com/analysis/health-day-checkup-of-medical-etfs-5-top-picks-200404219,200404219
128893,350408,BIIB,Biogen  BIIB  Dips More Than Broader Markets  What You Should Know,opinion,"Biogen  BIIB  closed at  237 58 in the latest trading session  marking a  0 9  move from the prior day  This change lagged the S P 500 s 0 61  loss on the day  Meanwhile  the Dow lost 0 72   and the Nasdaq  a tech heavy index  lost 0 56  
Prior to today s trading  shares of the biotechnology company had lost 23 03  over the past month  This has lagged the Medical sector s gain of 2 13  and the S P 500 s gain of 5 68  in that time 
BIIB will be looking to display strength as it nears its next earnings release  which is expected to be April 24  2019  The company is expected to report EPS of  6 87  up 13 55  from the prior year quarter  Our most recent consensus estimate is calling for quarterly revenue of  3 35 billion  up 7 1  from the year ago period 
BIIB s full year Zacks Consensus Estimates are calling for earnings of  28 65 per share and revenue of  13 71 billion  These results would represent year over year changes of  9 35  and  1 95   respectively 
Investors should also note any recent changes to analyst estimates for BIIB  These revisions help to show the ever changing nature of near term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 0 11  lower  BIIB is holding a Zacks Rank of  3  Hold  right now 
In terms of valuation  BIIB is currently trading at a Forward P E ratio of 8 37  This valuation marks a discount compared to its industry s average Forward P E of 21 31 
Also  we should mention that BIIB has a PEG ratio of 0 94  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  Medical   Biomedical and Genetics stocks are  on average  holding a PEG ratio of 2 03 based on yesterday s closing prices 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This group has a Zacks Industry Rank of 67  putting it in the top 27  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow BIIB in the coming trading sessions  be sure to utilize Zacks com ",2019-04-09,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-dips-more-than-broader-markets-what-you-should-know-200405307,200405307
128894,350409,BIIB,Biotechnology Market On A Tear  5 ETFs In Spotlight,opinion,The industry has kept its promise for solid returns so far  The rally in some major biotechnology indexes reflects the same  In this context  the has returned 17 6  year to date  Following the trend   has returned around 29  With time  biotechnology is emerging as a favored sector for investors with some risk appetite and looking for attractive returns  Let s delve deeper into the trends favoring the biotechnology market space in 2019 Mergers   AcquisitionsMergers and acquisitions  M As  are dominating the sector as sluggishness in mature products has forced companies to explore acquisitions to bolster their pipeline  The biggest deal of the year was Bristol Myers  acquisition offer of  74 billion to buy Celgene  NASDAQ CELG   Also  Eli Lilly and Company   NYSE LLY   has announced that it will take over Loxo Oncology for  8 billion to broaden its oncology suite to precision medicines or targeted therapies   read   Several other large cap pharma as well as bigger biotech companies are entering collaboration deals with smaller ones to boost their pipeline  Notably  Swiss pharma giant Roche Holdings   OTC RHHBY   has bet big on U S  based gene therapy company Spark Therapeutics   NASDAQ ONCE   in an effort to strengthen its presence in gene therapy  Similarly  in order to develop gene therapies targeting rare indications  Biogen  NASDAQ BIIB  has offered to buy Nightstar Therapeutics Furthermore  in licensing deals are consistently rising with bigwigs partnering with smaller and mid sized players that own promising mid to late stage pipeline candidates or interesting technology Regulatory TidingsThe companies within the biotech sector gain majorly from positive pipeline related advancements  Of late  the space has seen a series of developments  To begin with  Amgen  NASDAQ AMGN  and partner UCB recently received FDA approval for osteoporosis drug  Evenity  for the treatment of osteoporosis in postmenopausal women at high risk for fracture  Gilead Sciences  NASDAQ GILD  recently submitted a supplemental New Drug Application to the FDA for Descovy Moreover  Celgene submitted a Biologics License Application for the pipeline candidate  luspatercept  a first in class erythroid maturation agent that regulates late stage red blood cell maturation Moreover  biotech bigwigs are increasingly focusing on a few drug categories like biosimilars  neurological disorders  autoimmune diseases and gene therapies  In fact  per an article on   the FDA is increasingly encouraging companies to adopt means to develop gene therapy related products AI Ushers in a New EraThe implications of AI  cloud based technologies and increased R D focus have lent a competitive edge to companies within the biotech space  The use of AI has gradually begun to revolutionize research activities in the industry as it can drastically reduce time and costs involved in developing life saving drugs Let s take a look at some instances on how AI is being used to advance in biotech   has developed an application that uses AI to govern if and at what time the patient takes a pill  Moreover  it is now being used regularly in many clinical trials    AI system is used for genomics analysis of next generation sequencing data from hospitals and research institutions globally Moreover  Illumina   NASDAQ ILMN   released an open source artificial intelligence software for discovering previously overlooked noncoding mutations in patients with rare genetic diseases in the beginning of 2019 In fact  J J   NYSE JNJ    Pfizer   NYSE PFE   and Novartis   NYSE NVS   have tie ups with IBM  NYSE IBM  s Watson Health  Per the deals  the companies can use Watson Health s AI solutions and applications for drug discovery and to accelerate cancer research efforts ETFs in FocusThe favorable trends have been benefitting biotech ETFs as well  ARK Genomic Revolution Multi Sector ETF  stole the show  climbing 44 1  year to date  This was followed by gains of 30 8  for ALPS Medical Breakthroughs ETF   SI SBIO    30 4  for Virtus LifeSci Biotech Products ETF   BS BBP    29 3  for SPDR S P Biotech  NYSE XBI  ETF  and 28  for Principal Healthcare Innovators Index ETF   see  here  ARKGThis is an actively managed ETF focusing on companies that are expected to benefit from extension and enhancement of the quality of human by incorporating technological and scientific developments  improvements and advancements in genomics  The fund holds 35 stocks in its basket and has 0 75  in expense ratio  It has accumulated  394 million in its asset base and trades in average daily volume of 144 614 shares   read    The fund s top three holdings are Invitae Corp  10 5    Illumina  8 8   and Intellia Therapeutics  7 3   SBIO  This is a small cap centric fund targeting biotech sector  It provides exposure to around 70 companies with one or more drugs in Phase II or Phase III FDA clinical trials by tracking the Poliwogg Medical Breakthroughs Index  The product charges 50 basis points in fees per year from investors and trades in a moderate average daily volume of about 62 754 shares  It has AUM of  202 5 million in its asset base and has a Zacks ETF Rank  3 with a High risk outlook  read    The fund s top three holdings are Galapagos  5 2    Array BioPharma  4 6   and Immunomedics  4 3   BBPThe ETF follows the LifeSci Biotechnology Products Index  which measures the performance of biotechnology companies with at least one drug therapy approved by the FDA  Holding around 41 stocks  the product has moderate concentration across components  The product has accumulated AUM of about  38 8 million and charges 79 bps in fees per year  BBP has a Zacks ETF Rank  2 with a High risk outlook  The fund  trades in a moderate average daily volume of about 5 725 shares  read    The fund s top three holdings are Portola Pharmaceuticals  4 1    Ionis Pharmaceuticals  3 4   and Array BioPharma  3 3   XBIWith AUM of  4 48 billion  XBI provides equal weight exposure across 120 stocks by tracking the S P Biotechnology Select Industry Index  XBI has 0 35  in expense ratio and trades in an average daily volume of 5 8 million shares  It has a Zacks ETF Rank  2 with a High risk outlook  read    The fund s top three holdings are Ionis Pharmaceuticals  1 8    Ligand Pharmaceuticals  1 8   and Intercept Pharmaceuticals  1 7   BTECThis fund offers access to early phase companies developing treatments for conditions like migraines  Crohn s disease  multiple Sclerosis  diabetes  and other illnesses by tracking the Nasdaq Healthcare Innovators Index  It holds 194 stocks in its basket with around 61  concentration in biotech industry  BTEC charges 42 bps in annual fees and trades in an average daily volume of 2 409 shares  The product has accumulated  57 8 million in its asset base  It has a Zacks ETF Rank  2 The fund s top three holdings are Incyte  NASDAQ INCY  Corp  4    Teleflex  3 8   and Seattle Genetics  3 4   Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-04-11,Zacks Investment Research,https://www.investing.com/analysis/biotechnology-market-on-a-tear-5-etfs-in-spotlight-200406088,200406088
128895,350410,BIIB,Biogen  BIIB  Reports Next Week  Wall Street Expects Earnings Growth,opinion,"Wall Street expects a year over year increase in earnings on higher revenues when Biogen  BIIB  reports results for the quarter ended March 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on April 24  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This biotechnology company is expected to post quarterly earnings of  6 86 per share in its upcoming report  which represents a year over year change of  13 4  
Revenues are expected to be  3 38 billion  up 8  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 1 29  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Biogen 
For Biogen  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 95  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that Biogen will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Biogen would post earnings of  6 72 per share when it actually produced earnings of  6 99  delivering a surprise of  4 02  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Biogen appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-04-16,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-reports-next-week-wall-street-expects-earnings-growth-200407804,200407804
128896,350411,BIIB,Roche s  RHHBY  Q1 Sales Strong On Solid Demand For New Drugs,opinion,Roche Holding  SIX ROG  AG   OTC RHHBY   posted strong sales for the first quarter of 2019  propelled by demand for new drugs amid biosimilar competition for legacy drugs  Consequently  the company raised its guidance for the year  Roche s stock has gained 8  in the past six months against the  s decline of 1 1   The company reported sales of CHF 14 8 billion in the first quarter of 2019  up 9  from the year ago quarter The company reports results under two divisions   Pharmaceuticals and Diagnostics  All growth rates mentioned below are on a year over year basis and at constant exchange rates Sales at the Pharmaceuticals division increased 12   driven by strong growth of Ocrevus  Perjeta  Tecentriq and Hemlibra  The strong uptake of newly introduced medicines was partially offset by lower sales of Herceptin and MabThera Rituxan  The Diagnostics division sales climbed 1  Results in DetailHerceptin sales fell 6  owing to biosimilar competition since mid 2018  which more than offset the growth in the United States and China  Perjeta sales grew 41   following increased demand for adjuvant early breast cancer therapy  In total  the HER2 franchise  Herceptin  Perjeta and Kadcyla  sales were up 7  year over year Strong Ocrevus sales   67   further boosted the top line  The drug  used to treat two forms of multiple sclerosis  MS   continued to gain traction worldwide with sales of CHF 836 million Immuno oncology drug  Tecentriq  for advanced bladder cancer and advanced lung cancer   recorded 135  year over year growth in sales  This growth was driven by inclusion of the new indications   extensive stage small cell lung cancer and triple negative breast cancer Sales of lung cancer drug  Alecensa  surged 61  and witnessed solid growth across all regions   Oncology drug  Avastin  recorded 9  growth Performance of the immunology franchise was driven by increased sales of Actemra RoActemra   6   and Xolair   1    Gazyva Gazyvaro sales jumped 35  due to growth in the United States and Europe Sales of ophthalmology drug  Lucentis  grew 11   Roche has a collaboration agreement with Novartis   NYSE NVS   for this drug  The growth was driven by increased sales in all approved indications  However  sales of Rituxan MabThera declined 3  due to entry of biosimilars in Europe  Sales of Xeloda were up  5  Revenues at the Diagnostics division were up only 1  on the back of Molecular Diagnostics   7    led by the growth of its cervical cancer business  However  sales were impacted by one time  supply chain effects in Centralised and Point of Care Solutions in Asia Pacific and coagulation monitoring systems in North America 2019 Outlook RaisedSales in 2019 are expected to grow in mid single digits  The company expects core earnings to grow in line with sales   Roche anticipates to increase its dividend further Pipeline Progress    Roche made encouraging pipeline progress in the first quarter  In particular  label expansions of immuno oncology drug  Tecentriq  obtained approvals for various indications  The FDA approved Tecentriq in combination with carboplatin and etoposide  chemotherapy  for the initial  first line  treatment of adults with extensive stage small cell lung cancer The FDA granted accelerated approval to Tecentriq plus chemotherapy  paclitaxel protein bound particles for injectable suspension  for the treatment of adults with unresectable locally advanced or metastatic triple negative breast cancer in patients  whose tumours express PD L1 as determined by an FDA approved test The European Commission approved Tecentriq in combination with Avastin  paclitaxel and carboplatin for the first line treatment of adults with metastatic non squamous non small cell lung cancer  NSCLC   The European Commission also approved Hemlibra for routine prophylaxis of bleeding episodes in people with severe haemophilia A without factor VIII inhibitors The European Commission also approved MabThera for the treatment of adults with moderate to severe pemphigus vulgaris Roche submitted a supplemental Biologics License Application to the FDA for Kadcyla for adjuvant treatment of people with HER2 positive early breast cancer  eBC   with residual disease after neoadjuvant treatment Our TakeRoche posted strong sales in the first quarter  as it combated biosimilar competition in Europe  In particular  MS drug Ocrevus witnessed strong growth on increased demand amid stiff competition from Biogen   NASDAQ BIIB   drugs  The company continues to progress with its pipeline  as it looks to restructure the portfolio beyond oncology into MS and haemophilia  among others  Label expansion of Tecentriq for various indications should further boost sales   Meanwhile  Roche had earlier announced that it will acquire gene therapy company  Spark Therapeutics   NASDAQ ONCE    Earlier this month  the company withdrew its Premerger Notification and Report Form in connection with the pending acquisition of Spark Therapeutics Zacks RankRoche carries a Zacks Rank  3  Hold   You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-04-17,Zacks Investment Research,https://www.investing.com/analysis/roches-rhhby-q1-sales-strong-on-solid-demand-for-new-drugs-200408508,200408508
128910,350425,BIIB,MediciNova s ibudilast shows treatment effect in ALS patients  shares ahead 16  premarket,news,MediciNova   NASDAQ MNOV  is up 16  premarket  albeit on only 1 500 shares  in response to its announcement of positive preliminary results from a six month open label extension period evaluating MN 166  ibudilast  in patients with amyotrophic lateral sclerosis  ALS   The data were presented at the American Academy of Neurology 69th Annual Meeting in Boston ALS patients who completed both the six month treatment period in the Phase 2 clinical trial and the six month open label extension period  n 31  experienced significantly higher survival rates compared to patients who withdrew from the study before the open label period  n 16  In addition  26 ALS patients who completed the entire study period and then were evaluated after two weeks with no ibudilast treatment showed significant decreases in muscle strength  hip  leg and neck flexion  MN 166 is an orally available  small molecule phosphodiesterase 4 and  10 inhibitor and a macrophage migration inhibitory factor inhibitor that suppresses pro inflammatory cytokines and promotes neurotrophic factors  Its anti neuroinflammatory and neuroprotective actions are the basis for the potential treatment of diseases like ALS and multiple sclerosis  It has Fast Track status for both Now read  Biogen  NASDAQ BIIB  Jumps On Q1 Results  Analysis,2017-04-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/medicinova's-ibudilast-shows-treatment-effect-in-als-patients;-shares-ahead-16-premarket-477553,477553
128911,350426,BIIB,Biogen acquires late stage stroke candidate from Remedy Pharma for  120M upfront,news,Biogen  NASDAQ BIIB  acquires CIRARA  intravenous glyburide  from Remedy Pharmaceuticals  The target indication is the treatment of a severe form of ischemic stroke with brain swelling called large hemispheric infarction  LHI   In the U S  it has Orphan Drug and Fast Track status Under the terms of the transaction  Remedy will receive an upfront payment of  120M  undisclosed milestones and sales based royalties Remedy says CIRARA inhibits a specific channel called Sur1 Trpm4 that is upregulated following ischemic and traumatic injury  The channel allows excess sodium to move into cells followed by in influx of water which leads to swelling  damage and death Now read ,2017-05-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/biogen-acquires-late-stage-stroke-candidate-from-remedy-pharma-for-$120m-upfront-484283,484283
128912,350427,BIIB,Healthcare firms fail to swim against the tide  all groups down,news,The President Trump FBI scandal stoked sell off has not spared medical firms  IBB  1 5   BIB  2 9   XPH  1 1   IHI  0 7    As a consolation  all of the big names are down are light or average volume Representative tickers   BIIB  1 7   AMGN  1 2   GILD  1 1   ALXN  2 7   PFE  1   MRK  1   BMY  0 2   LLY  0 6   ABT  0 5   MDT  0 5  Now read ,2017-05-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare-firms-fail-to-swim-against-the-tide;-all-groups-down-485514,485514
128913,350428,BIIB,European regulators sign off on J J s Actelion buy contingent on spin off of one insomnia program,news,Regulatory authorities in the EU have approved Johnson and Johnson s  NYSE JNJ  planned  30B takeover of Actelion after the company pledged to spin off one of the combined firm s two insomnia pipeline programs Actelion s insomnia project will be transferred to a new company called Idorsia  J J has agreed to limit its stake in the new entity to 10  if it is the largest shareholder and 16  if not  It will not nominate a board member and cannot influence its strategy or obtain information on the drug in development J J s program with Minerva Neurosciences competes directly with  Actelion s  It has granted Minerva new rights over global development and has waived its royalty rights to Minerva sales in Europe EU regulators saw no problems in the multiple sclerosis space because Actelion s product candidate differs from Biogen  NASDAQ BIIB  s that J J s distributes in part of Europe Source  BloombergNow read ,2017-06-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/european-regulators-sign-off-on-j-j's-actelion-buy-contingent-on-spin-off-of-one-insomnia-program-493773,493773
128917,350432,BIIB,AbbVie s Psoriasis Drug Skyrizi Gets First Approval In Japan,opinion,AbbVie Inc    NYSE ABBV   announced that the Japanese Ministry of Health  Labour and Welfare  MHLW  has approved its key pipeline candidate  risankizumab  for the treatment of adult patients with plaque psoriasis  generalized pustular psoriasis  erythrodermic psoriasis and psoriatic arthritis  The interleukin 23  IL 23  inhibitor will be marketed under the trade name of Skyrizi Following this nod  Japan became the first country to approve Skyrizi for patients suffering psoriatic disease and failing to show an adequate response to the conventional therapies The approval was based on the safety and efficacy data from the phase II III studies  namely sustaIMM  ultIMMa 1 and IMMspire  which evaluated Skyrizi in the Japanese patients with plaque psoriasis  generalized pustular psoriasis and erythrodermic psoriasis  Also  a global phase II study evaluated Skyrizi for treating patients with active psoriatic arthritis  which also formed basis of its application filing in JapanAbbVie has developed Skyrizi in collaboration with the privately held Boehringer Ingelheim Shares of AbbVie have declined 13 7  so far this year against the increase of 3 7  We would like to remind investors that earlier this month  the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  rendered a positive opinion  recommending the marketing approval for Skyrizi to treat moderate to severe plaque psoriasis Notably  AbbVie had filed the marketing application in the EU last May and in the United States last April  AbbVie s application will now be reviewed by the European Commission  which will announce its decision in two months  time  The FDA s decision is also awaited in the first half of 2019 AbbVie expects an approval for another key pipeline candidate  upadacitinib  this year  Upadacitinib  an oral investigational JAK inhibitor  has been developed for the treatment of adult patients with moderate to severe rheumatoid arthritis  RA   The nod and the successful commercialization of upadacitinib are crucial for long term growth at AbbVie  especially as a biosimilar competition looms large on its blockbuster RA drug  Humira Several companies made biosimilar versions of Humira  With Humira accounting for around 61  of AbbVie s sales  the entry of biosimilars will leave a huge impact on the company s financials  Per settlements with a set of seven manufacturers including Amgen   NASDAQ AMGN    Biogen   NASDAQ BIIB    Pfizer   NYSE PFE    Momenta among others  Humira biosimilars are expected to be launched across the United States in 2023  However  AbbVie faces a direct biosimilar competition in Europe and other countries  accounting for approximately 25  of the total global Humira revenues  Humira biosimilars were first unveiled in the EU last October  In 2019  AbbVie fears a 30  plunge or a  2 billion decline in the international Humira sales Zacks RankAbbVie currently carries a Zacks Rank  3  Hold   You can see  Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-03-25,Zacks Investment Research,https://www.investing.com/analysis/abbvies-psoriasis-drug-skyrizi-gets-first-approval-in-japan-200401152,200401152
128918,350433,BIIB,Celgene  CELG  Submits NDA For MS Drug To FDA For Review,opinion,"Celgene Corporation   NASDAQ CELG   announced that it has submitted a New Drug Application  NDA  to the FDA for multiple sclerosis  MS  candidate  ozanimod 
Ozanimod  an oral  sphingosine 1 phosphate  S1P  receptor modulator  is currently being evaluated for the treatment of relapsing forms of multiple sclerosis  RMS  
The NDA contains efficacy and safety data from the SUNBEAM and RADIANCE part B phase III  multicenter  randomized  double blind  double dummy  active controlled studies 
We remind investors that the company suffered a setback early 2018  when it received Refusal to File letter from the FDA regarding its NDA for ozanimod  The FDA stated that the nonclinical and clinical pharmacology sections in the NDA were inadequate to allow a complete review 
Celgene has also submitted its application for review in Europe for the same 
Ozanimod is also being evaluated for ulcerative colitis and Crohn s disease 
Celgene s stock has lost 0 4  in the past six months compared with the  s decline of 18 4  

 
A tentative approval will boost Celgene s portfolio  but competition is stiff in the MS market from the likes of Biogen   NASDAQ BIIB   
Meanwhile  Celgene has been in the news lately due to a merger agreement with Bristol Myers Squibb Company   NYSE BMY   announced earlier this year  Per the deal  Bristol Myers will acquire Celgene for a whopping  74 billion  Celgene s shareholders will receive  50 plus one share of Bristol Myers and one tradeable Contingent Value Right  CVR   which will entitle the holder to receive a cash payment of  9 00 upon the achievement of FDA approval of three products in its pipeline   ozanimod  liso cel and bb2121   within specified time periods 
The company also has a co development and co promotion agreement with bluebird bio  Inc    NASDAQ BLUE   for bb2121  an experimental anti B cell maturation antigen  BCMA  chimeric antigen receptor  CAR  T cell therapy  for the potential treatment of patients with relapsed refractory multiple myeloma in the United States  The acquisition of Juno Therapeutics has added liso cel to Celgene s lymphoma pipeline 
However  Bristol Myers Squibb is facing opposition from some of its shareholders  putting the future of the merger with Celgene in jeopardy 
Zacks Rank
Celgene currently carries a Zacks Rank  1  Strong Buy   You can see  
Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-03-26,Zacks Investment Research,https://www.investing.com/analysis/celgene-celg-submits-nda-for-ms-drug-to-fda-for-review-200401236,200401236
128919,350434,BIIB,Novartis  NVS  Receives FDA Approval For MS Drug Mayzent,opinion,"Swiss pharma giant Novartis AG   NYSE NVS   announced that the FDA has approved pipeline candidate Mayzent  siponimod   a next generation  selective sphingosine 1 phosphate receptor modulator  for the treatment of adults with relapsing forms of multiple sclerosis  MS  
The FDA has approved the drug for the treatment of secondary progressive multiple sclerosis  SPMS  with active disease  relapsing remitting multiple sclerosis  RRMS  and clinically isolated syndrome  CIS  
The approval was based on data from the phase III EXPAND trial  a randomized  double blind  placebo controlled study which compared the efficacy and safety of Mayzent with that of placebo in SPMS patients 
The results showed that Mayzent significantly reduced the risk of disease progression  including impact on physical disability and cognitive decline 
The drug is also under review in Europe 
The approval will strengthen Novartis  MS portfolio  which includes approved drugs like Gilenya and Extavia  interferon beta 1b for subcutaneous injection   Notably  Extavia is approved in the United States for the treatment of relapsing forms of MS  The drug is approved in Europe to treat patients with RRMS and SPMS with active disease  Novartis also has other MS candidates in the pipeline like OMB157  ofatumumab   which is being evaluated for relapsing MS in a phase III program  The program  which was initiated in August 2016  is fully enrolled and on track for completion in 2019 
Novartis  generic division  Sandoz markets Glatopa  a generic version of Teva Pharmaceuticals    NYSE TEVA   Copaxone  both 20 and 40 mg   in partnership with Momenta Pharmaceuticals   NASDAQ MNTA   
Approval of new drugs and label expansion of existing drugs bode well for the company 
Novartis  shares have gained 12 7  in the year so far compared with the industry s growth of 6  

 
We note that Biogen  Inc    NASDAQ BIIB   holds a strong position in the MS market  with a wide range of products  including Avonex  Tysabri  Tecfidera and Plegridy 
Zacks Rank
Novartis currently carries a Zacks Rank  3  Hold   You can see  
Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-27,Zacks Investment Research,https://www.investing.com/analysis/novartis-nvs-receives-fda-approval-for-ms-drug-mayzent-200401636,200401636
128920,350435,BIIB,Merck KgaA s  MKGAF  MS Drug Mavenclad Gets FDA Approval,opinion,"Merck KgaA  announced that the FDA has granted approval to its oral multiple sclerosis   MS   drug  Mavenclad  The drug is indicated for treating adult patients with relapsing remitting MS   RRMS   and active secondary progressive MS   SPMS   The drug has achieved a proven efficacy of two years with oral treatment for a maximum of 20 days in clinical studies  Moreover  the drug is already approved in other geographies including Europe However  we note that the Mavenclad s label contains a boxed warning for potential risk of malignancy and the risk of teratogenicity  Due to its risky safety profile  the drug is recommended for patients who are having inadequate response or are intolerable to alternative treatments  The drug is contra indicated for clinically isolated syndrome   CIS   Merck s shares have increased 11 5  so far this year compared with the  s rise of 17 5   In clinical studies  including follow up studies  patients were treated with Mavenclad for a median of 4 8 years  Data from the study showed that treatment with the drug achieved 58  reduction in the annualized relapse rate compared to a placebo  Moreover  81  of patients did not have relapses after having the short course treatment over a period of two years versus 63  for placebo  Treatment with Mavenclad also reduced the risk of 3 month confirmed disability progression and lowered the number of injury damage to brain  lesions  Multiple sclerosis is a major factor leading to disability in young as well as adult patients  Per the press release  there are nearly a million people who are affected by MS in the United States  The majority  85   is initially diagnosed with RRMS and in most cases they progress to SPMS  An oral treatment with a short course can help several of these patients  thereby creating a significant opportunity for Mavenclad  However  malignancy risk may hamper its uptake In 2018  Mavenclad generated sales of almost  106 million for the company  With the U S  approval  sales are expected to get a boost Please note that Biogen   NASDAQ BIIB   holds a strong position in the United States with multiple drugs in its MS portfolio  Its MS drugs generated sales of almost  8 6 billion in 2018  Apart from Biogen  several pharma companies have approved treatments for MS including Roche s   OTC RHHBY   Ocrevus and Sanofi s   NASDAQ SNY   Aubagio  Last month  Novartis  MS drug  Mayzent  siponimod   received approval from the FDA for treating relapsing forms of multiple sclerosis  including RRMS  SPMS as well as CIS Merck KGaA Price
    Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-03-31,Zacks Investment Research,https://www.investing.com/analysis/merck-kgaas-mkgaf-ms-drug-mavenclad-gets-fda-approval-200402787,200402787
128921,350436,BIIB,Celgene Gets Positive CHMP Nod For Revlimid Label Expansion,opinion,"Celgene Corporation   NASDAQ CELG   announced that the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  has adopted positive opinions for label expansions of IMiD medications   leading oncology drug  Revlimid  lenalidomide  and Imnovid The CHMP recommended approval of the triplet regimen of Revlimid as combination therapy with Velcade and dexamethasone  RVd  for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant  The positive opinion was based on data from phase III study  SWOG S0777  which showed statistically significant progression free survival  PFS  and overall survival  OS  improvements in patients treated with RVd compared to those treated with Revlimid and dexamethasone  Rd  The committee also recommended approval of Imnovid in combination with Velcade and dexamethasone  PVd  for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen  including Revlimid   The positive opinion for PVd was based on the data from the phase III study  OPTIMISMM  which showed that patients receiving PVd achieved a significantly longer PFS than those in the Vd treatment arm We note that the European Commission generally follows the recommendation of the CHMP but is not bound by it  The committee is expected to make its final decision in approximately two months  A potential label expansion of the drugs will further boost sales 
Celgene s key growth driver  Revlimid  an oral immunomodulatory drug  is currently approved for several indications  including MM  myelodysplastic syndromes  MDS  and mantle cell lymphoma  MCL   Sales of the drug came in at  9 7 billion in 2018  up 18 3  from 2017 Concurrently  Celgene announced the settlement of its litigation with Alvogen for patents related to Revlimid  Per the settlement agreement  both the parties will file Consent Judgments with the United States District Court for the District of New Jersey that will stop Alvogen from marketing generic version of Revlimid before the expiration of the patents in suit 
Celgene has agreed to provide Alvogen with a license to its patents required to manufacture and sell certain volume limited amounts of generic Revlimid in the United States  beginning on a confidential date  some time after the March 2022 volume limited license date that Celgene previously provided to Natco    Alvogen is yet to obtain approval of an Abbreviated New Drug Application for Revlimid Celgene s stock has gained 2 7  in the past six months compared with the  s decline of 9 8  
 
Meanwhile  the current focus is on the company s impending merger with Bristol Myers Squibb Company   NYSE BMY    In January  Bristol Myers announced that it will acquire Celgene for approximately  74 billion  However  it is being opposed by a few shareholders  believing the deal to be overpriced  which will significantly increase shareholders  risk 
Bristol Myers recently announced that independent proxy advisory firms  Institutional Shareholder Services   ISS   and Glass Lewis   Co    Glass Lewis   recommend that shareholders should vote in favor of the approval of the impending merger with Celgene Corporation   The merger is expected to close in the third quarter The acquisition announcement prompted quite a few other deals  Another leading biotech  Biogen   NASDAQ BIIB   announced that it will acquire Nightstar Therapeutics  Swiss pharma giant  Roche   OTC RHHBY   announced that it will acquire Spark Therapeutics for  5 billion Zacks RankCelgene currently carries a Zacks Rank  1  Strong Buy   You can see  
Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-04-01,Zacks Investment Research,https://www.investing.com/analysis/celgene-gets-positive-chmp-nod-for-revlimid-label-expansion-200402847,200402847
128922,350437,BIIB,Alector  ALEC  Initiates Phase I Alzheimer s Study On AL003 ,opinion,Alector  Inc    NASDAQ ALEC   announced the initiation of the phase I INTERCEPT study on AL003 for the treatment of Alzheimer s disease  The randomized  double blind  placebo controlled  dose escalation study will investigate the safety  tolerability  pharmacokinetics  pharmacodynamics and immunogenicity of AL003 in healthy volunteers and patients with Alzheimer s disease AL003 is the company s second product candidate being developed for the treatment of patients with Alzheimer s disease in collaboration with AbbVie   NYSE ABBV    In November  Alector initiated a phase I INVOKE study to evaluate AL002 for the treatment of Alzheimer s disease Alector is focused on identifying and functionally repairing genetic mutations that cause dysfunction of the brain immune system  leading to neurodegeneration  AL003 targets SIGLEC 3  which is an inhibitory receptor expressed primarily on cells of myeloid lineage  including microglia  which constitute the brain s immune system Shares of the company were up almost 7  on the announcement of the news  Alector s stock price has increased 18 2  in the past year against the  s decline of 6 6  Alzheimer s is a fatal illness that causes progressive decline in memory  It has always been a highly challenging area  with not much progress being made in spite of significant investments  both funds and resources  by drug companies Companies continue to invest heavily in developing Alzheimer s disease treatments  The market has immense commercial potential  and companies coming up with new treatments could rake in billions of dollars In January 2019  Biogen  NASDAQ BIIB  inked two strategic collaborations  one each with C4 Therapeutics and Skyhawk Therapeutics to develop potential therapies for Alzheimer s disease  Parkinson s disease and other devastating neurological diseases In December 2018  Eli Lilly   Company   NYSE LLY   signed a collaboration agreement with Swiss biotech AC Immune SA   NASDAQ ACIU   to jointly develop tau aggregation inhibitors  which have the potential to treat Alzheimer s and other neurodegenerative diseases  Lilly has had its share of failures in Alzheimer s disease Zacks Rank   Stock to ConsiderAlector currently carries a Zacks Rank  3  Hold   You can see  Is Your Investment Advisor Fumbling Your Financial Future  See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-04-02,Zacks Investment Research,https://www.investing.com/analysis/alector-alec-initiates-phase-i-alzheimers-study-on-al003-200403644,200403644
128942,350457,BIIB,Wall Street slips with healthcare stocks  Nasdaq flat,news,"By Rodrigo Campos NEW YORK  Reuters    U S  stocks slipped on Thursday pressured by healthcare shares as traders cashed in gains from one of the best performing sectors so far this year  Proposals in President Donald Trump s budget signaled higher regulatory costs for the sector and a cut in federal funding for medical research  Though still a ways away from becoming a reality  they gave traders a reason to sell  The S P 500 healthcare index  SPXHC  dropped 0 9 percent  Financials  SPSY  outperformed in a rebound after the sector was the worst performer on Wednesday and as the benchmark U S  Treasury note yield rose  while utilities  SPLRCU  weakened  Biogen  O BIIB  weighed down the S P 500  falling 4 7 percent to  278 96 after two brokerages downgraded the stock   Healthcare is being dragged down by equipment and supplies  biotechnology  and tools and services  These sectors have actually done quite well year to date  so this is just a little speed bump   said Brian Jacobsen  chief portfolio strategist at  Wells Fargo   NYSE WFC  Funds Management in Menomonee Falls  Wisconsin   There s a push and a pull with these stocks as the President has promised to accelerate the  drug and device  approval process  but now he s proposing to cut the budget of the FDA  which could make it difficult to get expedited approvals   The Dow Jones Industrial Average  DJI  fell 15 55 points  or 0 07 percent  to close at 20 934 55  the S P 500  SPX  lost 3 88 points  or 0 16 percent  to 2 381 38 and the Nasdaq Composite  IXIC  added 0 71 point  or 0 01 percent  to 5 900 76  Oracle  N ORCL  surged to a record high of  46 99 before closing up 6 2 percent at  45 73  after it posted a better than expected quarterly profit   Tyson Foods   N TSN  slipped 1 7 percent to  62 00 on news that a form of bird flu that is highly lethal for poultry had infected a second farm that supplies Tyson  Advancing issues outnumbered declining ones on the NYSE by a 1 29 to 1 ratio  on Nasdaq  a 1 49 to 1 ratio favored advancers  The S P 500 posted 52 new 52 week highs and one new low  the Nasdaq Composite recorded 145 new highs and 52 new lows  
About 6 60 billion shares changed hands in U S  exchanges  below the 6 96 billion daily average over the last 20 sessions ",2017-03-16,Reuters,https://www.investing.com/news/stock-market-news/futures-up-on-fed's-dovish-rate-hike-outlook-466625,466625
128943,350458,BIIB,U S  stocks close mixed  Nasdaq ekes out a win ,news,"Investing com   U S  equities closed mostly lower on Thursday  as gains in Financials were offset by losses in health care  after President Trump s budget blueprint proposed budget cuts to the National Institutes of Health  NIH  
Healthcare stocks nosedived  as President Trump s budget blueprint proposed cutting the NIH budget by  5 8 billion while Financials  mostly banks  traded tentatively higher after the Federal Reserve hiked interest rates on Wednesday 
The Federal Reserve on Wednesday  raised interest rates by 0 25  to a target range of 0 75  to 1  but kept its previous forecast of three rate increases this year unchanged 
Meanwhile economic data failed to lift sentiment while U S  crude futures struggled to hold onto gains from the previous session 
U S crude futures settled slightly lower at  48 75  as focus shifted to the elevated levels of U S  crude stockpiles amid concerns that The Organization of the Petroleum Exporting Countries  OPEC  would not extend its production cuts beyond the six month period agreed last November 
Weekly initial jobless claims fell to 241 000  Housing starts rose to a seasonally adjusted annual rate of 1 288 million in February while the Philadelphia Fed Index topped forecasts at 32 8 for March  Both the Philadelphia Fed Index and the housing starts beat forecasts 
The Dow Jones Industrial Average closed 0 07  lower at 20 934  The S P 500 lost 0 16  and the Nasdaq Composite added 0 01  to close at 5 900 
In corporate earnings news  Adobe shares popped in after hours trade  after the software company posted better than expected quarterly results 
The top S P 500 gainers included Oracle Corporation  NYSE ORCL  up 6 2   and Frontier Communications Corporation  NASDAQ FTR  up 4 1   while  NRG Energy Inc   NYSE NRG  added 2 5  
Biogen Inc  NASDAQ BIIB  down 4 7   Illumina Inc  NASDAQ ILMN  down 3 9  and  Newmont Mining  Corporation  NYSE NEM  3 8   were among the worst S P 500 performers of the session ",2017-03-16,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stocks-close-lower:-nasdaq-ekes-out-a-win-466805,466805
128944,350459,BIIB,Biogen wins ruling in Tecfidera IP case  shares rise,news,"NEW YORK  Reuters    Biogen Inc  O BIIB  on Tuesday won an intellectual property rights ruling against hedge fund manager Kyle Bass over its top multiple sclerosis pill  Tecfidera  pushing shares up more than 1 percent on a day when most U S  stocks were down  The ruling came from the U S  Patent and Trademark Office s Patent Trial and Appeal Board in Washington  The decision should extend the time that Biogen can keep U S  sales of the drug out of the hands of generic competitors by four to five years  according to Mizuho analyst Salim Syed   Bass could appeal the ruling  Syed said in a research note  Neither Bass nor Biogen were immediately available for comment  The hedge fund manager s legal challenge centered on the so called 514 patent  which focuses on a method for dosing multiple sclerosis patients with 480 milligrams per day of certain fumarates  which are chemical intermediates  Bass has filed a number of lawsuits against multiple companies as part of an effort to eliminate drug patents that he believed were being improperly extended based on dosing schedules  preventing cheaper drugs from hitting the market  
Biogen shares rose  4 12  or 1 5 percent  to  278 92 in early afternoon Nasdaq trading  The Dow Jones Industrial Average  DJI   S P 500  SPX  and Nasdaq Composite  IXIC  were all down ",2017-03-21,Reuters,https://www.investing.com/news/stock-market-news/biogen-wins-ruling-in-tecfidera-ip-case;-shares-rise-467750,467750
128945,350460,BIIB,Jobless Claims Dip  Philly Fed Swings  Biogen  BIIB  Plummets,opinion,"Thursday  March 21  2019Like most Thursdays  today s pre market brings us fresh Initial Jobless Claims data  with results close to where they ve been for most of 2019 thus far  221K last week amounts to a drop of 9000 claims from the previous week s slightly upwardly revised 230K  Still toward the upper end of our long term 200 225K range  but consistent with the robust labor market we ve going back several years Continuing Claims fell just a tad  from 1 77 million the previous week to 1 75 million   again  up from the 50 year lows we d seen 6 months ago  but historically very sound  For all the challenges our domestic economy currently faces  employment is not one of them The Philly Fed survey for March has also come out this morning  with a surprise read to the upside  13 7  more than double what analysts had been expecting  This was also a healthy swing to the positive from February s  4 1  which was the first time Philly Fed manufacturing had gone negative since the first half of 2016 These reads are better taken in context with other municipal and state wide production reads  as they necessarily give regional statistics  And Philadelphia  for many years a city dropping in overall population and national status  has seen a gradual resurgence more recently  The Philly Fed Index records more volatility within these numbers  but the trajectory looks better for the former U S  Capital  1790 1800  look it up  overall One company that s not looking better this morning is biopharma major Biogen   NASDAQ BIIB    which is down more than 26  at this hour in early trading  Research on the company s latest treatment for Alzheimer s disease  which had been in phase 3 testing  has been halted  Alzheimer s disease affects at least 50 million people the world over Some analysts had issued warnings on the lack of data in phase 3 on the drug  called aducanumab  which was being developed with Tokyo based Eisai Company  Now  the entire hypothesis of the treatment   targeting protein deposits in the brain believed to bring on Alzheimer s disease   may be finished for addressing this malady Finally  Levi Strauss   Co   NYSE LEVI  begins trading this morning  after 34 years as a private company  The IPO price has been set at  17 per share  above the range of  14 16 originally reported  The IPO is expected to raise  620 million for a company currently valued at  6 6 billion Mark VickerySenior Editor
Breakout Biotech Stocks with Triple Digit Profit Potential
The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases 
Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-03-20,Zacks Investment Research,https://www.investing.com/analysis/jobless-claims-dip-philly-fed-swings-biogen-biib-plummets-200399867,200399867
128946,350461,BIIB,Initial Jobless Claims Decline,opinion,Like most Thursdays  today s pre market brings us fresh Initial Jobless Claims data  with results close to where they ve been for most of 2019 thus far  221K last week amounts to a drop of 9000 claims from the previous week s slightly upwardly revised 230K  Still toward the upper end of our long term 200 225K range  but consistent with the robust labor market we ve going back several years Continuing Claims fell just a tad  from 1 77 million the previous week to 1 75 million   again  up from the 50 year lows we d seen 6 months ago  but historically very sound  For all the challenges our domestic economy currently faces  employment is not one of them The Philly Fed survey for March has also come out this morning  with a surprise read to the upside  13 7  more than double what analysts had been expecting  This was also a healthy swing to the positive from February s  4 1  which was the first time Philly Fed manufacturing had gone negative since the first half of 2016 These reads are better taken in context with other municipal and state wide production reads  as they necessarily give regional statistics  And Philadelphia  for many years a city dropping in overall population and national status  has seen a gradual resurgence more recently  The Philly Fed Index records more volatility within these numbers  but the trajectory looks better for the former U S  Capital  1790 1800  look it up  overall One company that s not looking better this morning is biopharma major Biogen   NASDAQ BIIB    which is down more than 26  at this hour in early trading  Research on the company s latest treatment for Alzheimer s disease  which had been in phase 3 testing  has been halted  Alzheimer s disease affects at least 50 million people the world over Some analysts had issued warnings on the lack of data in phase 3 on the drug  called aducanumab  which was being developed with Tokyo based Eisai Company  Now  the entire hypothesis of the treatment   targeting protein deposits in the brain believed to bring on Alzheimer s disease   may be finished for addressing this malady Finally  Levi Strauss   Co   NYSE LEVI  begins trading this morning  after 34 years as a private company  The IPO price has been set at  17 per share  above the range of  14 16 originally reported  The IPO is expected to raise  620 million for a company currently valued at  6 6 billion ,2019-03-20,Zacks Investment Research,https://www.investing.com/analysis/initial-jobless-claims-decline-200399859,200399859
128947,350462,BIIB,Biogen Stock Crashes On Termination Of Alzheimer s Studies,opinion,"Biogen   NASDAQ BIIB   and its Japan based partner Eisai announced the discontinuation of two late stage studies evaluating their Alzheimer s disease candidate  aducanumab  The decision was taken following a futility analysis conducted by an independent data monitoring committee   IDMC    The analysis showed that the studies are unlikely to meet their primary endpoints  However  there were no safety concerns Biogen s shares crashed 29 2  following the disappointing news  Shares of the company decreased 24 6  so far this year against the  s rise of 14 4  Biogen and Eisai were evaluating aducanumab in two phase III studies   ENGAGE and EMERGE   in patients with mild cognitive impairment due to Alzheimer s disease and mild Alzheimer s disease dementia  Detailed data from these studies will be presented at future medical meetings The companies will also halt a phase II study   EVOLVE   and the long term extension of PRIME phase Ib  which were evaluating aducanumab  The initiation of phase III secondary prevention study depends on further evaluation of data from ENGAGE and EMERGE studies Biogen has a strong position in the multiple sclerosis   MS   market  However  sales from this segment were relatively flat in 2018   The presence of drugs like Novartis    NYSE NVS   Gilenya and Sanofi s   NASDAQ SNY   Aubagio has intensified competition in the market  Biogen is trying to build its portfolio beyond MS into Alzheimer s  Parkinson s  stroke and others Aducanumab was a key candidate in Biogen s pipeline  Successful completion of these late stage studies would have been a boon for Biogen as there are only a few treatments approved for Alzheimer s  One of them is Allergan s Namenda However  the companies have another promising Alzheimer s disease candidate  BAN2401  The candidate is in mid stage development and has shown potential as a possible remedy in previously completed clinical studies  Biogen is also evaluating BIIB092 in a phase II study for Alzheimer s disease Alzheimer s  a fatal illness that causes progressive decline in memory  is a highly challenging area as multiple pharma companies have failed in their attempts to develop treatment In January 2019  Roche   OTC RHHBY    two late stage studies evaluating its Alzheimer s disease candidate  crenezumab  The candidate was unlikely to meet primary endpoints of the studies as assessed by an IDMC In 2018  several large pharma companies including    and  stopped development of their Alzheimer s candidate either due to low possibility of success or safety concerns Despite the repeated failures  industry players remain committed to developing a treatment  given their strong commercial potential Companies that are currently working on Alzheimer s disease treatments include Biogen  Novartis  AstraZeneca  Eisai and Amgen  NASDAQ AMGN  Biogen Inc  Price
    Zacks RankBiogen currently carries a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-03-21,Zacks Investment Research,https://www.investing.com/analysis/biogen-stock-crashes-on-termination-of-alzheimers-studies-200400230,200400230
128948,350463,BIIB,S P Holds Onto 2800 Despite Sharp Selloff,opinion,"The market released a lot of pent up concerns and frustrations with Friday s sharp selloff  which ruined what could have been another solid week for the major indices 
	In the end though  this week s actual losses were not as brutal as today s session felt  The Dow was off by approximately 1 3   while the S P and NASDAQ each shed less than 1   The indices went into Friday s session with gains for the week so there was a good cushion for the pullback  while the S P still managed to stay above 2800 by a slim margin 
	Investors have been worried about a slowing global economy for a while now  and yet our market has still been moving higher  But soft manufacturing numbers out of Europe and the U S  were too much to handle today  especially coming after a sudden dovish turn from the Fed  Two days removed from the Committee s decision to not hike rates for the rest of 2019  already skittish investors are now wondering if the about face is indication that the slowdown is worse than expected 
	Adding to the cautious sentiment was the inverted yield curve between the 3 month Treasury bill and the 10 year note  Such a move is considered to be a signal of recession down the road  not immediately but several months from now  We ll see   
	That s a lot for the market to take in  It s no wonder that it didn t have the wherewithal to shrug it off on Friday in the wake of such a strong start to 2019 
	The NASDAQ was outperforming its counterparts all week as tech has been very strong  but today it took the biggest step back  The index slipped 2 5   or nearly 200 points  to 7642 67  The Dow dropped 1 77   or about 460 points  to 25 502 32 
	The S P had just as bad a day as the others  but this index was able to barely hang onto the important 2800 mark  It was down 1 9  to 2800 71 So is this the start of a broader pullback or a buying opportunity  The funny thing is that folks always talk about how healthy and necessary pullbacks are after long runups  yet when one actually comes along we turn it up to eleven and proclaim it as a harbinger of doom 
	It should take more than one sharp pullback to panic the bulls  Let s see what next week has in store before stampeding toward the exits Today s Portfolio Highlights   Healthcare Innovators  Shares of Biogen  NASDAQ BIIB  lost over 30     and  20  billion of market cap    in 2 days after its Alzheimer s drug failed Phase 3 trials  Now  the mega biotech may be looking to buy other small life sciences companies to help refortify its central nervous system pipeline  and Kevin thinks that bodes well for a gene editing innovator like Sangamo Therapeutics  SGMO   The company s zinc finger nuclease technology platform holds potential for treatments in several types of unmet medical needs  including Hemophilia A  Sickle Cell  and 3 other genetic expressions  The editor likes the risk reward with this name at under a  1 billion market cap  so he added it to the portfolio on Friday with specific buy window guidelines  Read the complete commentary for a detailed analysis on SGMO  including what the analysts are all saying Technology Innovators  There s a buying opportunity in the healthcare tech space  Shares of Inovalon Holdings  INOV  dropped approximately 20  after the company missed quarterly earnings estimates  However  guidance for the rest of the year was not terrible  so Brian Bolan decided to buy the dip and add INOV to the portfolio on Friday  The editor also sees a good recipe for a squeeze in this name as 17  of the float is sold short  Read the complete commentary for more on this new buy Value Investor   We ve also had yield inversion  which has meant a recession within 6 to 18 months afterwards  Some will maybe argue  this time will be different  but in the modern era  that simply hasn t been the case 
	 I ve been saying all along that we shouldn t fear a recession  They are a normal part of the business cycle  I know most people are scared because they remember 2009 all too well   Don t we all  
	 But do you remember the 2000 2001 recession  Most don t because  outside of Silicon Valley  it simply wasn t that bad  It was a standard  garden variety slowdown  After ten years of outsized growth  a slowdown is to be expected 
	 Let s see what the stock market does next week  Just because it was spooked on Friday  doesn t mean it will be on Monday  There s a lot going on  but there s no need to panic right now      Tracey Ryniec
	Have a Great Weekend 
	Jim Giaquinto 
Recommendations from Zacks  Private Portfolios   Believe it or not  this article is not available on the Zacks com website  The commentary is a partial overview of the daily activity from Zacks  private recommendation services  If you would like to follow our Buy and Sell signals in real time  we ve made a special arrangement for readers of this website  Starting today you can see all the recommendations from all of Zacks  portfolios absolutely free for 7 days  Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises  which we ve predicted with an astonishing 80   accuracy    Click here to  test drive  Zacks Ultimate for FREE   ",2019-03-24,Zacks Investment Research,https://www.investing.com/analysis/sp-holds-onto-2800-despite-sharp-selloff-200400534,200400534
128963,350478,BIIB,Biogen names two more execs to Bioverativ spin off,news,Biogen  NASDAQ BIIB  names additional executives for its hemophilia blood disorder focused spin off Bioverativ  Rogerio Vivaldi  M D  will serve as EVP and chief global therapeutic operations officer and John Greene will serve as EVP and chief financial officer The spin off should be completed in Q1 ,2016-11-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/biogen-names-two-more-execs-to-bioverativ-spin-off-440874,440874
128964,350479,BIIB,Eisai s BACE inhibitor for early Alzheimer s Fast Track d in U S ,news,The FDA designates Eisai s  OTC ESALF  OTCPK ESALY  Phase 3 stage E2609 for Fast Track review for the treatment of early Alzheimer s disease Fast Track status allows for more frequent interactions with the FDA review team and a rolling review of the NDA E2609  being jointly developed with Biogen  BIIB  0 4    inhibits an enzyme called BACE which plays a key role in the production of amyloid beta peptides  Inhibiting BACE may decrease the formation of amyloid plaques in the brain thereby slowing the progression of AD ,2016-11-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/eisai's-bace-inhibitor-for-early-alzheimer's-fast-track'd-in-u.s.-441807,441807
128965,350480,BIIB,New drug approvals fall to six year low in 2016,news,"By Ben Hirschler LONDON  Reuters    Last year turned out to be a disappointing one for new drug approvals with the U S  Food and Drug Administration clearing just 22 new medicines for sale  the lowest number since 2010 and sharply down on 2015 s tally of 45  Across the Atlantic  the European Medicines Agency recommended 81 new prescription products against a 2015 total of 93  Unlike the FDA  the EMA includes generic drugs in its list  The slowdown suggests the pharmaceuticals industry may be returning to more normal productivity levels after a spike in approvals in 2014 and 2015  when the haul of new drugs reaching the market hit a 19 year high  Several factors led to the fall in the approval rate in 2016  John Jenkins  the FDA s director of the office of new drugs  told a conference last month  Notably  five new drugs that had been scheduled for approval in 2016 ended up winning an early green light at the end of 2015  There was also a decline in drugs being filed for approval and the FDA rejected or delayed more applications in 2016 than in the previous two years  Some of the delayed drugs may yet go on to win approval in 2017  including Roche s multiple sclerosis treatment Ocrevus and Sanofi  PA SASY  and Regeneron s sarilumab for rheumatoid arthritis  Most industry executives remain upbeat about the hunt for new medicines  given recent advances in fighting cancer and an improved understanding of the genetic basis of other diseases  which has resulted in full development pipelines at many firms  But it remains challenging to get new drugs through the approval process and to secure a decent financial return once they are launched  given resistance from healthcare insurers and governments to the rising cost of medical treatment  According to consultancy Deloitte  returns on research and development investment at the top 12 pharmaceutical companies fell to just 3 7 percent in 2016 from a high of 10 1 percent in 2010  Increasing political pressure over the high prices of many modern medicines is a growing challenge at a time when biotech and pharma companies are developing more drugs targeted at niche patient populations  The issue is exemplified by the last drug to win FDA approval in 2016  Spinraza  from Biogen  NASDAQ BIIB  and Ionis Pharmaceuticals  is the first medicine to treat patients with spinal muscular atrophy  a rare and often fatal genetic disease  It comes at a huge cost of  125 000 per dose  That price  implying a total cost of  625 000 to  750 000 for patients in the first year and  375 000 in subsequent years  is likely to invite  a storm of criticism  up to and including Presidential tweets   according to Leerink analysts  President elect Donald Trump has vowed to bring down drug prices  
For a graphic on U S  FDA drug approvals  click  ",2017-01-02,Reuters,https://www.investing.com/news/stock-market-news/new-drug-approvals-fall-to-six-year-low-in-2016-450664,450664
128966,350481,BIIB,AbbVie Gets CHMP Nod For Psoriasis Candidate Risankizumab,opinion,AbbVie  Inc    NYSE ABBV   announced that the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  has given a positive opinion  recommending marketing approval for risankizumab  its investigational interleukin 23  IL 23  inhibitor  which has been developed for the treatment of moderate to severe plaque psoriasis  Risankizumab will be marketed by the trade name of Skyrizi AbbVie had filed the marketing application in the EU in May and in the United States in April  which was supported by data from four pivotal phase III studiesevaluating more than 2 000 patients  Data from these studies showed that more than half of the patients receiving risankizumab achieved complete skin clearance at one year AbbVie s application will now be reviewed by the European Commission  which will announce its decision in two months  time  The FDA s decision is also expected in the first half of the year AbbVie has developed risankizumab in collaboration with Boehringer Ingelheim and the candidate is also being evaluated in phase III studies in psoriasis  Crohn s disease and psoriatic arthritis AbbVie s stock has declined 13 1  this year so far against an increase of 3 9  recorded by the    AbbVie expects approval decision on another key pipeline candidate upadacitinib this year  Upadacitinib  an oral investigational JAK inhibitor  has been developed for the treatment of adult patients with moderate to severe rheumatoid arthritis  Approval and successful commercialization of upadacitinib are critical for long term growth at AbbVie  especially as biosimilar competition looms for its blockbuster RA drug  Humira Several companies have made biosimilar versions of Humira  With Humira accounting for around 61  of AbbVie s sales  the entry of biosimilars will have a huge impact on the company s financials  Per settlements with seven manufacturers including Amgen   NASDAQ AMGN    Biogen   NASDAQ BIIB    Pfizer   NYSE PFE   and Momenta  Humira biosimilars are expected to be launched in the United States in 2023  However  AbbVie faces direct biosimilar competition in Europe and other countries  which account for approximately 25  of total global Humira revenues  Humira biosimilars were first launched in the EU in October last year  In 2019  AbbVie expects a decline of 30   or  2 billion  in international Humira sales AbbVie currently carries a Zacks Rank  3  Hold   You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ,2019-03-03,Zacks Investment Research,https://www.investing.com/analysis/abbvie-gets-chmp-nod-for-psoriasis-candidate-risankizumab-200394435,200394435
128967,350482,BIIB,Company News For Mar 5  2019,opinion,The Children s Place  Inc  s   NASDAQ PLCE   shares tanked 10 3  after the company reported fourth quarter 2018 earnings per share of  1 10  lower than the Zacks Consensus Estimate of  2 11 a shareBiogen Inc  s   NASDAQ BIIB   shares declined 2 1  after the company announced that it had agreed to purchase Nightstar Therapeutics plc   NASDAQ NITE   for  25 50 a shareShares of Ascendis Pharma A S   NASDAQ ASND   rallied 74  after the company announced that its TransCon Growth Hormone trial had achieved the desired primary end resultShares of Takeda Pharmaceutical Company Limited   NYSE TAK    rose 5 2  after the company announced that it had entered into a partnership with Lupus Therapeutic Partners to start Phase 1 trial for lupus treatment,2019-03-04,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-mar-5-2019-200394803,200394803
128968,350483,BIIB,Biogen To Acquire Gene Therapy Company Nightstar For  800M,opinion,"Biogen   NASDAQ BIIB   announced that it has entered into an agreement to acquire London based clinical stage gene therapy company  Nightstar Therapeutics   NASDAQ NITE   
Shares of Nightstar gained 66  on the news  while Biogen shares lost 2  
Biogen s shares have plunged 5 6  in the past six months compared with the  s decline of 12 3  

 
Financial Terms of the Agreement
Per the agreement  Biogen will pay  25 50 in cash for each share of Nightstar or approximately  800 million on a fully diluted basis 
Biogen expects to complete the acquisition by mid 2019  
Strategic Implications
Nightstar is focused on adeno associated virus  AAV  treatments for inherited retinal disorders  The company has two potentially first in class mid  to late stage candidates as well as other preclinical programs 
The company s lead asset  NSR REP1 is being evaluated for the treatment of choroideremia  CHM  in an ongoing phase III STAR trial  Data from the trial is expected in the second half of 2020 
The second candidate is NSR RPGR  being evaluated for the treatment of X linked retinitis pigmentosa  XLRP   The phase I II data from the dose escalation portion of the XIRIUS trial for NSR RPGR demonstrated an increase in central retinal sensitivity  The phase II III dose expansion portion of the XIRIUS trial is currently ongoing 
The preclinical pipeline includes NSR ABCA4 for Stargardt disease  and potential programs targeting Best vitelliform macular dystrophy  Best disease  and other genetic forms of retinitis pigmentosa 
The acquisition is expected to accelerate Biogen s entry into ophthalmology space 
Our Take
Biogen holds a strong position in the multiple sclerosis  MS  market  with a wide range of products like Avonex  Tysabri  Tecfidera and Plegridy  The Nightstar acquisition will somewhat diversify Biogen s MS portfolio  Ophthalmology is an emerging growth area  and a potential approval of Nightstar candidates will boost Biogen s portfolio 
However  shareholders weren t that impressed and were probably asking for a bigger splash 
This year started with a bang for the biotech industry with the announcement of one of the biggest mergers of the sector  the Bristol Myers and Celgene  NASDAQ CELG  collaboration  This was followed by a slew of other announcements  Biogen becomes the latest company to join the M A bandwagon  In particular  gene therapy is a hot area of pursuit for most biotechs  given the potential of the therapy  
Swiss pharma giant Roche Holdings   OTC RHHBY   recently announced that it will acquire gene therapy company Spark Therapeutics   NASDAQ ONCE   for  4 3 billion 
Zacks Rank
Biogen currently carries a Zacks Rank  3  Hold   You can see  
Breakout Biotech Stocks with Triple Digit Profit Potential
The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases 
Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-03-05,Zacks Investment Research,https://www.investing.com/analysis/biogen-to-acquire-genetherapy-company-nightstar-for-800m-200394862,200394862
128969,350484,BIIB,Biotech Stock Roundup  BIIB To Acquire Nightstar  Other Pipeline News   More,opinion,"Mergers and acquisitions continue to grab headlines in the biotech sector  Shares of Nightstar Therapeutics   NASDAQ NITE   soared after Biogen   NASDAQ BIIB   announced an agreement to acquire the former  Meanwhile  as the reporting cycle draws to a close  regular pipeline updates and data read outs are also in news  Celgene Corporation   NASDAQ CELG   obtained a priority review for its drugs from the FDA while CHMP gave a positive opinion on the label expansion of Regeneron s Dupixent Recap of the Week s Top Stories Biogen to Acquire Gene Therapy Company Nightstar   Biogen announced that it has  Therapeutics  Per the deal  Biogen will pay  25 50 in cash for each share of Nightstar or approximately  800 million  Biogen expects to complete the buyout by mid 2019 Nightstar is focused on adeno associated virus  AAV  treatments for inherited retinal disorders  The company has two potentially first in class mid  to late stage candidates and other preclinical programs  The company s lead asset  NSR REP1  is being evaluated for the treatment of choroideremia  CHM  in an ongoing phase III STAR study  Data from the same is expected in the second half of 2020   The second candidate is NSR RPGR  currently evaluated for the treatment of X linked retinitis pigmentosa  XLRP  The phase I II results from the dose escalation portion of the XIRIUS investigation on NSR RPGR demonstrated an increase in central retinal sensitivity  The phase II III dose expansion part of the XIRIUS analysis is currently underway  The preclinical pipeline includes NSR ABCA4 for Stargardt disease and potential programs targeting Best vitelliform macular dystrophy  Best disease  and other genetic forms of retinitis pigmentosa  The transaction is expected to accelerate Biogen s foray into ophthalmology space Celgene Gets Priority Review for Myelofibrosis Drug   Celgene announced that the FDA has accepted its New Drug Application  NDA  for fedratinib and granted a priority review to the same  Fedratinib  a highly selective JAK2 inhibitor  is being evaluated for treating patients with myelofibrosis  The FDA has set an action date of Sep 3  2019   The NDA was based on encouraging outcomes from a randomized  placebo controlled  phase III probe  JAKARTA  on patients with primary or secondary myelofibrosis and a single arm  open label phase 2 evaluation  JAKARTA2  of patients with primary or secondary myelofibrosis  previously exposed to Jakafi  The candidate also enjoys an Orphan Drug designation for secondary and primary myelofibrosis  The company also plans to evaluate fedratinib in combination with luspatercept The FDA also granted a priority review designation to Celgene s supplemental New Drug Application  sNDA  for its lead drug   Revlimid   combined with rituximab  R   for the treatment of patients with previously treated follicular and marginal zone lymphoma  The FDA has set its action date as Jun 27  2019 
Celgene currently sports a Zacks Rank  1  Strong Buy   You can see  CHMP Provides Positive Opinion on Label Expansion of Dupixent   Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and partner Sanofi  PA SASY  announced that the European Medicines Agency s Committee for Medicinal Products for Human Use  CHMP  has issued a positive response to Dupixent  dupilumab  for asthma  The CHMP recommended Dupixent s approval for use in adults and adolescents aged 12 years or older as an add on maintenance treatment for severe asthma with type 2 inflammation  characterized by raised blood eosinophils and or raised fractional exhaled nitric oxide  FeNO   Such patients are inadequately controlled with high dose inhaled corticosteroid plus another medicinal product for maintenance therapy A decision from the European Commission is expected in the coming months  Dupixent is already approved in the European Union for administering to adults with moderate to severe atopic dermatitis  who are candidates for systemic therapy  A potential nod for asthma will broaden the sales potential of the drug  Last October  the FDA also approved Dupixent as an add on maintenance therapy for patients with moderate to severe asthma  aged 12 years or above with an eosinophilic phenotype or oral corticosteroid dependent asthma  Meanwhile  the FDA has granted a priority review to the sBLA for atopic dermatitis in adolescent patients and set a target action date of Mar 11  2019 Immunogen Crashes as Late Stage Study Disappoints  Shares of ImmunoGen   NASDAQ IMGN   plunged significantly after the company performed dismally in a late stage study on its ovarian cancer candidate   The FORWARD 1 study evaluated the efficacy of mirvetuximab soravtansine as a single agent therapy compared with chemotherapy for treating patients with platinum resistant ovarian cancer  whose tumors express high or medium levels of FR alpha and who have received up to three prior treatment regimens The phase III study failed to meet the primary endpoint of progression free survival  PFS    It did not achieve the PFS goal in the entire study population apart from the pre specified subset of patients with high FR  expression  Although the confirmed overall response rate was higher for mirvetuximab soravtansine than for chemotherapy  there was no significant difference in PFS  The company will further assess data from the FORWARD I study to determine potential future steps with a monotherapy approach PerformanceMedical   Biomedical and Genetics Industry 5YR   Return The NASDAQ Biotechnology index inched up 0 8  in the past five trading sessions  Among the major biotech biggies  Regeneron gained 2 6  of value  Over the past six months  shares of Alexion have rallied 14 8  while the Gilead  NASDAQ GILD  stock has declined 10 2    See the last biotech stock roundup here    What s Next in Biotech Stay tuned for regular pipeline updates Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-05,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-biib-to-acquire-nightstar-other-pipeline-news--more-200395083,200395083
128970,350485,BIIB,Celgene  CELG  Submits Application For MS Drug In Europe,opinion,"Celgene Corporation   NASDAQ CELG   announced that it has submitted a Marketing Authorization Application to the European Medicines Agency  EMA  for pipeline candidate  ozanimod The company is seeking approval of ozanimod  an oral  sphingosine 1 phosphate  S1P  receptor modulator  for the treatment of adults with relapsing remitting multiple sclerosis  RRMS  The application was based on results from the SUNBEAM and RADIANCE part B phase III  multicenter  randomized  double blind  double dummy  active controlled studies Celgene intends to submit a New Drug Application  NDA  to the FDA for relapsing forms of MS  RMS  by the end of this month We remind investors that Celgene suffered a setback early 2018  when it received Refusal to File letter from the FDA regarding its NDA for ozanimod  The FDA stated that the nonclinical and clinical pharmacology sections in the NDA were inadequate to allow a complete review Ozanimod is also being evaluated for ulcerative colitis and Crohn s disease Celgene s stock has lost 1 8  in the past six months compared with the  s decline of 13  A tentative approval will boost Celgene s portfolio but competition is stiff in the MS market with the likes of Biogen   NASDAQ BIIB   Meanwhile  Celgene has been in news lately due to a merger agreement with Bristol Myers Squibb Company   NYSE BMY   announced earlier in 2019  The latter will acquire the former for a whopping  74 billion  Per the terms  Celgene s shareholders will receive  50 plus one share of Bristol Myers and one tradeable Contingent Value Right  CVR   which will entitle the holder to receive a cash payment of  9 00 upon the achievement of FDA approval of all three products  ozanimod  liso cel and bb2121  within specified time periods Earlier  Celgene and partner bluebird bio   NASDAQ BLUE   completed enrollment in the KarMMa pivotal trial  evaluating bb2121 in patients with relapsed and or refractory multiple myeloma  RRMM  Zacks Rank
Celgene currently carries a Zacks Rank  1  Strong Buy   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-11,Zacks Investment Research,https://www.investing.com/analysis/celgene-celg-submits-application-for-ms-drug-in-europe-200396922,200396922
128975,350490,BIIB,The Zacks Analyst Blog Highlights  Visa  Honeywell  Biogen  Humana And EOG Resources,opinion,"For Immediate Release
Chicago  IL   March 13  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Visa   NYSE V    Honeywell   NYSE HON    Biogen   NASDAQ BIIB    Humana   NYSE HUM   and EOG Resources   NYSE EOG   
Here are highlights from Tuesday s Analyst Blog  
Top Stock Reports for Visa  Honeywell and Biogen
 The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Visa  Honeywell and Biogen  These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see all of today s research reports here    
Visa s shares have outperformed the Zacks Financial Transaction Services industry over the past year   22 3  vs   14 3    Visa s results were driven by growth in payments volume  cross border volume and processed transactions  and a lower tax rate  The Zacks analyst thinks numerous strategic acquisitions and alliances  technology upgrades and effective marketing have paved the way for long term growth and consistent increase in revenues 
Visa is well poised to gain from growing electronic payment processing and a solid brand name  Its strong capital position enables investments in business  Nevertheless  high client incentives and operating expenses  and foreign exchange volatility might put pressure on margins  Softness in cross border volumes is another concern 
Shares of Honeywell have underperformed the Zacks Diversified Operations industry in the past three months  gaining  10 3  vs  a  12 8  increase  Honeywell believes that strength in its commercial aftermarket and sensing businesses as well as solid demand for its productivity and commercial fire products will boost its revenues in the quarters ahead 
The Zacks analyst thinks stronger sales volumes  increased productivity and ongoing commercial effectiveness actions will likely boost near term profitability  Notably  the company anticipates generating organic sales growth in the range of 2 5  in 2019  Rising costs of revenues are a worry for the company s gross margin 
Also  analysts have become increasingly bearish on the company over the past couple of months  Increases in debt levels can increase its financial obligations 
Biogen s shares have underperformed the Zacks Biomedical and Genetics industry year to date   3 5  vs   11 9    Biogen has a strong position in the MS market with a wide range of products  The Zacks analyst likes its efforts to diversify beyond MS to other areas like Alzheimer s  Parkinson s and stroke  among others  Meanwhile  its newest drug Spinraza is performing well and has multi billion dollar potential 
Biogen s efforts to regularly in license assets to build its pipeline are encouraging with several having transformative potential  Multiple data readouts are expected in 2019 with multiple potential launches in the early 2020s  However  its core MS business  excluding Ocrevus royalties  has been largely flat 
Also  potential competition to Spinraza from competitors  gene therapy programs for SMA is a concern  Though Biogen s CNS pipeline is attractive  it is a high risk area 
Other noteworthy reports we are featuring today include Humana and EOG Resources 
Today s Best Stocks from Zacks 
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year 
See their latest picks free   
Media Contact
Zacks Investment Research
800 767 3771 ext  9339
 
 
Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2019-03-12,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-visa-honeywell-biogen-humana-and-eog-resources-200397264,200397264
128976,350491,BIIB,PDL BioPharma  PDLI  Q4 Earnings Top Mark  Revenues Fall Y Y,opinion,PDL BioPharma  Inc    NASDAQ PDLI   delivered earnings of 10 cents per share in the fourth quarter of 2018  beating the Zacks Consensus Estimate of 8 cents  However  the bottom line was lower than 17 cents in the year ago period The company s total revenues grossed  45 1 million in fourth quarter 2018  reflecting a 28 4  decrease year over year  This downside is mainly attributable to a decline in royalties as well as lower product sales Shares of PDL have rallied 20  so far this year  outperforming the  increase of 14 5  Full Year ResultsPDL generated revenues of  198 1 million in 2018  declining 38 1  year over year  Net income per share for 2018 was 39 cents compared with 64 cents in 2017 Quarter in DetailWe remind investors that Mr  Dominique Monnet assumed the role of the new chief executive officer  CEO  and president following the retirement of PDL s former CEO John P  McLaughlin s at the end of 2018 Product revenues for the quarter under review were  26 million  down 20 2  year over year  The same included  18 8 million from the sales of Noden products   Tekturna and Tekturna HCT   and  7 2 million from the sales of LENSAR laser system in the United States PDL recognized  19 1 million in revenues from royalty rights while royalties from PDL s licensees to the Queen et al  patents and interest revenues were both less than  0 1 million Royalty revenues from the Queen et al  licenses were significantly lower than the year ago period  mainly due to lower product supplies of Biogen s   NASDAQ BIIB   multiple sclerosis drug  Tysabri Other UpdatesPDL repurchased 8 7 million shares worth  25 5 million in the reported quarter  Last September  the company s board of directors approved a new  100 million worth share buyback program of the company s common stock  Since the initiation of this program  PDL has successfully repurchased 19 4 million shares Earlier this month  the authorized generic version of Tekturna  150 mg 300 mg tablets  was launched in the United States  The unveiling activities were carried out by the privately held pharmaceutical company Prasco  LLC  This introduction does not include an authorized generic version of Tekturna HCT PDL BioPharma  Inc  Price  Consensus and EPS Surprise   Zacks Rank   Other Stocks to ConsiderPDL currently carries a Zacks Rank  2  Buy   Other top ranked stocks in the biotech sector include Celgene Corporation   NASDAQ CELG   and Trevena  Inc    NASDAQ TRVN    both sporting a Zacks Rank  1  Strong Buy   You can see  Celgene s earnings estimates have moved 3 8  north for 2019 and 3 9  for 2020 over the past 60 days  The stock has surged 37 8  so far this year Trevena s loss per share estimates have been narrowed 12 9  for 2019 and 11  for 2020 in the last 60 days  The stock has skyrocketed 239 5  year to date Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-03-14,Zacks Investment Research,https://www.investing.com/analysis/pdl-biopharma-pdli-q4-earnings-top-mark-revenues-fall-yy-200398224,200398224
128984,350499,BIIB,Why Is Alkermes  ALKS  Up 4 7  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Alkermes  ALKS   Shares have added about 4 7  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Alkermes due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Alkermes Q4 Earnings   Revenues Surpass EstimatesAlkermesreported adjusted earnings of 34 cents per share in the fourth quarter of 2018  outperforming the Zacks Consensus Estimate of a loss of 6 cents  The bottom line also exceeded the adjusted earnings of 31 cents recorded in the year ago quarter The company s revenues of  315 8 million in the quarter increased 14 7  year over year  The top line beat the Zacks Consensus Estimate of  253 million Results were driven by strong growth in the company s proprietary products   Vivitrol and Aristada  Net sales for Vivitrol and Aristada were  132 7 million in the quarter  reflecting 28  increase from the year ago quarter Revenues RiseManufacturing and royalty revenues from Risperdal Consta  Invega Sustenna Xeplion and Invega Trinza Trevicta were  81 4 million  up 4 1  year over year  The same from Ampyra Fampyra were up 1 8  year over year to  38 8 million  Research and development revenues were  15 6 million  of which  14 4 million was related to the collaboration with Biogen Inc  NASDAQ BIIB   for BIIB098 Vivitrol sales improved 11  year over year to  83 8 million Aristada sales came in at  48 8 million  up 72  year over year Costs RiseResearch and Development  R D  expenses were  108 9 million  down 4 3  year over year Selling  General and Administrative  SG A  expenses were  141 2 million  up 27 4  year over year Full Year 2018 ResultsFor 2018  adjusted earnings came in at 61 cents per share compared with 17 cents in 2017 Revenues in 2018 increased 21  year over year to  1 09 billion 2019 OutlookThe company expects total revenues of  1 14  1 19 billion  driven by anticipated growth of the company s proprietary products and an expected  150 million milestone payment from Biogen in the fourth quarter  related to the potential FDA approval of diroximel fumarate  BIIB098  The Zacks Consensus Estimate for 2019 revenues is  1 10 billion Alkermes expects Vivitrol sales to be  330  350 million  while Aristada sales are anticipated to be  210  230 million  The company expects R D expenses to be  450  480 million  Alkermes  guidance for SG A expenses is  590  620 million Alkermes expects earnings per share to be 25 43 cents  The Zacks Consensus Estimate for 2019 earnings is 62 cents Pipeline UpdateIn November 2018  Alkermes announced positive top line results from ENLIGHTEN 2  a pivotal phase III study of ALKS 3831 compared to Lilly s Zyprexa  olanzapine  in patients with stable schizophrenia  In the study  ALKS 3831 met the pre specified co primary endpoints In December 2018  Alkermes and Biogen announced the submission of a new drug application  NDA  to the FDA for diroximel fumarate  a novel oral fumarate in development for the treatment of relapsing forms of multiple sclerosis In February 2019  Alkermes received a Complete Response Letter from the FDA regarding the NDA for ALKS 5461  for the adjunctive treatment of major depressive disorder 
How Have Estimates Been Moving Since Then 
Fresh estimates followed a downward path over the past two months  The consensus estimate has shifted  1166 67  due to these changes 
VGM Scores
Currently  Alkermes has a nice Growth Score of B  though it is lagging a lot on the Momentum Score front with an F  Charting a somewhat similar path  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Alkermes has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2019-03-15,Zacks Investment Research,https://www.investing.com/analysis/why-is-alkermes-alks-up-47-since-last-earnings-report-200398387,200398387
128996,350511,BIIB,U S  companies  stock buyback plans hit four year low  TrimTabs,news,"By Lewis Krauskopf NEW YORK  Reuters    The value of stock buyback announcements from U S  companies slowed to its lowest level in four years  TrimTabs Investment Research said on Tuesday  potentially undercutting one of the main drivers of the current bull market  At  1 8 billion a day  the amount of buyback announcements from U S  companies during the nearly completed second quarter earnings season is tracking to the lowest since the same period of 2012  according to TrimTabs  which compared six week periods during which companies report quarterly results  The number of companies announcing buybacks has also fallen  averaging 3 3 a day so far  the lowest since the third quarter of 2013 and well below the 6 1 per day during earnings season a year ago   Buyback activity has been disappointing in earnings season   said David Santschi  chief executive officer of TrimTabs   The reluctance to pull the trigger on share repurchases suggests corporate leaders are becoming less enthusiastic about what they see ahead   Stock buybacks prop up share prices as a decrease in the number of shares outstanding boosts earnings per share  and have been an important factor in propelling the market to record highs   While companies may have dialed back their buybacks  the extent of the slowdown remains to be seen  The strong current pace of corporate debt issuance could provide new fuel for ramping up stock repurchases  said Brian Reynolds  chief market strategist at New Albion Partners in New York   We have seen throughout this credit cycle  sometimes the buybacks grow faster and sometimes they grow slower   Reynolds said   Going forward  there is plenty of ammunition to boost share buybacks should CEOs feel the need   The latest buyback data shows the continued sluggish pace of repurchases this year  According to TrimTabs  the total amount of announced buybacks through July is down 21 percent from the same period a year ago   It s not a good sign  for the stock market  Santschi said   Buyback volume has a fairly high correlation with stock prices   
Five companies have announced buybacks of at least  3 billion during the current earnings season  TrimTabs said  including  5 billion plans from Biogen Inc  O BIIB    Visa Inc   N V  and CBS Corp  N CBS  ",2016-08-16,Reuters,https://www.investing.com/news/stock-market-news/u.s.-companies-cut-back-on-buyback-plans:-trimtabs-420627,420627
128997,350512,BIIB,Big Pharma vs Big Pharma in court battles over biosimilar drugs,news,"By John Miller ZURICH  Reuters    The line dividing makers of brand name drugs and copycat medicines is blurring as companies known for innovative treatments queue up to peddle copies of rivals  complex biological medicines  These drugmakers are now increasingly straddling both sides of the courtroom  too  protecting their high price products from biosimilars   biopharmaceutical drugs with the treatment properties of medicines they seek to mimic   while simultaneously challenging rivals  patent claims  Biologics  manufactured in living cells  then extracted and purified  are more complex than traditional medicines and cannot be copied with precision  and so their knock off versions are called biosimilars instead of generics  The allure of biosimilars is clear  with insurers and other payers counting on the steep discounts  U S  pharmacy benefit managers are already trimming brand name drugs from their rosters   With Novartis Chief Executive Joe Jimenez predicting biosimilar discounts of up to 75 percent  in part based on developments in Europe  makers of innovative drugs are fighting tooth and nail to protect their higher priced products for as long as possible    For instance  AbbVie has sued in Delaware claiming patent protection for its arthritis drug Humira  the world s best selling prescription medicine  until at least 2022 as it seeks to delay an Amgen  NASDAQ AMGN  replica that won U S  approval last week   Meanwhile  Amgen has gone to another U S  federal court seeking to protect its own arthritis medicine  Enbrel  from a Novartis biosimilar until 2029  With lawsuits pitting Big Pharma against Big Pharma piling up  lawyers said the legal landscape has gotten a lot more complex   One of the biggest surprises has been the number of innovator biopharma companies  like Amgen  now developing biosimilars to compete with the products of other innovator companies   said Don Ware  an expert on biosimilars at U S  law firm Foley Hoag in Boston    This creates conflicts for law firms like ours  because suddenly the clients we advise are adverse to each other   Ware said   And it makes it hard for the companies to retain top outside counsel without having to give them conflict waivers   Sanofi  Merck  NYSE MRK   Eli Lilly   Pfizer   NYSE PFE   Johnson   Johnson  NYSE JNJ  and Biogen  NASDAQ BIIB  are also embroiled in lawsuits over biosimilars  NOT BITTER ENEMIES Even so  some analysts say the lawsuits are business as usual and are unlikely to spill over into other areas  including research partnerships  Novartis and Amgen may be at each other s throats in court over the Swiss drugmaker s Enbrel copy  but the two are still cooperating on a drug for migraines   It s not like these companies are bitter enemies   Zuercher Kantonalbank analyst Michael Nawrath said   These court cases are simply the last resort of original drug makers to wring a few more months or a year of exclusivity from their blockbusters   Conflicts pitting big drugmakers against each other may have been inevitable after Europe in 2006 and the United States in 2010 created separate biosimilar approval rules   After all  Big Pharma s financial clout and expertise made large  sophisticated drugmakers the natural candidates to manufacture complex biosimilar copies that cost hundreds of millions to bring to market  far more than for generic off patent copies of simpler  small molecule drugs  
Some smaller companies and generics makers have jettisoned biosimilar programs after originally underestimating hurdles to entry  Richard Francis  head of Novartis s Sandoz division that makes biosimilars  said earlier this year   Just this week  Shire abandoned two biosimilar candidate drugs that accompanied its Baxalta takeover  copies of Amgen s Enbrel and AbbVie s Humira  to focus on rare diseases   The realization of what it s going to take to stay in this market and be successful has led to a change in the landscape and the players in it   Francis said ",2016-10-02,Reuters,https://www.investing.com/news/stock-market-news/big-pharma-vs-big-pharma-in-court-battles-over-biosimilar-drugs-429831,429831
128998,350513,BIIB,Biogen s nusinersen marketing applications accepted for review in U S  and Europe,news,The FDA accepts under Priority Review Biogen s  NASDAQ BIIB  1 3   New Drug Application  NDA  seeking approval of nusinersen for the treatment of spinal muscular atrophy  SMA   The European Medicines Agency has done the same  accepting the company s Marketing Authorization Application  MAA  under Accelerated Assessment status  Both shorten the review clock SMA is an inherited disorder characterized by the loss of motor neurons in the spinal cord and lower brain stem  leading to severe and progressive muscular atrophy and weakness  It is caused by a defect in or loss of the SMN1 gene which results in the insufficient production of survival motor neuron protein  essential for maintenance of motor neurons Nusinersen is an antisense drug designed to correct the splicing defect that causes SMA by increasing the production of fully functional SMN protein  Biogen licensed it from Ionis Pharmaceuticals  IONS  0 7   under their 2012 collaboration agreement  If approved  Ionis could earn up to  225M in total milestones in addition to mid teen royalties Biogen intends to market nusinersen under the brand name SPINRAZA ,2016-10-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/biogen's-nusinersen-marketing-applications-accepted-for-review-in-u.s.-and-europe-435656,435656
129007,350522,BIIB,Despite M A Spree  Biotech ETFs Slide On Mixed Earnings ,opinion,"This year  biotech stocks have seen their best ever start to a year since 2012  A solid merger and acquisition momentum has been instrumental in this rally  However  the momentum slackened of late on mixed earnings for the fourth quarter  read    
In the past few days  biotech giants such as Amgen Inc    NASDAQ AMGN    Gilead Sciences   NASDAQ GILD    Biogen Inc    NASDAQ BIIB   and Alexion Pharmaceuticals   NASDAQ ALXN   have come up with earnings results  of which some offered downbeat guidance while some failed to top estimates on both lines 
Earnings in Focus
In late Jan  Amgen reported fourth quarter 2018 earnings of  3 42 per share  which beat the Zacks Consensus Estimate of  3 26  Earnings increased 18  year over year driven by higher revenues  lower tax rate and reduced share count  Total revenues of  6 23 billion in the quarter surpassed the Zacks Consensus Estimate of  5 88 billion and increased 7  year over year 
Amgen issued its sales and earnings guidance for 2019  which indicates a decline from 2018 levels  The company expects revenues in the range of  21 8  22 9 billion  indicating a decline from 2018 levels  The Zacks Consensus Estimate is currently at  22 87 billion  Adjusted earnings per share are anticipated in the range of  13 10  14 30 in 2019  lower than the current Zacks Consensus Estimate of  14 45  The guided range indicates a decline from 2018 
In early Feb  Gilead Sciences reported mixed results for the fourth quarter  wherein earnings missed expectations but revenues beat on the same  Gilead reported earnings of  1 44 per share in the fourth quarter  down from  1 78 in the year ago quarter and missing the Zacks Consensus Estimate of  1 70  Total revenues of  5 79 billion beat the Zacks Consensus Estimate of  5 53 billion but declined 2 6  year over year 
Gilead expects net product sales of  21 3  21 8 billion compared to the Zacks Consensus Estimate of  22 01 billion  For the first quarter of 2019  Gilead expects product sales to decline sequentially by 12 14   primarily owing to the U S  seasonal inventory patterns and buying patterns of public payers that negatively impact payer mix 
In early Feb  Alexion Pharmaceuticals posted fourth quarter 2018 adjusted earnings of  2 14 per share  which increased 45  from the year ago quarter s  1 48  Earnings also beat the Zacks Consensus Estimate of  1 83  Strong product revenues drove the bottom line in the quarter 
Revenues rose 24  year over year to  1 128 billion and exceeded the Zacks Consensus Estimate of  1 060 billion  Revenues were driven by increased sales of Soliris  Strensiq and Kanuma  For 2019  Alexion projects revenues of  4 63  4 70 billion in 2019  The Zacks Consensus Estimate for earnings in 2019 is pegged at  8 78  while for sales it is  4 76 billion  Revenues for Soliris and Ultomiris are expected in the  3 97  4 02 billion range 
In late January Biogen reported fourth quarter 2018 earnings per share of  6 99  which beat the Zacks Consensus Estimate of  6 72  Earnings rose 32 9  year over year  backed by higher revenues  Sales came in at  3 53 billion  up 7  from the year ago quarter  Moreover  sales beat the Zacks Consensus Estimate of  3 39 billion 
For 2019 the company expects revenues of   13 6  13 8 billion  Earnings per share are expected between  28 00 and  29 00 The Zacks Consensus Estimate for revenues and earnings is  13 65 billion and  28 20 per share  respectively 
Biotech ETFs  iShares Nasdaq Biotechnology ETF   VanEck Vectors Biotech ETF   LON BBH   and First Trust Amex Biotechnology Index   LON FBT   all dipped in the past 10 trading days   period dotted with biotech releases 
Below  we have highlighted these popular ETFs with high exposure to the above mentioned companies  see  here  

IBB
This fund tracks the NASDAQ biotechnology index  It has 223 holdings with 29 11  weight age to the mentioned four companies  It has an AUM of  8 0 billion and an expense ratio of 0 47  
BBH
The fund tracks the MVIS US Listed Biotech 25 Index  It has a pool of 25 stocks with 25 19  weight to the mentioned four companies  It has an AUM of  403 1 million and an expense ratio 0 35  
FBT
It tracks the equal weighted NYSE Arca Biotechnology Index  There are 30 holdings in the basket with FBT holding 12 9   AUM is  2 73 billion  while expense ratio is 0 56  
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week  Get it free   ",2019-02-14,Zacks Investment Research,https://www.investing.com/analysis/despite-ma-spree-biotech-etfs-slide-on-mixed-earnings-200388353,200388353
129010,350525,BIIB,AbbVie s RA Candidate Upadacitinib Gets FDA Priority Review ,opinion,AbbVie Inc    NYSE ABBV   announced that the FDA has accepted its new drug application  NDA  for its oral investigational JAK inhibitor  upadacitinib  and also granted a priority review to the same  The company is seeking an approval for upadacitinib for treating adult patients with moderate to severe rheumatoid arthritis  RA   A decision from the regulatory body is expected in third quarter 2019 AbbVie used a priority review voucher to expedite the review of upadacitinib s NDA  The FDA generally assigns a priority review designation to drugs with potential of providing significant improvements in the safety and effectiveness of treatment and prevention or diagnosis of a serious disease The NDA submission was based on encouraging data from the phase III SELECT study  which evaluated more than 4000 patients across five phase III studies on RA  In all studies  upadacitinib met every primary and secondary endpoint Last December  AbbVie filed the NDA for upadacitinib with respect to RA  The candidate is also under review in the EU for the same indication Shares of AbbVie have plunged 31 7  in the past year against the  increase of 7 8  Notably  apart from rheumatoid arthritis  upadacitinib is being evaluated in a mid stage study for giant cell arteritis and late stage analyses for Crohn s disease  psoriatic arthritis  ulcerative colitis and atopic dermatitis Both approval and successful commercialization of upadacitinib are critical for long term growth of AbbVie  especially as biosimilar competition looms for its blockbuster RA drug  Humira Humira accounts for around 61  of AbbVie s revenues  The drug generated sales of  19 9 billion in 2018  reflecting an increase of 8 2  year over year  However  on fourth quarter earnings call  management stated that biosimilar competitors in the EU are offering more aggressive discounts than AbbVie anticipated  which severely hurt Humira s international sales  In 2019  the company expects a drop of 30  or  2 billion in international Humira sales In the United States  Humira biosimilars are expected to be launched in 2023  In the EU  Amgen   NASDAQ AMGN    Biogen   NASDAQ BIIB   and Novartis    NYSE NVS   generic subsidiary   Sandoz s   biosimilars were unveiled last October Zacks RankAbbVie currently carries a Zacks Rank  3  Hold   You can see Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-02-20,Zacks Investment Research,https://www.investing.com/analysis/abbvies-ra-candidate-upadacitinib-gets-fda-priority-review-200390307,200390307
129017,350532,BIIB,U S  biotech stocks win back investors in big July run,news,By Lewis Krauskopf NEW YORK  Reuters    Biotech returned to the good graces of investors this month and it may be the beginning of a revival for stocks in the industry  With one full trading day left in the month  the Nasdaq Biotechnology index  NBI  has climbed 11 percent in July  on pace for its biggest monthly percentage gain in three years  It was down 0 4 percent on Thursday as the broader market slipped  The index remains down 15 percent in 2016 and nearly 30 percent below its all time high a year ago  amid political rhetoric over high drug prices  Investors have sensed an opportunity to scoop up the stocks  analysts said   I am hearing from a lot of investors who were previously bearish or not involved that maybe now is the time to jump in   said Chris Raymond  an analyst with Raymond James   So we are maybe at the beginning here of a sentiment turn   The decline in the first half of the year pushed down the shares to historically cheap levels  Based on price to earnings ratios  a group of eight large U S  biotechnology companies have in recent weeks traded at their cheapest in more than four years  and are still trading at just 12 2 times earnings estimates for the next 12 months  compared to their five year average of 16 1 times   Based on my conversations with a lot of portfolio managers  people have figured out biotech was trading at essentially no pipeline value earlier this quarter   said Michael Yee  an analyst with RBC Capital Markets   These stocks simply got too cheap   Among large biotech companies  Biogen  O BIIB  shares have jumped 19 percent in July  as the company last week increased its financial forecasts and said its chief executive officer was leaving  while shares of rare drug disease maker Alexion Pharmaceuticals  O ALXN  have climbed 13 percent  Biotech s gains come as investors bullish on healthcare broadly have pointed to strong business and demographic trends supporting the overall industry s outlook  despite risks related to how the heavily regulated sector will fare under a new U S  president  JPMorgan  NYSE JPM  U S  equity strategist Dubravko Lakos Bujas this week upgraded healthcare as a sector to  overweight   noting that  uncertainties around the U S  election are already largely priced in   With biotech leading  the S P 500 healthcare sector  SPXHC  has gained 4 5 percent this month  against a 3 percent gain for the broader S P 500  SPX   The sector remains a slight laggard for 2016 ,2016-07-28,Reuters,https://www.investing.com/news/stock-market-news/u.s.-biotech-stocks-win-back-investors-in-big-july-run-417202,417202
129018,350533,BIIB,U S  stocks dragged down by Oil  Autos as Dow posts 7th straight loss,news,"Investing com    U S  stocks fell sharply on Tuesday  suffering their worst one day session in a month  as crude futures tumbled to fresh 14 month lows and investors largely shrugged off a major stimulus package approved hours earlier by the Japanese government  placing downward pressure on equities on Wall Street 
The Dow Jones Industrial Average lost 90 74 or 0 49  to 18 313 77  closing lower for the seventh consecutive session  At session lows  the Dow fell as much as 153 points  Since hitting an all time record high of 18 622 01 on July 22  the Dow has fallen back by more than 300 points over the last week and a half  Nevertheless  the Dow is still up by more than 1 100 points from its lows five weeks ago in the immediate aftermath of the surprising Brexit decision on June 24 
The NASDAQ Composite index fell by 46 47 or 0 90  to 5 137 73  snapping a five day winning streak  while the S P 500 Composite index dropped by 13 81 or 0 64  to 2 157 03  On the S P 500  all 10 sectors closed in the red  as stocks in the Consumer Services  Financials and Technology industries lagged 
The top performer on the Dow was  Exxon Mobil  Corporation  NYSE XOM   which added 0 88 or 1 02  to 86 74 during Tuesday s relief rally  Shares in ExxonMobil  NYSE XOM  are still down by more than 5  from their levels last week  before the world s largest oil companies reported their worst quarterly profits in 17 years  Exxon shares also rebounded in spite of continued declines in crude prices  which closed below  40 a barrel for the first time since April 
The worst performer was  Pfizer  Inc  NYSE PFE   which fell 0 82 or 2 20  to 36 49  While the pharmaceutical giant reported better than expected results for its second quarter on Tuesday  Pfizer  NYSE PFE  suffered a hit due to a disappointing period among its patent protected medicines  Though sales of Pfizer s branded drugs rose by 7  to  7 11 billion for the three month period ending in late June  they still fell sharply below analysts  forecasts for the quarter 
The biggest gainer on the NASDAQ was Biogen Inc  NASDAQ BIIB   which surged 28 46 or 9 43  to 330 29  Shares in Biogen  NASDAQ BIIB  popped in Tuesday s session after a report surfaced that the Cambridge  Massachusetts based biotech firm could emerge as an acquisition target for a larger company such as Merck  NYSE MRK  or Allergan  NYSE AGN pa   The worst performer was  DISH Network  Corporation  NASDAQ DISH   which fell 4 10 or 7 67  to 49 38 after the satellite TV network announced plans to raise  2 billion in a convertible debt sale  It came following reports that the Federal Communication Commission s  FCC  AWS 3 auction on radio spectrum from local TV broadcasting networks could be delayed even further until the completion of the fourth quarter  Leading telecom companies such as AT T Inc  NYSE T    VZ Holding AG   SIX VZN  and T Mobile US Inc  NASDAQ TMUS   which are expected to be among the top bidders in the auction  have been prohibited by regulators from holding strategic discussions  The Dish Network  which has accumulated approximately 80 MHz of radio spectrum for mobile video services  has yet to attract a partner among the aforementioned telecom companies 
Shares in both Ford Motor Company  NYSE F  and General Motors Company  NYSE GM  both slid more than 4  after the major U S  automakers reported disappointing sales last month  Both Ford and General Motors saw auto sales fall by more than 2  on the month  as passengers continued to show a preference for truck and SUV purchases over new cars  
On the New York Stock Exchange  declining issues outnumbered advancing ones by a 2 311 686 margin ",2016-08-02,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-stocks-dragged-down-by-oil,-autos-as-dow-posts-7th-straight-loss-418068",418068
129019,350534,BIIB,6 Stocks That Are Likely To Lead The Market Lower On February 21 ,opinion,"U S  Markets 
S P 500 Futures are pointing to a 1 decline on February 21 as of 8 15 AM
US 10 year  2 66 
Oil   57 50   0 31
VIX  14 05
Dollar Index  96 50
International Markets 
Japan Nikkei   0 15 
China Shanghai   0 34 
Hong Kong Hang Seng   0 41 
South Korea KOSPI   0 05 
Singapore STI   0 01 
UK FTSE   0 56 
German DAX   0 31 
German 10 year Bund  0 122 
Japanese 10 year JGB   0 047 
Global Growth Proxies
Copper   0 63   2 90
Platinum   1 28   823 40
Silver   1 93   15 865
Key Event 
Markit US Services PMI Est  54 3
Markit US Manufacturing PMI Est  54 7
German Markit Manufacturing PMI 47 6 vs  Est  49 7
German Market Services PMI 55 1 vs  Est  52 9
Outline for Trade between the US and China
Brexit vote maybe next week
International Trading
Despite the problems in Europe  the German DAX continues to rise and is nearing a potential break out should it rise above 11 535  It would likely send the index on to 11 891 

Reasons To Be Optimistic Longer Term
It seems hard to deny that no matter the troubles some of the economic indicators maybe flashing  stock markets continue to rise  The big question is whether it is part of a longer term dead cat bounce or if it is a sign an improving global outlook 
The critical industrial metals such as copper have seen a massive move higher in recent weeks  All of the significant steps higher in the stock markets of global export economies and metals such as Copper and Platinum  are at least pointing to a hint of optimism taking hold suggesting that perhaps the worst of the economic slowdown is behind us 

US Trading
The US equity market is pointing to a lower opening of about 1 point on the S P 500  It continues to be my view that equity prices are due for a minor pullback  I think at this point  it is pretty safe to say that I m obsessive over small details on daily movements of stock prices  However  it is just hard for me to ignore the glaring signs of a brief price decline that is in the works for stocks 
NASDAQ  QQQ 
The NASDAQ fell below the rising wedge yesterday  and that would suggest there are still declines on the way  perhaps by as much as 2 5  to 7 300  allowing the index to fill the gap  Again  nothing major  but hard to ignore the possibility 

S P 500  SPY  NYSE SPY  
For now  a zone of support for the S P 500 comes between 2 750 and 2 760 

Nike  NYSE NKE 
Nike is pulling back some this morning after one if sneakers fell apart during the middle of an NCAA basketball  Support for the stock comes at roughly  81 50 

Amazon  NASDAQ AMZN 
Amazon has struggled in recent days and continues to hug the  1 620 level  I ve said it before  and I shall repeat it  I still think this one is heading lower with a target for  1 520 

Johnson and Johnson  JNJ 
Johnson and Johnson has been subpoenaed over its baby powder  The stock hit its resistance on at  136 75 and in the short term  it could drop back to around  131 

Biogen  NASDAQ BIIB 
Biogen was downgraded this morning to hold from buy at Stifel with a  346 price target  Overall there is a downtrend to this stock and drop to  310 seems to be the most likely path 

Facebook  NASDAQ FB 
Facebook continues to work its way lower trying to fill the gap  The first stop on the chart is  157  and then  148 

Twitter  TWTR 
Twitter is failing at resistance at  31 90  and that means it may be on its way to  30 20

Original post",2019-02-21,Michael Kramer,https://www.investing.com/analysis/6-stocks-that-are-likely-to-lead-the-market-lower-on-february-21-200391309,200391309
129024,350539,BIIB,Energy  financial stocks give Wall St  modest lift,news,"By Chuck Mikolajczak NEW YORK  Reuters    Wall Street advanced modestly on Wednesday after a sharp rise in oil prices boosted energy shares  while better than anticipated data on the labor market helped financial stocks  U S  oil prices  CLc1  jumped more than 3 percent to settle at  40 83 a barrel after a larger than expected gasoline draw offset a surprise build in U S  crude stockpiles  WTI crude had settled below  40 for the first time since April on Tuesday   The S P energy index  SPNY  was up 1 8 percent as the best performing of the 10 major S P groups    The focus  at least near term  is definitely on energy prices and if we can hold  40  oil  the market is fine here  If it can t hold  40  there is going to be more pressure on the overall market   said Tim Ghriskey  chief investment officer of Solaris Group in Bedford Hills  New York    It s back to worries about oil and excess supply and demand that is OK but not great   Data showed the U S  private sector added 179 000 jobs in July  beating estimates of 170 000  The report comes ahead of the more comprehensive national payrolls report on Friday  If the labor market is able to build on its recent strength  it could make the case for the Federal Reserve to raise benchmark U S  interest rates later this year   Chicago Federal Reserve Bank President Charles Evans said on Wednesday that one rate hike may be appropriate this year  despite his worry that inflation is still undershooting the U S  central bank s 2 percent target   The possibility of a rate hike this year helped support financial stocks  along with a 7 3 percent jump in American International Group  N AIG  after the largest commercial insurer in the United States and Canada reported an operating profit that beat analysts  estimate   The S P financial sector  SPSY  rose 1 percent   Healthcare shares  SPXHC  were lower  weighed down by a 2 7 percent drop in Biogen  O BIIB   Reuters reported the company has not received any formal expressions of interest from potential acquirers a day after buyout reports on Tuesday sent the stock up more than 9 percent   The Dow Jones industrial average  DJI  rose 41 23 points  or 0 23 percent  to 18 355  the S P 500  SPX  gained 6 75 points  or 0 31 percent  to 2 163 78 and the Nasdaq Composite  IXIC  added 22 01 points  or 0 43 percent  to 5 159 74  Advancing issues outnumbered declining ones on the NYSE by a 2 10 to 1 ratio  on Nasdaq  a 1 92 to 1 ratio favored advancers  The S P 500 posted 10 new 52 week highs and one new low  the Nasdaq Composite recorded 69 new highs and 35 new lows   
About 6 67 billion shares changed hands in U S  exchanges  compared with the 6 6 billion daily average over the last 20 sessions ",2016-08-03,Reuters,https://www.investing.com/news/stock-market-news/futures-lower-ahead-of-economic-data-418180,418180
129034,350549,BIIB,Gilead shares look cheap but investors fret over growth,news,"By Lewis Krauskopf
NEW YORK  Reuters    Shares of  Gilead Sciences Inc   O GILD  are trading at ultra cheap levels as investors broadly shed biotech holdings and question what the company could do for an encore after several years of torrid growth 
While biotech and healthcare stocks have underperformed the broader market all year  Gilead stands out for its low forward price to earnings ratio  which is widely used by investors to value stocks 
The stock closed at  89 53 on Thursday  having lost more than one fourth of its value since hitting an all time high of  123 37 in June 
That put the share price at 7 3 times earnings estimates for the next 12 months  No other large U S  pharmaceutical or biotechnology company trades below a ratio of 10 9  according to Thomson Reuters data 
Gilead s valuation in recent weeks has been the lowest since it became a solidly profitable company more than a decade ago  Over the past 10 years  the stock has traded at a forward price to earnings ratio of 16 6 times  on average 
By other metrics  the stock does not look as appealing  Using a measure of a stock s value called a PEG ratio  which factors in Gilead s lackluster growth outlook and its price to earnings ratio  the shares look at least twice as expensive as the average big biotech stock  analysts  estimates show 
 People are just skeptical about the long term earnings power of the company   said John Fraunces  co manager for the Turner Investments medical sciences fund in Berwyn  Pennsylvania  which does not own Gilead shares 
VICTIM OF OWN SUCCESS
To an extent  Gilead is a victim of its own success  The company  the largest biotech by market value at  120 billion  built upon a leading HIV medicine franchise by adding hepatitis C treatments that revolutionized care for the serious liver disease 
That medical advance was reflected in its financial performance  From 2013 through last year  Gilead s sales tripled to nearly  33 billion  while earnings shot up more than six times to  12 61 per share 
But investors are concerned that Gilead s hepatitis C franchise sales may have peaked 
Earnings per share are expected to fall 3 percent this year with no growth expected through 2019  while sales are expected to recede to about  29 billion over the next four years  according to the average estimate of analysts polled by Thomson Reuters 
Gilead shares have declined 11 percent in 2016  though that is less than the 19 percent drops for big biotech peers Biogen Inc  O BIIB  and  Celgene Corp   O CELG   while the Nasdaq Biotechnology Index  NBI  has fallen 27 percent 
Investors said the company s future could rest in part on what it does with its balance sheet  Gilead amassed  26 2 billion in cash  cash equivalents and marketable securities by the end of 2015 
The company s dividend yield sits at 1 9 percent  below the roughly 2 3 percent average for companies in the S P 500 Health Care index  SPXHC   while it bought back  10 billion worth of its stock last year 
A major acquisition of promising companies or new medicines could help propel sales and earnings  but investors are worried about the price of buying such growth  They had also fretted over the  11 billion Gilead paid in 2011 for Pharmasset  but that deal ended up being the foundation for its hepatitis C franchise success 
 What investors are worried about is   Does management go out and overpay for an acquisition    said John Toohey  head of equities at USAA Investments in San Antonio  which owns Gilead shares 
The stock is  exceptionally cheap   Toohey said   The  valuation  gap is so big between Gilead and other stocks  we re willing to be patient  ",2016-03-18,Reuters,https://www.investing.com/news/stock-market-news/gilead-shares-look-cheap-but-investors-fret-over-growth-390731,390731
129042,350557,BIIB,S P edges closer to record high  energy shares lead,news,By Caroline Valetkevitch  Reuters    The S P 500 ended at its best level since July on Tuesday  helped by a big jump in energy shares and investor confidence that higher interest rates will not derail the economy  The index finished below its best levels of the session  though  while the Nasdaq ended lower  Biotech shares dropped following disappointing news from several key companies including Biogen  The Nasdaq Biotech Index  NBI  was down 2 5 percent  its biggest daily percentage decline since May 11  Giving the S P 500 its biggest boost  the S P energy index  SPNY  jumped 2 1 percent as oil prices reached 2016 highs due to supply constraints and a weak dollar   Exxon Mobil   N XOM  gained 1 5 percent to  90 71  Gains this week have once again put the S P 500 within striking distance of record highs reached in May 2015  Comments from Fed Chair Janet Yellen on Monday seemed to ease some worries about the economy  while underscoring views the Fed may be in no rush to raise rates   The big story for the market right now is  do we break out to all time highs   said Michael Sheldon  chief investment officer at Northstar Wealth Partners in West Hartford  Connecticut    If we do so in the near term  we could see a rush of money jump into the market from investors who had been sitting out on the sidelines  in fear missing out on further market gains   The Dow Jones industrial average  DJI  ended up 17 95 points  or 0 1 percent  to 17 938 28  and earlier broke above 18 000  while the S P 500  SPX  gained 2 72 points  or 0 13 percent  to 2 112 13  its highest close since July 22  The benchmark index now sits less than 19 points from its all time closing high of 2130 82  The Nasdaq Composite  IXIC  dipped 6 96 points  or 0 14 percent  to 4 961 75  Navistar International  N NAV  shares jumped 19 6 percent to  14 54 after it posted a surprise second quarter profit  On the downside  the S P 500 healthcare index  SPXHC  dropped 0 7 percent  dragged down by Biogen  O BIIB  and Alexion  O ALXN   Biogen tumbled 12 8 percent to  252 86 after its multiple sclerosis drug failed in a mid stage study  Alexion dropped 10 9 percent to  138 13 after its drug failed a trial  while Valeant  N VRX  slumped 14 6 percent to  24 64 after the drugmaker cut its full year forecast  About 6 4 billion shares changed hands on U S  exchanges  below the 6 9 billion daily average for the past 20 trading days  according to Thomson Reuters data  Advancing issues outnumbered declining ones on the NYSE by 1 896 to 1 136  for a 1 67 to 1 ratio on the upside  on the Nasdaq  1 462 issues rose and 1 364 fell for a 1 07 to 1 ratio favoring advancers  The S P 500 posted 43 new 52 week highs and one new low  the Nasdaq recorded 82 new highs and 22 new lows     additional reporting by Yashaswini Swamynathan in Bengaluru  Editing by Nick Zieminski ,2016-06-07,Reuters,https://www.investing.com/news/stock-market-news/stock-futures-up-after-yellen-eases-worries-over-economic-health-406939,406939
129048,350563,BIIB,Biogen  BIIB  Q4 Earnings Coming Up  What s In The Cards ,opinion,"Biogen Inc    NASDAQ BIIB   will report fourth quarter and full year 2018 results on Jan 29  before market open  Last quarter  the company delivered a positive earnings surprise of 8 82  Biogen s shares declined 2 9  in the past year compared with the  s decline of 21 3  in the same time frame   Biogen s earnings performance has been decent so far  The company delivered a positive surprise in three of the last four quarters  The average earnings beat over the last four quarters is 4 66  Biogen Inc  Price and EPS Surprise
    
Let s see how things are shaping up for this announcementFactors to ConsiderThe performance of Biogen s multiple sclerosis  MS  drugs has been stable lately  Tecfidera U S  revenues improved in the third quarter  Meanwhile  ex U S  sales were strong driven by patient growth across European markets  solid emerging market growth and particularly strong performance in Japan  which offset the impact of ongoing price decreases in certain European countries U S  sales of another MS drug  Tysabri have been hurt by Roche s   OTC RHHBY   newly launched MS drug  Ocrevus  Meanwhile  patient growth in all major European markets and solid emerging market growth is pushing up Tysabri s sales in ex U S  markets In the fourth quarter  Biogen expects worldwide MS product revenues to be stable from the year ago period  benefiting from a moderate inventory channel build and less significant impact of Ocrevus on a year over year basis The Zacks Consensus Estimate for sales of Tecfidera in the fourth quarter is pegged at  1 10 billion while that for Tysabri  Global In Market sales  is  452 million The combined number of patients using Avonex and Plegridy is expected to decline due to a shift to other oral MS therapies as well as higher discounts and allowance Biogen s new drug  Spinraza  approved for spinal muscular atrophy  performed well in the past two quarters  On the Q3 call  management was optimistic that Spinraza patient starts will grow in the United States in future quarters as it continues to capture the adult segment  which represents approximately 60  of all SMA patients  It had until then penetrated only 15  of the adult segment  Thus  this segment represents presents strong growth opportunity  In ex U S  markets  Spinraza s uptake in the fourth quarter is expected to be driven by continued patient growth  although at a more modest rate in mature markets Biosimilars sales in the third quarter rose both year over year and sequentially  Biogen markets two biosimilar products   Flixabi  a biosimilar referencing Remicade  and Benepali  a biosimilar referencing Enbrel   In the fourth quarter  Biogen expects relatively stable biosimilars revenues compared to the third quarter  Importantly  in October  Biogen launched Imraldi  its biosimilar version of AbbVie s blockbuster drug  Humira in several European markets  This should bring in additional sales in Q4 Revenues from Biogen s anti CD20 therapeutic programs  which include Biogen s shares of Rituxan and Gazyva operating profits  contributed significantly to the top line in the past two quarters primarily driven by Ocrevus royalties  We expect the positive trend to continue Overall  on the Q3 call  management had said that the fourth quarter of 2018 will face difficult comparisons from the prior year quarter as the latter had benefited from favorable timing of contract manufacturing Both R D and SG A expenses are expected to sequentially increase in the fourth quarter due to the timing of clinical trial expense and market expansion investments as well as seasonality Earnings WhispersOur proven model does not conclusively show that Biogen is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Earnings ESP  Its Earnings ESP is  0 17  as the Most Accurate Estimate stands at  6 71 while the Zacks Consensus Estimate is pegged higher at  6 72  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Biogen s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some large biotech stocks that have the right combination of elements to beat on earnings this time around Amgen  Inc    NASDAQ AMGN   has an Earnings ESP of  0 25  and a Zacks Rank  2  The company is slated to release results on Jan 29  You can see  Celgene Corporation   NASDAQ CELG   has an Earnings ESP of  2 31  and a Zacks Rank  3  The company is slated to release results on Jan 31 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-01-21,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-q4-earnings-coming-up-whats-in-the-cards-200377532,200377532
129050,350565,BIIB,The Zacks Analyst Blog Highlights  Pfizer  Biogen  Schwab  Sysco And Philips,opinion,For Immediate ReleaseChicago  IL   January 21  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Pfizer   NYSE PFE    Biogen   NASDAQ BIIB    Schwab   NYSE SCHW    Sysco   NYSE SYY   and Philips   NYSE PHG    Here are highlights from Friday s Analyst Blog  Top Stock Reports for Pfizer  Biogen and SchwabThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Pfizer  Biogen and Schwab  These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see Pfizer s shares have outperformed its peer group in the past one year   the stock is up  14 8  over this period vs  a  0 5  decline for the Zacks Large Cap Pharmaceuticals industry   Pfizer is facing top line headwinds like genericization of key drugs  supply challenges in the legacy Hospira portfolio  pricing pressure and rising competition  However  the Zacks analyst thinks products like Ibrance  cost cutting efforts  a lower tax rate and share buybacks can support bottom line growth  Pfizer also boasts a strong pipeline and looks well positioned to deliver several potential new breakthrough innovative medicines in the next five years  which can drive long term growth  Bavencio  though approved for two small indications currently  is being considered a key long term growth driver for Pfizer if it can gain label expansion approvals  Pfizer gained FDA approval for four new cancer drugs in 2018  which can boost oncology sales  Estimates have gone down slightly ahead of Q4 earnings release  Pfizer has a positive record of earnings surprises in recent quarters Shares of Biogen have outperformed the Zacks Biomedical and Genetics industry in the past one year   1 8  vs   19 8    Biogen has a strong position in the MS market with a wide range of products  The Zacks analyst likes its efforts to diversify beyond MS to other areas like Alzheimer s  Parkinson s and stroke  Spinraza is performing strongly and has multi billion dollar potential  Biogen s efforts to regularly in license assets to build its pipeline are encouraging since several of them have transformative potential  Multiple data readouts are expected in 2019  However  the launch of Ocrevus by Roche is having a negative impact on MS franchise sales in the United States  Also  potential competition to Spinraza from competitors  gene therapy programs for SMA is a concern  Though Biogen s CNS pipeline is attractive  it is a high risk area  However  estimates have gone up slightly ahead of Q4 earnings results  The company has a positive record of earnings surprises in recent quarters Schwab s shares have outperformed the Zacks Investment Brokers industry over the past three months  gaining  0 1  vs  6 2   The Zacks analyst emphasizes that the company has an impressive earnings surprise history  having surpassed expectations in each of the trailing four quarters  Its fourth quarter 2018 results were driven by a rise in interest income and trading revenues  The company remains well positioned to gain from the rising rate environment and its initiatives to strengthen trading income  Further  its steady capital deployment actions reflect a strong balance sheet position  However  continuously rising operating expenses remain a major concern and hurt bottom line growth to some extent  Also  the company s significant dependence on fee based revenue streams is cause for apprehension Other noteworthy reports we are featuring today include Sysco and Philips Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look    Media ContactZacks Investment Research800 767 3771 ext  9339     Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-01-21,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-pfizer-biogen-schwab-sysco-and-philips-200377523,200377523
129051,350566,BIIB,AbbVie  ABBV  Misses On Q4 Earnings   Revenues  Shares Down,opinion,"AbbVie Inc    NYSE ABBV   posted lower than expected fourth quarter 2018 earnings and revenues  Moreover  Humira sales growth slowed as biosimilar launch in Europe pulled down sales of the drug  Shares fell almost 5  in pre market trading Shares of AbbVie have declined 30 3  in a year s time against the  s 6 8  rise The biopharmaceutical company reported earnings of  1 90 per share in the fourth quarter  missing the Zacks Consensus Estimate of  1 92  However  the figure surged 28 4  year over year  Earnings per share were within the guided range of  1 89 and  1 91 The company posted revenues of  8 31 billion in the quarter under review  missing the Zacks Consensus Estimate of  8 36 billion  However  the top line increased 7 3  year over year  Excluding a 1  unfavorable impact from foreign exchange rate fluctuations  operational revenues rose 8 3   Revenue growth was higher than the projection of approximately 7  on an operational basis Quarter in DetailKey drug Humira recorded sales growth of 1 4  on an operational basis with revenues from the same coming in at  4 9 billion  The Zacks Consensus Estimate for Humira sales was  5 billion  Sales in the United States increased 9 1  to  3 6 billion  Humira sales in ex U S  markets were down 14 8  on an operational basis and 17 5  on a reported basis to  1 3 billion  International sales were severely impacted by the launch of several direct biosimilar drugs in Europe by other pharma companies including Amgen   NASDAQ AMGN    Sandoz and Biogen  NASDAQ BIIB  Fourth quarter net revenues from Imbruvica were  1 billion  up 42  year over year  U S  sales of Imbruvica grossed  839 million  up 43 2  from the year ago figure  AbbVie logged  167 million of international profit sharing with Johnson   Johnson   NYSE JNJ   The company s leukemia drug  Venclexta  brought in revenues of  124 million  up more than 100  year over year Other products that delivered an impressive performance include Duodopa  It recorded revenue growth of 16 7  on operational basis and 14  on reported basis  Another product  Creon witnessed an increase of 11 4  in revenues on both operational and reported basis HCV  chronic hepatitis C virus  products recorded sales of  862 million  up 71 4  operationally year over year  on the back of strong demand for Mavyret  which was launched in the second half of 2017  Mavyret sales more than doubled to  819 million Other drugs that recorded sales decline include Androgel  Kaletra and Sevoflurane  which fell 45 8   23 1  and 10 6   respectively  operationally  during the quarter Adjusted SG A expenses increased 9 2  to  1 8 billion while R D expenses rose 3 1  to  1 37 billion in the fourth quarter  Adjusted operating margin was 41 7  of sales Other UpdatesIn January  data from the phase III RESOLVE study showed that the Imbruvica combination failed to bring statistically significant improvement in progression free survival   PFS   and overall survival in patients with metastatic pancreatic adenocarcinoma  The study was evaluating Imbruvica in combination with chemotherapy agents nab paclitaxel and gemcitabine In December  AbbVie stopped enrolling patients in the phase III study  TAHOE  evaluating Rova T in second line small cell lung cancer   SCLC   on recommendation from an Independent Data Monitoring Committee Last month  the company submitted regulatory applications in the United States and EU for seeking approval for upadacitinib for treating adults with moderate to severe rheumatoid arthritis In October  a label expansion of cancer drug  Venclyxto  Venclexta   in combination with Roche s   OTC RHHBY   Rituxan  rituximab  for the treatment of patients with chronic lymphocytic leukemia   CLL    in second or later line setting was approved in Europe  A label expansion for the drug was approved in the United States for treating acute myeloid leukemia in first line setting during the quarter During the quarter  the company s board approved an increase of  5 billion in its present share repurchase program 2019 GuidanceAbbVie expects adjusted EPS to be in the range of  8 65  8 75 for 2019  The earnings guidance indicates a year over year increase of 10  at the mid point  The Zacks Consensus Estimate for current year earnings per share is pegged at  8 68 AbbVie Inc  Price  Consensus and EPS Surprise
    Zacks Rank AbbVie currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-01-24,Zacks Investment Research,https://www.investing.com/analysis/abbvie-abbv-misses-on-q4-earnings--revenues-shares-down-200379518,200379518
129052,350567,BIIB,Biogen  BIIB  Beats Revenues And Earnings Estimates In Q4,opinion,Cambridge  MA based Biogen Inc    NASDAQ BIIB   holds a strong position in the multiple sclerosis   MS   market with a wide range of products including Avonex  Tysabri  Tecfidera and Plegridy  However  as competition in the MS market intensifies  Biogen is trying to diversify beyond MS to other areas like Alzheimer s  Parkinson s  stroke  among others Biogen s earnings performance has been decent so far  The company delivered a positive surprise in three of the last four quarters  The average earnings beat over the last four quarters is 4 66  Currently  Biogen has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  Biogen s fourth quarter 2018 earnings beat expectations  The company posted earnings of  6 99 per share while our consensus called for EPS of  6 72 Revenues Beat  Biogen posted revenues of  3 53 billion  beating the consensus estimate of  3 39 billion  Revenue increased 7  year over year Key Statistics  The company s oral MS drug Tecfidera s sales rose 3  year over year to  1 10 billion  The other MS drug  Tysabri s sales were flat year over year at  464 million  Spinraza  spinal muscular atrophy  sales grew 30  year over year to  469 9 million driven by sales growth in both United States and in ex U S  markets Pre Market Trading  Shares decreased 0 46  in pre market trading Check back later for our full write up on this BIIB earnings report later  Biogen Inc  Price and EPS Surprise    Wall Street s Next Amazon  NASDAQ AMZN  Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-01-28,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-beats-revenues-and-earnings-estimates-in-q4-200380678,200380678
129053,350568,BIIB,Biogen  BIIB  Q4 Earnings Beat Estimates  Revenues Up Y Y,opinion,"Biogen Inc    NASDAQ BIIB   reported fourth quarter 2018 earnings per share of  6 99  which beat the Zacks Consensus Estimate of  6 72  Earnings rose 32 9  year over year  backed by higher revenues 
Sales came in at  3 53 billion  up 7  from the year ago quarter  Moreover  sales beat the Zacks Consensus Estimate of  3 39 billion 
Revenue growth was principally driven by higher sales of Spinraza  and higher contributions from biosimilars and Ocrevus royalties  Tecfidera sales also increased during the quarter 
Biogen s shares have decreased 8 9  in the past year compared with the  s decline of 24 6  

 
Quarter in Detail
Biogen s multiple sclerosis  MS  revenues were  2 30 billion in the reporter quarter  including approximately  152 million in royalties on the sales of Roche s   OTC RHHBY   MS drug  Ocrevus  MS revenues grew 2  year over year 
In the United States  MS sales are dented by the launch of Ocrevus  Though Ocrevus poses strong competition to Biogen s MS drugs  the company receives royalties on U S  sales of Ocrevus from Roche 
Tecfidera sales rose 3  year over year and 2  sequentially to  1 10 billion  This included U S  sales of  856 30 million  up 3  year over year  and ex U S  sales of  254 10 million  up 4 1   
Tysabri sales were flat year over year at  464 million  Tysabri U S  sales rose 1 9  to  256 80 million in the quarter  International revenues declined 1 4  to  207 60 million  Tysabri sales fell 1 2  sequentially 
Combined interferon revenues  Avonex and Plegridy  in the fourth quarter were  597 2 million  down 7 4  year over year and 1 2  sequentially  Avonex revenues declined 8  from the year ago quarter to  481 million  Plegridy contributed  116 million to revenues  which decreased 7  year over year 
U S  Interferon revenues have been declining due to transition of patients to other oral or high efficacy MS therapies as well as higher discounts and allowance 
Zinbryta generated no revenues in the quarter as the drug was withdrawn from the market in March 2018  due to growing safety concerns and limited commercial adoption  The drug had contributed  11 7 million to total revenues in the year ago quarter 
Spinraza  spinal muscular atrophy  sales grew 30  year over year to  469 9 million  driven by sales growth in both the United States and the ex U S  markets  However  sales fell 0 5  sequentially 
Spinraza U S  sales were  236 2 million in the fourth quarter  up 5 5  sequentially  driven by increased new patient demand  In ex U S  markets  Spinraza sales fell 4 1  sequentially to  233 7 million  due to lower volumes in some markets stemming from loading dose dynamics  unfavorable shipment timing in certain distributor markets and pricing dynamics in certain markets 
The number of patients on Spinraza grew approximately 9  in the United States and 18  outside the United States in the quarter compared with the end of the third quarter of 2018 
In the fourth quarter of 2018  Biogen recorded biosimilar revenues of  156 million  up 28  year over year and 13 3  sequentially  Biogen markets three anti TNF biosimilars in the EU   Flixabi  a biosimilar referencing J J   NYSE JNJ   Merck s Remicade   Benepali  a biosimilar referencing Amgen Pfizer s Enbrel  and Imraldi a biosimilar referencing AbbVie s   NYSE ABBV   Humira  
Revenues from Anti CD20 therapeutic programs  which include Biogen s share of Rituxan and Gazyva operating profits and Ocrevus royalties  increased almost 29  from the year ago period to  535 million 
Research and development  R D  expenses increased 2  year over year to  602 million  Selling  general and administrative  SG A  expenses were up 7  year over year to  591 million 
FY18 Results
The companyreported 2018 earnings per share of  26 20  which beat the Zacks Consensus Estimate of  25 84  Earnings rose 20 1  year over year  backed by higher revenues 
For full year  revenues came in at  13 45 billion  which increased 9 6  year over year and exceeded the Zacks Consensus Estimate of  13 31 billion 
2019 Guidance
Biogen provided its outlook for 2019  The company expects revenues of   13 6  13 8 billion  Earnings per share are expected between  28 00 and  29 00 
The Zacks Consensus Estimate for revenues and earnings is  13 65 billion and  28 20 per share  respectively 
Our Take
Biogen beat estimates for both earnings and sales in the fourth quarter  fueled mainly by strong performance of its newest drug  Spinraza  which we believe has a multi billion dollar potential  Biogen s efforts to diversify beyond MS to other areas like Alzheimer s  Parkinson s and stroke  among others and regularly in license assets to build its pipeline are impressive 
Several of these assets have transformative potential  However  the launch of Ocrevus by Roche is having a negative impact on MS franchise sales in the United States  which is a concern 
Biogen currently carries a Zacks Rank  3  Hold   You can see   
Biogen Inc  Price  Consensus and EPS Surprise

    
Wall Street s Next Amazon  NASDAQ AMZN  
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-01-29,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-q4-earnings-beat-estimates-revenues-up-yy-200380734,200380734
129061,350576,BIIB,U S  biotech to apply artificial intelligence to UK genome study,news,"By Julie Steenhuysen CHICAGO  Reuters    Berg  a private company that uses artificial intelligence to discover new drugs and diagnostics  will help England s national genomics project mine DNA and health data from thousands of British citizens for potential drug targets  Berg  based in Boston  was co founded in 2006 by Silicon Valley real estate billionaire Carl Berg  Since then  it has been working to change the way drugs are discovered  working in partnership with key players such as the U S  Department of Defense and the Parkinson s Institute Clinical Center  Its newest agreement is with the Genomics England 100 000 Genomes Project  which aims to accelerate development of new diagnostics and treatments through a year long industry trial  company executives told Reuters   The project focuses on patients with rare diseases and six common cancers  Industry partners include drugmakers such as Roche  Biogen  NASDAQ BIIB   AstraZeneca and GlaxoSmithKline  Berg uses artificial intelligence  to look at patterns in the data to find areas in the biology that are fingerprints of that disease   Niven Narain  Berg s co founder and president  said in an interview  It plans to open a UK office in the next year to shepherd the project and seek new collaborations with drug company and academic partners in Europe  Leading biotech companies are collecting genomic information on hundreds of thousands of patients to search for new drug leads  Berg says its approach allows it to add far more data points in addition to DNA  The company uses its artificial intelligence supercomputer platform   known to insiders as  Betsy    to look at what is going on inside cells  studying all the proteins  the lipids that form cell membranes and govern cell communication and the way cells metabolize energy  Since last April  it has worked with Beth Israel Deaconess Medical Center and the Pancreatic Cancer Research Team to hunt for leads on pancreatic cancer by analyzing blood samples from nearly 1 900 patients   The Berg approach essentially does away with the assumption that genes  by themselves  are responsible for disease or the absence of it   said Dr  James Moser of Beth Israel Deaconess  Berg is also planning Phase 2 trials in early 2016 for its experimental cancer drug called BPM 31510 aimed at treating solid tumors  Narain said  The treatment works by reversing changes in the metabolism of cancer cells that allow them to thrive  The drug was based on predictions from the computer model  which helped the company choose how to develop the drug   Early stage data suggests the drug helps shrink tumors when used alone  and increases the potency of chemotherapy when used in combination  
 We re seeing responses in gastric cancer  esophageal cancer  pancreatic cancer  liver cancer  renal cell sarcomas    all highly metabolic tumors  Narain said ",2015-09-30,Reuters,https://www.investing.com/news/general-news/u.s.-biotech-to-apply-artificial-intelligence-to-uk-genome-study-363863,363863
129062,350577,BIIB,Novartis biosimilar copycat takes aim at Amgen s drug Enbrel,news,"ZURICH  Reuters    The U S  Food and Drug Administration has accepted  Novartis   VX NOVN  unit Sandoz s regulatory submission for approval of a biosimilar copy of Amgen s  O AMGN  blockbuster Enbrel drug  the Swiss drugmaker said on Friday  Biosimilars aim to copy biologic products  which are made inside living cells  but they can never be exact duplicates  so biosimilar manufacturers need to conduct clinical trials to show their products work as intended  Enbrel  or etanercept as the drug is known generically  is a big prize since it was the world s fifth biggest selling medicine in 2014 with sales of nearly  9 billion  Amgen  which sells the drug in North America  booked Enbrel sales of  4 7 billion last year   Pfizer   N PFE  sells Enbrel elsewhere  Merck  N MRK  and Samsung  KS 005930  Bioepis last month won approval for biosimilar etanercept in South Korea and a copy is also on the way in Europe  where Samsung  SAGR UL  is working with Biogen  O BIIB   but Sandoz said it believed it was the first company to receive a U S  FDA file acceptance  Sandoz is seeking approval for all indications included in the label for Enbrel  a so called anti TNF drug  which is used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis  it said in a statement  Novartis last month launched the first biosimilar drug in the United States after a U S  appeals court declined to stop the sale of the company s copycat version of Amgen s blockbuster cancer drug Neupogen  Insurers and government healthcare systems hope biosimilars will cost the public 40 percent to 50 percent less than the original drugs and experience in Europe suggests that steep discounts are being offered in some markets   Sandoz believes that the totality of evidence in its submission  including two pivotal clinical studies  will demonstrate that the proposed biosimilar is essentially the same as the reference product   Novartis said on Friday  
The potential for biosimilars to take a large slice of the market is grabbing the attention of both healthcare providers  who see big budget savings  and investors  worried about the impact on the profits of companies making original products ",2015-10-02,Reuters,https://www.investing.com/news/stock-market-news/novartis-copycat-product-takes-aim-at-amgen's-enbrel-364326,364326
129063,350578,BIIB,Biogen to cut 11 percent of workforce  programs  shares rise,news,"By Bill Berkrot  Reuters    Biogen Inc  O BIIB  on Wednesday announced it was cutting 11 percent of its global workforce and eliminating the development of several drugs  including one for lupus  in moves that will reduce operating expenses by about  250 million this year  Wall Street signaled its approval of the belt tightening  as well as the better than expected third quarter sales of Biogen s multiple sclerosis drugs  sending its shares 9 0 percent higher on Wednesday   The U S  biotech stock had lost more than a third of its value since July  when it cut growth forecasts for its top selling MS drug Tecfidera  The cost savings will allow Biogen to focus on its most promising opportunities  including late stage development of its high profile Alzheimer s disease drug aducanumab  two other Alzheimer s programs  and its anti Lingo drug that aims to repair nerve damage caused by multiple sclerosis   The company will also pour some of its savings into direct to consumer marketing of Tecfidera in an effort to reignite growth in the United States and elsewhere  It cut a Tecfidera program in secondary progressive multiple sclerosis after disappointing trial results  Chief Executive George Scangos said even with mounting pressures to rein in prices of U S  prescription drugs  medicines like aducanumab and others it chose to focus on will get good reimbursement from payers if approved   In the end  things are going to be priced according to the value they bring to patients   Scangos said  The company said it may have found a way through dose titration to reduce a type of brain swelling that had been the most concerning side effect seen with aducanumab   Biogen  which had about 7 550 employees as of Dec  31  said it expects to incur charges of  85 million  95 million  primarily in the fourth quarter  relating to the jobs cuts  It also plans to announce other non labor related cost saving moves by year end  With strong third quarter sales  cost savings  and a  5 billion share repurchase campaign well underway  Biogen raised its full year sales and earnings forecasts  It now expects revenue growth of 8 0 percent to 9 0 percent  up from 6 0 to 8 0 percent  and sees adjusted earnings per share of between  16 20 and  16 50 versus its prior view of  15 50 to  15 95  The company reported adjusted third quarter earnings of  4 48 per share  sailing past analysts  tempered expectations of  3 80  according to Thomson Reuters I B E S  Tecfidera sales of  937 million for the quarter topped Wall Street expectations of about  895 million  
Revenue rose 11 percent to  2 8 billion ",2015-10-21,Reuters,https://www.investing.com/news/stock-market-news/biogen-to-cut-11-percent-of-global-workforce-367216,367216
129064,350579,BIIB,U S  stocks lower at close of trade  Dow Jones Industrial Average down 0 24 ,news,"Investing com   U S  stocks were lower after the close on Tuesday  as losses in the Oil   Gas  Telecoms and Industrials sectors led shares lower 
At the close in NYSE  the Dow Jones Industrial Average declined 0 24   while the S P 500 index fell 0 26   and the NASDAQ Composite index fell 0 09  
The best performers of the session on the Dow Jones Industrial Average were EI du Pont de Nemours and Company  N DD   which rose 2 78  or 1 68 points to trade at 62 05 at the close  Meanwhile  UnitedHealth Group Incorporated  N UNH  added 2 44  or 2 84 points to end at 119 37 and  Pfizer  Inc  N PFE  was up 2 43  or 0 83 points to 34 99 in late trade 
The worst performers of the session were International Business Machines  N IBM   which fell 4 04  or 5 80 points to trade at 137 86 at the close   Caterpillar  Inc  N CAT  declined 1 58  or 1 13 points to end at 70 39 and United Technologies Corporation  N UTX  was down 1 35  or 1 35 points to 98 88 
The top performers on the S P 500 were  Starwood Hotels    Resorts Worldwide  N HOT  which rose 9 13  to 74 81  Walgreens Boots Alliance Inc  O WBA  which was up 6 35  to settle at 95 16 and Biogen Inc  O BIIB  which gained 5 84  to close at 290 63 
The worst performers were CONSOL Energy Inc  N CNX  which was down 21 22  to 6 98 in late trade   Cummins Inc   N CMI  which lost 8 70  to settle at 102 35 and Xerox Corporation  N XRX  which was down 7 38  to 9 29 at the close 
The top performers on the NASDAQ Composite were Perseon Corp  O PRSN  which rose 142 96  to 0 680   River Valley  Bancorp  O RIVR  which was up 46 07  to settle at 32 69 and  Trivascular   O TRIV  which gained 38 89  to close at 7 00 
The worst performers were  Liquid Hlgs   O LIQD  which was down 50 40  to 0 037 in late trade  Endologix Inc  O ELGX  which unchanged 0 00  to settle at 8 77 and  Rent A Center Inc   O RCII  which was down 29 95  to 18 06 at the close 
Falling stocks outnumbered advancing ones on the New York Stock Exchange by 1964 to 568 and 1 ended unchanged  on the Nasdaq Stock Exchange  1830 fell and 718 advanced  while 45 ended unchanged 
Shares in CONSOL Energy Inc  N CNX  fell to 5 year lows  down 21 22  or 1 88 to 6 98  Shares in Cummins Inc  N CMI  fell to 52 week lows  losing 8 70  or 9 75 to 102 35  Shares in Xerox Corporation  N XRX  fell to 52 week lows  losing 7 38  or 0 74 to 9 29  Shares in International Business Machines  N IBM  fell to 5 year lows  losing 4 04  or 5 80 to 137 86  Shares in Liquid Hlgs  O LIQD  fell to all time lows  down 50 40  or 0 038 to 0 037  Shares in River Valley Bancorp  O RIVR  rose to all time highs  rising 46 07  or 10 31 to 32 69  Shares in Endologix Inc  O ELGX  unchanged to 3 years lows  unchanged 0 00  or 0 00 to 8 77  Shares in Rent A Center Inc  O RCII  fell to 5 year lows  falling 29 95  or 7 72 to 18 06  
The CBOE Volatility Index  which measures the implied volatility of S P 500 options  was up 0 98  to 15 44 
Gold for December delivery was up 0 07  or 0 80 to  1167 00 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in December fell 1 73  or 0 76 to hit  43 22 a barrel  while the December Brent oil contract fell 1 46  or 0 69 to trade at  46 84 a barrel 
EUR USD was down 0 14  to 1 1041  while USD JPY fell 0 52  to 120 45 
The US Dollar Index was up 0 11  at 97 02 ",2015-10-27,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stocks-lower-at-close-of-trade;-dow-jones-industrial-average-down-0.24-368314,368314
129065,350580,BIIB,Major drugmakers push back in U S  price debate,news,"By Caroline Humer SAN FRANCISCO  Reuters    With a backlash brewing over the price of medicines in the United States  drugmakers are pushing back with a new message  Most people don t pay retail      Top executives from Eli Lilly and Co  N LLY   Merck   Co  N MRK  and Biogen Inc  O BIIB  said in interviews with Reuters this week that the media focus on retail  or  list prices   for branded medications is misplaced   They stressed that the actual prices paid by prescription benefit managers  insurers and other large purchasers are reduced through negotiated discounts   A couple of dramatic price hikes in 2015 exposed the whole industry to ongoing scrutiny in Congress and on Wall Street  Turing Pharmaceuticals raised the price of a generic anti infective drug called Daraprim by 5 000 percent  and the larger Valeant Pharmaceuticals International  N VRX  raised the price on a heart drug Isuprel by more than 200 percent   The largest drugmakers quickly portrayed those cases as outliers  But the industry practice of raising prices each year for treatments used by millions of people is attracting new attention   Adam Schechter  Merck s president of Global Human Health  said the industry needs to better explain the value of drugs and how they can prevent healthcare costs down the line    We have to explain the difference between the list price and the net price   he said in an interview   Toward that end  two drugmakers at the JP Morgan Healthcare Conference in San Francisco this week shared with Reuters some limited information on actual pricing   Eli Lilly said the actual average price increase on Humalog  its injectable insulin used to treat diabetes  has been a modest 1 to 2 percent annually over the last five years  The company declined to provide a list price    Horizon Pharma  plc  O HZNP   a small drugmaker  raised list prices across its business about 7 percent for this year  Chief Executive Tim Walbert said in an interview  But he said he expects the company s actual price increases to be 4 percent or less  More recently   Pfizer  Inc  N PFE   one of the world s largest drugmakers  raised U S  list prices on more than 100 drugs as of Jan  1  according to data from information services company Wolters Kluwer that was published last week by UBS Securities   The list included a 9 4 percent rise for pain drug Lyrica and a nearly 13 percent increase for erectile dysfunction drug Viagra  Pfizer said in an email the prices don t reflect  considerable discounts  to many payers  but did not provide examples of net prices   EXPLAINING PRICE  Drugmakers keep actual pricing details close to guard their position in negotiations with commercial insurers and government health plans like Medicaid  There is no centralized catalog of U S  list prices or rebates for medicines   That drug executives at the San Francisco conference allowed even a glimpse into their actual pricing strategies reflects the intensity of the new attention being paid to their practices   In meetings at the event  investors pressed pharmaceutical executives for more transparency about pricing  said Les Funtleyder  a portfolio manager for E Squared Asset Management  which holds shares in Pfizer and Lilly    What they really want to know is  are you thinking about this issue   he said of the investors   They are looking for an acknowledgement on the management team s part    E Squared expects the new scrutiny will have an impact  projecting that drugmakers will raise U S  list prices by 4 percent to 6 percent in 2016  less than half the rate in 2015   The candor of some individual pharmaceutical executives follows earlier messaging by industry advocates  In a November blog post  the industry s main lobbying group PhRMA  reported that list prices grew 13 percent in 2014  but actual prices increased only 5 percent  U S  health insurers say that  even accounting for discounts  drug prices are rising at an unsustainable rate  and they are pressuring drugmakers for cuts   
 Whether it s a gross number  or a net number  it is still astronomical   said Daniel Hilferty  chief executive of Independence Blue Cross  which operates in Pennsylvania and New Jersey ",2016-01-15,Reuters,https://www.investing.com/news/stock-market-news/major-drugmakers-push-back-in-u.s.-price-debate-380327,380327
129085,350600,BIIB,Biogen Inks Two Deals To Make Drugs For Neurological Diseases,opinion,"Biogen Inc    NASDAQ BIIB   announced two strategic collaborations to develop potential therapies for Alzheimer s disease  Parkinson s disease and other devastating neurological diseases 
The first collaboration was with private biotech C4 Therapeutics  C4T   per which the latter s novel protein degradation platform would be leveraged to discover and develop potential novel targets for treating neurological conditions  such as Alzheimer s disease and Parkinson s disease  Under this deal  while Biogen and C4T have agreed to discover the potential targets together  Biogen will be responsible for advancing the candidates for future development and potential commercialization  For the deal  Biogen will be entitled to pay C4T up to a total of  415 million in upfront and potential future milestone payments plus potential future royalties 
The second deal is with Waltham based Skyhawk Therapeutics  under which Biogen will use Skyhawk s SkySTAR technology platform to develop potential targets using selective RNA modulating small molecules that can treat multiple sclerosis  spinal muscular atrophy and other neurological diseases  For its research services and the exclusive license to the SkySTAR s platform  Biogen made an upfront payment of  74 million to Skyhawk while the latter will also be entitled to potential future milestones and royalties  Biogen has also reserved the option to license any therapies resulting from this collaboration and will take care of its future development and commercialization 
The collaborations are in line with Biogen s strategic priority to build potential therapies for neurological conditions  In 2017  Biogen added seven new clinical stage programs to its neuroscience pipeline through advancing internal pipeline candidates and external deals  In 2018  Biogen signed five business development pacts with several having transformative potential 
Shares of Biogen were up almost 4  on Friday after it announced the two deals  The stock has dipped 3 5  in the past year compared with the  s decline of 18 9  
 

 
Several companies have lately invested in collaborations with smaller biotechs to discover potential treatments for AD and other neurological diseases 
Last month  Lilly   NYSE LLY   signed a collaboration agreement with Swiss biotech AC Immune SA   NASDAQ ACIU   to jointly develop tau aggregation inhibitors  which have potential to treat AD and other neurodegenerative diseases 
In October  Pfizer   NYSE PFE   announced the creation of a new biotech called Cerevel Therapeutics in partnership with private equity firm Bain Capital  LP  which will focus on developing drugs to treat central nervous system  CNS  disorders including Parkinson s and Alzheimer s disease 
Alzheimer s  a fatal illness that causes progressive decline in memory  has always been a highly challenging area with not much progress being made in spite of significant investments  both funds and resources  to that end  Several companies have failed to develop safe and effective treatment options for this deadly brain disease 
Despite several setbacks  the companies continue to invest heavily in developing Alzheimer s disease treatments  given the high commercial potential in this market  Success in this area means huge returns  This is because more than five million Americans are living with Alzheimer s disease with the numbers expected to triple by 2050  Data  Alzheimer s Association   The market has immense commercial potential and companies coming out with new treatments could rake in billions of dollars in sales 
Biogen currently carries a Zacks Rank  3  Hold   You can see  
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline 
So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2019-01-07,Zacks Investment Research,https://www.investing.com/analysis/biogen-inks-two-deals-to-make-drugs-for-neurological-diseases-200373429,200373429
129086,350601,BIIB,Will Biogen  BIIB  Beat Estimates Again In Its Next Earnings Report ,opinion,"Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report  Biogen  BIIB   which belongs to the Zacks Medical   Biomedical and Genetics industry  could be a great candidate to consider 
This biotechnology company has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  The average surprise for the last two quarters was 9 97  
For the most recent quarter  Biogen was expected to post earnings of  6 80 per share  but it reported  7 40 per share instead  representing a surprise of 8 82   For the previous quarter  the consensus estimate was  5 22 per share  while it actually produced  5 80 per share  a surprise of 11 11  
Price and EPS Surprise

Thanks in part to this history  there has been a favorable change in earnings estimates for Biogen lately  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the stock is positive  which is a great indicator of an earnings beat  particularly when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Biogen currently has an Earnings ESP of  0 20   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  3  Hold  indicates that another beat is possibly around the corner  We expect the company s next earnings report to be released on January 29  2019 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-01-16,Zacks Investment Research,https://www.investing.com/analysis/will-biogen-biib-beat-estimates-again-in-its-next-earnings-report-200376751,200376751
129087,350602,BIIB,3 Biotech Mutual Funds 2019,opinion,The U S  biotechnology sector finished 2018 on a high  As a matter of fact  health care was one of the only two sectors to have finished last year in the positive territory  with biotech as one of the best performing industries  A slew of strong earnings  a higher number of FDA approvals and continuous influx of foreign funds into biotech companies in America bolstered the industry s performance Such trends are expected to continue  In fact  an even higher number of biotech firms are expected to go public in 2019  Under such broadly encouraging conditions  investing in mutual funds having significant exposure to biotech companies seems prudent Biotech Indexes and ETFs on a TearBiotech ETFs and indexes have had a bullish run in the markets in the year to date period  iShares Nasdaq Biotechnology ETF  IBB   SPDR S P Biotech ETF  NYSE XBI   ProShares Ultra Nasdaq Biotechnology  BIB  and NASDAQ Biotechnology Index  NBI  have all rallied 13 2   14 5   27 8  and 12 7   respectively Factors Which Will Boost Health CareThe majority of health care companies in the United States benefit from consistent cash inflow and notable profit margins  Greater technological investment and innovation to increase efficiency and lessen wastages are likely to bring down overall treatment costs and medical product prices Further  job prospects across the health care sector remain promising  Per the latest report by the Bureau of Labor Statistics  BLS   the health care sector witnessed a surge in jobs by as much as 50 000 last month  Ambulatory health care services and hospitals added the greatest number of jobs across the industry Foreign Investment Breathe Life in U S  BiotechSilicon Valley and Cambridge  MA have primarily been the front runners in providing the largest growth of innovation in the biotechnology sector in the United States  This also reflects on the fact that the majority of foreign as well as domestic investors in the space target these areas  This has not only resulted in innovation but has also created newer jobs in the field and generated handsome dividends for investors Although North American investors account for about 99  of the funding in Silicon Valley and Cambridge  foreign funds  particularly from China  have risen steadily  Furthermore  a surge in the size of biopharma deals and investment rounds has not only resulted in successful IPOs but also M A exits  This trend is largely expected to continue through 2019 Venture Investment and IPOs to Propel Biotech in 2019There were about 76 health care IPOs in 2018  Coming to the average returns  health care IPOs posted an average return of 8 9  on total proceeds worth  9 1 billion  Meanwhile  Series A investments across the biopharma sector witnessed an increase of 56   led by oncology and platform firms  Analysts expect venture money pouring into health care to reach to about  8 billion in 2019 3 Best ChoicesWe have  thus  selected three biotechnology mutual funds carrying a Zacks Mutual Fund Rank  1  Strong Buy  that are poised to gain from such factors  Moreover  these funds have encouraging three and five year returns  Additionally  the minimum initial investment is within  5000 We expect these funds to outperform their peers in the future  Remember  the goal of the Zacks Mutual Fund Rank is to guide investors to identify potential winners and losers  Unlike most of the fund rating systems  the Zacks Mutual Fund Rank is not just focused on past performance  but also on the likely future success of the fund The question here is  why should investors consider mutual funds  Reduced transaction costs and diversification of portfolio without several commission charges that are associated with stock purchases are primarily why one should be parking money in mutual funds  read more    Fidelity Select Biotechnology  invests the majority of its assets in common stocks of companies principally engaged in the research  development and distribution of various biotechnological products  Biotech firms including Regeneron Pharmaceuticals Inc  NASDAQ REGN    Alexion Pharmaceuticals  NASDAQ ALXN   Inc   Amgen Inc  NASDAQ AMGN   and Biogen Inc  NASDAQ BIIB   are some of the fund s major holdings This Zacks sector   Health product has a history of positive total returns for more than 10 years  To see how this fund performed compared in its category  and other 1 and 2 Ranked Mutual Funds   FBIOXhas an annual expense ratio of 0 73   which is below the category average of 1 28   The fund has five year annualized returns of 6  Schwab Health Care  seeks long term capital growth by primarily investing the majority of its assets in securities issued by companies in the health care space  Biotech companies including Amgen  Biogen and Gilead Sciences  NASDAQ GILD  are some of the fund s top holdings This Zacks sector   Health product has a history of positive total returns for more than 10 years  To see how this fund performed compared in its category  and other 1 and 2 Ranked Mutual Funds   SWHFXhas an annual expense ratio of 0 80   which is below the category average of 1 28   The fund has three and five year returns of 6 1  and 9 5   respectively Vanguard Specialized Portfolios Health Care Fund  seeks long term capital growth by investing in securities of companies that are engaged in production and distribution of products and services from the health care industry  The fund may invest about half of its assets in non U S  stocks  Biotech companies including Biogen and Bristol Myers Squibb Company  NYSE BMY  are two of the fund s top holdings This Zacks sector   Health product has a history of positive total returns for more than 10 years  To see how this fund performed compared in its category  and other 1 and 2 Ranked Mutual Funds   VGHCX has an annual expense ratio of 0 38   which is below the category average of 1 28   The fund has three and five year returns of 3 3  and 9 8   respectively Want key mutual fund info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ,2019-01-17,Zacks Investment Research,https://www.investing.com/analysis/3-biotech-mutual-funds-2019-200377187,200377187
129088,350603,BIIB,Top Stock Reports For Pfizer  Biogen   Schwab ,opinion,"Friday  January 18  2018
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Pfizer  PFE   Biogen  BIIB  and Schwab  SCHW   These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
Pfizer s shares have outperformed its peer group in the past one year   the stock is up  14 8  over this period vs  a  0 5  decline for the Zacks Large Cap Pharmaceuticals industry   Pfizer is facing top line headwinds like genericization of key drugs  supply challenges in the legacy Hospira portfolio  pricing pressure and rising competition  
However  the Zacks analyst thinks products like Ibrance  cost cutting efforts  a lower tax rate and share buybacks can support bottom line growth  Pfizer also boasts a strong pipeline and looks well positioned to deliver several potential new breakthrough innovative medicines in the next five years  which can drive long term growth  Bavencio  though approved for two small indications currently  is being considered a key long term growth driver for Pfizer if it can gain label expansion approvals  
Pfizer gained FDA approval for four new cancer drugs in 2018  which can boost oncology sales  Estimates have gone down slightly ahead of Q4 earnings release  Pfizer has a positive record of earnings surprises in recent quarters 
 You can   
Shares of Biogen have outperformed the Zacks Biomedical and Genetics industry in the past one year   1 8  vs   19 8    Biogen has a strong position in the MS market with a wide range of products  
The Zacks analyst likes its efforts to diversify beyond MS to other areas like Alzheimer s  Parkinson s and stroke  Spinraza is performing strongly and has multi billion dollar potential  Biogen s efforts to regularly in license assets to build its pipeline are encouraging since several of them have transformative potential  Multiple data readouts are expected in 2019  
However  the launch of Ocrevus by Roche is having a negative impact on MS franchise sales in the United States  Also  potential competition to Spinraza from competitors  gene therapy programs for SMA is a concern  
Though Biogen s CNS pipeline is attractive  it is a high risk area  However  estimates have gone up slightly ahead of Q4 earnings results  The company has a positive record of earnings surprises in recent quarters 
 You can   
Schwab s shares have outperformed the Zacks Investment Brokers industry over the past three months  gaining  0 1  vs  6 2   The Zacks analyst emphasizes that the company has an impressive earnings surprise history  having surpassed expectations in each of the trailing four quarters  Its fourth quarter 2018 results were driven by a rise in interest income and trading revenues  
The company remains well positioned to gain from the rising rate environment and its initiatives to strengthen trading income  Further  its steady capital deployment actions reflect a strong balance sheet position  However  continuously rising operating expenses remain a major concern and hurt bottom line growth to some extent  Also  the company s significant dependence on fee based revenue streams is cause for apprehension 
 You can   
Other noteworthy reports we are featuring today include CSX Corporation  NASDAQ CSX   Sysco  SYY  and Philips  PHG  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look   

Mark Vickery
Senior Editor
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 

Today s Must Read
Pfizer  PFE  Boasts Solid Pipeline of Potential Blockbusters


Biogen  BIIB  Rides on Spinraza and In Licensing Agreements


Trading Focus  Higher Rates Aid Schwab  SCHW   Costs a Woe


Featured Reports
Sturdy U S  Business Drives Sysco  SYY   Cost Woes Linger
Per the Zacks analyst  Sysco s U S  Broadline operations have been gaining from rising local case volumes for 18 straight quarters 

Increasing Revenues Aid Growth at Discover Financial  DFS 
Per the Zacks analyst  the company s strong Direct Banking business and soaring card sales volume have driven the company revenues thus leading to overall growth 

SBA Communications  NASDAQ SBAC  Defies Merger Trends for Expansion
Per the Zacks analyst  SBA Communications aims to expand in select international markets with high growth characteristics despite industry consolidation and proliferation of satellite based services 

Ulta Beauty s  ULTA  E Commerce Business to Boost Sales
Per the Zacks analyst  Ulta Beauty is witnessing solid e commerce sales growth  which is aiding the company s results 

MGM Resorts  MGM  Banks on Improving Las Vegas Tourism 
Per the Zacks analyst  strong portfolio  focus on non gaming actions  with improving economy and tourism in Las Vegas should drive growth 

Cooper Companies  COO  Rides on Core CVI Amid Competition
The Zacks analyst is apprehensive about intense competition in the MedTech space 

Program Wins  Robust Healthcare Sector Aids Plexus  PLXS 
According to the Zacks analyst  new program wins coupled with strong demand for Plexus  services in the healthcare end market aids growth 

New Upgrades
Development Programs  Strong Financials Aid Edison  EIX 
Per the Zacks analyst  focus on transmission related infrastructure development will help Edison boost its top line  It boasts a solid financial position backed by strong cash generation capacity 

Volume Growth   Favorable Pricing Buoy CSX Corporation  CSX 
The Zacks analyst likes the overall volume growth which is aiding the company s top line  Pricing strength and improvement in operating ratio are further positives 

Yum  Brands   NYSE YUM  Rides on Digital Innovation   Franchising 
The Zacks analyst expects Yum  Brands  digital initiatives to drive growth  Further  by refranchising  the company is facilitating EPS growth and greater return on equity 

New Downgrades
Concerns over Tariff  Personal Healthcare Hurt Philips  PHG 
Per the Zacks analyst  tariff related concerns due to U S  China trade war along with sluggishness in Personal Healthcare business do not bode well for the company 

Higher Costs  Risky Loans Hurt Hancock Whitney  HWC  Growth
Per the Zacks analyst  as Hancock Whitney has been expanding inorganically and hiring additional employees  costs are expected to remain elevated  Exposure to risky loan portfolios is a concern 

High Input Costs  Low Tow Volumes Ail Eastman Chemical  EMN 
Per the Zacks analyst  Eastman Chemical faces headwinds from raw material cost inflation  Lower acetate tow sales volumes and prices are also hurting sales and margins of its fiber business ",2019-01-18,Zacks Investment Research,https://www.investing.com/analysis/top-stock-reports-for-pfizer-biogen--schwab-200377285,200377285
129090,350605,BIIB,Biogen slashes 2015 forecast as MS drug sales disappoint,news," Reuters    Sales of Biogen Inc s  O BIIB  roster of multiple sclerosis drugs failed to meet analysts  expectation  prompting the company to slash its full year profit and sales forecast  The company s shares fell 8 6 percent to  352 in trading before the bell on Friday  Sales of Biogen s flagship oral multiple sclerosis  MS  drug  Tecfidera  came in below expectations for the second quarter in a row  hurt by higher discounting  saturation in the U S  market and reports of serious brain infections linked to the drug  Tecfidera s sales were  833 million in the second quarter ended June 30  well below Wall Street s estimate of about  933 million  according to Evercore ISI  Sales of Biogen s injectable MS drug Tysabri came in at  463 million  also falling short of estimates of about  505 million  Biogen s interferon based MS drugs Avonex and its new longer lasting Plegridy raked in sales of  690 million  far below expectations of about  767 million  Overall  the U S  biotechnology company s sales rose less than expected  Revenue of  2 59 billion missed analysts  average estimate of  2 71 billion  according to Thomson Reuters I B E S  Net profit attributable to Biogen rose 30 percent to  927 3 million  or  3 93 per share  Excluding items  it earned  4 22 per share  
The Cambridge  Massachusetts based company slashed its full year sales growth forecast to 6 8 percent from 14 16 percent  It also chopped its adjusted profit forecast to  15 50  15 95 per share from  16 60  17 per share ",2015-07-24,Reuters,https://www.investing.com/news/stock-market-news/biogen-slashes-2015-forecast-as-ms-drug-sales-disappoint-352778,352778
129091,350606,BIIB,U S  stocks extend losing skid to four  in spite of surge from Amazon,news,"Investing com    U S  equities markets fell broadly on Friday closing lower for a fourth consecutive session  as lagging performances from stocks in the Basic Materials  Health Care and Energy industries weighed on the major indices 
The Dow Jones Industrial Average posted mild losses to remain in negative territory for the year  while the NASDAQ Composite index and the S P 500 Composite index each fell by more than 1  to extend prior losses on the week  The Dow lost 163 39 or 0 92  to close at 17 568 39  while the NASDAQ dropped 57 78 or 1 12  to end the week at 5 088 63 
The S P 500 fell 22 50 or 1 07   as all 10 sectors closed in the red  Stocks in the Health Care  Basic Materials and Energy industries lagged  each falling more than 2  on the session  
Amazon com Inc  NASDAQ AMZN  shares skyrocketed as much as 20 4  to an all time high of  580 57 after attaining unexpected profits when its quarterly earnings were released on Thursday after the bell  Amazon  which ended the session as the top performer on the NASDAQ and the S P 500  fell back slightly to close at 529 42  up 47 24 or 9 80  
The top performer on the Dow was  Visa Inc   NYSE V   which rose more than 4 2  to 74 80 after reporting stronger than expected earnings on Thursday after the close  The worst performer was DD  which fell 1 54 or 2 63  to 56 94 
On the NASDAQ  Amazon finished just ahead of  Vodafone  Group  LONDON VOD  PLC  NASDAQ VOD  which gained 0 72 or 1 99  to 36 91  The worst performer was Biogen Inc  NASDAQ BIIB   which plunged to a seven month low after slashing sales expectations fo its Multiple Sclerosis drug Tecfidera amid slowing demand  Shares in Biogen fell more than 22  to close on Friday at 300 03 
On the S P 500  New Jersey based medical equipment manufacturer BCR jumped more than 4  to 187 75 after beating analysts  forecasts with its second quarter earnings  C R Bard finished just below Amazon as the top performer of the session  Biogen also finished as the worst performer on the S P 500  just above travel website TRIP  which plummeted 12 51 or 13 40  to 80 86  Earlier this week  Trip Advisor s reported quarterly earnings below analysts  expectations amid soaring costs during the period 
On the New York Stock Exchange  declining issues outnumbered advancing ones by a 2 299 to 858 margin ",2015-07-24,Investing.com,"https://www.investing.com/news/commodities-news/u.s.-stocks-extend-losing-skid-to-four,-in-spite-of-surge-from-amazon-352871",352871
129092,350607,BIIB,U S  biotech bloodbath hits hedge funds but some bargains emerge,news,"By Sinead Carew  Reuters    A seven day selloff of U S  biotechnology stocks has hit sector investors   especially hedge funds   hard  But some managers say it was overdone and are already eyeing bargains such as  Gilead Sciences Inc   O GILD  and  Amgen Inc   O AMGN    The Nasdaq Biotechnology index  NBI  has fallen 18 7 percent over the last seven sessions as investors took flight after Hillary Clinton  front runner to be the Democratic nominee in next year s U S  presidential election  vowed on Sept  21 to take steps to curb high drug prices  Since its July 20 high  the index has fallen around 27 percent  The selloff was exacerbated by general market volatility as investors have been grappling with uncertainty about when policy makers will raise U S  interest rates and concerns over the global economy  Biotech stocks  which had risen 31 percent this year to their July high after annual increases for the last six years  were also in sellers  sights because they had become richly valued  And the selling was intensified as investment managers did not want to issue third quarter reports showing big holdings in a beaten down sector   What you re seeing is that generalist money is getting very worried and thinking that maybe the healthcare trade is over and they re rotating into something else   said John Fraunces  co portfolio manager of the  137 million Turner Medical Sciences Long Short fund in Berwyn  Pennsylvania   Health focused hedge funds including Baker Brothers Advisors  Healthcor Management  Palo Alto Investors  and Deerfield Management are each nursing losses of more than 10 percent for September based on their publicly disclosed portfolio at the end of June  data calculated by industry tracking firm Symmetric IO show  Symetric data points to broad holdings of specialty biopharmaceutical company  Horizon Pharma   O HZNP   which has tumbled 47 3 percent in the last 7 days and which was listed in six hedge fund portfolios  The stock was a big holding for Deerfield  which manages  7 5 billion  for Healthcor  which oversees  2 6 billion  and for Broadfin Capital  which has held the stock for nearly two years  Horizon Pharma s losses also weighed on Iguana Healthcare Management      At the same time  a sharp drop in pharmaceutical company Valeant  N VRX   TO VRX  weighed on a number of hedge funds  including prominent activists Pershing Square Capital Management and Jana Partners  A lot of selling took place in healthcare ETFs such as the iShares Nasdaq Biotechnology EFT  O IBB   which fell almost 19 percent in the last seven days with an average daily trading volume that was 1 6 times higher than its 50 day average  NIBBLES AROUND THE EDGES  In the options market  most of the activity was still on the side of expecting further declines  with protective puts outweighing other biotech index trades  But some traders appear to have been snapping up call options in hopes for a sharp rebound  said Jim Smith  options strategist at OTR Global    People who are in the sector are looking for hedges and people who are not in it are looking for bargains   he said  Fraunces has been shorting the ETF  but now he and other investors are already eyeing bargains in the sector  He has been moving money to companies including Horizon Pharmaceuticals  one of the biggest casualties in the biotech sell off  Some big name stocks  such as Gilead  Amgen  Biogen Inc  O BIIB  and  Celgene Corp   O CELG  have sold off sharply enough to make their valuations attractive  according to several investors   Gilead s forward valuation of 8 1 is now less than half its 10 year median of 16 7 and its competitors  average valuations of 14 4  Amgen s forward P E is 12 5 compared with an average valuation of 16 for its peers  Meanwhile the S P 500 s forward P E was 15 4 on Tuesday  according to Thomson Reuters data    That s pretty unusual because the absolute growth rate for those companies is two to three times higher than the S P   said Sven Borho  founding general partner and fund manager at health science investment specialist Orbimed Advisors LLC  in New York  High valuations prompted Seattle based Smead Capital Management to cut biotech and pharma holdings in its  1 2 billion Smead Value Investor fund in the last 18 months to 16 5 percent from 29 percent  Tony Scherrer  director of research said  
But Scherrer  now interested in Amgen and Gilead  described the last week s ETF trading as  throwing out the baby with the bathwater  ",2015-09-29,Reuters,https://www.investing.com/news/stock-market-news/u.s.-biotech-bloodbath-hits-hedge-funds-but-some-bargains-emerge-363829,363829
129107,350622,BIIB,Roche s SMA Candidate Risdiplam Gets PRIME Designation In EU,opinion,"Roche Holding  SIX ROG  AG   OTC RHHBY   announced that the European Medicines Agency  EMA  has granted PRIME  PRIority MEdicines  designation to the company s investigational oral medicine risdiplam  RG7916  for the treatment of people with spinal muscular atrophy  SMA   The EMA grants PRIME status to drugs that have a major therapeutic advantage over existing treatments  or benefit patients without treatment options 
We note that Roche is developing risdiplam  an oral SMN2 splicing modifier  as part of a collaboration with the SMA Foundation and PTC Therapeutics   NASDAQ PTCT   
The designation is primarily based on results from Part 1 of the pivotal studies FIREFISH and SUNFISH  in children and adults with Type II and III SMA  
FIREFISH is an open label  two part pivotal clinical trial in infants with Type I SMA  Part 1 was a dose escalation study in 21 infants  while Part 2 is a pivotal  single arm study on risdiplam in approximately 40 infants with Type I SMA for 24 months  followed by an open label extension 
The primary objective of Part 1 was to assess the safety profile of risdiplam in infants and determine the dose for Part 2  The preliminary data from Part 1 of the FIREFISH study showed that infants with Type I SMA are meeting developmental milestones  including sitting without support 
Six out of 14 infants  43   were able to sit  with or without support   including three  21   who achieved unassisted stable sitting after eight months of treatment  Additionally  four infants  29   demonstrated rolling to the side along with seven  50   kicking and six  43   achieving upright head control 
SUNFISH is a two part  double blind  placebo controlled pivotal clinical trial in children and young adults  two to 25 years old  with Type II and III SMA  Part 1 determined the dose for the confirmatory Part 2  Roche completed enrollment in Part 2 in September 2018 
The preliminary data from Part 1 of the SUNFISH study showed improvements in motor function in patients with Type II III SMA  The follow up studies are ongoing for the confirmatory Part 2 portions of both the studies 
Roche is also conducting a third study  JEWELFISH  which is an open label exploratory trial in people aged 12 60 years with Type II or III SMA who have been previously treated with SMN targeting therapy as part of a clinical study 
The company also plans to initiate a new trial  RAINBOWFISH in pre symptomatic SMA  by early 2019 
Notably  Biogen s   NASDAQ BIIB   Spinraza is already approved to treat children and adults with SMA  which reflects the prevailing competition in the market 
Roche has a strong presence in the oncology market  In particular  the company dominates the breast cancer space with strong demand for its HER2 franchise drugs  which include Herceptin  Perjeta and Kadcyla 
The company is making efforts to develop its portfolio beyond oncology  into immunology and neuroscience  Approval of new drugs and diagnostics tests  and label expansion of existing drugs bode well for Roche  given its current challenges 
Year to date  shares of Roche have increased 1 6   compared with the  s growth of 8 4   Roche s legacy drugs like Herceptin and MabThera are facing competition from biosimilars  Novartis   NYSE NVS   has already launched its biosimilar version of Rituxan  MabThera in Europe  Amgen  NASDAQ AMGN  too has got its biosimilar of Avastin 

 Roche Holding AG Price

    
Zacks Rank 
Roche currently carries a Zacks Rank  2  Buy   You can see  
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-12-17,Zacks Investment Research,https://www.investing.com/analysis/roches-sma-candidate-risdiplam-gets-prime-designation-in-eu-200368911,200368911
129110,350625,BIIB,Exclusive  Biogen shortens name  expands ambitions in Alzheimer s  ALS,news,"By Bill Berkrot NEW YORK  Reuters     Biogen Idec Inc   NASDAQ BIIB  has seen its market value quadruple in three years to more than  100 billion on the back of its successful multiple sclerosis drugs  Now it has new ambitions in its sights  The Massachusetts based company  which made headlines last week when it announced better than expected clinical trial results for its experimental Alzheimer s drug  aducanumab  said that it will drop Idec from its name as of Monday and adopt a new logo  The company merged with Idec Pharmaceuticals more than a decade ago  Chief Executive George Scangos says that going forward he will keep Biogen focused on developing drugs for some of the hardest to treat diseases    Five years down the road  with some luck  we ll have an Alzheimer s drug that s getting approved   Scangos told Reuters   I hope we can transform the treatment of MS  By that time  we will have made substantial progress on ALS and other nerve degenerative diseases  spinal muscular atrophy in kids  All that stuff is on our plate   he said   I am sure of two things   he added   Not all of it is going to work  and some of it will   Investors  excited by the aducanumab news  sent Biogen shares up 9 7 percent on Friday  and the company s stock touched an all time high of  480 18 during the session  The small trial showed the treatment significantly slowed cognitive impairment in patients with mild symptoms  a rare bit of good news in a field littered with high profile failures from the likes of  Pfizer  Inc  NYSE PFE  and Eli Lilly and Co But some patients  especially those with a gene predisposing them to Alzheimer s  developed localized brain swelling  The symptom was most common among patients with the gene who were receiving the highest doses of aducanumab  leading about 1 3 of the participants in that category to discontinue the treatment  The company said the swelling was generally  asymptomatic or with mild  transient symptoms   Biogen plans to begin a larger trial later this year   If they can replicate the Alzheimer s data in Phase III  they could conceivably have the biggest drug on the planet   JMP Securities analyst Michael King said  As many as 75 million people are expected to develop the disease by 2030  For Biogen  which is also working on Alzheimer s drugs that use other mechanisms of action  research on dementia drugs represents an expansion of the company s potential reach    If the Alzheimer s thing works  then we re not just an MS company  We are broadly focused on neuro degenerative diseases   Scangos said  The company is also developing a drug it hopes will address not just symptoms but the cause of MS  potentially changing the way the disease is treated   The future looks pretty exciting for us   said Scangos  who became Biogen CEO in July 2010 following a period of upheaval in which activist investor Carl Icahn pushed for management changes and the sale of the company  Scangos  who previously led the tiny biotech firm Exelixis Inc  was recommended for the CEO post by Icahn lieutenants on the Biogen board  BIGGER MOVE INTO BIOSIMILARS As it works on new medicines for unmet needs  Biogen is also planning a bigger move into the fledgling field of biosimilars  manufacturing cheaper versions of older biotech drugs as they lose patent protection  Health regulators this month approved the first such drug for the U S  market  a biosimilar version of  Amgen Inc   NASDAQ AMGN  s white blood cell booster Neupogen  Biogen previously disclosed plans to develop six biosimilar drugs in collaboration with Samsung  LONDON 0593xq    We will expand that to include more   Scangos said  It has filed for European approval of biosimilars of two blockbuster rheumatoid arthritis drugs  Amgen s Enbrel and Johnson   Johnson  NYSE JNJ  s Remicade  Scangos shrugged off the potential impact to Biogen of biosimilars that replicate its own products  even though such competition could result in far cheaper alternatives to its drugs   I view biosimilars as a good thing   he said   When they come for our drugs  they come    Biogen s ambitions are not without risk  The company saw a  spectacular failure   as Scangos put it  with a large trial of an ALS drug a few years ago  highlighting the challenge ahead  
 There was no effect at all   Scangos said   We ve gone back to the drawing board  ",2015-03-23,Reuters,"https://www.investing.com/news/stock-market-news/exclusive:-biogen-shortens-name,-expands-ambitions-in-alzheimer's,-als-333649",333649
129111,350626,BIIB,AbbVie  ABBV  Seeks Approval For RA Candidate Upadacitinib,opinion,"AbbVie Inc    NYSE ABBV   announced that it has filed a new drug application   NDA   to the FDA and a marketing authorization application   MAA   to the European Medicines Agency   EMA   for its oral investigational JAK inhibitor  upadacitinib  The company is seeking approval of upadacitinib for the treatment of adult patients with moderate to severe rheumatoid arthritis   RA   
The regulatory submissions were based on encouraging data from the phase III SELECT study  which evaluated more than 4000 patients across five phase III studies on RA  In all the studies  upadacitinib met all primary and secondary endpoints 
Data from the SELECT study showed that treatment with upadacitinib  both as a monotherapy and in combination with conventional synthetic DMARDs  led to improved symptoms of RA  better physical function and inhibited radiographic progression 
Shares of AbbVie were up 2 2   following the announcement of the news of Thursday  However  the stock has plunged 11 7  year to date  against the  increase of 1 6  

Approval and successful commercialization of upadacitinib are critical for long term growth at AbbVie  especially as biosimilar competition looms for its blockbuster RA drug  Humira 
Humira accounts for around 65  of AbbVie s revenues  The drug generated sales of  15 billion in the first nine months of 2018  an increase of 10 9  year over year  However  biosimilar competition for the drug could hurt sales for the company 
Though biosimilar versions of Humira are already approved by the FDA  per settlements with several companies biosimilar entry in the United States is scheduled for 2023  However  in the EU  Amgen   NASDAQ AMGN    Biogen   NASDAQ BIIB   and Sandoz s biosimilars were launched in October this year  while others like Momenta  Pfizer   NYSE PFE   and Fresenius Kabi will launch their versions as soon as they get EMA s approval 
Notably  other than rheumatoid arthritis  upadacitinib is also being evaluated in a mid stage study for giant cell arteritis  and late stage studies for Crohn s disease  psoriatic arthritis  ulcerative colitis and atopic dermatitis 
Zacks Rank
AbbVie currently carries a Zacks Rank  3  Hold   You can see 
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-12-21,Zacks Investment Research,https://www.investing.com/analysis/abbvie-abbv-seeks-approval-for-ra-candidate-upadacitinib-200370351,200370351
129112,350627,BIIB,Wall Street down for second straight day  energy weak,news,"By Chuck Mikolajczak NEW YORK  Reuters    U S  stocks fell for a second straight session on Tuesday  with equities maintaining a tight range that corresponded with currency fluctuations as traders focused on the dollar s strength and its possible effect on corporate earnings  Data from home sales to inflation and manufacturing indicated the U S  economy remains strong  but failed to alter expectations of a faster or steeper monetary policy tightening path at the Federal Reserve  Traders have honed in on how the Fed will react to economic data  as a June interest rate increase remains a possibility  Stocks have been inversely correlated to the U S  dollar and several multinational companies have given earnings forecasts that cited a negative impact from a strong greenback   I don t think there is a tremendous amount of trepidation about earnings season  We will clearly see the impact of lower energy prices as well as the stronger dollar   said David Lefkowitz  Senior Equity Strategist at UBS in New York    Those two factors are fairly well known  so I don t expect it is going to be much in the way of a surprise for most companies when they do report earnings  but clearly those temporary factors are going to weigh on the growth for the first quarter    The S P energy index  lost 0 8 percent as Brent crude  settled down 1 5 percent at  55 11 a barrel after the dollar gained ground against the euro   The dollar index  DXY  zigzagged between gains and losses against a basket of major currencies and was up 0 14 percent on the day   The Dow Jones industrial average  DJI  fell 104 9 points  or 0 58 percent  to 18 011 14  the S P 500  SPX  lost 12 92 points  or 0 61 percent  to 2 091 5 and the Nasdaq Composite  IXIC  dropped 16 25 points  or 0 32 percent  to 4 994 73  Declines on the Nasdaq were tempered by a boost from Google  O GOOGL   up 2 2 percent to  577 54   Morgan Stanley  s  N MS  chief financial officer is leaving the bank to join Google   Biotechs were down for a second straight session  pulled lower by a 2 4 percent drop in Biogen  O BIIB  to  452 71  The Nasdaq biotech index  NBI  is down 2 9 percent in the past two sessions after snapping an eight day winning streak    Whiting Petroleum Corp   N WLL  plunged 19 5 percent to  30 91  North Dakota s largest oil producer announced an offering of 35 million shares and a  1 75 billion mix of notes and convertible notes to help cut its near  6 billion debt load  Volume was light  with about 5 29 billion shares traded on U S  exchanges  below the 6 8 billion average so far this month  according to BATS Global Markets   Declining issues outnumbered advancing ones on the NYSE by 1 708 to 1 317  for a 1 30 to 1 ratio  on the Nasdaq  1 415 issues fell and 1 284 advanced  for a 1 10 to 1 ratio favoring decliners  
The S P 500 posted 22 new 52 week highs and 1 new low  the Nasdaq Composite recorded 104 new highs and 22 new lows ",2015-03-24,Reuters,https://www.investing.com/news/stock-market-news/stock-futures-tick-up-ahead-of-data-333881,333881
129113,350628,BIIB,Biogen quarter one results disappoint Wall Street as Tecfidera sales slow,news," Reuters    Biogen  NASDAQ BIIB  Inc posted lower then expected quarterly profit and revenue as its key oral multiple sclerosis  MS  drug Tecfidera showed signs of slowing growth  sending the company s shares down 3 percent in premarket trading on Friday  The drug s sales have shown little sign of slowing after falling short of analysts  estimates for the first time in the third quarter of 2014  Sales of Tecfidera beat the average analyst estimate by about  36 million last quarter  Tecfidera raked in sales of  824 9 million in the first quarter ended March 31  compared with  506 million a year earlier  but missed consensus projections of about  931 million  according to  Deutsche Bank   XETRA DBKGn   Sales of the drug fell 10 percent compared with the fourth quarter of 2014  the company said  We saw moderating patient growth of Tecfidera in the United States and Germany  Chief Executive George Scangos said in a statement  Net income attributable to Biogen rose to  822 5 million  or  3 49 per share in the first quarter  from  480 million  or  2 02 per share  a year earlier  Excluding items  the company earned  3 82 per share  well below the average analyst estimate  3 91 per share  according to Thomson Reuters I B E S  Revenue rose about 20 percent to  2 55 billion  missing Wall Street s projections of  2 66 billion  
The Cambridge  Massachusetts based company s stock was down about 3 percent at  416 55 before the bell ",2015-04-24,Reuters,https://www.investing.com/news/stock-market-news/biogen-first-quarter-profit-jumps-71-percent-as-ms-drug-tecfidera-shines-338754,338754
129129,350644,BIIB,Energy shares lead Wall Street higher  telecoms slip,news,"By Rodrigo Campos  NEW YORK  Reuters    U S  stocks rose on Tuesday as energy stocks led the S P 500 and Dow  while Biogen s rally on news about an experimental treatment for Alzheimer s disease topped gains at the Nasdaq   The day s gains were broad  with nine of the 10 S P 500 industry sectors higher  The only group to fall was telecoms   down 1 8 percent with AT T  N T  down 2 2 percent at  34 29 and Verizon  N VZ  down 1 8 percent at  49 11  Sprint announced it will cut in half the monthly price of service for Verizon and AT T customers who switch to Sprint   Energy shares on the S P 500  rose 1 3 percent even as crude oil prices resumed their fall  U S  crude  fell 2 4 percent to near a five year low while Brent  lost 2 3 percent   Exxon Mobil  N XOM  and Chevron  N CVX  were among the largest gainers on both the Dow and the S P  up about 2 percent each    The market is sniffing out a bottom in the underlying commodity and we are seeing a bounce in energy stocks from having been oversold in the last month or so   said John Manley  chief equity strategist at Wells Fargo Funds Management in New York    It s in no one s interest for oil to go any lower  not in ours  or OPEC s   he said  adding that it is still a big benefit for consumers but the marginal gain with even lower gas would not be much bigger   The Dow Jones industrial average  DJI  rose 102 75 points  or 0 58 percent  to 17 879 55  a record high  The S P 500  SPX  gained 13 11 points  or 0 64 percent  to 2 066 55 and the Nasdaq Composite  IXIC  added 28 46 points  or 0 6 percent  to 4 755 81   Carmaker shares advanced as the top six automakers sold more cars and trucks in November than analysts expected  GM  N GM  gained 1 percent to  33 26 and Fiat Chrysler  N FCAU  gained 3 percent to  13 09   Biogen Idec  O BIIB  advanced 6 4 percent to  328 27  The company is planning a late stage trial of its experimental treatment for Alzheimer s disease after the drug significantly improved cognition in a small early stage study   Avanir Pharmaceuticals  O AVNR  was among the most traded stocks on the Nasdaq  rising 12 8 percent to  16 92  Japanese drugmaker Otsuka Holdings  4578 T  plans to buy it for about  3 5 billion   About two issues advanced for every decliner on both the NYSE and Nasdaq   The S P 500 posted 89 new 52 week highs and 5 new lows  the Nasdaq Composite set 102 new highs and 95 new lows   
About 6 6 billion shares changed hands on U S  exchanges  according to BATS Global Markets data  above the daily average last month of about 6 17 billion     Reporting by Rodrigo Campos  Editing by Nick Zieminski ",2014-12-02,Reuters,"https://www.investing.com/news/stock-market-news/stock-futures-slightly-higher-after-decline,-oil-down-again-318740",318740
129130,350645,BIIB,Dow ends above 18 000 for first time on strong GDP report,news,"By Ryan Vlastelica  NEW YORK  Reuters    U S  stocks rose on Tuesday  with the Dow closing above 18 000 for the first time ever and the S P 500 ending at a record after an unexpectedly strong report on economic growth   The Nasdaq ended modestly lower  pressured by the biggest selloff in biotech names in many months  while trading was light ahead of the Christmas holiday  Markets will close early on Wednesday and will be closed all of Thursday   Both the Dow and S P 500 hit intraday records in their fifth straight day of gains  The Dow rose as high as 18 069 22 and is up about 175 percent from a 12 year closing low hit on March 9  2009  The S P s record close was its 51st such record this year   The final estimate for third quarter U S  economic growth was revised up to a 5 percent annual pace  its quickest in 11 years and easily topping expectations for growth of 4 3 percent    Everyone is surprised  and I m definitely pleased   said Wayne Kaufman  chief market analyst at Phoenix Financial Services in New York   But the question is  how can inflation be so low when GDP is so high  Either this is just a one off and GDP will fall back dramatically  or we ll see a pickup in inflation  which could put more pressure on the Fed    The report spurred a broad rally  with nine of the ten primary S P 500 sectors higher on the day  The only group to fall was healthcare   down 2 2 percent alongside a massive drop in biotech stocks   The Nasdaq biotech index  NBI  fell 4 6 percent  its biggest one day decline since April 10  Components of the index made up the top six percentage decliners on the S P Celgene Corp  O CELG  fell 6 5 percent to  106 12 while Biogen  O BIIB  lost 4 7 percent to  335 76  Regeneron Pharmaceuticals  O REGN  fell 4 6 percent to  394 05   Gilead Pharmaceuticals  O GILD  fell 3 7 percent to  89 45  extending Monday s drop of 14 percent  which came after Express Scripts  O ESRX  said it would abandon covering Gilead s hepatitis C treatment in favor of a cheaper option    This is just a knee jerk reaction  based on a bear thesis that Express Scripts will start to dictate prices   said Kaufman   I don t see how this is any different than any other company in another sector getting more competition  Soon people will go through the stocks one by one to see which got oversold    The Dow Jones industrial average  DJI  rose 64 67 points  or 0 36 percent  to 18 024 11  the S P 500  SPX  gained 3 64 points  or 0 18 percent  to 2 082 18 and the Nasdaq Composite  IXIC  dropped 16 00 points  or 0 33 percent  to 4 765 42   Advancing issues outnumbered declining ones on the NYSE by 1 990 to 1 090  for a 1 83 to 1 ratio on the upside  on the Nasdaq  1 399 issues rose and 1 353 fell for a 1 03 to 1 ratio favoring advancers   The benchmark S P 500 index was posting 124 new 52 week highs and 5 new lows  the Nasdaq Composite was recording 182 new highs and 53 new lows   
About 5 41 billion shares traded on all U S  platforms  according to BATS exchange data  compared with the month to date average of 7 78 billion     Editing by Meredith Mazzilli ",2014-12-23,Reuters,https://www.investing.com/news/stock-market-news/futures-little-changed-after-latest-record;-data-on-tap-321295,321295
129131,350646,BIIB,Alkermes  ALKS  Down 14 2  Since Last Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Alkermes  ALKS   Shares have lost about 14 2  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Alkermes due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Alkermes Exceeds Q3 Earnings Estimates  Raises OutlookAlkermes reported adjusted earnings of 7 cents per share in the third quarter of 2018  while the Zacks Consensus Estimate was a loss of 6 cents  The bottom line also exceeded the adjusted earnings of 3 cents recorded in the year ago quarter The company s revenues of  248 7 million in the quarter were up 14  year over year  The top line beat the Zacks Consensus Estimate of  236 million The results were driven by strong growth of the company s proprietary products  Vivitrol and Aristada  Net sales for Vivitrol and Aristada were  116 0 million in the quarter  reflecting a 24  increase from the year ago quarter  Revenues RiseManufacturing and royalty revenues from Risperdal Consta  Invega Sustenna  Xeplion and Invega Trinza Trevicta were  77 2 million  down 2 8  year over year  The same from Ampyra Fampyra were down 17 1  year over year to  20 3 million  Research and development revenues were  16 3 million  of which  15 7 million was related to the collaboration with Biogen Inc  NASDAQ BIIB   for BIIB098 Vivitrol sales improved 15  year over year to  79 9 million Aristada sales came in at  36 1 million  up 48  year over year  During the quarter  the company launched Aristada Initio  the newest addition to the Aristada product family  and the early trends of the products showed encouraging results Costs RiseResearch and Development  R D  expenses were  101 3 million  down 3  year over year Selling  General and Administrative  SG A  expenses were  128 8 million  up 29 3  year over year 2018 OutlookThe company expects total revenues to be  1 015  1 045 billion  above its previous expectation of  975 million to  1 025 billion  This increase was driven by Ampyra  following the delayed generic competition in 2018   The Zacks Consensus Estimate for 2018 is  1 01 billionThe company continues to expect Vivitrol sales to be  300  330 million  while Aristada sales are anticipated to be  140  160 million  The company reaffirmed its R D expenses to be  415  445 million  Alkermes reiterated its guidance for SG A expenses of  515  545 million For 2018  the company expects earnings per share to be 12 31 cents compared with the previous expectation of loss per share of 6 12 cents  The Zacks Consensus Estimate for 2018 is earnings of 9 cents per share Pipeline UpdateDuring the quarter  the company initiated clinical evaluation of ALKS 4230 in combination with Merck s PD 1 inhibitor  Keytruda  pembrolizumab  On Nov 1  2018  there will be a joint meeting of the Psychopharmacologic Drugs Advisory Committee  and the Drug Safety and Risk Management Advisory Committee to review the new drug application  NDA  for ALKS 5461  being evaluated for adjunctive treatment of major depressive disorder  An action date of Jan 31  2019 has been set for the same The company also expects to release top line data from ALKS 3831 s ENLIGHTEN 2 pivotal study in schizophrenia  in the fourth quarter of 2018 The company is on track to submit the NDA for BIIB098 for multiple sclerosis by the end of 2018  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates  The consensus estimate has shifted  14 47  due to these changes 
VGM Scores
At this time  Alkermes has a great Growth Score of A  a grade with the same score on the momentum front  However  the stock was allocated a grade of F on the value side  putting it in the bottom 20  quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of these revisions looks promising  Notably  Alkermes has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-11-21,Zacks Investment Research,https://www.investing.com/analysis/alkermes-alks-down-142-since-last-earnings-report-can-it-rebound-200361785,200361785
129132,350647,BIIB,Why Is Biogen  BIIB  Up 4 5  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Biogen  BIIB   Shares have added about 4 5  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Biogen due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Biogen Tops Earnings   Sales in Q3Biogen reported third quarter 2018 earnings per share of  7 40  which beat the Zacks Consensus Estimate of  6 80  Earnings rose 17  year over year backed by higher revenues and a lower tax rate and share count Sales came in at  3 44 billion  up 12  from the year ago period  Moreover  sales beat the Zacks Consensus Estimate of  3 33 billion  Revenue growth was principally driven by higher sales of Spinraza and higher contribution from biosimilars and Ocrevus royalties  Higher other revenues benefiting from greater contract manufacturing revenues also pulled up total revenues in the quarter  Meanwhile  the MS franchise was stable from second quarter levels Quarter in DetailBiogen s multiple sclerosis  MS  revenues were  2 31 billion in the reporter quarter including approximately  137 million in royalties on the sales of Roche s MS drug  Ocrevus  MS revenues were flat year over year as well as sequentially The number of patients on Biogen s MS products globally was flat year over year In the fourth quarter  Biogen expects worldwide MS product revenues to be stable from the year ago period  benefitting from a moderate inventory channel build and as Ocrevus impact will become less significant on a year over year basis Tecfidera s sales rose 2  year over year to  1 09 billion  This included U S  sales of  842 1 million  up 0 7  year over year  and ex U S  sales of  247 9 million  up 6 3    However  Tecfidera sales were flat sequentially Tecfidera U S  revenues were relatively stable in the third quarter compared against the declines seen in the first and the second quarters  Meanwhile  the strong ex U S  performance was driven by patient growth across European markets  solid emerging market growth and particularly strong performance in Japan  which offset the impact of ongoing price decreases in certain European countries Tysabri s sales were flat year over year at  470 million  Tysabri U S  sales declined 5 2  to  253 0 million in the quarter hurt by Ocrevus launch  International revenues rose 7 2  to  217 2 million driven by patient growth in all major European markets  except Germany and strong double digit patient growth in emerging markets  Tysabri s sales rose 1  sequentially Combined interferon revenues  Avonex and Plegridy  in the third quarter were  590 million  down 11  year over year and 6  sequentially  Avonex revenues declined 10  from the year ago period to  482 million  Plegridy contributed  108 million to revenues  which decreased 13  year over year U S  Interferon revenues are experiencing declining trends due to patients transitioning to other oral or high efficacy MS therapies Zinbryta generated no revenues in the quarter as the drug was withdrawn from the market in March 2018 due to growing safety concerns and limited commercial adoption  The drug had contributed  14 million to total revenues in the year ago quarter Spinraza  spinal muscular atrophy  sales grew 73  year over year and 11  sequentially to  468 million driven by sales growth in both the United States and in the ex U S  markets Spinraza U S  sales were  223 9 million in the third quarter  up 8 7  sequentially driven by increased new patient demand among adults  In ex U S  markets  Spinraza sales rose 12 5  sequentially to  243 8 million driven by strong patient uptake  expansion into new regions and accelerated pace of reimbursement across multiple geographies Overall commercial patients on Spinraza rose approximately 20  in the quarter  The number of patients on Spinraza grew approximately 11  in the United States and 29  outside the United States in the quarter compared with the end of the second quarter In the United States  the number of adult patients on Spinraza rose more than 20  in the quarter compared to last quarter  with the company capturing the under penetrated adult segment  In the third quarter  more than 50  of the new patient starts in the United States comprised adults Management is optimistic that patient starts will grow in the United States as it continues to capture the adult segment  which represents approximately 60  of all SMA patients  It has till now penetrated only 15  of the adult segment and thus this segment represents a potential growth opportunity  In ex U S  markets  Spinraza s uptake will continue to be driven by continued patient growth  although at a more modest rate in more mature markets Biogen said that approximately 60  of U S  sales in the third quarter were from patients who received less intensive maintenance doses  dosing only once 4 months  versus 55  in the previous quarter In the third quarter of 2018  Biogen recorded biosimilar revenues of  135 million  up 33  year over year and 6  sequentially In the fourth quarter  Biogen expects relatively stable biosimilars revenue compared to the third quarter Revenues from Anti CD20 therapeutic programs  which include Biogen s share of Rituxan and Gazyva operating profits and Ocrevus royalties  increased almost 26  from the year ago period to  511 7 million Research and development  R D  spend increased 14  year over year to  508 million  Selling  general and administrative  SG A  spend was up 14  year over year to  495 million  However  both SG A and R D costs declined sequentially in the third quarter In the quarter  the board of directors authorized a share buyback program of up to  3 5 billion  The company also said that it is evaluating opportunities for potential business development and M A activity Pipeline SetbacksOn the third quarter conference call  management announced a few pipeline setbacks Regarding the company s gene therapy program for SMA  which is on clinical hold  Biogen said the FDA had raised questions on the company s preclinical data package and that it is assessing options to determine if there is a viable path forward for the gene therapy program in SMA Biogen also said that a phase IIb study evaluating vixotrigine  Nav1 7 inhibitor  in painful lumbosacral radiculopathy did not meet its primary or secondary efficacy endpoints  Accordingly  the company has discontinued development of the candidate in this challenging indication  The company has delayed the start of a phase III study on the candidate in trigeminal neuralgia as interactions are ongoing with the FDA regarding the design of the phase III study Fourth Quarter OutlookThe fourth quarter of 2018 will face difficult comparisons from the prior year quarter as the latter benefited from favorable timing of contract manufacturing Both R D and SG A expenses are expected to sequentially increase in the fourth quarter due to the timing of clinical trial expense and market expansion investments as well as seasonality 
How Have Estimates Been Moving Since Then 
It turns out  fresh estimates have trended upward during the past month 
VGM Scores
Currently  Biogen has a nice Growth Score of B  a grade with the same score on the momentum front  Following the exact same course  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending upward for the stock  and the magnitude of these revisions looks promising  Notably  Biogen has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-11-21,Zacks Investment Research,https://www.investing.com/analysis/why-is-biogen-biib-up-45-since-last-earnings-report-200361780,200361780
129133,350648,BIIB,Teva s Rituxan Biosimilar Gets FDA Nod In Non Hodgkin Lymphoma,opinion,"Teva Pharmaceutical Industries Ltd    NYSE TEVA   and its South Korean partner Celltrion announced that the FDA has approved their monoclonal antibody  mAb  biosimilar to Roche s   OTC RHHBY   blockbuster cancer drug  Rituxan  rituximab   The biosimilar will be available in the United States by the trade name of Truxima  CT P10 Rituxan is approved to treat Non Hodgkin s lymphoma   NHL    chronic lymphocytic leukemia  rheumatoid arthritis  Wegener s granulomatosis and microscopic polyangiitis  However  Teva s Truxima has received approval for only three NHL indications  Rituxan is marketed by Biogen   NASDAQ BIIB   and Genentech USA  a subsidiary of Roche Truxima is the first Rituxan biosimilar to get approval in the United States for the indications mentioned above Shares of Teva have increased 15 3  year to date against the  s decrease of 10 6   In October 2016  Teva entered into an exclusive biosimilar commercial partnership with Celltrion  gaining exclusive rights to commercialize two of Celltrion s mAbs biosimilar candidates   CT P10 and CT P6   in the United States and Canada CT P6 is a proposed mAb biosimilar to Roche s key breast cancer drug  Herceptin  trastuzumab   The candidate is under review in the United States Per the financial terms of the deal  once the mAb biosimilars are commercialized  Teva and Celltrion will share the profits  Rituxan has recorded sales of nearly  3 3 billion in the first nine months of 2018  which reflects significant market for its biosimilars  However  adoption of Truxima in NHL indication remains to be seen We remind investors that Novartis   NYSE NVS   has already launched its biosimilar version of Rituxan  MabThera in Europe  It has given a significant boost to the company s Biopharmaceuticals segment  However  Novartis received a complete response letter from the FDA in May 2018 for its regulatory application looking for approval of Rituxan biosimilar in the United States  Earlier this week  Teva announced the launch of the generic version of Mylan s allergy treatment  EpiPen in the United States Teva Pharmaceutical Industries Ltd  Price
    Zacks RankTeva currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-28,Zacks Investment Research,https://www.investing.com/analysis/tevas-rituxan-biosimilar-gets-fda-nod-in-nonhodgkin-lymphoma-200363645,200363645
129134,350649,BIIB,AbbVie Presents Long Term Data On Cancer Drugs At ASH 2018,opinion,"AbbVie Inc    NYSE ABBV   presented encouraging long term follow up data from two clinical studies evaluating Venclexta  venetoclax  combo therapy and Imbruvica  ibrutinib  monotherapy at the annual meeting of the American Society of Hematology   ASH   The phase III MURANO study evaluated Venclexta in combination with Roche   OTC RHHBY   Biogen s   NASDAQ BIIB   Rituxan  rituximab  compared to the current standard of care regimen  in relapsed refractory chronic lymphocytic leukemia  r r CLL    Teva Pharmaceutical s   NYSE TEVA   Treanda  bendamustine  plus Rituxan  Follow up data from the study showed that the Venclexta combination achieved superior results as 71 4  patients achieved progression free survival   PFS   at 36 months versus 15 2  of patients in the standard of care  At 24 months  84 9  and 36 3  patients achieved PFS for Venclexta combination and standard of care  respectively The patients were treated for a fixed duration of 24 months and treatment was stopped thereafter  The three year estimated overall survival rate was 87 9  for Venclexta combination and 79 5  for standard of care Please note that regulatory applications seeking approval for including MURANO study data on Venclexta s label were approved in the United States in June and in the EU in October  Label expansion for this indication has expanded the patient population for Venclexta significantly  which will boost its commercial potential Meanwhile  long term follow up data from the phase Ib II study  which evaluated Imbruvica in CLL small lymphocytic lymphoma   SLL   patients showed that the drug sustained PFS in 80  of previously untreated patients over seven years of treatment duration  It also showed that 32  of highly pre treated patients whose disease had relapsed maintained PFS  The analysis of the data demonstrated Imbruvica achieved better PFS rates in r r patients when treated in earlier line settings  especially after one or two prior lines of therapy The long term efficacy data for Imbruvica in CLL SLL patients may boost the adoption of the drug  thereby  driving its sales higher AbbVie s shares have lost 2 5  this year so far against the  s rally of 11 3  We remind investors that Venclexta is approved in combination with Rituxan for second or later line CLL SLL and in combination with a hypomethylating agent  azacitidine or decitabine  or low dose cytarabine for newly diagnosed acute myeloid leukemia in elderly patients Imbruvica is approved for several indications  which include mantle cell lymphoma  CLL SLL  Waldenstr m s macroglobulinemia  marginal zone lymphoma and chronic graft versus host disease While Imbruvica is a blockbuster drug  having recorded  2 9 billion in the first nine months of 2018  Venclexta generated  220 million in the same period  Both the drugs have shown strong growth this year on the back of label expansions in broader patient population  The company is committed to expand the label of the drugs further  evaluating them in several clinical studies AbbVie Inc  Price
    Zacks RankAbbVie currently has a Zacks Rank  3  Hold   You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-12-02,Zacks Investment Research,https://www.investing.com/analysis/abbvie-presents-longterm-data-on-cancer-drugs-at-ash-2018-200364457,200364457
129135,350650,BIIB,FDA Accepts BLA   Gives Priority Review To Novartis  AVXS 101,opinion,Novartis AG   NYSE NVS   announced that the FDA has accepted the company s Biologics License Application  BLA  for AVXS 101  now known as Zolgensma  onasemnogene abeparvovec xxxx  The FDA also granted a Priority Review to Zolgensma and regulatory action is expected in May 2019 Priority Review designation from the FDA is generally granted to drugs with potential to provide significant improvements in the safety and effectiveness of the treatment along with prevention or diagnosis of a serious disease Zolgensma  an investigational gene replacement therapy  is being developed for the treatment of spinal muscular atrophy  SMA   a neurodegenerative disease accounting for the highest genetic cause of death in infants The filing was supported by data from the START study  which demonstrated a dramatic increase in survival and transformative improvement in achieving developmental milestones compared to the natural history of SMA Type 1 Notably  both the FDA and the European Medicines Agency  EMA  have granted Zolgensmaan Orphan Drug designation for the treatment of SMA  The FDA has also granted Zolgensmaa fast track status for the treatment of SMA Type 1  The regulatory agency has also granted a Breakthrough Therapy designation to AVXS 101 for addressing SMA Type 1 in pediatric patients The company also secured PRIME and Sakigake designations for the candidate in Europe and Japan  respectively  In Europe  a decision on the Marketing Authorization Application  MAA  is expected in mid 2019 If approved  Zolgensmawould be the first ever one time gene replacement therapy for SMA in the United States We remind investors that Zolgensma was added to Novartis  portfolio when the company acquired U S  based clinical stage gene therapy company  AveXis  Inc  in April 2018 Significantly  an approved product for the cure of SMA in the United States is Biogen s   NASDAQ BIIB    Spinraza  nusinersen   the first and the only treatment to get an FDA nod in the country for this indication Other companies like Axovant Sciences   NASDAQ AXON   and uniQure N V    NASDAQ QURE   have been steadily developing their pipeline candidates using gene therapy The company s shares have gained 12 9  in the year so far  compared with the  s growth of 13 8  Further  Novartis also announced the initiation of phase III studies on ligelizumab  QGE031    a high affinity monoclonal anti IgE antibody   in chronic spontaneous urticaria  CSU  patients whose symptoms are inadequately controlled by H1 antihistamines  The phase III studies  PEARL1 and PEARL 2 are planned to include more than 2 000 CSU patients  The studies will establish efficacy and safety of ligelizumab in adolescent and adult patients aged 12 years or above with CSU who remain symptomatic despite the use of H1 antihistamines Results from the phase IIb study showed that ligelizumab met the primary endpoint by demonstrating a clear dose response relationship and improvements over Xolair  omalizumab  in CSU patients Novartis AG Price    Zacks RankNovartis carries a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-12-03,Zacks Investment Research,https://www.investing.com/analysis/fda-accepts-bla--gives-priority-review-to-novartis-avxs101-200364895,200364895
129136,350651,BIIB,Why Is Model N  MODN  Up 2 4  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Model N  MODN   Shares have added about 2 4  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Model N due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Model N s Q4 Results Benefit from Strengthening Revenue Cloud Platform   Expanding Customer BaseModel N  Inc  delivered fourth quarter fiscal 2018 non GAAP earnings of 6 cents per share comparing favorably with the year ago quarter s loss of 6 cents per share  The Zacks Consensus Estimate was pegged at a loss of 2 cents Revenues of  36 7 million increased 3 1  from the year ago quarter  outpacing the Zacks Consensus Estimate of  35 million  The figure also outpaced the guided range of  35 2  35 7 million Management noted that the company is making steady progress in its transformation to a 100  Software as a Service  SaaS  based model Quarter in DetailModel N has two reportable segments namely SaaS   Maintenance and License   Implementation SaaS   Maintenance revenues of almost  35 million grew 18 1  year over year  Model N is accelerating its transition of revenue management to cloud and is on track to shift business to a 100  SaaS and Maintenance revenue model License   Implementation revenues of  1 7 million declined 71 1  on a year over year basis  The company no longer sells on premise perpetual licenses  Management had anticipated the decline in fourth quarter due to backlog burn off and transition of customers to cloud Expanding Customer BaseModel N made significant efforts in its go to market strategy in order to improve growth  Management is optimistic about its Revenue Cloud offering for med tech  pharma and high tech companies The company is leaving no stone unturned to enable customers  transition to cloud from an on premise infrastructure  Management is elated on the rapid adoption witnessed among life sciences companies in particular  including Biogen  NASDAQ BIIB   Novo Nordisk  CO NOVOb   among others  which subscribed to Revenue Cloud Additionally  Model N s growth prospects in the life sciences   high technology are bright due to increasing redundancy of legacy systems  The company s solutions provide higher Return on Investment   ROI   as well as plug gaps in the end to end revenue management process that legacy systems fail to do The company has enhanced Revenue Cloud with Amazon  NASDAQ AMZN  Web Services  AWS  infrastructure as part of its cloud optimization initiative  This has enabled it to aid companies like Allegro Microsystems  Edwards Life Sciences  Ipsen and Shionogi  among others in their transition Management is also optimistic regarding Seagate s increased utilization of Revenue Cloud  Seagate recently subscribed to Model N s Channel Data Management solution Integra Life Sciences intends to deploy Revenue Cloud across its international business units  In this regard  the life sciences company added an acquired business entity to Revenue Cloud The growing clout of Model N s Global Price Management solution  Model N CPQ  Configure  Price and Quote   Model N Channel Cloud and Revenue Cloud for High Tech suites is notable The company s Revenue Management platform aimed at enhancing digital reinvention experience also bodes well Operating DetailsNon GAAP gross profit increased to  23 million from  22 7 million recorded in the year ago quarter  Non GAAP margin surged to 62 8   up from 61 3  reported in the year ago quarter  adjusted for deferred revenues  Adjusted EBITDA was  2 5 million compared with  1 million in the year ago quarter  Non GAAP income from operations was  2 million against year ago figure of  0 1 million Balance Sheet   Cash FlowModel N exited the quarter with cash and cash equivalent balance of  56 7 million compare with  57 6 million reported in the previous quarter  The company had total debt  long term plus current portion  of  53 7 million  as of Sep 30  2018 Net cash generated in operating activities came in at  2 5 million in fiscal 2018 compared with approximately  12 million used in fiscal 2017 Fiscal 2018 at a GlanceFor fiscal 2018  total revenues increased 17 8  year over year to  154 6 million  Year over year growth was primarily driven by a surge of 25 7  in SaaS and maintenance revenues which came in at  135 9 million  Recurring revenues came in at  98 3 million Non GAAP earnings for fiscal 2018 came in at  0 04 per share  compared with the   0 59  reported in fiscal 2017 GuidanceModel N will report financial results as per ASC 606 guidelines from first quarter fiscal 2019  The company expects fiscal first quarter 2019 GAAP revenues to come in the range of  34 million to  34 4 million  The company anticipates deferred revenues to be negatively impacted by roughly  8 million Non GAAP earnings  loss  are likely to be between  1 cent  and 1 cent per share for the first quarter  Adjusted EBITDA is anticipated to be in the range of  2 million to  2 4 million For fiscal 2019  Model N expects GAAP revenues to be in the range of  138  142 million Non GAAP earnings are expected to be in the range of 5 17 cents per share  Adjusted EBITDA is projected to be in the range of  8 5  12 5 million 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted 5 13  due to these changes 
VGM Scores
Currently  Model N has a strong Growth Score of A  though it is lagging a lot on the Momentum Score front with an F  Following the exact same course  the stock was allocated a grade of F on the value side  putting it in the bottom 20  quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision indicates a downward shift  Notably  Model N has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-12-05,Zacks Investment Research,https://www.investing.com/analysis/why-is-model-n-modn-up-24-since-last-earnings-report-200365679,200365679
129163,350678,BIIB,Dow Hits Record  Internet Names Advance,news,"By    Stocks rallied on Monday  with the Dow 30 hitting a record high and the S P 500 within striking distance of its own record  while shares of Internet and biotech shares jumped 
Internet and biotech names were among the strongest advancers of the day  Biogen Idec Inc  NASDAQ BIIB  gained 4 7 percent to  300 12 while TripAdvisor Inc  NASDAQ TRIP  shot up 6 4 percent to  90 02 
Both groups   often described as  momentum  stocks due to massive gains in recent months   have been wildly volatile in recent sessions  moving on concerns over valuation and hopes for high levels of growth 
The day s advance was broad  with S P cyclical sector indexes such as materials  SPLRCM  industrials  SPLRCI and consumer discretionary  SPLRCD all up more than 1 percent 
The rally came despite a vote by pro Russian rebels in favor of self rule in eastern regions of the country in a referendum dismissed by Kiev and Western governments as illegal  The European Union is set to step up pressure on Russia by taking steps to extend sanctions to companies  as well as individuals 
 The vote seemed like a negative  but the violence that many thought would happen didn t  and at this point  no news is good news when it comes to Ukraine   said Channing Smith  co portfolio manager of the Capital Advisors Growth Fund at Capital Advisors in Tulsa  Oklahoma 

The Dow Jones industrial average rose 113 43 points or 0 68 percent  to 16 696 77  the S P 500 gained 17 29 points or 0 92 percent  to 1 895 77 and the NASDAQ Composite added 70 61 points or 1 73 percent  to 4 142 482 
The Russel 2000 index of small cap stocks climbed 2 5 percent  Last week  it flirted with correction territory  dropping nearly 10 percent from its all time closing high 
Hillshire Brands Company  NYSE HSH  agreed to buy Pinnacle Foods Inc  NYSE PF  in a deal valued at about  6 6 billion  including debt  Pinnacle jumped 12 3 percent to  34 20 while Hillshire fell 4 9 percent to  35 14 ",2014-05-13,International Business Times,https://www.investing.com/news/stock-market-news/dow-hits-record;-internet-names-advance-283759,283759
129164,350679,BIIB,InterMune drug may offer big upside to Roche if aimed at liver,news,"By Ransdell Pierson and Bill Berkrot
 Reuters    Roche Holding AG s planned  8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug  but the smaller company s development pipeline may end up giving the Swiss drugmaker a far bigger bang for its buck 
Industry analysts have forecast annual sales of about  2 billion for the pulmonary fibrosis treatment  pirfenidone  once it gains U S  approval  giving Roche a valuable addition to its respiratory franchise 
But the company is expected next year to begin clinical trials of ten fold more potent next generation drugs that could also treat similar damage to the liver and kidneys as well as lungs 
Success there could be a game changer  given the unmet medical need to treat liver and kidney scarring that can be caused by factors such as obesity  diabetes and alcohol and drug abuse 
 Liver fibrosis is a huge  multibillion dollar market that s far bigger than the lung fibrosis market   said Katherine Xu  an analyst with William Blair   Co   It involves millions of patients in the United States  versus 100 000  
Pirfenidone  a pill with annual sales of about  150 million in Europe and Canada  treats a progressive scarring condition of the lungs called idiopathic pulmonary fibrosis that typically kills patients within a few years 
Roche announced its proposed  8 3 billion cash purchase of InterMune on Sunday 
The two companies have barely mentioned the liver potential of the newer formulations as they focus on unlocking the value of pirfenidone by winning U S  approval of the drug for lung fibrosis  The Food and Drug Administration awarded the medicine its  breakthrough  designation   a signal the agency sees it as a potentially important new therapy 
The FDA approval is expected this year following large trials that showed it prolonged patient lives  A rival drug from privately held Boehringer Ingelheim is also expected to gain U S  approval this year 
While the focus has been on the potential of pirfenidone to treat lung damage  Dr Talmadge King  chairman of the Department of Medicine at the University of California  San Francisco  said fibrosis is believed to occur in a similar way throughout the body  including the heart 
 If you can get the drug to the site and slow or prevent the process from occurring     it has the potential to have a positive effect in a number of organ systems  so I would assume that that s where it s going to head in time   said King  a lung specialist who led the large late stage trial of pirfenidone upon which InterMune based its U S  marketing application 
InterMune s research chief  Scott Seiwert  said animal studies suggest that the newer formulations of pirfenidone have  a much milder side effect profile  
InterMune has said trials of its potent next generation pirfenidone analogues could involve patients with lung  liver or kidney fibrosis  Seiwert declined to predict what the Roche strategy will be 
Many analysts have yet to delve into the InterMune pipeline s potential of treating liver and kidney fibrosis 
 It s not something we ve included in our valuation  of InterMune  said Morningstar analyst Karen Andersen  given the many failures of other drugs that have attempted to treat liver fibrosis  and InterMune s focus on preparing for the U S  launch of pirfenidone 
She noted that huge sales of new drugs for hepatitis C  especially Gilead Sciences Inc s Sovaldi   have drawn a lot more attention to liver related diseases  

Gilead and Biogen Idec Inc are developing injectable drugs against pulmonary fibrosis  with Gilead also testing its drug against liver fibrosis  But they are a few years away from seeking approval  and Andersen predicted InterMune will be the entrenched leader 
 Reporting by Ransdell Pierson and Bill Berkrot in New York  editing by Matthew Lewis ",2014-08-27,Reuters,https://www.investing.com/news/stock-market-news/intermune-drug-may-offer-big-upside-to-roche-if-aimed-at-liver-306048,306048
129165,350680,BIIB,Wall Street posts gains for fourth week  ends flat for day ,news,"By Caroline Valetkevitch  NEW YORK  Reuters    U S  stocks posted a fourth straight week of increases but ended Friday little changed as losses in healthcare shares offset gains in energy   Apple shares rose 1 2 percent to  114 18  another record high  The stock lifted the Nasdaq  which outperformed other indexes   Biotech stocks were among biggest decliners in the S P health care index  which fell 0 8 percent and was the biggest drag on the S P 500  Gilead fell 2 1 percent to  102 06  while Biogen Idec lost 3 9 percent to  305 43 and was the biggest percentage decliner on both the S P 500 and Nasdaq    The Nasdaq biotech index shed 2 percent  its biggest drop in about a month    Energy stocks rose 0 8 percent following a bounceback in oil prices   Also helping to limit the day s losses was a stronger than expected rise in October retail sales   The S P 500  which hasn t made a 1 percent move this month  is now up 10 4 percent for the year     Most portfolio managers are lagging the indices and there are going to be some aggressive efforts to make up for performance in the next six weeks  Those that are under invested are going to want to be more invested   said Michael James  managing director of equity trading at Wedbush Securities in Los Angeles     The market will either tread water or move higher from here to the end of the year  barring a huge drop in oil prices  he said   The Dow Jones industrial average fell 18 05 points  or 0 1 percent  to 17 634 74  the S P 500 gained 0 49 points  or 0 02 percent  to 2 039 82 and the Nasdaq Composite added 8 40 points  or 0 18 percent  to 4 688 54   For the week  the Dow and S P 500 rose 0 4 percent and the Nasdaq climbed 1 2 percent   Shares of Hertz Global Holdings fell 4 6 percent to  21 69 after it said it would restate 2012 and 2013 financial results    Shares of low cost airline Virgin America Inc soared 30 4 percent in their market debut   
Volume was again light  About 6 billion shares changed hands on U S  exchanges  below the 6 5 billion average this month  according to BATS Global Markets  NYSE advancers outnumbered decliners 1 618 to 1 452  for a 1 11 to 1 ratio on the upside  on the Nasdaq  1 380 issues fell and 1 309 advanced for a 1 05 to 1 ratio favoring decliners  The S P 500 posted 27 new 52 week highs and four new lows  the Nasdaq Composite recorded 65 new highs and 53 new lows     Additional reporting by Chuck Mikolajczak  Editing by Nick Zieminski ",2014-11-14,Reuters,https://www.investing.com/news/stock-market-news/futures-little-changed-ahead-of-data-316787,316787
129166,350681,BIIB,Earnings Speculators Bet On Big Moves For Biogen Stock,opinion,"Shares of Biogen Inc  NASDAQ BIIB  are hovering around breakeven today at  318 97  as traders gear up for the company s third quarter earnings report  The pharma name is scheduled to report before the market opens this Tuesday  Oct  23  and speculative traders are banking on a much bigger than usual post event price swing for BIIB stock 
On the charts  BIIB has had a volatile run in 2018  The stock fell as low as  249 17 on April 24  but bounced back to hit a three year peak of  388 67 as soon as July 25  As a result  a 50  Fibonacci retracement of the aforementioned annual low and multi year high rests at  318 92    just pennies below the stock s current trading levels  and in line with BIIB s year to date breakeven mark of  318 57 

Digging into its earnings history  BIIB closed higher the day after reporting in six of the last eight quarters  including the last three in a row  Looking broader  the shares have averaged a 2 6  move the day after earnings over the last two years  regardless of direction  This time around  BIIB options traders are expecting nearly four times that average move  with a 10 6  swing priced in for Tuesday s trading 
Data from the International Securities Exchange  ISE   Chicago Board Options Exchange  CBOE   and NASDAQ OMX PHLX  PHLX  shows BIIB with a 10 day put call volume ratio of 1 43  which ranks in the 96th percentile of its annual range  This suggests that puts have been purchased over calls at a near annual high pace during the past two weeks  with traders showing a distinct preference for bearish bets on BIIB ahead of earnings 
Conversely  analyst sentiment has been extremely optimistic toward the drug stock  This is per the overwhelming 18 of 24 brokerage firms that sport a  buy  or better rating  Plus  BIIB s average 12 month price target of  390 88 stands at a 22 5  upside to current levels 
Given the technical significance of the  318  319 neighborhood where the stock is currently trading  traders will certainly be watching this area closely in the aftermath of BIIB s quarterly results  And with sentiment polarized ahead of earnings  the stage could be set for an extreme move in one direction or the other in the wake of the report ",2018-10-23,Schaeffer's Investment Research,https://www.investing.com/analysis/earnings-speculators-bet-on-big-moves-for-biogen-stock-200349841,200349841
129167,350682,BIIB,Biotech ETFs In Focus On String Of Q3 Earnings Beat,opinion,"Though the biotech sector is down in October  it shows promise for the long term due to a wave of mergers   acquisitions and a positive regulatory backdrop  Strong Q2 earnings results have also added to the strength as most of the biotech giants such as Amgen Inc    NASDAQ AMGN    Gilead Sciences   NASDAQ GILD    Biogen Inc    NASDAQ BIIB   and Alexion Pharmaceuticals   NASDAQ ALXN   have topped the estimates on both earnings and revenues  barring Alexion Pharmaceuticals  which missed on revenue estimates slightly  read     
Earnings in Focus
Amgen reported third quarter earnings per share of  3 69  which beat the Zacks Consensus Estimate of  3 42 and improved from the year ago earnings of  3 27  Revenues of  5 9 billion also came ahead of the estimated  5 8 billion and were up from  5 8 billion reported in the year ago quarter 
Amgen raised its sales and earnings guidance for 2018  Better than expected second quarter results and an optimistic outlook for the rest of the year led to the increase in earnings guidance  The company now expects revenues in the range of  23 2 23 5 billion compared with the previous prediction of  22 5  23 2 billion  Adjusted earnings are now anticipated in the range of  14 00  14 25 in 2018 compared with the previous projection  13 30  14 00  read    
Gilead Sciences beat earnings estimates by 14 cents and but came in 53 cents lower than the year ago quarter  The revenue estimates were beaten by  160 million  Year ago quarter revenues were reported at  6 51 billion 
Gilead expects net product sales of  20 8  21 3 billion compared with the earlier estimate of  20  21 billion  read    
Alexion Pharmaceuticals beat the Zacks Consensus Estimate on earnings by 27 cents and showed a year over year improvement of 45 3   Revenues missed the estimate narrowly by  1 million and but saw a year over year improvement of 19 6  
The company raised its earnings per share and revenue guidance for 2018  It expects earnings per share to be  7 45  7 60  up from the previous forecast of  7 00  7 15  Alexion projects revenues of  4 02  4 05 billion  up from its previous expectation of  3 98  4 01 billion
Biogen reported a positive surprise of 8 8  on earnings and 3 3  on revenues  Earnings improved year over year by 17 3  and revenues grew by 2 4  
Biotech ETFs  iShares Nasdaq Biotechnology ETF  VanEck Vectors Biotech ETF   LON BBH    andFirst Trust Amex Biotechnology Index   LON FBT    have dipped in the last 4 trading days period dotted with biotech releases by 0 8   2  and 1 7  respectively  as of Oct 30   Below  we have highlighted the four most popular ETFs with high exposure to the above mentioned companies 
 IBB
This fund tracks the NASDAQ biotechnology index  It has 191 holdings with 29 11  weight age to the mentioned four companies  It has an AUM of  8 6 billion and an expense ratio of 0 47   Year to date loss is 3 6  
BBH
The fund tracks the MVIS US Listed Biotech 25 Index  It has a pool of 25 stocks with 25 19  weight to the mentioned four companies  It has an AUM of  432 2 million and an expense ratio 0 35   Year to date loss is 6 8    
FBT
It tracks the equal weighted NYSE Arca Biotechnology Index  There are 30 holdings in the basket with FBT holding 12 9   AUM is  3 18 billion  while expense ratio is 0 56   Year to date return is 4 7    
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/biotech-etfs-in-focus-on-string-of-q3-earnings-beat-200353435,200353435
129168,350683,BIIB,Probiodrug  Support For Abeta Theory From Biogen Eisai ,opinion,"We believe one of the main reasons for the devaluation of Probiodrug AG  AS PDB  shares over the past year was the largely disappointing industry newsflow frustrating research on Abeta theory  even though Probiodrug s technology is differentiated from all other Abeta therapies studied in late stage trials  The recent surprise announcement of disease modifying effect obtained by Biogen Eisai with their MAb BAN2401 in a Phase II trial may reignite interest in the amyloid theory and in the Alzheimer s disease  AD  field in general  While funding and lack of visibility on a partnering deal are near term risks  we find Probiodrug s asset PQ912  a small molecule glutaminyl cyclase  QC  inhibitor  and its Phase IIa data interesting  In our view  any progress with raising new funds or finding a partnering would unlock substantial upside from the current low valuation level 

Spotlight on Abeta MAbs after Biogen s Ph II results
Over the last decade there has been no lack of disappointing industry news on AD research  including multiple failures of Abeta targeting antibodies  There have been three BACE inhibitor failures so far this year  verubecestat  Merck   atabecestat  Janssen  and lanabecestat  Eli Lilly  NYSE LLY   AstraZeneca   This negative news dampened investor confidence in Abeta targeting strategies  However  results from Biogen  NASDAQ BIIB  and Eisai s Phase II trial with Abeta antibody BAN2401 showed a statistically significant disease modifying effect  which is a holy grail in AD research  and revived some hope for Abeta targeted therapies 
To read the entire report Please click on the pdf File Below  ",2018-11-01,Edison,https://www.investing.com/analysis/probiodrug-support-for-abeta-theory-from-biogeneisai-200352910,200352910
129175,350690,BIIB,PDL BioPharma  PDLI  Q3 Earnings Top  Revenues Rise  Stock Up,opinion,PDL BioPharma  Inc    NASDAQ PDLI   delivered earnings of 9 cents per share in the third quarter of 2018  beating the Zacks Consensus Estimate of 7 cents  However  the bottom line was lower than 14 cents in the year ago period The company s total revenues grossed  67 9 million in the reported quarter  reflecting an 8 2  increase year over year  This upside is mainly attributable to a sharp rise in royalties as well as product revenues Higher royalties are because of an increase in value of royalty rights from Depomed  In August  the company paid  20 million to buy Depomed s remaining 50  interest in royalties payable on sales of the type II diabetes products licensed by Depomed  Following the amendment  PDL now receives 100  royalties rather than a 50 50 share with Depomed Shares of PDL BioPharma were up almost 18  following its earnings release on Nov 6  In fact  the stock has gained 5 9  so far this year against the  decline of 16 4   Quarter in DetailProduct revenues for the quarter under review were  24 4 million  up 21 5  year over year  The same included  17 8 million from the sales of Noden products   Tekturna and Tekturna HCT   and  6 6 million from the sales of LENSAR laser system in the United States PDL recognized  42 2 million in revenues from royalty rights   0 5 million of royalties from PDL s licensees to the Queen et al  patents and  0 8 million of interest revenues Royalty revenues from the Queen et al  licenses were lower than the year ago period  mainly due to lower product supplies of Biogen s   NASDAQ BIIB   multiple sclerosis drug  Tysabri Research and development  R D  expenses for the third quarter summed  0 7 million  up 11 1  from the prior year level  This upside was owing to a contribution of additional cost of product revenues from Noden products and LENSAR laser system in ex U S  marketsGeneral and administrative expenses escalated 10 9  to  13 9 million from the level registered in comparable quarter last year In September 2018  PDL BioPharma announced that its board of directors approved a new  100 million worth share buyback program of the company s common stock  This is the third and the largest stock repurchase program after having completed a  30 million program in June 2017 and a subsequent  25 million program in third quarter 2018  The company expects to have substantial cash in hand to execute this strategy Along with earnings release  PDL BioPharma reported that its president Dominique Monnet will assume the role of chief executive officer  CEO  following its current CEO John P  McLaughlin s retirement at this year end PDL BioPharma  Inc  Price  Consensus and EPS Surprise   Zacks Rank   Stocks to ConsiderPDL BioPharma currently carries a Zacks Rank  3  Hold   Two better ranked stocks in the healthcare sector are Gilead Sciences  Inc    NASDAQ GILD   and Alexion Pharmaceuticals  Inc    NASDAQ ALXN    both sporting a Zacks Rank  1  Strong Buy   You can see  Gilead Sciences  earnings estimates have been revised 4 4  upward for 2018 and 4 2  for 2019 over the past 60 days The stock has inched up 1 2  so far this year Alexion s earnings estimates have moved 4 8  north for 2018 and 1 8  for 2019 over the past 60 days  The stock has gained 6 4  so far this year Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-07,Zacks Investment Research,https://www.investing.com/analysis/pdl-biopharma-pdli-q3-earnings-top-revenues-rise-stock-up-200357071,200357071
129176,350691,BIIB,Model N  MODN  Q4 Earnings   Revenues Surpass Estimates,opinion,Model N  Inc    NYSE MODN   delivered fourth quarter fiscal 2018 non GAAP earnings of 6 cents per share comparing favorably with the year ago quarter s loss of 6 cents per share  The Zacks Consensus Estimate was pegged at a loss of 2 cents Revenues of  36 7 million increased 3 1  from the year ago quarter  outpacing the Zacks Consensus Estimate of  35 million  The figure also outpaced the guided range of  35 2  35 7 million Management noted that the company is making steady progress in its transformation to a 100  Software as a Service  SaaS  based model Quarter in DetailModel N has two reportable segments namely SaaS   Maintenance and License   Implementation SaaS   Maintenance revenues of almost  35 million grew 18 1  year over year  Model N is accelerating its transition of revenue management to cloud and is on track to shift business to a 100  SaaS and Maintenance revenue model License   Implementation revenues of  1 7 million declined 71 1  on a year over year basis  The company no longer sells on premise perpetual licenses  Management had anticipated the decline in fourth quarter due to backlog burn off and transition of customers to cloud Expanding Customer BaseModel N made significant efforts in its go to market strategy in order to improve growth  Management is optimistic about its Revenue Cloud offering for med tech  pharma and high tech companies The company is leaving no stone unturned to enable customers  transition to cloud from an on premise infrastructure  Management is elated on the rapid adoption witnessed among life sciences companies in particular  including Biogen  NASDAQ BIIB   Novo Nordisk  CO NOVOb   among others  which subscribed to Revenue Cloud Additionally  Model N s growth prospects in the life sciences   high technology are bright due to increasing redundancy of legacy systems  The company s solutions provide higher Return on Investment   ROI   as well as plug gaps in the end to end revenue management process that legacy systems fail to do The company has enhanced Revenue Cloud with Amazon s   NASDAQ AMZN   Amazon Web Services  AWS  infrastructure as part of its cloud optimization initiative  This has enabled it to aid companies like Allegro Microsystems  Edwards Life Sciences  Ipsen and Shionogi  among others in their transition Management is also optimistic regarding Seagate s   NASDAQ STX   increased utilization of Revenue Cloud  Seagate recently subscribed to Model N s Channel Data Management solution  Integra Life Sciences intends to deploy Revenue Cloud across its international business units  In this regard  the life sciences company added an acquired business entity to Revenue Cloud The growing clout of Model N s Global Price Management solution  Model N CPQ  Configure  Price and Quote   Model N Channel Cloud and Revenue Cloud for High Tech suites is notable The company s Revenue Management platform aimed at enhancing digital reinvention experience also bodes well Model N  Inc  Price  Consensus and EPS Surprise   Operating DetailsNon GAAP gross profit increased to  23 million from  22 7 million recorded in the year ago quarter  Non GAAP margin surged to 62 8   up from 61 3  reported in the year ago quarter  adjusted for deferred revenues  Adjusted EBITDA was  2 5 million compared with  1 million in the year ago quarter  Non GAAP income from operations was  2 million against year ago figure of  0 1 million Balance Sheet   Cash FlowModel N exited the quarter with cash and cash equivalent balance of  56 7 million compare with  57 6 million reported in the previous quarter  The company had total debt  long term plus current portion  of  53 7 million  as of Sep 30  2018 Net cash generated in operating activities came in at  2 5 million in fiscal 2018 compared with approximately  12 million used in fiscal 2017 Fiscal 2018 at a GlanceFor fiscal 2018  total revenues increased 17 8  year over year to  154 6 million  Year over year growth was primarily driven by a surge of 25 7  in SaaS and maintenance revenues which came in at  135 9 million  Recurring revenues came in at  98 3 million Non GAAP earnings for fiscal 2018 came in at  0 04 per share  compared with the   0 59  reported in fiscal 2017 Model N  Inc  Revenue  TTM    GuidanceModel N will report financial results as per ASC 606 guidelines from first quarter fiscal 2019  The company expects fiscal first quarter 2019 GAAP revenues to come in the range of  34 million to  34 4 million  The company anticipates deferred revenues to be negatively impacted by roughly  8 million Non GAAP earnings  loss  are likely to be between  1 cent  and 1 cent per share for the first quarter  The Zacks Consensus Estimate is pegged at break even Adjusted EBITDA is anticipated to be in the range of  2 million to  2 4 million For fiscal 2019  Model N expects GAAP revenues to be in the range of  138  142 million Non GAAP earnings are expected to be in the range of 5 17 cents per share  The Zacks Consensus Estimate is pegged at 20 cents Adjusted EBITDA is projected to be in the range of  8 5  12 5 million Zacks Rank and Stock to ConsiderModel N carries a Zacks Rank  3  Hold  Cadence Design Systems  Inc    NASDAQ CDNS   is a stock worth considering in the broader technology sector  It sports a Zacks Rank  1  Strong Buy   You can see  Long term earnings growth rate for Cadence Design is pegged at 12  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-11-08,Zacks Investment Research,https://www.investing.com/analysis/model-n-modn-q4-earnings--revenues-surpass-estimates-200357717,200357717
129192,350707,BIIB,UPDATE 1 Biogen gains rights to Acorda s MS drug,news,"   110 mln up front payment
   Biogen gains ex U S  rights to Fampridine SR
 NEW YORK  July 1  Reuters    Biogen Idec Inc  has
licensed rights to Acorda Therapeutics Inc s 
experimental multiple sclerosis drug outside the United States
as the large biotech company expands its MS franchise  the
companies said on Wednesday 
 Biogen will pay Acorda  110 million up front for rights to
Fampridine SR  It will also pay up to  400 million more based
on the drug achieving regulatory and sales milestones 
 Elan Corp   which manufactures Fampridine SR  will
gain portions of the payments Acorda receives from Biogen 
 Fampridine broadens the MS franchise for Biogen  which
sells the drugs Avonex and Tysabri 
 In the United States  where Acorda is maintaining rights to
Fampridine  the drug is under review by regulators and a
decision is expected by Oct  22  The drug is not yet filed for
approval in Europe 
  Reporting by Lewis Krauskopf  Editing by Derek Caney ",2009-07-01,Reuters,https://www.investing.com/news/equities-news/update-1-biogen-gains-rights-to-acorda's-ms-drug-68043,68043
129193,350708,BIIB,WRAPUP 2 European drug groups shine through recession,news,"  Swiss Actelion posts  stellar  results  ups forecast
   Ireland s Elan also beats expectations
   Elan gives J J option to buy Biogen MS drug stake
   US biotechs Gilead  Genzyme  Celgene also report this week
   Actelion shares up 1 2 percent  Elan up 0 1 percent

  Adds more comment  updates shares 
 By Sam Cage and Padraic Halpin
 ZURICH DUBLIN  July 21  Reuters    European drugmakers
Actelion and Elan both beat profit forecasts on Tuesday  as
sales of key medicines helped shield them from the recession 
 The strong results from Actelion  Europe s largest biotech
company  and Irish drugmaker Elan set the stage for results from
U S  biotechs Gilead  Genzyme and Celgene 
 Actelion raised its full year outlook after its
second quarter profit beat expectations  helped by strong sales
of key drug Tracleer    results which Vontobel analyst Andrew
Weiss described as  stellar  
 Elan  also beat expectations  aided by a jump in sales of
multiple sclerosis drug Tysabri  even though it posted a wider
net loss 
 The Irish company  which this month sold an 18 4 percent
stake to U S  healthcare group Johnson   Johnson  also confirmed
it has given J J an option to acquire Biogen Idec Inc s 50
percent stake in the multiple sclerosis drug Tysabri  should
there be a change of control at Biogen 
  Actelion is trying to cut its dependence on Tracleer for
  pulmonary arterial hypertension  which rakes in more than  1
billion a year  by developing it for new indications and pushing
other new drugs to market 
 However  it reported some delays in its promising portfolio
of new medicines    a key driver for biotech groups    including
sleep drug almorexant  which is being developed with Britain s
GlaxoSmithKline 
 Actelion Chief Executive Jean Paul Clozel said the group was
in talks with U S  regulators over labelling for almorexant  a
potential billion dollar seller  which would mean a delay of
eight to nine months 
 Actelion shares were up 1 2 percent to 58 2 Swiss francs by
1347 GMT  versus a 1 percent rise in the DJ Stoxx European
health care index  Elan shares  which jumped 9 percent on Monday
following media reports that it may invest in a biologics
operation in Ireland  were up 0 1 percent to 5 685 euros 
  Despite the strong financial results  we are disappointed
to learn that the pipeline has experienced several delays   said
Olav Zilian  an analyst at brokerage Helvea 
 
 MS BOOST FOR ELAN
 Elan s results were driven by a 30 percent jump in sales of
its multiple sclerosis drug Tysabri  which the company said
about 43 300 patients worldwide were taking by the end of June 
 Elan and partner Biogen Idec originally predicted 100 000
patients would be taking Tysabri by the end of 2010  While they
still expect to reach that figure  which would mean the drug
could bring in  2 billion to  3 billion a year  they do not
expect to reach it within that timeframe 
 Jack Gorman  an analyst at Davy Stockbrokers  said that
giving away the right on the potential blockbuster drug Tysabri 
may actually be a good move for Elan 
  Looking at it another way  such a provision may indicate
that J J has more than a passing interest in the Tysabri asset
   if it was ultimately to become Elan s partner in MS  we would
view this as a good result   Gorman said in a note 
  Additional reporting by Paul Arnold in Zurich  Editing by
Erica Billingham ",2009-07-21,Reuters,https://www.investing.com/news/forex-news/wrapup-2-european-drug-groups-shine-through-recession-73251,73251
129194,350709,BIIB,UPDATE 2 Elan gives J J potential option to buy Biogen MS stake,news,"  J J can finance Elan purchase of 50 pct Tysabri stake
   Deal contingent on change of control at Biogen
   J J and Elan would enter fresh 50 50 collaboration
   Elan shares up 1 2 pct
 
  Adds analyst comment  update share price 
 By Padraic Halpin
 DUBLIN  July 21  Reuters    Ireland s Elan  said on
Tuesday it gave U S  healthcare conglomerate Johnson   Johnson
 the potential option to acquire Biogen Idec Inc s
 50 percent stake in multiple sclerosis drug Tysabri 
 The potential option is part of a recent deal in which J J
agreed to pay  1 billion for an 18 4 percent stake in Elan and
 500 million for a majority stake in its pipeline of
experimental Alzheimer s disease drugs 
 Elan and Biogen  which is based in Cambridge  Massachusetts 
have a 50 50 partnership under which each has the right to
acquire full control of Tysabri should there be a change of
control at either company 
 But in the event of a change of control at Biogen  J J can
now choose to finance a possible Elan purchase of Biogen s
rights to Tysabri  which is on track to make  1 billion a year 
  We have entered into an arrangement with Johnson   Johnson
that would allow them to finance us to purchase the other 50
percent of Tysabri in the event that there was a change of
control at Biogen   Elan Chief Financial Officer Shane Cooke
told a news conference 
  If J J were to finance us to do that  then we would enter
into a collaboration with J J on a 50 50 basis   he said  adding
that its change of control agreement with Biogen was unchanged 
 
 GOOD PARTNER
 Analysts said the arrangement  while hypothetical  gives
Elan more control over the fate of Tysabri and takes an element
of risk out of the partnership with Biogen 
  My initial reaction was  what are they doing here  but it
is really just covering their position   Ian Hunter  an analyst
at Goodbody Stockbrokers said  
  They now know who their potential partner could be if
anything happened at Biogen Idec  There s no uncertainty   
 Dublin based Elan confirmed the new agreement after Reuters
learned of it from sources with knowledge of the  1 5 billion
deal  ID nN20149879  
 Elan  which beat expectations with a 14 percent rise in
second quarter revenues  said around 43 300 patients worldwide
were on Tysabri therapy at the end of June 
 Biogen and Elan originally predicted 100 000 patients would
be taking Tysabri by the end of 2010  While they still expect to
reach that figure  which would generate  2 billion to  3 billion
a year  they don t expect to reach it within that timeframe 
  J J would be a pretty good partner in the event that all
these things triggered that particular situation   said Jack
Gorman  an analyst at Davy brokerage 
  J J would bring plenty of commercial clout  autoimmune and
infusion expertise and  given they re a big pharma with biotech
capability  presumably they d also have manufacturing
capability  
 Elan shares were down 2 3 percent at 5 58 euros by 1545 GMT
after jumping 9 percent on Monday following media reports that
it may invest in a biologics operation in Ireland 
  Editing by Erica Billingham and Lin Noueihed ",2009-07-21,Reuters,https://www.investing.com/news/equities-news/update-2-elan-gives-j-j-potential-option-to-buy-biogen-ms-stake-73336,73336
129205,350720,BIIB,PTC Therapeutics  Spinal Muscular Atrophy Study Successful,opinion,"Shares of PTC Therapeutics  Inc    NASDAQ PTCT   gained 27 5  on Jun 18  following the presentation of encouraging preliminary data from part I of the pivotal FIREFISH study  The study is evaluating its pipeline candidate  risdiplam  RG7916   in babies with type 1 spinal muscular atrophy   SMA    The early stage data has shown promising motor function improvements and milestones achievement in babies  Data was presented over the last weekend at the Annual SMA Researcher Meeting Data from the study showed that risdiplam achieved a four point increase from baseline in CHOP INTEND score in more than 90  babies below two years at day 182  CHOP INTEND is a test to determine motor milestone development of patients with SMA Type 1 The FIREFISH study is a two part program in collaboration with Roche   OTC RHHBY   and SMA foundation  The part I was a dose escalation and safety assessment study  Part II will evaluate the selected dose from part I in babies with type I SMA for 24 months  Enrollment in part II of the FIREFISH study is underway Following this presentation  shares of rival company  Biogen Inc    NASDAQ BIIB   fell more than 5  on Monday  We remind investors that Biogen s Spinraza is available for the treatment of SMA in pediatric and adult patients  A successful development of risdiplam will likely have an unfavorable impact on Spinraza sales  which generated 14 4  of Biogen s total product sales in the first quarter of 2018 We note that following the completion of acquisition of AveXis  Novartis will also add a SMA candidates to its pipeline  creating a potential large cap competitor for Biogen and PTC Therapeutics So far this year  PTC Therapeutics  shares have skyrocketed 187 1  compared with a 4 6  increase registered by the  PTC Therapeutics is evaluating risdiplam in several clinical studies apart from FIREFISH  The candidate is being evaluated in another two part pivotal study  SUNFISH  for the treatment of patients with type II or III SMA  An exploratory study is currently evaluating risdiplam in patients who have received treatment with another therapy targeting SMN2 splicing in clinical studies SMA is a rare neuromuscular disorder  which causes muscle atrophy due to the loss of motor neurons within the spinal cord leading to impaired movement in patients  Per the press release  one in 11 000 new born babies has this debilitating disease PTC Therapeutics  Inc  Price
    Zacks Rank   Stocks to ConsiderPTC Therapeutics currently carries a Zacks Rank  3  Hold  Aeglea BioTherapeutics  Inc    NASDAQ AGLE   is a better ranked stock in the pharma sector carrying a Zacks Rank  2  Buy   You can see  Aeglea s loss estimates narrowed from  1 93 to  1 67 for 2018 and from  3 86 to  3 57 for 2019 over the last 60 days  The company delivered positive earnings surprise in three of the trailing four quarters with an average beat of 19 32   Its share price has increased 101 3  so far this year Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-06-18,Zacks Investment Research,https://www.investing.com/analysis/ptc-therapeutics-spinal-muscular-atrophy-study-successful-200326170,200326170
129208,350723,BIIB,Biogen Swells On Trial Results,opinion,"Biotech firm Biogen  NASDAQ BIIB  traded 20  higher on Friday morning  after announcing encouraging results for a phase 2 trial related to Alzheimer s disease 
Biogen s drug  known as BAN2401  showed positive results compared to a placebo in the latest trials  The study used 18 months of data from 856 patients with early stage Alzheimer s disease  Chief Medical Officer Alfred Sandrock explained   The prospect of being able to offer meaningful disease modifying therapies to individuals suffering from this terrible disease is both exciting and humbling   The drug was developed in partnership with Japanese pharmaceuticals company Eisai  ESALY  
In analyzing the weekly chart for BIIB  we can see the stock is in the rising phase of its current minor cycle  Having pulled back from its highs of the session  we see this coming down to the  340 level by the end of the cycle 
Longer term cycles suggest that BIIB may be in the early stages of this move higher  As such  if it does pull back to the  340 support  that would be our buy area for a potential jump to a new high  The brackets at the bottom of the chart represent the market cycles for this stock  
For more from Slim  or to learn about cycle analysis  check out the askSlim Market Week show every Friday on our YouTube channel ",2018-07-06,Steve Miller,https://www.investing.com/analysis/biogen-swells-20-but-investors-might-wait-for-pullback-before-swallowing-the-pill-200329615,200329615
129211,350726,BIIB,Week Ahead  Investors Primed To Drive Equities To New Highs,opinion,"US jobs report positive for equities  negative for dollar and yields
US equities expected to rally in July and second half 2018
S P blew out bearish pattern  Dow Jones crossed back above 200 DMA
WTI developing bullish pattern

Bullish investors will start the coming week with a resounding nod to keep on pushing higher from Friday s mixed jobs report nonfarm payrolls increased but average hourly earnings disappointed  The release suggests the possibility of a slower pace to monetary tightening  in our view paving the way in July for heights yet unexplored 
The results boosted equities  while pulling yields and the dollar lower  All major US indices  including the S P 500  Dow and NASDAQ finished the day and the week higher  Overall  the favorable employment report signals that the economy has been growing despite the negative sentiment surrounding an expanding trade war  Even more encouraging  we believe the positive equity market finish  both for the day and week  indicates a likely trajectory for the month and the second half of the year  We think investors are primed to boldly go where no one has gone before  Here s why 
It s the Economy Stupid
The addition of 213 000 new jobs in June  which beat the 195 000 estimate  is the third strongest showing of the year  for a total of 1 3 million jobs added since the start of 2018  That s a 15 percent acceleration of the 1 1 million jobs in the preceding six month period  And while unemployment rose to 4 percent  slightly higher than the previous reading  it s still the lowest since 1969  An increase this minimal  off a near 50 year low remains an obvious sign of improving job prospects  Wages rose 2 7 percent YoY  increasing from last year s 2 4 percent mark 
June s report provides hard proof that the US economy is improving  It also offers a positive outlook for additional economic expansion since more jobs and higher wages would support consumer spending  which makes up the lion s share of the US GDP  a necessary component for yet more growth 
As for investor bullishness  even after the fear of tariffs materialized  time and again demand continued to support prices within uptrends  The favorable employment report indicates that despite the negative sentiment of an escalating trade war  the economy still keeps growing  By pushing stocks higher  investors continue to demonstrate that they don t believe a full fledged trade war will end economic growth but instead view it as a negotiating strategy  a way for the US president to strengthen his hand 
Market Internals Almost All Green
The S P 500 advanced on Friday  up 0 85 percent  with all 11 sectors in the green  led by Healthcare   1 44 percent  after biotech shares drove gains following a report that Biogen s  NASDAQ BIIB  Alzheimer s drug showed positive results in a large clinical trial  The strong finish boosted the leading benchmark to a 1 52 percent gain on the week  led once again by Healthcare   3 06 percent   though Energy   0 36 percent  finished the week in the red  following volatile oil prices down 
The Dow Jones Industrial Average climbed 0 4 percent on Friday  ending the week 0 85 percent higher  halting a three week slump  The NASDAQ Composite jumped 1 35 percent Friday  gaining 2 4 percent for the week  It s now within 1 5 percent from its all time high two weeks ago 
The Russell 2000 outperformed  surging 0 85 percent  for the fourth straight day  to a 3 14 percent advance  to 0 8 percent from its highest price on record  the week before last 

From a technical perspective  the S P 500 Index blew out a bearish pennant  trading entirely above the negative pattern on Friday  Even the Dow Jones the major index underperformer during a trade war  because its multinational mega cap companies rely on exports for growth closed above a bearish pennant  as well as back above the 200 DMA for the first time after nine sessions 
Bulls have trampled all of the bears  red lines  suggesting the path is now clear for another charge higher 

While the nonfarm payrolls report buoyed equities  the release weighed on yields  including the 10 year Treasury  as the wages component missed estimates  the second time in a row  Average hourly earnings were up just 2 7 percent year over year  one tenth of a percentage point below expectations 
This offers another example of the different perspectives held by equity traders versus bond traders  equity traders focused on the positive side of the report  the higher YoY number  bond traders paid attention to the lower than expected result  The slower outlook for interest rate hikes increased demand for long term bonds at the current rates  dragging yields down 

The lower outlook for rates weighed on the greenback  which found support for now by an uptrend line since mid May 
Week Ahead
All times listed are EDT
Monday
2 00  Germany   Trade Balance  May   surplus expected to rise to  21 2 billion from  20 4 billion
21 30  Australia   NAB Business Confidence  June   index expected to rise to 9 from 6 
21 30  China   CPI  June   expected to be 1 9  YoY and  0 1  MoM  from 1 8  and  0 2  respectively 
Tuesday
4 30  UK   Trade Balance  May   deficit forecast to narrow to  1 2 billion from  5 3 billion 

The FTSE 100 has been trading within a falling channel  An upside surprise may knock it off its downward trajectory  Otherwise  it is expected to continue with its trend lower 
5 00  Germany   ZEW Economic Sentiment  July   forecast to rise to  14 from  16 1
20 30  Australia   Westpac Consumer Confidence  July   index forecast to fall to 100 from 102 2 
Wednesday
8 30  US   PPI  June   forecast to be 0 1  from 0 5  MoM  while core PPI falls to 0 2  from 0 3  
10 00  Canada   BoC Rate Decision  rates expected to remain at 1 25  
10 30  US   EIA Crude Inventories  w e 6 July   stockpiles expected to fall by 230 000 barrels from a 1 5 million barrel drop a week earlier 

The price of oil is trading within a bullish  falling flag  An upside breakout would suggest the resumption of the underlying uptrend since June 21 when the price was at  64 
Thursday
5 00  Eurozone   Industrial Production  May   expected to be 2 8  YoY and 0 8  MoM  from 1 7  and  0 9  respectively 
8 30  US   CPI  June   Initial Jobless Claims  w e 7 July   headline CPI to be 2 9  YoY and 0 2  MoM  from 2 8  and 0 2  respectively  Core CPI to be 0 2  MoM and 2 3  YoY  from 0 2  and 2 2  respectively  Initial jobless claims to fall to 227 000 for the week  from 231 000 a week earlier
11 00  China   Trade Balance  June   exports expected to rise 10 3  from 12 6  YoY 
Friday
10 00  US   Michigan Consumer Confidence Index  July  preliminary   forecast to fall to 98 1 from 98 2 ",2018-07-08,Pinchas Cohen/Investing.com,https://www.investing.com/analysis/week-ahead-200329713,200329713
129212,350727,BIIB,Oryzon Genomics  Awaiting For Eventful 2019 ,opinion,"The next year is shaping up to be transformative for Oryzon Genomics SA  MC ORY  with two data readouts from Phase IIa trials with ORY 2001 in Alzheimer s disease  AD  and multiple sclerosis  MS   In addition  an innovative design basket trial with ORY 2001 in several neuropsychiatric disorders may also deliver first results next year  Oryzon is resuming the development of ORY 1001 in acute myeloid leukaemia  AML  and small cell lung cancer  SCLC   While Roche s departure was a setback in 2017  the stars started to align again after the Biogen  NASDAQ BIIB  Abeta antibody data provided a much needed boost for AD research industry and indirectly for Oryzon s ORY 2001  Furthermore  a fundamental study published in Cell described the potential of LSD1 inhibition in immunooncology setting adding a new dimension to ORY 1001 s potential  We value Oryzon at  328m or  9 6 share  vs  9 4 share  

Broadening ORY 2001 programme  catalysts in 2019
Two Phase IIa trials with ORY 2001  a dual LSD1 MAOB inhibitor for CNS indications  are underway  A randomised  double blind  placebo controlled  36 week Phase IIa SATEEN study  n 24  will evaluate ORY 2001 in patients with relapsing remitting MS and secondary progressive MS  A second randomised  double blind  placebo controlled  24 week Phase IIa ETHERAL trial  n 90  with ORY 2001 in mild to moderate AD started enrolling patients in May 2018  The data readouts from both studies are planned around mid 2019  Most recent R D update from Oryzon now includes a planned  CTA filed  so called basket trial that will use a novel strategy employed in oncology trials to simultaneously test ORY 2001 in several neuropsychiatric disorders for reduction in aggression  While still an exploratory trial with limited patient numbers  if positive signals are obtained it would mark a significant step beyond neurodegenerative disorders like MS and AD 
To read the entire report Please click on the pdf File Below ",2018-07-19,Edison,https://www.investing.com/analysis/oryzon-genomics-awaiting-for-eventful-2019-200331718,200331718
129230,350745,BIIB,Should You Invest In The PowerShares Dynamic Biotechnology   Genome Portfolio  PBE  ,opinion,"Looking for broad exposure to the Healthcare   Biotech segment of the U S  equity market  You should consider the PowerShares Dynamic Biotechnology   Genome Portfolio  PBE   a passively managed exchange traded fund launched on 06 23 2005 
While an excellent vehicle for long term investors  passively managed ETFs are a popular choice among institutional and retail investors due to their low costs  transparency  flexibility  and tax efficiency 
Sector ETFs are also funds of convenience  offering many ways to gain low risk and diversified exposure to a broad group of companies in particular sectors  Healthcare   Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification  It is currently ranked 11  placing it in bottom 31  
Index Details
The fund is sponsored by Invesco Powershares  It has amassed assets over  248 76 M  making it one of the average sized ETFs attempting to match the performance of the Healthcare   Biotech segment of the U S  equity market  PBE seeks to match the performance of the Dynamic Biotechnology   Genome Intellidex Index before fees and expenses 
This is comprised of stocks of 30 U S  biotechnology and genome companies  These are companies that are principally engaged in the research  development  manufacture and marketing and distribution of various biotechnological products  services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research 
Costs
Expense ratios are an important factor in the return of an ETF and in the long term  cheaper funds can significantly outperform their more expensive counterparts  other things remaining the same 
Annual operating expenses for this ETF are 0 58   making it on par with most peer products in the space 
It has a 12 month trailing dividend yield of 0 42  
Sector Exposure and Top Holdings
It is important to delve into an ETF s holdings before investing despite the many upsides to these kinds of funds like diversified exposure  which minimizes single stock risk  And  most ETFs are very transparent products that disclose their holdings on a daily basis 
This ETF has heaviest allocation in the Healthcare sector  about 100  of the portfolio 
Looking at individual holdings  Illumina Inc  NASDAQ ILMN  accounts for about 5 68  of total assets  followed by Qiagen Nv  QGEN  and Biogen Inc  NASDAQ BIIB  
The top 10 holdings account for about 46 80  of total assets under management 
Performance and Risk
So far this year  PBE has gained about 8 76   and it s up approximately 18 19  in the last one year  as of 05 17 2018   During this past 52 week period  the fund has traded between  41 77 and  54 07 
The ETF has a beta of 1 38 and standard deviation of 27 96  for the trailing three year period  making it a high risk choice in the space  With about 31 holdings  it has more concentrated exposure than peers 
Alternatives
PowerShares Dynamic Biotechnology   Genome Portfolio holds a Zacks ETF Rank of 2  Buy   which is based on expected asset class return  expense ratio  and momentum  among other factors  Because of this  PBE is an outstanding option for investors seeking exposure to the Health Care ETFs segment of the market  There are other additional ETFs in the space that investors could consider as well 
SPDR S P Biotech ETF  MX XBI  tracks S P Biotechnology Select Industry Index and the iShares Nasdaq Biotechnology ETF  IBB  tracks Nasdaq Biotechnology Index  SPDR S P Biotech ETF has  5 23 B in assets  iShares Nasdaq Biotechnology ETF has  8 86 B  XBI has an expense ratio of 0 35  and IBB charges 0 47  
Bottom Line
To learn more about this product and other ETFs  screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe  please visit  ",2018-05-16,Zacks Investment Research,https://www.investing.com/analysis/should-you-invest-in-the-powershares-dynamic-biotechnology--genome-portfolio-pbe-200317228,200317228
129232,350747,BIIB,Pfizer Boosts Venture Capital Efforts  Neuroscience In Focus,opinion,Pfizer  Inc    NYSE PFE   said it plans to invest  600 million in Pfizer Ventures  its venture capital arm  This funding will be invested in small biotechs and other emerging growth companies  About 25     150 million   of the newly available fund will be earmarked for companies involved in promising early stage neuroscience research  Pfizer Ventures will first invest in companies focussed on neuro degeneration  neuro inflammation and neuro metabolic disorders Pfizer Ventures already has investments in six neuroscience companies including Aquinnah  Autifony  Cortexyme  MindImmune  MISSION  and Neuronetics  In 2015  Pfizer became part of the Dementia Discovery Fund  DDF   which was formed to speed up the development of new treatments for neurological diseases by bringing together major pharma companies  the U K  government and Alzheimer s Research UK  The fund is involved in the financing of new  early stage drug development projects  Since its launch in October 2015  DDF has raised more than  190 million  which has been invested in dementia drug discovery companies and projects  Other investors in DDF include Biogen   NASDAQ BIIB    Eli Lilly   NYSE LLY   and Glaxo   NYSE GSK    among others Other than neuroscience  the venture capital arm s area of interest will include oncology  inflammation and immunology  rare disease  internal medicine and vaccines  Pfizer Ventures  which manages more than 40 companies currently  will have five new members   Pfizer has already invested  500 million in the venture capital arm  With the latest funding  the total assets under management add up to more than  1 billion  This year so far  Pfizer s shares have increased 0 4  against a decrease of 4 6  for the Ironically  the news comes in less than six months after Pfizer said that it will drop its plans to develop treatments for neurodegenerative disorders like Alzheimer s and Parkinson s disease  These are highly challenging areas with not much progress being made despite significant investments  funds as well as resources  Pfizer currently carries a Zacks Rank  3  Hold   You can see Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-06-06,Zacks Investment Research,https://www.investing.com/analysis/pfizer-boosts-venture-capital-efforts-neuroscience-in-focus-200323014,200323014
129233,350748,BIIB,Roche Rituxan Label Expanded By FDA For Pemphigus Vulgaris,opinion,"Roche Holdings   OTC RHHBY   announced that the FDA has approved Rituxan  rituximab  for the treatment of adults with moderate to severe pemphigus vulgaris  PV  Per the company  Rituxan is the first biologic therapy approved by the FDA for PV  We remind investors that the FDA had granted Priority Review  Breakthrough Therapy Designation and Orphan Drug Designation to Rituxan for the treatment of PV Being an autoimmune blistering disease affecting the skin and mucous membranes  PF affects 30 000 to 40 000 people in the United States  As a result of this approval  Rituxan is now approved to treat four autoimmune diseases like rheumatoid arthritis  RA   granulomatosis with polyangiitis  GPA   microscopic polyangiitis  MPA  and PV The approval was based on data from the Ritux 3 trial  which compared the Ritux 3 regimen  EU approved rituximab product plus short term corticosteroids  CS   to CS alone as a first line treatment in patients with newly diagnosed moderate to severe pemphigus  The results from the study showed that 90  of PV patients treated with the Ritux 3 regimen met the endpoint compared to 28  of PV patients treated with CS alone We note that Roche s subsidiary  Genentech and Biogen   NASDAQ BIIB    have a collaboration agreement for Rituxan in the United States while Roche markets MabThera  brand name of Rituxan outside the United States  in the rest of the world  except Japan  where Rituxan is co marketed by Chugai and Zenyaku Kogyo Co  Ltd Approval of new drugs and a potential label expansion of existing drugs bode well for Roche  as its legacy drugs like Herceptin and MabThera are facing competition from biosimilars  Sales of MabThera Rituxan were down 8  in the first quarter of 2018 as sales in Europe  down 44   were adversely impacted by the market entry of biosimilars Roche s stock has lost 9 3  in the last six months compared with  decline of 2 2   Novartis   NYSE NVS   has already launched its biosimilar version of Rituxan MabThera in Europe  Amgen   NASDAQ AMGN   has also obtained FDA approval for a biosimilar version of Avastin for treatment of five types of cancers including lung cancer  colorectal cancer  glioblastoma  renal cell carcinoma and cervix cancer Zacks RankRoche currently carries a Zacks Rank  3  Hold   You can see  
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-06-07,Zacks Investment Research,https://www.investing.com/analysis/roche-rituxan-label-expanded-by-fda-for-pemphigus-vulgaris-200323341,200323341
129236,350751,BIIB,Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset,opinion,Biogen Inc   NASDAQ BIIB   announced that it has signed an option agreement with private biotech  TMS Co   Ltd  to acquire the latter s phase II acute stroke candidate TMS 007 and backup compounds Biogen is expected to pay  4 million upfront and an additional  18 million if it exercises the option with up to  335 million payable as potential milestone payments TMS 007 designed to restore blood flow following acute stroke is being evaluated in a phase II study  In August 2015  the candidate completed the phase l study With this acquisition  Biogen aims to boost its acute neurology portfolio  a strategic move for the company s growth  To pursue innovative approaches in therapeutic area  Biogen already has a phase III ready pipeline candidate  BIIB093  under development for the prevention and treatment of edema in large hemispheric infarction  a severe type of stroke However  in February 2018  Biogen s multiple sclerosis  MS  drug  Tysabri  natalizumab   failed to meet the primary and secondary endpoints in a phase IIb program  evaluating it for another indication  acute ischemic stroke  AIS  Some investors believe that natalizumab s failure in the AIS study could be a reason behind this buyout from TMS Biogen s core business area is multiple sclerosis  MS   a disabling disease of the brain and spinal cord  Key multiple sclerosis drugs in its portfolio are Tecfidera  Avonex and Tysabri  However  it is looking to diversify its business and aims at being a leader in neuroscience and adjacent therapeutic space In 2017  Biogen added seven new clinical stage programs to its neuroscience pipeline through advancing internal pipeline candidates as well as via external deals This year in March  Biogen agreed to acquire a phase IIb ready candidate  PF 04958242  for cognitive impairment associated with schizophrenia  CIAS  from Pfizer   NYSE PFE    In January  Biogen acquired the rights to Karyopharm s phase I ready investigational oral compound  KPT 350  for certain neurological and neurodegenerative conditions  primarily focused on amyotrophic lateral sclerosis or ALS  Biogen plans to start a phase I trial by the end of 2018 Shares of Biogen have lost 4 2  year to date  outperforming the  decline of 6 7   Biogen currently carries a Zacks Rank  3  Hold   Better ranked stocks in the same sector include CRISPR Therapeutics AG   NASDAQ CRSP   and Genomic Health Inc   NASDAQ GHDX    both sporting a Zacks Rank  1  Strong Buy   You can see  CRISPR Therapeutics  loss per share estimates has narrowed by 7 8  for 2018 and 9  for 2019 in the last 60 days  The stock has skyrocketed 185 4  year to date Genomic Health s earnings estimates surged 42 4  for 2018 and 2 7  for 2019 in the past 60 days  The stock has soared 51 2  so far this year Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-06-07,Zacks Investment Research,https://www.investing.com/analysis/biogen-inks-deal-with-tms-to-acquire-phase-ii-stroke-asset-200323423,200323423
129242,350757,BIIB,Biotech Stock Roundup  AXON Soars  Amgen Drugs Get FDA  EC Nod ,opinion,"The biotech sector was in focus last week with regular pipeline updates and collaboration licensing deals  While biotech bigwig Amgen s   NASDAQ AMGN   drugs won both FDA and EC approvals  Axovant   NASDAQ AXON   soared on a licensing deal Oxford BioMedica  Meanwhile  Regeneron   NASDAQ REGN    collaborated with Zoetis to discover new veterinary treatments Recap of Important Stories Amgen Gets FDA Nod to Addition of Data to Kyprolis  Amgen announced that the FDA has approved its supplemental New Drug Application  sNDA  to add the positive overall survival  OS  data from the phase III trial  ASPIRE  to myeloma drug  Kyprolis   The data added to the label showed that Kyprolis  Revlimid and dexamethasone  KRd  significantly reduced the risk of death by 21  and extended overall survival by 7 9 months versus Revlimid and dexamethasone alone  Rd  in patients with relapsed or refractory multiple myeloma  In addition  the European Commission  EC  approved a label expansion for Prolia  denosumab  for the treatment of bone loss associated with long term systemic glucocorticoid therapy in adult patients at increased risk of fracture   This is the third indication for which Prolia has received EC approval  Read more      Regeneron Collaborates With Zoetis  Regeneron announced a five year collaboration agreement with Zoetis whereby the latter will use its monoclonal antibody therapeutics in animals and discover new veterinary treatments  Per the terms  Regeneron has granted Zoetis a license for its proprietary VelocImmune antibody technology  which the latter will use to develop monoclonal antibodies modified for species specific use in companion and livestock animals  In exchange  Regeneron will receive a license fee  approval and sales milestone payments and royalties on any potential veterinary treatments  Axovant Sciences Soar on Gene Therapy Deal  Shares of Axovant Sciences gained after the company announced that it has licensed the exclusive worldwide rights to develop and commercialize AXO LentiPD from Oxford BioMedicafor Parkinsons  disease  AXO LentiPD  formerly OXB 102  is an experimental gene therapy being developed for Parkinson s disease  which delivers three genes encoding a critical set of enzymes required for dopamine synthesis in the brain  Axovant plans to initiate a phase I II dose escalation study on AXO LentiPD in patients with advanced Parkinson s disease  by the end of 2018  Per the terms of the agreement  Axovant will make an initial payment of  30 million in cash to obtain rights to AXO Lenti PD  as well as its predecessor product  ProSavin  Out of this  30 million   5 million is applied as a credit against the process development work and clinical supply that Oxford BioMedica will provide to Axovant  In addition  Oxford BioMedica will also be entitled to receive additional development  regulatory and commercial milestone payments  potentially in excess of  812 million and tiered royalties on net sales of AXO Lenti PD  if approved  Meanwhile  Axovant will receive  25 million equity financing from Roivant Sciences to support clinical development of AXO Lenti PD and additional business development  The company also got a new chief technology officer  Fraser Wright   Read more    Axovant currently sports a Zacks Rank  1  Strong Buy   You can see  Biogen Acquires Asset for Thrombosis  Biogen   NASDAQ BIIB   entered into an exclusive option agreement with TMS Co   Ltd  to acquire TMS 007 and backup compounds for an upfront payment of  4 million  The agreement also includes an additional  18 million payment if Biogen exercises its option  with up to  335 million in potential development and commercialization milestones as well as tiered royalties  TMS 007  a plasminogen activator  enables to restore blood flow following acute stroke  with an extended treatment window versus the current standard of care  The candidate is currently being evaluated in a double blind  placebo controlled phase II study in Japan for the safety and efficacy of a single IV administration of TMS 007 in approximately 60 90 patients with AIS up to 12 hours after stroke onset  The first patient was dosed in February 2018  The acquisition is in line with Biogen s efforts to broaden its neurology portfolio Alexion Teams With Complement Pharma  Alexion Pharmaceuticals  Inc    NASDAQ ALXN   announced a partnership with Complement Pharma to co develop the preclinical C6 complement inhibitor  CP010  for neurodegenerative disorders  CP010 is a humanized monoclonal antibody in preclinical stages that binds to C6 in circulation to inhibit its function throughout the body by preventing MAC formation in both the periphery and the central nervous system  Alexion and Complement Pharma will collaborate on the development program for CP010  Complement Pharma will be responsible for conducting preclinical and phase I studies as well as manufacturing CP010  In exchange  Alexion will provide Complement Pharma with up to  14 million in milestone dependent payments through phase Ib development   Alexion is looking to develop its pipeline and reduce dependence on key drug Soliris for pipeline development   Read more   PerformanceMedical   Biomedical and Genetics Industry 5YR   Return
 The NASDAQ Biotechnology Index gained 1 59  over the last five trading sessions  Among the major biotech stocks  Vertex gained 3 62   Over the past six months  Celgene  NASDAQ CELG  has lost 28 9   while Vertex has gained 7 15     See the last biotech stock roundup here    What s Next in Biotech Stay tuned for regulatory updates and pipeline development news The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-06-12,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-axon-soars-amgen-drugs-get-fda-ec-nod-200324611,200324611
129244,350759,BIIB,Drug Stocks  The Next Hot Industry Or Value Traps ,opinion," 0     Drug Stocks  Value Traps or Opportunity   1     Tracey s Top Stock Picks 11     Health Service Industry 14     Episode Roundup  Welcome to Episode  96 of the Value Investor Podcast
Every week  Tracey Ryniec  the editor of Zacks   shares some of her top value investing tips and stock picks 
Recently  investors on Stocktwits and Twitter have been asking about some of the drug stocks 
If you look at the valuations  you can see why 
Many are dirt cheap  with some trading with single digit P Es 
Problem is  the Street hates them  which makes them perfect for value investors  
Retail and energy stocks were hated over the last several years too but have staged big turnarounds in 2018 
Will the drug stocks be the next big turnaround success story 
Definition of a Value Trap
Remember  a value trap is a stock that looks cheap based on basic value fundamentals like the P E ratio 
Who doesn t like a company trading at 5x earnings 
But sometimes there s a reason for the cheapness  Investors have to look beyond the value fundamentals at earnings 
Are they rising or falling 
Rising earnings with a low P E tells you that something right is going on at a company  But an earnings decline can be a sign that the company has lost its way 
Value Stock or a Trap 
1        Gilead Sciences   NASDAQ GILD   has a forward P E of just 11 8  Shares are down 13 3  over the last 2 years while the S P 500 has gained 34 5  in that time  What are the earnings expected to do in 2018 
2        Biogen   NASDAQ BIIB   is trading with a forward P E of 12 9  Year to date  the shares are down 8 4  but they ve gained 28 5  over the prior 2 years  Estimates for 2018 have been cut in the last 60 days  but is there earnings growth 
3        Celgene   NASDAQ CELG   has taken a beating this year with shares falling 27  year to date  It s now trading with a forward P E of just 9 2  That s cheap  But is it a trap 
4        Lannett   NYSE LCI   is the cheapest among this group  It has a forward P E of only 5 3  Should you take a chance  Shares are down 31  year to date and have fallen 35  the prior 2 years 
5        Valeant   NYSE VRX   has had its problems the last few years but the shares have rebounded in 2018 and are up 22  compared to the S P s return of 3 4   It s also cheap  with a forward P E of just 8  Is this the bottom of the earnings decline 
There are lots of categories in the healthcare sector including the insurers  hospitals  device manufacturers  staffing and others 
But the drug companies have been hit especially hard 
Just because they re cheap  however  doesn t mean they re a good buy  Investors need to do their homework 
Value stock or a trap 
Find out on this week s podcast 
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-06-13,Zacks Investment Research,https://www.investing.com/analysis/drug-stocks-the-next-hot-industry-or-value-traps-200324761,200324761
129245,350760,BIIB,Zacks Value Investor Highlights  Gilead Sciences  Biogen  Celgene  Lannett And Valeant,opinion,For Immediate ReleaseChicago  IL   June 15  2018   Zacks Value Investor is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec  Every week  Tracey will be joined by guests to discuss the hottest investing topics in stocks  bonds and ETFs and how it impacts your life  To listen to the podcast  click here    Drug Stocks  Next Hot industry or Value Traps  Welcome to Episode  96 of the Value Investor Podcast Every week  Tracey Ryniec  the editor of Zacks   shares some of her top value investing tips and stock picks Recently  investors on Stocktwits and Twitter have been asking about some of the drug stocks If you look at the valuations  you can see why Many are dirt cheap  with some trading with single digit P Es Problem is  the Street hates them  which makes them perfect for value investors  Retail and energy stocks were hated over the last several years too but have staged big turnarounds in 2018 Will the drug stocks be the next big turnaround success story Definition of a Value TrapRemember  a value trap is a stock that looks cheap based on basic value fundamentals like the P E ratio Who doesn t like a company trading at 5x earnings But sometimes there s a reason for the cheapness  Investors have to look beyond the value fundamentals at earnings Are they rising or falling Rising earnings with a low P E tells you that something right is going on at a company  But an earnings decline can be a sign that the company has lost its way Value Stock or a Trap 1        Gilead Sciences   NASDAQ GILD   has a forward P E of just 11 8  Shares are down 13 3  over the last 2 years while the S P 500 has gained 34 5  in that time  What are the earnings expected to do in 2018 2        Biogen   NASDAQ BIIB   is trading with a forward P E of 12 9  Year to date  the shares are down 8 4  but they ve gained 28 5  over the prior 2 years  Estimates for 2018 have been cut in the last 60 days  but is there earnings growth 3        Celgene   NASDAQ CELG   has taken a beating this year with shares falling 27  year to date  It s now trading with a forward P E of just 9 2  That s cheap  But is it a trap 4        Lannett   NYSE LCI   is the cheapest among this group  It has a forward P E of only 5 3  Should you take a chance  Shares are down 31  year to date and have fallen 35  the prior 2 years 5        Valeant   NYSE VRX   has had its problems the last few years but the shares have rebounded in 2018 and are up 22  compared to the S P s return of 3 4   It s also cheap  with a forward P E of just 8  Is this the bottom of the earnings decline There are lots of categories in the healthcare sector including the insurers  hospitals  device manufacturers  staffing and others But the drug companies have been hit especially hard Just because they re cheap  however  doesn t mean they re a good buy  Investors need to do their homework Value stock or a trap Find out on this week s podcast Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius Zacks Restaurant Recommendations  In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector  Tracey Ryniec is the Value Stock Strategist for Zacks com  She is also the Editor of the Insider Trader and Value Investor services  You can follow her on twitter at  TraceyRyniec and she also hosts the Zacks Market Edge Podcast on iTunes About ZacksZacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time    Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2018-06-14,Zacks Investment Research,https://www.investing.com/analysis/zacks-value-investor-highlights-gilead-sciences-biogen-celgene-lannett-and-valeant-200325228,200325228
129248,350763,BIIB,Roche Announces Positive Data On Gazyva And MS Drug Ocrevus,opinion,"Roche   OTC RHHBY   announced encouraging data from the final analysis of the CLL11 study  evaluating Gazyva based treatment in previously untreated chronic lymphocytic leukaemia  CLL  
The phase III  multicenter  open label  randomized three arm study was conducted to evaluate the safety and efficacy profile of Gazyva in combination with chlorambucil compared to MabThera in combination with chlorambucil or chlorambucil alone  in nearly 800 patients with previously untreated CLL and comorbidities 
The final results  after a follow up of almost five years  showed clinically meaningful improvements with Gazyva plus chlorambucil across multiple endpoints  including progression free survival  PFS  and overall survival  OS   when compared head to head with Rituxan plus chlorambucil 
These long term data confirm Gazyva s efficacy to extend the lives of patients suffering from CLL  compared to that of MabThera Rituxan 
Gazyva based treatment reduced the risk of death by 24  compared to MabThera Rituxan based treatment  Gazyva is approved in combination with chlorambucil  for patients with previously untreated CLL 
Roche is a leader in the oncology market with a wide portfolio of drugs for breast cancer and CLL among others 
Additionally  Roche announced new data on multiple sclerosis  MS  drug  Ocrevus  which will be presented at the 4th Congress of the European Academy of Neurology  EAN  from Jun 16 19 in Lisbon  Portugal 
The data from a new exploratory analysis  from the extended control period of the phase III study  ORATORIO  in primary progressive multiple sclerosis  PPMS  patients  showed that Ocrevus may significantly delay the time to need a wheelchair by seven years  as measured by the length of time until a person reaches Expanded Disability Status Scale seven or greater  EDSS 7   using 24 week confirmed disability progression  CDP  
Patients  treated with Ocrevus  showed a 46  reduction in the risk of progressing to a wheelchair compared to the placebo treated group  The analysis also showed that the placebo treated patient population studied in Oratorio had similar disability progression rates to an untreated real world PPMS population  The extrapolated median time to wheelchair  EDSS 7  for placebo treated people in the Oratorio study was 12 1 years 
The longer term efficacy and safety data are consistent with the drug s favourable benefit risk profile  for both PPMS and relapsing MS  RMS  
In addition  a new global study  FLOODLIGHT Open  is now enrolling patients in the United States  The study uses proprietary FLOODLIGHT mobile technology to collect and monitor anonymized patient data to help gain a better understanding of MS disease progression  The study is an observational  open access study aimed to enroll 10 000 people globally  including people with relapsing and progressive forms of MS  within five years 
Roche will be initiating two new phase IIIb studies of Ocrevus in 2018 
While the MS market holds immense potential  competition is stiff with the likes of Biogen  Inc    NASDAQ BIIB   
Approval of new drugs and a potential label expansion of existing drugs bode well for Roche  as its legacy drugs like Herceptin and MabThera are facing competition from biosimilars 
Roche s stock has lost 12 7  in the last six months compared with   decline of 3 1  
 

 
Novartis   NYSE NVS   has already launched its biosimilar version of Rituxan in Europe  Amgen   NASDAQ AMGN   has also obtained FDA approval for a biosimilar version of Avastin for treatment of five types of cancers including lung cancer  colorectal cancer  glioblastoma  renal cell carcinoma and cervix cancer 
Zacks Rank
Roche currently carries a Zacks Rank  3  Hold   You can see  
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-06-15,Zacks Investment Research,https://www.investing.com/analysis/roche-announces-positive-data-on-gazyva-and-ms-drug-ocrevus-200325456,200325456
129263,350778,BIIB,Selecting Deep In The Money Strikes  A Real Life Example Using BIIB,opinion,"Option selection is the second required skill when selling call and put options  On 9 26 2017  George shared with me a trade he executed with Biogen  Inc   NASDAQ BIIB   An in the money strike was sold and share price immediately accelerated  George was inquiring about how deep in the money  ITM  the strike prices should be set 
George s initial trade

Buy 100 x BIIB at  313 80
Sell  1 month   307 50 call for  8 20
9 26 2017  Stock trading at  318 46

We use in the money strikes when concerned about potential price decline of the underlying security 
Calculating initial timer value returns

Using the multiple tab of the   we see an initial time value return of 0 6  with a   of that initial profit not breakeven  of 2   When evaluating if this was the best strike to select we must first define what the goals were prior to entering the trade  If the return goal and protection goals were met  then yes this was the appropriate strike  If not  a more relevant option should be considered 
One month later
With BIIB trading at  328 78 on 10 23 2017  let s view the  for in the money strikes and assume a goal of 2    4  for initial time value returns  my personal preference  

We will evaluate three in the money strikes   315 00   317 50 and  320 00  by entering the information into the multiple tab of the Ellman Calculator 

The initial time value returns of all 3 strike prices approximate our 2    4  1 month goals  If we are looking to generate the most protection of the time value profit  we would favor the  315 00 strike  4 2    If we preferred the greatest time value profit  then the  325 00 strike should be considered  The  320 00 strike is an excellent compromise 
Discussion
When deciding on which in the money strike to select  initial time value goals must first be established  From there  the amount of profit protection should be considered  Once those two components are defined  strike selection will become apparent 
Market tone
This week s economic news of importance 

Retail sales march 0 6   0 4  expected 
Housing starts March 1 319 million  1 255 million expected 
Building permits March 1 354 million  1 321 last 
Weekly jobless claims 4 14 232 000  230 000 expected 
Leading economic indicators March 0 3   0 7  last 

THE WEEK AHEAD
Mon April 23rd

Markit manufacturing PMI April Markit services PMI AprilExisting home sales March

Tue April 24th

Case Shiller home prices Feb
Consumer confidence index April
New home sales March

Wed April 25th

None scheduled

Thu April 26th

Weekly jobless claims through 4 21
Durable goods orders March

Fri April 27th

GDP Q1
Consumer sentiment index April

For the week  the S P 500 moved up by 0 52  for a year to date return of     0 13  
Summary
IBD  Market in confirmed uptrend
  6 6  Sell signal since market close of March 23  2018
BCI  Selling 2 in the money strikes for every 1 out of the money strike for all new positions  Earnings season should be a positive for the market 
WHAT THE BROAD MARKET INDICATORS  S P 500 AND VIX  ARE TELLING US
The 6 month charts point to a bearish sentiment  In the past six months  the S P 500 was up 2  while the VIX  16 79  moved up by 75   The VIX has calmed a bit more from the prior week 
Wishing you much success ",2018-04-22,Dr. Alan Ellman,https://www.investing.com/analysis/selecting-deep-inthemoney-strikes-a-reallife-example-200307576,200307576
129271,350786,BIIB,Roche  RHHBY  Presents Encouraging Data On MS Drug Ocrevus ,opinion,Roche Holding  SIX ROG  AG   OTC RHHBY   announced encouraging data on multiple sclerosis   MS   drug Ocrevus at the 70th American Academy of Neurology   AAN   Annual Meeting  held from Apr 21 27 in Los Angeles  CA  The data revealed the efficacy of Ocrevus in relapsing multiple sclerosis   RMS   through several measures of underlying disease activity and disability progression  including magnetic resonance imaging   MRI    cognitive function  and spinal fluid biomarkers of inflammation and neurodegeneration The data showed that four years of continuous treatment with Ocrevus showed a sustained reduction in underlying disease activity in RMS from the open label extension period Patients who continued with Ocrevus maintained low numbers of T1 gadolinium enhancing  T1Gd   lesions  0 017 pre OLE to 0 17 T1Gd  lesions per scan at year four  year two of the OLE phase   and new enlarging T2  N ET2  lesions  0 052 pre OLE to 0 080 N ET2 lesions per scan  through year two of the OLE phase The safety data was consistent with the drug s favorable benefit risk profile in both relapsing and primary progressive multiple sclerosis Additonally  a second four year analysis presented in a poster at AAN also revealed that patients who stayed on Ocrevus through year two of the OLE period sustained low annualized relapse rates  and 24 week confirmed disability progression Those who switched from interferon beta 1a to Ocrevus experienced a significant decline in ARR by year one that was maintained through year two  Further  Ocrevus reduced the risk of 12  and 24 week confirmed cognitive decline  as defined by confirmed worsening on the Symbol Digit Modalities Test of at least four points  by 38 and 39   p 0 001 and p 0 002  respectively  during the 96 week period in people with RMS  compared to interferon beta 1a Pooled data from phase III studies  OPERA I and OPERA II data  showed that patients with RMS at increased risk of progressive disease  as determined by baseline Expanded Disability Status Scale and pyramidal Kurtzke Functional Systems scores of at least four and two points  respectively  and treated with Ocrevus experienced a significant improvement in cognitive function compared with those taking interferon beta 1a through 96 weeks In March 2017  the FDA approved Ocrevus to treat adults with relapsing forms of MS and primary progressive multiple sclerosis  However  there were uncertainties over Ocrevus being a new innovation or a reformulation of Roche s older drug Rituxan  The drug sales aren t that impressive yet either   Roche s stock has lost 10 6  over a year  as against the industry s gain of 8 7  Last week  Novartis   NYSE NVS   also announced encouraging data from the phase III study  EXPAND  on oral  once daily siponimod  BAF312  in patients with secondary progressive multiple sclerosis   SPMS   Given the complexity of the market  MS drugs have a long history of serious side effects  making it a risky therapeutic area   An autoimmune inflammatory disease of the centrol nervous system  MS disrupts the normal functioning of the brain  optic nerves and spinal cord through inflammation and tissue loss  There are three types of MS widely known to affect adults   relapsing remitting MS  SPMS and primary progressive MS Competition is also stiff in the market  Biogen   NASDAQ BIIB   is a dominant player in the MS market with drugs like Avonex  Tysabri  Tecfidera  Plegridy and Zinbryta   The FDA recently issued Refusal to File letter to Celgene s   NASDAQ CELG   New Drug Application for ozanimod  which is in development for the treatment of patients with relapsing forms of multiple sclerosis Zacks RankRoche currently carries a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-04-22,Zacks Investment Research,https://www.investing.com/analysis/roche-rhhby-presents-encouraging-data-on-ms-drug-ocrevus-200307894,200307894
129272,350787,BIIB,Drug Biotech Stock Q1 Earnings Due On Apr 24  LLY  BIIB  AMGN,opinion,The first quarter 2018 earnings season started on a solid note  showing signs of yet another reporting cycle emerging strong  Per the latest   87 S P 500 members   accounting for 17 4  of the index   have already released financial figures as of Apr 20  2018 Total earnings for these index participants jumped 25  from the year ago quarter  driven by 10 7  improved revenues  The beat ratio was 82 8  for the bottom line and 67 8  for the top line Further good news is that the ongoing earnings phase seems to have also begun encouragingly for the Drug Biotech sector  Among the major large cap players  Johnson   Johnson   NYSE JNJ   kicked off the season strongly  beating the Zacks Consensus Estimate for both earnings as well as sales in first quarter 2018  Another large cap player having reported earnings performance last week is Novartis   NYSE NVS    which also surpassed both earnings and revenue expectations this quarter We remind investors that though the Drug biotech sector faced severe volatility since the last couple of months due to broader market pressure  mainly driven by the U S  China trade war  the sector is still likely to improve as the year progresses We expect a surge in new product sales in sync with rising demand  This apart  a successful innovation and product line expansion  strong clinical study results  more frequent FDA approvals  a consistently sturdy performance of key products  growing demand for drugs  especially to address rare to treat diseases  an ageing populace and an increased healthcare expenditure are some of the factors that should keep the sector well in place Also  according to the Earnings Preview  the broader Medical sector  inclusive of drug  biotech as well as Medical Device companies  is likely to record 6 8  year over year growth in revenues and a 9 4  rise in earnings in the period under discussion Three pharma biotech giants are scheduled to report earnings numbers on Apr 24  Let s see  how things are shaping up for the companies in the upcoming releases Eli Lilly and Company   NYSE LLY  Eli Lilly and Company Price and EPS Surprise    Lilly is slated to release first quarter earnings before the market opens  The company delivered a positive surprise of 5 56  last quarter  Moreover  the company s performance has been impressive in the recent past with its earnings surpassing expectations in all the trailing four quarters with an average positive surprise of 4 08  However  our proven model does not conclusively show that Lilly is likely to beat on earnings this quarter  Though the company s favorable Zacks Rank  2  Buy  increases the predictive power of ESP  its of  0 48  leaves surprise prediction inconclusive as the company requires a positive ESP to be confident about a probable surprise  The Zacks Consensus Estimate for the quarterly earnings is pegged at  1 13 per share Lilly s strong uptake of new products like Trulicity  Taltz  Basaglar  Cyramza  Jardiance and Lartruvo should compensate the sales decline of its established products  namely Zyprexa  Alimta  Cialis  Strattera and Effient  We expect this uptrend to find reflection in the results of the soon to be reported quarter   Read More    Biogen Inc    NASDAQ BIIB  Biogen Inc  Price and EPS Surprise    Biogen is also slated to release first quarterearnings before the market opens  The company s track record has also been impressive so far  It delivered a positive surprise in three of the trailing four quarters with an average beat of 6 91   However  Biogen came up with a negative surprise of 3 31  in fourth quarter 2017 Moreover  our proven model does not conclusively show that Biogen is likely to beat on earnings this quarter  Though the company s favorable Zacks Rank  3  Hold  increases the predictive power of ESP  its Earnings ESP of  0 51  leaves surprise prediction inconclusive  The Zacks Consensus Estimate is pegged at  5 93 per share  You can see  Sales of Biogen s multiple sclerosis drugs improved  Patient growth across major European markets as well as growth in the strong emerging market drove international Tecfidera sales while inventory build in the quarter benefited U S  sales  We expect this momentum to continue in the impending results of the soon to be reported quarter   Read More    Amgen Inc    NASDAQ AMGN  Amgen Inc  Price and EPS Surprise    Amgen is scheduled to release first quarter earnings after market close  The company delivered a negative surprise of 4 93  in the previous quarter  Amgen s earnings performance has been quite robust with the metric beating expectations in three of the last four quarters while missing the same in the remaining one with an average beat of 2 93  Our proven model shows that Amgen is likely to beat on earnings this quarter  The combination of Amgen s Zacks Rank of 3  which increases the predictive power of ESP and a positive Earnings ESP of  3 34  makes us confident about an earnings beat in the upcoming report  The consensus mark for the quarter to be reported is pegged at  3 23 per share You can uncover the best stocks to buy or sell before they re reported with our  Amgen s latest products like Prolia  Kyprolis  Xgeva and Blincyto are likely to perform well backed by higher demand  This upside might make up for the weak sales on stiff competition of mature brands such as  Enbrel  Aranesp  Epogen  Neulasta and Neupogen in the to be reported quarter  Read More    Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-04-23,Zacks Investment Research,https://www.investing.com/analysis/drugbiotech-stock-q1-earnings-due-on-apr-24-lly-biib-amgn-200308007,200308007
129273,350788,BIIB,Biogen  BIIB  Q1 Earnings Beat  Sales Miss  Shares Down,opinion,"Biogen Inc  s   NASDAQ BIIB   reported first quarter 2018 earnings per share of  6 05  which beat the Zacks Consensus Estimate of  5 93 by 2   Moreover  the bottom line rose 16  year over year 
Sales came in at  3 13 billion  up 11  from the year ago period  However  the metric marginally missed the Zacks Consensus Estimate of  3 15 billion  The top line  excluding hemophilia revenues  grew 15  year over year 
We remind investors that last year Biogen spun off its hemophilia business into a new company called Bioverativ  Earlier this January  Sanofi   NYSE SNY   announced that it has entered into an agreement with Bioverativ to buy the latter for  11 6 billion 
Shares of Biogen were down more than 2 5  in pre market trading  The stock has declined 19 3  this year so far  underperforming the  s 9  decrease 

Quarter in Detail
Biogen s multiple sclerosis  MS  revenues were  2 1 billion  down 4  year over year  in the reporter quarter including approximately  77 million in royalties on the sales of Roche s   OTC RHHBY   MS drug  Ocrevus  Per a deal with Roche  Biogen is entitled to receive royalties on U S  sales of Ocrevus 
Oral MS drug Tecfidera s sales increased 3  year over year but decreased 8  sequentiallyto  987 million  The other MS drug Tysabri s sales declined 15  year over year but was flat sequentially with  462 million 
Combined interferon revenues  Avonex and Plegridy  in the first quarter were  550 million  down 15  both year over year and sequentially  Avonex revenues declined 16  from the year ago period to  451 million  Plegridy contributed  100 million to revenues  which decreased 11  year over year and 20   sequentially 
U S  Interferon revenues are experiencing declining trends due to patients transitioning to other oral MS therapies as well as due to higher discounts and allowance 
Zinbryta  launched in collaboration with AbbVie   NYSE ABBV    contributed  1 million to revenues in the first quarter compared with  12 million in fourth quarter 2017 
Notably  in March 2018  Biogen announced the decision to withdraw Zinbryta from the markets  within less than two years of its FDA approval  due to growing safety concerns and limited commercial adoption of the drug because of its restrictive label  Both companies decided to discontinue the drug s marketing on grounds of its complex and evolving benefit risk profile 
Biogen s newest drug Spinraza  spinal muscular atrophy  logged revenues of  364 million in the first quarter  almost in line with the previous one 
Spinraza U S  sales were  188 million in the first quarter  decreasing 13 8  sequentially  However  in the ex U S  markets  Spinraza recorded sales of  176 million  up 22  sequentially  Significantly  the number of patients receiving Spinraza grew 16  in the United States and 56  outside the United States in the quarter under review compared with the preceding period 
The company said that Spinraza international revenues were mainly grossed from Germany  Turkey and Japan 
In the first quarter of 2018  Biogen recorded biosimilar revenues of  128 million compared with  122 million in the fourth quarter of 2017 
Revenues from Anti CD20 therapeutic programs  which include Biogen s shares of Rituxan and Gazyva operating profits  climbed 30 1  from the year ago period to  443 2 million 
The R D spend increased 18  year over year but decreased 15  sequentially to  497 million  On the other hand  while SG A spend were up 3  year over year  it decreased 10  sequentially to  497 million Biogen Inc  Price  Consensus and EPS Surprise

   Zacks Rank
Biogen carries a Zacks Rank  3  Hold   You can see  
Will You Make a Fortune on the Shift to Electric Cars  
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2018-04-23,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-q1-earnings-beat-sales-miss-shares-down-200308536,200308536
129280,350795,BIIB,Novartis Multiple Sclerosis Drug Gets FDA Nod For Adolescents,opinion,Novartis AG   NYSE NVS   announced that the FDA has approved the label expansion for its multiple sclerosis   MS   drug Gilenya  fingolimod   The drug has been approved for the treatment of children and adolescents aged between 10 and 18 with relapsing forms of multiple sclerosis   RMS    The drug is the first disease modifying therapy indicated for individuals aged between 10 and 18 We note that Gilenya is already approved in the United States for the first line treatment of RMSin adults and in Europe for adult patients with highly active relapsing remitting MS   RRMS   The approval of Gilenya in patients aged between 10 and 18 was supported by data from the phase III PARADIGMS study  The study met its primary endpoint and showed that oral Gilenya resulted in a significant and clinically meaningful reduction in the number of relapses  annualized relapse rate  by about 82 in children adolescentsover a period of up to two years  compared to interferon beta 1a intramuscular injectionsNovartis stock has lost 7 6  year to date compared with the  s 3 4  decline Apart from  Gilenya  Novartis  MS portfolio includes Extavia  interferon beta 1b for subcutaneous injection  which is approved for the treatment of relapsing forms of MS  The company also other pipeline candidates like BAF312  siponimod  and OMB157  ofatumumab   under investigation in relapsing MS  Novartis  generic division  Sandoz  markets Glatopa  a generic version of Teva Pharmaceutical s   NYSE TEVA   Copaxone  both 20 and 40 mg  We note that Biogen  Inc    NASDAQ BIIB   holds a strong position in the MS market with a wide range of products including Avonex  Tysabri  Tecfidera and Plegridy Zacks Rank   Stock to ConsiderNovartis currently carries a Zacks Rank  3  Hold  A better ranked stock from the same space is Ligand Pharmaceuticals   NASDAQ LGND    sporting a Zacks Rank  1  Strong Buy   You can see  Ligand s earnings per share estimates moved up from  4 07 to  4 09 for 2018 over the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with an average beat of 31 79   The company s shares have rallied 30 1  year to date Novartis AG Price    5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions  New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-05-13,Zacks Investment Research,https://www.investing.com/analysis/novartis-multiple-sclerosis-drug-gets-fda-nod-for-adolescents-200315986,200315986
129283,350798,BIIB,5 Trade Ideas For Monday  AMTD  BIIB  DEO  FITB  TECK,opinion,"TD Ameritrade Holding Corporation  NASDAQ AMTD 

TD Ameritrade   AMTD  started moving higher in May 2017  It continued to a peak in March and then started to consolidate  It has moved sideways against resistance above and the 50 day SMA below since  The RSI is now making a higher high in the bullish zone with the MACD positive and rising  Look for a push through resistance to participate   
Biogen  NASDAQ BIIB 

Biogen   BIIB  pulled back from a top in January  finding support in March  over  100 lower  It has consolidated there ever since  Last week it pushed through the 50 day SMA for the first time since early in the fall and it closed over resistance Friday  The RSI is now in the bullish zone with the MACD rising and positive  Look for continuation to participate higher   
Diageo  LON DGE  PLC ADR  NYSE DEO  

Diageo   DEO  gapped higher in July last year and then continued to move up  It eventually reached a top in January and started to pull back  The pullback found support in February and bounced against it before it touched the 200 day SMA in late March  This propelled it higher  A pull back to a higher low reversed and now it is back at the top  The RSI is strong in the bullish zone with the MACD rising and bullish  Look for a new high to participate to the upside   
Fifth Third Bancorp  NASDAQ FITB 

Fifth Third   FITB  dipped below the 200 day SMA in September  and then took off on a trip to the upside that lasted until early March  It pulled back to the 100 day SMA from there and consolidated  After reporting earnings it gapped higher and stopped just short of the high  It pulled back to a higher low and then reversed  Now it is back at the high  The RSI is in the bullish zone and the MACD is rising  Look for continuation to participate higher   
Teck Resources Ltd B  NYSE TECK 

Teck Resources   TECK  rose off of its 200 day SMA in November  reaching a top in January  It made a shallow pullback and then retested the top in February but failed to move higher  It confirmed a double top in early March but then quickly found support and settled into consolidation  A recent touch at the 200 day SMA has pushed it back higher and it is testing the top of consolidation  The RSI is rising and bullish with the MACD rising and positive  Look for continuation to participate higher   
Up Next  Bonus Idea
After reviewing over 1 000 charts  I have found some good setups for the week  This week s list contains the first five below to get you started early  These were selected and should be viewed in the context of the broad  picture reviewed Friday which heading into May options expiration week saw the equity markets have regained some swagger short term  but remain consolidating below all time highs 
Elsewhere look for Gold to continue its short term bounce off of the bottom of a range while Crude Oil continues to move higher  The US Dollar Index may be ending its short term bounce while US Treasuries consolidate at recent lows  The Shanghai Composite is bouncing off of support but Emerging Markets continue to build a bull flag off of their January high 
Volatility looks to continue to drift lower towards very low levels keeping the bias higher for the equity index ETF s SPDR S P 500  NYSE SPY   iShares Russell 2000  NYSE IWM  and PowerShares QQQ Trust Series 1  NASDAQ QQQ   Their charts all confirmed short term uptrends this week  making higher highs following higher lows  and look set to continue  Longer term they still have work to do to resume the uptrend  with the IWM on the verge of that confirmation and the QQQ and SPY trailing behind  Use this information as you prepare for the coming week and trad em well 
DISCLAIMER  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2018-05-14,Gregory W. Harmon,https://www.investing.com/analysis/5-trade-ideas-for-monday-td-ameritrade-biogen-diageo-fifth-third--teck-resour-200315842,200315842
129314,350829,BIIB,Why Multiple Sclerosis Is A Promising But Risky Space ,opinion,The Multiple Sclerosis  MS  space hit the headlines once again following biotech bigwig  Biogen   NASDAQ BIIB   and partner AbbVie s   NYSE ABBV   decision to withdraw their jointly owned MS drug  Zinbryta voluntarily on a worldwide basis due to risk of liver injury  Both companies decided to withdraw the drug on grounds of the complex and evolving benefit risk profile of Zinbryta  given the limited number of patients treated In November 2017  the European Medicines Agency  EMA  concluded its review of Zinbryta  The review found that unpredictable and potentially fatal immune mediated liver injury can occur during treatment with Zinbryta and for up to 6 months after stopping treatment  In clinical trials  1 7  of patients receiving Zinbryta had a serious liver reaction Given the complexity of the market  MS drugs have a long history of serious side effects  making it a risky therapeutic area   An autoimmune inflammatory disease of the centrol nervous system  MS disrupts the normal functioning of the brain  optic nerves and spinal cord through inflammation and tissue loss  There are three types of MS widely known to affect adults   relapsing remitting MS  RRMS   secondary progressive MS  SPMS  and primary progressive MS  PPMS  The market for MS changed drastically with the introduction of oral formulations which are mostly preferred than injections  While there a variety of drugs available for MS  they come with their own set of risks mostly Biogen is a dominant player in the MS market with drugs like Avonex  Tysabri  Tecfidera  Plegridy and Zinbryta   However  the company has been under the scrutiny for pricing of MS drugs in 2017  Earlier  the emergence of progressive multifocal leukoencephalopathy  PML  cases  a type of brain infection  associated with the use of Tysabri and Tecfidera had marred the prospects of MS drugs  The FDA thereafter updated the label of Tecfidera  Nevertheless  the company is a name to reckon with in the MS market Earlier  the FDA also issued a warning against Novartis    NYSE NVS   Gilenya for PML  The drug was recently granted Breakthrough Therapy designation to Gilenya for the treatment of children and adolescents 10 years of age or older with relapsing MS  The drug is already approved for the same among adults  Novartis has another MS drug in its portfolio  Glatopa  a generic version of Copaxone 20 mg   Sandoz  the company s generic arm  recently won FDA approval for a generic version of Copaxone 40mg Israel based Teva Pharmceuticals   NYSE TEVA   has long been in the MS market through its widely used drug Copaxone which is facing stiff competition for the last few years Meanwhile  in the past  seizures were known side effects of another MS drug  Ampyra  Seizure risk was seen to increase with higher blood levels of the drug   As a result  the FDA had to update Ampyra s label to clarify recommendations that kidney function should be checked in patients before starting Ampyra and monitored at least annually while Ampyra treatment continues Nevertheless  the risks associated with the drugs have not deterred newer entrants which claim better formulations with lesser side effects  Consequently  the market has become too crowded In March 2017  the FDA approved Roche s  RHHBY  Ocrevus to treat adults with relapsing forms of MS and primary progressive multiple sclerosis  However  there were questions if Ocrevus was a new innovation or a reformulation of Roche s older drug Rituxan  The drug sales aren t that impressive yet either The FDA recently issued Refusal to File letter to Celgene s   NASDAQ CELG   New Drug Application  NDA  for ozanimod  which is in development for the treatment of patients with relapsing forms of multiple sclerosis  The FDA determined that the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a complete review  Hence  the company is now gearing up to meet the FDA and determine the future course of action  While there haven t been any safety issues reports  the delay will definitely open up avenues for competition Given that so much is happening in this space  we expect investors to remain glued for further updates The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-15,Zacks Investment Research,https://www.investing.com/analysis/why-multiple-sclerosis-is-a-promising-but-risky-space-200298827,200298827
129315,350830,BIIB,Biogen Cracks The Case With AbbVie For Humira Biosimilar,opinion,Biogen Inc    NASDAQ BIIB   and partner Samsung  KS 005930  Bioepis have announced resolution of an ongoing patent dispute with AbbVie   NYSE ABBV   regarding Biogen s biosimilar version  Imraldi  of AbbVie s blockbuster arthritis drug  Humira  in the EU  Per the settlement agreement  Biogen Samsung Bioepis plans to launch Imraldi in Europe on Oct 16  2018 Also in the United States  Samsung Bioepis entered into a settlement agreement with AbbVie  which would allow the former to bring Humira biosimilar into the U S  market by Jan 31  2023 Imraldi  or SB5  will be used for a whole range of indications including rheumatoid arthritis  axial spondyloarthritis  ankylosing spondylitis  plaque psoriasis  psoriatic arthritis  Crohn s disease  ulcerative colitis  polyarticular juvenile idiopathic arthritis  active enthesitis related arthritis  hidradenitis suppurativa and non infectious uveitis Notably  Imraldi is the second biosimilar version of Humira to be launched in the EU  Another biotechnology company  Amgen  NASDAQ AMGN   is also expected to launch its biosimilar version of Humira  in the EU come October this year as Amjevita  per a settlement with AbbVie Notably  Amjevita was approved in the EU last March and approved in the United States in September 2016 In the United States  per settlement with AbbVie  Amjevita is likely to be launched on Jan 31  2023 Shares of Biogen have underperformed its  this year so far  The stock has lost 16 6  compared with the industry s decrease of 6 3     We remind investors that Biogen has a joint venture with Samsung BioLogics for biosimilars called Samsung Bioepis  which already markets a couple of biosimilars in the EU  namely Flixabi  a biosimilar referencing J J Merck s   NYSE MRK   Remicade and Benepali  a biosimilar referencing Amgen Pfizer s   NYSE PFE   Enbrel  This development in turn makes Imraldi the third anti TNF biosimilar from Biogen to receive a marketing authorization in the EU Biogen is also working with Samsung BioLogics to introduce new biosimilars to the market Importantly  Biogen grossed biosimilar revenues of  380 million for a 12 month period ending December 2017 compared with  101 million  logged in 2016  This upside was primarily driven by Benepali  which recorded revenues of  370 8 million compared with the year ago figure of  100 6 million on increased market share Biogen Inc  Price    Zacks RankBiogen carries a Zacks Rank  3  Hold   You can see  Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-04-05,Zacks Investment Research,https://www.investing.com/analysis/biogen-cracks-the-case-with-abbvie-for-humira-biosimilar-200303697,200303697
129316,350831,BIIB,Novartis Inks  8 7 Billion Gene Therapy Deal To Buy AveXis,opinion,Novartis   NYSE NVS   announced that it has inked a deal to acquire the U S  based clinical stage gene therapy company  AveXis  Inc   NASDAQ AVXS   AveXis is focused on developing novel treatments for patients suffering from rare and life threatening neurological genetic diseases Pursuant to the agreement  Novartis will execute the acquisition through its subsidiary for a cash tender offer of  218 per share   8 7 billion  of AveXis  common stock  representing a premium of 88 1   The culmination of this transaction is subject to customary closing conditions  Novartis anticipates completion of this buyout in the second half of 2018  Boards of both companies have approved the acquisition deal Shares of Novartis  a Swiss drug maker  inched up 1 58  in pre market trading on Apr 9  following the news release  The AveXis stock also soared 83 8  in pre market trading session  The Novartis stock has outperformed the  year to date  having lost 3 7  comapred with the industry s decline of 4 8   The impending buyout will add AveXis  lead candidate  AVXS 101  to the acquirer s portfolio  strengthening the latter s presence in gene therapy and neuroscience space  AVXS 101 is being developed or the treatment of spinal muscular atrophy  SMA   a neurodegenerative disease  accounting for the highest genetic cause of death in infants Notably  both the FDA and the European Medicines Agency  EMA  have granted AVXS 101 an orphan drug designation for the treatment of SMA and the FDA has granted AVXS 101  a fast track status for the treatment of SMA Type 1  The regulatory agency has also granted a breakthrough therapy designation to AVXS 101 for addressing SMA Type 1 in pediatric patients A regulatory filing in the United States is expected in the second half of this year with a launch anticipated in 2019  The company also secured PRIME and Sakigake designations for the candidate in Europe and Japan  respectively Significantly  an approved product for the cure of SMA in the United States is Biogen s   NASDAQ BIIB    Spinraza  nusinersen   the first and the only treatment to get an FDA nod in the country for the indication However  if approved  AVXS 101 would be the first ever one time gene replacement therapy for SMA in the United States Apart from AVXS 101  the deal will also expand Novartis pipeline into other genetic disorders including Rett Syndrome and amyotrophic lateral sclerosis Initially  though the acquisition is anticipated to negatively impact Novartis  operating income due to increased research   development expenses  it is later on expected to substantially contribute to the company s bottom line from 2020 onward We remind investors that in January 2018  Novartis entered into a licensing agreement with Spark Therapeutics to develop and commercialize the latter s gene therapy  Luxturna  voretigene neparvovec   in the markets outside the United States We note that Luxturna was approved in the United States last December as a one time gene therapy to restore functional vision in children and adult patients with biallelic mutations of the RPE65  retinal pigment epithelial 65 kDa protein  gene Novartis AG Price    Zacks Rank   Key PickNovartis carries a Zacks Rank  3  Hold   A better ranked stock in the health care sector is Ligand Pharmaceuticals Incorporated   NASDAQ LGND    sporting a Zacks Rank  1  Strong Buy   You can see  Ligand s earnings per share estimates have moved north from  3 78 to  4 20 for 2018 and from  4 75 to  5 32 for 2019 in the last 60 days  The company delivered a positive surprise in three of the trailing four quarters with an average beat of 24 88   Share price of the company has surged 49 6  over a year Zacks Editor in Chief Goes  All In  on This Stock Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ,2018-04-08,Zacks Investment Research,https://www.investing.com/analysis/novartis-inks-87-billion-gene-therapy-deal-to-buy-avexis-200304140,200304140
129317,350832,BIIB,AbbVie s RA Candidate Meets Primary Endpoints In Phase III,opinion,"AbbVie Inc    NYSE ABBV   has announced that its pipeline candidate  upadacitinib  met the primary endpoints in the 4th phase III study from its SELECT program  which evaluated the candidate for the treatment of patients with rheumatoid arthritis  RA   Upadacitinib is an investigational oral JAK1 selective inhibitor  which is being studied as a once a day oral therapy 
The phase III SELECT COMPARE study is designed to evaluate the efficacy and safety of upadacitinib  15 mg  compared with placebo and AbbVie s marketed drug  Humira  adalimumab   over 12 weeks on patients with moderate to severe RA  who are on a stable background of methotrexate and had an inadequate response  In the study  upadacitinib met both the primary as well as secondary endpoints compared with placebo while showing superiority as compared to Humira 
The primary endpoints of the study registered ACR20 responses and clinical remission  Data from the trial demonstrated that 71  of patients receiving the 15 m oral once daily dose of upadacitinib 15 mg achieved an ACR20 response compared with 36  of patients receiving placebo at week 12  Moreover  29  of subjects treated with upadacitinib achieved complete remission in comparison to 6  with placebo 
Additionally  data from the study also showed that 45  of patients experienced low disease activity  secondary endpoint  when treated with upadacitinib compared with 29  receiving Humira and 14   receiving placebo at week 12 
Notably  SELECT COMPARE is the fourth of the six ongoing phase III studies under the SELECT RA clinical trial program conducted on upadacitinib 
We remind investors that last December  AbbVie announced that upadacitinib met the primary endpoints in the 3rd phase III study from its SELECT trial 
Other researches are also underway on upadacitinib for treating Crohn s disease  ulcerative colitis and atopic dermatitis 
Shares of AbbVie have rallied 42 7  in the past year  outperforming the  s 6 4  rise 

Notably  AbbVie already has a strong presence in the RA market with its blockbuster drug  Humira  However  several companies are working on developing biosimilar versions of Humira which could induce competition in the market for the company  Also  the RA market is extremely crowded including drugs like Johnson   Johnson s Simponi and UCB s Cimzia among others 
Significantly  Eli Lilly s   NYSE LLY   JAK inhibitor  Olumiant  was approved in the EU for RA last February and Pfizer s   NYSE PFE   Xeljanz is marketed in the United States for the same indication  which might pose a strong competition for upadacitinib on approval 
Also  of late  Biogen   NASDAQ BIIB   has announced resolution of the ongoing patent dispute with AbbVie regarding Biogen s biosimilar version of Humira  in the EU  Per the settlement agreement  Biogen plans to launch Humira biosimilar in Europe by October  2018 
However  if upadacitinib is approved  it might reduce the potential negative impact of Humira generics on AbbVie s top line AbbVie Inc  Price

   Zacks Rank
AbbVie carries a Zacks Rank  3  Hold   You can see  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-04-10,Zacks Investment Research,https://www.investing.com/analysis/abbvies-ra-candidate-meets-primary-endpoints-in-phase-iii-200304518,200304518
129318,350833,BIIB,Biotech Stock Roundup  Spectrum Up  Incyte Down  AveXis To Merge With Novartis ,opinion,"The biotech sector was on a bumpy ride over the week as shares of Spectrum surged on positive data from a phase II study  while that of Incyte plunged on the failure of melanoma study  In an effort to bolster its presence in the gene therapy space Swiss giant Novartis announced the acquisition of AveXis Inc Spectrum Surges on Lung Cancer Data  Shares of Spectrum Pharmaceuticals  Inc    NASDAQ SPPI   surged after the company reported encouraging results from a phase II study on poziotinib in EGFR Exon 20 Mutant non small cell lung cancer patients  The results show that the confirmed objective response rate was 64  in the first 11 patients  better than the expectations of 20  and 30   These early data suggest that poziotinib may have a meaningful impact on outcomes for patients who have limited treatment options  The median progression free survival rate has still not been reached after a median follow up period of 6 5 months  Meanwhile  the original cohort of 30 EGFR patients is fully enrolled and the expanded cohort of 20 patients is nearing the completion of enrollment AveXis Skyrockets on Novartis Deal  AveXis  Inc  s   NASDAQ AVXS   shares skyrocketed on the news of a merger with Swiss pharma giant Novartis   NYSE NVS     Per the agreement  Novartis will pay  8 7 billion for this clinical stage gene therapy company  AveXis lead product candidate  AVXS 101  is being evaluated as one time gene replacement therapy for spinal muscular atrophy  a disease which results in early death or life long disability with considerable healthcare costs  The acquisition will poise Novartis in the promising gene therapy space  The acquisition will be completed in mid 2018  The candidate enjoys a breakthrough therapy designation in the United States and Prime designation in Europe  The FDA also granted AVXS 101  a fast track status for the treatment of SMA Type 1   A regulatory filing in the United States is expected in the second half of this year with a launch anticipated in 2019   Read more   Incyte Plunges on Study Failure  Shares of Incyte Corporation   NASDAQ INCY   plunged after an external Data Monitoring Committee review of the phase III study  ECHO 301 KEYNOTE 252 evaluating Incyte s epacadostat in combination with Merck s Keytruda in patients with unresectable or metastatic melanoma determined that the study did not meet the primary endpoint of improving progression free survival in the overall population when compared to Keytruda monotherapy  Moreover  the second primary endpoint of overall survival is not expected to reach statistical significance either  Hence  the study will be stopped The failure of the late stage candidate disappointed investors as Incyte had pinned hopes on the success given the improved response rates in mid stage studies   Read more   Conatus Pharmaceuticals Sinks on Study Failure   Conatus Pharmaceuticals   NASDAQ CNAT   plummeted after it reported that its pipeline candidate  emricasan  failed in a phase IIB study   POLT HCV SVR  The candidate did not achieve primary endpoint in the study  which evaluated patients with fibrosis or cirrhosis undergoing liver transplant   Data from the POLT HCV SVR study showed that emricasan did not achieve a better overall response rate compared to placebo in the overall patient population However  in patient subset with advanced fibrosis or early cirrhosis  emricasan provided evidence of an anti fibrotic treatment effect in 95  of the patients compared to 58 3  for placebo  The company may evaluate emricasan further in this particular subset   Read more   Biogen Settles Litigation With AbbVie For Humira Biosimilar  Biogen Inc    NASDAQ BIIB   and partner Samsung  KS 005930  Bioepis announced an agreement with AbbVie   NYSE ABBV   for the commercialization of Imraldi  a biosimilar of Humira  Per the terms  AbbVie will grant patent licenses for the use and sale of Imraldi in Europe  on a country by country basis  and Biogen and Samsung Bioepis will make royalty payments to AbbVie  Both companies have agreed to dismiss all pending patent litigation  Biogen plans to launch the biosimilar in Europe in October 2018 Samsung Bioepis entered into a settlement agreement with AbbVie  which would allow the former to bring Humira biosimilar into the U S  market by Jan 31  2023   Read more   Biogen carries a Zacks Rank  3  Hold   You can see  Performance The NASDAQ Biotechnology Index lost 0 05  over the last four trading sessions  Among major biotech stocks  Alexion fell 2 81    Over the last six months  Celgene  NASDAQ CELG  lost 35 97  while Vertex gained 4 30   see the last biotech stock roundup here    Medical   Biomedical and Genetics Industry 5YR   Return
  
What s Next in the Biotech World Stay tuned for more regulatory and pipeline updates 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-04-10,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-spectrum-up-incyte-down-avexis-to-merge-with-novartis-200304797,200304797
129319,350834,BIIB,Mylan Fujifilm Kyowa Team Up To Market Humira Biosimilar,opinion,"Mylan N V    NASDAQ MYL   is partnering with Fujifilm Kyowa Kirin Biologics Co   Ltd  to commercialize a biosimilar to AbbVie s   NYSE ABBV   blockbuster arthritis drug Humira  adalimumab   Adalimumab is developed by Fujifilm Kyowa Kirin Biologics 
Mylan intends to seek approval and commercialize the product in Europe  The European Medicines Agency   EMA   accepted a marketing authorization application for review for the proposed biosimilar to Humira in May 2017  and the companies expect to receive the EMA s decision during the second half of 2018  
Under the agreement  Mylan will have an exclusive license to commercialize the biosimilar in Europe and will receive an upfront fee from Fujifilm Kyowa Kirin  The company will also be responsible for the sales activity of the product in European countries  On the other hand  Fujifilm Kyowa Kirin Biologics will be eligible to receive a subsequent commercialization milestone payment and sales royalties  
Over a year  shares of Mylan increased 6 2  compared with the  s fall of 27 9  

Humira is a TNF inhibitor aimed at treating multiple chronic inflammatory conditions  It is approved in Europe for the treatment of rheumatoid arthritis  juvenile idiopathic arthritis  psoriatic arthritis  ankylosing spondylitis  Crohn s disease  ulcerative colitis  plaque psoriasis  hidradenitis suppurativa and uveitis 
We note that few days ago  Biogen Inc    NASDAQ BIIB   and partner Samsung  KS 005930  Bioepis announced resolution of an ongoing patent dispute with AbbVie regarding Biogen s biosimilar version  Imraldi  of AbbVie s Humira  in the EU  Per the settlement agreement  Biogen Samsung Bioepis plans to launch Imraldi in Europe on Oct 16  2018 
Also in the United States  Samsung Bioepis entered into a settlement agreement with AbbVie  which would allow the former to bring Humira biosimilar into the U S  market by Jan 31  2023 
Notably  Imraldi is the second biosimilar version of Humira to be launched in the EU  Another biotechnology company  Amgen   NASDAQ AMGN    is also expected to launch its biosimilar version of Humira  in the EU come October this year as Amjevita  per a settlement with AbbVie 
Notably  Amjevita was approved in the EU last March and approved in the United States in September 2016 
In the United States  per settlement with AbbVie  Amjevita is likely to be launched on Jan 31  2023 Mylan N V  Price

    
Zacks Rank
Mylan carries a Zacks Rank  3  Hold   You can see  
Today s Stocks from Zacks  Hottest Strategies 
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-04-12,Zacks Investment Research,https://www.investing.com/analysis/mylan-fujifilm-kyowa-team-up-to-market-humira-biosimilar-200305138,200305138
129320,350835,BIIB,Novartis  NVS  Reports Encouraging Data On MS Candidate ,opinion,Novartis AG   NYSE NVS   announced encouraging data from the phase III study  EXPAND  on oral  once daily siponimod  BAF312  in patients with secondary progressive multiple sclerosis   SPMS   Siponimod is an investigational  selective modulator of specific subtypes of the sphingosine 1 phosphate  S1P  receptor The results will be presented at the 70th American Academy of Neurology Annual Meeting  in Los Angeles which is scheduled to be held from Apr 21 to 27 The randomized  double blind  placebo controlled  EXPAND study is comparing the efficacy and safety of siponimod versus placebo in SPMS patients Data from the study showed that siponimod reduced the risk of disability progression largely disassociated from relapses in patients with SPMS New post hoc analysis also demonstrated that the risk reduction with siponimod is largely disassociated from relapses  The data from the study showed that siponimod resulted in significant benefit on cognitive processing speed  the key cognitive function impacted by MS which impacted the affected patients Meanwhile  Novartis has initiated the submission of siponimod in the United States for the approval in SPMS  Filing for EU approval is planned to follow later in 2018 A potential approval will strengthen Novartis  MS portfolio which includes Gilenya  fingolimod  an S1P modulator  approved for relapsing forms of MS and is also in development for pediatric MS  Extavia  interferon beta 1b for subcutaneous injection  is approved in the United States for the treatment of relapsing forms of MS Novartis also has another MS candidate in its pipeline apart from siponimod  ofatumumab  OMB157   a fully human monoclonal antibody being evaluated in two phase III studies for relapsing MS  The generic division  Sandoz  markets Glatopa  glatiramer acetate injection  20 mg mL and 40 mg mL  generic versions of Teva s   NYSE TEVA   Copaxone Given the complexity of the market  MS drugs have a long history of serious side effects  making it a risky therapeutic area   An autoimmune inflammatory disease of the centrol nervous system  MS disrupts the normal functioning of the brain  optic nerves and spinal cord through inflammation and tissue loss  There are three types of MS widely known to affect adults   relapsing remitting MS  SPMS and primary progressive MS However  the competition is stiff in the market  Biogen   NASDAQ BIIB   is a dominant player in the MS market with drugs like Avonex  Tysabri  Tecfidera  Plegridy and Zinbryta   The FDA recently issued Refusal to File letter to Celgene s   NASDAQ CELG   New Drug Application for ozanimod  which is in development for the treatment of patients with relapsing forms of multiple sclerosis    Novartis  stock has lost 4 5  in the last six months compared with the  s 6 0  decline Shares have declined further following first quarter results which were reported yesterday  While revenues and earnings beat estimates  sales of psoriasis drug Cosentyx fell short of expectations while Sandoz revenues declined due to pricing pressure Zacks RankNovartis currently carries a Zacks Rank  3  Hold   You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-04-19,Zacks Investment Research,https://www.investing.com/analysis/novartis-nvs-reports-encouraging-data-on-ms-candidate-200307471,200307471
129348,350863,BIIB,Biogen  BIIB  Down 17 2  Since Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Biogen Inc    NASDAQ BIIB    Shares have lost about 17 2  in the past month  underperforming the market 
Will the recent negative trend continue leading up to its next earnings release  or is BIIB due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts 
Biogen Tops Sales in Q4  Misses EarningsFourth quarter 2017 earnings per share were  5 26  which missed the Zacks Consensus Estimate of  5 44 by 3 3   Earnings however rose 4  year over year as higher revenues made up for higher operating costs Sales came in at  3 31 billion  up 15  from the year ago period  Sales also surpassed the Zacks Consensus Estimate of  3 07 billion by 7 6  Higher MS sales and Spinraza outperformance led to the strong top line performance in the quarter  Sales in the quarter also benefited from  40 million in inventory build and increased contract manufacturing  other revenues  The top line  excluding hemophilia revenues  grew 26  year over year Quarter in DetailBiogen s MS revenues were  2 3 billion  up 5   in the quarter including approximately  77 million in royalties on the sales of Roche s MS drug Ocrevus Tecfidera s sales increased 7  year over year and 1  sequentially to  1 08 billion  This included the U S  sales of  831 6 million  up 4  year over year  and ex U S  sales of  244 million  up 20 6   Patient growth across major European markets and strong emerging market growth drove international Tecfidera sales while a  20 million inventory build in the quarter benefited U S  sales Fourth quarter Tysabri revenues were  463 million which decreased 2  year over year and 1  sequentially Tysabri U S  sales declined 13  to  252 1 million in the quarter  Biogen said that since Ocrevus launch  it has witnessed a decrease in the number of patient starts and an increase in discontinuation of Tysabri in the United States  International revenues rose 14  to  210 6 million in the quarter helped by a large order in Russia and patient growth in all major European countries following the label update in 2017 Combined interferon revenues  Avonex and Plegridy  in the fourth quarter were  645 million  down 6  from the year ago period  Avonex revenues declined 8  from the year ago period to  520 million  Plegridy contributed  125 million to fourth quarter 2017 revenues  flat year over year as well as sequentially U S  Interferon revenues are experiencing declining trends due to patients transitioning to other oral or high efficacy MS therapies as well as due to higher discounts and allowance Zinbryta  launched in collaboration with AbbVie  contributed  12 million to revenues in the fourth quarter compared with  14 million in third quarter 2017 Newly launched Spinraza brought in revenues of  363 million in the fourth quarter  registering growth of 34  sequentially  As expected  Spinraza sales in the fourth quarter were mainly driven by ex U S  markets Spinraza U S  sales were  218 million in the fourth quarter  slightly better than  198 million in the third quarter  Biogen said that 25  of U S  sales in the fourth quarter were from patients who receive less intensive maintenance doses  dosing only once 4 months   versus 10  in the third quarter According to Biogen  50  of Spinraza revenues will be derived from maintenance dosing by the end of 2018  which will help stabilize the growth trajectory However  Biogen said the number of patients on therapy in the United States rose 33   from the third quarter In ex U S  markets  Spinraza recorded sales of  144 million  significantly higher than  73 3 million in the third quarter as it almost doubled the number of commercial patients on therapy  The company said that Germany  Turkey  and Japan accounted for over two thirds of ex U S  revenues In the quarter  Biogen recorded biosimilar revenues of  122 million compared with  101 million in the third quarter  driven primarily by Benepali  which recorded revenues of  117 6 million  up 18 5  sequentially  on increase in market share  Flixabi recorded revenues of  4 3 million compared with  2 2 million in the third quarter Revenues from Anti CD20 therapeutic programs  which include Biogen s shares of Rituxan and Gazyva operating profits  climbed 6  from the year ago period to  338 million As expected  operating expenses were higher in the fourth quarter as the company continues to invest in its strategic priorities  R D spend rose 11  year over year and 32  sequentially to  588 million  while SG A spend rose 15  year over year and 28  sequentially to  554 million 2017 ResultsFull year 2017 sales of  12 27 billion topped the Zacks Consensus Estimate of  12 04 billion  Sales rose 7  year over year  The top line  excluding hemophilia revenues  grew 15  year over year Adjusted earnings for 2017 were  21 81 per share  falling short of the Zacks Consensus Estimate of  21 98  Earnings rose 8  year over year 2018 OutlookBiogen guided earnings in the range of  24 20 and  25 20 per share  representing growth of 11  to 16   Revenues are expected in the range of  12 7  13 0 billion in 2018  representing year over year growth of 3 5  to 6  In 2018  Biogen said its MS franchise s sales growth  including Ocrevus royalties  will be roughly flat from 2017 levels  Excluding Ocrevus royalties  MS sales are expected to decline in a low single digit range  As far as Spinraza is concerned  in 2018  a significant portion of the revenue growth is expected to come from outside the United States While R D expenses are expected to be approximately 16  to 17  of total revenues in 2018  SG A is expected in the range of 15  to 16   both lower than 2017 levels First Quarter 2018 OutlookOn the call  the company said that seasonality and absence of inventory build  that benefitted fourth quarter 2017 results  will hurt the performance of its MS franchise in first quarter Meanwhile  operating expenses are expected to be lower in the first quarter of 2018 compared with the fourth quarter of 2017  However  earnings growth is expected to be higher in the second and fourth quarters of the year 
How Have Estimates Been Moving Since Then 
It turns out  fresh estimates flatlined during the past month  There has been one revision higher for the current quarter compared to one lower  While looking back an additional 30 days  we can see even more upward momentum  There have been ten moves higher compared to five lower two months ago Biogen Inc  Price and Consensus     
VGM Scores
At this time  BIIB has a nice Growth Score of B  a grade with the same score on the momentum front  Following the exact same course  the stock was also allocated a grade of B on the value side  putting it in the second quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is equally suitable for value  growth and momentum investors 
Outlook
BIIB has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-02-26,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-down-172-since-earnings-report-can-it-rebound-200294057,200294057
129349,350864,BIIB,Are Alzheimer s Focused Stocks Set For A Financial Windfall ,opinion,In spite of the increasing incidence of Alzheimer s  there is no recognized drug that can cure or slow the progress of the disease   claims that in every 66 seconds  an American develops Alzheimer s  People living with Alzheimer s find it extremely difficult to carry out daily functions and hence need to be under supervision round the clock Coming to other life threatening conditions  CNBC reports that deaths related to Alzheimer s have skyrocketed 89  while those following heart diseases have dropped 14  since the turn of the century Detection Years Before Onset of Alzheimer sA blood test has been introduced to detect Alzheimer s almost two decades before a patient shows any noticeable symptoms  Last year  Dr  Randall Bateman of Washington University announced that the test will be able to detect the accumulation of amyloid beta in the brain  The buildup of the toxic protein is among the first signs of the deadly disease Also  in January  a team of researchers from Japan and Australia introduced a blood test with accuracy as high as 90  for the detection of the disease  Dr  Bateman employed the mass spectrometry testing for identifying the protein  According to the email of Bateman to CNBC  scientists from Japan had developed an identical mass spectrometry investigative procedure for protein detection which came up with similar results   Blood Tests to Speed Up Drug ResearchClinical trials for drugs that could delay the start of the disease failed a number of times  thanks to the unavailability of a decent number of qualified patients  revealed Dr  Jeff Cummings of the Cleveland Clinic  Hence  the wider the patient base  higher will be the possibility of meaningful clinical trials With the new blood tests  doctors will be able to detect patients early and include them in clinical trials for the development of effective preventive treatments  Also  there would be proper utilization of millions of dollars of federal government funding for the preventive treatment Importantly  the blood tests will be the most efficient way to detect Alzheimer s as other alternatives are quite expensive  Lumbar puncture for the early diagnosis is among the alternatives that collect cerebrospinal fluid  For the process  a needle is inserted in the lower back of patients  giving rise to the need for local anesthetic  Positron emission tomography is another process that could cost at least  7000  Also  the accuracy of the PET scans is significantly lower than the blood tests Dr  Robert Vassar of Northwestern University has also backed the efficiency of blood tests over other methods for the diagnosis of Alzheimer s  Meanwhile  Dr  Bateman added that the blood tests will be more in demand once proper preventive measures have been established Stocks to GainPeople all over the world will likely gain access to the tests in the coming few years  per Dr  Bateman However  the question that looms large is what is the next course of action for those who find out that they are at a risk of developing Alzheimer s  Meanwhile  the launch of the blood tests paves the way for advanced clinical trials More than 5 million people are estimated to be living with the disease in the United States  per The Alzheimer s Association  Notably  the health organization expects this number to rise more than three times by 2050 As Alzheimer s is a pressing concern  there is massive business potential in this space  Hence  the launch of the blood tests will help companies focused on developing preventive treatments make billions Based in Cambridge  MA  Biogen Inc    NASDAQ BIIB   has been paying particular attention on stepping up research work on Alzheimer s  The company surpassed the Zacks Consensus Estimate in three of the last four quarters  the average positive earnings surprise being 6 9   Also  we expect the company to witness earnings growth of 13 7  and 4 7  in 2018 and 2019  respectively It has been almost 30 years that Eli Lilly and Company   NYSE LLY     headquartered in Indianapolis  IN   is fighting Alzheimer s  The company beat the Zacks Consensus Estimate in all of the last four quarters  We also expect the company to post earnings growth of 13 1  and 8 8  in 2018 and 2019  respectively In fact  for treating patients with early Alzheimer s symptoms  AstraZeneca PLC   NYSE AZN   and Eli Lilly are jointly developing Lanabecestat   a small molecule therapy candidate Merck   Co   Inc    NYSE MRK    headquartered in Kenilworth  NJ  has been focusing on research for treating Alzheimer s  The company is expected to post earnings growth of 4 8  and 2 9  in 2018 and 2019  respectively  Merck also managed to beat the Zacks Consensus Estimate in the last four quarters Biogen  Eli Lilly and Merck carry a Zacks Rank  3  Hold   You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-03-06,Zacks Investment Research,https://www.investing.com/analysis/are-alzheimersfocused-stocks-set-for-a-financial-windfall-200296162,200296162
129350,350865,BIIB,Biotech Stock Round Up  Regeneron Submits SBLA  Biogen To Withdraw Zinbryta,opinion,"Key highlights of the week include FDA s acceptance of Regeneron Sanofi s Dupixent sBLA for asthma  Biogen AbbVie s decision to withdraw multiple sclerosis drug  Zinbryta  due to risk of liver failure and Celgene s completion of Juno acquisition Recap of the Week s Most Important StoriesRegeneron Sanofi s Dupixent sBLA for Asthma Accepted by FDA  Regeneron   NASDAQ REGN   and partner Sanofi  PA SASY   SNY  announced that the FDA has accepted for review the supplemental Biologics License Application  sBLA  of Dupixent  dupilumab  as an add on maintenance treatment in adults and adolescents  12 years of age or older  with moderate to severe asthma  The FDA has set a target action date of Oct 20  2018 per the Prescription Drug User Fee Act  The sBLA was supported by results from the three pivotal trials from the LIBERTY ASTHMA clinical development program  Sanofi and Regeneron are studying dupilumab in a broad range of clinical development programs for diseases driven by Type 2 inflammation  including pediatric atopic dermatitis  phase III   nasal polyps  phase III  and eosinophilic esophagitis  phase III   Read more   Regeneron is a Zacks Rank  1  Strong Buy  stock  You can see  Biogen AbbVie To Withdraw Zinbryta  Biogen   NASDAQ BIIB   and partner AbbVie   NYSE ABBV   announced that both the companies will withdraw multiple sclerosis drug  Zinbryta voluntarily on a worldwide basis due to risk of liver injury  Both companies decided to withdraw the drug on grounds of the complex and evolving benefit risk profile of Zinbryta  given the limited number of patients being treated   The drug is currently available in Europe and United States  Switzerland  Canada and Australia  While AbbVie distributes Zinbryta in the United States  Biogen distributes the drug in ex U S  markets   The European regulatory authorities provisionally restricted the use of Zinbryta in adult patients with highly active relapsing disease despite a full and adequate course of treatment with at least one DMT or with rapidly evolving severe relapsing MS who are unsuitable for treatment with other DMTs following the report of a case of fatal fulminant liver failure  as well as four cases of serious liver injury Gilead Reports New Data on Biktarvy  Gilead   NASDAQ GILD   announced encouraging results at 48 weeks from a phase III study  Study 1961  among 470 virologically suppressed adult women with HIV infection at the International Workshop on HIV and Women and at the 2018 Conference on Retroviruses and Opportunistic Infections   CROI   in Boston  Poster 2539   Biktarvy was found to be statistically non inferior to regimens containing a bPI or boosted elvitegravir and demonstrated no treatment emergent resistance at 48 weeks in the ongoing study  Biktarvy  Gilead s latest triple therapy  was approved by the FDA in February 2018 as a complete regimen for the treatment of HIV 1 infection in adults who have no antiretroviral treatment history  Read more   Celgene Completes Juno Acquisition  Celgene Corporation   NASDAQ CELG   announced that it has completed the previously announced acquisition of Juno Therapeutics  Inc for  9 billion Juno focuses on the development of CAR  chimeric antigen receptor  T and TCR  T cell receptor  therapeutics with a promising pipeline evaluating multiple targets and cancer indications  The acquisition will add JCAR017  lisocabtagene maraleucel  liso cel  to Celgene s lymphoma pipeline  JCAR017 is a best in class CD19 directed CAR T currently in a pivotal program for relapsed and or refractory diffuse large B cell lymphoma  DLBCL   The candidate is expected to obtain regulatory approval in the United States in 2019 with potential global peak sales of approximately  3 billion  PerformanceMedical   Biomedical and Genetics Industry 5YR   ReturnThe NASDAQ Biotechnology Index gained 4 52  over the last five trading sessions  Among major biotech stocks  Regeneron gained 3 93   Over the last six months  Celgene lost 36 4  while Vertex gained 6 7   see the last biotech stock roundup here    What s Next in the Biotech World Stay tuned for more regulatory and pipeline updates 
The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-03-07,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-round-up-regeneron-submits-sbla-biogen-to-withdraw-zinbryta-200296623,200296623
129351,350866,BIIB,PDL BioPharma  PDLI  Q4 Earnings Beat  Revenues Rise Y Y,opinion,PDL BioPharma  Inc    NASDAQ PDLI   has reported earnings of 17 cents per share in the fourth quarter of 2017  substantially surpassing the Zacks Consensus Estimate of 3 cents  However  the company reported a loss of 5 cents in the year ago quarter The company generated total revenues of  68 million in the quarter  up 2 3  from  66 5 million  registered a year earlier  This upside is mainly attributable to rise in royalty rights primarily on the back of an increase in fair value of the Depomed royalty asset in the reported period Notably  the company received cash payments of  32 8 million from the royalty rights acquired from Depomed  primarily related to Glumetza  a product marketed by Valeant Pharmaceuticals International  Inc    NYSE VRX    An authorized generic version of Glumetza was also launched by a Valeant subsidiary in February 2017 for which  PDL BioPharma got royalties per the same terms as the branded Glumetza agreement PDL BioPharma s shares rallied 19  in after hours trading on Mar 8 owing to higher earnings  Moreover  the company has outperformed the in a year s time  The stock has jumped 23 2  against the industry s decrease of 3 5   Quarter in DetailRevenues included royalties of  4 5 million from licenses to the Queen et al  patents  interest revenues of  0 8 million and product revenues of  32 6 million  sales of Noden products   Tekturna and Tekturna HCT in the United States and leasing of the LENSAR Laser System  Revenues of  4 5 million from the Queen et al  licenses were lower than the prior year figure of  15 5 million  This downside was mainly due to expiration of a patent license agreement of PDL BioPharma with Roche s   OTC RHHBY   subsidiary  Genentech  for its humanized antibody products  The Queen et al  licenses royalty including royalties from the sale of Biogen s   NASDAQ BIIB   multiple sclerosis drug  Tysabri  also declined in the quarter under review on lower sales of the product Research and development  R D  expenses for the fourth quarter came in at  0 7 million  down 63 2  from the level  recorded a year ago General and administrative expenses also decreased 22 2  to nearly  9 8 million from the figure in comparable quarter last year 2017 ResultsWhile full year sales surged 31  year over year to  320 million  full year earnings of 64 cents per share were lower than the year ago tally of 66 cents PDL BioPharma  Inc  Price  Consensus and EPS Surprise    Zacks RankPDL BioPharma carries a Zacks Rank  3  Hold   You can see  Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks  has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ,2018-03-08,Zacks Investment Research,https://www.investing.com/analysis/pdl-biopharma-pdli-q4-earnings-beat-revenues-rise-yy-200296937,200296937
129380,350895,BIIB,The Zacks Analyst Blog Highlights  Novartis  BP And Biogen,opinion,For Immediate ReleaseChicago  IL   February 9  2018   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Novartis   NYSE NVS    BP  LON BP    NYSE BP   and Biogen   NASDAQ BIIB   Here are highlights from Thursday s Analyst Blog  Top Research Reports for Novartis  BP and BiogenThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Novartis  BP and Biogen  These research reports have been hand picked from the roughly 70 reports published by our analyst team today Novartis  shares have underperformed the Zacks Large Cap Pharmaceuticals industry   0 8  vs   3 2    over the last six months  Novartis  fourth quarter results beat both earnings and sales estimates on strong performance of Cosentyx and Entresto  The generic division  Sandoz also combatted pricing pressure strongly buoyed by biosimilar launches of Rixathin and Erelzi Novartis has a strong oncology portfolio of drugs like Afinitor  Exjade  Jakavi  Zykadia  Tasigna  Jadenu and Kisqali  The approval of Kymriah for acute lymphoblastic leukemia is a major boost given the potential in the CAR T therapy space Meanwhile  the strategic decision on Alcon to retain the business or separation via capital market transactions such as a spin off or an initial public offering has been postponed for 2019  However  the loss of patent protection for some of the key drugs in Novartis  portfolio is a cause of concern  Moreover  Kisqali s uptake has been slow Shares of BP are up  16 1  over the last one year  outperforming the Zacks International Integrated Oil industry  up  7 2    During 2017  the leading integrated energy firm brought online seven key upstream projects  BP is also expected to bring online five more developments in 2018 All these projects along with the developments placed online during 2016 will likely help the energy giant add 800 000 barrels of oil equivalent per day to net production capacity by 2020  The firms  fourth quarter 2017 earnings skyrocketed year over year  courtesy of record oil and gas production and higher commodity price realizations However  the bottom line missed expectations  thanks to a surge in exploration expenses  Moreover  the oil spill incident of 2010 in the BP operated Macondo Prospect continues to affect the company  BP anticipates cash out flow related to the incident of  3 billion through 2018 against the prior projection of slightly more than  2 billion Biogen s shares have outperformed the Zacks Biomedical and Genetics industry over the last year   20 9  vs   0 8    Biogen had a mixed fourth quarter as it beat estimates for earnings but missed the same for sales  However  Biogen issued an upbeat outlook for 2018 Biogen has a strong position in the MS market with a wide range of products including Avonex  Tysabri  Tecfidera   Plegridy  The Zacks analyst likes its efforts to diversify beyond MS to other areas like Alzheimer s  Parkinson s and stroke  among others  Meanwhile  its newest drug Spinraza has witnessed strong patient uptake in the U S  and internationally However  weakening MS trends is a concern  Tecfidera is witnessing slight decline in U S  patient demand due to increasing competition from oral medicines and a slowdown in the overall MS market  Meanwhile  the launch of Ocrevus by Roche is beginning to have a negative impact on MS franchise sales in the U S   mainly on Tysabri Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2018-02-08,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-novartis-bp-and-biogen-200288939,200288939
129381,350896,BIIB,Merck  MRK  Halts Another Late Stage Study On Alzheimer s ,opinion,Merck   Co   Inc    NYSE MRK   announced that it is discontinuing another study evaluating verubecestat for the treatment of prodromal Alzheimer s disease as its success was unlikely APECS was a phase III study evaluating the efficacy and safety of verubecestat  an oral   amyloid precursor protein site cleaving enzyme  BACE  inhibitor  versus placebo The study was stopped on the recommendation of an external data monitoring committee  which assessed the study s overall benefit risk during a recent interim safety analysis  The committee said that the chances of observing positive risk benefit profile in the study  if it continued  were slim Shares of Merck declined almost 1  on Tuesday  In the past year  Merck s shares have underperformed the   Merck s shares have declined 15 8  in the period against a 10  increase for the industry In February last year  Merck had discontinued another study  EPOCH  phase II III   on verubecestat  which was evaluating it for mild to moderate Alzheimer s disease due to lack of efficacy  At that time  the committee had recommended that the APECS study continue unchanged  The Alzheimer s disease market has attracted a lot of attention from several companies  However  the successful development of therapies for the treatment of Alzheimer s disease is challenging and we note that several companies have failed in this regard Last month  Pfizer   NYSE PFE   reportedly said in a statement that it will end R D efforts in the Alzheimer s and Parkinson s disease areas  which will result in about 300 layoffs Long back  Pfizer shelved its late stage Alzheimer s candidate  bapineuzumab IV after it failed two phase III studies In December 2017  Biogen   NASDAQ BIIB   announced that an Alzheimer s disease study on BAN2401 failed to show early positive results  which raised investor concern about the candidate s chances of success In November 2016  Lilly s   NYSE LLY   anti amyloid candidate solanezumab failed to meet the primary endpoint in a late stage AD study  Lilly decided to drop the development of solanezumab  Lilly also suffered a major setback in August 2010  when it had to halt the development of another phase III Alzheimer s candidate  semagacestat The Alzheimer s disease market represents huge commercial potential and a successfully developed product could generate billions of dollars in sales once launched Merck carries a Zacks Rank  3  Hold   You can see  Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks  has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ,2018-02-13,Zacks Investment Research,https://www.investing.com/analysis/merck-mrk-halts-another-late-stage-study-on-alzheimers-200290316,200290316
129389,350904,BIIB,Acorda  ACOR  Q4 Earnings Miss Estimates  Revenues Beat,opinion,Acorda Therapeutics  Inc    NASDAQ ACOR   reported adjusted earnings of 61 cents per share in the fourth quarter of 2017  which missed the Zacks Consensus Estimate of  1 09  However  the bottom line significantly increased from the year ago figure of 5 cents Acorda s shares decreased almost 2  following its earnings release  In fact the stock has dipped 0 8  in a year s time  comparing favorably with the  s 1 6  decline  Total revenues came in at  188 4 million  surpassing the Zacks Consensus Estimate by 9 5   Moreover  the top line improved 34  year over year owing to higher net product as well as royalty revenues Quarter in DetailMajority of Acorda s net product revenues were generated by the company s key drug Ampyra  which raked in sales of  167 2 million in the quarter  Revenues grew around 26  both year over year and sequentially Ampyra is marketed in the ex U S  markets by Biogen Inc    NASDAQ BIIB   under the trade name  Fampyra  Biogen pays royalties to Acorda on the outside U S  sales of Fampyra  Fampyra royalties were  3 1 million  up 14 8  year over year Notably  in the fourth quarter  royalty revenues massively surged to  16 million from the year ago figure of  4 4 million Acorda s research and development  R D  expenses declined 35 2  year over year to  32 9 million  Selling  general and administrative  SG A  expenses also lowered 35 7  to  34 1 million Pipeline UpdatesIn December 2017  Acorda resubmitted the new drug application  NDA  to the FDA for its pipeline candidate  Inbrija  as a treatment option to address the OFF period symptoms in Parkinson s affected people udergoing a carbidopa   levodopa regimen  The company expects a response from the regulatory agency this month We remind investors that last August  the company had received a refusal to file letter from the FDA in connection with the NDA for Inbrija  The regulatory body deemed the application incomplete after a preliminary review and wanted some additional supporting information to reassess the filing  Subsequently  after discussing with the FDA to resolve the issue  the company resubmitted the same in the aforementioned period Notably  Acorda has deferred its plan to submit regulatory applications for Inbrija in the EU to the first quarter of 2018  earlier expected to be filed by 2017 end In November 2017  the company announced to have discontinued the phase III study on one of its lead Parkinson s disease candidates  tozadenant  This decision was prompted by a serious safety issue detected in the study  Acorda expects to report the efficacy and safety data from the phase III trial in the first quarter of 2018 2017 ResultsFull year sales increased 13 2  year over year to  588 3 million  beating the Zacks Consensus Estimate of  578 6 million  The top line also surpassed the preliminary results of  542 million The full year earnings of  1 75 per share missed the Zacks Consensus Estimate of  1 81  However  the bottom line is significantly higher than the year ago figure of 25 cents 2018 GuidanceThe company maintained its Ampyra net sales guidance for 2018 in the range of  330  350 million  This is lower than the Ampyra full year 2017 revenue of  543 3 million due to the expected generic entry of the drug in the United States in July  2018 The company continues to project its R D and SG A expenses for 2018 in the band of  100  110 million and  170  180 million  respectively Acorda awaits a positive cash balance in excess of  300 million by the end of 2018 Acorda Therapeutics  Inc  Price  Consensus and EPS Surprise    Zacks Rank   Key PicksAcorda carries a Zacks Rank  4  Sell  Two better ranked stocks in the health care sector are Exelixis  Inc    NASDAQ EXEL   and XOMA Corporation   NASDAQ XOMA    While Exelixis sports a Zacks Rank  1  Strong Buy   XOMA carries a Zacks Rank  2  Buy   You can see  Exelixis  earnings per share estimates have been revised upward from 72 cents to 77 cents for 2018 over the last 60 days  The company pulled off a positive surprise in all the trailing four quarters with an average beat of 572 92   Share price of the company has surged 31 5  in a year s time XOMA s loss per share estimates have narrowed from 99 cents to 42 cents for 2018 over the last 60 days  The company came up with an average beat of 47 92   The stock has skyrocketed 416 1  in the last 12 months Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-02-15,Zacks Investment Research,https://www.investing.com/analysis/acorda-acor-q4-earnings-miss-estimates-revenues-beat-200291456,200291456
129403,350918,BIIB,Top Stock Reports For Home Depot  CVS Health   Biogen ,opinion,"Friday  January 12  2018
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Home Depot  NYSE HD   CVS Health  NYSE CVS  and Biogen  NASDAQ BIIB   These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
Home Depot s shares have gained  44 2  over the last one year  compared with the  37 8  gain of the Zacks Retail Building Products industry  backed by its five year long trend of beating earnings estimates  The company delivered bottom line beat in third quarter fiscal 2017  while sales topped estimates for the fifth straight quarter  Results gained from strength in core business as well as relentless focus on affording innovative products  boosting interconnected customer experience and driving productivity  Steady housing market recovery and strong customer demand also remained tailwinds  Home Depot raised top and bottom line guidance for fiscal 2017  based on the solid year to date performance and anticipated gains from hurricane recovery activities  While hurricane related activities aided comps growth  gross margins on such sales were significantly below average  This led to a decline in gross margin  which is likely to continue in fiscal 2017  Moreover  competition from online retailers may impact performance 
 You can   
Shares of CVS Health have outperformed the Zacks Drug Stores industry over the last six months gaining  1 4  vs  a decline of  2 3   The company has been gaining on the back of strong Pharmacy Services segment that benefited from the upside in the Specialty Pharmacy  The Zacks analyst is also encouraged to note that  despite a soft bottom line scenario  the company reiterated its earnings outlook for 2017 indicating chances of recovery ahead  CVS Health s on going strong 2018 PBM selling season is another upside  Also  CVS Health s plan to acquire Aetna  NYSE AET  might change the Healthcare landscape in the United States  On the flip side  the company has been suffering from softness in Retail LTC business and a weak margin scenario 
 You can   
Biogen s shares have outperformed the Zacks Biomedicals and Genetics industry over the last one year   17 0  vs   0 9    Biogen has a strong position in the MS market  The Zacks analyst also likes its efforts to diversify beyond MS to other areas like Alzheimer s  Parkinson s  stroke  among others  Meanwhile  Spinraza has witnessed strong patient uptake in the U S  and internationally  However  Tecfidera is witnessing slight decline in U S  patient demand due to increasing competition from oral medicines and a slowdown in the overall MS market  Meanwhile  the recent Ocrevus launch by Roche is beginning to have a negative impact on MS franchise sales in the U S  At the call  the company said that seasonality and continued competitive pressure from Ocrevus  launch will hurt the performance of its MS franchise in Q4  Estimate movement has been mixed ahead of Q4 earnings results  The company has a positive record of earnings surprises in recent quarters 
 You can   
Other noteworthy reports we are featuring today include Raytheon  RTN   Alphabet  NASDAQ GOOGL  and Western Digital  WDC  
Zacks Editor in Chief Goes  All In  on This Stock 
Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report 

Mark Vickery
Senior Editor
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read









Featured Reports

While Encana s strong focus on the Montney and Permian plays will drive production growth  the Zacks analyst is concerned about the firm s negative free cash flow over the past few quarters 


Per a Zacks analyst  Nordson s Sonoscan acquisition will solidify its test and inspection business while Infiniti Dosing s PCP products buyout will expand the dispensing and dosing business 


Per the Zacks analyst  new product additions will enhance the Western Digital s existing product portfolio and aid it in securing a strong foothold in the global SSD market 


The Zacks analyst believes that Alphabet s focus on diversification artificial intelligence  Android OS and hardware is a positive 


Per the Zacks analyst  a number of profitable acquisitions like NetSpend  TransFirst along with its consistent focus on new product initiatives  technology modernization have driven top line growth 


Per the Zacks analyst  solid online and in store traffic  alongside momentum at AE and Aerie brands should drive sales 


Per the Zacks analyst  E TRADE s efforts to enhance trading business by introduction of new brokerage products and services might support its growth 

New Upgrades

Per the Zacks analyst  foreign military contracts continue to be a vital growth driver for Raytheon  Also the company has been witnessing strong demand for its varied kind of surveillance radars 


Toyota is partnering with technology companies to raise its hold in the electric   self driving cars market  Per the Zacks analyst  this will help meet rising demand for multi faceted transportation 


The Zacks analyst is encouraged by Brinker s operational efficiencies like remodeling of outlets  Other sales boosting efforts like menu innovation and digital advancement should drive growth 

New Downgrades

Per the Zacks analyst  rise in supply of residential housing assets in Mid America Apartment s key markets will likely lower rent and occupancy growth  Also  higher interest rates will hamper growth 


Per the Zacks analyst  A  O  Smith is struggling with high selling  general   administrative expenses in China  Continuous rise in steel prices and intensive competition also remain a concern 


The Zacks analyst is concerned that Teva is facing significant challenges like generic competition for Copaxone  pricing erosion in the U S  generics business and a massive debt load ",2018-01-12,Zacks Investment Research,https://www.investing.com/analysis/top-stock-reports-for-home-depot-cvs-health--biogen-200280036,200280036
129404,350919,BIIB,Roche MS Drug Ocrevus Gets Marketing Authorization In Europe,opinion,Roche Holdings   OTC RHHBY   announced that the European Commission  EC  has granted marketing authorization for multiple sclerosis  MS  drug Ocrevus The drug is approved for patients suffering from active relapsing forms of multiple sclerosis defined by clinical or imaging features and for patients with early primary progressive multiple sclerosis in terms of disease duration and level of disability  and with imaging features characteristic of inflammatory activity The approval was based on data from three pivotal phase III studies from the ORCHESTRA trial program which met the primary and nearly all the key secondary endpoints   The drug also demonstrated a favorable benefit risk profile demonstrated in three large Phase III studies with a diverse patient population  including those early in the disease We remind investors that the drug was also approved in the United States in March 2017 for both relapsing and primary progressive forms of multiple sclerosis The approval boosts Roche s neuroscience portfolio  Roche has more than a dozen pipeline candidates in the neuroscience portfolio for diseases that include multiple sclerosis  Alzheimer s disease  spinal muscular atrophy  Parkinson s disease and autism   Roche s stock has rallied 10 2  in the past one year compared with  s gain of 22 8  MS market has immense potential in Europe  The disease affects approximately 700 000 people in Europe  of which around 96 000 have the highly disabling primary progressive form However  the competition is stiff in MS space In August 2017  the European Commission Merck  NYSE MRK  approved KGaA  s  Mavenclad for the treatment of MS  In the United States  Biogen Inc    NASDAQ BIIB   has a strong position in the MS market backed by a wide range of products including Avonex  Tysabri  Tecfidera   Plegridy Meanwhile  Roche has a strong presence in the oncology market  The company dominates the breast cancer space with strong demand for its HER2 franchise drugs like Herceptin  Perjeta and Kadcyla  We are also impressed by the company s efforts to develop its portfolio beyond oncology into immunology  New drug launches  such as Tecentriq  Cotellic and Alecensa boosted sales and is expected to continue to do so in the upcoming quarters Zacks Rank   Key Pick    Roche carries a Zacks Rank  3  Hold  A better ranked stock in the healthcare sector is Exelixis  Inc    NASDAQ EXEL   with a Zacks Rank  1  Strong Buy   You can see  Exelixis  earnings per share estimates have moved up from 72 cents to 73 cents for 2018 over the last 60 days  The company delivered a positive earnings surprise in the last four quarters  with an average beat of 572 92  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-01-15,Zacks Investment Research,https://www.investing.com/analysis/roche-ms-drug-ocrevus-gets-marketing-authorization-in-europe-200280253,200280253
129406,350921,BIIB,Will These 4 Large Cap Drug Stocks Be Big Winners This Earnings Season ,opinion,"2017 was a good year for pharma and biotech stocks with the sector witnessing some positive developments that led to a much awaited recovery A key reason for the sector s improved performance was the willingness of investors to look beyond the drug pricing controversy and focus more on fundamentals instead  Although the drug pricing controversy  which was a major overhang in 2016  will remain a headline risk  investors seem more comfortable with the issue  Moreover  a significantly higher number of FDA approvals in 2017 has restored investor confidence in the sector  The approval of the first gene cell therapy last year was a major breakthrough for the sector Hopes of more mergers and acquisitions  M As  have also gone up with tax reform in place and big players on the lookout for companies with innovative pipelines technology  There has already been quite a bit of M A buzz this year about potential deals with Celgene rumored to be interested in buying Juno   NASDAQ JUNO    Biogen   NASDAQ BIIB   in Acorda and Sanofi   NYSE SNY   in Bioverativ  Meanwhile  Novo Nordisk  CO NOVOb  recently confirmed that it is looking to acquire Belgium based biopharma company Ablynx though Ablynx rejected Novo Nordisk s offer Looking forward  new product sales ramp up  R D success and innovation  continued strong performance from key products  more M A activity  growing demand for drugs especially for rare to treat diseases  an aging population and increased health care spending are some of the factors that should keep the momentum in 2018 Headwinds include drug pricing scrutiny  pricing pressure  increasing competition  the growing presence of biosimilars  generic competition  a slowdown in the growth of legacy products  concerns regarding Amazon s interest in entering the healthcare arena and major pipeline setbacks 4 Biotech   Pharma Stocks to Keep an Eye on This Earnings SeasonAccording to the Zacks  article  the medical sector  which has been among the better performing sectors over the last several quarters  is expected to record earnings growth of 3  on revenue growth of 4 7  in the fourth quarter Given this scenario and with medical sector earnings round the corner  it would make sense to look at some pharma and biotech stocks that are expected to report a positive earnings surprise in the quarter Investing in such stocks could prove beneficial for investors as an earnings beat usually leads to significant share price appreciation With the help of the Zacks   we have zeroed in on four pharma and biotech stocks that sport a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  and have a positive   Earnings ESP is a very valuable tool for investors looking for stocks that are most likely to beat earnings estimates  Moreover  adding a Zacks Rank of  1  2 or 3 has produced a positive surprise 70  of the time  While you can see   you can uncover the best stocks to buy or sell before they re reported with our  Alexion Pharmaceuticals  Inc    NASDAQ ALXN    Alexion has a strong presence in the rare diseases market  Marketed drugs include Soliris  for the treatment of patients with paroxysmal nocturnal hemoglobinuria   PNH    atypical hemolytic uremic syndrome  aHUS   and anti acetylcholine receptor  AchR  antibody positive generalized myasthenia gravis  gMG    Strensiq  enzyme replacement therapy for patients with hypophosphatasia   HPP    and Kanuma  enzyme replacement therapy for patients with lysosomal acid lipase deficiency  LAL D   Alexion is focusing on growing and maximizing its presence in the rare disease business  Core areas of focus include hematology  nephrology  neurology and metabolic disorders  Alexion has consistently surpassed earnings expectations in each of the last four quarters with an average surprise of 11 9   The Zacks Rank  3 stock  which will report fourth quarter results on February 8  has an Earnings ESP of  5 93  for the quarter  While 2017 Soliris revenues are expected in the range of  3 090 million    3 125 million  metabolic revenues are expected in the range of  385    400 million 
Celgene Corporation   NASDAQ CELG    Celgene is focused on the discovery  development and commercialization of treatments for cancer and inflammatory diseases through next generation solutions in protein homeostasis  immuno oncology  epigenetics  immunology and neuro inflammation  Earlier this month  the company announced preliminary results for the fourth quarter with revenues expected to be about  3 5 billion and earnings to be approximately  2 00 per share  Celgene has surpassed earnings in each of the last four quarters with an average surprise of 2 5   The Zacks Rank  3 stock  which will be reporting fourth quarter results on January 25  has an Earnings ESP of  0 94  
AbbVie   NYSE ABBV    AbbVie  which is known for its blockbuster drug  Humira  is focused on the development of treatments across four primary therapeutic areas  immunology  oncology  virology and neuroscience  2017 earnings are expected to be about  5 54 per share on revenue growth of approximately 10   Humira is expected to remain a key growth driver with sales expected to cross  18 billion in 2017  AbbVie will be reporting its fourth quarter results on January 26  The company has a decent track record having surpassed earnings expectations in each of the last four quarters with an average surprise of 1 1   The Zacks Rank  3 stock has an Earnings ESP of  1 3  for the fourth quarter  AbbVie s shares are up 71 6  over the last one year  significantly surpassing the 23 9  rally of the  it belongs to 
Merck   NYSE MRK    Merck will be reporting fourth quarter results on February 2  The company has a strong earnings track record and is expected to deliver a surprise of  1 06  in the fourth quarter  Growth drivers include Keytruda  Gardasil  a few hospital and specialty products and the Animal Health division which should help offset the impact of the genericization of Zetia and Vytorin  Merck is also a Zacks Rank  3 stock 
The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-01-21,Zacks Investment Research,https://www.investing.com/analysis/will-these-4-largecap-drug-stocks-be-big-winners-this-earnings-season-200282294,200282294
129412,350927,BIIB,What s In The Cards For Biogen  BIIB  This Earnings Season ,opinion,"Biogen Inc    NASDAQ BIIB    a well known name in the multiple sclerosis  MS  market  will report fourth quarter 2017 results on Jan 25  before the market opens  Last quarter  the company delivered a positive earnings surprise of 10 70  Biogen s shares have risen 24  this year  better than the  s growth of 5 8  in the same time frame   Biogen s earnings performance has been pretty impressive so far  having delivered a positive surprise in each of the last four quarters  The average earnings beat over the last four quarters is 8 09  Biogen Inc  Price and EPS Surprise    
Let s see how things are shaping up for this announcement Factors to ConsiderOn the third quarter call  the company had warned that seasonality and continued competitive pressure from Roche s   OTC RHHBY   newly launched MS drug  Ocrevus will hurt the performance of its MS franchise in the fourth quarter Meanwhile  the combined number of patients using Avonex and Plegridy will continue to decline with patients transitioning to other oral MS therapies as well as due to higher discounts and allowance Spinraza  approved for spinal muscular atrophy in December 2016  witnessed faster than anticipated adoption in the United States in the first half of 2017 backed by robust underlying demand  However Spinraza U S  sales were slow in the third quarter due to unfavorable timing of induction doses as patients transitioned from intensive Spinraza treatment to a less intensive maintenance schedule  On the third quarter call  the company had said that due to the impact of the dosing scheduling  Spinraza sales in the fourth quarter will mainly be driven by ex U S  markets Biogen s biosimilar products   Flixabi  a biosimilar referencing Remicade  and Benepali  a biosimilar referencing Enbrel  are also generating higher revenues  The trend should continue this quarter as well On the third quarter call  the company had also said that operating expenses will be higher in the fourth quarter compared to the third with the company investing in its strategic priorities Investor focus on the fourth quarter call will remain on management s comments on the impact of Ocrevus competition on Tecfidera s sales prescription trends  performance of Spinraza  pipeline progress and acquisition plans Earnings WhispersOur proven model does not conclusively show that Biogen is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  Its Earnings ESP is  0 64  as the Most Accurate estimate stands at  5 42 while the Zacks Consensus Estimate is pegged higher at  5 45  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Biogen s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderBiotech stocks that have both a positive ESP and a favorable Zacks Rank include Alexion Pharmaceuticals  Inc    NASDAQ ALXN    scheduled to release results on Feb 8  has an Earnings ESP of  5 93  and a Zacks Rank  3  You can see  Emergent BioSolutions Inc    NYSE EBS   has an Earnings ESP of  22 65  and a Zacks Rank  3  The company is expected to release results next month The Hottest Tech Mega Trend of AILast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2018-01-21,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-biogen-biib-this-earnings-season-200282271,200282271
129414,350929,BIIB,Biogen  BIIB  Q4 Earnings Miss  Sales Top  Stock Up ,opinion,Cambridge  MA based Biogen Inc    NASDAQ BIIB   holds a strong position in the multiple sclerosis  MS  market with a wide range of products including Avonex  Tysabri  Tecfidera and Plegridy  However  as competition in the MS market intensifies  Biogen is trying to diversify beyond MS to other areas like Alzheimer s  Parkinson s  stroke  among others  Meanwhile  in Feb 2017  the company spinned off its hemophilia business which allows it to focus on neurology  its key area of expertise BIIB has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 8 09  Currently  Biogen has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Miss  Biogen s fourth quarter 2017 earnings missed expectations  The company posted earnings of  5 26 per share while our consensus called for EPS of  5 44 Revenues Beat  Biogen posted revenues of  3 31 billion  beating the consensus estimate of  3 07 billion  Revenue increased 15  year over year Key Statistics  Oral MS drug Tecfidera sales increased 7  year over year and 1  sequentially to  1 08 billion  The other MS drug  Tysabri s sales decreased 2  year over year and 1  sequentially Pre Market Trading  Shares were up more than 3  in pre market trading Check back later for our full write up on this BIIB earnings report later Biogen Inc  Price and Consensus    Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-01-24,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-q4-earnings-miss-sales-top-stock-up-200283531,200283531
129415,350930,BIIB,Biogen  BIIB  Q4 Earnings Miss  Sales Top  2018 View Upbeat,opinion,Biogen Inc    NASDAQ BIIB   reported fourth quarter 2017 earnings per share of  5 26  which missed the Zacks Consensus Estimate of  5 44 by 3 3   Earnings however rose 4  year over year as higher revenues made up for higher operating costs Sales came in at  3 31 billion  up 15  from the year ago period  Sales also surpassed the Zacks Consensus Estimate of  3 07 billion by 7 6  We remind investors that last year Biogen spun off its hemophilia business into a new company called Bioverativ   NASDAQ BIVV    Sanofi   NYSE SNY    earlier this week  announced that it has offered to buy Bioverativ for  11 6 billion Quarter in DetailBiogen s multiple sclerosis  MS  revenues were  2 3 billion  up 5   in the quarter including approximately  77 million in royalties on the sales of Roche s   OTC RHHBY   MS drug  Ocrevus  Per a deal with Roche  Biogen is entitled to receive royalties on U S  sales of Ocrevus In the quarter  MS sales in the United States included inventory buildup of  40 million  which benefited revenues Oral MS drug  Tecfidera s sales increased 7  year over year and 1  sequentially to  1 08 billion  The other MS drug  Tysabri s sales decreased 2  year over year and 1  sequentially to  463 million Combined interferon revenues  Avonex and Plegridy  in the fourth quarter were  645 million  down 6  from the year ago period  Avonex revenues declined 8  from the year ago period to  520 million  Plegridy contributed  125 million to fourth quarter 2017 revenues  flat year over year as well as sequentially U S  Interferon revenues are experiencing declining trends due to patients transitioning to other oral MS therapies as well as due to higher discounts and allowance Zinbryta  launched in collaboration with AbbVie  contributed  12 million to revenues in the fourth quarter compared with  14 million in third quarter 2017 Newly launched Spinraza brought in revenues of  363 million in the fourth quarter  registering growth of 34  sequentially Spinraza U S  sales were  218 million in the fourth quarter  much better than  198 million in the third quarter  Inventory levels were flat in the fourth quarter  In ex U S  markets  Spinraza recorded sales of  144 million  significantly higher than  73 3 million in the third quarter  The company said that Spinraza international revenues were mainly from Germany  Turkey  and Japan In the quarter  Biogen recorded biosimilar revenues of  122 million compared with  101 million in the third quarter Revenues from Anti CD20 therapeutic programs  which include Biogen s shares of Rituxan and Gazyva operating profits  climbed 6  from the year ago period to  338 million As expected  operating expenses were higher in the fourth quarter as the company continues to invest in its strategic priorities  R D spend rose 11  year over year and 32  sequentially to  588 million  while SG A spend rose 15  year over year and 28  sequentially to  554 million 2017 ResultsFull year 2017 sales of  12 27 billion topped the Zacks Consensus Estimate of  12 04 billion  Sales rose 7  year over year  The top line  excluding hemophilia revenues  grew 15  year over year Adjusted earnings for 2017 were  21 81 per share  falling short of the Zacks Consensus Estimate of  21 98  Earnings rose 8  year over year 2018 OutlookBiogen guided earnings in the range of  24 20 and  25 20 per share  above the Zacks Consensus Estimate of  24 18 per share  Revenues are expected in the range of  12 7  13 0 billion in 2018  The Zacks Consensus Estimate is pegged at  12 72 billion While R D expenses are expected to be approximately 16  to 17  of total revenues in 2018  SG A is expected in the range of 15  to 16  Our TakeBiogen had a mixed fourth quarter as it beat estimates for earnings but missed the same for sales  Higher MS sales and strong Spinraza performance led to the strong top line performance in the quarter  The revenue beat and the upbeat outlook for 2018 led shares to rise more than 3  in pre market trading Biogen s shares have risen 19 6  in the past year  better than the  s growth of 9 6  in the same time frame Biogen has a strong portfolio of MS products  However  the overall growth trends in the multiple sclerosis market are gradually slowing down  Tecfidera s U S  patient demand has been declining due to increasing competition from oral medicines and a slowdown in the overall MS market  As competition in the MS market intensifies  Biogen is diversifying beyond MS to other areas like Alzheimer s  Parkinson s and stroke  among others  The company said it has made seven additions to its neuroscience pipeline in 2017 and expects several important data readouts in 2018 Biogen carries a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-01-24,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-q4-earnings-miss-sales-top-2018-view-upbeat-200283552,200283552
129444,350959,BIIB,3 Pharma   Biotech Pipeline Areas To Keep An Eye On In 2018,opinion,Although there are still a few days left for the year to end  2017 has turned out to be pretty good for the pharma and biotech sector where FDA approvals are concerned  Till date  the regulatory agency has given its nod to 43 novel drugs  well above the 22 drugs approved last year  Immuno oncology was a key focus area in 2017  whether it was to do with scientific conferences  clinical trial collaborations  acquisitions or FDA approvals The approval of Novartis s   NYSE NVS   Kymriah  a gene cell therapy  and Gilead s   NASDAQ GILD   Yescarta  a CAR T  chimeric antigen receptor T cells  cell treatment  ensured that the highly lucrative immuno oncology market remained in the limelight The  11 9 billion acquisition of immuno oncology focused Kite by Gilead also increased interest in this category with investors expecting more acquisition announcements in this area While we see 2017 as a year focused on immuno oncology  here is a look at three therapeutic areas that we think will garner a lot of interest in 2018 Immuno OncologyImmuno oncology will remain a key focus area in 2018 as well  The basic concept of cancer immunotherapy or immuno oncology is to utilize certain parts of the immune system to fight the disease  This can be done by stimulating the immune system to attack cancer cells or by introducing immune system components into the body  While some immuno oncology treatments have the potential to be effective as monotherapies  others may be more effective when combined with other treatments Different types of immunotherapies include monoclonal antibodies mAbs  man made versions of immune system proteins which can be designed to attack a very specific part of a cancer cell   immune checkpoint inhibitors  recognize and attack cancer cells   vaccines  help prevent or treat cancer  and others that boost the overall immune system Encouraging results generated by some companies demonstrating partial and complete responses in late stage cancer patients and the recent FDA approval of Kymriah and Yescarta has raised hopes for cancer patients and increased interest in this segment of the cancer market  With immuno oncology set to change the treatment paradigm for cancer  this area represents huge commercial potential Companies that have progressed quite a bit in this area include Juno Therapeutics   NASDAQ JUNO    Incyte and bluebird bio   NASDAQ BLUE   with these companies often considered to be acquisition targets Alzheimer s DiseaseAlzheimer s disease is an area where many companies have tried their luck though not with much success  Over the last several years  big players like Merck  NYSE MRK   Lilly   NYSE LLY    Pfizer  NYSE PFE  and J J have all faced setbacks in their quest to find a treatment for Alzheimer s Companies that are currently working on Alzheimer s disease treatments include players like Biogen   NASDAQ BIIB    Novartis  AstraZeneca  Eisai and Amgen  NASDAQ AMGN  Biogen s aducanumab is one of the most important candidates in the company s pipeline with the candidate currently in a couple of late stage studies  Biogen is also working on elenbecestat  E2609   a BACE inhibitor in a phase III program and BAN2401  a humanized beta amyloid antibody in phase II development with top line results expected by the end of January 2018  All three candidates are being developed in collaboration with Eisai   Lilly also has quite a few Alzheimer s disease candidates in its pipeline including lanabecestat  which is being developed in collaboration with AstraZeneca with data readout expected in 2019  Meanwhile  Novartis and Amgen are collaborating for BACE1 inhibitor CNP520 which has fast track status in the United Status  Roche is also collaborating with AC Immune for the development of Alzheimer s disease treatments Although Alzheimer s has historically been a very challenging therapeutic area with quite a few stocks stumbling in their efforts to find a treatment  the market is highly lucrative  As a result  several companies continue to invest heavily in developing Alzheimer s disease treatments  According to the Alzheimer s Association  in the 10 years from 2002 2012  244 drugs were tested for Alzheimer s in studies registered with clinicaltrials gov out of which only one succeeded and went on to gain FDA approval While these numbers are far from encouraging  success in this area means huge returns considering more than five million Americans are living with Alzheimer s disease with the numbers expected to increase to as much as 16 million by 2050  Data  Alzheimer s Association   It is considered to be one of the biggest burdens of society and is the sixth leading cause of death across all ages in the United States  The market has immense commercial potential and companies coming out with new treatments could rake in billions of dollars in sales Medical MarijuanaAnother segment of the pharma and biotech industry that will remain in the limelight next year is the medical marijuana industry  The industry got its first exchange traded fund   ETF   earlier this year and has been attracting interest from investors over the last few quarters  The industry is expected to grow rapidly with legislators allowing or looking to allow more legal uses of marijuana and marijuana related products  especially in the medical and life sciences industry Some of the key players in this area include GW Pharmaceuticals plc   NASDAQ GWPH    INSYS Therapeutics  Corbus Pharmaceuticals Holdings and Zynerba Pharmaceuticals GW Pharma commercialized the world s first plant derived cannabinoid prescription drug  Sativex  which is approved for the treatment of spasticity due to multiple sclerosis  However  the company has been in the news for its lead cannabinoid pipeline candidate  Epidiolex  cannabidiol or CBD   which is in development for a number of rare childhood onset epilepsy disorders  The company is currently seeking FDA approval for Epidiolex for Dravet syndrome and Lennox Gastaut syndrome   approval could come as early as mid 2018 if priority review is granted  Epidiolex represents blockbuster potential especially if it is approved across all possible indications  GW Pharma has several new formulations of CBD in development including improved liquid formulations  a solid dose form and an intravenous formulation Specialty pharma company  INSYS  uses its proprietary spray technology and capabilities for the development of pharmaceutical cannabinoids for a wide range of indication including treating addiction to opioids  opioid overdose  epilepsy  and other disease areas with significant unmet need  While GW Pharma and INSYS are both Zacks Rank  3  Hold  stocks  you can see  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2017-12-19,Zacks Investment Research,https://www.investing.com/analysis/3-pharma--biotech-pipeline-areas-to-keep-an-eye-on-in-2018-200274761,200274761
129445,350960,BIIB,The Zacks Analyst Blog Highlights  Pfizer  FedEx  Abbott  Biogen And Marathon Petroleum,opinion,For Immediate ReleaseChicago  IL   Dec 22  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Pfizer   NYSE PFE    FedEx   NYSE FDX    Abbott   NYSE ABT    Biogen   NASDAQ BIIB   and Marathon Petroleum   NYSE MPC   Today  Zacks is promoting its   Buy   stock recommendations   Here are highlights from Thursday s Analyst Blog  Top Research Reports for Pfizer  FedEx and AbbottThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Pfizer  FedEx and Abbott  These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see Pfizer s shares have underperformed the peer group so far this year  the stock is up  12 2  over this period vs  a  16 1  increase for the Zacks Large Cap Pharmaceuticals industry   Pfizer has been working on strengthening its product portfolio through acquisitions and licensing deals However  Pfizer continues to face headwinds in the form of genericization of key drugs  supply challenges in the legacy Hospira portfolio  pricing pressure and rising competition  which are hurting the top line  Nonetheless  the Zacks analyst thinks new products like Ibrance  contribution from acquisitions  cost cutting efforts and share buybacks should help the company achieve its guidance The company also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years  including around 15 products that have blockbuster potential  Pfizer s growing immuno oncology portfolio offers a strong potential  Bavencio is being considered a key long term growth driver for Pfizer  You can   Shares of Buy rated FedEx have outperformed the Zacks Air Freight and Cargo industry and rival United Parcel Service  NYSE UPS  on a year to date basis  The company has gained 34 8  while the industry it belongs to and UPS have rallied 14  and 3 2   respectively  in the same period  Ushering in further good news  FedEx also outperformed in the second quarter of fiscal 2018 driven by increased package volumes during the current holiday season Growth was witnessed across all the major segments of the company  In fact  the strong growth of e commerce is a huge positive for the company  Meanwhile  FedEx is on track to deliver a strong performance in the ongoing holiday season  Efforts to reward its shareholders through dividend payments and share buybacks are also encouraging  High costs are  however  hurting the bottom line  You can   Abbott s shares have gained  8 6  over the last three months  outperforming the Zacks Medical Products industry  which has gained  3 1  over the same period Post promising third quarter results by Abbott  the Zacks analyst is optimistic about the strong and consistent EPD and Medical Devices performance  However  the ongoing sluggish trend in the Nutrition business is a downside  However  the company continues to benefit from the recently completed St  Jude Medical buyout Meanwhile  Alere acquisition close is an upside too  Through 2017  Abbott is effectively focusing on core therapeutic areas  Recently  its FreeStyle Libre Flash received the FDA approval  Also  it has received approval for MR conditional labeling for Ellipse ICD  Also  emerging market performance remains promising on several new strategic developments  On the flip side  sluggish pediatric nutrition business in some global markets continues to dent growth  Also economic problems in Venezuela are likely to remain unresolved  You can   Other noteworthy reports we are featuring today include Biogen and Marathon Petroleum Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors Today  Zacks is promoting its   Buy   stock recommendations   About Zacks Equity ResearchZacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year Follow us on Twitter  Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2017-12-21,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-pfizer-fedex-abbott-biogen-and-marathon-petroleum-200275394,200275394
129446,350961,BIIB,Biogen s Alzheimer s Drug Misses Goal In Interim Analysis,opinion,Shares of Biogen Inc    NASDAQ BIIB   declined by almost 3 3  after the company s Alzheimer s candidate  BAN2401  failed to meet the criteria for success based on a 12 months interim analysis as the primary endpoint in a mid stage trial  The company is developing the candidate in collaboration with Eisai Co   Ltd So far this year  shares of Biogen have gained 13 7  compared with the  s growth of 3  The phase II study  Study 201  involves 856 patients with prodromal or mild Alzheimer s disease and positive biomarkers for brain amyloid pathology  The study uses Bayesian Adaptive Randomization Design which allows automatic changes to the design during the study  For early success  Study 201 will explore efficacy and the dose response of BAN2401 with 16 interim analyses  a 12 month evaluation based on Eisai s in house developed Alzheimer s disease Composite Score  ADCOMS  and an 18 month comprehensive assessment of treatment with placebo or 5 active arms  The Bayesian analysis at 12 months indicated that  success was judged as an 80  or higher probability of achieving  at least a 25  reduction in the rate of decline of ADCOMS versus placebo The 16 interim analyses assessed potential for futility or stopping for safety  Neither of these conditions was met and the study continues to a full analysis at 18 months Biogen stated that the 18 month blinded study will continue further analysis  following the predefined study protocol   A comprehensive final analysis will be conducted at 18 months looking to demonstrate clinically significant results   Data from the study are expected in the second half of 2018 Biogen is looking to strengthen its AD and other neurodegenerative disorders pipeline  Notably  the company s Alzheimer s disease  AD  pipeline comprises candidates with different mechanisms of action including anti tau candidate  BIIB092 BMS 986168 with potential in AD as well as progressive supranuclear palsy  PSP    anti amyloid  aducanumab  candidates as well as a BACE inhibitor  elenbecestat  program However  the successful development of therapies for the treatment of Alzheimer s disease is challenging and we note that several companies have failed in developing treatments for the same  In November 2016  Eli Lilly   Company s   NYSE LLY   anti amyloid candidate   solanezumab failed to meet the primary endpoint in a late stage AD study  Consequently  Lilly decided to drop the development of the candidate Meanwhile  Pfizer   NYSE PFE   shelved its late stage Alzheimer s candidate  bapineuzumab IV  after it failed two phase III studies  Pfizer was developing the candidate in collaboration with Johnson   Johnson   NYSE JNJ   and Elan Corporation The Alzheimer s disease market represents a huge commercial potential and a successfully developed product could generate billions of dollars in sales once launched Biogen Inc  Price   Zacks RankBiogen carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-12-21,Zacks Investment Research,https://www.investing.com/analysis/biogens-alzheimers-drug-misses-goal-in-interim-analysis-200275379,200275379
129447,350962,BIIB,Pfizer To Stall R D For Alzheimer s Parkinson s  Cut Jobs,opinion,Pfizer  Inc    NYSE PFE   reportedly said in a statement that it will end R D efforts in the Alzheimer s and Parkinson s disease areas  which will result in about 300 layoffs The decision to end the neuroscience discovery program will mainly affect employees at facilities in Andover and Cambridge   MA  and Groton   CT  Pfizer  however  intends to continue development of pain candidate  tanezumab  which it is developing in late stage studies in partnership with Eli Lilly   NYSE LLY    label expansion efforts for pain drug Lyrica and its rare disease program Shares of Pfizer have risen 10 2  in the past year  comparing unfavorably with a 16 5  increase for the  The successful development of therapies for the treatment of Alzheimer s disease is challenging and we note that several companies have failed in this regard In fact Pfizer itself shelved its late stage Alzheimer s candidate  bapineuzumab IV after it failed two phase III studies  Pfizer was developing the candidate in collaboration with Johnson   Johnson   NYSE JNJ   and Elan Corporation In November 2016  Lilly s anti amyloid candidate solanezumab failed to meet the primary endpoint in a late stage AD study  Lilly decided to drop the development of solanezumab  Lillyalso suffered a major setback in August 2010  when it had to halt the development of another phase III Alzheimer s candidate  semagacestat Last month  Biogen  Inc    NASDAQ BIIB   announced that an Alzheimer s disease study on BAN2401 failed to show early positive which raised investor concern about the candidate s chances of success Pfizer plans to use savings from the terminated programs to re allocate spend on potentially more fruitful pipeline projects Pfizer expects approximately 25 to 30 drug approvals over the next five years  of which around 15 products have blockbuster potential  These include line extensions for cancer drugs  Xtandi and Ibrance as well as rheumatoid arthritis drug  Xeljanz  Half of these potential blockbusters are expected to receive approval by 2020 Pfizer carries a Zacks Rank  3  Hold  You can see    5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-01-07,Zacks Investment Research,https://www.investing.com/analysis/pfizer-to-stall-rd-for-alzheimersparkinsons-cut-jobs-200278505,200278505
129448,350963,BIIB,Alzheimer s Takes Another Hit As Pfizer Ends Research In This Area,opinion,"The Alzheimer s disease   AD   area is in focus once again with Pfizer Inc    NYSE PFE   saying that it will be dropping its plans to develop treatments for Alzheimer s and Parkinson s disease  According to news sources  Pfizer expects its decision to result in the elimination of 300 positions from the neuroscience discovery and early development programs  We expect additional details to be available at the company s presentation at the 36th Annual JPMorgan  NYSE JPM  Healthcare Conference today Pfizer has had a long association with the Alzheimer s disease research area  In 2015  the company became a part of the Dementia Discovery Fund  which was formed to speed up the development of new treatments for neurological diseases by bringing together major pharma companies  the UK government and Alzheimer s Research UK  The Fund is involved in the financing of new  early stage drug development projects However  Alzheimer s has always been a highly challenging area with not much progress being made despite the investment of a lot of funds and resources  In fact  Pfizer itself had faced a major setback way back in 2012 in its development efforts for an Alzheimer s disease treatment  The company and its partner  Johnson   Johnson   NYSE JNJ    decided to discontinue the development of bapineuzumab IV following a late stage failure Other companies like Eli Lilly and Company   NYSE LLY   and Merck   NYSE MRK   have also stumbled in their efforts to develop treatments for Alzheimer s  Lilly decided in November 2016 that it would not seek approval for its investigational AD treatment  solanezumab  following disappointing results from a late stage study  The candidate was being evaluated to see whether it can slow the progression of memory problems associated with amyloid  a protein that forms plaques in the brains of people with Alzheimer s Meanwhile  the evaluation of Merck s investigational Alzheimer s disease treatment  verubecestat  was halted in a phase II III study  EPOCH  in February 2017 based on an interim analysis by an external Data Monitoring Committee  eDMC  that the study might fail  Another study is ongoing with results expected in February 2019 Biogen  NASDAQ BIIB  also suffered a setback recently when an Independent Data Monitoring Committee said that BAN2401 did not meet the criteria for success based on a Bayesian analysis at 12 months as the primary endpoint in the phase II study  The failure to show an early positive result came as a major disappointment for Biogen which is developing the candidate in association with Eisai Clinical stage biopharmaceutical company Axovant Sciences   NASDAQ AXON   suffered a major setback in September 2017 when its investigational Alzheimer s disease candidate failed to meet the co primary efficacy endpoints in a late stage study  The company decided to discontinue development of the 35 mg dose for the treatment of Alzheimer s disease  Over the last one year  the company s shares are down 59 7  compared to the 1 7  decline of the  it belongs to According to the Alzheimer s Association  in the 10 years from 2002 2012  244 drugs were tested for Alzheimer s in studies registered with clinicaltrials gov out of which only one succeeded and went on to gain FDA approval 
The Road AheadDespite all these setbacks  several companies continue to invest heavily in developing Alzheimer s disease treatments given the high commercial potential in this market  Success in this area means huge returns considering more than five million Americans are living with Alzheimer s disease with the numbers expected to triple by 2050  Data  Alzheimer s Association   It is considered to be one of the biggest burdens of society and is the sixth leading cause of death across all ages in the United States  The market has immense commercial potential and companies coming out with new treatments could rake in billions of dollars in sales Companies that are currently working on Alzheimer s disease treatments include Biogen  Novartis   NYSE NVS    AstraZeneca  Eisai and Amgen   NASDAQ AMGN    Biogen s aducanumab is one of the most important candidates in the company s pipeline with the candidate currently in a couple of late stage studies  Biogen is also working on elenbecestat  E2609   a BACE inhibitor in a phase III program  These candidates are being developed in collaboration with Eisai   Lilly also has quite a few Alzheimer s disease candidates in its pipeline including lanabecestat  which is being developed in collaboration with AstraZeneca with data readout expected in 2019  Meanwhile  Novartis and Amgen are collaborating for BACE1 inhibitor  CNP520  which has fast track status in the United Status  Roche is also collaborating with AC Immune for the development of Alzheimer s disease treatments While companies like Pfizer  Lilly and Merck are all Zacks Rank  3  Hold  stocks  you can see  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-01-08,Zacks Investment Research,https://www.investing.com/analysis/alzheimers-takes-another-hit-as-pfizer-ends-research-in-this-area-200278408,200278408
129467,350982,BIIB,PDL BioPharma  PDLI  Q3 Earnings Beat  Revenues Rise Y Y,opinion,PDL BioPharma  Inc    NASDAQ PDLI   reported earnings of 14 cents per share in the third quarter of 2017  surpassing the Zacks Consensus Estimate of 13 cents  The bottom line was also higher than the year ago figure of 8 cents The company generated total revenues of  63 million in the quarter  up 17  when compared with the year earlier figure of  53 6 million  This upside is mainly driven by rise in royalty rights   change in fair value   primarily on the back of the current period s increase in fair value of the Depomed royalty asset  Also  increase in net product revenues contributed to a stronger top line this quarter Notably  the company received cash payments of  26 3 million from the royalty rights acquired from Depomed  primarily related to Glumetza  a product marketed by Valeant Pharmaceuticals International  Inc    NYSE VRX    An authorized generic version of Glumetza was also launched by a Valeant subsidiary in February for which  PDL BioPharma receives 50  of the gross margin Shares of the company have outperformed the  so far this year  The stock has surged 38 7  compared with the industry s increase of 2 3  Quarter in DetailRevenues included royalties of  1 4 million from licenses to the Queen et al  patents  which consisted of royalties earned on sales of Tysabri  net royalty payments from the acquired royalty rights and a change in fair value of the royalty rights assets of 35 4 million  interest revenues of  6 1 million and product revenues of  20 1 million  sales of Noden products   Tekturna and Tekturna HCT in the United States and leasing of the LENSAR Laser System  Revenues of  1 4 million from the Queen et al  licenses were lower than the year ago figure of  15 million due to recognition of a refund liability of  13 5 million for the potential overpayment amount received from Biogen   NASDAQ BIIB    This is related to royalties on Tysabri sales in the United States  Spain  Italy and South Africa Research and development  R D  expenses for the quarter came in at  0 6 million  down 68 7  from the year ago quarter General and administrative expenses escalated 61 4  to nearly  12 million from the year ago figure PDL BioPharma  Inc  Price  Consensus and EPS Surprise   Zacks Rank   Key PickPDL BioPharma carries a Zacks Rank  3  Hold   A better ranked stock in the health care sector is Ligand Pharmaceuticals Inc    NASDAQ LGND    sporting a Zacks Rank  1  Strong Buy   You can see  Ligand s earnings per share estimates have moved up from  3 68 to  3 70 for 2018 over the last 30 days  The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 6 19   Share price of the company has surged 43 6  year to date Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-11-02,Zacks Investment Research,https://www.investing.com/analysis/pdl-biopharma-pdli-q3-earnings-beat-revenues-rise-yy-200258149,200258149
129468,350983,BIIB,Biotech ETFs  What Lies Ahead ,opinion,"So far  it s been a good year for biotech stocks with the Nasdaq Biotechnology Index soaring 19 6  year to date  This is in sharp contrast to last year s performance when the Index was down 19 1  with several factors including the drug pricing controversy weighing on the sector 
2016 was disappointing from an R D perspective as well with a fewer number of drugs managing to gain FDA approval and quite a few companies suffering from high profile pipeline failures  Mixed results  slower than expected new product launches and increasing competition were some of the other challenges for the sector    Read   
However  ramp up in new product sales  R D success and innovation  strong results  a higher number of FDA approvals and continued strong performance from key products are some of the factors that have helped the sector recover this year  Moreover  investors now seem more comfortable with the drug pricing scenario and are focusing more on the fundamentals of the sector 
Increasing Threat from Biosimilars
Although biosimilars are yet to pick pace  they remain a major threat for biotech stocks specially companies that are set to lose patent protection for major blockbuster drugs in the next few years  While a relatively new area  the market for biosimilars is huge and highly lucrative with several blockbuster biologics including Humira and Lantus slated to lose patent protection by 2020  Biosimilars are expected to reduce healthcare costs and provide a large number of patients with access to much needed biologic treatments  Biosimilars are also gaining acceptance across formularies 
According to information provided by Express Scripts  about  250 billion could be saved in the next decade  2014   2024  if biosimilars for 11 products including Neupogen  Avastin  Epogen  Humira  Neulasta  Remicade and Rituxan are approved  According to the company  Neupogen and Remicade biosimilars alone represent potential savings of more than  22 billion 
Mergers and Acquisitions  M As  Yet to Pick Pace
Although expectations were high that M A activity would pick up in 2017  this did not happen  While several small deals were announced  big ticket M A activity was more or less limited with major acquisition news including Johnson   Johnson s  30 billion acquisition of Actelion and Gilead s  11 9 billion acquisition of Kite   Read   
The sector will receive an additional boost if more M A deals are announced  though companies are likely to adopt a  wait and see  stance as they await more clarity on the drug pricing situation and tax reforms  Another major deterrent could be high valuations with companies remaining wary of bidding wars leading to over priced deals 
Higher Number of Drugs Approved So Far in 2017
So far in 2017  the FDA has granted approval to 34 novel drugs  surpassing last year s total tally of 22  Key approvals in the biotech sector this year include Gilead s Yescarta  CAR T therapy for certain types of large B cell lymphoma  and Vosevi  hepatitis C virus   Puma s Nerlynx  to reduce the risk of breast cancer returning   Regeneron Sanofi s Kevzara  rheumatoid arthritis  and eczema treatment  Dupixent  TESARO s PARP inhibitor  Zejula and BioMarin s Brineura  treatment of a specific form of Batten disease  among others  Quite a few of these drugs have blockbuster potential 
The FDA is working on streamlining the development process for drugs for rare diseases as well as for targeted cancer therapies  The agency is also working on clearing up a backlog of orphan drug applications   Read   
Innovative Pipelines   Catalysts
Biotech companies continue to work on bringing innovative new treatments to market  and there could be significant catalysts in the coming quarters in the form of important new product approvals as well as major data read outs especially in key therapeutic areas like immuno oncology  Alzheimer s  central nervous system disorders  and immunology inflammation 
ETFs in Focus
Highlighted below are some biotech ETFs    ETFs present a low cost and convenient way to get a diversified exposure to the sector 
iShares Nasdaq Biotechnology     
IBB  launched in February 2001 by BlackRock Investments LLC  tracks the Nasdaq Biotechnology Index  The fund mainly covers biotech stocks  81 9   with pharma accounting for 9 3   The top 3 holdings include Amgen  NASDAQ AMGN   8 4    Biogen  NASDAQ BIIB  Inc   8 28   and Gilead Sciences  Inc   7 85    The total assets of the fund as of Oct 30  2017 were  9 65 billion representing 159 holdings  The fund s expense ratio is 0 47  while dividend yield is 0 22   The trading volume is roughly 1 268 319 shares per day 
SPDR S P Biotech  MX XBI  ETF   
XBI  launched in January 2006 by State Street Global Advisors  tracks the S P Biotechnology Select Industry Index  The fund covers health care stocks only  Key holdings include Juno Therapeutics  Inc   2 61    Sarepta Therapeutics  2 51    and Exelixis  Inc   2 42    The total assets of the fund as of Oct 30  2017 were  4 billion representing 102 holdings  The fund s expense ratio is 0 35  while dividend yield is 0 22   The trading volume is roughly 4 782 719 shares per day 
First Trust NYSE Arca Biotech ETF   
FBT  launched in June 2006 by First Trust Advisors  tracks the NYSE Arca Biotechnology Index  The top 3 holdings include Alnylam Pharmaceuticals  Inc   3 68    Juno Therapeutics  Inc   3 64    and Neurocrine Biosciences  Inc   3 61    The total assets of the fund as of Oct 27  2017 were  1 2 billion representing 30 holdings  The fund s expense ratio is 0 56  while dividend yield is nil  The trading volume is roughly 33 108 shares per day 
VanEck Vectors Biotech ETF   
BBH  launched in December 2011 by Van Eck  tracks the Market Vectors US Listed Biotech 25 Index  The fund covers health care stocks  The top 3 holdings include Amgen  11 62    Celgene Corporation  NASDAQ CELG   11 26   and Gilead Sciences Inc  NASDAQ GILD    11 18    The total assets of the fund as of Oct 30  2017 were  668 8 million representing 25 holdings  The fund s expense ratio is 0 35  while dividend yield is 0 2   The trading volume is roughly 43 186 shares per day 
PowerShares Dynamic Biotech   Genome ETF   
PBE  launched in June 2005 by Invesco PowerShares  tracks the Dynamic Biotech   Genome Intellidex Index  The top 3 holdings include Illumina  NASDAQ ILMN   Inc   5 31    Biogen  5 29    and Gilead Sciences  Inc   5 11    The total assets of the fund as of Oct 30  2017 were  237 million representing 31 holdings  The fund s expense ratio is 0 58  while dividend yield is 0 84   The trading volume is roughly 13 247 shares per day 
Conclusion
Although the sector may face some volatility due to the drug pricing issue  pipeline success in innovative and important therapeutic areas  cost cutting  share buybacks  new products  increased pipeline visibility and appropriate utilization of cash should help maintain investor confidence in this sector  
Want key ETF info delivered straight to your inbox     
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2017-11-13,Zacks Investment Research,https://www.investing.com/analysis/biotech-etfs-what-lies-ahead-200264714,200264714
129498,351013,BIIB,Biogen  BIIB  Q3 Earnings  Will It Deliver A Beat Again ,opinion,We expect Biogen Inc    NASDAQ BIIB    a well known name in the multiple sclerosis  MS  market  to beat expectations when it reports third quarter 2017 results on Oct 24  before the market opens  Last quarter  the company delivered a positive earnings surprise of 15 60  Biogen s shares have risen 21 4  this year  better than the  s growth of 12 4  in the same time frame Biogen s earnings performance has been pretty impressive so far  having delivered a positive surprise in each of the last four quarters  The average earnings beat over the last four quarters is 6 41  Let s see how things are shaping up for this announcement Factors to ConsiderGlobal patient growth is driving prescription trends and sales of Biogen s MS drugs  We expect the trend to continue in the third quarter  However  rising competition from Roche s   OTC RHHBY   newly launched MS drug Ocrevus may hurt sales of Tysabri modestly as in the second quarter  The Zacks Consensus estimate for key MS drugs  Tysabri and Tecfidera are  479 million and  1 08 billion  respectively Meanwhile  the combined number of patients using Avonex and Plegridy will continue to decline with patients transitioning to other oral MS therapies as well as due to higher discounts and allowance Spinraza  approved for spinal muscular atrophy in December 2016  witnessed faster than anticipated adoption in the United States in the first half backed by robust underlying demand  In June July  Spinraza was approved in the EU  Canada and Japan  which should boost sales in Q3  However  at the Q2 call  management had mentioned that Spinraza U S  sales may slow in the second half  as more difficult to treat patients are coming on and patient transition from intensive Spinraza treatment during induction to a less intensive maintenance schedule Biogen s biosimilar products   Flixabi  a biosimilar referencing Remicade  and Benepali  a biosimilar referencing Enbrel    are also generating higher revenues  The trend should continue this quarter as well Headcount reduction and restructuring initiatives are expected to continue to lower operating expenses  Meanwhile  R D expenses are expected to increase due to increased business development payments Investor focus will remain on Tecfidera s scrip trends  sales rampup of Spinraza  pipeline progress and acquisition plans Earnings WhispersOur proven model shows that Biogen is likely to beat estimates because it has the right combination of two key ingredients  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for a likely positive surprise and Biogen has the right mix Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate   5 72 per share  and the Zacks Consensus Estimate   5 68 per share   is  0 71   You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Biogen has a Zacks Rank  3  The combination of Biogen s Zacks Rank  3 and positive ESP makes us confident of an earnings beat in the upcoming release Sell rated stocks  Zacks Rank  4 or 5   on the other hand  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Biogen Inc  Price and EPS Surprise   Other Stocks to ConsiderSome other stocks in the biotech pharmaceuticals sector that have both a positive ESP and a favorable Zacks Rank includeBristol Myers Squibb Company   NYSE BMY    scheduled to release results on Oct 26  with an Earnings ESP of  2 35  and a Zacks Rank  3  You can see  Pfizer  Inc    NYSE PFE   with an Earnings ESP of  1 85  and a Zacks Rank  3  The company is scheduled to release results on Oct 31 The Hottest Tech Mega Trend of All             Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2017-10-17,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-q3-earnings-will-it-deliver-a-beat-again-200219550,200219550
129499,351014,BIIB,Zacks Market Edge Highlights  Gilead  Biogen  Teva  AbbVie And Aetna,opinion,For Immediate ReleaseChicago  IL   October 19  2017   Zacks Market Edge is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec  Every week  Tracey will be joined by guests to discuss the hottest investing topics in stocks  bonds and ETFs and how it impacts your life  To listen to the podcast  click here    Where to Find Value in Healthcare Stocks Welcome to Episode  103 of the Zacks Market Edge Podcast Every week  host and Zacks stock strategist  Tracey Ryniec  will be joined by guests to discuss the hottest investing topics in stocks  bonds and ETFs and how it impacts your life In this episode  Tracey is joined by Zacks Senior Strategist Kevin Cook who is also the editor of Zacks   It holds about 30 healthcare and medical stocks for the long term Tracey has been getting questions from listeners wondering if there is any value in healthcare stocks right now  Are any of them cheap Biotechs on FireThe biotechs are hot again  The S P Biotech ETF has soared 47  this year while the iShares NASDAQ Biotechnology ETF has gained 27  But can some value still be found in the biotechs  And what about all the other healthcare industries Zacks  Medical Sector has over 800 companies  including drug companies  hospitals  managed care insurers  medical device companies  dental companies and others  They re not all created equal Tracey and Kevin ran a screen to quickly find basic value stocks within the sector  They looked only in the Medical sector and chose a current year forward P E less than 20 and a next year forward P E of under 15 They didn t screen for Zacks Rank It returned 61 stocks Tracey and Kevin discuss about a dozen of them on this week s podcast including these 5 big names 5 Cheap Healthcare Stocks1       Gilead  Nasdaq   NASDAQ GILD       has been cheap for years  It trades with a forward P E of just 9 1  But earnings are on the decline  The company made  11 57 last year and expects to just make  8 74 this year  It recently bought KITE but will that be enough to give earnings a boost  Or is it a value trap 2       Biogen  Nasdaq   NASDAQ BIIB       is another big biotech that is cheap  It trades with a forward P E of just 15 6  Two analysts just raised their price targets to over  400 on the stock  Unlike Gilead  it s expected to see earnings growth this year and next year 3       Teva  NYSE   NYSE TEVA       is the cheapest in the group  It trades with a forward P E of 3 4 but investors have to be concerned about those falling earnings estimates  It made  5 14 in 2016 and is expected to make just  3 82 in 2018  Is it a value trap 4       AbbVie  NYSE   NYSE ABBV       has the rare combination of an attractive P E at just 16 4 and rising earnings estimates  Earnings are expected to jump 14  in 2017 and another 19  in 2018  Should ABBV be on your short list 5       Aetna  NYSE   NYSE AET       is in the managed care group  which  is one of the most difficult areas to be in right now due to Obamacare uncertainty  But Aetna has been reducing its exposure to the exchanges and it trades with a forward P E of just 15 9 There are other industries that are also in the cone of uncertainty due to the unknowns surrounding Obamacare  including the hospitals Tracey Ryniec manages the Insider Trader and Value Investor portfolios at Zacks com  She hosts 2 weekly podcasts   and the   You can also catch her on Twitter at  About ZacksZacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros   In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time    Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2017-10-18,Zacks Investment Research,https://www.investing.com/analysis/zacks-market-edge-highlights-gilead-biogen-teva-abbvie-and-aetna-200219829,200219829
129501,351016,BIIB,Biogen  BIIB  Tops Q3 Earnings   Sales  Spinraza Sales Up,opinion,"Biogen Inc    NASDAQ BIIB    a well known name in the multiple sclerosis  MS  market  surpassed expectations both for earnings and sales in the third quarter of 2017  The company s revenue was driven by continued a strong performance of its newest drug Spinraza  for spinal muscular atrophy 
Despite better than expected results  Biogen s shares were down almost 3  in pre market trading  This was probably due to the fact that the sales of its multiple sclerosis franchise were below expectations amid an increasingly competitive market  However  we note that Biogen s shares have gained 15 8  so far this year  comparing unfavorably with the  s increase of 9  

Third quarter 2017 earnings per share were  6 31  which comfortably beat the Zacks Consensus Estimate of  5 70 by 10 7   Earnings also rallied 22  year over year 
Sales came in at  3 08 billion  up 4  from the year ago period  Sales also surpassed the Zacks Consensus Estimate of  3 04 billion by 1 6   The top line  excluding hemophilia revenues  grew 13  year over year  The company spun off its hemophilia business in February this year 
Quarter in Detail                           
Biogen s MS revenues were  2 3 billion in the quarter including approximately  65 million in royalties on the sales of Roche s MS drug Ocrevus 
Tecfidera sales increased 3  from the year ago period to  1 07 billion  However  the drug recorded a 4  sequential drop in revenues  This included the U S  sales of  836 3 million and ex U S  sales of  233 3 million  In the United States  Tecfidera Inventory levels in the third quarter were relatively flat compared with the year ago levels  which hurt sales in the reported quarter 
Third quarter Tysabri revenues were  469 million  U S   266 8 million  ex U S   202 6 million   which decreased 9  year over year and 5  sequentially  We believe Ocrevus  launch has put pressure on Tysabri s U S  sales in the quarter 
Combined interferon revenues  Avonex and Plegridy  in the third quarter were  662 million  U S   473 3 million  ex U S   188 7 million   down 7  from the year ago period  Avonex revenues declined 7  from the year ago period to  538 million  Plegridy contributed  124 million to third quarter 2017 revenues  down 3  year over year and 7  sequentially 
U S  Interferon revenues are experiencing declining trends due to patients transitioning to other oral MS therapies as well as higher discounts and allowance 
Zinbryta  launched in collaboration with AbbVie Inc    NYSE ABBV   in August last year  contributed  14 million to revenues in the third quarter  down 11  sequentially 
Newly launched Spinraza brought revenues of  271 million  U S  revenues  197 6 million  in the third quarter  registering growth of 33 5  sequentially as the drug witnesses a strong demand in the United States  The company is working on expanding access to all patients 
This quarter  Biogen recorded biosimilar revenues of  101 million compared with  91 million in second quarter 2017  The company markets Benepali  a biosimilar referencing Amgen Inc  s   NASDAQ AMGN   Enbrel in Europe  Benepali recorded revenues of  99 2 million  registering a growth rate of 11 8  sequentially  Biogen also markets Flixabi  a biosimilar referencing Johnson   Johnson s   NYSE JNJ   blockbuster drug  Remicade  which recorded revenues of  2 2 million in the reported quarter compared with  1 9 million in the second quarter 
Revenues from anti CD20 therapeutic programs  which include Biogen s shares of Rituxan and Gazyva operating profits  climbed 28  from the year ago period to  406 million in the third quarter 
R D spend decreased 15 6  in the reported quarter to  446 4 million  while SG A spend declined 6 2  year over year to  433 8 million  
Collaboration Agreement
This month  Biogen announced restructuring of collaboration arrangements with Eisai and Neurimmune to improve long term value of Alzheimer candidate aducanumab  which is presently in a phase III study 
Concurrent with the earnings release  Biogen announced a renegotiation of its agreement with Neurimmune by making a one time payment of  150 million in exchange of a reduction in Neurimmune s 15  royalty rate on the potential sales of aducanumab  The re negotiated deal thus increases aducanumab s profit potential 
On Oct 23  Biogen and partner Eisai refined their existing Alzheimer collaboration  Biogen already has an agreement with Eisai to develop the phase III BACE inhibitor  E2609 and the phase II amyloid beta antibody  BAN240 for Alzheimer s disease  However  Biogen has announced that Eisai has exercised the option to jointly develop and commercialize aducanumab  The company will now receive 55  of aducanumab s potential profits in the United States  68 5  in Europe and 20  in Japan Biogen Inc  Price  Consensus and EPS Surprise

   Zacks Rank
Biogen currently carries a Zacks Rank  3  Hold   You can see  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-10-24,Zacks Investment Research,https://www.investing.com/analysis/biogen-biib-tops-q3-earnings--sales-spinraza-sales-up-200220748,200220748
129502,351017,BIIB,Key Predictions For Q3 Earnings Reports Of ABBV  MRK,opinion,"The third quarter reporting cycle is witnessing revenue acceleration and a positive revisions trend for Q4 
Results from about one third  164 companies  of the S P 500 members are already out  The revenue beat ratio for these companies is 68 3   slightly below the preceding quarter  68 9    which itself was unusually high comparing historically 
Total earnings for the 164 S P 500 members that have reported already are up 7  from the same period last year on 4 8  higher revenues  with 72  beating EPS estimates According to the latest  report  these 164 S P 500 companies account for 38 2  of the index s total market capitalization  Per the report  total earnings of S P 500 companies in Q3 are expected to grow 3 6  year over year on 5  higher revenues Among the biotech pharma bigwigs  Eli Lilly and Company   NYSE LLY    Biogen Inc    NASDAQ BIIB   and Amgen Inc    NASDAQ AMGN   have reported their third quarter results this week All the three companies beat expectations for both earnings and sales Lilly also raised its earnings and sales outlook for 2017  While Amgen slightly raised the lower end of the previously issued sales outlook  it raised the earnings guidance on the back of effective cost management However  shares of Biogen and Amgen declined following their results announcements  Concerns regarding Biogen s multiple sclerosis franchise sales as well as U S  sales of its recently launched spinal muscular atrophy   SMA   treatment  Spinraza  hurt investor sentiment  While for Amgen  the year over year decline in sales led to the share price fall Here we have large pharma companies that are set to report third quarter results on Oct 27  Let s see how things are shaping up for this quarter AbbVie Inc    NYSE ABBV  AbbVie  which is scheduled to release earnings before the market opens  had delivered a positive earnings surprise of 1 43  last quarter  Lilly s earnings performance has been mixed with earnings breaking even in two of the last four quarters while beating the same in the other two  bringing the average surprise to 0 76  For this quarter  Abbvie has an  of almost 0 00  and a Zacks Rank  3  Hold   The Zacks Consensus Estimate is pegged at  1 39 per share  You can uncover the best stocks to buy or sell before they re reported with our  The company s key drug  Humira  is likely to remain the main growth driver in Q3  backed by higher demand  This quarter  AbbVie expects Humira sales to rise in the high teens range while internationally  the same are estimated to increase in a mid single digit range on an operational basis  Other drugs like Duopa and Creon are also expected to continue to perform well in the soon to be reported quarter    Read More    AbbVie Inc  Price and Consensus    Merck   Co   Inc    NYSE MRK  Merck which is scheduled to release earnings before the market opens  Merckhad delivered a positive earnings surprise of 16 09  last quarter  The company s earnings performance has been pretty impressive so far  having delivered a positive surprise in each of the last four quarters  The average earnings beat over the last four quarters is 8 11  The company also has an Earnings ESP of almost 0 00 and a Zacks Rank  3   The Zacks Consensus Estimate is pegged at  1 03 per share  You can see  Merck s new products like Keytruda  cancer   Zepatier  HCV  and Bridion  sugammadex  Injection are likely to drive the top line this quarter  Keytruda sales in the United States are gaining particularly on the back of strong momentum in the new indication of first line lung cancer   Read More  Our previous article showed that Merck was likely to beat on earnings this quarter  However  estimates changed thereafter and we are not certain of a beat this earnings season  Merck   Company  Inc  Price and Consensus    Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-10-25,Zacks Investment Research,https://www.investing.com/analysis/key-predictions-for-q3-earnings-reports-of-abbv-mrk-200221275,200221275
129503,351018,BIIB,3 ETFs To Watch On Biotech Earnings,opinion,"The earnings season is off to a flying start with equity markets scaling record highs  owing to a slew of upbeat economic data  strong corporate performance and President Donald Trump s tax reform proposal  However  the performance has been a mixed bag for biotech companies  with some beating market expectations  while a few failing to do so  read    
We will now discuss the performance of a few biotech giants such as Amgen Inc   NASDAQ AMGN    Gilead Sciences   NASDAQ GILD    Biogen Inc   NASDAQ BIIB   and Alexion Pharmaceuticals   NASDAQ ALXN    read    
Earnings in Focus
 reported third quarter 2017 adjusted earnings of  3 27 per share on Oct 25  2017  surpassing the Zacks Consensus Estimate of  3 09 and increasing 8 3  from  3 02 per share in the year ago quarter  The company also beat the Zacks Consensus Estimate on the revenue front  Amgen reported revenues of  5 773 billion  surpassing the Zacks Consensus Estimate of  5 743 billion but decreased 0 7  from  5 811 billion in the year ago quarter 
The company updated its full year non GAAP EPS guidance to the range  10 96  11 20 from the previous guided range of  10 79  11 37  owing to hurricane recovery costs  It also updated its revenue guidance to the range of  22 7  23 billion from the previous guided range of  22 5  23 billion  The company s shares lost around 0 8  during after hours trading on Oct 25  2017  after it revised down its guidance 
 reported third quarter 2017 adjusted earnings of  2 06 per share on Oct 26  2017  missing the Zacks Consensus Estimate of  2 09 and decreasing more than 25 1  from  2 75 per share in the year ago quarter  However  the company beat the Zacks Consensus Estimate on the revenue front  The company reported revenues of  6 512 billion  surpassing the Zacks Consensus Estimate of  6 329 billion but decreased more than 13 2  from  7 500 billion in the year ago quarter 
The company updated its full year revenue guidance to the range of  24 5  25 5 billion from the previous guided range of  24  25 5 billion  The company s shares fell around 3 8  in after hours trading on Oct 26  2017  owing to the EPS miss 
 reported third quarter adjusted earnings per share of  6 31 on Oct 24  2017  surpassing the Zacks Consensus Estimate of  5 70 and increasing 21 6  from  5 19 per share in the year ago quarter  The company reported revenues of  3 078 billion  surpassing the Zacks Consensus Estimate of  3 036 billion and increasing roughly 4 1  from  2 956 billion in the year ago quarter 
The company s shares declined 3 9  at market close on Oct 24 due to weaker than expected sales of its sclerosis franchise 
 reported third quarter adjusted earnings per share of  1 44 on Oct 26  2017  surpassing the Zacks Consensus Estimate of  1 33 and increasing roughly 17 1  from  1 23 per share in the year ago quarter  The company reported revenues of  859 million  which failed to beat the consensus estimate of  867 million but increased roughly 7 5  from  799 million in the year ago quarter 
The company updated its full year non GAAP EPS guidance to the range of  5 50  5 65 and increased its revenue guidance to  3 475  3 525 billion  The company s shares declined around 4 5  at market close on Oct 26  2017  primarily due to the revenue miss 
We will now discuss a few ETFs with high exposure to the companies discussed 
iShares Nasdaq Biotechnology ETF 
This fund seeks to provide exposure to the biotech industry  It has AUM of  9 5 billion and charges a fee of 47 basis points a year  The fund has 8 4  exposure to Amgen  8 3  to Biogen  8 0  to Gilead and 3 9  to Alexion  as of Oct 25  2017   The fund has returned 17 3  in a year and 18 3  year to date  as of Oct 26  2017   It has a Zacks ETF Rank  3  Hold  with a High risk outlook 
VanEck Vectors Biotech ETF   LON BBH  
This fund has AUM of  668 8 million and charges a fee of 35 basis points a year  The fund has 10 0  exposure to Amgen  9 5  to Gilead  5 5  to Biogen and 4 2  to Alexion  as of Oct 26  2017   The fund has returned 18 2  in a year and 17 5  year to date  as of Oct 26  2017   It has a Zacks ETF Rank  3 with a High risk outlook 
ProShares Ultra Nasdaq Biotechnology ETF 
This fund has AUM of  486 9 million and charges a fee of 95 basis points a year  The fund has 8 4  exposure to Amgen  7 9  to Biogen  7 7  to Gilead and 3 9  to Alexion  as of Sep 30  2017   The fund has returned 15 75  in the last one year and 41 79  year to date  as of Oct 26  2017  
Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2017-10-29,Zacks Investment Research,https://www.investing.com/analysis/3-etfs-to-watch-on-biotech-earnings-200256839,200256839
129533,351048,BIIB,Emergent BioSolutions Acquires Sanofi s Smallpox Vaccine Unit,opinion,Emergent BioSolutions Inc    NYSE EBS   announced that it completed the acquisition of FDA licensed smallpox vaccine s business of Sanofi   NYSE SNY     ACAM2000   The company paid an upfront payment of  97 5 million and  20 million in milestone payments  The deal also includes a potential milestone payment of up to  7 5 million  tied to the achievement of remaining regulatory milestone event ACAM2000 includes ACAM2000 the only vaccine licensed by the FDA for active immunization against smallpox disease for people determined to be at high risk of smallpox infection  It also includes a cGMP live viral manufacturing facility and office as well as warehouse space  both in Canton  MA  and a cGMP viral fill finish facility in Rockville  MD Emergent BioSolutions will also assume responsibility for Sanofi s existing 10 year Centers for Disease Control and Prevention or CDC contract with a remaining value of up to approximately  160 million for deliveries of ACAM2000 to the Strategic National Stockpile  The CDC contract was originally valued at up to  425 million which will expire and be up for renewal or extension in 2018  Pursuant to the acquisition  Emergent BioSolutions  anticipates completing the tech transfer of an upstream portion of ACAM2000 manufacturing to the Canton facility Emergent s shares have outperformed the industry year to date  The stock has surged 23 3  compared with the  s gain of 14 1  The acquisition of ACAM2000 is a strategic fit for Emergent BioSolutions which will enable the latter to expand existing smallpox countermeasure offering along with diversify its portfolio and enabling it to contribute to revenues meaningfully in 2018  Further  it will aid in achieving the goal of  1 billion in total revenues by 2020  The company also expects to generate more than 10  of total revenues from international markets from the deal  Emergent Biosolutions  Inc  Price    Zacks Rank   Stocks to ConsiderEmergent carries a Zacks Rank  3  Hold   Some better ranked stocks in health care sector include ACADIA Pharmaceuticals Inc    NASDAQ ACAD    Biogen Inc    NASDAQ BIIB    each carrying a Zacks Rank  2  Buy   You can see  ACADIA s loss per share estimates have narrowed from  2 63 to  2 52 for 2017 and from  1 92 to  1 85 for 2018 in the last 60 days  The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 7 97   Share price of the company has climbed 33 6  year to date Biogen s earnings per share estimates have moved up  21 38 to  21 48 for 2017 and from  23 12 to  23 29 for 2018 in the last 60 days  The company pulled off positive earnings surprises in all the trailing four quarters  with an average beat of 6 41   The share price of the company has increased 15 4  year to date Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-10-08,Zacks Investment Research,https://www.investing.com/analysis/emergent-biosolutions-acquires-sanofis-smallpox-vaccine-unit-200217713,200217713
129557,351072,BIIB,Lilly  LLY  Makes Leadership Changes To Executive Positions,opinion,"Eli Lilly and Company   NYSE LLY   announced a number of leadership changes in order to focus on bringing newer drugs to the market  In this regard  the company promoted Josh Smiley to the post of Chief Financial Officer  CFO  effective Jan 1  2018  In June 2017  the company announced that its current CFO  Derica Rice  would retire at year end 
The company also promoted Dan Skovronsky to senior vice president for the Science And Technology and President of Lilly Research Labs  The change will be effective June 1  2018 
Also  Myles O Neill has been promoted to Senior Vice President and President of Manufacturing Operations while Aarti Shah  who is a Senior Vice President and Chief Information Officer  has been offered the post of an executive officer 
All four of them will become a part of Lilly s executive committee  In addition to these appointments  the company also announced two retirements of Maria Crowe  President of Manufacturing Operations  who will retire in December after 35 years of service  Jan Lundberg  Vice President for Science and Technology and President of Lilly Research Labs  will retire at the end of May 2018 after eight years with Lilly 
So far this year  Lilly s share price has increased 16 3  compared with the  s gain of 16 4  

We note that the company has made these changes in order to focus on new medicines in diabetes  cancer  immunology  neurodegeneration and pain  Last month  the company also announced some restructuring initiatives in order to streamline its operations so that it can focus on developing new medicines and improve its cost structure  It announced plans to reduce its global workforce by approximately 3 500 positions  These initiatives are expected to amass annualized savings of approximately  500 million  beginning 2018 
Furthermore  it is also closing down several sites  a plant in Iowa  a R D office in New Jersey and a R D center in China to save costs 
However  the company faces its share of challenges  Several key drugs in its portfolio like Zyprexa and Cymbalta are facing generic competition due to loss of exclusivity  Meanwhile  blockbuster drug  Alimta s U S  sales are also being affected by the entry of immuno oncology agents in the market while outside the United States sales are already being hurt due to loss of exclusivity in several countries 
Other headwinds include competition from immuno oncology agents as well as recent high profile pipeline setbacks  Also  Lilly s Animal Health segment did not do too well in the first half due to worldwide competitive pressure Eli Lilly and Company Price   Zacks Rank   Stocks to Consider
Lilly carries a Zacks Rank  3  Hold   Some better ranked stocks in health care sector include Regeneron Pharmaceuticals  Inc    NASDAQ REGN    Biogen Inc    NASDAQ BIIB   and Aduro BioTech  Inc    NASDAQ ADRO    While Regeneron sports a Zacks Rank  1  Strong Buy   Biogen and Aduro carry a Zacks Rank  2  Buy   You can see  
Regeneron s earnings per share estimates have increased from  13 84 to  14 99 for 2017 and from  15 79 to  16 65 for 2018 over the last 60 days  The company pulled off positive earnings surprises in two of the trailing four quarters  with an average beat of 10 11   The share price of the company has increased 21 8  year to date 
Biogen s earnings per share estimates have moved up  21 37 to  21 42 for 2017 and from  23 11 to  23 23 for 2017 over the last 60 days  The company delivered positive earnings surprises in all the trailing four quarters  with an average beat of 6 41   The share price of the company has increased 10 3  year to date 
Aduro s loss estimates per share have narrowed from  1 36 to  1 29 for 2017 over last 60 days  The company came up with positive earnings surprises in two of the trailing four quarters  with an average beat of 2 53  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-10-02,Zacks Investment Research,https://www.investing.com/analysis/lilly-lly-makes-leadership-changes-to-executive-positions-200216545,200216545
129558,351073,BIIB,Novo Nordisk s Fiasp Gets FDA Nod For Diabetes In Adults,opinion,"Novo Nordisk  CO NOVOb    NYSE NVO   announced that the FDA has approved its fast acting mealtime insulin aspart  Fiasp  for the treatment of adults with diabetes The FDA approval was based on results from a phase III study showing that Fiasp improved overall blood sugar  HbA1c  and post meal sugar  postprandial glucose or PPG  control over 52 weeks compared with conventional insulin aspart  NovoRapid  
The  company had resubmitted the new drug application  NDA  for Fiasp as a class II re submission to the FDA in March 2017 
In October 2016  Novo Nordisk announced that it had received a Complete Response Letter from the FDA regarding the NDA for fast acting insulin aspart  In the letter  the FDA requested additional information related to the assay for the immunogenicity and the assay used to generate the clinical pharmacokinetics data before the review of the NDA could be completed 
Novo Nordisk s shares have outperformed the industry year to date  The stock has rallied 36 7  compared with the  s gain of 16 5  in the same time frame 

Fiasp is already approved in Europe for improving the control of postprandial glucose  PPG  excursions in patients with type I and type II diabetes as well as for pump treatment 
In fact  the company has a strong presence in the diabetes care market with a global value market share of 27   Also  the company has strong presence in the total insulin market  and modern and new generation insulin market with a global value market share of 46  and 45   respectively  Notably  Novo Nordisk has one of the broadest diabetes portfolios in the industry Novo Nordisk A S Price

   Zacks Rank   Stocks to Consider
Novo Nordisk carries a Zacks Rank  3  Hold   Some better ranked stocks in health care sector include Regeneron Pharmaceuticals  Inc    NASDAQ REGN    Biogen Inc    NASDAQ BIIB   and Aduro BioTech  Inc    NASDAQ ADRO    While Regeneron sports a Zacks Rank  1  Strong Buy   Biogen and Aduro carry a Zacks Rank  2  Buy   You can see  
Regeneron s earnings per share estimates have increased from  13 84 to  14 99 for 2017 and from  15 79 to  16 65 for 2018 over the last 60 days  The company pulled off positive earnings surprises in two of the trailing four quarters  with an average beat of 10 11   The share price of the company has increased 21 8  year to date 
Biogen s earnings per share estimates have moved up  21 37 to  21 42 for 2017 and from  23 11 to  23 23 for 2017 over the last 60 days  The company delivered positive earnings surprises in all the trailing four quarters  with an average beat of 6 41   The share price of the company has increased 10 3  year to date 
Aduro s loss estimates per share have narrowed from  1 36 to  1 29 for 2017 over last 60 days  The company came up with positive earnings surprises in two of the trailing four quarters  with an average beat of 2 53  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-10-02,Zacks Investment Research,https://www.investing.com/analysis/novo-nordisks-fiasp-gets-fda-nod-for-diabetes-in-adults-200216543,200216543
129559,351074,BIIB,Mallinckrodt  NeuroproteXeon Team Up For Inhalation Therapy,opinion,"Mallinckrodt plc   NYSE MNK   announced that it has entered into a licensing agreement with NeuroproteXeon  The agreement relates to the development and commercialization of NeuroproteXeon s investigational  pharmaceutical grade xenon gas for inhalation therapy The therapy is being evaluated to improve survival and functional outcomes for patients resuscitated after a cardiac arrest  Per the terms  Mallinckrodt will pay  10 million upfront with cash on hand to reimburse NeuroproteXeon for certain product development costs  This will give Mallinckrodt exclusive rights to commercialize the therapy  Mallinckrodt will make an additional milestone payment of up to  25 million A tentative approval of xenon for inhalation will expand Mallinckrodt s portfolio of hospital drug device combination products providing therapies for patients The phase III registration trial will begin in early 2018  It is designed to confirm a potential clinical benefit associated with the positive biomarker outcome as demonstrated on magnetic resonance imaging  MRI  scans of patients who were treated with hypothermia therapy plus xenon gas for inhalation that was seen in a phase IIb study The trial is being conducted under Special Protocol Agreement with the FDA   The trial will measure the clinical benefit of xenon for inhalation in terms of improved 30 day survival and improved functional outcomes  The Special Protocol Assessment that has been approved by the FDA entitles an interim analysis at 50  of trial completion of the primary endpoint follow up Assuming the primary and secondary endpoints are positive  the trial will be halted  However  if the primary or secondary endpoints are not met the trial will be stopped  Mallinckrodt expects the regulatory submission to be a drug and delivery device combination upon a full completion of the trial  tentative approval expected in 2018  Mallinckrodt expects bottom line dilution for the remainder of 2017 to be 10 to 15 cents  with slightly lower dilution in 2018 Mallinckrodt s stock price has declined 22 6  year to date  compared with the  s fall of 19 0  We note that Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non core asset divestitures to transform the portfolio and become a high performing specialty pharmaceutical company  The company recently acquired privately held InfaCare Pharmaceutical Corporation  This specialty pharmaceutical company focuses on the development and commercialization of proprietary pharmaceuticals for neo natal and pediatric patients The company s generic segment continues to face weakness as various product categories are witnessing stiff competition  which is hurting both volumes and prices  The company expects double digit declines in revenues from this segment  In addition  continued expected weakness in this segment will adversely impact gross profit margins also  The company sold its Nuclear Imaging business due to persistent challenging conditions The company also sold its Intrathecal Therapy business to focus on key areas  While Acthar sales continue to be strong on the back of increased formulary positions and access for appropriate patients in both the commercial and public environments  sales of Therakos is expected to decline Zacks Rank   Stocks to ConsiderMallinckrodt carries a Zacks Rank  3  Hold   Some better ranked stocks in health care sector are Regeneron Pharmaceuticals  Inc    NASDAQ REGN    Biogen Inc    NASDAQ BIIB   and Aduro BioTech  Inc    NASDAQ ADRO    While Regeneron sports a Zacks Rank  1  Strong Buy   Biogen and Aduro carry a Zacks Rank  2  Buy  each  You can see  Regeneron s earnings per share estimates have increased from  13 84 to  14 99 for 2017 and from  15 79 to  16 65 for 2018 over the last 60 days  The company posted positive earnings surprises in two of the trailing four quarters  with an average of 10 11   The share price of the company has increased 21 8  year to date Biogen s earnings per share estimates have moved up  21 37 to  21 42 for 2017 and from  23 11 to  23 23 for 2017 over the last 60 days  The company delivered positive earnings surprises inthe trailing four quarters  with an average of 6 41   The share price of the company has increased 10 3  year to date Aduro s loss estimates per share have narrowed from  1 36 to  1 29 for 2017 over last 60 days  The company reported positive earnings surprises in two of the trailing four quarters  with an average of 2 53  
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2017-10-03,Zacks Investment Research,https://www.investing.com/analysis/mallinckrodt-neuroprotexeon-team-up-for-inhalation-therapy-200216779,200216779
129560,351075,BIIB,Endocyte Inks Deal For Prostate Cancer Candidate  Shares Up,opinion,"Shares of Endocyte  Inc    NASDAQ ECYT   have soared more than 150  on Oct 2  after it acquired an exclusive worldwide license to develop and commercialize ABX GmbH s phase III ready prostate cancer candidate 177Lu PSMA 617 
Also  the share price increased more than 50  in pre market trading on Oct 3  The company made an upfront payment of  12 million to ABX 
Consequently  Endocyte s shares have outperformed the  year to date  The stock has rallied 142 4  compared with the industry s gain of 3 5  in the same time frame 

The deal provides Endocyte with the most advanced targeted radioligand therapeutic  RLT   which is being developed for the treatment of prostate cancer and represents a greater than  1 billion market opportunity   
In fact  177Lu PSMA 617 targets the prostate specific membrane antigen  PSMA   present in about 80  of patients with metastatic castration resistant prostate cancer  mCRPC   The candidate has also shown high response rates in late stage prostate cancer patients in the studies presented at recent European Society for Medical Oncology 
177Lu PSMA 617 has the potential to be the first in class RLT to address both bone and soft tissue disease and is a very important for patients suffering from mCRPC 
Going forward  Endocyte intends to seek regulatory approval to commence a phase III study of 177Lu PSMA 617 in early 2018  The company expects the study to complete by 2020  Also  it plans to utilize and focus our resources on the development of 177Lu PSMA 617 
In June 2017  Endocyte announced its plans to reduce its workforce by about 40  in order to better focus its resources on the more valuable opportunities  Interestingly  the company plans to shift its focus on its most promising programs  which include its CAR T cell SMDC adaptor platform  the dual targeted DNA crosslinker drug EC2629 and the cohort of taxane exposed patients receiving EC1169 
Moreover  the company narrowed the EC1169 development program to focus only on the cohort of taxane exposed  mCRPC patients  Further the company stopped enrollment in the EC1456 trial  where the level of clinical activity necessary to support continued advancement of this candidate was not met 
The deal seems to be lucrative for the company and should bode well for its future Endocyte  Inc  Price

   Zacks Rank   Stocks to Consider
Endocyte carries a Zacks Rank  4  Sell   Some better ranked stocks in health care sector include Regeneron Pharmaceuticals  Inc    NASDAQ REGN    Biogen Inc    NASDAQ BIIB   and Aduro BioTech  Inc    NASDAQ ADRO    While Regeneron sports a Zacks Rank  1  Strong Buy   Biogen and Aduro carry a Zacks Rank  2  Buy   You can see  
Regeneron s earnings per share estimates have increased from  13 84 to  14 99 for 2017 and from  15 79 to  16 65 for 2018 over the last 60 days  The company pulled off positive earnings surprises in two of the trailing four quarters  with an average beat of 10 11   The share price of the company has increased 21 8  year to date 
Biogen s earnings per share estimates have moved up  21 37 to  21 42 for 2017 and from  23 11 to  23 23 for 2018 over the last 60 days  The company delivered positive earnings surprises in all the trailing four quarters  with an average beat of 6 41   The share price of the company has increased 11 8  year to date 
Aduro s loss estimates per share have narrowed from  1 36 to  1 29 for 2017 over last 60 days  The company came up with positive earnings surprises in two of the trailing four quarters  with an average beat of 2 53  
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2017-10-03,Zacks Investment Research,https://www.investing.com/analysis/endocyte-inks-deal-for-prostate-cancer-candidate-shares-up-200216833,200216833
129571,351086,BIIB,Seeking Confirmations In The US Market  USD  S P 500 And Tightening ,opinion,"Seeking Confirmations
We have several inputs forecasting change  market pivots  ranging from seasonal tendencies to an expected US dollar rally  Fed monetary tightening  such as it is   the 30 month S P 500 cycle  not to mention a presidential administration in utter disarray and not having done much  if anything  to further the fiscal stimulation  which  the story goes  would replace the Fed s monetary stimulation under the previous administration  view that much of the stock market s post election euphoria was built upon 
In other words  we have working plans for two main themes  a correction in the stock market and in the mirror  a tradable rally in the gold sector  Based on an email exchange with a subscriber  I want to be clear that yes  I think the stock market has probably topped out for something more than a routine pullback  but no  we do not have the all clear on that from a technical confirmation standpoint just yet  although the sector breakdowns noted in a Friday update held that status to close the week 
As for the precious metals  gold shot above and closed below our 1st target of 1300 on Friday and HUI broke above  and closed below short term resistance  Despite that little head fake the sector is constructive insofar as the stock market seemed to change character and did not put on an op ex Friday relief  short covering  rally  implying a waning of confidence  But the gold sector has not technically confirmed 
US Stock Market
This chart shows what I mean about  seeking confirmations   Who s broken down  The Dow  It is above the SMA 50  Semis  What if just maybe that is a Symmetrical Triangle targeting much higher levels  Small Caps  Bear biased but no breakdown 

In TA it is absolutely important to have facts to go with opinions  My opinion is that a correction is beginning  not ending  But the facts are that not one of the items above is broken down in standard technical terms  Although in a Friday update we did note Health Care Select Sector SPDR  NYSE XLV  to be in a breakdown posture with a target of 75  This chart would expand that to 74  SMA 200  to 76  trend line  

Looking closer at Healthcare  we see strong lateral support for XLV at 75      a reasonable target for Devices  which I ve taken the liberty to short since we d taken the liberty of being quite bullish the sector a year ago  is around 150  assuming a market pullback  and we can still anticipate 290 to 295 on the Biotech ETF 

Here is said Biotech ETF  NASDAQ IBB  and some of its top components looking for lower levels  with Biogen  NASDAQ BIIB  in a relative still bullish state  

The Device sector has been following MDT into breakdown mode  TMO in particular  looks like it is setting up for significantly lower levels  I shorted the ETF rather than individual companies to back out individual company risk  I tend not to be that sort of gung ho player from the short side  But boy  that TMO looks toppy 

NFTRH 461 then covered the balance of the US stock market  Financials  Industrials  Technology  Materials  Energy  Transports  Utilities and Consumer Staples   Discretionary  before moving on to Market Internals  a detailed look at 18 different global markets  commodities  precious metals  currencies  bonds  sentiment and well  the whole shootin  match ",2017-08-21,Gary Tanashian,https://www.investing.com/analysis/seeking-confirmations--us-stock-market-200208325,200208325
129573,351088,BIIB,Biogen s Humira Biosimilar Imraldi Gets Approval In EU ,opinion,Biogen Inc    NASDAQ BIIB   announced that its biosimilar version of AbbVie  Inc  s   NYSE ABBV   top selling blockbuster drug  Humira has been approved by the European Commission  The biosimilar will be marketed by the trade name of Imraldi Imraldi  or SB5  will be used for a whole range of indications including rheumatoid arthritis  axial spondyloarthritis  ankylosing spondylitis  plaque psoriasis  psoriatic arthritis  Crohn s disease  ulcerative colitis  polyarticular juvenile idiopathic arthritis  active enthesitis related arthritis  hidradenitis suppurativa and non infectious uveitis We remind investors that the biosimilar was granted a positive opinion by the Committee for Medicinal Products for Human Use  CHMP  in June this year Biogen has a joint venture with Samsung  KS 005930  BioLogics for biosimilars  Samsung Bioepis  the joint venture between the two companies  already marketsa couple of biosimilars in the EU   Flixabi  a biosimilar referencing J J Merck   Co   Inc  s    NYSE MRK    Remicade  and Benepali  a biosimilar referencing Amgen Pfizer s Enbrel   This makes Imraldi the third anti TNF biosimilar from Biogen to receive a marketing authorization in the EU Benepali is doing quite well  generating sales of  154 million in the first half of 2017 while Flixabi recorded sales of  2 5 million in the same period We note that earlier this year  Amgen  Inc    NASDAQ AMGN   gained EU approval for Amgevita  its biosimilar version of Humira Biogen s shares have risen 0 6  this year so far while the  recorded an increase of 7 9  Biogen carries a Zacks Rank  3  Hold   You can see 4 Surprising Tech Stocks to Keep an Eye OnTech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really takes off ,2017-08-24,Zacks Investment Research,https://www.investing.com/analysis/biogens-humira-biosimilar-imraldi-gets-approval-in-eu-200209641,200209641
129575,351090,BIIB,Company News For August 29  2017,opinion,          Shares of Expedia Inc    NASDAQ EXPE   declined 4 5  after the company s Chief Executive Officer Dara Khosrowshahi announced that he would be joining Uber as CEO          Biogen Inc  s   NASDAQ BIIB   shares surged 2 5  following positive results from an Alzhiemer s drug study          Shares of Gilead Sciences Inc    NASDAQ GILD   increased 1 2  after it entered into an agreement with Kite Pharma Inc    NASDAQ KITE   to acquire the company for a whopping  11 billion in cash          Johnson   Johnson s   NYSE JNJ   shares increased almost 0 1  after it announced favorable results in a phase 3 study of its blood thinning drug Xarelto,2017-08-28,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-august-29-2017-200210203,200210203
129580,351095,BIIB,Biogen Alzheimer s Drug Shows Promise In Long Term Study,opinion,Biogen Inc    NASDAQ BIIB   announced data from a long term study on its Alzheimer s disease  AD  candidate  aducanumab  Data from the study showed a continued benefit in the rate of amyloid decline over a two three year period in patients with prodromal or mild Alzheimer s disease when treated with aducanumab Shares were up 2 5  on Monday  in response to the promise shown by the anti amyloid candidate The company said the results from a recently conducted analysis of the long term extension  LTE  of its ongoing phase Ib study  PRIME  of aducanumab were consistent with the previously reported data from PRIME PRIME is a randomized  double blind  placebo controlled  multiple dose phase Ib study being conducted to evaluate the safety  tolerability  pharmacokinetics and pharmacodynamics of aducanumab in patients suffering from prodromal or mild AD So far this year  Biogen s shares have risen 3  while the recorded an increase of 7 2  Biogen is conducting two other phase III studies  ENGAGE and EMERGE  on aducanumab for the treatment of early AD  The results from LTE study support the design of ENGAGE and EMERGE studies Biogen is looking to strengthen its AD and other neurodegenerative disorders pipeline  Biogen s AD pipeline comprises candidates with different mechanisms of action including anti tau candidate  BIIB092 BMS 986168   with potential in AD as well as progressive supranuclear palsy  PSP    anti amyloid  aducanumab  candidates as well as a BACE inhibitor  elenbecestat  program However  the successful development of therapies for the treatment of Alzheimer s disease is challenging and we note that several companies have failed in developing treatments for the same  In November last year  Eli Lilly   Company s   NYSE LLY   anti amyloid candidate solanezumab failed to meet the primary endpoint in a late stage AD study  Lilly decided to drop the development of solanezumab  Lilly suffered a major setback in Aug 2010  when it had to halt the development of another phase III Alzheimer s candidate semagacestat Meanwhile  Pfizer   NYSE PFE   shelved its late stage Alzheimer s candidate  bapineuzumab IV  after it failed two phase III studies  Pfizer was developing the candidate in collaboration with Johnson   Johnson   NYSE JNJ   and Elan Corporation The Alzheimer s disease market represents a huge commercial potential and a successfully developed product could generate billions of dollars in sales once launched Biogen has a Zacks Rank  3  Hold   You can see  Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ,2017-08-28,Zacks Investment Research,https://www.investing.com/analysis/biogen-alzheimers-drug-shows-promise-in-longterm-study-200210259,200210259
129581,351096,BIIB,AbbVie Submits NDA For Endometriosis Candidate To The FDA,opinion,AbbVie Inc    NYSE ABBV   and partner Neurocrine Biosciences announced that the new drug application  NDA  for their pipeline candidate  elagolix  has been submitted to the FDA  AbbVie is looking to get elagolix approved as an oral medicine for the management of pain associated with endometriosis The NDA filing is supported by positive results from two replicate pivotal phase III trials evaluating elagolix  a gonadotropin releasing hormone  GnRH  antagonist  in this indication  The detailed data from the study  presented in October last year  showed that treatment with elagolix resulted in statistically significant reductions in menstrual and non menstrual pelvic pain associated with endometriosis compared to placebo  Data from the studies also demonstrated superiority compared to placebo in reducing painful intercourse associated with endometriosis Endometriosis affects an estimated one in 10 women of reproductive age and is associated with pain symptoms  At present there is no cure for endometriosis  The pain associated with endometriosis is currently managed with oral contraceptives  progestins  danazol  NSAIDS  opioids  and GnRH agonists  Many of these medicines are not specifically indicated for the treatment of endometriosis So far this year  AbbVie s share price has increased 23   comparing favorably with a gain of 11 8  recorded by the  Elagolix is also being evaluated in phase III studies for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids  Data from the pivotal study is expected by end of 2017Apart from elagolix  AbbVie has several candidates in different stages of development across a wide range of therapeutic areas and has partnerships with companies like Roche   OTC RHHBY    Bristol Myers   NYSE BMY   and Biogen   NASDAQ BIIB   AbbVie carries a Zacks Rank  3  Hold   You can see  One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ,2017-09-06,Zacks Investment Research,https://www.investing.com/analysis/abbvie-submits-nda-for-endometriosis-candidate-to-the-fda-200211959,200211959
129595,351110,BIIB,Drug Stocks Q2 Earnings Roster For Aug 8  ACAD  JAZZ   More,opinion,"The second quarter 2017 earnings season is nearing its last leg and the picture so far appears to be quite encouraging   After a few turbulent quarters  earnings for the second quarter of 2017 showed solid strength  As of Aug 4  approximately 420 S P 500 companies or 86 1  of the index s total market capitalization have reported results   A deep look into the results show that earnings for the companies reported are up 11 6  year over year on 5 6  higher revenues  Of these  74 3  have topped earnings estimates while 68 3  have beat on revenue estimates resulting in a blended beat of 55 0  Growth in the second quarter came on the back of strong contribution from the Finance  Technology and Energy sectors  The growth is expected to persist in the second half of 2017 as well  Even though the pace of growth has been sluggish  total Q2 earnings for the index are currently up 10  from the same period last year on 5 1  higher revenues  much better than the 7 9  earnings growth projected at the start of the quarter  Going forward  the estimate for Q3 growth is 4 3   down from 6 3  projected at the start of July How Did the Medical Sector Perform The Medical sector has more or less combated the overall decline in the financial markets and maintained momentum  So far 83 6  of the companies in the sector have reported results  Earnings are up 7 1  on 4  higher revenues resulting in a blended beat of 65 2    Among these  industry bellwether Johnson   Johnson   NYSE JNJ   reported mixed second quarter results  beating on earnings but missing on sales estimates  Biotech giants Gilead Sciences   NASDAQ GILD   and Biogen  NASDAQ BIIB  Inc  surpassed expectations both for earnings and sales in the second quarter of 2017 and raised their annual guidance Let s take a look at the pharma biotech companies that are set to report second quarter results on Aug 8 ACADIA Pharmaceuticals Inc    NASDAQ ACAD   is scheduled to report after the closing bell  The company has a dismal track record  ACADIA has missed estimates in two of the trailing four quarters  beat once and reported in line results in the remaining quarter  resulting in an average negative surprise of 10 2 Currently  the company has a Zacks Rank  3  Hold  and a 0 00     Although the current rank increases the predictive power of ESP  its 0 00  ESP makes it unlikely for the stock to beat estimates this quarter  You can uncover the best stocks to buy or sell before they re reported with our  The FDA s approval of Nuplazid in Apr 2016 was a major boost for the company  The drug is approved for the treatment of hallucinations and delusions associated with Parkinson s disease psychosis and the drug has shown promising growth since its launch in May 2016   Read more    ACADIA Pharmaceuticals Inc  Price and EPS Surprise
    Jazz Pharmaceuticals Public Limited Company   NASDAQ JAZZ   is scheduled to report results after the closing bell  Jazz has an encouraging earnings track record  The company has topped estimates in three of the last four quarters with an average positive earnings surprise of 14 48   Currently  the company has a Zacks Rank  3 and a 0 00  Earnings ESP Investor focus will be on the performance of Jazz s lead product  Xyrem  for cataplexy and excessive daytime sleepiness  Investors will also be looking out for the company s pipeline progress  Defitelio s sales ramped up in the U S   while Xyrem face issues related to patent litigations  The company s business development plans are also expected to draw attention   Read more    Jazz Pharmaceuticals PLC Price and EPS Surprise
    Kite Pharma  Inc    NASDAQ KITE   is expected to report results before the market opens  The company has a mixed record of earnings surprises  It has reported positive earnings surprises in two and negative surprise in the other two of the last fourquarters  bringing the average surprise to a positive 2 07  Currently  the company has a Zacks Rank  3 and a ESP of  0 51  With no approved products in its portfolio  investor focus will primarily be on Kite Pharma s cash burn and pipeline updates  Kite Pharma s lead drug axicabtagene ciloleucel is currently under priority review in the U S  for treating aggressive non Hodgkin lymphoma with a FDA decision expected on Nov 29   Read more    Kite Pharma  Inc  Price and EPS Surprise
    Mallinckrodt plc   NYSE MNK   is set to report second quarter 2017 results  Mallinckrodt has delivered an average positive earnings surprise of 5 27  in the trailing four quarters  Mallinckrodt currently carries has a Zacks Rank  3 and an ESP of  0 58   The combination of Mallinckrodt s Zacks Rank  3 and positive ESP makes us reasonably optimistic of an earnings beat Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non core asset divestitures  Acthar  Ofirmev and Inomax should drive the upside in our view  However  Mallinckrodt s Specialty Generics segment continues to be a laggard  The weakness is expected to persist as stiff competition continues to hurt both volumes and prices   Read more    Mallinckrodt PLC Price and EPS Surprise
    Endo International plc   NASDAQ ENDP   is expected to report second quarter 2017 before the opening bell  The company has delivered a positive surprise in each of the trailing four quarters  recording an average positive surprise of 14 4  Endo currently carries a Zacks Rank  4  Sell  and an ESP of  1 35  We caution against stocks with a Zacks Rank  4 or 5  Strong Sell  going into the earnings announcement 2017 will continue to be challenging year for Endo as the generics base business and the legacy branded pain franchise are expected to decline further  Further  In Jul 2017  Endo had to withdraw opioid pain medication Opana ER  oxymorphone hydrochloride extended release  from the market following the FDA s request in June  The move comes in wake of the widespread opioid abuse epidemic   Read more   
 Endo International PLC Price and EPS Surprise
     5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-08-06,Zacks Investment Research,https://www.investing.com/analysis/drug-stocks-q2-earnings-roster-for-aug-8-acad-jazz--more-200205783,200205783
129598,351113,BIIB,PDL BioPharma  PDLI  Q2 Earnings Beat  Revenues Rise Y Y,opinion,"PDL BioPharma  Inc    NASDAQ PDLI   reported earnings of 26 cents per share in the second quarter of 2017  surpassing both the Zacks Consensus Estimate and the year ago earnings of 9 cents per share 
The company generated total revenue of  143 8 million in the quarter  significantly skyrocketing 583  compared with the year earlier figure of  21 million  This increase in revenue is mainly driven by royalties from PDL BioPharma s licensees to the Queen et al  patents  Also  a rise in royalty rights   change in fair value   contributed to higher revenues this quarter  This was primarily due to the current period s increase in fair value of the Depomed royalty asset 
Notably  the company received cash payments of  34 6 million from the royalty rights acquired from Depomed  primarily related to Glumetza  a product marketed by Valeant Pharmaceuticals International  Inc    NYSE VRX    An authorized generic version of Glumetza was also launched by a Valeant subsidiary in February for which  PDL BioPharma receives 50  of the gross margin 
The company s shares rallied more than 10  at after hours trading on Monday  Shares of the company have outperformed the  so far this year  The shares have climbed 12 7  compared with the industry s increase of 8 9  

 Quarter in Detail
Revenues included royalties of  16 3 million from licenses to the Queen et al  patents  which consisted of royalties earned on sales of Tysabri  net royalty payments from the acquired royalty rights and a change in fair value of the royalty rights assets of 83 7 million  interest revenues of  5 5 million  product revenues of  18 2 million  sales of Noden products   Tekturna and Tekturna HCT in the U S  and leasing of the LENSAR Laser System  and license and other revenues of  19 5 million 
Revenues of  16 2 million from the Queen et al  licenses were higher than the year ago figure of  14 2 million  courtesy higher royalties on Tysabri from Biogen Inc    NASDAQ BIIB   
Research and development  R D  expense for the quarter came in at  4 2 million  No R D costs were recorded in the year ago quarter 
General and administrative expenses surged 61 4  to nearly  11 3 million from the year ago figure PDL BioPharma  Inc  Price  Consensus and EPS Surprise

   Zacks Rank   Key Picks
PDL BioPharma currently carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is Enzo Biochem  Inc    NYSE ENZ    carrying a Zacks Rank  2  Buy   You can see  
Enzo Biochem s loss per share estimates narrowed down from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018  over the last 60 days  The company delivered positive earnings surprises in all the trailing four quarters with an average beat of 55 83   The company s share price has surged 64 5  year to date 
5 Trades Could Profit  Big League  from Trump Policies 
If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course 
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-08-07,Zacks Investment Research,https://www.investing.com/analysis/pdl-biopharma-pdli-q2-earnings-beat-revenues-rise-yy-200205826,200205826
129599,351114,BIIB,3 Drug Stocks Poised To Surpass Estimates In Q2 Earnings,opinion,"The pharma biotech sector has picked up pace this year after being battered by the drug pricing controversy in 2016  The first half has been pretty strong for companies in the space The sector does have its share of challenges in the form of rising competition  high profile pipeline setbacks  slowdown in growth of mature products and loss of exclusivity for certain key drugs  Though the drug pricing issue still prevails  investors  lately  are hoping that steep pricing will not be as damaging as feared previously Nonetheless  strong performance of newer drugs  evolving pipelines  impressive clinical trial results  new drug approvals  continued strong performance of legacy products and rising demand are some of the factors that promise a sustained recovery in the sector Meanwhile  though M A activities and collaborations deals have slowed down this year  chances are that they will pick up in the second half Q2 Performance so FarThe second quarter reporting cycle is almost over  The earnings season has turned out to be very good  witnessing an abundance of positive earnings surprises and broad based growth  As of Aug 4  2017  420 S P 500 members  accounting for 86 7  of the index s total market capitalization  reported results  according to  
Total earnings for these 420 index members increased 11 6  from the year ago quarter on a 5 6  improvement in revenues  The beat ratio was 74 3  for earnings and 68 3  for revenues In the Medical sector  while 87  of the company beat earnings expectations  69 6  beat revenues estimates  indicating that the season has been quite strong for the pharma biotech and the medical device companies Johnson   Johnson  NYSE JNJ  began the earnings season for the pharma sector with mixed second quarter results  While it beat estimates for earnings  it missed the same for sales  Novartis AG  NVS   Eli Lilly   Company  LLY   Merck   Co   Inc   NYSE MRK   Amgen  Inc   NASDAQ AMGN   Celgene Corporation  NASDAQ CELG   AbbVie Inc   NYSE ABBV   and Biogen Inc   NASDAQ BIIB  beat estimates for both earnings and revenues  Lilly and Biogen also raised their earnings and revenue estimates for 2017  However  the generic drugmakers had a dismal quarter  Teva Pharmaceutical Industries Limited s  NYSE TEVA  Q2 earnings and sales missed expectations  It also slashed its 2017 earnings and sales outlook and cut its dividend by 75  How to Make the Right PickGiven the enormity of the healthcare space  selecting stocks that have the potential to beat estimates could appear to a daunting task  But our proprietary methodology makes it fairly simple  One way to narrow down the list of choices this earnings season is by looking at stocks that have the combination of a favorable Zacks Rank   Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    and a positive    More often than not  a positive earnings surprise delivered by a company leads to stock price appreciation Earnings ESP is our proprietary methodology for identifying stocks that have high chances of surprising with their upcoming earnings announcement  It shows the percentage difference between the Most Accurate estimate and the Zacks Consensus Estimate  Our research shows that for stocks with this combination  the chance of a positive earnings surprise is as high as 70    You can uncover the best stocks to buy or sell before they re reported with our  
Here are three small drug biotech stocks that yet to report and are poised to beat estimates in the second quarter according to our methodology Our first pick is Puma Biotechnology  Inc      This small biotech has an Earnings ESP of  3 33  and a Zacks Rank  3  You can see  
The Zacks Consensus Estimate for the second quarter is a loss of  2 10 per share  The company s earnings surprise track record has been mixed  as it missed estimates in two of the trailing four quarters and met expectations in the other two  The company delivered an average positive surprise of 2 53  in the last four quarters This Los Angeles  CA based company is likely to report results this month Our next choice is Alnylam Pharmaceuticals  Inc      Carrying a Zacks Rank  3  the stock has an Earnings ESP of  5 93   The Zacks Consensus Estimate for the second quarter is pegged at a loss of  1 18 per share  This Cambridge  MA based company has a mixed earnings surprise track record as it beat estimates in two of the past four quarters and missed in the other two  The average earnings surprise over the four trailing quarters is 3 69  Alnylam is scheduled to announce results on Aug 9 after market hours Impax Laboratories  Inc     also looks poised to beat expectations in the second quarter  This Hayward  CA based company carries a Zacks Rank  3 and has an Earnings ESP of  7 14   The Zacks Consensus Estimate is pegged at 14 cents per share Impax is scheduled to report results on Aug 9  before market open Bottom Line  Challenges in the form of competitive and pricing pressure will remain in the healthcare sector  However  a number of companies in the space have fared well  Picking some outperformers from the space  backed by a solid Zacks Rank and a positive Earnings ESP  could lead investors to gain this earnings season Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-08-08,Zacks Investment Research,https://www.investing.com/analysis/3-drug-stocks-poised-to-surpass-estimates-in-q2-earnings-200206058,200206058
129600,351115,BIIB,Will Nektar s  NKTR  Candidates Enhance Growth In 2017 ,opinion,On Aug 11  2017  we issued an updated report on Nektar Therapeutics   NASDAQ NKTR    a biopharmaceutical company  focused on development of treatments by utilizing PEGylation and advanced polymer conjugate technology platforms Nektar s shares have significantly outperformed the  so far this year  having surged 48 9   while the industry registered a decrease of 3 4  The company s portfolio comprises two drugs   Movantik for opioid induced constipation  OIC  and Adynovate for treating hemophilia A Nektar has a global license agreement with AstraZeneca   NYSE AZN   under which  the latter was granted with a worldwide  exclusive  license to develop  market and sell rights for Movantik as well as fixed dose combination products The company also has a licensing  collaboration and manufacturing contract with Shire plc   NASDAQ SHPG   for Adynovate  It receives royalties and sales milestones related to both the drugs Also  Nektar has made a significant progress with its lead candidate  Onzeald  formerly known as NKTR 102   currently under accelerated assessment in the EU for treating adults with advanced breast cancer as well as brain metastases  A response is anticipated soon Nektar has also initiated a randomized phase III confirmatory study  ATTAIN  on Onzeald  compared with the single agent chemotherapy of physician s choice  The trial is being conducted on patients with advanced breast cancer  who shortly complain of brain metastases  Positive results from this study could support a regulatory filing in the U S The company is further developing several other candidates across important therapeutic areas including oncology  pain  anti infectives and immunology  Interesting ones include NKTR 181  phase III   chronic pain   NKTR 214  phase I II   solid tumor  and NKTR 358  phase I autoimmune disease  We remind investors that in July  Nektar announced positive top line results from an oral human abuse potential  HAP  study on NKTR 181 in order to assess the abuse potential compared with oxycodone  Notably  the FDA granted a Fast Track designation to the NKTR 181 development program Successful development and commercialization of these candidates will in turn boost the company s top line  considering the lucrative markets they are targeting Importantly  Nektar entered into a co development deal with Eli Lilly and Company   NYSE LLY   for NKTR 358 this month  Pursuant to this agreement  Nektar will be responsible for completing the ongoing phase I study on the candidate  However  going forward with the phase II study on the same  Lilly will be capturing 75  of the total costs to possibly lower the company s development expenses on NKTR 358 However  Nektar s proprietary market products as well as the candidates under development are subject to stiff competition from various pharmaceutical and biotechnology companies The company is expected to face intense rivalry in the pain market with several manufacturers developing pain therapies  Competitors include Collegium Pharmaceutical s Xtampza and Teva Pharmaceutical s naproxen to name a few  Also  players in PEGylation and polymer conjugate chemistry technology space are Biogen  NASDAQ BIIB   Savient Pharmaceuticals  Dr  Reddy s and Novo Nordisk  CO NOVOb  among others Nektar s heavy reliance on partners for revenues remains a concern  since partnership related setbacks may seriously weigh on the company Nektar Therapeutics Price and Consensus   Zacks RankNektar currently carries a Zacks Rank  3  Hold   You can see  5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-08-13,Zacks Investment Research,https://www.investing.com/analysis/will-nektars-nktr-candidates-enhance-growth-in-2017-200207086,200207086
129601,351116,BIIB,What You See  And What You Get  The Neurology Of Perception,opinion,"  1     Neuroscience  The 4 Theaters Of The Brain 5     Investors Train Their Brains to Trade  Assumption and Perception 10     Neurology Is The New Oncology  The Boom In Brain Sciences 14     Biotech Companies With Breakthrough Research 21     Appreciating Differences  The Story Of A Misdiagnosis 34     Episode Roundup  Welcome back to Mind Over Money  I m Kevin Cook  your field guide and story teller for the fascinating arena of behavioral economics  Today s episode is all about your brain  from three different angles 
First  I want to share with you a lesson I used to teach beginning and intermediate traders about their perception and their assumptions 
Second  I m going to talk about some of the exciting biotechnology companies doing breakthrough research in neurological and neurodegenerative diseases like Parkinson s  multiple sclerosis  and Alzheimer s 
And last  I am going to tell you a story about a young woman who led a torturous first third of her life with a neurological condition that went undiagnosed  and where no drugs would have helped anyway 
That story comes from a terrific book I m reading by Dr  John Ratey  a clinical professor of psychiatry at Harvard Medical School   
A User s Guide to the Brain  Perception  Attention  and the Four Theaters of the Brain
Ratey s Four Theaters is a description that really appeals to me based on my reading of other neuroscience books over ten years ago  Back then I concluded that behavior and identity are a complex dance created by several sometimes competing forces   what I call your  multi mind  
And this ties into something I realized in the early 2000 s when I was training traders  First  the reason short term trading is so hard is because our brains evolved for very different challenges than those of watching our money fluctuate up and down wildly on a screen full of red and green arrows 
So I say  your brain wasn t made to trade  because we are barely equipped to manage probability and risk in long term planning  let alone minute by minute  We naturally do the wrong things like keep losing positions and take profits too quickly  the two ingredient recipe for trading failure 
This is why over 95  of those who try short term trading in stocks  currencies  or commodities    especially with leverage    will fail and lose most  if not all  of their money  Even though the odds are better than Vegas  we stack them against ourselves with unconscious cognitive biases and bad habits of emotional decision making 
To hear a powerful analogy I use to teach traders about their biases and their  multi mind   be sure to listen to my full podcast attached to this article 
Meet Tony Coles of Yumanity
Doing some preliminary research for this podcast  I found a great article by Matthew Herper writing for Forbes in February of 2015  Matt says  I cover science and medicine  and believe this is biology s century   I couldn t agree more 
That s why I love running a new portfolio here at Zacks called  where I get to focus on the megatrends of science and medicine 
Matt s story  The Coming Boom In Brain Medicines  starts out with a great introduction to a scientist you should know   
TONY COLES COULD have had any job he wanted in the drug industry  In five years at the helm of cancer drug developer Onyx Pharmaceuticals he increased its market cap eightfold by purchasing an experimental blood cancer drug for  800 million  developing it into a big seller and flipping the whole company to Amgen  NASDAQ AMGN  for  10 4 billion in October 2013  He personally made  60 million on the deal  Biotech watchers expected him to start another cancer company or even command a drug giant like Merck  NYSE MRK  or Pfizer  NYSE PFE  
Instead  Coles  54  is using his own money to build a Cambridge  Mass  based startup called Yumanity that is using yeast  the microbes that help make bread and beer  to study how misfolded proteins in the brain cause Alzheimer s  Lou Gehrig s disease and Parkinson s  and to create drugs based on that knowledge  There s already interest from Big Pharma  Coles says he chose to attack brain diseases  not tumors  because the need is so dire and the science is so fresh 
 We ve got 50 million people around the world who have these diseases  costing  650 billion a year  and lots of families like mine that have been affected   says Coles   I had a grandmother who died of the complications of Alzheimer s disease  I think about my own health as well  
 end of excerpt from Matthew Herper s Forbes article 
The New Next Frontier in Biotechnology
In my Healthcare Innovators portfolio  I am very focused on the frontiers of cancer research  Especially exciting is the field of  immuno oncology  where researchers are learning to harness a patient s own immune system to fight his or her cancer  The research and the treatments are costly  but the rewards could be enormous    and life saving 
A second disease fighting frontier I follow is that of  gene editing  where the science is allowing a person s genome to be altered and possibly cure inherited ailments 
But the new frontier I have very limited experience with as a healthcare investor is the neurological and neurodegenerative diseases  One company I have favored and owned for its Parkinson s psychosis treatment was Acadia Pharmaceuticals  ACAD  
And I currently own Sarepta Therapeutics  SRPT  for the successful launch of their drug for the treatment of Duchenne muscular dystrophy 
Alfred Sandrock  the Chief Medical Officer of Biogen  NASDAQ BIIB  has said that  neurology is the new oncology   And I find it thrilling that this  60 billion company with 12 month trailing sales of  11 7 billion  is so engaged in the new next frontier in biotech 
In the podcast  I describe other companies involved on this frontier like Alkermes  ALKS  and Neurocrine Biosciences  NBIX  
I also own Sangamo Therapeutics  SGMO  primarily for their  zinc finger  gene editing technology  But it doesn t hurt that they have early stage programs in Huntington s disease and Alzheimer s in their R D pipeline too 
Appreciating Differences  Appreciating Health
I close the podcast with a 10 minute story that Ratey shares of a woman named Rickie  who was actually the subject of the 1990 book of the same name by Frederic Flach  a psychiatric researcher at Cornell University 
It s an incredible story ofpersonal tragedy and eventual triumph that you must hear 
My goal is not just to help you learn about the brain and perception but also to encourage you to recognize others who may seem very  different  than you and why that might be 
And also to appreciate your own health  to the degree you have it  That s one I often take for granted myself 
Disclosure  I own shares of SRPT and SGMO for the  portfolio 
Kevin Cook is a Senior Stock Strategist for Zacks Investment Research where he runs the Healthcare Innovators portfolio ",2017-08-15,Zacks Investment Research,https://www.investing.com/analysis/what-you-see-and-what-you-get-the-neurology-of-perception-200207387,200207387
129626,351141,BIIB,Lilly  LLY  Q2 Earnings Top  Baricitinib Re Filing Delayed,opinion,Eli Lilly and Company   NYSE LLY   reported second quarter 2017 adjusted earnings per share of  1 11  which beat the Zacks Consensus Estimate of  1 04 by 6 7   Earnings rose 29  from the year ago quarter backed by volume driven pharma sales growth and higher profits Revenues BeatQuarterly revenues of  5 82 billion beat the Zacks Consensus Estimate of  5 59 billion by 4 2   Sales grew 8  year over year backed by higher volumes and realized prices  However  foreign exchange pulled down sales by 1  Volumes rose 5  as higher volumes of new products like Trulicity  Taltz  Basaglar  Jardiance and Lartruvo offset lower volumes of established products like Zyprexa  Alimta  Cialis and Strattera Pharmaceutical volumes rose 8  in the quarter  However  worldwide competitive pressure hurt sales in Lilly s Animal Health segment Revenue in DetailU S  revenues grew 15  to  3 32 billion  reflecting higher volume of products like Trulicity  Taltz  Basaglar  Jardiance and Lartruvo  which offset lower volumes of established drugs Ex U S  revenues declined 1  to  2 5 billion mainly due to lower volumes  increased competition and lower realized prices  Higher volumes of newer products like Cyramza and Trulicity were offset by lower volumes of Zyprexa  Cymbalta and Alimta due to the loss of exclusivity  Cymbalta has lost exclusivity in Europe and Canada  Zyprexa in Japan and Alimta in several countries  Lower sales of food and companion animal products hurt outside U S  sales as well Established products that recorded growth during the quarter include Forteo  up 22  to  446 7 million   Humulin  up 8  to  357 8 million  and Effient  up 6  to  142 9 million  Alimta sales  however  declined 12  to  532 9 million  reflecting lower demand in the U S  due to competitive pressure  mainly from immuno oncology agents  Outside the U S   sales of Alimta were hurt by loss of exclusivity in several countries  increased competition and lower realized prices Zyprexa sales declined 33  to  140 8 million due to loss of exclusivity Humalog sales decreased 3  in the quarter to  678 4 million due to lower realized prices and volumes in the U S Cialis sales were flat at  627 3 million hurt by lower demand in the U S  as well as increased competition from generic sildenafilErbitux sales declined 12  to  159 1 million in the quarter  Strattera sales declined 17  to  186 6 million  Cymbalta sales declined 13  to  206 6 million Among new products  Trulicity generated revenues of  480 2 million  up 139  year over year  with U S  revenues benefiting from growth in the GLP 1 market and market share gains Cyramza revenues were  186 3 million  up 27  year over year  backed mainly by higher outside U S  revenues  Cyramza s ex U S  revenues benefited from strong volumes in Japan  However  U S  revenues increased only 1  as higher realized prices made up for lower demand due to competitive pressure Jardiance sales  up 157  to  103 2 million  were driven by increased market share within the growing SGLT2 class Basaglar recorded revenues of  86 6 million compared with  46 0 million in the previous quarter  Basaglar   Lilly and partner Boehringer Ingelheim s follow on insulin to Sanofi s   NYSE SNY   blockbuster drug  Lantus   was launched in the U S  in mid Dec 2016 where it generated revenues of  59 5 million in the quarter Taltz brought in sales of  138 7 million compared with  96 6 million in the previous quarter  reflecting strong launch uptake Lartruvo  olaratumab  generated revenues of  47 4 million in the second quarter of 2017 compared with  42 1 million in the previous quarter  Lartruvo was launched in the U S  and the EU for soft tissue sarcoma in the fourth quarter of 2016  U S  revenues were  39 7 million compared with  36 million in the previous quarter Meanwhile  Lilly and partner Incyte Corporation s   NASDAQ INCY   rheumatoid arthritis  RA  drug Olumiant  baricitinib  was approved in EU in Feb 2017  The drug generated sales of  4 8 million in the second quarter of 2017 compared with  1 9 million in the previous quarter  The drug received marketing approval in Japan earlier this month However  in the U S   the companies received a complete response letter  CRL  from the FDA in April regarding the new drug application  NDA  for baricitinib  Concurrent with the earnings release  Lilly announced that the NDA resubmission for baricitinib will not occur this year and will be delayed by a minimum of 18 months  The company said that the FDA has indicated that an additional clinical study will be needed for a resubmission Lilly s Animal Health segment sales declined 9  to  784 8 million despite inclusion of revenues from the acquisition of Boehringer Ingelheim Vetmedica s U S  feline  canine and rabies  acquired in Jan 2017   Animal Health revenues were hurt due to global competitive pressure that affected sales of both food animal and companion animal revenues in the quarter Gross Margin   Operating Income RiseAdjusted gross margin of 76 7  in the quarter increased 70 basis points primarily driven by higher realized prices and manufacturing efficiencies Operating income increased 31  to  1 51 billion on higher gross margins  Operating expenses remained flat in the quarter  However  total operating expenses  as a percent of revenues  declined 390 basis points in the quarter 2017 Outlook UppedLilly raised its previously issued 2017 adjusted earnings and sales outlook  Adjusted earnings per share are now expected in the range of  4 10 to  4 20 compared with  4 05 to  4 15 previously  Revenues are expected in the range of  22 0  22 5 billion compared with  21 8  22 3 billion expected previously  The Zacks Consensus Estimate for earnings and revenues is  4 12 per share and  22 18 billion  respectively Gross margin is expected to be approximately 76   lower than 77  previously  Adjusted tax rate is still expected to be approximately 22  Marketing  selling and administrative expenses are still expected in the range of  6 4  6 6 billion  while research and development expenses are projected to be  5 0  5 2 billion  slightly higher than  4 9  5 1 billion expected previously Our TakeLilly s second quarter 2017 results were strong with the company beating estimates on both counts  The pharma giant also raised its sales and earnings outlook for the year  However  the news of the delay in re filing for baricitinib sent shares down almost 2  in pre market trading  So far this year  Lilly s share price has risen 15 2  compared with an increase of 11 8  for the  The company also said that it will build on its oncology portfolio and work on developing next generation immunotherapies  It will prioritize development of seven pipeline candidates Going forward  new products like Trulicity  Taltz  Basaglar  Cyramza  Jardiance and Lartruvo are expected to see higher revenues  Lilly also expects some established products like Trajenta  Forteo and Humalog to continue doing well  However  Alimta will continue to be impacted by competition  Other headwinds include competition from immuno oncology agents as well as loss of exclusivity for many drugs in emerging markets  Meanwhile  the recent high profile pipeline setbacks are an investor concern and so is the weak performance of the Animal Health segment in the first half Lilly carries a Zacks Rank  2  Buy   You can see    Eli Lilly and Company Price  Consensus and EPS Surprise   Biogen Inc    NASDAQ BIIB    which also reported second quarter results today  beat estimates for both earnings and sales  Shares were up almost 4  in pre market trading More Stock News  Tech Opportunity Worth  386 Billion in 2017 From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity   Most importantly  it reveals 4 stocks with massive profit potential ,2017-07-24,Zacks Investment Research,"https://www.investing.com/analysis/lilly-(lly)-q2-earnings-top,-baricitinib-re-filing-delayed-200203269",200203269
129627,351142,BIIB,4 Stocks To Watch On Big Earnings Day,opinion,"Domino s Pizza Group Plc  NYSE DPZ  Releasing 7 25 17 BMO
The Estimize consensus calls for EPS of  1 25  three cents higher than the Wall Street consensus  Currently  the Estimize community is looking for revenues of  616 35M  just slightly higher than the Street s expectation for  609 58M 
 is showing some impressive numbers this quarter  with a P E ratio of 45 73 and a dividend yield of 0 86   Likewise  the Estimize community is showing positive numbers for YoY growth for both EPS and Revenue  28  and 13   respectively  Last quarter  DPZ saw a negative return on equity of 12 21  and a net margin of 9 06   Despite Domino s  simple food products  they focus their resources on elaborate marketing strategies and cross company collaborations  For example  they are introducing a  pizza theater  store front to make picking up your pizza the ultimate experience  as well as partnering with Twitter for an e commerce wedding registry to order Domino s for your bachelor bachelorette parties and or guests 
AT T Inc   NYSE T  Releasing 7 25 17 AMC
The Estimize consensus calls for EPS of  1 25  three cents higher than the Wall Street consensus  Currently  the Estimize community is looking for revenues of  616 35M  just slightly higher than the Street s expectation for  609 58M 
 is displaying a strong dividend yield of 5 4  but other problems such as competition from wireless networks and controversy over a potential merger may drive the stock downwards  Other wireless providers such as T Mobile and Sprint have cleaned up their act and have taken some shares from AT T  T Mobile is also showing strong numbers for Q2  something analysts think is a result from previous AT T customers going to T Mobile instead  Moreover  AT T has been in talks with CNN and HBO for a potential merger  Media and pay TV corporations have presented this to the justice department is a problem because this merger would favor in house programming  Even President Trump chimed in and said that this merger would further concentrate media power 
JetBlue Airways Corporation  NASDAQ JBLU  Releasing 7 25 17 BMO
The Estimize consensus calls for EPS of  0 55  even with the Wall Street consensus  Currently  the Estimize community is looking for revenues of  1 810B  just slightly lower than the Street s expectation for  1 815B 
Interesting things are happening for   something tristaters would specifically like to consider  The airline company is in talks to build a new terminal at JFK that would increase capacity  better the clients  experiences  and allow for partnerships with more airlines  as well as a  10 billion revamp of JFK  Currently JetBlue operates out of Terminal 5  but they are proposing to expand to Terminal 6 and connect the two  JBLU is predicted to show YoY earnings growth of 4  and revenue growth of 10  
Biogen Inc  NASDAQ BIIB  Releasing 7 25 17 BMO
The Estimize consensus calls for EPS of  4 60  slightly higher than the Wall Street s consensus of  4 40  Currently  the Estimize community is looking for revenues of  2 826B  just slightly higher than the Street s expectation for  2 812B 
There are interesting things happening for spinal muscular atrophy drug  Spiranza  Recently the company released that they made  47m in sales and  10m in inventory build  Likewise  there is a 5  increase in shares since the beginning of the year  Despite this  the biotech industry in general has been under pressure and is expected to be one of the laggards in the health care industry this quarter  Even Biogen is estimated to see YoY EPS growth fall 11  and revenues decrease by 2  ",2017-07-25,Estimize,https://www.investing.com/analysis/four-stocks-to-keep-an-eye-on-before-a-big-earnings-day-tomorrow-200203153,200203153
129628,351143,BIIB,Biogen  BIIB  Tops Q2 Earnings   Sales  Spinraza Sales Up,opinion,"Biogen Inc    NASDAQ BIIB    a well known name in the multiple sclerosis  MS  market  surpassed expectations both for earnings and sales in the second quarter of 2017  The drugmaker also raised its revenue guidance for 2017 as sales of its newest drug Spinraza  spinal muscular atrophy  witnessed faster than expected adoption in the U S 
Shares of Biogen rose almost 5  in pre market trading in response to the strong results  However  we note that Biogen s shares have inched up 0 8  so far this year  comparing unfavorably with the  s increase of 12 7  

Biogen reported second quarter 2017 earnings per share of  5 04  which beat the Zacks Consensus Estimate of  4 36 by 15 6   However  earnings decreased 3  year over year 
Sales came in at  3 08 billion  up 6  from the year ago period  Sales also surpassed the Zacks Consensus Estimate of  2 81 billion by 9 6   The top line  excluding hemophilia revenues  grew 15  year over year  The company spun off its hemophilia business in February 
Quarter in Detail                           
Biogen s MS revenues grew 5  year over year in the second quarter of 2017 with stable global share 
Tecfidera sales rallied 13  from the year ago period to  1 11 billion  The drug recorded a 16  sequential surge in revenues  This included the U S  sales of  875 million and ex U S  sales of  235 6 million  In the U S   Tecfidera revenues benefited from seasonal recovery in both unit volumes and discounts as well as allowances 
Second quarter Tysabri revenues were flat year over year and the same decreased 9  sequentially to  496 million  U S   289 4 million  ex U S   206 6 million  
Note that Tysabri revenues in the first quarter of 2017 benefited by approximately  45 million in the ex U S  markets due to an agreement with the Price and Reimbursement Committee of the Italian National Medicines Agency  AIFA  related to Tysabri sales  This benefit was missing in the second quarter  leading to the sequential decline 
Combined interferon revenues  Avonex and Plegridy  in the second quarter were  691 million  U S   501 7 million  ex U S   188 9 million   down 5  from the year ago period  Avonex revenues declined 8  from the year ago period to  557 million  Plegridy contributed  133 million to second quarter 2017 revenues  up 8  year over year and 19  sequentially 
U S  Interferon revenues are experiencing declining trends due to patients transitioning to other oral MS therapies as well as higher discounts and allowance 
Zinbryta  launched in collaboration with AbbVie Inc    NYSE ABBV   in August last year  contributed  16 million to revenues in the second quarter compared with  11 million in first quarter 2017 
Newly launched Spinraza brought revenues of  203 million  U S  revenues  195 million  in the second quarter  registering massive growth of 328  sequentially as the drug witnesses a strong demand in the U S  U S  Spinraza revenues included approximately  30 million related to an inventory build in the U S  The company is working on expanding access to all patients 
Notably in Jun 2017  Spinraza was granted a marketing authorization in the EU for treatment of 5q spinal muscular atrophy  SMA   It was also approved of in Japan and Canada recently 
This quarter  Biogen recorded biosimilar revenues of  91 million compared with  66 million in first quarter 2017  The company markets Benepali  a biosimilar referencing Amgen Inc  s   NASDAQ AMGN   Enbrel in Europe  Benepali recorded revenues of  88 7 million  thus registering a growth rate of 35 8  sequentially  Biogen also markets Flixabi  a biosimilar referencing Johnson   Johnson s   NYSE JNJ   blockbuster drug Remicade  which recorded revenues of  1 9 million in the reported quarter compared with  0 6 million in the first quarter 
Revenues from Anti CD20 therapeutic programs  which include Biogen s shares of Rituxan and Gazyva operating profits  climbed 14  from the year ago period to  397 million in the second quarter 
R D spend soared 68  in the reported quarter to  796 million  while SG A spend decreased 12  year over year to  430 million  
This quarter  the company repurchased 2 9 million shares worth  782 million under its  5 0 billion share repurchase program 
2017 Outlook
Biogen raised its earnings and revenue outlook for 2017 
Biogen now expects earnings in the range of  20 80  21 40 per share  old guidance   20 45  21 25 per share  for 2017 
Revenues are now expected in a range of  11 5  11 8 billion comapred with the earlier guidance of  11 1  11 4 billion in 2017  This increase from prior guidance is primarily attributed to faster than anticipated adoption of Spinraza in the U S 
In terms of percentage of the total revenue  the company s R D and SG A expenses are expected to be 19  and 16  respectively Biogen Inc  Price  Consensus and EPS Surprise

   Zacks Rank
Biogen currently carries a Zacks Rank  3  Hold   You can see  
More Stock News  Tech Opportunity Worth  386 Billion in 2017
From driverless cars to artifical intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future 
Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity   Most importantly  it reveals 4 stocks with massive profit potential ",2017-07-25,Zacks Investment Research,"https://www.investing.com/analysis/biogen-(biib)-tops-q2-earnings---sales,-spinraza-sales-up-200203380",200203380
129629,351144,BIIB,Biotech Stocks Jul27 Q2 Earnings Roster  BMY  CELG   ALXN,opinion,"The second quarter earnings season is off to a strong start  As of July 25  approximately 128 S P 500 companies or 36 1  of the index s total membership have reported results   A deep look into the results show that earnings for the companies reported so far are up 7  year over year on 4 2  higher revenues  Of these  77 3  have topped earnings estimates while 70 3  have beat on revenue estimates  However  the pace of growth is below the first quarter but in line with the four quarter average and has improved over the 12 quarter average  Going forward  estimates for the third quarter are going down  The estimate for Q3 growth is 4 8   down from 6  at the start of the quarter The Pharma sector has more or less combated the overall decline in the financial markets and maintained momentum   Last week  industry bellwether Johnson   Johnson   NYSE JNJ   reported mixed second quarter results  beating on earnings but missing on sales  Swiss major Novartis AG   NYSE NVS   reported encouraging second quarter results  Meanwhile  biotech giant Biogen Inc    NASDAQ BIIB   surpassed expectations both for earnings and sales in the second quarter of 2017 and raised its annual guidance Let s take a look at three biotech companies that are set to report second quarter results on Jul 27 Bristol Myers Squibb Company   NYSE BMY   is scheduled to report before the opening bell  Last quarter  the company beat earnings estimates by 16 7  Bristol Myers has a decent track record so far  The company s earnings beat estimates in three of the trailing four quarters  with an average positive surprise of 8 39   Currently  the company has a Zacks Rank  3  Hold  and a 0 00     Although the current rank increases the predictive power of ESP  its 0 00  ESP makes it unlikely for the stock to beat estimatesthis quarter You can uncover the best stocks to buy or sell before they re reported with our  Bristol Myers  high profile immuno oncology drug  Opdivo  is expected to continue to drive the company s top line in the to be reported quarter  Although the first quarter saw some stability in the second line lung cancer  the recent FDA approval of Merck   Co   Inc     NYSE MRK   Keytruda for the first line treatment of metastatic nonsquamous NSCLC will impact sales   Read more   Bristol Myers Squibb Company Price and EPS Surprise
    Celgene Corporation   NASDAQ CELG   is scheduled to report before the opening bell  Last quarter  the company beat expectations by 4 08  Celgene s key product  Revlimid  is expected to continue to be the main growth driver as in the first quarter  driven by share gains in important markets and longer treatment duration in newly diagnosed multiple myeloma  MM   Other key products   Pomalyst Imnovid  Abraxane and Otezla continue to perform well  In the second quarter call  investors are expected to remain focused on the company s performance and label expansion efforts  along with updates on the pipeline front  Celgene has submitted a new drug application to the FDA for Idhifa in relapsed refractory AML in 2016  The NDA for Idhifa was granted Priority Review with a Prescription Drug User Fee Act  PDUFA  action date of Aug 30 Celgene s track record has been pretty decent with the company toppingearnings estimates thrice in the trailing four quarters  Overall  the company has delivered an average positive surprise of 3 01   Currently  the company carries a Zacks Rank  3  and an Earnings ESP of  0 62  which indicates a likely earnings beat in the quarter   Read more   Celgene Corporation Price and EPS Surprise
    Alexion Pharmaceuticals  Inc    NASDAQ ALXN   is scheduled to report results before the opening bell In the last reported quarter  the company s earnings surpassed the Zacks Consensus Estimate Alexion s blockbuster drug  Soliris  continues to perform well  Label expansion of the drug for additional indications is expected to boost revenues  Among new products  while Strensiq is doing well  Kanuma lagged expectations and management is reassessing its strategy for the drug going forward Alexion s track record is excellent as the company has consistently topped expectations in the last four quarters with an average positive earnings surprise of 7 49   Currently  the company carries a Zacks Rank  3  and an Earnings ESP of  6 48  which indicates that it is likely to beat estimates in the quarter   Read more   
 Alexion Pharmaceuticals  Inc  Price and EPS Surprise
     The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2017-07-25,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stocks-jul27-q2-earnings-roster:-bmy,-celg---alxn-200203560",200203560
129637,351152,BIIB,Acorda  ACOR  Q2 Earnings Miss Estimates  Revenues In Line ,opinion,"Acorda Therapeutics  Inc    NASDAQ ACOR   reported adjusted earnings of 6 cents per share in the second quarter of 2017  including the impact of stock based compensation expenses   compared with a loss of 41 cents per share in the year ago quarter 
Acorda s shares have lost more than 3  on Thursday  following its second quarter earnings release  However  shares of the company have rallied 15 4  so far this year compared with the  s 10  increase 

Including the impact of stock based compensation expenses as well as other non recurring items  the second quarter loss amounted to 18 cents per share  which significantly missed the Zacks Consensus Estimate of earnings of 13 cents  The company had incurred a loss of 40 cents per share a year ago 
Total revenue came in at  139 4 million  up 9  year over year mainly due to increase in net product revenues  However  revenues were almost in line with the Zacks Consensus Estimate 
Quarter in Detail
The majority of Acorda s net product revenue was generated by Ampyra  which raked in sales of  131 6 million in the reported quarter  Revenues grew 8  year over year and rallied 17 5  sequentially 
Ampyra is marketed in the ex U S  markets by Biogen Inc    NASDAQ BIIB   under the trade name  Fampyra  Biogen pays royalties to Acorda on the outside U S  sales  Fampyra royalties were  2 9 million  up 7 4  year over year 
Acorda s research and development  R D  expenses  including stock based compensation expenses but excluding re structuring costs  decreased 9 3  year over year to  45 6 million 
Selling  general and administrative  SG A  expenses  including stock based compensation expenses but excluding re structuring costs  also declined 10 9  to  47 3 million 
Pipeline Updates
In Jun 2017  the company has submitted a new drug application  NDA  to the FDA for Inbrija for treatment of patients suffering from Parkinson s disease  PD   The NDA was submitted under section 505 b  2  to the FDA  Based on current guidelines  the company expects the FDA to notify  if the submission is accepted for full review by September end this year  The NDA submission was supported by data from one phase III safety and efficacy study  SPAN PD  and from two ongoing long term safety studies  CVT 301 005 and CVT 301 004E  on patients with Parkinson s 
Acorda is also planning to submit regulatory applications for an approval of Inbrija in the EU by the end of 2017 for the given indication 
Notably  the company has another late stage pipeline candidate  tozadenant  in its PD portfolio  The company expects data from an ongoing phase III study in the first quarter of 2018 
2017 Guidance
The company maintained its Ampyra net sales guidance in the range of  535  545 million The company continues to expect its R D expenses for 2017 in the range of  160  170 million  excluding share based compensation 
The company also maintained its SG A expenditure in the band of  170  180 million  excluding share based compensation 
Acorda awaits a positive cash balance in excess of  200 million by the end of 2017 Acorda Therapeutics  Inc  Price  Consensus and EPS Surprise

   Zacks Rank   Key Picks
Acorda currently carries a Zacks Rank  5  Strong Sell  
Some top ranked stocks in the healthcare sector are Enzo Biochem  Inc    NYSE ENZ   and Exelixis  Inc    NASDAQ EXEL    each sporting a Zacks Rank  1  Strong Buy   You can see  
Exelixis s earnings per share estimates inched up from 53 cents to 55 cents for 2018  over the last 30 days  The company has delivered positive earnings surprises in all the trailing four quarters with an average beat of 512 11   Exelixis s shares have soared 81 8  so far this year 
Enzo Biochem s loss per share estimates narrowed down from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018  over the last 60 days  The company delivered positive earnings surprises in all the trailing four quarters  with an average beat of 55 83   The share price of the company has surged 58 1  year to date 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2017-07-28,Zacks Investment Research,"https://www.investing.com/analysis/acorda-(acor)-q2-earnings-miss-estimates,-revenues-in-line-200204385",200204385
129658,351173,BIIB,Nektar  NKTR  Stock Rallied Almost 50  This Year  Here s Why,opinion,"Shares of Nektar Therapeutics   NASDAQ NKTR   are up almost 46 7  this year so far  outperforming the Zacks classified  industry s registered increase of 3  during this period  Let s analyze the factors that led to the rally San Francisco  CA based Nektar Therapeutics is a biopharmaceutical company  focused on development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms Nektar s PEGylation technology has facilitated the development of 10 approved products in the U S  and the EU  through partnerships with healthcare companies  namely  AstraZeneca s   NYSE AZN   Movantik  UCB s Cimzia and Amgen s   NASDAQ AMGN   Neulasta among others  These partnerships have significantly contributed to the company s royalty stream and enhanced its financial position The company s lead candidate Onzeald  formerly known as NKTR 102  is a long acting topoisomerase I inhibitor  currently under an accelerated assessment in the EU for treating adults with advanced breast cancer who have brain metastases  A response is anticipated by the end of the first half of 2017 A randomized phase III confirmatory study  ATTAIN  on Onzeald is also under process compared with the single agent chemotherapy of physician s choice  in the patients with advanced breast cancer  having brain metastases shortly  Positive results from the study could support a regulatory filing in the U S Apart from Onzeald  Nektar is working on developing other candidates  In Feb 2017  the company announced a positive phase I clinical data  evaluating its lead immuno oncology agent NKTR 214  in patients with renal cell carcinoma  RCC   Detailed data were presented at ASCO GU in Jun 2017 Notably on May 2017  the company has entered into a research collaboration with Takeda Pharmaceuticals to explore the combination of NKTR 214 with five oncology compounds from Takeda s cancer portfolio The opioid based candidate NKTR 181 is being evaluated in a phase III study for treating patients with moderate to severe chronic low back pain without causing potential abuse and addiction In Mar 2017  the company posted positive results from the study  It met the primary efficacy endpoint  significantly demonstrating an improved chronic back pain relief under the effect of NKTR 181 compared with placebo Key secondary endpoints of the study were also met with high statistical significance  The FDA has granted a track designation to NKTR 181 for the same indication During the same month  the company announced that it has started dosing in a phase I clinical study  evaluating NKTR 358  which is being developed to treat a wide range of auto immune diseases and inflammatory disorders  The phase I study will evaluate single ascending doses of NKTR 358 in approximately 50 healthy subjects Owing to a number of key data readouts shares of Nektar have consistently propelled this year Though the PEGylation and advanced polymer conjugate chemistry platforms provide an immense commercial potential  candidates currently under development are set to face an intense competition  upon approval  However  the company s robust pipeline looks promising at this juncture and its collaborations bode well for growth  Players in PEGylation and polymer conjugate chemistry technology space include Biogen   NASDAQ BIIB    Savient Pharmaceuticals  Dr  Reddy s and Novo Nordisk  CO NOVOb  among others 
Nektar carries a Zacks Rank  3  Hold  You can see  Nektar Therapeutics Price and Consensus

   3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy   
Last year  it was generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ",2017-06-16,Zacks Investment Research,https://www.investing.com/analysis/nektar-(nktr)-stock-rallied-almost-50-this-year:-here's-why-200195730,200195730
129659,351174,BIIB,It s All About Biotech  Stocks To Watch,opinion,"Michael Bay s latest installment in the Transformers series came out this week and based on the early reviews  it s worse than the rest  Instead of wasting a couple hours of your time on that particular mix of biological beings and technology  you should spend a couple minutes catching up on another  more exciting development in the biotechnology sphere  namely this week s big breakout in biotech stocks 
The world s largest biotech fund  the iShares Nasdaq Biotech ETF  NASDAQ IBB   has had a quiet couple of months  For the last four  the fund has been consolidating in a tight range between about 285 and 303  That changed abruptly this week as prices surged above that range  hitting a high above 320 

Source  Stockcharts com
As the daily chart above shows  IBB has already hit its  measured move  objective of the range breakout  In other words  after being contained to an 18 point range for four months  IBB has surged over 18 points after breaking out this week  Given the rapid thrust higher  there s definitely a chance that we could see a profit taking dip in the coming week  especially with the Fourth of July holiday looming the following week  That said  if we take a step back  there s reason for optimism in IBB from a longer term perspective 

Source  Stockcharts com
As the weekly chart above shows  IBB also broke out of a longer term ascending triangle pattern this week  The  measured move  objective of that setup actually suggests that IBB could revisit 2015 s lofty highs  which would put it closer to 400    in the coming months  Of course no pattern is infallible and there will inevitably be setbacks along the way   even if IBB eventually rises to that aggressive target 
Fundamentally speaking  many biotech stocks have continued to increase their earnings and bolster pipelines over the last couple of years  while stock prices have held relatively steady or even pulled back  After a year and a half of relatively  quiet  price action  this week s price action may mark a major turning point for the planet s largest biotech ETF 
IBB Components
Getting a bit more granular  IBB s largest holdings include Celgene  NASDAQ CELG   Biogen  NASDAQ BIIB    NASDAQ AMGN   Regeneron Pharmaceuticals  NASDAQ REGN  and Gilead Sciences  NASDAQ GILD   all of which traded higher by at least 5  this week  Indeed  REGN rallied by a staggering 11 5  in the four full trading days since Monday s open 
While we wouldn t be surprised to see a pullback in these names over the next week  the big breakout in IBB bodes well for their longer term outlook  We re currently viewing short term dips as buying opportunities as long as IBB holds above 305 
While many are wasting their time and money watching a movie about transforming cars  our readers should be sure to note the more interesting  transformation  taking place in biotech stocks",2017-06-23,Matthew Weller,https://www.investing.com/analysis/it's-all-about-biotech:-stocks-to-watch-200197256,200197256
129660,351175,BIIB,Can Biogen  BIIB  Keep The Earnings Streak Alive In Q2 ,opinion,"Biogen Inc    NASDAQ BIIB    a well known name in the multiple sclerosis  MS  market  will report second quarter 2017 results on Jul 25  before the market opens  Last quarter  the company delivered a positive earnings surprise of 4 63  
Biogen s shares have declined 0 4  this year so far while the Zacks classified  industry recorded an increase of 8 8  

Biogen s earnings performance has been pretty impressive so far  having delivered back to back positive surprises  The average earnings beat over the last four quarters is 5 29  
Let s see how things are shaping up for this announcement 
Factors to Consider
At the first quarter call  the company had said that it expects relatively stable demand for both Tecfidera and Tysabri  its multiple sclerosis drugs  in 2017 as patient growth in ex U S  markets offsets the modest decline in the U S  due to rising competition from drugs like Roche s Ocrevus  It remains to be seen whether its second quarter performance reflects the trend 
Meanwhile  the combined number of patients using Avonex and Plegridy is on the decline as patients transition to other oral multiple sclerosis therapies or other high efficacy products 
Zinbryta  launched in collaboration with AbbVie Inc    NYSE ABBV   in Aug 2016  is expected to continue to contribute to revenues in the U S  and the EU  The drug benefits from increased use of high efficacy products 
Spinraza approved for spinal muscular atrophy in Dec 2016 was off to a promising start backed by robust underlying demand Notably  Spinraza  which added  47 4 million to the top line in the first quarter of 2017  should contribute further to sales  At the Q1 conference call  the company had said that it is working on expanding access to Spinraza to all patients 
However  at the call  the company had warned of possible logistics and coverage restriction on the drug in the U S  as well as other markets  We expect management to provide an update on the issue at its second quarter conference call 
Biogen s biosimilar products   Flixabi  a biosimilar referencing Remicade  and Benepali  a biosimilar referencing Enbrel  are also generating higher revenues  The trend should continue this quarter as well 
Headcount reduction and restructuring initiatives are expected to continue to lower operating expenses  Meanwhile  R D expenses are expected to increase due to increased business development payments 
At the second quarter call  investor focus will remain on Tecfidera s scrip trends  sales ramp up of Spinraza  pipeline progress and acquisition plans 
Earnings Whispers
Our proven model does not conclusively show that Biogen is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below 
Zacks ESP  Its Earnings ESP is  5 61  as the Most Accurate estimate stands at  4 21 while the Zacks Consensus Estimate is pegged higher at  4 46  You can uncover the best stocks to buy or sell before they re reported with our 
Zacks Rank  Biogen s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat 
We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Biogen Inc  Price and EPS Surprise
    Stocks to Consider
Stocks in the pharmaceuticals sector that have both a positive ESP and a favorable Zacks Rank include
Eli Lilly   Company   NYSE LLY    scheduled to release results on Jul 25  with an Earnings ESP of  0 97  and a Zacks Rank  2  You can see  
Pfizer  Inc    NYSE PFE   with an Earnings ESP of  1 54  and a Zacks Rank  3  The company is scheduled to release results on Aug 1 
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-07-18,Zacks Investment Research,https://www.investing.com/analysis/can-biogen-(biib)-keep-the-earnings-streak-alive-in-q2-200202125,200202125
129697,351212,BIIB,Merck  MRK  Buys Rights To Anti tau Antibody For Alzheimer,opinion,"Merck   Co   Inc    NYSE MRK   announced that it has bought exclusive worldwide license from Teijin Pharma for the development  manufacture and commercialization of an investigational preclinical anti tau antibody 
Merck sees potential in the development and commercialization of the candidate for the treatment of Alzheimer s disease  AD  and other neurological diseases  The company will make an undisclosed upfront payment to Teijin Pharma  which is also eligible to receive development  regulatory and sales milestone payments  Further  Teijin Pharma will receive royalties on product sales and retains an option to co promote an approved product in Japan 
Merck s shares are up 10 4  year to date  comparing unfavorably with an increase of 10 7  witnessed by the Zacks classified  industry 

The addition of the anti tau antibody to its portfolio will complement Merck s other AD candidates  This includes MK 6240  a tau ligand which is currently being assessed as a potential Positron Emission Tomography  PET  imaging agent for quantifying the brain burden of neurofibrillary tangle pathology in people with AD  Merck is also is evaluating verubecestat  MK 8931   a BACE1 inhibitor  to see if it can slow or stop the progression of AD 
Notably in Apr 2017  Biogen Inc    NASDAQ BIIB   announced that it has inked a deal to buy worldwide rights for Bristol Myers Squibb s   NYSE BMY   anti tau antibody  BMS 986168  for an upfront payment of  300 million 
Biogen sees significant potential in the development and commercialization of BMS 986168 for the treatment of both AD and progressive supranuclear palsy  PSP   The deal is anticipated to be closed in the second quarter of 2017 
BMS 986168 is an antibody targeting extracellular tau  which is a protein that deposits in the brain associated with AD and other neurodegenerative tauopathies such as PSP  Biogen plans to soon initiate phase II studies for BMS 986168 in both AD and PSP 
However  we want to remind investors that in Feb 2017  the EPOCH study for Merck s verubecestat was stopped after an interim analysis by an external Data Monitoring Committee  eDMC  indicated that the study might fail  While the EPOCH study was stopped due to lack of efficacy  another study  APECS  continues as the eDMC noted that the safety signals observed in the other study were not enough to stop APECS 
In a separate release  Merck also announced that it will collaborate with Optum  the health services business of UnitedHealth Group Incorporated   NYSE UNH    to advance value based contracting of pharmaceuticals  Under outcomes based risk sharing agreements  OBRSAs   health plans   other payers  the companies will reimburse drug manufacturers on basis of clinical outcomes achieved  Optum and Merck plan to publicly share analytic insights  findings and recommendations to help inform and facilitate the understanding and use of pragmatic approaches to OBRSAs in the health care system 
 Merck   Company  Inc  Price
    Zacks Rank and Other Key Picks
Merck currently carries a Zacks Rank  2  Buy   You can see  
Looking for Ideas with Even Greater Upside 
Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2017-05-25,Zacks Investment Research,https://www.investing.com/analysis/merck-(mrk)-buys-rights-to-anti-tau-antibody-for-alzheimer-200191615,200191615
129698,351213,BIIB,The Week Ahead  Will A Big Week For Data Bring Volatility ,opinion,"The holiday shortened week ahead features many economic reports  including the most important  The biggest news is at week s end  so both market participants and pundits will have time to settle in after the long weekend  When they get around to the calendar  I expect many to be asking 
Will we finally see some volatility 
Last Week
Last week the economic news was mixed  but the market showed strength anyway 
Theme Recap
In my last WTWA I predicted a quiet week for data with plenty of talk about the Fed  That was a reasonable guess  but there was not really a dominant theme  There was some discussion about the Fed balance sheet and policy changes  but it was competing with plenty of other news 
The Story in One Chart
I always start my personal review of the week by looking at a chart of S P 500 market performance 

While there were not many big swings  the 1 4  gain for the week also took markets to intra day highs 
The News
Each week I break down events into good and bad  Often there is an  ugly  and on rare occasion something very positive  My working definition of  good  has two components  The news must be market friendly and better than expectations  I avoid using my personal preferences in evaluating news   and you should  too 
The economic news last week was mixed  but the market reaction was positive  
The Good
Q1 GDP revised higher to 1 2   This is backward looking  of course  but a small positive 
Indicators in all time frames show continuing strength   is a great source  This week s conclusion 
The nowcast for the economy remains positive  as does the near term view  with both stocks and jobless claims leading the way  The longer term forecast remains neutral to positive  shading a little closer to neutral based on the tightening yield curve  less robust growth in real money supply  and the miss in corporate profits 


The Philly Fed index improved again  Steven Hansen    has the analysis 

Q1 Earnings show continued strength  This includes not only earnings and revenue  but profit margins    Also see earnings guru Brian Gilmartin in the quant section  below  

Initial jobless claims beat expectations and registered a decline in the widely followed four week moving average  For a full analysis see Steven Hansen    
The Bad
New home sales declined 11   Most sources cited a normal decline from the gains in March as well as weather  The Capital Spectator has a solid and typical explanation  That said  this was a disappointment and deserves careful attention next month   that it was a reasonable report  noting that sales are up 11 3  compared to the same four month period last year  It is always difficult to interpret highly volatile reports 
Durable goods orders dropped 0 7   the first decline in five months     
Existing home sales dropped 2 3    notes the effect of lower inventory on this report  Bill sees this as the key market factor 

The Ugly
Terrorism in London  UK home to   and Egypt lead the week s  ugly  news  This is another  headline  event that is important  but not currently deemed to be a  market  story 
Noteworthy
Did you know that 40  of millennials use Facebook s  NASDAQ FB   as their sole source of news  Decades ago  warned that the public relied too much on TV news  Things change 
The Silver Bullet
I occasionally give the Silver Bullet award to someone who takes up an unpopular or thankless cause  doing the real work to demonstrate the facts  This week s award goes  once again  to Josh Brown  He is often a candidate and one of the most frequent recipients  This week  a Fast Money guest who  came on to discuss the Plunge Protection Team urban legend as a bonafide explanation for why the market has been acting the way it has   He goes on to write 

Now obviously  the existence of a Plunge Protection Team  or PPT   is demonstrably ridiculous  Especially when you consider the fact that we ve seen the market cut in half twice during the last 17 years  with dozens of instances of 10 and 15 percent corrections all along the way over the last 29 years since the end of Reagan s term  The idea that there could be some clandestine  bipartisan shadow organization  with enough money to prop up a global stock market  and the solemnity required to faithfully do so across a half dozen Presidential administrations and all manner of Congressional configurations  is akin to believing in the Area 51 myths or the moon landing hoax 

Readers will certainly note the relevance to this week s theme  Read the entire post for more background and some great comparisons 
The Week Ahead
We would all like to know the direction of the market in advance  Good luck with that  Second best is planning what to look for and how to react  That is the purpose of considering possible themes for the week ahead  You can make your own predictions in the comments 
The Calendar
We have the biggest week of the year for economic reports   and it is jammed into a holiday shortened week 
The  A  List
Employment report  F   Job market tightening  Implication for wage costs 
ISM index  Th   Good concurrent read on economic changes with some leading qualities as well 
Consumer confidence  T   Conference Board version has been very strong  A slight decline is expected 
ADP private employment data  Th   Non government source is a good alternative to the official report  and often changes expectations 
Auto sales  Th   Even greater interest in recent months as the  peak auto  debate continues 
Personal income and spending  T   Continuing growth expected  Consumer spending remains crucial to economic growth 
Initial jobless claims  Th   Continues with record low levels  Not part of the Friday data sample 
The  B  List
Pending home sales  W   While not directly tied to construction spending  it is a good read on the housing market 
Fed Beige Book  W   Anecdotal evidence from each Fed district will be in front of FOMC members at the June meeting 
Construction spending  Th   April data  Rebound from the March decline is expected 
Trade balance  F   Deficit is expected to increase by 1 or 2   More interest in this topic because of current debate over trade policy 
Chicago PMI  W   A hint for the ISM report  this index has been very strong 
Crude inventories  Th   Recently showing even more impact on oil prices  Rightly or wrongly  that spills over to stocks 
There is daily FedSpeak on the schedule 
Next Week s Theme
In a sharp change from the last few weeks  we have a big calendar for economic reports  These include the most important  They come in a holiday shortened week  with a relatively slow start  Last week I noted that the A Teams would head for the beach on Friday  It was indeed a very quiet day  It might be Wednesday before action is back to normal 
If this combination can t generate some action  what will  Pundits will be asking 
Is it finally time for some volatility 
As always  there are several viewpoints 

The lack of volatility is a bad omen  Just as night follows day  we should expect the worst   Citations omitted to protect the guilty  
Much is wrong in the world  The Fed is raising rates and plans to cut the balance sheet  Why no reaction     Barron s  
The market is broken and manipulated  Normal trading strategies do not work  Discussed and refuted by  
The move to passive investing has quashed volatility 
Lower volatility is a known coincident effect of bull markets  Nice analysis from The Fat Pitch 


As usual  I ll have more in my Final Thought 
Quant Corner
We follow some regular featured sources and the best other quant news from the week 
Risk Analysis
Whether you are a trader or an investor  you need to understand risk  Think first about your risk  Only then should you consider possible rewards  I monitor many quantitative reports and highlight the best methods in this weekly update 
The Indicator Snapshot

The Featured Sources 
Bob Dieli  The  C Score  which is a weekly estimate of his Enhanced Aggregate Spread  the most accurate real time recession forecasting method over the last few decades   His subscribers get  including both an economic overview of the economy and employment 
Holmes  Our cautious and clever watchdog  who sniffs out opportunity like a great detective  but emphasizes guarding assets 
RecessionAlert  Many  for both economic and market analysis  While we feature his recession analysis  Dwaine also has several interesting approaches to asset allocation  Try out his new public  
Georg Vrba  The  and much more   for an array of interesting methods  Georg  Bob Dieli s enhanced aggregate spread  considering when it might first give a recession signal  His interpretation suggests the probability creeping higher  but still after nine months 
Brian Gilmartin  Analysis of expected earnings for the overall market as well as coverage of many individual companies  In his most recent post  Brian notes that long term estimates remain strong   double digit percentage increases  The expected downward revisions have recently been absent 
Doug Short  The   and much more   His  is the single best method to monitor the key indicators used by the National Bureau of Economic Research in recession dating 
The Brooklyn Investor has some  about bubbles 
Marc Chandler notes that the oil price price stock correlation has broken down  I say   At last   This never made any logical sense  but it worked because it was working 

How to Use WTWA  especially important for new readers 
In this series  I share my preparation for the coming week  I write each post as if I were speaking directly to one of my clients  Most readers can just  listen in   If you are unhappy with your current investment approach  we will be happy to talk with you  I start with a specific assessment of your personal situation  There is no rush  Each client is different  so I have eight different programs ranging from very conservative bond ladders to very aggressive trading programs  A key question 
Are you preserving wealth  or like most of us  do you need to create more wealth 
Most of my readers are not clients  While I write as if I were speaking personally to one of them  my objective is to help everyone  I provide several free resources  Just write to info at newarc dot com for our current report package  We never share your email address with others  and send only what you seek   Like you  we hate spam  
Best Advice for the Week Ahead
The right move often depends on your time horizon  Are you a trader or an investor 
Insight for Traders
We consider both our models and the top sources we follow 
Felix  Holmes  and Friends
We continue with a strongly bullish market forecast  Most of our models are fully invested  The exception  Road Runner  is fussy about entry criteria  The group meets weekly for a discussion they call the    In each post I include a trading theme  ideas from each of our five technical experts  and some rebuttal from a fundamental analyst  This week our dip buying Holmes model discusses why he is trading Biogen  NASDAQ BIIB   RoadRunner plays upward trending channels and likes Align Technology  NASDAQ ALGN   See  for charts and a lively discussion 
Top Trading Advice
 features a guest post from   You may find some of the ten lessons controversial  but all are interesting 
Do you over emphasize each trade  Dr  Brett has the touch for explaining important concepts   is both entertaining and informative  He explains why single people should go on many first dates and few second ones   Maybe Mrs  OldProf will now see why I was sending Valentine s flowers to several women in the days before we got engaged   Brett s great advice is to view first trades as  small and exploratory  
Insight for Investors
Investors have a longer time horizon  The best moves frequently involve taking advantage of trading volatility 
Best of the Week
If I had to pick a single most important source for investors to read this week it would be Wade Slome s frank and accurate discussion of the   He cites a list of the regular flops   Schiff  Whitney  Mauldin  Roubini  Greenspan  and Merton and Scholes  Pedigree is not the test here for these  radical forecasters  
He has a great list of quotes on predictions  and this advice 

Rather than paying attention to crazy predictions by academics  economists  and strategists who in many cases have never invested a penny of outside investor money  ordinary investors would be better served by listening to steely investment veterans or proven prediction practitioners  

In the quote  he goes on to cite Billy Beane   not my idea of a market forecaster  but the concept is solid  There are experts  They do not always have precision forecasts  but it is often enough to provide an edge 
Finding the best experts is an important challenge 
Stock Ideas
 takes up the mystery of Amazon s  NASDAQ AMZN  valuation  Stock strength  dominant sales position  relatively low earnings and high PE  How should we explain this anomaly  Chuck concludes 

Historically  Amazon has not been an especially profitable company  On the other hand  it has generated extremely high revenue and operating cash flow growth  So far  the market has been willing to give it a pass on earnings  Unfortunately  I have never owned the stock but find myself wishing that I had 


Nevertheless  I think it s only fair to offer some caution  Before an investor makes a buy  sell or hold decision on Amazon  they should at least consider whether the market will be willing to continue to overlook their lack of profitability  So far so good  caveat emptor 

 unearths a handful of  tasty  restaurant stocks 
Merrill s list of five stocks with higher price targets due to  blow out  earnings     
The top ten from   ultimate stock pickers  

Our  always has some fresh ideas  There are ideas from five different approaches  I agree with Oscar and Holmes about the current potential in biotech 
 that markets may react excessively to news driven events  Waiting it out in Cognizant Technology Solutions  NASDAQ CTSH  made good sense  as you can see from his chart   Eddy s ETF  where you can buy his picks with one trade and a low fee  is also   

Investing for Yield
 suggests Iron Mountain  NYSE IRM   a storage REIT that seems to be in a growth market 
 another of his  attractive high yield blue chips for contrarians   It is publicly traded Enterprise Products Partners  NYSE EPD  

Currency Effects
While most investors do not trade directly in currencies  they should follow the impacts on stocks  Stocks benefit differentially based upon dollar strength  The recent weakness has been a big story 
 Davidson   via   sees continuing signs of economic strength  supporting the dollar 
Graduates
Interested in a finance career  starting with your liberal arts degree  Here is   It makes sense to me  Writing skills and critical thinking are always important 
Personal Finance
Professional investors and traders have been making Abnormal Returns a daily stop for over ten years  If you are a serious investor managing your own account  this is a must read  Even the more casual long term investor should make time for a weekly trip on Wednesday  Tadas always has first rate links for investors in his  As usual  investors will find value in several of them  but my favorite is about retirement  The White Coat Investor offers the  
Seeking Alpha Senior Editor Gil Weinreich continues to provide advisors and investors alike with intriguing ideas and links  I particularly enjoyed  about behavioral finance  In addition  his  is a close runner up for best of the week  Gil explains about the changing CFA curriculum and the dangers of blind data crunching  This is a very complex topic  but Gil is right on target with his concern 

The CFA curriculum change leaves the impression that finding alpha today requires this elephantine effort at data crunching  Even if not  I think it s better to take hawkeyec s approach  following a simple plan whose success is not dependent on trying to outsmart everyone else 

 Hawkeyec is an astute and regular commenter whom I follow at Seeking Alpha  For convenience  here is the   
Watch out for 
Mall REITs  Again  Last week we featured   This week we have a nice analysis from   The somewhat contrarian viewpoint describes how some mall owners are evolving  Like last week s citation  it shows that investors should look more deeply rather than making a decision on the entire group 
Analyst sell signals  Ten stocks cited by  
Final Thoughts
Much of the ongoing market discussion centers on a mystery  Why are stock prices higher than many think they should be 
The explanation has gone through many variants during the long bull market  The latest versions relate to market manipulation  low volatility  and ignoring the obvious geopolitical risks 
Perhaps the explanation is much simpler  I discussed this in a recent post on Occam s Razor and Valuation   for the full list of the ever changing excuses for failed valuation methods 
What should we consider instead 
Expected earnings are increasing nicely   now at a double digit pace  These have been better predictors than any of the oft cited bearish valuation methods 
The chance of a recession  the biggest historical threat to markets  remains very low 
The list of  geopolitical concerns and headwinds  does not translate into an impact on earnings 
And especially  Beware of those who twist good news into bad 
It is quite normal for financial stress to be low when times are good  Why expect high volatility  Good times eventually get worse  but good news is not itself an effective forecast of trouble 
Those who reason this way remind me of Chauncey Gardiner  the simple minded hero of one of the all time great movies    Everyone believes his  wisdom   derived entirely from television and gardening 
This might be the best summer investment movie  Few things could help the average investor more than recognizing the slogans and old news in the typical commentary ",2017-05-28,Jeff Miller,https://www.investing.com/analysis/weighing-the-week-ahead:-will-a-big-week-for-data-(finally)-bring-volati-200191798,200191798
129699,351214,BIIB,The Zacks Analyst Blog Highlights  UnitedHealth Group  Union Pacific  Biogen  United Technologies And Accenture,opinion,"For Immediate Release

	Chicago  IL   May 31  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include UnitedHealth Group Inc  NYSE           Union Pacific Corp   NYSE           Biogen  NASDAQ BIIB  Inc  NASDAQ           United Technologies Corp   NYSE          and Accenture Plc  NYSE          

	Today  Zacks is promoting its   Buy   stock recommendations     

Here are highlights from Tuesday s Analyst Blog  

Top Research Reports for UnitedHealth  Union Pacific   Biogen  

	Today s Research Daily features new research reports on 16 major stocks  including UnitedHealth Group Inc  NYSE           Union Pacific Corp   NYSE          and Biogen Inc  NASDAQ           You can see      

	Buy Rated UnitedHealth Group s continued strong growth at Optum as well as UnitedHealthcare segments are driving growth  Its international business and strong capital position are other positives  Moreover  the company has reduced its exposure to the troubled public exchange business  Though this move will shield it from losses in this business  the company s premium revenues are likely to be affected 

	UnitedHealth shares have underperformed the Zacks Medical HMOs industry in the year to date period  UnitedHealth is up  10 9  vs   15 2  gain for the industry    You can      

Union Pacific s  improvement in the coal scenario is very encouraging  Coal volumes are expected to increase in the second quarter  continuing the trend displayed in the first quarter of 2017  The Zacks analyst is also impressed by the company s efforts to reward investors and control costs 

	The buy ranked company has appreciated 31 4  in the last year  but has underperformed the Zacks categorized Transportation Rail industry s increase of 39   In fact  the stock has lagged fellow railroad operator Norfolk Southern  NYSE NSC   whose shares have gained 45 5  in the last year   You can      

Biogen shares have been laggards for a while now  the stock has underperformed the Biomed Genetics industry in the year to date   11 5  vs   0 3    Emergence of new PML cases for Tecfidera would weigh heavily on the stock as would pipeline setbacks  However  Biogen has a strong position in the multiple sclerosis market  backed by a wide range of products including Avonex  Tysabri  Tecfidera   Plegridy  The Zacks analyst is also encouraged by Biogen s efforts to diversify beyond MS to other areas like Alzheimer s disease   You can      

	Other noteworthy reports we are featuring today include United Technologies Corp   NYSE         and Accenture Plc  NYSE          

Today s Private Buys   Sells from Zacks Research 

	While we share the above news with the public  our sensitive recommendations are hidden from everyone but selected members  Would you like to peek behind the curtain and view them  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time from value to momentum       from stocks under  10 to ETF and option moves       from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors      

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-05-30,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-unitedhealth-group,-union-pacific,-biogen,-united-technologies-and-accenture-200192348",200192348
129700,351215,BIIB,Why Is Acorda  ACOR  Down 8 4  Since The Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Acorda Therapeutics  Inc    NASDAQ ACOR    Shares have lost about 8 4  in that time frame  underperforming the market 
Will the recent negative trend continue leading up to the stock s next earnings release  or is it due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts Acorda First Quarter Loss Wider Than Expected  Revenues MissAcorda Therapeutics reported loss of  0 25 per share in the first quarter of 2017  including the impact of stock based compensation expenses   wider than the Zacks Consensus Estimate of a loss of  0 16  The company had reported a gain of  0 09 per share in the year ago quarter Including the impact of stock based compensation expenses as well as other non recurring items  first quarter loss amounted to  0 41 per share  The company had incurred a loss of  0 01 per share a year ago Total revenue came in at  119 4 million  up 3   Revenues missed the Zacks Consensus Estimate of  126 million by 5 2  Quarter in DetailThe majority of Acorda s net product revenue was generated by Ampyra  which raked in sales of  112 million in the reported quarter  Revenues grew 2  year over year but decreased 15 3  sequentially Ampyra is marketed in ex U S  markets by Biogen  NASDAQ BIIB  under the trade name Fampyra  Biogen pays royalties to Acorda on outside U S  sales  Fampyra royalties were  2 5 million  flat year over year Zanaflex capsules and tablets  including authorized generic capsules  recorded revenues and royalties of  1 7 million  up 41 6  from the year ago period Acorda s research and development  R D  expenses  including stock based compensation expenses  increased 4 3  year over year to  46 5 million due to increased investment in late stage programs  INBRIJA or CVT 301 and tozadenant  as well as the addition of Biotie s R D expenses  Last September  Acorda acquired the remaining stake in Biotie  thereby completing its acquisition Selling  general and administrative  SG A  expenses  including stock based compensation expenses and Biotie transaction costs  decreased 1  to  51 7 million 2017 GuidanceThe company maintains its Ampyra net sales guidance in the range of  535  545 million The company lowered its R D expenses for 2017 and the costs are now expected in the range of  160  170 million  old guidance   185  195 million   excluding share based compensation The company also lowered its SG A expense guidance to a range of  170  180 million  old guidance   195  205 million   excluding share based compensation 
How Have Estimates Been Moving Since Then  
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions Acorda Therapeutics  Inc  Price and Consensus
    VGM Scores
At this time  Acorda s stock has a poor Growth Score of  F   however its Momentum is doing a lot better with a  B   Charting an exact same path  the stock was allocated a grade of  B  on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of  C   If you aren t focused on one strategy  this score is the one you should be interested in 
Our style scores indicate that the stock is suitable for momentum and value investors 
Outlook
Notably  the stock has a Zacks Rank  3  Hold   We are expecting an inline return from the stock in the next few months ",2017-06-01,Zacks Investment Research,https://www.investing.com/analysis/why-is-acorda-(acor)-down-8.4-since-the-last-earnings-report-200192621,200192621
129701,351216,BIIB,Biogen Loses Top Executive Again  CFO Clancy To Join Alexion,opinion,Biogen Inc  s   NASDAQ BIIB   chief financial officer  CFO  for the last 10 years  Paul Clancy  is joining Alexion Pharmaceuticals  Inc    NASDAQ ALXN   next month Shares of Alexion were up 3 7  in after hours trading on Tuesday while Biogen s shares declined 1 3   This year  Biogen s shares have declined 9 9  so far while the Zacks classified industry has gained 2 2  Clancy who also held the position of executive vice president  Finance at Biogen will join Alexion on Jul 10 while assuming the role of CFO from Jul 31  He has been with Biogen for 16 years  Prior to that  Clancy served at food beverage giant PepsiCo  Inc    NYSE PEP   in various executive roles for 13 years  Clancy will replace Dave Anderson  who will become a senior adviser to chief executive officer  CEO  Ludwig Hantson  Alexion had announced Anderson s resignation last month  Anderson will be with Alexion through end of August Biogen also announced that its present chief accounting officer  Greg Covino  will serve as the company s interim principal financial officer  as the search for a new CFO is conducted Several key executives at Biogen have departed over the past couple of years  which has given rise to concerns that the company may be in trouble  These include R D head  Douglas Williams and HR head Kenneth DiPietro in 2015  chief information officer  in 2016 and technology head Adriana Karabout in March this year Importantly  George A  Scangos resigned as CEO in Jul 2016  He was replaced by present CEO  Michel Vounatsos  who assumed responsibilities in January Meanwhile  Alexion appointed its present CEO Hantson in March this year Biogen carries a Zacks Rank  3  Hold   You can see  A better ranked stock in the large cap pharma sector is Bayer Aktiengesellschaft   OTC BAYRY   with a Zacks Rank  2  Buy  Shares of Bayer have risen 29 1  this year so far while estimates for both 2017 and 2018 have risen around 2  in the past 30 days Zacks  2017 IPO Watch List    Before looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth,2017-06-13,Zacks Investment Research,"https://www.investing.com/analysis/biogen-loses-top-executive-again,-cfo-clancy-to-join-alexion-200195188",200195188
129734,351249,BIIB,4 Drug Stocks Poised To Beat This Earnings Season,opinion,"This earnings season started on a promising note for the pharma biotech sector after a challenging 2016  The sector has been going through a rough patch due to media and political focus on steep drug pricing issues  Interestingly  the NASDAQ Biotechnology Index   NBI  and the NYSE ARCA Pharmaceutical Index   DRG  gained 9 4  and 6 2   respectively so far in the year  reflecting the strong start witnessed by the sector M A and licensing deals as well as drug pricing issues are expected to remain in focus in 2017  Investors will also be glued to new product approvals along with label expansion of existing drugs and regular pipeline updates for key drugs Factors Influencing the QuarterWith the earnings season drawing to a close and majority of the bigwigs having reported results we can conclude that the pharma healthcare sector has witnessed a mixed performance Industry bellwether Johnson   Johnson  NYSE JNJ     reported mixed results for the first quarter wherein earnings surpassed expectations  revenues missed estimates  Eli Lilly  LLY  and Pfizer  NYSE PFE  too reported mixed results   On the other hand  biotech bigwig Gilead Sciences  NASDAQ GILD     beat on earnings but missed on sales  Biogen  Inc   NASDAQ BIIB  reported better than expected results in first quarter 2017  The company surpassed expectations both for earnings and sales Although a major chunk of the sector has already reported  it is still not too late to join the bandwagon  There are still a bunch of companies left to report results  We shall help you to zero in on a number of stocks that are poised to beat earnings estimates this quarter  An earnings beat should help these stocks gain investor confidence and show favorable price movements A Guideline to Make Prudent ChoicesGiven the enormity of the healthcare space  selecting stocks that have the potential to beat estimates could appear to be quite daunting  However  our proprietary methodology makes it fairly simple  One way to narrow down the list of choices this earnings season is by looking at stocks that have the combination of a favorable Zacks Rank   Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    and a positive    More often than not  a positive earnings surprise delivered by a company leads to stock price appreciation Earnings ESP is our proprietary methodology for identifying stocks that have high chances of surprising with their upcoming earnings announcement  It shows the percentage difference between the Most Accurate estimate and the Zacks Consensus Estimate  Our research shows that for stocks with this combination  the chance of a positive earnings surprise is as high as 70    You can uncover the best stocks to buy or sell before they re reported with our 
4 Solid PicksHere are four healthcare stocks that are poised to beat estimates in the first quarter according to our methodology Endo International plc    is scheduled to report first quarter 2017 results on May 9  before the opening bell  Endo posted a positive surprise in each of the trailing four quarters  with an average positive surprise of 12 7   Last quarter  the company delivered a positive earnings surprise of 8 59   Endo announced an accelerated restructuring of its generics product and R D portfolio  as well as the manufacturing facility network  This initiative is expected to boost the company s bottomline   Endo currently carries a Zacks Rank  3  The combination of Zacks Rank  3 and an ESP of  1 79 makes us confident of an earnings beat in the upcoming release Immune Design    is expected to report first quarter results on May 9  The company has a decent track record so far having reported a wider than expected loss in one of the four trailing quarters and a narrower than expected loss in the two other occasions  bringing the positive average surprise to 4 31   Being a development stage biopharmaceutical company  Immune Design has not generated any product revenues yet and hence investors should keep an eye on the company s progress with its pipeline candidates  Immune Design is developing multiple candidates using its two discovery platforms   ZVex and GLAAS   for the treatment of various types of cancers  Key pipeline candidates include CMB305  solid tumor  and G100  merkel cell carcinoma   The company currently carries a Zacks Rank  3 and has an earnings ESP of  11 3  which makes it likely to post an earnings beat in the upcoming release Ionis Pharmaceuticals  Inc     is scheduled to report first quarter 2017 results on May 9  Last quarter  the company recorded a positive earnings surprise of 265   Ionis  track record has been mixed so far  Over the four trailing quarters  the company posted an average positive earnings surprise of 62 20   having beaten estimates in two quarters and missing the same twice  The company is a RNA targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases  In a significant boost  Ionis and Biogen received FDA s approval for Spinraza  nusinersen   an antisense drug  for the treatment of spinal muscular atrophy  SMA  in Dec 2016  The company currently carries a Zacks Rank  3 and has an Earnings ESP of  250  which hints at an earnings beat in the upcoming release Editas Medicine  Inc     is a genome editing company which is focused on treating patients with genetically defined diseases by correcting their disease causing genes  The company has collaborated with Juno Therapeutics  Inc   to develop novel engineered T cell therapies for cancer  The company is expected to report first quarter results on May 15  Although the track record is dismal  the company s favorable Zacks Rank  3 and an Earnings ESP of  32 26   is likely to help it to surpass expectations Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time   One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-05-08,Zacks Investment Research,https://www.investing.com/analysis/4-drug-stocks-poised-to-beat-this-earnings-season-200187827,200187827
129735,351250,BIIB,Biotech Giant Eyes Key Support,opinion,"Leading biotechnology stock Biogen  NASDAQ BIIB  has been under pressure lately  The stock has been selling off since the company reported earnings on April 25  On that day  BIIB traded as high as  291 90 a share  Since then  the biotech giant has shed nearly  34  Currently  Biogen is at  258 86 a share 
Traders should note that the charts are signaling institutional support around the  250 area  This is a solid number that institutional traders usually like to play  It s also a level where the stock was defended in the past  Traders should note that this trade level was chart support in late January 2017 and late October 2016  Frequently  past support levels have been solid bounce levels when retested ",2017-05-10,Nicholas Santiago,https://www.investing.com/analysis/biotech-giant-eyes-key-support-200188353,200188353
129736,351251,BIIB,Sangamo Therapeutics Shares Increase On Better Than Expected Results,opinion,"Sangamo Therapeutics Inc  NASDAQ SGMO 
Sangamo Therapeutics  Inc   SGMO   a clinical stage biopharmaceutical company yesterday reported their first quarter 2017 financial results  Sangamo reported a first quarter earnings loss of  0 23 per share which beat analyst expectations of a loss of  0 26 per share 
Sangamo reported a first quarter revenues of  3 4 million which fell short of analyst expectations of  3 9 million  Sangamo also announced that it will receive a  70 million payment from Pfizer  NYSE PFE  for a marketing collaboration for a hemophilia A treatment 
Sangamo Therapeutics  Inc  CEO s Comments

 Our team continues to make significant operational progress across all four lead clinical programs  Three Phase 1 2 in vivo genome editing clinical trials are now screening subjects  and the fourth trial evaluating SB 525  a cDNA gene therapy approach for Hemophilia A  will open later this quarter   said Dr  Sandy Macrae  CEO of Sangamo   We are initiating multiple sites for each program over the next few months to ensure we can accrue patients rapidly into these studies  We remain on course and expect to announce data from each program late this year or in early 2018   

SGMO Technical Analysis
Sangamo Therapeutics Chart
SGMO opened trading yesterday at  4 30 which was down from the previous day s trading close of  4 40  SGMO closed trading yesterday at  4 35 and spiked up after market to  6 30  equivalent to a 45  increase from the closing price  Taking a look at the daily chart we can see that the last time SGMO traded above these levels we have to go back to August 3rd  2016 when it traded at  6 84 
Taking a closer look at the daily chart we can see that before the spike up SGMO had already been in an overall upward trend dating back to December 28th when it traded at  2 90  SGMO has a float of 65 32 million shares and traded 1 81 times the normal daily trading volume on Wednesday 
For trading purposes  I would like to see SGMO open trading on Thursday above  5 65 and if it does I would be looking to take a long position at the bell  My stop loss would be  0 20 from my entry position fearing anything more than that and the stock would start to fill in the gap up 
Company Profile
Sangamo Therapeutics  Inc   a clinical stage biopharmaceutical company  focuses on translating ground breaking science into genomic therapies that transform patients  lives using platform technologies in genome editing  gene therapy  gene regulation  and cell therapy  The company s proprietary zinc finger DNA binding protein  ZFP  technology enables specific genome editing and gene regulation  The ZFPs could be engineered to make ZFP nucleases  ZFNs   proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes  and ZFP transcription factors  ZFP TFs   proteins that can be used to turn genes on or off  Its therapeutic products include SB 728 T  a ZFN mediated autologous T cell product for human immunodeficiency virus and acquired immunodeficiency syndrome  HIV AIDS   which is in Phase II and Phase I clinical trials  and SB 728 HSPC that is in Phase I II clinical trials for HIV AIDS 
The company also engages in Phase I II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B  Hemophilia A  and Mucopolysaccharidosis I  MPS  and MPS II  which are lysosomal storage disorder  LSD   proprietary preclinical programs in other LSDs  and research stage programs in certain central nervous system disorders and cancer immunotherapies  It has collaborative partnerships with Biogen  NASDAQ BIIB  Inc  to develop therapeutic genome editing products in hemoglobinopathies  and with Shire International GmbH to develop the preclinical development program in Huntington s disease  as well as license agreement with Sigma Aldrich Corporation to develop ZFP based laboratory research reagents and Dow AgroSciences  LLC to modify the genomes or alter protein expression of plant cells  plants  or plant cell cultures  The company was formerly known as Sangamo BioSciences  Inc  and changed its name to Sangamo Therapeutics  Inc  in January 2017  Sangamo Therapeutics  Inc  was founded in 1995 and is headquartered in Richmond  California ",2017-05-11,Warrior Trading,"https://www.investing.com/analysis/sangamo-therapeutics,-inc.-$sgmo-stock-shares-increase-on-better-tha-200188522",200188522
129737,351252,BIIB,The Zacks Analyst Blog Highlights  Regeneron  Amgen And Celgene,opinion,"For Immediate Release

	Chicago  IL   May 25  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Regeneron  NASDAQ           Amgen  NASDAQ          and Celgene  NASDAQ          

	Today  Zacks is promoting its   Buy   stock recommendations     

Here are highlights from Wednesday s Analyst Blog  

	Major news in the biotech sector include FDA approval for Regeneron s  NASDAQ         rheumatoid arthritis  RA  treatment  Kevzara  as well as data from companies like Amgen  NASDAQ          and Celgene  NASDAQ          Recap of the Week s Most Important StoriesRegeneron Sanofi  PA SASY  RA Drug Gets FDA Nod Second Time Round   It proved to be second time lucky for Regeneron and partner Sanofi with the companies gaining FDA approval for their RA treatment  Kevzara  The companies had got a complete response letter  CRL  for the IL 6R antibody in Oct 2016 due to manufacturing issues  While Kevzara has blockbuster potential  the RA market is highly crowded given the presence of treatments like Humira and Xeljanz among others  Regeneron and Sanofi have priced Kevzara at  39 000 year  a discount of about 30  to the U S  wholesale acquisition cost for the two most widely used TNF alpha inhibitors  Moreover  the patient population is huge with many patients spending years on different treatments without achieving their treatment goals  With RA affecting about 1 3 million Americans  Kevzara represents a new treatment option for patients  Read more      Regeneron is a Zacks Rank  1  Strong Buy  stock  You can see   Celgene MS Drug Tops Study but Falls Short on Disability Endpoint    Celgene reported positive data on its experimental multiple sclerosis  MS  drug  ozanimod  from a second phase III study with the candidate meeting the primary endpoint in patients with relapsing multiple sclerosis  RMS   However  the drug failed to meet the disability endpoint in a pooled analysis  While the failure in the disability endpoint is disappointing  it should not really hamper the drug s chances to gain approval though it may impact sales  Celgene remains on track to file for FDA approval by year end  We note that ozanimod  which has blockbuster potential  is also being evaluated for ulcerative colitis and Crohn s disease  both representing significant commercial potential  Read more    Amgen Osteoporosis Drug Hit by Safety Event   Amgen and partner UCB s plans for their experimental osteoporosis drug  Evenity  met a roadblock with a new safety signal emerging in a late stage study  Although Evenity met both the primary endpoints and the key secondary endpoint in the study  the companies said that an imbalance in positively adjudicated cardiovascular serious adverse events was observed  Evenity is currently under regulatory review in the U S   Canada and Japan but based on the new safety event  Amgen said that it does not expect FDA approval in 2017  Read more     
	While Amgen s shares were down 2 2  on the news  Radius Health s shares shot up 6 6     Radius  osteoporosis drug  Tymlos  gained FDA approval just last month  A delay in FDA approval for Evenity will give Radius  drug some breathing space before new competition enters the market Alexion Shares Hit by Top Management Shakeup   Alexion s shares were down 9 3  with the company announcing changes in its executive leadership team  The company announced the appointment of a new Chief Commercial Officer  while the existing Chief Financial Officer will resign his position at the end of August  The Executive Vice President  Head of Research   Development will also be retiring from Alexion at the end of 2017  The Executive Vice President  Chief Human Resources Officer  will also be leaving the company effective Jun 1  2017  Year to date  Alexion s shares are down 14 5   lagging the Zacks categorized  industry which is up 0 4  so far in 2017 Another Indication for Vertex CF Drug  Vertex gained FDA approval for the use of its cystic fibrosis  CF  drug Kalydeco in patients 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator  CFTR  gene  More than 900 people in the U S  have one of these mutations  Following the approval  Vertex upped its Kalydeco 2017 revenue guidance to  740 million    770 million 
	Vertex is also working on gaining rapid approval for more than 600 additional people who have mutations responsive to Kalydeco  including one of five  splice  mutations  Read more     Bioverativ To Buy North Therapeutics  Strengthen Pipeline    Biogen s spin off  Bioverativ which is focused on developing treatments for hemophilia and other rare blood disorders  will be acquiring privately held  clinical stage rare disease biotech company True North Therapeutics for  400 million upfront plus assumed cash  The company will also shell out as much as  425 million on the achievement of development  regulatory and sales milestones 
	With this acquisition  which is scheduled to close in mid 2017  Bioverativ will add TNT009 to its pipeline  TNT009  True North s lead candidate  is being evaluated for the treatment of cold agglutinin disease  CAD   a rare and chronic hemolytic condition affecting about 16 people per million globally including 5 000 people in the U S  There are currently no approved treatments for CAD 

	The NASDAQ Biotechnology Index declined 1 5  over the last five trading sessions  Among major biotech stocks  Regeneron gained 1 5  on the back of FDA approval for Kevzara while Alexion lost 13  during this period  Over the last six months  Vertex was up 33 5  while Biogen  NASDAQ BIIB  was down 18 9   See the last biotech stock roundup here     

	Biotech World

	Puma which saw its shares shoot up 52 9  this week on what is being viewed as favorable FDA briefing documents for the advisory panel meeting of the company s experimental breast cancer treatment  neratinib  will get to know about the FDA s Oncologic Drugs Advisory Committee s recommendation today Looking for Stocks with Skyrocketing Upside 
	Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
	Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look 

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  







	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-05-24,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-regeneron,-amgen-and-celgene-200191386",200191386
129758,351273,BIIB,Bristol Myers And Nordic Ink Biomarker Collaboration Deal,opinion,Bristol Myers Squibb Company   NYSE BMY   recently announced that it has inked a collaboration agreement with Nordic Bioscience  a Danish company specializing in biomarker technologies  The partnership will focus on developing translational biomarkers and diagnostics for the evaluation of non alcoholic steatohepatitis  NASH  in pre clinical models of fibrotic diseases and in clinical settings A biomarker is a molecule that may be used to diagnose a disease  or predict disease progression and indicate response to therapy Bristol Myers  shares have underperformed the Zacks classified  industry so far this year  Shares of the company lost 9 4   while the industry registered an increase of 5 4  Please note that Bristol Myers has a robust pipeline of investigational compounds to address areas of high unmet need in fibrosis  including nonalcoholic steatohepatitis  NASH   It has several candidates in early to mid stage development for fibrotic diseases  Some candidates that deserve mention are pentraxin 2  LPA1 antagonist and PEG FGF21 Bristol Myers is also highly active on the deal signing acquisition front  The company is actively signing deals in therapeutic areas like oncology  fibrosis and genetically defined diseases  Earlier last week  Bristol Myers entered into an agreement with Biogen   NASDAQ BIIB   for an upfront payment of  300 million to license its anti eTau compound  BMS 986168  for progressive supranuclear palsy  PSP   Under the licensing deal  Bristol Myers will receive an additional  410 million as milestone payments and potential royalties Per the company s press release  NASH is will likely be the leading cause of liver transplant by 2030  Approximately 20 million patients in the U S  have NASH and there are currently no approved pharmacological treatments  No wonder  development of such technology will enable the company to cater to the huge unmet need of patients suffering from the disease Bristol Myers Squibb Company Price    Zacks Rank   Key PicksBristol Myers currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector are Heska Corporation   NASDAQ HSKA   and Galena Biopharma  Inc    NASDAQ GALE    Each of these stock sports a Zacks Rank  1  Strong Buy   You can see  Heska s earnings per share estimates increased from  1 53 to  1 65 for 2017 and from  1 90 to  2 01 for 2018 over the last 60 days  The company posted positive surprises in three of the four trailing quarters with an average beat of 291 54  Galena s loss per share estimates narrowed from  1 12 to 58 cents for 2017 and over the last 30 days  The company posted positive earnings surprises in two of the four trailing quarters  with an average beat of 53 83  5 Trades Could Profit  Big League  from Trump Policies If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-04-17,Zacks Investment Research,https://www.investing.com/analysis/bristol-myers-and-nordic-ink-biomarker-collaboration-deal-200183409,200183409
129759,351274,BIIB,What s In Store For Biogen  BIIB  This Earnings Season ,opinion,"Biogen Inc    NASDAQ BIIB    a well known name in the multiple sclerosis  MS  market  will report first quarter 2017 results on Apr 25  before the market opens  Last quarter  the company delivered a positive earnings surprise of 1 41  Biogen s shares rose 4  this year so far while the Zacks classified industry recorded an increase of 2 9  Biogen s earnings performance has been pretty impressive so far  having delivered back to back positive surprises  The average earnings beat over the last four quarters is 5 86  Let s see how things are shaping up for this announcement Factors to ConsiderAt the fourth quarter 2016 conference call  management had informed that U S  market share of its oral MS drug  Tecfidera  declined slightly in 2016 with increasing competition from oral medicines and slowdown in the overall MS market  However  Tecfidera is seeing patient growth in ex U S  markets  Sales of the drug also declined sequentially in the fourth quarter of 2016  Sales of another MS drug  Tysabri also declined in the quarter Biogen expects relatively stable demand for both Tecfidera and Tysabri in 2017 as patient growth in ex U S  markets offsets the modest decline in the U S   It remains to be seen if sales trends of both these drugs improve in the first quarter of 2017 Meanwhile  the combined number of patients using Avonex and Plegridy will continue to decline as patients shift to other oral MS therapies or other high efficacy products Zinbryta  launched in collaboration with AbbVie Inc    NYSE ABBV   in Aug 2016  is expected to contribute to revenues in the U S  and the EU  The drug is also benefiting from increased use of high efficacy products We remind investors that FDA approved Biogen and partner Ionis  Spinraza for spinal muscular atrophy in Dec 2016  Notably  Spinraza is the first approved treatment for the disease  which will allow it to address an untapped market  thereby offering the company a huge boost  Spinraza  which added  5 million to the top line in the fourth quarter of 2016  should contribute further to sales in the first quarter of 2017 At the fourth quarter conference call  the company warned of possible logistics and access related hurdles for Spinraza launch  We expect management to provide an update on the issue at the latest conference call Meanwhile  headcount reduction and restructuring initiatives are expected to continue to lower operating expenses  Cost of goods sold  as a percentage of sales  are expected to rise in 2017 due to higher royalty payments related to the sales of Spinraza Investor focus on the fourth quarter call will remain on Tecfidera s scrip trends  launch progress on Spinraza  pipeline progress and acquisition plans Earnings WhispersOur proven model does not conclusively show that Biogen is likely to beat on earnings this quarter  This is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  The Earnings ESP is  1 80  as the Most Accurate estimate stands at  4 90 while the Zacks Consensus Estimate is pegged higher at  4 99  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Biogen s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Biogen Inc  Price and EPS Surprise   
Stocks to ConsiderStocks in the pharmaceuticals sector that have both a positive ESP and a favorable Zacks Rank are Amgen  Inc    NASDAQ AMGN   is scheduled to release results on Apr 26  The company has an Earnings ESP of  1 99  and a Zacks Rank  3  You can see  Celldex Therapeutics  Inc    NASDAQ CLDX   has an Earnings ESP of  7 14  and a Zacks Rank  3  The company is expected to release results early next month Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-04-19,Zacks Investment Research,https://www.investing.com/analysis/what's-in-store-for-biogen-(biib)-this-earnings-season-200183993,200183993
129760,351275,BIIB,Is Pain Ahead For Healthcare ETFs After Weak JNJ Q1 ,opinion,The hot healthcare sector has made a nice comeback this year on cheap valuation  robust earnings results  encouraging industry trends  and a slew of positive actions taken by the President despite the collapse of the healthcare bill  read    This is especially true as popular funds   Health Care Select Sector SPDR Fund  XLV   Vanguard Health Care ETF   AX VHT    iShares U S  Healthcare ETF  and Fidelity MSCI Health Care Index ETF     have gained at least 8  so far this year  easily outpacing the gain of 5 7  for the broad market fund   AX SPY   However  the ETFs took hit from lackluster Johnson   Johnson   NYSE JNJ   quarterly results last week as the company lagged our revenue estimate for the second consecutive quarter on sluggish drug sales  JNJ occupies the top position in the above mentioned ETFs with double digit allocation    Results from the world s biggest maker of health care products could be a warning sign for other drug makers as many of them are losing their exclusivity with the launch of biosimilars  As a result  the sector is expected to post modest earnings growth of 0 8  and revenue growth of 6 3   as per the latest   read    Let s delve deeper into the earnings picture of some of the largest companies in the healthcare space that are expected to report this week and in the next and have the potential to drive the performance of the above mentioned funds Some of the big names dominating the funds include Pfizer   NYSE PFE    Merck   NYSE MRK    Amgen   NYSE AMG     AbbVie   NYSE ABBV    Gilead Sciences   NASDAQ GILD   and Bristol Myers Squibb   NYSE BMY    All these stocks collectively account for 27 3  share in XLV  26 1  in IYH  23 9  in VHT and 23 6  in FHLC According to the our surprise prediction methodology  a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  when combined with a positive  increases the chance of an earnings beat  while a Zacks Rank  4 or 5  Sell rated  are best avoided You can uncover the best stocks to buy or sell before they re reported with our  Inside Our Surprise Prediction of These StocksPfizer has a Zacks Rank  3 and an Earnings ESP of 0 00   which makes surprise prediction difficult  The Zacks Consensus Estimate for first quarter 2017 is 67 cents  up a nickel over the past three months  The stock delivered positive earnings surprises in two of the past four quarters  with an average beat of 4 36   Additionally  it has an impressive Value and Momentum Style Score of B and A  respectively  though a Growth Style Score of C is unfavorable  Pfizer is scheduled to report earnings on May 2 before the opening bell Merck is expected to report its results on May 2 before the market opens  It has a Zacks Rank  3 and an Earnings ESP of 0 00   which makes surprise prediction difficult  Though the stock witnessed a negative earnings estimate revision of four cents over the past 90 days for the to be reported quarter  it delivered positive earnings surprises in the last four quarters  with an average beat of 4 03   Merck seems a triple play stock with strong Value  Growth and Momentum Style Score of B each Amgen has a Zacks Rank  3 and an Earnings ESP of  2 33   indicating a reasonable chance of beating estimates this quarter  The earnings surprise track over the past four quarters is robust with an average positive surprise of 7 38   Amgen witnessed positive earnings estimate revision of a nickel over the past 90 days for the yet to be reported quarter  Though the stock has a solid Value and Momentum Style Score of B and A  respectively  the Growth Style Score of D looks dull  Amgen will report earnings on April 26 after market close  read    AbbVie has a Zacks Rank  3 and an Earnings ESP of 0 00   which makes surprise prediction difficult  The company delivered positive earnings surprises in the last four quarters  with an average beat of 1 92  and saw positive earnings estimate revision by a penny over the past three months for the to be reported quarter  The stock has a solid Value and Momentum Style Score of B each while the Growth Style Score of D is unimpressive  The company is scheduled to report on April 27 before the opening bell     Gilead is expected to release earnings on May 2 after market close  It has a Zacks Rank  3 and an Earnings ESP of  2 77   indicating a reasonable chance of beating estimates  Gilead delivered positive earnings surprises in two of the last four quarters  with an average beat of 2 88  but saw a negative earnings estimate revision of 34 cents over the past three months for the to be reported quarter  Though it has a solid Value and Momentum Style Score of A each  the Growth Style Score of C looks ugly Bristol Myers will likely report its earnings on April 27 before the opening bell  It has a Zacks Rank  3 and an Earnings ESP of  1 37   indicating less chances of beating estimates this quarter  The stock delivered positive earnings surprises in three of the past four quarters with an average beat of 7 26  and witnessed no earnings estimate revision for the to be reported quarter  It has an unfavorable Value  Growth and Momentum Style Score of C each  see    Summing UpGiven a few earnings surprises in store this season  healthcare ETFs are likely to remain range bound  The funds also have a Zacks ETF Rank  3 each Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2017-04-23,Zacks Investment Research,https://www.investing.com/analysis/is-pain-ahead-for-healthcare-etfs-after-weak-jnj-q1-200184690,200184690
129761,351276,BIIB,Biogen  BIIB  Q1 Earnings   Sales Top  Spinraza Sales Strong,opinion,Biogen Inc    NASDAQ BIIB   reported better than expected results in the first quarter of 2017  The company surpassed expectations both for earnings and sales  Shares of Biogen rose more almost 5  in pre market trading in response to the strong results  However  we note that Biogen s shares declined 2 3  so far this year  which compares unfavorably with the Zacks classified  industry s increase of 3 2  Coming back to the results  Biogen reported first quarter 2017 earnings per share of  5 20  which beat the Zacks Consensus Estimate of  4 97 by 4 6   The bottom line also improved 9  year over year Sales came in at  2 81 billion  up 3  from the year ago period  Sales also surpassed the Zacks Consensus Estimate of  2 73 billion by 2 9   The top line  excluding hemophilia revenues  grew 8   The company spun off its hemophilia business in Feb 2017 Quarter in DetailSales of oral multiple sclerosis  MS  drug Tecfidera rose 1  from the year ago period to  958 million  However  the drug recorded a 4 4  sequential decline in revenues  This included U S  sales of  751 1 million and ex U S  sales of  207 1 million First quarter Tysabri revenues increased 14  year over year and 15  sequentially to  545 million  U S   305 5 million  ex U S   239 5 million  Combined interferon revenues  Avonex and Plegridy  in the first quarter were  648 3 million  U S   464 8 million  ex U S   183 5 million   down 3 3  from the year ago period and 5 8  sequentially  Avonex revenues declined 5  from the year ago period to  537 million Plegridy contributed  112 million to first quarter 2017 revenues  up 5  year over year but down 10  sequentially Zinbryta  which was launched in collaboration with AbbVie Inc    NYSE ABBV   in August last year  contributed  10 7 million to revenues in the quarter compared with  5 9 million in fourth quarter 2016 In the quarter  Biogen recorded biosimilar revenues of  66 million compared with  53 million in fourth quarter 2016  Biogen markets Flixabi  a biosimilar referencing Johnson   Johnson s   NYSE JNJ   blockbuster drug Remicade  The company also markets Benepali  a biosimilar referencing Amgen Inc  s   NASDAQ AMGN   Enbrel in Europe Revenues from Anti CD20 therapeutic programs  which include Biogen s share of Rituxan and Gazyva operating profits  increased 3 4  from the year ago period to  340 6 million in the first quarter Newly launched Spinraza brought revenues of  47 4 million in the first quarter compared with  4 6 million in fourth quarter 2016  The company said that Spinraza  approved for the treatment of patients with spinal muscular atrophy  is off to a strong start  Sales in the quarter were much better than market expectations In April  Biogen announced that the Committee for Medicinal Products for Human Use  CHMP  adopted a positive opinion recommending marketing approval for Spinraza in the EU Research and development expenses rose 4  in the reported quarter to  421 million  SG A spend increased 3  year over year to  483 million In the quarter  the company repurchased shares worth  584 million Biogen Inc  Price  Consensus and EPS Surprise    Zacks Rank   Key PicksBiogen currently carries a Zacks Rank  3  Hold   You can see  Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-04-24,Zacks Investment Research,"https://www.investing.com/analysis/biogen-(biib)-q1-earnings---sales-top,-spinraza-sales-strong-200185138",200185138
129762,351277,BIIB,Lilly  LLY  Tops Q1 Earnings  Misses Sales  Shares Down,opinion,"Eli Lilly and Company   NYSE LLY   reported first quarter 2017 adjusted earnings per share of 98 cents  which beat the Zacks Consensus Estimate of 96 cents by 2 1   Earnings rose 18  from the year ago quarter backed by volume driven pharma sales growth and higher profits  Including a charge related to the acquisition of CoLucid Pharmaceuticals  acquired in Mar 2017  and other special items  the company reported a loss of 10 cents against earnings of 41 cents per share in the year ago quarter Revenues MissQuarterly revenues of  5 23 billion marginally missed the Zacks Consensus Estimate of  5 26 billion by 0 6   However  sales grew 7  year over year  Excluding the unfavorable impact of foreign exchange  1    worldwide revenues grew 6  Volumes rose 8  as higher volumes of new products like Trulicity  diabetes   Cyramza  lung cancer  and Taltz  psoriasis  and older products like Humalog  diabetes  offset lower volumes of established products like Zyprexa  Alimta and Cymbalta Pharmaceutical volumes rose 9  in the quarter  However  worldwide competitive pressure hurt sales somewhat in Lilly s Animal Health segment Quarter in DetailU S  revenues grew 15  to  2 93 billion  reflecting higher volume of products like Trulicity  Taltz and Lartruvo as well as companion animal products  Higher realized prices also propelled U S  sales Ex U S  revenues declined 1  to  2 3 billion mainly due to lower volumes and realized prices  Higher volumes of newer products like Cyramza and Trulicity were offset by lower volumes of Zyprexa  Cymbalta and Alimta due to the loss of exclusivity  Cymbalta has lost exclusivity in Europe and Canada  Zyprexa in Japan and Alimta in several countries Products that recorded growth during the quarter include Forteo  up 9  to  347 5 million   Humalog  up 17  to  708 4 million  and Strattera  up 4  to  196 2 million  Alimta sales  however  declined 13  to  489 9 million  reflecting lower demand in the U S  due to competitive pressure mainly from immuno oncology agents  Outside the U S   sales of Alimta were hurt by loss of exclusivity in several countries and lower realized prices Zyprexa sales declined 31  to  147 5 million due to loss of exclusivity Humulin sales decreased 12  in the quarter to  314 5 million due to lower sales in the U S  as well as outside U S Erbitux sales declined 8  to  154 4 million in the quarter Cialis sales declined 7  to  533 6 million hurt by lower demand in the U S Among new products  Trulicity generated revenues of  372 9 million  up 160  year over year  with U S  revenues benefiting from growth in the GLP 1 market and market share gains  Cyramza revenues were  171 2 million  up 31  year over year backed mainly by higher outside U S  revenues  Cyramza s ex U S  revenues benefited from strong volumes in Japan  However  U S  revenues declined  being hurt by lower demand due to competitive pressure Jardiance sales  up 94  to  74 million  were driven by increased market share within the growing SGLT2 class  In Dec 2016  the FDA approved Jardiance for the CV indication  launched in Jan 2017  while the American Diabetes Association updated its diabetes treatment guidelines  Management believes that both these factors will drive growth of Jardiance and the SGLT 2 class Basaglar recorded revenues of  46 0 million compared with  39 5 million in the previous quarter  Basaglar   Lilly and partner Boehringer Ingelheim s follow on insulin to Sanofi s   NYSE SNY   blockbuster drug  Lantus   was launched in the U S  in mid Dec 2016 where it generated revenues of  22 0 million in the quarter Taltz brought in sales of  96 6 million compared with  61 3 million in the previous quarter  reflecting strong launch uptake Lartruvo  olaratumab  generated revenues of  42 1 million in the first quarter of 2017 compared with  11 9 million in the previous quarter  Lartruvo was launched in the U S  and the EU for soft tissue sarcoma in the fourth quarter of 2016  U S  revenues were  38 1 million compared with  11 4 million in the previous quarter Portrazza brought in sales of  3 6 million Meanwhile  Lilly and partner Incyte Corporation s   NASDAQ INCY   rheumatoid arthritis  RA  drug Olumiant  baricitinib  was approved in EU in Feb 2017  The drug generated sales of  1 9 million in the first quarter of 2017  reflecting initial sales in Germany However  in the U S   the drug is under review  Last week  the companies announced that they have received a complete response letter  CRL  from the FDA regarding the new drug application  NDA  for baricitinib  The letter stated that the FDA is unable to approve the application in its present form  The agency has asked for additional data to determine the most appropriate doses and further characterize safety concerns across treatment arms  The investment community expects a delay in approval of the drug Lilly s Animal Health segment sales increased 2  to  769 4 million as higher sales of companion animal products offset the decline in food animal revenues  The inclusion of revenues from the acquisition of Boehringer Ingelheim Vetmedica s U S  feline  canine and rabies vaccine boosted sales of companion animal products  However  global competitive pressure hurt sales of both food animal and companion animal revenues in the quarter Gross Margin   Operating Income RiseAdjusted gross margin of 78 1  in the quarter increased 180 basis points primarily driven by increased volume in the U S  and manufacturing efficiencies Operating income increased 28  to  1 30 billion due to higher revenues  Total operating expenses  R D  marketing  selling and administrative expenses  increased 3 3  in the quarter Full Year Outlook ReiteratedLilly maintained its previously issued adjusted 2017 sales and earnings outlook Adjusted earnings per share are expected in the range of  4 05 to  4 15  representing growth rate of 15  to 18   Revenues are expected in the range of  21 8  22 3 billion  Gross margin is expected to be approximately 77   Adjusted tax rate is expected to be approximately 22  Marketing  selling and administrative expenses are expected in the range of  6 4  6 6 billion  while research and development expenses are projected to be  4 9  5 1 billion Our TakeLilly s first quarter 2017 results were mixed with the company beating on earnings and slightly missing sales estimates  Shares declined 1 7  in pre market trading  So far this year  Lilly s share price has risen 13 4  compared with an increase of 4  for the Zacks classified industry In 2017  new products like Trulicity  Taltz  Basaglar  Cyramza  Jardiance and Lartruvo are expected to see higher revenues  Lilly also expects some established products like Trajenta  Forteo and Humalog to continue doing well  However  Alimta will continue to be impacted by competition  Other headwinds include competition from immuno oncology agents as well as loss of exclusivity for many drugs in emerging markets Lilly carries a Zacks Rank  3  Hold   You can see    Eli Lilly and Company Price  Consensus and EPS Surprise
    Biogen Inc    NASDAQ BIIB    which also reported today  beat estimates for both earnings and sales in the first quarter  Shares were up almost 5  in pre market trading Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-04-24,Zacks Investment Research,"https://www.investing.com/analysis/lilly-(lly)-tops-q1-earnings,-misses-sales,-shares-down-200185126",200185126
129763,351278,BIIB,Acorda  ACOR  Q1 Loss Wider Than Expected  Revenues Miss ,opinion,Acorda Therapeutics  Inc    NASDAQ ACOR   reported loss of 25 cents per share in the first quarter of 2017  including the impact of stock based compensation expenses   wider than the Zacks Consensus Estimate of a loss of 16 cents  The company had reported a gain of 9 cents per share in the year ago quarter Acorda s shares lost more than 10  following its first quarter earnings release  However  shares of the company have lost 17 3  so far this year  while the Zacks classified  industry gained 4 8  Including the impact of stock based compensation expenses as well as other non recurring items  first quarter loss amounted to 41 cents per share  The company had incurred a loss of 1 cent per share a year ago Total revenue came in at  119 4 million  up 3   Revenues missed the Zacks Consensus Estimate of  126 million by 5 2  Quarter in DetailThe majority of Acorda s net product revenue was generated by Ampyra  which raked in sales of  112 million in the reported quarter  Revenues grew 2  year over year but decreased 15 3  sequentially Ampyra is marketed in ex U S  markets by Biogen Inc    NASDAQ BIIB   under the trade name Fampyra  Biogen pays royalties to Acorda on outside U S  sales  Fampyra royalties were  2 5 million  flat year over year Zanaflex capsules and tablets  including authorized generic capsules  recorded revenues and royalties of  1 7 million  up 41 6  from the year ago period Acorda s research and development  R D  expenses  including stock based compensation expenses  increased 4 3  year over year to  46 5 million due to increased investment in late stage programs  INBRIJA or CVT 301 and tozadenant  as well as the addition of Biotie s R D expenses  Last September  Acorda acquired the remaining stake in Biotie  thereby completing its acquisition Selling  general and administrative  SG A  expenses  including stock based compensation expenses and Biotie transaction costs  were decreased 1  to  51 7 million Pipeline UpdatesOn Feb 2017  the company announced positive phase III clinical data on CVT 301  INBRIJA   which is being evaluated for the treatment of Parkinson s disease  Data from the studies showed a statistically significant improvement in motor function in patients treated with CVT 301  Moreover  the company is currently conducting two studies to assess the long term safety of CVT 301  In March  the company announced results from the two studies  The data from the study are consistent with the previously reported data from phase IIb and phase III studies  The company is planning to submit a new drug application  NDA  to the FDA and marketing authorization application  MAA  to the EU by the end of 2017 In Dec 2016  the company completed phase I special population studies evaluating another early stage candidate  CVT 427  for the treatment of acute migraine  The company is presently evaluating the next steps for the program as CVT 427 will not advance into a phase II study by the end of 2017  as previously expected 2017 GuidanceThe company maintains its Ampyra net sales guidance in the range of  535  545 million The company lowered its R D expenses for 2017 and costa are now expected in the range of  160  170 million  old guidance   185  195 million   excluding share based compensation The company also lowered its SG A expenditure in the range of  170  180 million  old guidance   195  205 million   excluding share based compensation Acorda Therapeutics  Inc  Price  Consensus and EPS Surprise   Zacks Rank   Key PicksAcorda currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector are Heska Corporation   NASDAQ HSKA   and Galena Biopharma  Inc    NASDAQ GALE    Each of these stock sports a Zacks Rank  1  Strong Buy   You can see  Heska s earnings per share estimates increased from  1 53 to  1 65 for 2017 and from  1 80 to  2 01 for 2018  over the last 60 days  The company posted positive surprises in three of the four trailing quarters with an average beat of 291 54  Galena s loss per share estimates narrowed from  2 03 to 58 cents for 2017  over the last 60 days  The company posted positive earnings surprises in two of the four trailing quarters with an average beat of 53 83  Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-04-27,Zacks Investment Research,"https://www.investing.com/analysis/acorda-(acor)-q1-loss-wider-than-expected,-revenues-miss-200185961",200185961
129781,351296,BIIB,Biotech Lags Again  IBB Closes Down Nearly 1  To Trail All ETFs,opinion,"The iShares Nasdaq Biotechnology  NASDAQ IBB  underperformed all other non leveraged  non inverse exchange traded products in the U S  today on a percentage basis  producing a  0 94  one day return and trailing the wider markets by a total of 0 68 percentage points 
Behind The Losses
IBB closed on Monday at  270 85 per share  down  2 57   0 94    Putting this move in context  the S P 500 index   largely considered the most popular and useful benchmark for equity performance   closed down   0 59   0 26   on the day 
IBB s trading volume today was a total of 1 144 840 shares  which was a decrease of 34  versus its average daily trading volume of 1 741 339  Rising trading volume generally an indicator of increased demand for a particular security  and is typically associated with a specific news event or trend that draws investors into or out of specific asset classes  or sectors or subsectors within those classes 
Including any dividends as well as today s losses  IBB has now fallen a total of  2 06  year to date  versus a  1 17  gain in the S P 500 during the same timeframe 
A Look Under The Hood
iShares Nasdaq Biotechnology Index Fund is a Equity focused product issued by BlackRock  Its expense ratio of 0 47  makes it the  19 cheapest ETF among 35 total funds in the  category 
IBB currently boasts  7 90B in assets under management  AUM   placing it  2 of 35 ETFs in its category  and  71 of 1922 total ETFs in the U S  exchange traded universe  This massive fund has plenty of investor interest  despite its relative underperformance 
The investment objective of the iShares Nasdaq Biotechnology ETF seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ  Top holdings include Amgen  NASDAQ AMGN   8 49    Gilead Sciences Inc  NASDAQ GILD   7 72    Celgene  NASDAQ CELG   7 62    Biogen  NASDAQ BIIB   7 58    and Regeneron Pharmaceuticals Inc  NASDAQ REGN   6 57    These companies have struggled mightily amid fears of rising drug price regulation 
IBB SMART Grade
IBB currently has an  of B  Buy   and is ranked  13 of 36 funds in the  category ",2017-01-24,ETF Daily News,"https://www.investing.com/analysis/biotech-lags-again,-ibb-closes-down-nearly-1-to-trail-all-etfs-200173430",200173430
129782,351297,BIIB,5 Stocks To Watch Before The Market Opens Today,opinion,"Ford Motors  NYSE F   Donald Trump s public shaming of American automakers General Motors and Ford puts pressure on forward looking estimates for fiscal 2017  If automakers move operations back to the United States  that would cause a great deal of pressure on overall performance  As for the fourth quarters  Ford experienced strong sales volumes in major markets and a considerable upswing in emerging ones 
Sales in China reportedly grew 14  to 1 27 million units in 2016  making Asia the company s fastest growing sector  European sales came in about 6  higher to 1 25 million vehicles over the same time period  The combination of new product launches and low gas prices during 2016 helped boost sales volume  As gas prices start to rise sales of high margin SUVs and trucks will likely stagnate and thereby put pressure on profitability  Meanwhile a  3 billion pre tax loss related to employee benefits place additional constraints on the bottom line 
Caterpillar  NYSE CAT   Investors expect industrial stocks to lead the way under under the Trump administration  with names like Caterpillar poised to make the biggest move  But given Caterpillar s growing presence in international markets  Trump s potential protectionist policies would cause more harm than good  Despite better than expected results lately  Caterpillar effectively continues to deliver negative growth for 8 quarters and counting 
The strength of the dollar remains a near term threat that affects metal prices and mining operations  Meanwhile political risks in China and Europe put operations in those regions at risk of slowing down and thereby hurting sales  Ongoing initiatives to reduce costs and restructure helps offset any losses incurred in domestic or international markets 
JetBlue  NASDAQ JBLU   In a statement made in early 2017  JetBlue reported a 4 5  increase in traffic on a 3 1  capacity increase for the month of December  The figures pale in comparison to traffic results from November and October that came in 7 1  and 6 5  higher  respectively  Overall preliminary revenue per available seat mile for the three months fell by an average of 1 5   largely due to the negative impact of Hurricane Matthew in October  Investors can also expect compressed margins amid rising fuel and labor costs 
To offset some of the downturn  JetBlue turned its sights to expanding flight coverage and improving the customer experience  The airline recently decided to resume commercial flights to Havana and expand service to Bermuda  highlighting its new focus on international markets  Meanwhile  all flights will now include free Wi Fi access in addition to free streaming video service and 36 channels of DIRECTTV 
Celgene  NASDAQ CELG   Financial performance continues to trend higher as Celgene makes a splash in the biotech industry  The company s core drugs and main growth drivers focus on treating cancer and inflammatory drugs  They include Revlimid  Pomalyst Imnovid and Abraxane  each of which continue to gain traction  Revlimid  in particular  is expected to deliver considerable improvement this quarter on consistent market share gains  Meanwhile the company intends to secure additional reimbursements internationally to boost drugs sales  Label expansion in markets like Japan and in the European Union will help edge higher 
Biogen  NASDAQ BIIB   Lowering drug prices falls under President Trump s list of actions he intends to take as a means to Make America Great  That poses a problem for companies like Biogen and Celgene that thrived in this hands off type of environment  If Trump can break ground on the issue it would likely come at the cost of margins and profitability 
Any reference to Trump or drug prices in Biogen s conference call could make a sizeable impact on forward estimates  For the fourth quarter though  performance will be driven by newer drugs like Zinbryta and legacy ones like Tecfidera  Ongoing restructuring initiatives  cost controls and headcount reduction put in place last year intend to lower operating expense and boost margins for the fourth quarters ",2017-01-26,Estimize,https://www.investing.com/analysis/5-stocks-to-watch-before-the-market-opens-tomorrow-200173626,200173626
129783,351298,BIIB,AbbVie s Elagolix Meets Primary Endpoint In Phase II Study,opinion,AbbVie Inc    NYSE ABBV   along with Neurocrine Biosciences  Inc    NASDAQ NBIX   announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids  The data from the study were presented at the third Congress of the Society of Endometriosis and Uterine Disorders  SEUD  We note that AbbVie s shares have outperformed the Zacks classified  industry so far this year  AbbVie s shares returned 5 8  year to date  better than 4 7  gain for the industry Data from the study showed that elagolix met its primary endpoint by significantly reducing the number of heavy bleeding days rapidly within the assessment period of six months from the baseline in comparison to a placebo  utilizing the alkaline hematin method  The treatment also increased hemoglobin concentration in such patients The randomized  double blind phase IIb uterine fibroids study  M12 813  evaluated elagolix treatment regimens in two parallel groups with dosage of 300mg twice daily and 600mg once daily  It studied elagolix alone as well as in combination with two add back therapies  estradiol   norethindrone acetate   Data from only 300 mg cohort were presented while 600 mg cohort results will be published later The ongoing phase III program on elagolix for uterine fibroids includes two replicate  pivotal  six month efficacy and safety studies followed by a six month safety and efficacy extension studyElagolix is also being evaluated for the treatment of premenopausal women who suffer from endometriosis  In October last year  AbbVie  and Neurocrine Biosciences announced positive results from two replicate pivotal phase III trials evaluating elagolix in this indication  The detailed data showed that treatment with elagolix resulted in statistically significant reductions in menstrual and non menstrual pelvic pain associated with endometriosis compared to placebo at month three and month six  AbbVie plans to submit a NDA to the FDA for endometriosis in 2017 Apart from elagolix  AbbVie has several candidates in different stages of development across a wide range of therapeutic areas and has partnerships with companies like Roche  Bristol Myers Squibb Company   NYSE BMY   and Biogen Inc    NASDAQ BIIB   AbbVie currently carries a Zacks Rank  3  Hold   You can see  Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-04-09,Zacks Investment Research,https://www.investing.com/analysis/abbvie's-elagolix-meets-primary-endpoint-in-phase-ii-study-200182074,200182074
129784,351299,BIIB,Biogen To License Alzheimer Candidate From Bristol Myers,opinion,Biogen Inc    NASDAQ BIIB   recently announced that it has inked a deal to buy worldwide rights for Bristol Myers Squibb s   NYSE BMY   anti tau antibody  BMS 986168  for an upfront payment of  300 million Biogen sees significant potential in the development and commercialization of BMS 986168 for the treatment of both Alzheimer s disease  AD  and progressive supranuclear palsy  PSP   The deal is expected to be closed in the second quarter of 2017 BMS 986168 is an antibody targeting extracellular tau  which is a protein that deposits in the brain associated with AD and other neurodegenerative tauopathies such as PSP  Biogen plans to soon initiate phase II studies for BMS 986168 in both AD and PSP Under the licensing deal  Bristol Myers will receive an additional  410 million as milestone payments and potential royalties Biogen s shares have underperformed the Zacks classified  industry so far this year  Shares of the company lost 4 1   while the industry registered an increase of 2 9  The addition of BMS 986168 reflects Biogen s rising focus on AD  We expect this move to enhance the company s portfolio of rare neurodegenerative diseases  Promising pipeline candidates include aducanumab  BIIB037  Alzheimer s disease  We note that Biogen also has a partnership agreement with Japan based pharma company  Eisai  to develop and commercialize potential treatments for Alzheimer s disease  As part of the collaboration  the companies are jointly developing Eisai s two candidates E2609 and BAN2401  Both these candidates are designed to target build ups of amyloid plaque in the brain  reduce current levels of build up and stop the formation of new plaques We believe that the company will continue to pursue deals to add late stage and commercial assets to its portfolio Per the company s press release  around 25 million individuals were living with AD worldwide in 2010  Moreover  three to six in every 100 000 people worldwide are estimated to be affected by PSP  Hence  approval of the candidate will provide the company access to a huge patient base suffering from the disease Biogen Inc  Price    Zacks Rank   Key PicksBiogen currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector are Heska Corporation   NASDAQ HSKA   and Galena Biopharma  Inc    NASDAQ GALE    Each of these stocks sports a Zacks Rank  1  Strong Buy   You can see  Heska s earnings per share estimates increased from  1 53 to  1 65 for 2017 and from  1 90 to  2 01 for 2018 over the last 30 days  The company posted a positive surprise in three of the four trailing quarters with an average beat of 291 54  Galena s loss per share estimates narrowed from  1 12 to 58 cents for 2017 and over the last 30 days  The company posted positive earnings surprises in two of the four trailing quarters  with an average beat of 53 83  Sell These Stocks  Now  Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ,2017-04-16,Zacks Investment Research,https://www.investing.com/analysis/biogen-to-license-alzheimer-candidate-from-bristol-myers-200183132,200183132
129808,351323,BIIB,Lilly s Alzheimer Drug Fails Phase III Study  Stock Down,opinion,"Lilly s Eli Lilly and Company   NYSE LLY   announced that its key pipeline candidate  solanezumab  failed to meet the primary endpoint in a phase III study  EXPEDITION3  in patients with mild Alzheimer s dementia  The drugmaker s shares declined almost 11  on Wednesday following the disappointing news Solanezumab is an anti amyloid beta monoclonal antibody which Lilly was co developing with TPG Axon Capital Data from the study showed that treatment with solanezumab did not result in statistically significant slowing in cognitive decline   the primary endpoint   compared to placebo  Moreover  while many secondary endpoints favored solanezumab  they had only a small magnitude of benefits LILLY ELI   CO Price
    Lilly has decided not to pursue the regulatory submissions for solanezumab for the treatment of mild dementia due to Alzheimer s disease  Lilly also said that it will evaluate the impact of these results on the development plans for solanezumab and Lilly s other Alzheimer s pipeline candidates We remind investors that Lilly changed the primary endpoint for the EXPEDITION3 study in Mar 2016  While the original study design included co primary endpoints of cognition and function  the company decided to proceed with only a single primary endpoint of cognition This is not the first time that solanezumabhas failed to meet the primary endpoint in late stage trials  Top line data on solanezumab from two phase III EXPEDITION studies conducted on patients with mild to moderate Alzheimer s disease were announced back in Aug 2012  Solanezumab failed to meet its primary endpoints in both the EXPEDITION studies The unfavorable results of the EXPEDITION3 study is expected to result in a fourth quarter charge of approximately  150 million  pre tax   or approximately 9 cents per share  after tax   Lilly will provide an updated 2016 financial guidance and discuss its 2017 financial guidance next month Meanwhile  Biogen Inc    NASDAQ BIIB   is evaluating its Alzheimer s disease candidate  aducanumab  in phase III studies  Aducanumab is being evaluated in two phase III studies   ENGAGE and EMERGE   in patients with early stage Alzheimer s disease  Shares of Biogen declined almost 4  as Lilly s disappointing outcome cast a dark cloud over Alzheimer s programs like aducanumab which are based on the beta amyloid hypothesis The Alzheimer s disease market has attracted a lot of attention from several companies  However  the successful development of therapies for the treatment of Alzheimer s disease is challenging and we note that several companies have failed in developing treatments for the same  In fact  Eli Lilly has faced failure before in this field  The company suffered a major setback in Aug 2010  when it had to halt the development of another phase III Alzheimer s candidate semagacestat  LY450139  Meanwhile  Pfizer   NYSE PFE   shelved its late stage Alzheimer s candidate  bapineuzumab IV  after it failed two phase III studies  Pfizer was developing the candidate in collaboration with Johnson   Johnson   NYSE JNJ   and Elan Corporation  The Alzheimer s disease market represents a huge commercial potential and a successfully developed product could generate billions of dollars in sales once launched Lilly carries a Zacks Rank  3  Hold   You can see  Zacks  Best Investment Ideas for Long Term ProfitToday you can gain access to long term trades with double and triple digit profit potential rarely available to the public  Starting now  you can look inside our stocks under  10  home run and value stock portfolios  plus more  Want a peek at this private information ",2016-11-24,Zacks Investment Research,"https://www.investing.com/analysis/lilly's-alzheimer-drug-fails-phase-iii-study,-stock-down-200166456",200166456
129809,351324,BIIB,Biotech Stock Roundup  Actelion Soars On Acquisition Talks  Another Clinical Hold For Juno,opinion,"Switzerland based Actelion   OTC ALIOF   confirmed that it is in preliminary talks with Johnson   Johnson  NYSE JNJ   which is looking to acquire the company that is focused on the discovery  development and commercialization of drugs for diseases with significant unmet medical needs  Meanwhile  Juno   NASDAQ JUNO   was hit by yet another clinical hold on its phase II ROCKET study Recap of the Week s Most Important StoriesActelion Shoots Up on Acquisition Talks  Actelion s shares soared 34 9  ever since rumors surfaced about the company being in acquisition talks with Johnson   Johnson  While both companies confirmed that they are in discussions  a deal is yet to be announced  According to sources  J J has hiked its offer though Actelion is reportedly not interested in a complete takeover  Actelion has often been considered an attractive takeover target mainly due to its rare disease portfolio  In addition to holding a strong position in the pulmonary arterial hypertension  PAH  market  Actelion s portfolio also has treatments approved in certain countries for specialist diseases like type I Gaucher disease  Niemann Pick type C disease  digital ulcers in patients suffering from systemic sclerosis  and mycosis fungoides type cutaneous T cell lymphoma  We note that Actelion has consistently outperformed the Zacks categorized Medical Biomedical Genetics industry year to date  YTD  with the company gaining 50 7  while the Zacks categorized Medical Biomedical Genetics industry declined 23 5  Juno Hit by Another Clinical Hold  Juno s phase II ROCKET study on JCAR015 has been placed on clinical hold after two patients suffered severe cerebral edema and died eventually  This is the second time this year that the ROCKET study  in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia  has been placed on clinical hold  Earlier in July  the FDA had placed the pivotal study on hold after two patients died following the recent addition of fludarabine to the pre conditioning regimen  The hold was subsequently lifted with the study continuing under a revised protocol With the latest clinical hold  some of the options for Juno include continuing the study with a modified protocol  starting a new study or terminating the JCAR015 program  The company s decision regarding the path forward will take into account feedback from the FDA  the data safety monitoring board as well as the treating physicians in the study  Juno will provide an update once the analysis is completed  Not surprisingly  Juno s shares were down on the latest clinical hold  Read more     Since the first clinical hold in July  Juno has been underperforming the Zacks categorized Medical Biomedical Genetics industry    while the Zacks categorized Medical Biomedical Genetics industry gained 0 4  since July  Juno declined 48 1  during this period Amicus Shares Plunge on Fabry Drug Regulatory Update  Amicus   NASDAQ FOLD   saw its shares declining 21 8  on the company s regulatory update for its Fabry disease drug  migalastat  Migalastat is already approved in the EU under the trade name Galafold but the U S  regulatory process has not been smooth  Based on discussions with the FDA  the company said that it needs to collect additional data on gastrointestinal  GI  symptoms in Fabry patients who have an amenable mutation  Amicus will be conducting a study  scheduled to start enrolling next year  with data expected in 2019  Although the FDA acknowledged that there is significant unmet medical need for Fabry disease  the agency also said that kidney globotriaosylceramide  GL 3  is currently not considered a basis for an accelerated approval under Subpart H  Read more     YTD  Amicus has underperformed the Zacks categorized Medical Biomedical Genetics industry with shares declining 32 9  Momenta Biosimilar Scores in Phase III Study  Momenta s   NASDAQ MNTA   confirmatory late stage study on M923  its biosimilar version of AbbVie s blockbuster drug Humira  met the primary endpoint in patients with moderate to severe chronic plaque psoriasis  We note that a biosimilar version of Humira has already been approved by the FDA    in Sep 2016  Amgen s   NASDAQ AMGN   Amjevita  adalimumab atto  was approved for use in all eligible indications of the reference product  Humira  which is used for a wide range of inflammatory diseases Full Approval and Label Expansion for ARIAD s Iclusig  Cancer focused ARIAD   NASDAQ ARIA   gained full FDA approval as well as a label update for its leukemia drug  Iclusig  Iclusig was initially approved in Dec 2012 under the FDA s accelerated approval program  Full approval was based on 48 month follow up data from the pivotal phase II PACE study  ARIAD recorded Iclusig sales of  34 3 million in the third quarter of 2016 and  133 3 million in the first nine months of 2016  On its third quarter call  ARIAD had reaffirmed its guidance for global Iclusig net product and royalty revenue of  170 million    180 million  ARIAD is a Zacks Rank  2  Buy  stock  You can see  Performance
Medical   Biomedical and Genetics Industry Price Index
The NASDAQ Biotechnology Index declined 0 4  over the last four trading days  Among major biotech stocks  Alexion was up 7 3  while Biogen   NASDAQ BIIB   declined 4 8  on concerns regarding its Alzheimer s disease treatment following the failure of Lilly s investigational Alzheimer s disease treatment  Read more     Over the last six months  Celgene  NASDAQ CELG  was up 15 7  while Alexion lost 16 8   See the last biotech stock roundup here    
What s Next in the Biotech World Watch out for the usual pipeline and regulatory updates from biotech companies  Several companies will be present at the upcoming meeting of the American Society of Hematology  ASH  with data on approved drugs as well as pipeline candidates Now See Our Private Investment IdeasWhile the above ideas are being shared with the public  other trades are hidden from everyone but selected members  Would you like to peek behind the curtain and view them  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time from value to momentum        from stocks under  10 to ETF and option moves       from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2016-11-30,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stock-roundup:-actelion-soars-on-acquisition-talks,-another-clinical-hold-for-juno-200167424",200167424
129810,351325,BIIB,GW Pharmaceuticals  GWPH   What Awaits In Q4 Earnings ,opinion,GW Pharmaceuticals plc   NASDAQ GWPH   is scheduled to report fourth quarter fiscal 2016 results on Dec 5  before the opening bell  The company has an impressive track record so far  In fact  in the four trailing quarters  GW Pharma has surpassed estimates every time  with an average positive surprise of 41 67  In the last reported quarter too  the company has comfortably beaten expectations with a positive surprise of 57 80   Let s see how things are shaping up for this quarter Factors at PlayGW Pharma s key growth driver is Sativex  which is approved outside the U S  for the treatment of spasticity due to multiple sclerosis  Sativex is expected to keep up the past several quarters  growth trend  Moreover  the company is evaluating Sativex in a phase II study in children with spasticity due to cerebral palsy Meanwhile  GW Pharma has made significant progress with its lead cannabinoid pipeline candidate  Epidiolex  During the quarter ended Sep 2016  the company announced positive phase III data on Epidiolex for the third time this year  The company reported favorable data from the second pivotal phase III study on Epidiolex for the treatment of seizures associated with Lennox Gastaut syndrome  LGS  In Jun 2016  it had reported data from the first pivotal phase III study on Epidiolex for LGS  GW Pharma has also reported positive top line data from the first pivotal phase III study on the candidate for the treatment of seizures associated with Dravet syndrome  GW Pharma is presently enrolling patients in the second phase III study on the candidate for Dravet syndrome The company expects to file for an FDA approval of Epidiolex for both Dravet syndrome and LGS in the first half of fiscal 2017  Assuming all goes well on the regulatory front  the company anticipates simultaneous approval in the two indications  The company has already started pre launch commercialization activities for Epidiolex in the U S  and Europe R D expenses are expected to rise due to costs associated with the development of Epidiolex At the upcoming earnings release  focus will be on the company s overall performance  Investors are also expected to keenly await updates on Epidiolex and other pipeline updates What Our Model IndicatesOur proven model does not conclusively show that GW Pharma is likely to beat estimates this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to post positive surprise  But that is not the case here  as you will see below Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of  1 48  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  GW Pharma currently carries a Zacks Rank  3  Although the company s Zacks Rank  3 enhances the predictive power of the ESP  its 0 00  ESP makes a surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions GW PHARMA ADR Price and EPS Surprise    Stocks That Warrant a LookHere are a few health care stocks that have the right combination of elements to post an earnings beat in their next release  All the three stocks carry a Zacks Rank  3  You can see  AVEO Pharmaceuticals  Inc    NASDAQ AVEO   has an Earnings ESP of  18 18  Biogen Inc    NASDAQ BIIB   has an Earnings ESP of  1 20  Clovis Oncology  Inc    NASDAQ CLVS   has an Earnings ESP of  5 99  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-30,Zacks Investment Research,https://www.investing.com/analysis/gw-pharmaceuticals-(gwph):-what-awaits-in-q4-earnings-200167710,200167710
129811,351326,BIIB,Biotech   Pharma ETFs To Suffer In 2017 Too ,opinion,"Be it Clinton or Trump  there seems to be no relief for biotech and pharma stocks and ETFs  Clinton s presidential candidature had hammered the sapce as she was vehemently against the price gouging issue in the pharma sector  read    
While the space got a break from controversies post Trump s win  albeit for a shorter period  it again succumbed to a fall on December 7 after he pledged to lower drug costs  iShares Nasdaq Biotechnology ETF  was off over 2 9  on December 7  SPDR S P Pharmaceuticals  NYSE XPH  ETF   HN XPH   lost over 2  

Inside Painful Past ofBiotech   Pharma ETFs
The space has been under trouble since September 2015 following Clinton s tweet about a 5 455  price hike  in about two months  of a drug called Daraprim  used to treat malaria and toxoplasmosis  This gigantic leap in pricing action was taken by a privately held biotech company Turing Pharmaceuticals  Later  EpiPen allergy shot maker Mylan  NASDAQ MYL  NV and Valeant Pharmaceuticals  NYSE VRX  also suffered public outrage over the price gouging issue  read    
As a result  biotech and pharma ETFs were crushed on election uncertainty since Clinton s tweet in September 2015 with IBB and XPH losing about 22  and 32   respectively  as of December 7  2016   So far this year  as of December 7  2016   XPH is off 24 7  and IBB has retreated 21 3   respectively  triggering the question whether 2017 be another year of underperformance for the space 
Trump s Step Toward Lowering Drug Prices
The space had a short peaceful period post election only to be at gunpoint all over again as Trump announced that he will cut down prescription drug prices  As per an article published on    drug company executives and industry observers have already said that Trump may scrutinize their prices as a populist issue  
As per   Trump is in favor of reduced regulations and  prescription drugs are possibly the most regulated products in America   Trump also commented that  renegotiating Medicare prices would save  300 billion a year as the government is the biggest purchaser of prescription drugs   Plus  the possibility of a repeal of Obamacare in the Trump presidency may hurt drug companies 
Thanks to these uncertainties  most of the ETFs in the space were in the red  ALPS Medical Breakthroughs ETF   SI SBIO    SPDR S P Biotech  MX XBI  ETF  and Loncar Cancer Immunotherapy ETF  lost in the range of 4  to 4 2   see  here  
What Lies Ahead 
Though it is too early to predict how harsh Trump will be to the sector  investors are likely to stay away from it for the coming few days  Investors should note that things are not too bad for the sector either as corporate tax reform and cash access may facilitate biotech stocks and ETFs in the Trump presidency 
In his campaign  Trump indicated that he will reduce corporate tax to 15  and provide a one time repatriation holiday of 10   This lower tax rate would do wonders for big biotech companies like Biogen  NASDAQ BIIB  which can see EPS rising by about 10   as per an article published on  
Smaller cap biotech firms would be especially benefited as they are so cash stripped that their present cash holdings can fund just 11 months of research  as per Reuters  This new found source of cash would help several biotech companies to indulge in merger and acquisition activities  read    
Are There Any Healthcare ETF Survivors  
Amid all these upheavals  iShares U S  Medical Devices ETF   MT IHI    down just 0 2  on December 7  and SPDR S P Health Care Equipment  NYSE XHE  ETF   up 0 1  on December 7  have managed to stay afloat  IHI and XHE are up 7 4  and 11 2   respectively  so far this year  as of December 7  and may see relatively smooth trading ahead 
Want key ETF info delivered straight to your inbox  
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2016-12-08,Zacks Investment Research,https://www.investing.com/analysis/biotech---pharma-etfs-to-suffer-in-2017-too-200169024,200169024
129832,351347,BIIB,Company News For November 08  2016,opinion,"     Shares of Berkshire Hathaway Inc   NYSE BRKa     gained 2 8  after the company posted third quarter earnings per share of  1 97 that beat the Zacks Consensus Estimate of  1 88 
	     Shares of LendingClub Corp    surged 15 2  after the company reported third quarter loss per share of  0 04  lower than the Zacks Consensus Estimate was a loss of  0 10
	     Shares of Sothebys    soared 11 2  after the company s revenues in the latest quarter came in at  91 5 million  above analysts  forecasts of  82 million
	     Biogen  NASDAQ BIIB  Inc  s    shares gained 6 7  after the biotech company and Ionis Pharmaceuticals Inc    said that their Phase 3 trial of spinal muscular atrophy drug met its primary endpoint",2016-11-07,Zacks Investment Research,"https://www.investing.com/analysis/company-news-for-november-08,-2016-200163492",200163492
129833,351348,BIIB,Biotech ETFs Slumping On Q3 Results ,opinion,"The biotech sector has faced rough trading since the beginning of 2016  continuing the volatile trend from the second half of 2015  Media and political focus on the high prices of drugs and increasing competition have made things difficult for the sector  Democratic presidential candidate  Hillary Clinton has been vocal about the steep pricing of drugs and has pledged to find ways to institute reforms to curb rising drug prices  read    Although the scenario improved with encouraging second quarter results  the third quarter earnings season failed to continue the momentum  The sector has failed to gain investor confidence so far in the third quarter  Although well known biotech industry players like Amgen Inc    NASDAQ AMGN    Biogen   NASDAQ BIIB   and Celgene Corporation   NASDAQ CELG   managed to beat estimates on both earnings and revenues  several other companies including Gilead   NASDAQ GILD   and Alexion Pharmaceuticals   NASDAQ ALXN   reported mixed results Quite expectedly  investors will keep an eye on the biotech sector to assess whether it can pull off another turnaround supported by strong pipelines  innovative treatments  growing demand for drugs  especially for rare to treat diseases  an aging population and increased health care spending  read     Biotech Earnings in Detail Biotech behemoth  Amgen  beat both earnings and revenue estimates in the third quarter  The company s third quarter 2016 earnings of  3 02 per share surpassed the Zacks Consensus Estimate of  2 79 and improved 11  from the year ago earnings  Also  total revenue grew 2  to  5 81 billion  which beat the Zacks Consensus Estimate of  5 74 billion  The company also upgraded its outlook for 2016 earnings to  11 40  11 55 per share from  11 10  11 40 per share  The company also pushed up the lower end of its revenue guidance to  22 6  22 8 billion from  22 5  22 8 billion  However  the stock fell post results owing to soft performance of Enbrel  a key product at Amgen Meanwhile  Biogen also beat on earnings and revenues  The company s earnings per share of  5 19 were well above the Zacks Consensus Estimate of  4 99  Earnings grew about 16  year over year while revenues increased 6   Revenues came in at  2 96 billion  ahead of the Zacks Consensus Estimate of  2 90 billion Similarly  Celgene reported encouraging results with earnings of  1 39 per share  including stock based compensation expenses  beating the Zacks Consensus Estimate of  1 31 and revenues of  2 98 billion topping the Zacks Consensus Estimate of  2 85 billion  Both earnings and revenues rose year on year in the reported quarter by 28  each  Net sales of the drug Revlimid  the backbone of Celgene  saw a year over year rise of 28   The company has upped its 2016 outlook  The company now anticipates earnings in the range of  5 88  5 92 per share compared with the old guidance of  5 70  5 75 per share On the other hand  Alexion came up with a mixed third quarter results with lower than expected earnings and revenues beating estimates  Third quarter 2016 earnings  including stock based compensation expense  of  1 03 per share missed the Zacks Consensus Estimate of  1 04  Nevertheless  Alexion s revenues climbed 20 1  year over year in the third quarter to  799 million  surpassing the Zacks Consensus Estimate of  784 million  For 2016  the company expects adjusted earnings per share and revenues to be at the higher end of the previously guided range of  4 50  4 65 and  3 05  3 1 billion  respectively Gilead also reported mixed third quarter results as the company beat on revenues but lagged the Zacks Consensus Estimate for earnings  The biotech giant s third quarter earnings  including stock based compensation expenses  of  2 70 per share missed the Zacks Consensus Estimate by 4 cents  Reported earnings were 15 4  lower than the year ago period Quarterly revenues were down 9 6  to  7 5 billion as lower hepatitis C virus  HCV  sales pulled back results  Revenues edged past the Zacks Consensus Estimate of  7 4 billion  Meanwhile  the company reiterated its 2016 product sales guidance  The company expects product sales in the range of  29 5  30 5 billion ETFs in FocusDue to unimpressive results  biotech ETFs with considerable exposure to the five aforementioned stocks ended in the red in the last 10 trading sessions  as of November 4  2016   Below we discuss four of these ETFs having a sizeable exposure to the above stocks  see   iShares Nasdaq Biotechnology ETF This top player in the biotech ETF space tracks the NASDAQ Biotechnology Index  holding 181 securities in the basket  Amgen  Celgene  Gilead Sciences  Biogen and Alexion are placed among the top 6 holdings with a combined exposure of about 38  in the fund  The fund has an asset base of more than  6 7 billion and trades in an average volume of nearly 1 6 million shares a day  It has an expense ratio of 0 47  and lost 5 9  in the above mentioned timeframe  IBB currently has a Zacks ETF Rank  3  Hold  with a High risk outlook  read   VanEck Vectors Biotech ETF   CM BBH  This fund follows the MVIS U S  Listed Biotech 25 Index and holds 26 securities in its basket  Gilead Sciences  11 9    Amgen  11 5    Celgene  10 6    Biogen  6 7   and Alexion  5 3   take the top six spots in the fund  It has amassed nearly  508 5 million in its asset base and trades in moderate volumes of roughly 80 000 shares a day  The product charges an annual fee of 35 bps per year and lost almost 5 1  in the said timeframe  It currently carries a Zacks ETF Rank  3 with a High risk outlook PowerShares Dynamic Biotechnology   Genome Portfolio The fund tracks the Dynamic Biotech   Genome Intellidex Index  The top 10 holdings include Alexion  5 7    Biogen  5 2    Gilead  5 2   and Amgen  4 6    Total assets of the fund amount to  217 8 million  representing 30 holdings  The fund s expense ratio is 0 58   The trading volume is roughly 32 000 shares per day  The fund has lost 5 6  in the past 10 trading sessions  It currently carries a Zacks ETF Rank  3 with a High risk outlook First Trust NYSE Arca Biotech ETF   LON FBT  FBT tracks the NYSE Arca Biotechnology Index and holds 30 securities in the basket  The fund is well diversified with no stock holding more than 4  weight  Biogen  Amgen  Celgene  Alexion and Gilead have a combined exposure of about 16  in the fund  Total assets of the fund are  720 2 million  The fund s expense ratio is 0 55   The trading volume is roughly 77 000 shares per day  It currently carries a Zacks ETF Rank  3 with a High risk outlook  The fund has lost 5 7  in the last 10 trading sessions  read    
Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2016-11-08,Zacks Investment Research,https://www.investing.com/analysis/biotech-etfs-slumping-on-q3-results-200163520,200163520
129855,351370,BIIB,Can Biogen  BIIB  Keep The Earnings Streak Alive In Q3 ,opinion,"Biogen Inc    NASDAQ BIIB    a well known name in the multiple sclerosis  MS  market  will be reporting third quarter 2016 earnings on Oct 26  before market open Last quarter  the company delivered a positive earnings surprise of 11 09  Biogen s performance has been pretty impressive  with consistent positive surprises  The average earnings beat over the last four quarters is 11 39  BIOGEN INC Price and EPS Surprise
    Let s see how things are shaping up for this announcement Factors to ConsiderSince the emergence of the first progressive multifocal leukoencephalopathy  PML  related death in a patient on oral MS drug  Tecfidera  investor focus has been on its performance Biogen is working on growing Tecfidera sales  Tecfidera demand is expected to remain relatively stable in the U S  in the quarter  Outside the U S   Tecfidera s performance in Germany will remain in focus While Tysabri should remain on a stable trajectory  the number of patients using Avonex and Plegridy combined will continue to decline as patients move toward oral treatments Zinbryta is expected to contribute modestly to revenues in the U S  and EU  Zinbryta was launched in collaboration with AbbVie Inc    NYSE ABBV   in August Meanwhile  Biogen intends to spin off its hemophilia business in early 2017  The new company will be named Bioverativ and will focus on the discovery  research  development and commercialization of treatments for hemophilia and other blood disorders Head count reduction and restructuring initiatives announced last year are expected to benefit operating expenses by about  250 million this year Focus on Call  Investor focus on the third quarter call will remain on Tecfidera s scrip trends  news regarding additional PML cases  pipeline progress and acquisition plans Earnings WhispersOur proven model does not conclusively show that Lilly is likely to beat on earnings this quarter  That is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  The Earnings ESP is  1 41  as the Most Accurate estimate stands at  4 90 while the Zacks Consensus Estimate is pegged higher at  4 97 Zacks Rank  Lilly s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderSome stocks in the large cap healthcare sector that have both a positive Earnings ESP and a favorable Zacks Rank are Amgen Inc    NASDAQ AMGN    which is slated to report results on Oct 27  The company has an Earnings ESP of  1 79  and a Zacks Rank  3  You can see  Novartis AG   NYSE NVS   with an Earnings ESP of  0 84  and a Zacks Rank  3  The company is scheduled to release results on Oct 25 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-19,Zacks Investment Research,https://www.investing.com/analysis/can-biogen-(biib)-keep-the-earnings-streak-alive-in-q3-200159768,200159768
129856,351371,BIIB,7 Drug Stocks To Consider As Biosimilars Pick Up Pace,opinion,"Interest in biosimilars has picked up considerably with Pfizer  Inc  s   NYSE PFE   announcement this week regarding its plans to launch a biosimilar version of Johnson   Johnson s blockbuster drug  Remicade  in late November What are Biosimilars 
A biosimilar is a biologic product whose approval is based on evidence that it is highly similar to an approved biologic  known as the reference product  Moreover  there should be no clinically meaningful differences between the biosimilar and the reference product where safety and effectiveness is concerned While biosimilars have been available in the EU for quite a while  they are a new entrant in the U S  where a regulatory pathway was implemented recently Sandoz  a Novartis AG   NYSE NVS   company  was the first to gain approval for and launch a biosimilar in the U S  The company launched Zarxio  filgrastim sndz   a biosimilar version of Amgen Inc  s   NASDAQ AMGN   Neupogen last year    The second biosimilar to gain approval in the U S  was Pfizer and Celltrion s Inflectra  infliximab dyyb  with the reference product being Remicade This was followed by the FDA approval of biotech giant Amgen s Amjevita  adalimumab atto   Amjevita is approved for use in all eligible indications of the reference product  Humira  adalimumab   which is used for a wide range of inflammatory diseases Biosimilars Set to Change the Competitive LandscapeThe market for biosimilars is huge and highly lucrative  Several blockbuster biologics including Humira and Lantus will lose patent protection by 2020  Biosimilars are expected to reduce healthcare costs and provide a large number of patients with access to much needed biologic treatments  According to new research released by the IMS Institute for Healthcare Informatics earlier this year  increasing acceptance of biosimilars across different therapeutic areas plus an active pipeline of 56 candidates are expected to lead to total savings of about  110 billion to health systems across Europe and the U S  through 2020 The report further says that by 2020  biosimilars will start competing with biologics that currently have annual sales of  50 billion  About 30 companies are developing biosimilars of 16 molecules   most of the biosimilars in development are for reference products like Remicade  Enbrel  etanercept   Rituxan  rituximab  and Humira  adalimumab  What about Formulary Coverage Biosimilars are also gaining acceptance across formularies  CVS Health  NYSE CVS  announced that biosimilars and follow on biologics will be a key part of its 2017 standard formulary strategy  replacing higher cost drugs within the categories  The company said that its formulary list will include Zarxio  replacing Neupogen  to decrease the risk of infection in patients receiving treatment for certain forms of cancer  and the follow on product Basaglar  replacing Lantus  for the treatment of diabetes Meanwhile  UnitedHealth Group  NYSE UNH  will be moving Basaglar from Tier 3 to Tier 1 effective Apr 1  2017  Basaglar is expected to enter the market in mid December  Sanofi s Lantus SoloStar and Lantus Vials will remain on Tier 3 until Mar 31  2017 after which they will be excluded  Zarxio will be on Tier 2  Pharmacy benefit manager Express Scripts said that the basal insulins category may be reassessed later in the year to reflect anticipated product launches Stocks to ConsiderWith biosimilars picking up pace  it makes sense to zero in on companies that are in the biosimilars business  Here is a mix of pharma  generic and biotech stocks that should benefit from the biosimilars opportunity especially given the current scenario of increased political  media and public pressure on drug pricing  the growing interest in developing biosimilars and the potential of biosimilars to reduce healthcare costs Sandoz  a Novartis company  has a strong presence in the biosimilars market being the first to launch a biosimilar  Omnitrope  in the EU way back in 2006  in Japan  Somatropin BS S C   2009  as well as in the U S   Zarxio  2015   Earlier this year  Sandoz announced that it will launch 5 biosimilars of major cancer and immunology biologics in key geographies by 2020  Some of the biosimilars that Sandoz is working on include biosimilar versions of Enbrel  Humira  Neulasta  Remicade and Rituxan   these biologics generated global sales of approximately  43 6 billion in 2015  Novartis is a Zacks Rank  3  Hold  stock 
NOVARTIS AG ADR Price and Consensus   Pfizer also has a strong presence in the biosimilars market  The acquisition of Hospira significantly expanded Pfizer s biosimilar capabilities and gave the company access to Hospira s lucrative biosimilar portfolio of both marketed and pipeline assets  The company has three marketed products in Europe and several programs including four in late stage development  Rituxan  Humira  Herceptin  and Avastin   The Zacks Rank  3 stock will be launching Inflectra in late November and has decided to price it at a 15  discount to the current wholesaler acquisition cost of Remicade 
PFIZER INC Price and Consensus   Merck   Co   Inc    NYSE MRK   has an agreement with Samsung  KS 005930  Bioepis for the development and commercialization of multiple biosimilar candidates in certain partnered territories  Earlier this year  Merck announced the filing of a Biologics License Application  BLA  for SB2  infliximab   a biosimilar version of Remicade  Moreover  Merck recently launched a website to provide clarity on and increase awareness about biosimilars  Merck is a Zacks Rank  2  Buy  stock  You can see  
MERCK   CO INC Price and Consensus   Cambridge  MA based Momenta Pharmaceuticals Inc    NASDAQ MNTA   is a biotech company with a focus in three areas   complex generics  biosimilars and novel drugs for autoimmune diseases  The most advanced biosimilars in the company s pipeline include M923  reference drug  Humira  and M834  reference drug  Orencia   The Zacks Rank  3 stock has a collaboration agreement with Mylan  NASDAQ MYL  for the development  manufacture and commercialization of six biosimilar candidates including M834 
MOMENTA PHARMA Price and Consensus   Although Amgen itself is a major target of biosimilar competition  the company has been quick to recognize the commercial potential of the biosimilars market and has already made significant progress in this field with quite a few late stage biosimilar candidates in its pipeline  Last month  Amgen got FDA approval for its biosimilar version of AbbVie s multi billion dollar drug  Humira  The Zacks Rank  3 stock is developing biosimilar versions of Avastin  Herceptin  Rituxan  and Remicade as well 
AMGEN INC Price and Consensus   Biogen Inc    NASDAQ BIIB   is another biotech company that is working on bringing biosimilars to market  The Zacks Rank  3 stock is collaborating with Samsung Biologics for the development  manufacturing and marketing of biosimilars 
BIOGEN INC Price and Consensus   Israel based Teva Pharmaceutical Industries Limited   NYSE TEVA   is another company which is focusing on building its presence in the biosimilar market  Earlier this month  Teva signed up with Celltrion to commercialize a couple of Celltrion s mAb biosimilar candidates  reference products   Rituxan and Herceptin  in the U S  and Canada  The deal also led to rumors that Teva may be interested in acquiring Celltrion  Teva is a Zacks Rank  3 stock  
TEVA PHARM ADR Price and Consensus   Where Do Zacks  Investment Ideas Come From You are welcome to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buy  stocks free of charge  There is no better place to start your own stock search  Plus you can access the full list of must avoid Zacks Rank  5  Strong Sells  and other private research ",2016-10-19,Zacks Investment Research,https://www.investing.com/analysis/7-drug-stocks-to-consider-as-biosimilars-pick-up-pace-200159764,200159764
129857,351372,BIIB,Pharma Industry Outlook   November 2016,opinion,"It s been a rough year for pharma and biotech stocks with several factors weighing on the sector including media and political focus on the high price of drugs  mixed performance results  slower than expected new product launches and increasing competition 
The impact of these issues is more evident on biotech stocks  with the NASDAQ Biotechnology Index declining 20 9  year to date  YTD  while the NYSE ARCA Pharmaceutical Index has lost 10 9  YTD 
Drug Pricing to Remain in Focus
Right now  the biggest issue that is weighing on the sector is the political rhetoric regarding drug pricing With presidential candidates  policymakers  the media and the general public focusing on the high price tags for drugs  the drug pricing controversy is not likely to die down easily 
In fact  the drug pricing issue heated up recently given the price hikes taken by Mylan  NASDAQ MYL   MYL  for its life saving combination product EpiPen  Democratic Presidential candidate Hillary Clinton announced a health care plan that will address the excessive price hikes of treatments that have been around for years and also reaffirmed her earlier broader plan  announced in Sep 2015  with the aim to lower drug prices for all Americans 
Insulin drugmakers like Lilly  LLY  and Novo Nordisk  CO NOVOb  are also under attack with Senator Bernie Sanders posting a series of tweets questioning the prices of their insulin drugs 
Will M As Pick Up Pace 
With the major price correction resulting in reasonable valuations  expectations are high that more M A deals will be announced in the coming quarters  So far in 2016  some of the announced completed acquisitions include Shire Baxalta  Bristol Myers Padlock  and Pfizer  NYSE PFE   PFE  Medivation  among others 
In fact  the Pfizer Medivation deal  valued at approximately  14 billion  has raised hopes that major M As will pick pace once elections are over while licensing deals and small bolt on acquisitions will continue 
Several pharma companies are focusing on in licensing mid to late stage pipeline candidates that look promising  instead of developing a product from scratch  which involves a lot of funds and time  Small biotech companies are open to such deals  with most of them finding it challenging to raise cash  thereby making it difficult to survive and continue with the development of promising pipeline candidates  Therefore  it makes sense to seek deals with pharma companies sitting on huge piles of cash 
Divestment of Non Core Assets   Restructuring Activities
Another trend being witnessed is the divestment of non core business segments  Companies like Pfizer  UCB  Novartis  NVS   Glaxo and AstraZeneca have all been a part of this trend  More recently  Sanofi  PA SASY  is looking to divest its generics portfolio in Europe while Valeant is in discussions for various divestitures including the Salix business  The monetization of non core assets allows these companies to focus on their areas of expertise 
Restructuring activities are also gaining momentum as large pharma companies look to cut costs and streamline operations  Most of these companies are re evaluating their pipelines and discontinuing programs with an unfavorable risk benefit profile 
New Products Should Gain Traction 
Highly awaited new products that gained approval last year should contribute significantly to revenues  Some of the important new product approvals include Vertex s cystic fibrosis treatment  Orkambi  Amgen s  AMGN  heart failure treatment  Corlanor  Pfizer s cancer treatment  Ibrance  Novartis  psoriasis treatment  Cosentyx  PCSK9 inhibitors   Amgen s Repatha and Sanofi Regeneron s Praluent  Roche s advanced melanoma treatment  Cotellic and Gilead s Genvoya  HIV  
Meanwhile  so far in 2016  the FDA has approved 19 new drugs including Zinplava  c  difficile infection   Lartruvo  soft tissue carcinoma   Exondys 51  Duchenne muscular dystrophy   Epclusa  HCV   Ocaliva  rare  chronic liver disease   Zinbryta  multiple sclerosis   Tecentriq  urothelial cancer   Venclexta  chronic lymphocytic leukemia in patients with a specific chromosomal abnormality   Taltz  moderate to severe plaque psoriasis   Cinqair  severe asthma  and Zepatier  HCV  among others  The FDA also expanded the label of cancer drugs like Kyprolis  Imbruvica and Xalkori 
Biosimilars Gaining Importance
With the FDA approving the first biosimilar in the U S   Zarxio  a biosimilar version of Amgen s blockbuster drug  Neupogen   the floodgates have opened  While biosimilars have been available in the EU for quite a while  there was no regulatory pathway for biosimilars in the U S 
The second biosimilar to gain approval in the U S  was Pfizer and Celltrion s Inflectra  infliximab dyyb  with the reference product being Remicade 
This was followed by the FDA approval of biotech giant Amgen s Amjevita  adalimumab atto   Amjevita is approved for use in all eligible indications of the reference product  AbbVie  ABBV  Humira  adalimumab   which is used for a wide range of inflammatory diseases 
And then there is Lillyand Boehringer Ingelheim s Basaglar  which while technically not approved as a biosimilar  is a  follow on  insulin glargine product approved through an abbreviated approval pathway    Basaglar was found to be sufficiently similar to Sanofi s Lantus to scientifically justify reliance  and to establish its safety and efficacy for the approved uses  Lilly and Boehringer expect to launch Basaglar in mid December while Pfizer will be launching Inflectra in late November 
Biosimilars should cut healthcare costs and provide a large number of patients with access to much needed biologic treatments  According to information provided by Express Scripts  about  250 billion could be saved in the next decade  2014   2024  if biosimilars for 11 products including Neupogen  Avastin  Epogen  Humira  Neulasta  Remicade and Rituxan are approved  According to the company  Neupogen biosimilars alone represent potential savings of about  5 7 billion 
Apart from Novartis and Pfizer  companies like Merck  NYSE MRK   MRK   Amgen  NASDAQ AMGN   Biogen  NASDAQ BIIB  and Allergan  NYSE AGN pa  are targeting the highly lucrative biosimilars market  Among these companies  Merck is a Zacks Rank  2  Buy  stock  You can see  
Earnings Trends
It seems like so far so good for the Medical sector this earnings season    60 4  of the sector has reported results with earnings growing 12 3  on revenue growth of 8 7  from the year ago period  The earnings as well as revenue beat ratio is 59 4  
Looking at consensus earnings expectations  the Medical sector  which has performed well so far in 2016  is expected to see earnings growth of 4 4  and revenue growth of 7 4  in Q3  New products should start contributing significantly and increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector 
For a detailed look at the earnings outlook for the Medical and other sectors  please check our  report 
Zacks Industry Rank
Within the Zacks Industry classification  pharma and biotech are broadly grouped into the Medical sector  one of 16 Zacks sectors  and further sub divided into four industries at the expanded level  large cap pharma  med biomed gene  med drugs and med generic drugs 
We rank all the 260 plus industries in the 16 Zacks sectors based on the earnings outlook and fundamental strength of the constituent companies in each industry 
As a point of reference  the outlook for industries with Zacks Industry Rank  88 and lower is  Positive   between  89 and  176 is  Neutral  and  177 and higher is  Negative  
The Zacks Industry Rank for large cap pharma is  114   192 for med generic drugs   101 for med biomed gene and  112 for med drugs  Analyzing the Zacks Industry Rank for different medical segments  it is obvious that the outlook is Neutral for large cap pharma  med drugs and med biomed gene while Negative for med generic drugs 
 
Confidential from Zacks 
Beyond this Industry Outlook  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-03,Zacks Investment Research,https://www.investing.com/analysis/pharma-industry-outlook---november-2016-200162806,200162806
129860,351375,BIIB,Fundamentals Remain Strong In The Pharma Sector,opinion,"Although pharma and biotech stocks are facing challenges in the form of increasing focus on the high prices of drugs  a changing competitive scenario and mixed results  the sector s fundamentals remain strong    mergers and acquisitions  M As   product approvals and positive data flow should act as catalysts 
M As to Pick Pace 
The overall pharma industry has seen a lot of consolidation over the last few years  with quite a few deals being announced completed this year as well  With the major price correction resulting in reasonable valuations  we could see several M A agreements being announced in the coming quarters  though companies are wary of bidding wars leading to over priced deals 
The Pfizer Medivation deal  valued at approximately  14 billion  has raised hopes that M As will pick up pace while licensing deals will continue  Big players like Sanofi  PA SASY  and J J have expressed an interest in pursuing M A deals  Allergan  NYSE AGN pa   AGN  has also been very active on the acquisition and deal making front  While some of these companies are looking to replace sales of blockbuster products that are facing loss of patent exclusivity  others are looking to build their pipelines both through acquisitions as well as licensing agreements 
Companies with innovative technologies and pipelines are highly sought after  Niche disease areas like nonalcoholic steatohepatitis  NASH   immuno oncology  multiple sclerosis and hepatitis C virus  HCV  are in demand  Treatments for orphan diseases are also much sought after with quite a few deals being signed in these areas 
Innovative Pipelines
Pharma and biotech companies continue to work on bringing innovative new treatments to market and there could be significant catalysts in the coming quarters in the form of important new product approvals as well as major data read outs especially in important therapeutic areas like immuno oncology  Alzheimer s  hepatitis C virus  HCV   central nervous system disorders  and immunology inflammation 
Among these  immuno oncology has been attracting a lot of interest as these therapies have the potential to change the treatment paradigm for cancer    they basically use the natural capability of the patient s own immune system to fight the cancer  Major players in this field include Bristol Myers  BMY   AstraZeneca  Merck  NYSE MRK  and Roche 
Deals targeting immuno oncology are being inked by companies like Pfizer  NYSE PFE   Merck KGaA  Bristol Myers  AstraZeneca and Incyte  Companies like Kite and Juno are also advancing in this area  Interest in PARP inhibitors has also increased considerably as they could well be the next major class of therapeutics in oncology 
New Product Sales Should Ramp Up
Sales of products that gained approval last year as well as line extensions should ramp up and boost growth  Some recently approved products with blockbuster potential include Amgen s  AMGN  PCSK9 inhibitor  Repatha  Regeneron Sanofi s PCSK9 inhibitor Praluent  Novartis  psoriasis treatment  Cosentyx  Pfizer s cancer treatment  Ibrance  and Gilead s Genvoya  HIV   Cancer treatments like Kyprolis and Imbruvica should also bring in more sales thanks to label expansions 
Meanwhile  so far in 2016  the FDA has approved 19 new drugs including Zinplava  c  difficile infection   Lartruvo  soft tissue carcinoma   Exondys 51  Duchenne muscular dystrophy   Epclusa  HCV   Ocaliva  rare  chronic liver disease   Zinbryta  multiple sclerosis   Tecentriq  urothelial cancer   Venclexta  chronic lymphocytic leukemia in patients with a specific chromosomal abnormality   Taltz  moderate to severe plaque psoriasis   Cinqair  severe asthma  and Zepatier  HCV  among others  The FDA also expanded the label of cancer drugs like Kyprolis  Imbruvica and Xalkori 
Earnings Performance
Despite the different issues being faced by the sector  several pharma and biotech companies have topped earnings as well as revenue expectations in the third quarter  Companies like J J  Merck  Biogen  NASDAQ BIIB   BIIB   Celgene and Bristol Myers have in fact topped earnings estimates in all three quarters of 2016 
Stock Picks
Although it may take a while for the dust around the drug pricing issue to settle down  pipeline success in innovative and important therapeutic areas  cost cutting  share buybacks  new products  increased pipeline visibility and appropriate utilization of cash should help restore investor confidence in this sector 
Here are a few stocks that have been witnessing positive estimate revisions and carry a favorable Zacks Rank     1  Strong Buy  or  2  Buy  
Merck   Co   Inc   MRK   This Zacks Rank  2 stock has a good earnings track record with the stock beating estimates in each of the last four quarters with an average surprise of 4 3   The stock is up almost 13  year to date  YTD  and is witnessing positive estimate revisions for 2016  up 0 5   as well as 2017  up 2 4   over the last 30 days 
Celgene Corporation  NASDAQ CELG   CELG   Following the release of strong third quarter results  Celgene is witnessing positive estimate revisions for both 2016  up 3 3   and 2017  up 0 5   over the last 7 days  The Zacks Rank  2 stock also raised its outlook for 2016  You can see  
ARIAD Pharmaceuticals Inc   ARIA   Oncology focused ARIAD is also witnessing positive estimate revisions with 2016 estimates revised upwards by 25  over the last 7 days  Moreover  the Zacks Rank  2 stock has seen its share price shoot up 49 2  so far in 2016  The company is often in the news as an attractive takeover target 
All said and done  the pharma sector s fundamentals remain strong    robust pipelines  innovative treatments  impressive results  growing demand for drugs especially for rare to treat diseases  an aging population and increased health care spending should support growth  To know more about this sector  check out our latest  
 
Confidential from Zacks 
Beyond this Industry Outlook  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-04,Zacks Investment Research,https://www.investing.com/analysis/fundamentals-remain-strong-in-the-pharma-sector-200163004,200163004
129864,351379,BIIB,Zacks Industry Outlook Highlights  Bristol Myers  Biogen  Merck  Celgene And ARIAD Pharmaceuticals,opinion,"For Immediate Release

	Chicago  IL   November 07  2016   Today  Zacks Equity Research discusses the Pharmaceuticals  Part 2  including Bristol Myers    NYSE         Biogen  NASDAQ BIIB     NASDAQ         Merck  NYSE MRK    Co   Inc     NYSE         Celgene Corporation  NASDAQ CELG     NASDAQ      and  ARIAD Pharmaceuticals Inc     NASDAQ        

	Industry  Pharmaceuticals  Part 2

	Link  

	Although pharma and biotech stocks are facing challenges in the form of increasing focus on the high prices of drugs  a changing competitive scenario and mixed results  the sector s fundamentals remain strong    mergers and acquisitions  M As   product approvals and positive data flow should act as catalysts 

M As to Pick Pace 

	The overall pharma industry has seen a lot of consolidation over the last few years  with quite a few deals being announced completed this year as well  With the major price correction resulting in reasonable valuations  we could see several M A agreements being announced in the coming quarters  though companies are wary of bidding wars leading to over priced deals 

	The Pfizer Medivation deal  valued at approximately  14 billion  has raised hopes that M As will pick up pace while licensing deals will continue  Big players like Sanofi  PA SASY  and J J have expressed an interest in pursuing M A deals  While some of these companies are looking to replace sales of blockbuster products that are facing loss of patent exclusivity  others are looking to build their pipelines both through acquisitions as well as licensing agreements 

	Companies with innovative technologies and pipelines are highly sought after  Niche disease areas like nonalcoholic steatohepatitis  NASH   immuno oncology  multiple sclerosis and hepatitis C virus  HCV  are in demand  Treatments for orphan diseases are also much sought after with quite a few deals being signed in these areas 

Innovative Pipelines

	Pharma and biotech companies continue to work on bringing innovative new treatments to market and there could be significant catalysts in the coming quarters in the form of important new product approvals as well as major data read outs especially in important therapeutic areas like immuno oncology  Alzheimer s  hepatitis C virus  HCV   central nervous system disorders  and immunology inflammation 

	Among these  immuno oncology has been attracting a lot of interest as these therapies have the potential to change the treatment paradigm for cancer    they basically use the natural capability of the patient s own immune system to fight the cancer  Major players in this field include Bristol Myers    NYSE         AstraZeneca  Merck and Roche 

	Deals targeting immuno oncology are being inked by companies like Pfizer  NYSE PFE   Merck KGaA  Bristol Myers  AstraZeneca and Incyte  Companies like Kite and Juno are also advancing in this area  Interest in PARP inhibitors has also increased considerably as they could well be the next major class of therapeutics in oncology 

New Product Sales Should Ramp Up

	Sales of products that gained approval last year as well as line extensions should ramp up and boost growth  Some recently approved products with blockbuster potential include Regeneron Sanofi s PCSK9 inhibitor Praluent  Novartis  psoriasis treatment  Cosentyx  Pfizer s cancer treatment  Ibrance  and Gilead s Genvoya  HIV   Cancer treatments like Kyprolis and Imbruvica should also bring in more sales thanks to label expansions 

	Meanwhile  so far in 2016  the FDA has approved 19 new drugs including Zinplava  c  difficile infection   Lartruvo  soft tissue carcinoma   Exondys 51  Duchenne muscular dystrophy   Epclusa  HCV   Ocaliva  rare  chronic liver disease   Zinbryta  multiple sclerosis   Tecentriq  urothelial cancer   Venclexta  chronic lymphocytic leukemia in patients with a specific chromosomal abnormality   Taltz  moderate to severe plaque psoriasis   Cinqair  severe asthma  and Zepatier  HCV  among others  The FDA also expanded the label of cancer drugs like Kyprolis  Imbruvica and Xalkori 

Earnings Performance

	Despite the different issues being faced by the sector  several pharma and biotech companies have topped earnings as well as revenue expectations in the third quarter  Companies like J J  Merck  Biogen    NASDAQ         Celgene and Bristol Myers have in fact topped earnings estimates in all three quarters of 2016 

Stock Picks

	Although it may take a while for the dust around the drug pricing issue to settle down  pipeline success in innovative and important therapeutic areas  cost cutting  share buybacks  new products  increased pipeline visibility and appropriate utilization of cash should help restore investor confidence in this sector 

	Here are a few stocks that have been witnessing positive estimate revisions and carry a favorable Zacks Rank     1  Strong Buy  or  2  Buy  

Merck   Co   Inc     NYSE           This Zacks Rank  2 stock has a good earnings track record with the stock beating estimates in each of the last four quarters with an average surprise of 4 3   The stock is up almost 13  year to date  YTD  and is witnessing positive estimate revisions for 2016  up 0 5   as well as 2017  up 2 4   over the last 30 days 

Celgene Corporation    NASDAQ        Following the release of strong third quarter results  Celgene is witnessing positive estimate revisions for both 2016  up 3 3   and 2017  up 0 5   over the last 7 days  The Zacks Rank  2 stock also raised its outlook for 2016  You can see   

ARIAD Pharmaceuticals Inc     NASDAQ           Oncology focused ARIAD is also witnessing positive estimate revisions with 2016 estimates revised upwards by 25  over the last 7 days  Moreover  the Zacks Rank  2 stock has seen its share price shoot up 49 2  so far in 2016  The company is often in the news as an attractive takeover target 

	All said and done  the pharma sector s fundamentals remain strong    robust pipelines  innovative treatments  impressive results  growing demand for drugs especially for rare to treat diseases  an aging population and increased health care spending should support growth  To know more about this sector  check out our latest  

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact
	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-11-06,Zacks Investment Research,"https://www.investing.com/analysis/zacks-industry-outlook-highlights:-bristol-myers,-biogen,-merck,-celgene-and-ariad-pharmaceuticals-200163142",200163142
129877,351392,BIIB,Stock Market News For September 21  2016,opinion,"Benchmarks finished slightly higher on Tuesday ahead of the two day policy meetings of the Fed and Bank of Japan  BOJ  ending today  Inventors eagerly awaited any major policy decisions from the two central banks  Moreover  gains in healthcare stocks offset declines in energy stocks  While acquisition news boosted the healthcare sector  crude oversupply concerns weighed on energy stocks 

	For a look at the issues currently facing the markets  make sure to read today s  article 

	The Dow Jones Industrial Average  DJI  increased 0 1   to close at 18 129 96  The S P 500 rose 0 64 points to close at 2 139 76  The tech laden Nasdaq Composite Index closed at 5 241 35 gaining 0 1   The fear gauge CBOE Volatility Index  VIX  increased 2 5  to settle at 15 92  A total of around 5 8 billion shares were traded on Tuesday  significantly lower than the last 20 session average of 6 7 billion  Decliners outpaced advancing stocks on the NYSE  For 54  stocks that declined  43  advanced 

Fed and BOJ in Focus

	Investors are now focused on the two day policy meeting of the Fed ending today  According to CME Groups  FedWatch Tool  probability of a rate hike this month is only 15   Investors are not only waiting for Fed Chief Janet Yellen s speech to find clues for further rate hikes this year  but are also focused on Governor of BOJ Haruhiko Kuroda s news conference 

	As it is widely expected that the Fed will keep rates unchanged  BOJ s monetary decisions are grabbing the spotlight  It is speculated that BOJ might opt for a further rate cut and might continue to buy short term debt securities  while reducing long term bonds purchase 

Healthcare Stocks Post Gains

	Tobira Therapeutics  Inc s    shares jumped 720 9  after Allergan  NYSE AGN pa  plc     decided to acquire the company for  1 7 billion  Tobira develops products which are used to treat a common liver disease called nonalcoholic steatohepatitis  or NASH  Following this news  shares of Gilead Sciences Inc  NASDAQ GILD        which also develops drugs to treat NASH  rose 3 5    Read More    

	Gains in Gilead Sciences helped the Health Care Select Sector SPDR  XLV  to increase 0 3  and emerge as the best performer among the S P 500 sectors  The iShares Nasdaq Biotechnology  IBB  rose 1 4   Both its two key holdings  Biogen  NASDAQ BIIB  Inc     and Amgen Inc  NASDAQ AMGN      advanced 1 2   Both the two companies possess a Zacks Rank  3  Hold   You can see   

Energy Slumps amid Oversupply Worries 

	Oil prices closed mixed yesterday after Colonial Pipeline said that worries over supply disruptions from Gulf Coast refiners have faded as the gasoline line is expected to restart functioning from today  This in turn offset hopes of a possible agreement between major oil producing nations to freeze crude production  WTI crude rose 0 3  to  43 44 per barrel  but Brent crude fell 0 2  to  45 88 a barrel 

	Also  Exxon Mobil  NYSE XOM  Corporation s    shares fell 1 5  on news that the U S  Securities and Exchange Commission is reportedly inspecting the way the oil giant s assets are being valued amid decline in oil prices  This in turn led the Energy Select Sector SPDR  XLE  NYSE XLE   to decrease 0 7  and emerge as the worst performer among the S P 500 sectors 

Housing Data Upsets

	Housing starts fell 5 8  in August from July to a seasonally adjusted annual rate of 1 142 000  missing the consensus estimate of 1 188 000  according to the U S  Department of Commerce  Moreover  building permits went down 0 4  from July to a seasonally adjusted annual rate of 1 139 000 last month  It was also lower than the consensus estimate of 1 160 000 

Stocks That Made Headlines Today



	FedEx Corporation s     first quarter fiscal 2017 earnings per share  on an adjusted basis  and revenues beat the Zacks Consensus Estimate     



	Petroleo Brasileiro S A  or Petrobras    announced a steep cut in its capital spending budget for the period 2017 21    



	KB Home    reported impressive third quarter fiscal 2016 adjusted earnings that surpassed the Zacks Consensus Estimate    



	Facebook Inc    has snapped up startup   Nascent Objects   for an undisclosed amount    



	Sonoco Products Co  s    unit Sonoco ThermoSafe has acquired London based Laminar Medica from Clinimed  Holdings  Limited    

Confidential from Zacks

	Beyond this Tale of the Tape  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-20,Zacks Investment Research,"https://www.investing.com/analysis/stock-market-news-for-september-21,-2016-200154737",200154737
129878,351393,BIIB,6 Healthcare Stocks Investors Can t Miss In Q3 Earnings,opinion,"Controversies surrounding drug prices are again making it to the headlines  this time spurred by the EpiPen price hike issue  Generic drug maker Mylan  NASDAQ MYL  N V  drew flak from lawmakers for over pricing its epinephrine auto injector  EpiPen  severe allergic reactions  around the end of Aug 2016 Tweets  Deals   Biosimilars
The situation heated up after a tweet by Presidential candidate Hillary Clinton  which read  EpiPens can be the difference between life and death  There s no justification for these price hikes   Clinton even proposed a health care plan to keep drug prices under control  protecting consumers from unreasonable price hikes and making drug makers accountable 
The issue came to the forefront last year  with drug makers like Valeant Pharmaceuticals  NYSE VRX  International  Inc  among others coming into the spotlight due to massive price hikes of their drugs  Last September  Clinton s  price gouging  tweet led to a major sell off in the healthcare sector  particularly the biotech space  cutting the bull run of health care stocks short 
On the bright side  mergers and acquisitions  and licensing and collaboration deals continued to impress investors  At present  the most talked about merger is that of German drug maker  Bayer AG  DE BAYGN  and U S  seed giant Monsanto Company  NYSE MON   Last month  after months of negotiations  Bayer finally announced that it has inked a definitive agreement to acquire Monsanto in an all cash deal worth  66 billion  Meanwhile  biotech company Horizon Pharma plc declared plans to take over California based Raptor Pharmaceuticals Corp 
Further  in June  Shire plc acquired Baxalta to boost its rare disease and added key products to its hematology  oncology and immunology franchises  while Pfizer  NYSE PFE  purchased oncology focused company  Medivation  Inc   last month for approximately  14 billion 
Meanwhile  Allergan  NYSE AGN pa  announced a string of small bolt on acquisitions last month  The company will be acquiring clinical stage biotech company  Vitae Pharmaceuticals  Inc   to boost its dermatology pipeline  It has also inked a couple of acquisition deals with Tobira Therapeutics  Inc  and Akarna Therapeutics Ltd   targeting the non alcoholic steatohepatitis market 
While most partnerships between large cap and development stage companies were in the field of immuno oncology  other therapeutic areas like autoimmune  cardiovascular  central nervous system disorders also saw action  Mergers  acquisitions and licensing deals are expected to continue in the future as companies look to boost their pipeline and gain a competitive edge 
In addition  news of product approvals  label expansion of existing drugs and regular pipeline updates have been coming in quite often  lifting investor spirits significantly 
While last year  the FDA approved the first biosimilar  Zarxio  a biosimilar version of Amgen Inc  s  NASDAQ AMGN  blockbuster drug  Neupogen   September saw the regulatory approval of Amgen s Amjevita  adalimumab atto   a biosimilar version of AbbVie Inc  NYSE ABBV   s Humira 
In this context  it is important to note that biosimilars are being touted as the next big thing in the healthcare sector 
What is the Trends Report Saying 
Firstly  Medical is one of the five sectors expected to record positive earnings growth in Q3 
Earnings in the Medical sector are expected to grow 2 8  on a 7 5  improvement in revenues  per our latest  report Pick the Likely Q3 Winners
Given the enormity of the healthcare space  selecting stocks that have the potential to beat estimates could appear daunting  But our proprietary methodology makes it fairly simple  One way to narrow down the list of choices this earnings season is by looking at stocks that have the combination of a favorable Zacks Rank   Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold    and a positive   More often than not  a positive earnings surprise delivered by a company leads to stock price appreciation 
Earnings ESP is our proprietary methodology for identifying stocks that have high chances of surprising with their upcoming earnings announcement  It shows the percentage difference between the Most Accurate estimate and the Zacks Consensus Estimate  Our research shows that for stocks with this combination  the chance of a positive earnings surprise is as high as 70  
Here are six healthcare stocks that we believe are poised to beat estimates  as per our methodology 
Our first pick is the bellwether of healthcare companies  Johnson   Johnson  NYSE JNJ      which has a solid presence in the pharmaceutical  medical devices and consumer care markets across the world  This New Brunswick  NJ based company has a Zacks Rank  3 and an Earnings ESP of  4 88   The Zacks Consensus Estimate is pegged at  1 64  The company has consistently beaten earnings expectations  In fact  Johnson   Johnson s earnings have surpassed expectations in each of the last four quarters  with an average positive surprise of 2 88  
Johnson   Johnson is set to reveal Q3 results on Oct 18  before the opening bell 
Our next choice is biotech major  Amgen     With a Zacks Rank  3  the stock carries an Earnings ESP of  2 14   The Zacks Consensus Estimate stands at  2 80  This Thousand Oaks  CA based company has a pretty impressive track record  with the company beating earnings estimates consistently  The average earnings surprise over the last four trailing quarters is 11 55  
Amgen is expected to report Q3 results on Oct 26 
A well known name in the multiple sclerosis market  Biogen  NASDAQ BIIB  Inc     made it to our list of the likely Q3 outperformers  thanks to its Zacks Rank  3 and 2 20  Earnings ESP  The Zacks Consensus Estimate is  5 00  This Cambridge  MA based company has beaten expectations in all of the past four quarters  bringing the average earnings surprise to 11 39  
Biogen is scheduled to report Q3 results on Oct 26  before the opening bell 
Large cap pharma company  Bristol Myers Squibb Company  NYSE BMY     exhibits an impressive track record  having consistently beaten earnings expectations  The company s earnings surpassed estimates in each of the four trailing quarters  with an average positive surprise of 15 56   This New York based company carries a Zacks Rank  3 and has an Earnings ESP of  4 69   Thus  its prospects for Q3 appear pretty bright  The Zacks Consensus Estimate stands at 64 cents 
Bristol Myers is scheduled to report Q3 results on Oct 27  before the opening bell 
Biotech company  United Therapeutics Corporation    is another solid bet  Based in Silver Spring  MD  United Therapeutics recorded an average positive earnings surprise of 43 93  over the trailing four quarters  The stock currently has an Earnings ESP of  5 46  and it sports a Zacks Rank  1  Strong Buy   You can see  
United Therapeutics is expected to release Q3 results on Oct 25  with the Zacks Consensus Estimate currently pegged at  3 48 
The last company on our list is Exact Sciences Corporation     with a Zacks Rank  2 and an Earnings ESP of  6 98   The Zacks Consensus Estimate stands at a loss of 43 cents  Based in Madison  WI  Exact Sciences is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer  It has registered an average positive surprise of 9 48  over the trailing four quarters 
Exact Sciences is set to release Q3 results on Oct 26  before market opens Bottom Line  
Even as challenges in the form of competitive and pricing pressure persist in the healthcare sector  a number of healthcare companies are recording improvements in their financial numbers  A sneak peek into this space for some outperformers  that boast a solid Zacks Rank and a positive Earnings ESP  could be a great idea for investors to gain during the upcoming earnings season Confidential  Zacks  Best Investment Ideas 
Would you like to see a hand picked  all star  selection of investment ideas from the man who heads up Zacks  trading and investing services  Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-07,Zacks Investment Research,https://www.investing.com/analysis/6-healthcare-stocks-investors-can't-miss-in-q3-earnings-200157718,200157718
129883,351398,BIIB,Teva Acquires Rights To Oncology Biosimilar Candidates,opinion,"Generic drug maker Teva Pharmaceutical Industries Ltd    NYSE TEVA   has entered into an exclusive biosimilar commercial partnership with Korean biopharmaceutical company Celltrion  Inc and its distribution partner Celltrion Healthcare Per the deal  Teva gets exclusive rights to commercialize two of Celltrion s phase III biosimilar monoclonal antibodies  mAbs  biosimilar candidates   CT P10 and CT P6   in the U S  and Canada  pending regulatory approvals  Celltrion will  however  be responsible to finish off their clinical development and regulatory formalities CT P10 is a proposed mAb biosimilar to Roche Holding  SIX ROG  AG s   OTC RHHBY   drug Rituxan  rituximab  which is approved to treat non Hodgkin s lymphoma  NHL   chronic lymphocytic leukemia  rheumatoid arthritis  Wegener s Granulomatosis and Microscopic Polyangiitis  CT P6  on the other hand  is a proposed mAb biosimilar to Roche s key breast cancer drug Herceptin  trastuzumab  Both the candidates have met their primary endpoints in the respective late stage phase III studies  While CT P10 is under review in the EU  CT P6 is planned to be submitted for review to the European Medicines Agency  EMA  this quarter TEVA PHARM ADR Price
    Per the financial terms of the deal  Teva will pay Celltrion Healthcare  160 million upfront  Once the mAb biosimilars are commercialized  Teva and Celltrion Healthcare will share profits from the same The deal is in line with Teva s plans to strengthen its biosimilar pipeline  In fact  the pharmaceutical industry is set to see an approaching wave of biosimilars  which are essentially generic versions of expensive biologic drugs Several pharma as well as biotech companies are involved in the development of biosimilars  The first biosimilar to gain approval in the U S  was Sandoz s  Novartis AG s   NYSE NVS   generic arm  Zarxio  a biosimilar version of Amgen Inc  s   NASDAQ AMGN   Neupogen Other approved biosimilars include Pfizer s Inflectra  a biosimilar to Janssen Biotech  Inc  s Remicade  infliximab  and Sandoz s Erelzi  a biosimilar to Amgen s Enbrel  etanercept   Last month  Amgen s biosimilar version of Abbvie s Humira   Amjevita   gained FDA aaproval Several other companies like Merck  NYSE MRK   Pfizer  NYSE PFE   Biogen  NASDAQ BIIB  and Allergan  NYSE AGN pa  are targeting the highly lucrative biosimilars market Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-10,Zacks Investment Research,https://www.investing.com/analysis/teva-acquires-rights-to-oncology-biosimilar-candidates-200158214,200158214
129903,351418,BIIB,Biotech Stock Roundup  Medivation To Pfizer  Clovis Priority Review,opinion,"The big news this week in the biotech sector was Pfizer s announcement that it will acquire cancer focused Medivation   NASDAQ MDVN   for  14 billion  This announcement has revived acquisition chatter in the sector with much speculation regarding which biotech company may be the next acquisition target Recap of the Week s Most Important Stories1  Medivation finally agreed to be acquired with Pfizer  NYSE PFE  shelling out  14 billion for the company  Medivation was a part of acquisition talks for quite a while with the company first receiving an offer from French drugmaker Sanofi  PA SASY   Last month  Medivation announced that it is open to acquisition talks and entered into confidentiality agreements with several firms that had expressed an interest in exploring a potential transaction  Since then  quite a few companies were rumored to be interested in acquiring Medivation 2  Clovis   NASDAQ CLVS    another cancer focused company  got some good news with the FDA granting its lead pipeline candidate  rucaparib  priority review  With Clovis submitting its regulatory application for the experimental ovarian cancer treatment in June  a response from the FDA is expected by Feb 23  2017  Investors cheered the development with shares increasing more than 27  on the news  Read more    3  Regeneron   NASDAQ REGN   is teaming up with the Biomedical Advanced Research and Development Authority  BARDA  of the U S  Department of Health and Human Services  HHS  to manufacture and study two antibody therapies for the prevention and treatment of Middle East Respiratory Syndrome  MERS   At present  no medicines or vaccines are approved for the treatment or prevention of MERS  which causes severe respiratory tract infections and is associated with high death rates  Read more    4  The European Commission expanded the label of Gilead s   NASDAQ GILD   HIV drug  Truvada  once daily  making it the first antiretroviral medicine to be licensed in Europe for pre exposure prophylaxis  in combination with safer sex practices  to reduce the risk of sexually acquired HIV 1 in uninfected adults at high risk  Read more   5  Portola s   NASDAQ PTLA   shares were down on news that the company got a Complete Response Letter  CRL  from the FDA for AndexXa  andexanet alfa   an antidote for Factor Xa inhibitors when reversal of anticoagulation is needed due to life threatening or uncontrolled bleeding  The agency has asked for more information related to manufacturing as well as additional data to support inclusion of edoxaban and enoxaparin in the label  Read more   Performance
MEDICAL BIOMED GENETICS Industry Price Index
The NASDAQ Biotechnology Index gained 1 9  over the last five trading days  While all major biotech stocks were up  Alexion   NASDAQ ALXN   was up 3 3   Over the last six months  Biogen   NASDAQ BIIB   was up 23 7  while Gilead  GILD  lost 8 8   See the last biotech stock roundup here    
What s Next in the Biotech World Watch out for the usual pipeline and regulatory updates from biotech companies Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-08-24,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stock-roundup:-medivation-to-pfizer,-clovis-priority-review-200149872",200149872
129905,351420,BIIB,Biotech Stocks Bounce Back In Monday Trading  3 Picks,opinion,The healthcare sector has been choppy since the beginning of 2016  continuing the volatile trend from the second half of 2015  Media and political focus on the high prices of drugs have made things difficult for the pharma biotech sector since the past one year Democratic presidential candidate  Hillary Clinton has pledged to find ways to institute reforms to curb rising drug prices and thereby lower prescription drug costs for all Americans  The situation worsened when Mylan  NASDAQ MYL  N V   increased the price of its life saving combination product EpiPen  This month  Clinton  in a statement on her website  announced measures to curb  unjustified  price hikes of lifesaving treatments  especially the ones that have been in the market for long Shares of many biotech companies declined this month after Clinton s latest statement However  the picture seems to be improving now with share price of a large number of pharma biotech companies bouncing back on Monday  Sep 12  Among the larger companies  Eli Lilly and Company   NYSE LLY    Sanofi   NYSE SNY    Merck  Inc    NYSE MRK   and Pfizer  Inc    NYSE PFE   rose more than 1   Biogen Inc    NASDAQ BIIB   rose more than 2  while Amgen Inc    NASDAQ AMGN   and AstraZeneca PLC   NYSE AZN   were up more than 3  on Monday After a weaker first quarter  the pharma biotech sector picked up pace in the second quarter with a number of healthcare companies faring better than expected  Bigwigs like Johnson   Johnson   NYSE JNJ    Novartis AG   NYSE NVS   and Abbott Laboratories   NYSE ABT   were able to beat expectations comfortably  In the biotech space  major players like Biogen topped both earnings and revenues expectations  while Gilead Sciences   NASDAQ GILD   beat on earnings  Amgen   NASDAQ AMGN   and AbbVie  Inc   also managed to surpass both earnings and sales estimates and lifted their outlook Healthcare merger and acquisition activity is also gaining strength  In August  Pfizer announced the acquisition of oncology focused Medivation for approximately  14 billion  This was preceded by the buyout of Anacor in Jun 2016 and Hospira in Sep 2015  In Jun 2016  Shire plc  acquired Baxalta to further strengthen its rare disease portfolio  Aegerion Pharmaceuticals   NASDAQ AEGR   and QLT Inc   entered into a definitive merger agreement in Jun 2016 to form a new company  Novelion Therapeutics Inc Merger and acquisitions are expected to increase in the back half of the year  Meanwhile  small bolt on acquisitions  in licensing activities and collaborations for the development of pipeline candidates are expected to continue On the other hand  new product approvals  along with label expansion of existing drugs and regular pipeline updates related to key drugs should keep investors  attention glued to the pharma biotech sector Given the strong fundamentals  biotech companies with new therapies or interesting pipeline candidates promise bountiful opportunities for investors  These stocks are well positioned in today s market environment and could see considerable upside riding on the aforementioned trends We have narrowed down the list of choices by focusing on stocks with a favorable Zacks Rank of  1  Strong Buy  or  2  Buy  and  of  A  of  B PDL BioPharma  Inc    NASDAQ PDLI  Nevada based  PDL BioPharma manages a portfolio of patents and royalty assets in the United States and Europe  The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases  It has a Zacks Rank  2 and a VGM score of  B  The stock has also witnessed positive estimate revisions in the past 30 days Its 2016 earnings estimate rose 20  while that for 2017 is up a massive 200  over the past 30 days Vanda Pharmaceuticals  Inc    NASDAQ VNDA  This Washington based biopharmaceutical company focuses on developing products for central nervous system disorders  Its estimated loss for 2016 narrowed down over the past 30 days while for 2017  estimates switched from a loss of 3 cents to earnings of 16 cents over the same time frame  The company has a VGM score of  B  and a Zacks Rank  2  You can see  Neogenomics Inc  This clinical laboratory specializes in cancer genetics diagnostic testing  It has a Zacks Rank  2 and a VGM score of  B  Bottom Line  Although obstacles remain in the form of biosimilars and currency headwinds  investors would do well to keeps an eye on these fast growing biotech stocks Zacks  Best Investment Ideas for Long Term ProfitToday you can gain access to long term trades with double and triple digit profit potential rarely available to the public  Starting now  you can look inside our stocks under  10  home run and value stock portfolios  plus more  Want a peek at this private information ,2016-09-12,Zacks Investment Research,https://www.investing.com/analysis/biotech-stocks-bounce-back-in-monday-trading:-3-picks-200153255,200153255
129906,351421,BIIB,Perrigo Up As Starboard Reveals Stake  Changes Proposed,opinion,"Perrigo Company plc s   NYSE PRGO   shares gained 7 4  after the New York based activist investor  Starboard Value LP  revealed in a letter its 4 6  stake in the company  making it one of Perrigo s largest shareholders 
In a letter dated Sep 12  2016  Starboard Managing Member  Jeffrey C  Smith  urged the Chief Executive Officer of Perrigo  John Hendrickson  and its board of directors to consider improving the company s poor operating and financial performance 
Smith mentioned that Perrigo undertook several operational and financial  missteps  last year  which has led to a decline in the company s valuation  Smith pointed out that Perrigo went to great extent  using unrealistic forecasts to reject an unsolicited takeover offer from Mylan N V    NASDAQ MYL   last year 
Also  the management and board spent more than  100 million in advisor fees in order to defend their move  Smith added that  had the offer been accepted  it would have sent Perrigo  shares above 88  than its current stock price 
Starboard said that not only has Perrigo failed to deliver what it promised after rejecting Mylan s offer  but also the Mar 2015 Omega Pharma acquisition  which created Branded Consumer Healthcare BCH business  has been grossly mismanaged  Further  the company has committed numerous execution errors and considerably lowered its financial guidance on the past two earnings calls 
However  Starboard believes Perrigo holds a strong franchise with valuable assets and significant opportunities to unlock shareholders value 
Starboard believes that the combination of Perrigo s core Consumer Healthcare business and the BCH business offer the company with a unique global over the counter  OTC  market position  However  Perrigo owns quite a few non core assets  Starboard believes that there exist limited synergies between Prescription Pharmaceuticals  Rx Pharmaceuticals  business and the core OTC businesses 
Moreover  Perrigo  which receives royalties on global sales of Biogen Inc  s   NASDAQ BIIB   multiple sclerosis drug Tysabri  should consider divestment or explore other broader strategic alternatives including its Rx Pharmaceuticals business 
PERRIGO CO PLC Price   We remind investors that while announcing second quarter 2016 results  Perrigo had lowered its 2016 earnings outlook  The company expects earnings in the range of  6 85 to  7 15 per share  previously guided within that of  8 20 to  8 60  The cut in the earnings guidance was due to continued price erosion and changing market dynamics in the Rx business  in addition to lower expectations from BCH business 
Perrigo in its press release said that it will evaluate the letter and engage in talk with Starboard 
Perrigo is a Zacks Rank  5  Strong Sell  stock  Geron Corporation   NASDAQ GERN   is a better ranked stock in the health care sector  sporting a Zacks Rank  1  Strong Buy  You can see  
Confidential from Zacks
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-13,Zacks Investment Research,"https://www.investing.com/analysis/perrigo-up-as-starboard-reveals-stake,-changes-proposed-200153331",200153331
129909,351424,BIIB,Intro Guide To The AB Large Cap Growth A  APGAX  Fund,opinion,"AB Large Cap Growth A Fund     a Zacks Rank  2  Buy  was incepted in September 1992 and is managed by Alliance Capital Management  The objective of APGAX is to seek long term growth of capital by investing in a limited number of large  carefully selected  high quality U S  companies  APGAX combines in depth fundamental research on a company by company basis with opportunistic trading around core portfolio positions 

	This Large Blend product  as of the last filing  allocates their fund in two major groups  Large Growth and Small Growth  Further  as of the last filing  Alphabet  NASDAQ GOOGL  Inc  Facebook Inc  NASDAQ FB  and Biogen  NASDAQ BIIB  Inc were the top holdings for APGAX 

	The AB Large Cap Growth A fund  managed by   carries an expense ratio of 1 21   Moreover  APGAX requires a minimal initial investment of  2 500 

	APGAX has a history of positive total returns for over 10 years  Specifically  the fund s returns over the 3  5 year benchmarks  3 year 15 30  and 5 year 16 25   To see how this fund performed compared in its category  and other  1 and  2 Ranked Mutual Funds   

	APGAX s performance  as of the last filing  when compared to funds in its category was in the top 20  over the past 1 year  in the top 1  over the past 3 years  and in the 1  over the past 5 years 

Want key mutual fund info delivered straight to your inbox 

	Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ",2016-09-15,Zacks Investment Research,https://www.investing.com/analysis/intro-guide-to-the-ab-large-cap-growth-a-(apgax)-fund-200153952,200153952
129928,351443,BIIB,3 Healthcare Stocks Poised To Beat Q2 Earnings ,opinion,"After a tumultuous start to 2016 and a lackluster first quarter  things are finally looking up as we approach the end of the second quarter earnings cycle  A large chunk of companies fared better than expectations  giving investors enough to cheer for 
The healthcare sector witnessed a particularly rough time in the first half of 2016  braving a challenging business environment fraught with headwinds like unfavorable currency movements and biosimilars  This lead to the issuance of bleak outlook for 2016 by most of the companies in the sector  Nevertheless  in the second quarter  results have managed to outpace expectations so far  which will let investors heave a sigh of relief at last 
Bigwigs like Johnson   Johnson  NYSE JNJ   Novartis AG  NVS  and Abbott Laboratories  NYSE ABT  were able to beat expectations comfortably  In the biotech space  major players like Biogen Inc   NASDAQ BIIB  topped both earnings and revenues expectations  while Gilead Sciences  NASDAQ GILD  beat on earnings  Amgen  NASDAQ AMGN  and AbbVie  Inc   ABBV  also managed to surpass both earnings and sales expectations  and both have lifted their outlooks 
M A and licensing deals should continue to take the center stage  In Jan 2016  Abbott Labs inked a definitive agreement to buy Alere Inc   ALR  for  5 8 billion  Later in April  the company again entered into a definitive agreement to acquire St  Jude Medical  STJ   Meanwhile  Pfizer Inc   NYSE PFE  acquired Anacor in Jun 2016  following its completion of the Sep 2015 Hospira takeover  In the biotech space  Shire plc  SHPG  acquired Baxalta to further strengthen its rare disease portfolio  Swiss major Novartis is reportedly eyeing to buy AstraZeneca  AZN   as per Reuters 
Going ahead  new product approvals  along with the label expansion of existing drugs and regular pipeline updates related to key drugs  should keep investor attention glued to the sector 
Although the Q2 earnings cycle has almost ended  it is not too late to enter the promising healthcare sector given the strong fundamentals  healthy pipelines and the drive to find innovative treatments for rare diseases  Here  we will help you to identify a few companies in the healthcare sector that have the potential to beat earnings in their upcoming releases  These stocks are well positioned in today s market environment  and could see considerable upside due to the aforementioned trends  An earnings beat should help these stocks gain investor confidence and show a favorable price movement How to Pick 
Given a large number of industry participants  pinpointing stocks that have the potential to beat estimates could appear to be quite daunting  But our proprietary methodology makes it fairly simple  One way to narrow down the list of choices this earnings season is by looking at stocks that have the combination of a favorable Zacks Rank   Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold    and a positive  
The Earnings ESP is our proprietary methodology for identifying stocks that have high chances of surprising in their next earnings announcement  It shows the percentage difference between the Most Accurate estimate and the Zacks Consensus Estimate 
Our research shows that for stocks with this combination  the chance of a positive earnings surprise is as high as 70  
Below we list a few stocks that are expected to conclude the earnings season with a positive surprise Asterias Biotherapeutics  Inc     currently carries a Zacks Rank  3 and an Earnings ESP of  42 11   This biotechnology company is presently developing proprietary cell therapy programs that are based on its immunotherapy and pluripotent stem cell platform technologies  Immunotherapy is a key area of focus in the medical sector and Asterias  pipeline looks interesting at this juncture  The company s pipeline candidates include AST OPC1  oligodendrocyte progenitor cells  currently in a phase I IIa dose escalation clinical study for spinal cord injury   Another candidate  AST VAC1  antigen presenting autologous dendritic cells   showed positive results for a phase II study in acute myelogenous leukemia  AML   The third candidate  AST VAC2  antigen presenting allogeneic dendritic cells   represents a second generation  allogeneic immunotherapy  phase I II clinical trial of AST VAC2 in non small cell lung cancer slated to start in 2017   We expect investor focus on pipeline updates when the company releases second quarter results on Aug 15 Bio Blast Pharma Ltd     is a development stage biopharmaceutical company focused on the identification  licensing  acquisition  development and commercialization of drugs for rare and ultra rare genetic diseases  Such diseases generally have few or no treatments available  thereby underscoring the need for new ones  The company has developed and in licensed potential treatments for a range of diseases  At present  the company has several drug candidates in clinical or preclinical development targeting neuromuscular central nervous system  CNS  and mitochondrial diseases  Bio Blast is expected to release second quarter results on Aug 19  With an impressive track record  a Zacks rank  3 and an Earnings ESP of  22 22   we are hopeful of an earnings beat this quarter Evoke Pharma  Inc     currently carries a Zacks Rank  3 and has an Earnings ESP of  4 65   This specialty pharmaceutical company focuses on treatments for gastrointestinal  GI  diseases  The company is currently developing EVK 001  a metoclopramide nasal spray  for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus  The spray formulation is designed to provide systemic delivery of metoclopramide through nasal administration  The company s track record is mixed  having beaten estimates in three of the four quarters and missing the same once  Nevertheless  a favorable Zacks Rank and a positive ESP makes us positive about an earnings beat this quarter  Evoke is scheduled to release second quarter results on Aug 15 Bottom Line  

Although obstacles remain in the form of biosimilars and currency headwinds  investors would do well to keep an eye on these potential outperformers given their solid Zacks Rank and positive Zacks Earnings ESP 
Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-08-10,Zacks Investment Research,https://www.investing.com/analysis/3-healthcare-stocks-poised-to-beat-q2-earnings-200147494,200147494
129932,351447,BIIB,The Zacks Analyst Blog Highlights  Regeneron  BioMarin  AbbVie  Amgen And Biogen,opinion,"For Immediate Release

	Chicago  IL   August 12  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include   Regeneron     BioMarin     AbbVie     Amgen  NASDAQ AMGN       and Biogen  NASDAQ BIIB     

	Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Thursday s Analyst Blog  

Biotech Stock Roundup  AbbVie Tries to Block Humira Copycat

	Several small and mid sized as well as big biotech companies like Regeneron    and BioMarin     reported second quarter results last week  Meanwhile  among other major updates  AbbVie    filed a patent infringement lawsuit against Amgen     Amgen is seeking FDA approval for its biosimilar version of Humira 

Recap of the Week s Most Important Stories
	1  First a look at earnings results of companies like BioMarin and Regeneron  BioMarin once again reported better than expected results and raised its revenue guidance with both Kuvan and Vimizim performing well  Read more      Regeneron s earnings also surpassed expectations with Eylea continuing to perform well  Read more     
	2  Biogen s    partner Eisai said that their experimental treatment for early Alzheimer s disease  BACE inhibitor E2609  has got the green signal from the FDA for advancement into phase III studies  Biogen also announced the name of the new hemophilia focused company that will be created through the spin off of the company s hemophilia franchise currently comprising marketed products like Eloctate and Alprolix  The company will be named Bioverativ and will trade under the symbol BIVV on the NASDAQ Stock Market  The spin off is scheduled to be completed early next year 
	Meanwhile  rumors surfaced last week that Biogen could be acquired by companies like Allergan  NYSE AGN pa  or Merck  NYSE MRK   But  according to sources  the biotech company is not interested in a takeover 
	4  AbbVie has initiated a patent infringement lawsuit against Amgen to protect its flagship product  Humira  from biosimilar competition  The move was largely expected considering Humira accounts for a major part of AbbVie s sales  61 4  of total sales in 2015  and the earlier than expected entry of biosimilars would have a huge impact on the company s financials  Amgen s biosimilar version got the support of an FDA advisory panel  A final decision regarding the approval status of the product is expected by Sep 25  2016 

	Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days   

	Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

	Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

	Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-08-11,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-regeneron,-biomarin,-abbvie,-amgen-and-biogen-200147660",200147660
129934,351449,BIIB,Top 3 Research Reports For August 15  2016,opinion,"Monday  August 15  2016
Today s must read reports are for AstraZeneca  AZN   Caterpillar  NYSE CAT  and Exelon  NYSE EXC  
AstraZeneca shares have rallied from the mid June lows  erasing most of the stock s earlier underperformance  The Pound weakness following the Brexit vote has been helpful to this London based pharma giant  The company has also benefited from the failure of Bristol Myers  cancer drug  which has put the spotlight on its candidates in that space  These immediate catalysts aside  the analyst likes AstraZeneca s strong diversified portfolio  expanding presence in emerging markets  ongoing cost cutting initiatives and robust pipeline   You can  
Caterpillar shares have been strong performers this year  up more than 22  year to date on hopes that the worst was behind this beleagured mining and construction equipment maker  Caterpillar s earnings picture continues to remain challenged  as the 22  drop in Q2 earnings shows  This tough operating environment has forced management to squeeze more expenses out of the operation  The analyst also points to the improving construction sector as a potential offset to the weak mining sector   You can  
Exelon shares continue to benefit from the market s hunger for yield  it yields a juicy 3 6    But a safe dividend isn t Excelon s sole claim to fame   it reported solid results for the June quarter  partly boosted by contributions from the acquired Pepco Holdings assets  The analyst likes the utility s investments  which will strengthen its infrastructure and expand operations  Additionally  its decision to shut down loss making nuclear plants will drive performance   You can  
You can find all of today s stock research reports 
Today s Private Buys   Sells from Zacks Research  While we share the above news with the public  our sensitive recommendations are hidden from everyone but selected members  Would you like to peek behind the curtain and view them  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time from value to momentum        from stocks under  10 to ETF and option moves       from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors  
Sheraz Mian
Director of Research
Note  Sheraz Mian regularly provides earnings analysis on Zacks com and appears frequently in the print and electronic media  His weekly earnings related articles include  and   He also provides weekly commentary to subscribers and manages the  and portfolios  
If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read









Featured Reports

The Zacks analyst believes that despite coal related headwinds  the Q2 earnings beat is a positive  Norfolk Southern s efforts to reward shareholders are also encouraging 


The Zacks analyst thinks that Moneygram s investment in its digital channel and cost control initiatives will bring long term growth  


The Zacks analyst believes that Bayer s Q2 results were mixed with the company topping bottom line estimates but missing on revenues marginally 


The Zacks analyst believes that Intrexon s efforts to expand through collaborations and acquisitions are encouraging  


Kite s posted wider than expected Q2 loss  However  the Zacks analyst is encouraged by Kite s progress with KTE C19 which could be filed for FDA approval in late 2016 

New Upgrades

The Zacks analyst believes that increase in residential broadband offerings and government satellite business is proving to be conducive to ViaSat s top line growth 


According to the covering analyst  MS franchise sales   cost cutting efforts will continue driving Biogen s performance  The company is also progressing with its pipeline 

New Downgrades

The Zacks analyst thinks that despite Q2 earnings beat  higher expenses related to acquired outdoor advertising assets could reduce Lamar s free cash flow and strain its margins 


According to the covering analyst  despite Apache s initiatives to align capital spending with its cash flows  oil market turmoil and low prices have made the Zacks analyst turn cautious on the stock ",2016-08-15,Zacks Investment Research,"https://www.investing.com/analysis/top-3-research-reports-for-august-15,-2016-200148048",200148048
129948,351463,BIIB,4 Biotech Stocks Poised To Surprise This Earnings Season,opinion,"Despite the lackluster start to the year  things are now looking up as we stand in the thick of the Q2 earnings season  A majority of the companies that have reported so far fared better than expectations  giving investors something to cheer for 
Amid a challenging macro backdrop  the healthcare sector has been choppy since the beginning of 2016  continuing the volatile streak from the second half of 2015  The biotech sector also took a beating in the second half of 2015 due to pricing issues  The NYSE ARCA Biotech Index   BTK  and NASDAQ Biotechnology Index   NBI  have declined 7 1  and 10 1   respectively  so far this year 
Notwithstanding the decline  things appear far better now than they did a quarter ago for the biotech sector  Biogen  NASDAQ BIIB  Inc     topped both earnings and revenues expectations  while Gilead Sciences  NASDAQ GILD     beat on earnings but missed on revenues  Amgen  NASDAQ AMGN     and AbbVie  Inc     also managed to top both earnings and sales expectations and lifted their view 
Meanwhile  M A and licensing deals should continue to take center stage in the sector  In Jun 2016  Shire plc    acquired Baxalta to further strengthen its rare disease portfolio  Aegerion Pharmaceuticals    and QLT Inc     entered into a definitive merger agreement in Jun 2016 to form a new company  Novelion Therapeutics Inc   while Swiss major Novartis    is reportedly looking to buy AstraZeneca     as per Reuters 
On the other hand  new product approvals  along with label expansion of existing drugs and regular pipeline updates related to key drugs  should keep investors  attention glued to the sector 
Given the strong fundamentals  healthy pipelines and the drive to find innovative treatments for rare diseases  the biotech space promises bountiful opportunities for investors  Here we help you to identify some companies in the biotech sector that have the potential to beat earnings in their upcoming releases  These stocks are well positioned in today s market environment  and could see considerable upside riding on the aforementioned trends  An earnings beat should help these stocks gain investor confidence and show a favorable price movement How to Pick 
Given a large number of industry participants  pinpointing stocks that have the potential to beat estimates could appear to be quite daunting  But our proprietary methodology makes it fairly simple  One way to narrow down the list of choices this earnings season is by looking at stocks that have the combination of a favorable Zacks Rank   Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold    and a positive Earnings ESP  
Earnings ESP is our proprietary methodology for identifying stocks that have high chances of surprising in their next earnings announcement  It shows the percentage difference between the Most Accurate estimate and the Zacks Consensus Estimate 
Our research shows that for stocks with this combination  the chance of a positive earnings surprise is as high as 70  
Below are four biotech stocks we believe are best positioned to stand out in the ongoing earnings season 
Cambridge  MA based Ironwood Pharmaceuticals     carries a Zacks Rank  2 and has an Earnings ESP of  13 30   This commercial stage biotechnology company is focused on the development and commercialization of treatments primarily addressing gastrointestinal diseases 
The company s lead drug  Linzess  is indicated for patients suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation  The company is working to boost Linzess sales  which should aid its own performance  Ironwood is scheduled to report second quarter results on Aug 4  Although it has a mixed track record  having beaten estimates in two of the last four quarters and missed the same in the other two  the combination of a positive Earnings ESP and a favorable rank indicates a likely earnings beat this quarter 
San Rafael  CA based BioMarin Pharmaceutical Inc     carries a Zacks Rank  3 and an Earnings ESP of  4 00   The company is scheduled to report second quarter 2016 results on Aug 4  The company has five approved products in its portfolio   Vimizim  Naglazyme  Kuvan  Aldurazyme and Firdapse  BioMarin s track record has been decent so far  with the company beating estimates in three out of the last four quarters  A consistently strong performance of Vimzim should enable the company to beat estimates this quarter 
Another stock that appears poised to beat earnings this quarter is Wilmington  DE based Incyte Corporation     a biopharmaceutical company focused on the discovery  development and commercialization of proprietary therapeutics  The company s approved drug  Jakafi  is approved for the treatment of patients with intermediate or high risk myelofibrosis and patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea 
In Jun 2016  Incyte entered into a share purchase agreement with Ariad Pharmaceuticals    whereby it gained the latter s European business as well as the rights to its leukemia drug  Iclusig  in the EU and 22 other countries  The deal has expanded Incyte s footprint in Europe  Moreover  the company has an impressive track record with a trailing four quarter average positive surprise of 101 83   Incyte s current Zacks Rank  2 and Earnings ESP of  300 00  indicate a likely earnings beat this quarter  The company will report results on Aug 9 
Acceleron Pharma Inc      a clinical stage biopharmaceutical company  is scheduled to report second quarter results on Aug 4  The company is focused on the discovery and development of novel therapeutic candidates that engage the body s ability to rebuild and repair its own cells and tissues  Its pipeline comprises luspatercept  sotatercept  dalantercept and ACE 083  The company has a mixed track record but its current Zacks Rank  3 and a positive Earnings ESP of  7 41  makes us reasonably confident of an earnings beat this quarter Bottom Line  

Although obstacles remain in the form of biosimilars and currency headwinds  investors would do well to keep an eye on these potential outperformers given their solid Zacks Rank and positive Zacks Earnings ESP 
Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-08-03,Zacks Investment Research,https://www.investing.com/analysis/4-biotech-stocks-poised-to-surprise-this-earnings-season-200145833,200145833
129950,351465,BIIB,Drug Stocks  Earnings To Watch On Aug 5  PETX  DVAX   More,opinion,"How does the earnings picture look like as we near the tail end of the second quarter reporting cycle   are turning out to be less ominous than what was expected  With 73 5   as of Jul 29  of the S P 500 members having already reported results  this trend is expected to continue through the end of the earnings season  Of the 317 S P 500 companies that have reported as of Jul 29  72 9  topped earnings expectations while 53 6  surpassed revenue estimates 
Notwithstanding this  modest improvement   growth still remains elusive and Q2 is headed to be the fifth quarter in a row to record an earnings decline for the S P 500 index 
Now with several pharma and major biotech companies having released their earnings results  it is clear that Medical is one of the few sectors witnessing earnings and revenue growth this season  Our Q2 scorecard shows that 63 5  of the Medical sector have reported results with a blended beat of 75 8   the percentage of companies that have beaten both EPS as well as revenue estimates  with the sector recording 5 4  earnings growth on revenue growth of 10 5  
Per our  report  Medical is one of the six sectors expected to record earnings growth in Q2 
This is also corroborated by the second quarter performance of some well known names in the Medical sector  Companies like Johnson   Johnson   NYSE JNJ    Novartis  Abbott  Biogen  NASDAQ BIIB   Amgen  NASDAQ AMGN   AbbVie  Bristol Myers  and Celgene  NASDAQ CELG  have surpassed expectations  and some among these even raised their outlook for the year  However  the biggest drag was biotech major Gilead Sciences Inc  s   NASDAQ GILD   results  The company barely managed to beat earnings by a penny and even cut its product sales guidance for the year 
Still  several mid  and small sized pharma and biotech companies are yet to report Q2 results  Let s take a sneak peek at four such companies 
Will these Drug Stocks Pull a Surprise 
Pet therapeutics company  Aratana Therapeutics  Inc    NASDAQ PETX   is focused on licensing  developing and commercializing innovative biopharmaceutical products for companion animals  This Leawood  KS based company has a decent track record  The company has beaten estimates in three of the last four quarters with an average positive surprise of 10 69   Aratana currently carries a Zacks Rank  3  The stock s Zacks Rank  3 when combined with an  of 0 00  makes surprise prediction uncertain  The company will report second quarter results on Aug 5 ARATANA THERAP Price and EPS Surprise   Headquartered in Berkeley  CA  Dynavax Technologies Corporation   NASDAQ DVAX   is a biopharmaceutical company focused on the discovery and development of vaccines and therapeutics  Dynavax s track record so far has been mixed with the company surpassing expectations on two occasions  while missing estimates in the other two  Overall  the company has delivered a negative surprise of 4 19   This Zacks Rank  3  Hold  stock also has an ESP of 0 00  making a surprise prediction difficult this quarter  The company is expected to release Q2 results on Aug 5 DYNAVAX TECH CP Price and EPS Surprise   Based in Redwood City  CA  Heron Therapeutics  Inc    NASDAQ HRTX   is a biotechnology company focused on the development of novel  patient focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain  Heron s track record has also been mixed with the company surpassing expectations on two occasions  while missing the same on the other two  Heron currently has a Zacks Rank  4  Sell  and an ESP of  3 13   As it is  we caution against Sell rated stocks   4 or  5  going into an earnings announcement The company is expected to release Q2 results on Aug 5 HERON THERAPEUT Price and EPS Surprise   San Diego  CA based La Jolla Pharmaceutical Co    NASDAQ LJPC   is a biopharmaceutical company focused on the discovery  development and commercialization of innovative treatments for patients suffering from life threatening diseases  La Jolla s performance has been mostly disappointing with the company missing expectations in three of the last four quarters with an average negative surprise of 9 18   Though the stock s Zacks Rank  3 increases the predictive power of the ESP  it also has an ESP of 0 00   making a surprise prediction uncertain this quarter  The company is expected to report second quarter results on Aug 5 LA JOLLA PHARMA Price and EPS Surprise  ",2016-08-03,Zacks Investment Research,"https://www.investing.com/analysis/drug-stocks'-earnings-to-watch-on-aug-5:-petx,-dvax---more-200146064",200146064
129951,351466,BIIB,Exelixis  EXEL  Posts Narrower Loss In Q2  Beats On Revenues,opinion,"Exelixis  Inc    NASDAQ EXEL   posted a second quarter 2016 loss of 16 cents  narrower than both the Zacks Consensus Estimate of a loss of 27 cents and the year ago loss of 22 cents 

Net revenue came in at  36 2 million  up from  8 0 million  which easily surpassed the Zacks Consensus Estimate of  15 6 million 
Quarter in Detail
Exelixis  lead drug  Cometriq  is approved for the treatment of progressive  metastatic medullary thyroid cancer 
Of the total revenue   31 6 million came from product sales  Cabozantinib is marketed in the capsule form as Cometriq for progressive  metastatic MTC  Exelixis was evaluating a tablet formulation of cabozantinib  distinct from the capsule form  for advanced renal cell carcinoma  RCC  in the METEOR trial  The company received a significant boost in Apr 2016  when the FDA approved its tablet formulation under the brand name  Cabometyx  for the treatment of RCC in patients who have received prior anti angiogenic therapy 
In the reported quarter  research and development expenses decreased 6 2  to  23 million due to lower clinical trial costs and allocation of general corporate costs  Selling  general and administrative expenses jumped to  35 8 million from  12 8 million due to higher personnel related expenses resulting from an increase in headcount  which in turn  was due to sales force expansion in the U S  for supporting the launch of Cabometyx 
Pipeline Update
The European Medicines Agency  EMA  has accepted a Marketing Authorisation Application  MAA  for Cabometyx for review for the treatment of advanced RCC in adults following prior vascular endothelial growth factor  VEGF  targeted therapy  The Committee for Medicinal Products for Human Use  CHMP  has given a positive opinion on an approval of Cabometyx 
In May 2016  the company announced that an independent randomized phase II trial  CABOSUN  on cabozantinib in patients with previously untreated advanced RCC  met its primary endpoint  The trial demonstrated a statistically significant and clinically meaningful improvement in progression free survival  compared with sunitinib  in patients with advanced intermediate  or poor risk RCC  Consequently  Exelixis is discussing the results with regulatory authorities and evaluating further actions in the development and submission strategy for cabozantinib as a first line treatment for patients with advanced RCC 
We remind investors that Exelixis has an exclusive licensing agreement with Ipsen for the commercialization and further development of cabozantinib  Per the terms of the agreement  Ipsen will enjoy exclusive commercialization rights for current and potential future indications of the drug outside the U S   Canada and Japan  The companies will jointly work for the development of cabozantinib in the current and future potential indications 
Meanwhile  Exelixis is evaluating cabozantinib in the CELESTIAL trial for advanced hepatocellular carcinoma  The company anticipates top line results from the study in 2017 
Exelixis is also working with partner Roche Holding   OTC RHHBY   to commercialize Cotellic  the other drug in its portfolio  in the U S  We note the drug was approved in the U S  in Nov 2015 for the treatment for patients with a BRAF V600E or V600K mutation positive advanced melanoma  in combination with Zelboraf  In Jun 2016  Roche initiated a phase III trial  COTEZO  on a combination of Cotellic and atezolizumab in unresectable locally advanced or metastatic colorectal cancer 
2016 Guidance Updated
Exelixis expects operating expenses of around  250  270 million  This includes about  30 million of incremental  non cash  stock based compensation expenses EXELIXIS INC Price and Consensus 
   Our Take
Exelixis  second quarter results were impressive with the company reporting a narrower than expected loss and beating on revenues  Further  the FDA approval of Cabometyx is a major boost for the company  It is currently focused on launching Cabometyx tablets as a treatment for patients with advanced RCC  Initial uptake of the drug was encouraging and will propel the top line in the forthcoming quarters 
The successful commercialization of Cotellic in the U S  will also boost the top line  However  expenses are expected to increase as the company focuses on commercializing Cabometyx in the U S 
Exelixis currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the healthcare sector are Actelion Ltd   OTC ALIOF   and Biogen  Inc    NASDAQ BIIB    Both the stocks carry a Zacks Rank  2  Buy  ",2016-08-04,Zacks Investment Research,"https://www.investing.com/analysis/exelixis-(exel)-posts-narrower-loss-in-q2,-beats-on-revenues-200146160",200146160
129953,351468,BIIB,The Zacks Analyst Blog Highlights  Aratana Therapeutics  Dynavax Technologies  Heron Therapeutics And La Jolla Pharmaceutical,opinion,"For Immediate Release 

Chicago  IL   August 05  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Aratana Therapeutics  Inc      Dynavax Technologies Corporation     Heron Therapeutics  Inc     and La Jolla Pharmaceutical Co     

Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Thursday s Analyst Blog  

Drug Stock Earnings to Watch for Friday

How does the earnings picture look like as we near the tail end of the second quarter reporting cycle   are turning out to be less ominous than what was expected  With 73 5   as of Jul 29  of the S P 500 members having already reported results  this trend is expected to continue through the end of the earnings season  Of the 317 S P 500 companies that have reported as of Jul 29  72 9  topped earnings expectations while 53 6  surpassed revenue estimates 

Notwithstanding this  modest improvement   growth still remains elusive and Q2 is headed to be the fifth quarter in a row to record an earnings decline for the S P 500 index 

Now with several pharma and major biotech companies having released their earnings results  it is clear that Medical is one of the few sectors witnessing earnings and revenue growth this season  Our Q2 scorecard shows that 63 5  of the Medical sector have reported results with a blended beat of 75 8   the percentage of companies that have beaten both EPS as well as revenue estimates  with the sector recording 5 4  earnings growth on revenue growth of 10 5  

Per our  report  Medical is one of the six sectors expected to record earnings growth in Q2 

This is also corroborated by the second quarter performance of some well known names in the Medical sector  Companies like Johnson   Johnson  NYSE JNJ   Novartis  Abbott  Biogen  NASDAQ BIIB   Amgen  NASDAQ AMGN   AbbVie  Bristol Myers  and Celgene  NASDAQ CELG  have surpassed expectations  and some among these even raised their outlook for the year  However  the biggest drag was biotech major Gilead Sciences  NASDAQ GILD   The company barely managed to beat earnings by a penny and even cut its product sales guidance for the year 

Still  several mid  and small sized pharma and biotech companies are yet to report Q2 results  Let s take a sneak peek at four such companies 

Will These Drug Stocks Pull a Surprise 

Pet therapeutics company  Aratana Therapeutics  Inc     is focused on licensing  developing and commercializing innovative biopharmaceutical products for companion animals  This Leawood  KS based company has a decent track record  The company has beaten estimates in three of the last four quarters with an average positive surprise of 10 69   Aratana currently carries a Zacks Rank  3  The stock s Zacks Rank  3 when combined with an  of 0 00  makes surprise prediction uncertain  The company will report second quarter results on Aug 5 

   

Headquartered in Berkeley  CA  Dynavax Technologies Corporation     is a biopharmaceutical company focused on the discovery and development of vaccines and therapeutics  Dynavax s track record so far has been mixed with the company surpassing expectations on two occasions  while missing estimates in the other two  Overall  the company has delivered a negative surprise of 4 19   This Zacks Rank  3  Hold  stock also has an ESP of 0 00  making a surprise prediction difficult this quarter  The company is expected to release Q2 results on Aug 5 

   

Based in Redwood City  CA  Heron Therapeutics  Inc     is a biotechnology company focused on the development of novel  patient focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain  Heron s track record has also been mixed with the company surpassing expectations on two occasions  while missing the same on the other two  Heron currently has a Zacks Rank  4  Sell  and an ESP of  3 13   As it is  we caution against Sell rated stocks   4 or  5  going into an earnings announcement  The company is expected to release Q2 results on Aug 5 

   

San Diego  CA based La Jolla Pharmaceutical Co     is a biopharmaceutical company focused on the discovery  development and commercialization of innovative treatments for patients suffering from life threatening diseases  La Jolla s performance has been mostly disappointing with the company missing expectations in three of the last four quarters with an average negative surprise of 9 18   Though the stock s Zacks Rank  3 increases the predictive power of the ESP  it also has an ESP of 0 00   making a surprise prediction uncertain this quarter  The company is expected to report second quarter results on Aug 5 

   

Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days   

Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact
	Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-08-04,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-aratana-therapeutics,-dynavax-technologies,-heron-therapeutics-and-la-jolla-pharmaceutical-200146367",200146367
129954,351469,BIIB,Zacks com Featured Highlights  AngloGold Ashanti  Biogen  QUALCOMM  Tallgrass Energy GP And Steel Dynamics,opinion,"For Immediate Release

Chicago  IL   August 05  2016   Stocks in this week s article include  AngloGold Ashanti Ltd      Biogen  NASDAQ BIIB  Inc      QUALCOMM Inc      Tallgrass Energy GP  LP    and Steel Dynamics Inc      

Screen of the Week of Zacks Investment Research 5 Best PEG Stocks for Lucrative Value Investing 

Value investors with varied risk appetite are most unlikely to hit upon the price earnings to growth  PEG  ratio as an investment option among a number of other popular metrics like price earnings  P E   price sales or price book value  P B   This is because they often find this ratio complicated considering the limitations in calculating the future earnings growth potential of a stock 

But  in a year full of volatility  it is pointless to ponder on methods which don t consider a stock s future growth rate while calculating its intrinsic merit  Yardsticks such as dividend yield  P E or P B are most commonly used to single out whether a stock is trading at a discount 

But will a discount based on these multiples ensure success  What if there is a dearth of catalysts to propel growth even though the stock is at a discount right now  In such a case  even if you buy a stock at less than its fair value  you might still end up paying more  And here comes the importance of this not so popular but crucial value investing metric  the PEG ratio 

The PEG ratio is defined as   Price  Earnings   Earnings Growth Rate

A lower PEG ratio is always better for value investors 

While P E fails to identify a true value stock  PEG helps to find the intrinsic value of a stock 

There are some drawbacks to using the PEG ratio though  It doesn t consider the very common situation of changing growth rates such as the forecast of the first three years at a very high growth followed by a sustainable but lower growth rate in the long term 

Hence  PEG based investing can turn out to be even more rewarding if some other relevant parameters are also taken into consideration 

Here are the screening criteria for a winning strategy 

PEG Ratio less than X Industry Median

 P E Ratio  using F1  less than X Industry Median 
	 For more accurate valuation purpose  

Zacks Rank of 1 Strong Buy  or 2  Buy   whether good market conditions or bad  stocks with a Zacks Rank  1  Strong Buy  or  2  Buy  have a proven history of success  

Market Capitalization greater than  1 Billion  This helps us to focus on companies that have strong liquidity 

Average 20 Day Volume greater than 50 000  A substantial trading volume ensures that the stock is easily tradable  

Percentage Change F1 Earnings Estimate Revisions  4 Weeks  greater than 5   Upward estimate revisions add to the optimism  suggesting further bullishness  

Value Score of less than or equal to B   Our research shows that stocks with a Style Score of  A  or  B  when combined with a Zacks Rank  1 or 2 offer the best upside potential 

Here are 5 of the 18 stocks that qualified the screening 

AngloGold Ashanti Ltd        This gold mining and exploration company currently carries a Zacks Rank  1 and a Value Style Score  B   The company also has an impressive expected five year growth rate of 27 6  

Biogen Inc        This popular name in the biopharma market works on innovative therapies in the field of serious neurological  autoimmune  and rare diseases  The company can be an impressive value investment pick with its Zacks Rank  2 and Value Style Score  B   Apart from a discounted PEG and P E  the stock also has an impressive expected five year growth rate of 10 2  

QUALCOMM Inc        QUALCOMM is a digital communications products and services company with business spread out in China  South Korea  Taiwan  and the U S  This Zacks Rank  2 and Value Style Score  B  company also has an impressive expected five year growth rate of 10 8  

Tallgrass Energy GP  LP      This provider of crude oil transportation to customers in Wyoming and Colorado can also be an impressive value investment pick with its Zacks Rank  1 and Value Style Score  A  

Steel Dynamics Inc        This manufacturer and seller of steel products in the U S  holds a Zacks Rank  2 and a Value Style Score  A   The company has delivered an earnings surprise of 3 57  in its last reported quarter with a trailing 12 month earnings beat of 12 29  

Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and backtesting software 

The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out 

  

Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  

Disclosure  Performance information for Zacks  portfolios and strategies are available at     

Zacks Restaurant Recommendations   In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector  

Sign up now for your free trial today and start picking better stocks immediately  And with the backtesting feature  you can test your ideas to see how you can improve your trading in both up markets and down markets  Don t wait for the market to get better before you decide to do better  Start learning how to be a better trader today  


Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  

About Screen of the Week 

Zacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine  But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use  Each week  Zacks Profit from the Pros free email newsletter shares a new screening strategy  Learn more about it here 

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Contact  Jim Giaquinto
	Company  Zacks com
	Phone  312 265 9268
	Email  

Visit  

Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer    

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-08-04,Zacks Investment Research,"https://www.investing.com/analysis/zacks.com-featured-highlights:-anglogold-ashanti,-biogen,-qualcomm,-tallgrass-energy-gp-and-steel-dynamics-200146362",200146362
129956,351471,BIIB,Merrimack  MACK  Q2 Loss Wider Than Expected  Sales Top ,opinion,"Merrimack Pharmaceuticals  Inc    NASDAQ MACK   reported a loss of 40 cents per share in the second quarter of 2016  wider than the Zacks Consensus Estimate of 34 cents 

Quarter in Detail
Total revenue came in at  33 7 million  up from  21 3 million reported last quarter  and comfortably beat the Zacks Consensus Estimate of  26 1 million 
In Oct 2015  Merrimack Pharma s first product  Onivyde  gained approval in the U S   in combination with fluorouracil  5 FU  and leucovorin  for the treatment of patients suffering from metastatic adenocarcinoma of the pancreas  who were previously treated with Gemzar based therapy  The drug was subsequently launched in the U S  on Oct 26 
Further  the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  has given a positive opinion on the approval of Onivyde 
Onivyde sales in the reported quarter amounted to  12 9 million  up 29  sequentially  We note that the drug was added to the National Comprehensive Cancer Network  NCCN  2016 Clinical Practice Guidelines in Oncology as a category I Treatment Option for patients with metastatic pancreatic adenocarcinoma who have previously been treated with Gemzar based therapy 
Merrimack Pharma earned collaboration revenues of  19 3 million  up 70 9  sequentially 
Research and development expenses were  41 million  up 24 7   General and administrative expenses were also up 16 2  to  20 7 million 
 
 MERRIMACK PHAR Price and EPS Surprise
   Pipeline Update
Currently  Merrimack Pharma is evaluating Onivyde in a phase II study for previously untreated front line metastatic pancreatic cancer  Data from the phase II study are expected in 2017 
The company also initiated a phase I study on MM 151  in combination with Onivyde plus 5 FU and leucovorin  in patients with RAS wild type metastatic colorectal cancer as well as a phase I study to evaluate the safety and tolerability of MM 151  in combination with seribantumab  in patients with heregulin positive tumors  Apart from these studies  the company also commenced a trial on MM 151  in combination with MM 141  in patients with IGF 1 positive tumors  and in combination with a MEK inhibitor  trametinib  in patients with KRAS NRAS mutant tumors 
A phase II study  HERMIONE  on MM 302 for HER2 positive metastatic breast cancer is ongoing and results are expected in 2017  The trial is designed to support a potential accelerated approval application to the FDA  In addition  a phase II trial on MM 141 for the treatment of patients with front line metastatic pancreatic cancer who have high serum levels of free IGF 1 is also ongoing and results are expected in 2018 
Outlook
The company anticipates research and development and selling  general and administrative expenses in the range of  243 5 million to  263 5 million in 2016  compared with its earlier projection of  263 5  283 5 million 
Our Take
Merrimack Pharma reported a wider than expected loss in the second quarter as expenses continued to increase  Nevertheless  uptake of Onivyde has been strong and should boost the top line  going forward  Inclusion of the drug in the NCCN pathway should prove to be a big boost for the company and accelerate patient access to the drug 
Merrimack Pharma carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Actelion Ltd    OTC ALIOF    Agenus Inc   and Biogen  NASDAQ BIIB  Inc    All the three stocks carry a Zacks Rank  2  Buy  ",2016-08-05,Zacks Investment Research,"https://www.investing.com/analysis/merrimack-(mack)-q2-loss-wider-than-expected,-sales-top-200146440",200146440
129959,351474,BIIB,Intercept  ICPT  Reports Narrower than Expected Q2 Loss,opinion,Shares of Intercept Pharmaceuticals  Inc    NASDAQ ICPT   were down 5  after the company reported second quarter 2016 results  The company posted a loss of  3 14 per share in the second quarter of 2016  narrower than the Zacks Consensus Estimate of a loss of  3 76 but wider than the year ago loss of  1 99 The company generated revenues of  5 5 million  down significantly from  0 4 million in the year ago quarter and much higher than the Zacks Consensus Estimate of  61 000 Quarter in DetailIn May 2016  Intercept s lead drug  Ocaliva  was granted accelerated approval in the U S   in combination with UDCA  for the treatment of primary biliary cholangitis  PBC    previously known as primary biliary cirrhosis   in adults with inadequate response to UDCA or as monotherapy in adults who are intolerant to UDCA  The FDA has approved Ocaliva under its accelerated approval program based on a reduction in alkaline phosphatase  ALP   since an improvement in survival or disease related symptoms has not been established yet  Continued approval in this indication may be contingent upon the verification and description of clinical benefit in confirmatory studies The company generated net sales of  75 000 in the second quarter  Research and development expenses shot up 46 1  year over year to  41 3 million primarily due to increased staff and respective expenses as well as higher activities related to the research and development program for Ocaliva General and administrative expenses increased to  42 3 million from  21 0 million in the year ago quarter driven by infrastructure expansion to support corporate and pre commercial activities related to Ocaliva  along with increased market research for supporting pre launch activities in preparation for commercialization INTERCEPT PHARM Price and EPS Surprise   2016 OutlookIntercept expects operating expenses near the lower end of the previously provided range of  360 million to  400 million  higher in the second half   These expenses would support continued clinical development programs for Ocaliva in PBC  nonalcoholic steatohepatitis  NASH  and Primary Sclerosing Cholangitis  PSC   increased manufacturing activities  continued development of INT 767 and other preclinical programs  as well as commercial activities in the U S  and pre commercial activities internationally  The company is also gearing up for an initial launch in key European countries in 2017 Pipeline UpdateA phase IV study  COBALT on Ocaliva is ongoing for confirmatory outcomes  A marketing authorisation application for the product for the treatment of PBC was accepted by the European Medicines Authority  EMA  in Jun 2015 and is currently under review  A decision is expected around 2016 end Meanwhile  Intercept is evaluating Ocaliva for other indications including NASH and PSC  The company initiated a phase III study  REGENERATE  on Ocaliva for the treatment of non cirrhotic NASH in patients with advanced liver fibrosis  Enrolment is currently ongoing and the study would be fully enrolled by the first half of 2017 while interim results are expected in 2019 Intercept also initiated a phase II study  CONTROL  Combination OCA aNd sTatins for monitoRing Of Lipids   on OCA  The study is being conducted to evaluate the effect of OCA  in combination with statin therapy  on lipid metabolism in patients with NASH  Enrolment in the study is expected to be completed by 2016 end  A double blind phase II study  AESOP  for PSC is also ongoing  Enrolment in the AESOP study for the PSC indication is expected to be complete by the end of this year  Apart from these  the company initiated a phase I study on INT 767 and expects to complete the study by 2016 end Our TakeIntercept s narrower than expected loss in the second quarter of 2016 was encouraging  The FDA s approval of Ocaliva for PBC in May 2016 was a major boost for Intercept and will improve the company s growth prospects  A potential approval in Europe around 2016 end will further boost Intercept s portfolio and enable the company to record its first international sales in 2017  However  expenses are expected to remain high as the company invests in commercial activities related to Ocaliva Intercept currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Actelion Limited   OTC ALIOF    Agenus Inc    NASDAQ AGEN   and Biogen Inc    NASDAQ BIIB    All three stocks carry a Zacks Rank  2  Buy  ,2016-08-07,Zacks Investment Research,https://www.investing.com/analysis/intercept-(icpt)-reports-narrower-than-expected-q2-loss-200146656,200146656
129987,351502,BIIB,The Zacks Analyst Blog Highlights  Biogen  Gilead  AbbVie  Amgen And Celgene,opinion,"For Immediate Release

	Chicago  IL   July 28  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include   Biogen  NASDAQ BIIB      Gilead     AbbVie     Amgen  NASDAQ AMGN       and Celgene  NASDAQ CELG      

	Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Wednesday s Analyst Blog  

Biotech Stock Roundup  Q2 Earnings Beats

	Earnings season for the biotech sector has kicked off with two big biotech names  Biogen    and Gilead     reporting second quarter results  Meanwhile  companies like AbbVie    and Amgen     provided updates on their pipeline efforts 

Recap of the Week s Most Important Stories
	1  Two major biotech companies reported second quarter results over the last few days   Biogen and Gilead  First a look at Biogen s results   Biogen s second quarter results were pretty good with the company surpassing earnings expectations by a huge margin and beating on revenues as well 

	The company also raised its outlook for the year  However  Biogen s CEO announced that he will be stepping down once a successor is identified  Read more     
	Meanwhile  Gilead s results were mixed with the company beating on earnings by a penny and revenues falling short of expectations  Moreover  Gilead cut its product sales outlook for the year  Read more     with its hepatitis C virus  HCV  segment under pressure 
	2  AbbVie  which will be reporting second quarter results later this week  came out with quite a few updates on the pipeline and regulatory front  The company s extended release once daily version of HCV treatment  Viekira Pak  gained FDA approval  Viekira XR is approved for the treatment of patients with chronic genotype 1  GT1  HCV  including those with compensated cirrhosis  Child Pugh A  
	Additionally  AbbVie is a step closer to gaining EU approval for a 12 week regimen of Viekirax with ribavirin for genotype 4  GT4  chronic HCV infected adult patients with or without compensated cirrhosis  with the CHMP issuing a positive opinion 
	AbbVie also entered into a clinical trial collaboration with Bristol Myers under which the safety  tolerability and efficacy of AbbVie s investigational biomarker specific antibody drug conjugate rova T  rovalpituzumab tesirine  will be evaluated in combination with Bristol Myers  Opdivo and Opdivo   Yervoy regimen for the treatment of relapsed extensive stage small cell lung cancer  SCLC   Rova T became a part of AbbVie s pipeline following the recent Stemcentrx acquisition 
	3  Celgene    has decided it will not seek marketing approval for the expansion of the label of its blockbuster drug  Revlimid  as maintenance treatment in a certain type of diffuse large B cell lymphoma  DLBCL  patients  The decision is based on data from a phase III study   while patients on Revlimid showed an improvement in progression free survival  an interim analysis revealed that no benefit was seen in the Revlimid arm where overall survival is concerned 
	4  Amgen also provided some updates on the pipeline front  Firstly  the company and its partner  UCB  have filed for FDA approval of their experimental osteoporosis treatment  romosozumab  The other update came from the biosimilar front   Amgen and partner Allergan  NYSE AGN pa  said that their biosimilar version of cancer treatment  Herceptin  trastuzumab  fared well in a late stage study  We note that Amgen has nine biosimilars in its pipeline and recently got a favorable FDA advisory panel recommendation for its Humira biosimilar 

	Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days  

	Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

	Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

	Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-07-27,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-biogen,-gilead,-abbvie,-amgen-and-celgene-200144706",200144706
129988,351503,BIIB,2 Large Cap Drug Stocks To Watch For Earnings  ABBV   MRK ,opinion,Q2 earnings season has picked up pace with 208 S P 500 members  accounting for 50 5  of the index s total market capitalization  having reported results While total earnings for these 208 index members are down 4 7  from the year ago quarter  revenues are up 0 4  year over year  with 73 1  beating earnings estimates and 51 9  surpassing top line expectations However  with growth remaining problematic  Q2 is on track to be the 5th quarter in a row of earnings declines for the S P 500 index How have Drug Stocks Fared So Far Quite a few major pharma and biotech companies have reported results so far with performance being mixed  While it was a  beat and raise  quarter for companies like Johnson   Johnson   NYSE JNJ    Amgen Inc    NASDAQ AMGN   and Biogen  Inc    NASDAQ BIIB    Gilead Sciences  Inc    NASDAQ GILD    a big name in the biotech sector  lowered its product sales outlook Meanwhile  a look at our  report  as of Jul 27  2016  shows that 36 5  of Medical companies  within the S P 500 index  have reported results with earnings declining 0 3  from the year ago period while revenues are up 12 6   The Medical sector is expected to be among the better performing sectors in Q2 with earnings expected to grow 2 3  on revenue growth of 7 7  On Jul 29  two major large cap drug stocks will be reporting second quarter results  Let s see how these companies are placed ahead of the scheduled announcements North Chicago  IL based AbbVie Inc    NYSE ABBV    which will be reporting results before the market opens tomorrow  has a pretty good track record with the company surpassing earnings expectations in three of the last four quarters and reporting in line results in the remaining quarter  On its first quarter call  AbbVie had guided towards second quarter earnings per share of  1 19    1 21  AbbVie s flagship drug  Humira  should drive growth along with cancer treatment  Imbruvica  However  hepatitis C virus  HCV  treatment  Viekira  will continue to be impacted by the addition of liver injury warnings to the labels of AbbVie s HCV treatments as well as the presence of new competition in the market AbbVie currently has a Zacks Rank  3  Hold  and an  of 0 00   which makes surprise prediction difficult  Read more    ABBVIE INC Price and EPS Surprise   Large cap pharma stock  Merck   Co  Inc    NYSE MRK   will also be reporting second quarter results tomorrow before the market opens  The Kenilworth  NJ based company s performance has been pretty impressive with the company beating earnings expectations consistently  However  will the company beat estimates again this quarter MERCK   CO INC Price and EPS Surprise   Merck s Earnings ESP  which was previously 0 00  and is now a negative 1 09   when combined with Zacks Rank  3 makes surprise prediction difficult  Genericization as well as the impact of the Venezuelan financial crisis will continue to be headwinds for Merck this quarter while contribution from new products like Keytruda should increase  Read more      Stay tuned and check later on our full write up on earnings releases of these stocks Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-07-28,Zacks Investment Research,https://www.investing.com/analysis/2-large-cap-drug-stocks-to-watch-for-earnings:-abbv---mrk-200144615,200144615
129989,351504,BIIB,UCB  UCBJF  Posts 1H16 Results  Reaffirms 2016 Guidance,opinion,UCB S A   reported results for the first six months of 2016  Revenues were up 5  year over year at constant exchange rates  CER  to  2 0 billion   1 8 billion  driven by strong sales of the company s main products   Cimzia  Vimpat and Neupro All growth rates mentioned below are on a year over year basis and at CER Quarterly HighlightsCimzia sales soared 24  to  602 million driven by expanded patient access for inflammatory tumor necrosis factor mediated diseases Vimpat sales surged 18  to  379 million on the back of strong demand in the epilepsy indication  Neupro  approved for the treatment for Parkinson s disease and restless legs syndrome  generated sales of  143 million  up 12  However  sales of anti epileptic drug  Keppra  declined 8  to  354 million due to the impact of different shipment patterns Pipeline UpdateUCB continues to progress with the candidates in its pipeline  The company  along with Amgen Inc    NASDAQ AMGN    submitted a Biologics License Application  BLA  for romosozumab in the U S  for the treatment of osteoporosis in postmenopausal women at increased risk of fracture Moreover  the company  in collaboration with Biogen Inc    NASDAQ BIIB    initiated a phase IIb program on dapirolizumab pegol for the treatment of systemic lupus erythematosus  Results from the study are expected in the second half of 2018 UCB SA Price   Outlook MaintainedUCB reiterated its guidance for 2016  The company expects revenues of approximately  4 0  4 1 billion and core earnings per share of  2 90  3 20 Our TakeUCB s first half 2016 results were impressive  wherein solid revenue growth was driven by the company s main products  We are encouraged by UCB s efforts on growing its epilepsy portfolio with launch of Briviact in the U S  and the EU  as well as the approval of Vimpat in Japan UCB currently carries a Zacks Rank  3  Hold   Nektar Therapeutics   NASDAQ NKTR   is a better ranked stock in the health care sector  sporting a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-07-28,Zacks Investment Research,"https://www.investing.com/analysis/ucb-(ucbjf)-posts-1h16-results,-reaffirms-2016-guidance-200144969",200144969
129990,351505,BIIB,What Awaits MNK   Other Drug Stocks This Earnings Season ,opinion,The Q2 earnings season is picking up pace and so far  we have seen better than expected results from the majority of the companies  Going into specifics  approximately 317 companies  accounting for 73 5  of the S P 500 index s total market capitalization  have come up with earnings results  with a whopping 72 9  beating bottom line expectations and 53 6  topping revenues  However  earnings recorded a 3 3  year over year decline due to 0 9  lower revenues Although Q2 is still on track to be the fifth quarter in a row to record negative earnings growth  the rate of growth has improved modestly last quarter s levels  Similarly  even though estimates for the third quarter are still moving south  the magnitude of the fall has declined considerably  By the end of this week  nearly 87  members of the benchmark index will have reported quarterly numbers  making the earnings picture even clearer How did the Medical Sector Perform Medical is one of the few sectors that are poised to record positive earnings growth this quarter  Encouragingly  the sector has exceeded expectations based on the quarterly results of 63 5  member companies  Average earnings in the sector recorded 5 4  growth on 10 5  higher revenues  resulting in a blended beat of 75 8   Bigwigs like Johnson   Johnson   NYSE JNJ    Novartis AG   NYSE NVS   and Abbott Laboratories   NYSE ABT   were able to beat expectations comfortably  In the biotech space  Gilead Sciences   NASDAQ GILD   missed on revenues in spite of an earnings beat  while Biogen   NASDAQ BIIB   topped bottom line estimates  AbbVie   NYSE ABBV   and Merck   Co  Inc    NYSE MRK   were also able to top earnings expectations Let s see what s in store for a few medical companies that are expected to declare quarterly numbers on Aug 2 Dublin  Ireland based Mallinckrodt plc   NYSE MNK   is expected to report third quarter fiscal 2016 results  Mallinckrodt s strategic acquisitions over the last few years have broadened its portfolio significantly and boosted growth prospects  The company s Specialty Brands segment is performing well and should help the company meet the raised outlook for fiscal 2016  The company has an impressive track record having beaten estimates in all of the last four quarters  bringing the positive average earnings surprise to 12 4   However  the combination of Mallinckrodt s Zacks Rank  2  Buy  and 0 00   makes surprise prediction difficult for this quarter   Read more   MALLINCKRODT PL Price and EPS Surprise   Prothena Corporation plc   NASDAQ PRTA   is expected to report second quarter 2016 results  It is a development stage biotechnology company focused on the development of novel protein immunotherapies that can be used for the treatment of diseases involving amyloid or cell adhesion  Prothena s track record has been has dismal so far  Over the four trailing quarters  the company s earnings have missed estimates thrice  managing to beat only once  bringing the average negative earnings surprise to 6 51   Although Prothena s Zacks Rank  3  Hold  increases the predictive power of ESP  its 0 00  ESP makes surprise prediction difficult   Read more   PROTHENA CP PLC Price and EPS Surprise   Pfizer Inc    NYSE PFE   is scheduled to report second quarter 2016 results  Pfizer has been strengthening its product portfolio and its pipeline through strategic acquisitions and licensing deals  The company has an impressive track record  Its earnings have surpassed expectations in each of the last four quarters  with an average positive surprise of 12 80   In the last reported quarter  Pfizer posted a positive earnings surprise of 21 82   The company currently carries a Zacks Rank  3  However  its Earnings ESP of 0 00  has come down from  1 61   The present combination of Pfizer s Zacks Rank  3 and 0 00  ESP makes surprise prediction difficult   Read more   PFIZER INC Price and EPS Surprise   Sagent Pharmaceuticals  Inc    NASDAQ SGNT   is expected to report second quarter results  The company recently entered into a definitive merger agreement with Nichi Iko Pharmaceutical Co   under which the latter will acquire Sagent for a total consideration of approximately  736 million  The company has a mixed track record  having beaten expectations twice  missed them once and met them once in the last four trailing quarter  Although the company s Zacks Rank  2 increases the predictive power of ESP  its 0 00  ESP makes surprise prediction difficult this quarter SAGENT PHARMA Price and EPS Surprise   Stay tuned  Check later for our full write up on earnings releases of these stocks ,2016-07-31,Zacks Investment Research,https://www.investing.com/analysis/what-awaits-mnk---other-drug-stocks-this-earnings-season-200145375,200145375
129991,351506,BIIB,Pharma ETFs Soaring On Solid Q2 Earnings ,opinion,"Like the past several quarters  the healthcare sector has impressed with strong Q2 earnings  This is especially true as total earnings for 71 9  of the sector s total market capitalization are up 5 4  on revenue growth of 10 5   Earnings and revenue beat ratios of 87 9  and 81 8   respectively  also look encouraging  In fact  healthcare is one of the best performing sectors in terms of earnings growth trailing autos  construction  conglomerates and utilities Among the most notable players  Johnson   Johnson   NYSE JNJ   was the first major drug company to report earnings on July 19  followed by Eli Lilly and Company   NYSE LLY   and Bristol Myers Squibb Company   NYSE BMY   on July 26 and July 28  respectively  Two other major U S  drug companies   Merck   NYSE MRK   and Pfizer   NYSE PFE     reported on July29 and August 2  respectively  These industry primes posted solid results  raising their full year outlook that boosted investor confidence in the space Johnson and Johnson Earnings in FocusThe world s biggest maker of healthcare products continued its long streak of earnings beat  Earnings per share came in at  1 74  7 cents ahead of the Zacks Consensus Estimate and 1 8  higher than the year ago figure  Revenues were up 3 9  year over year to  18 5 billion and edged past the Zacks Consensus Estimate of  17 9 billion  read    Johnson   Johnson raised its guidance for 2016  The company now expects revenues in the range of  71 5  72 2 billion compared with the previous forecast of  71 2  71 9 billion  Additionally  the earnings per share guidance has been raised from  6 53  6 68 to  6 63  6 73  The Zacks Consensus Estimate at the time of earnings release was  71 73 billion for revenues and  6 65 for earnings per share Pfizer Earnings in FocusThe U S  drug giant also topped the Zacks Consensus Estimate for both the top and the bottom line  and reiterated its guidance for 2016  Earnings per share of 64 cents and revenues of  13 1 billion were ahead of our estimates by 2 cents and  0 2 billion  respectively  Notably  earnings per share grew 14  while revenues jumped 11  year over year For 2016  Pfizer continues to expect earnings of  2 38  2 48 per share on revenues of  51  53 billion  The Zacks Consensus Estimate was  52 6 billion for revenues and  2 46 for earnings per share at the time of earnings release Merck Earnings in FocusEarnings per share came in at 93 cents  a penny ahead of the Zacks Consensus Estimate and 8 1  higher than the year ago earnings  Revenues inched up 1  year over year to  9 8 billion and were in line the Zacks Consensus Estimate Merck now expects earnings per share in the range of  3 67  3 77 and revenues in the band of  39 1  40 1 billion for 2016  The Zacks Consensus Estimate at the time of release was  3 72 for earnings per share and  39 6 billion for revenues  see    Meanwhile  Merck is also rumored to be interested in buying biotech major Biogen   NASDAQ BIIB   Bristol Myers Earnings in FocusBristol Myers reported earnings per share of 69 cents  outpacing our estimate by 2 cents and increasing 30  from the year ago quarter  Also  revenues rose 17  to  4 87 billion and edged past the Zacks Consensus Estimate of  4 63 billion Like other drug makers  the company also revised its earnings per share outlook upward to  2 55 to  2 65 from  2 50 to  2 60 for fiscal 2016  Our estimate of  2 63 at the time of the earnings announcement was within the guided range Eli Lilly Earnings in FocusEarnings of 86 cents at Eli Lilly beat the Zacks Consensus Estimate by a penny but came in 4  lower than the year ago earnings  Revenues grew 9  to  5 4 billion  ahead of our estimate of  5 1 billion  Eli Lilly maintained its 2016 earnings per share guidance at  3 50  3 60 and revenue guidance at 20 6  21 1 billion  The Zacks Consensus Estimate at the time of earnings release was  3 56 for earnings and  20 91 billion for revenues ETF AngleThe string of earnings beat and upbeat outlook boosted pharma stocks and ETFs despite the industry grappling with drug pricing issues  read    Below  we have highlighted the ETFs in detail PowerShares Dynamic Pharmaceuticals Portfolio Fund   WA PJP  This is by far the most popular choice in the pharma space that follows the Dynamic Pharmaceuticals Intellidex Index  The product has AUM of about  1 2 billion and sees good volume of around 159 000 shares a day  The fund charges 56 bps in fees and expenses from investors  Holding 23 stocks  the fund invests around 5  share each in the in focus five firms  The ETF gained about 3 9  over the past 5 days and has a Zacks ETF Rank of 3 or  Hold  rating with a High risk outlook  read    iShares U S  Pharmaceuticals ETF This ETF provides exposure to 39 pharma stocks by tracking the Dow Jones U S  Select Pharmaceuticals Index  The in focus firms are among the top six holdings in the basket accounting for a combined exposure of almost40  of total assets  suggesting heavy concentration  The product has  657 million in AUM and charges 44 bps in fees and expense  Volume is moderate as it exchanges about 42 000 shares a day  The fund has gained4 1  over the past 5 days and has a Zacks ETF Rank of 3 with a Medium risk outlook SPDR S P Pharmaceuticals ETF   HN XPH  This fund provides exposure to pharma companies by tracking the S P Pharmaceuticals Select Industry Index  With AUM of over  548 million  it trades in volume of around 196 000 shares a day and charges 35 bps in fees a year  In total  the product holds 39 securities with the in focus five firms taking around4 5  share each  The product was up 5 8  in the same period and has a Zacks ETF Rank of 3 with a High risk outlook VanEck Vectors Pharmaceutical ETF   LON PPH  This ETF follows the MVIS US Listed Pharmaceutical 25 Index and holds 26 stocks in its basket  Pfizer  Bristol Myers  Johnson   Johnson and Merck make up for over 5  share each while Eli Lilly accounts for 4 8  of assets  The product has amassed  265 3 million in its asset base and trades in a moderate volume of about 83 000 shares a day  Expense ratio came in at 0 36   The fund has surged2 5  over the past 5 days  It has a Zacks ETF Rank of 2 or  Buy  rating with a Medium risk outlook  read    

Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-08-03,Zacks Investment Research,https://www.investing.com/analysis/pharma-etfs-soaring-on-solid-q2-earnings-200145857,200145857
130023,351538,BIIB,Medical Stocks To Post Earnings This Week  ABT  BIIB  ALIOF ,opinion,As the first half of the year draws to a close  investors are looking forward to the second quarter earnings season  which kick started on a rather encouraging note earlier this month  As per our  report  approximately 32 S P 500 members  representing 7 6  of the index s total market capitalization  have reported quarterly results so far  Out of these  65 6  recorded an earnings beat  while 43 8  were able to top sales estimates  The recent turnaround in oil prices and fading effects of dollar strength led to modest negative revisions for the quarter  which in turn  may lead to better than expected results  However  total earnings are estimated to be down 5 9  on a year over year basis What Awaits Healthcare Stocks  Medical is one of the few sectors that are poised to report earnings growth this quarter  While the sector s second quarter earnings are projected to improve 0 5   revenues are expected to grow 7 7   Among the big names of the sector  Swiss oncology major Novartis AG   NYSE NVS   was able to beat estimates  Let s find out what s in store for a few companies scheduled to report results later this week Illinois based Abbott Laboratories   NYSE ABT   is scheduled to report second quarter results before the opening bell on Jul 20  The company has a diversified portfolio that was reshaped through strategic acquisitions divestitures in recent times  Abbott Labs has an impressive track record so far  having surpassed estimates in each of the four trailing quarters with an average earnings surprise of 3 17   Strengthening of the dollar against almost every other currency has been denting the company s performance over the past few quarters  However  strong first quarter results  along with an improving exchange rate outlook  led to a raised earnings guidance for 2016  Nevertheless  the combination of Abbott Labs  Zacks Rank  3  Hold  and a 0 00   makes surprise prediction difficult  read more    ABBOTT LABS Price and EPS Surprise   Multiple sclerosis  MS  market leader Biogen Inc    NASDAQ BIIB   is scheduled to report second quarter results on Jul 21  Biogen has beaten expectations in all of the past four quarters  bringing the average earnings surprise to 9 54   However  the company currently carries a Zacks Rank  3 and an Earnings ESP of  1 92   making it difficult to conclusively predict an earnings beat this quarter  The first progressive multifocal leukoencephalopathy  PML  related death of a patient using oral MS drug  Tecfidera  brought the drug under the spotlight and we expect investor focus to remain on the same  read more    BIOGEN INC Price and EPS Surprise   Switzerland based Actelion Ltd    OTC ALIOF   is scheduled to report first half results on Jul 21  The company boasts a leading franchise in pulmonary arterial hypertension with drugs like Tracleer  Ventavis  Veletri and Opsumit  The company has an impressive track record  having beaten expectations in each of the four quarters with an average beat of 12 37   The company currently carries a Zacks Rank  3  which when combined with its 0 00  Earnings ESP  makes surprise prediction difficult ACTELION LTD Price and EPS Surprise  ,2016-07-18,Zacks Investment Research,"https://www.investing.com/analysis/medical-stocks-to-post-earnings-this-week:-abt,-biib,-aliof-200142780",200142780
130024,351539,BIIB,Biotech Stock Roundup  Celgene In Immuno Oncology Deal  Zafgen Drops Lead Drug ,opinion,"This week  there were the usual regulatory and pipeline updates in the biotech sector  Biosimilars are taking center stage with quite a few companies in the news this week related to their progress in this area 
Meanwhile  Zafgen   NASDAQ ZFGN    a company focused on obesity and complex metabolic disorders  has decided to suspend the development of its lead pipeline candidate  In other news  immuno oncology continues to attract deals with Celgene   NASDAQ CELG   agreeing to shell out up to  2 561 billion under a collaboration agreement Recap of the Week s Most Important Stories1  The obesity market continues to pose challenges with yet another company deciding to change its priorities  Zafgen said that it has decided to suspend the development of its lead pipeline candidate  beloranib  and to refocus its resources on the development of a second generation MetAP2 inhibitor  ZGN 1061  in severe and complicated obesity Beloranib was placed on full clinical hold in Dec 2015 by the FDA  Following discussions with the agency  Zafgen decided that the obstacles  costs and development timelines for beloranib did not justify additional investment in the program  Zafgen also announced a workforce reduction A few weeks back  Arena  which has a marketed obesity drug in its portfolio  had announced a cut in its workforce and said that it would be shifting its priorities to its proprietary clinical stage pipeline  Though Arena did get some good news this week    the FDA granted approval for a new once daily formulation of the company s obesity drug  Belviq   2  Amgen   NASDAQ AMGN    which is facing the prospect of biosimilar competition for many of its core drugs  got a bit of a breather recently with the FDA issuing a complete response letter  CRL  for Sandoz s biosimilar version of Amgen s Neulasta  pegfilgrastim   Amgen is already facing biosimilar competition from Zarxio   Sandoz s biosimilar version of Neupogen while an FDA advisory panel recently voted in favor of approving Sandoz s biosimilar version of Enbrel Amgen itself is working on bringing biosimilars to market and recently got a favorable vote from an FDA advisory panel for its biosimilar version of AbbVie s   NYSE ABBV   top selling drug  Humira  Last week  Amgen signed up with Japanese company  Daiichi Sankyo  to commercialize nine biosimilars in Japan including the biosimilar version of Humira  Read more    3  Biogen   NASDAQ BIIB   is also progressing with the development of biosimilars  Samsung  KS 005930  Bioepis  the joint venture between Samsung BioLogics and Biogen  said that its regulatory application for SB5  a biosimilar version of Humira  has been accepted for review 4  Celgene has entered into a strategic worldwide collaboration with immuno oncology focused company Jounce  Celgene could end up paying up to  2 561 billion for the deal which provides Celgene with the option to jointly develop and commercialize Jounce s lead candidate  JTX 2011  and additional innovative immunotherapies targeting B cells  T regulatory cells and tumor associated macrophages  This deal once again outlines the growing importance of immuno oncology Meanwhile  Celgene gained EU approval for the use of its blockbuster cancer drug  Revlimid in adult patients with relapsed or refractory mantle cell lymphoma  a rare sub type of aggressive non Hodgkin s lymphoma  Read more    5  Juno   NASDAQ JUNO    in the news recently related to its lead pipeline candidate being in and out of a clinical hold in the U S   acquired a privately held company last week  With the acquisition of RedoxTherapies  Juno has gained an exclusive license to vipadenant  a small molecule adenosine A2a  A2a  receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers  Juno plans to evaluate vipadenant in combination with engineered T cells PerformanceMEDICAL BIOMED GENETICS Industry Price IndexThe NASDAQ Biotechnology Index was down 1  over the last five trading days  While Biogen gained 2 6  over the last five trading days  Vertex declined 2 5  during this period  Over the last six months  Amgen was up 7 4  while Alexion lost 20 8   See the last biotech stock roundup here    
What s Next in the Biotech World Quite a few major biotech companies will be reporting second quarter results over the next few days including Biogen  Gilead   NASDAQ GILD    Vertex and Amgen Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-07-20,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stock-roundup:-celgene-in-immuno-oncology-deal,-zafgen-drops-lead-drug-200143091",200143091
130025,351540,BIIB,The Zacks Analyst Blog Highlights  Zafgen  Celgene  Amgen  AbbVie And Biogen,opinion,"For Immediate Release 

Chicago  IL   July 21  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Zafgen     Celgene  NASDAQ CELG      Amgen  NASDAQ AMGN      AbbVie    and Biogen  NASDAQ BIIB      

Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Wednesday s Analyst Blog  

Biotech Stock Roundup  Q2 Earnings on the Way

This week  there were the usual regulatory and pipeline updates in the biotech sector  Biosimilars are taking center stage with quite a few companies in the news this week related to their progress in this area 

Meanwhile  Zafgen      a company focused on obesity and complex metabolic disorders  has decided to suspend the development of its lead pipeline candidate  In other news  immuno oncology continues to attract deals with Celgene     agreeing to shell out up to  2 561 billion under a collaboration agreement Recap of the Week s Most Important Stories
	1  The obesity market continues to pose challenges with yet another company deciding to change its priorities  Zafgen said that it has decided to suspend the development of its lead pipeline candidate  beloranib  and to refocus its resources on the development of a second generation MetAP2 inhibitor  ZGN 1061  in severe and complicated obesity 
	Beloranib was placed on full clinical hold in Dec 2015 by the FDA  Following discussions with the agency  Zafgen decided that the obstacles  costs and development timelines for beloranib did not justify additional investment in the program  Zafgen also announced a workforce reduction 
	A few weeks back  Arena  which has a marketed obesity drug in its portfolio  had announced a cut in its workforce and said that it would be shifting its priorities to its proprietary clinical stage pipeline  Though Arena did get some good news this week    the FDA granted approval for a new once daily formulation of the company s obesity drug  Belviq 
	2  Amgen      which is facing the prospect of biosimilar competition for many of its core drugs  got a bit of a breather recently with the FDA issuing a complete response letter  CRL  for Sandoz s biosimilar version of Amgen s Neulasta  pegfilgrastim   Amgen is already facing biosimilar competition from Zarxio   Sandoz s biosimilar version of Neupogen while an FDA advisory panel recently voted in favor of approving Sandoz s biosimilar version of Enbrel 
	Amgen itself is working on bringing biosimilars to market and recently got a favorable vote from an FDA advisory panel for its biosimilar version of AbbVie s    top selling drug  Humira  Last week  Amgen signed up with Japanese company  Daiichi Sankyo  to commercialize nine biosimilars in Japan including the biosimilar version of Humira  Read more     
	3  Biogen    is also progressing with the development of biosimilars  Samsung  KS 005930  Bioepis  the joint venture between Samsung BioLogics and Biogen  said that its regulatory application for SB5  a biosimilar version of Humira  has been accepted for review 
	4  Celgene has entered into a strategic worldwide collaboration with immuno oncology focused company Jounce  Celgene could end up paying up to  2 561 billion for the deal which provides Celgene with the option to jointly develop and commercialize Jounce s lead candidate  JTX 2011  and additional innovative immunotherapies targeting B cells  T regulatory cells and tumor associated macrophages  This deal once again outlines the growing importance of immuno oncology 
	Meanwhile  Celgene gained EU approval for the use of its blockbuster cancer drug  Revlimid in adult patients with relapsed or refractory mantle cell lymphoma  a rare sub type of aggressive non Hodgkin s lymphoma  Read more     

Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days   

Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact
	Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-07-20,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-zafgen,-celgene,-amgen,-abbvie-and-biogen-200143299",200143299
130026,351541,BIIB,Biogen  BIIB  Stock Up On Q2 Earnings Beat  Raised Outlook,opinion,"Biotech company  Biogen  NASDAQ BIIB  Inc  s  shares were up more than 5  in pre market trading with the company surpassing earnings expectations by a wide margin  Revenues also surpassed expectations 
	The company reported second quarter 2016 earnings per share of  5 21  well above the Zacks Consensus Estimate of  4 69 and 23  above the year ago earnings 



	Sales came in at  2 9 billion  increasing 12  from the year ago period and surpassing the Zacks Consensus Estimate of  2 8 billion  Currency negatively impacted revenues by  44 million MS Franchise and Hemophilia Business Drive Revenues
	Oral multiple sclerosis  MS  drug Tecfidera  which grew 12  from the year ago period to  987 million  recorded a 4  sequential improvement in revenues  This included U S  sales of  780 3 million and ex U S  sales of  206 2 million 
	Second quarter Tysabri revenues increased 7  to  497 million  U S   304 9 million  ex U S   192 5 million  from the year ago period 
	Combined interferon revenues  Avonex and Plegridy   in the second quarter  were  728 million  U S   519 million  ex U S   209 3 million   up 6  from the year ago period and 9  sequentially  Avonex revenues declined 2  from the year ago period to  606 million 
	Plegridy contributed  123 million to second quarter 2016 revenues  up 16  sequentially 
	Anti CD20 revenues grew 3  from the year ago period to  349 million in the second quarter 
	Alprolix and Eloctate  Biogen s hemophilia treatments  recorded revenues of  80 million and  125 million  respectively  showing sequential growth of 7  and 16   respectively 
	R D spend declined 3 7  in the reported quarter to  473 million while SG A spend came in at  489 million  down 0 6  Raises 2016 Outlook
	Biogen raised its outlook for 2016 and now expects earnings of  19 70    20 00 per share on revenues of  11 2    11 4 billion  Earlier this year  the company had guided towards 2016 earnings of  18 30    18 60 per share on revenues of  11 1    11 3 billion  The Zacks Consensus estimate for revenues and earnings is currently  11 3 billion and  19 04 per share  respectively 
	Guidance includes contribution from the hemophilia business with the spin off expected in early 2017 
	The Board also authorized a share buyback program worth up to  5 billion  Biogen expects to execute the program over the next three years  Biogen still has about 1 3 million shares left under its Feb 2011 share repurchase program CEO to Step Down
	Biogen also announced that its Chief Executive Officer  George A  Scangos  will step down in the coming months after a successor is identified 


		BIOGEN INC Price


   


Our Take
	Biogen s second quarter results were impressive with the company surpassing earnings expectations by a huge margin  The stock  which has been under pressure on concerns regarding a slowdown in Tecfidera s growth rate as well as overall concerns regarding pricing in the biotech sector  saw its MS franchise recording a sequential improvement in performance  Investors should be cheered by this in addition to the raised outlook  The hemophilia franchise also performed well 
	Biogen is a Zacks Rank  3  Hold  stock  Some better ranked stocks in the health care sector include ANI Pharmaceuticals Inc   Innoviva  Inc   and Gilead Sciences Inc  NASDAQ GILD     While ANI and Innoviva are Zacks Rank  1  Strong Buy  stocks  Gilead is a Zacks Rank  2  Buy  stock 
	Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-07-20,Zacks Investment Research,"https://www.investing.com/analysis/biogen-(biib)-stock-up-on-q2-earnings-beat,-raised-outlook-200143279",200143279
130027,351542,BIIB,Medical Stocks Reporting Early Next Week   GILD  LLY   More ,opinion,"Q2 earnings season is gaining momentum with 103  as of Jul 21  of the S P 500 members having already reported results  With 56 3  of these members beating top line estimates and 68 9  surpassing bottom line expectations  
Admittedly  there are some signs of improvement in the aggregate earnings picture that are expected to lift hopes for the second half and thereafter  The quarterly results of some big names across sectors were not only better than expected  but also showed signs of real momentum  That said  earnings are headed south for the fifth quarter in a row  As the rest report Q2 results over the coming weeks  visibility should improve 
Notably  the Medical sector  which was among the best performing sectors in Q1  is again touted to feature on the best performers  list  The Medical sector is expected to be one of the seven sectors to record earnings growth in Q2  Earnings in the Medical sector are expected to grow 1 7  on revenue growth of 7 7   per our  article 
This fact cannot be refuted  Healthcare bellwether Johnson   Johnson   NYSE JNJ   kick started the season by posting a beat on both earnings and revenues  Moreover  the company has raised its earnings outlook for the year yet again  Among biotechs  Biogen Inc    NASDAQ BIIB   is the only major company to have released Q2 results  Biogen like Johnson   Johnson not only managed to beat earnings estimates by a wide margin  but also upped its guidance for the year 
Meanwhile  Novartis AG   NYSE NVS   and Abbott Laboratories   NYSE ABT   also posted encouraging results  beating on both fronts 
A number of pharma and biotech companies are yet to report Q2 results  Let s see what awaits these four medical stocks when they report earnings results early next week 
What to Expect from these Medical Stocks 
Biotech company  Gilead Sciences Inc    NASDAQ GILD   known for its presence in the hepatitis C virus  HCV  market because of its blockbuster HCV drugs  Sovaldi and Harvoni  has a pretty good track record with beats in three of the last four quarters  This Zacks Rank  2  Buy  stock  which has a positive  of 6 91   looks set to beat estimates in Q2  Focus will be on the performance of the HCV and HIV franchises given that the company has gained quite a few promising approvals over the last few quarters with an eye also on deals acquisitions  Moreover  Gilead s share buyback program should boost the bottom line  read more    
Gilead is scheduled to report Q2 results on Jul 25  after the market closes GILEAD SCIENCES Price and EPS Surprise   Another healthcare company looking up this earnings season is Eli Lilly and Company   NYSE LLY    The combination of Lilly s Zacks Rank  3  Hold  and  1 18  ESP makes us reasonably confident of an earnings beat this season  Lilly is set to report Q2 results on Jul 26  before the market opens  Lilly has an impressive track record when it comes to earnings  The company s earnings have surpassed expectations in three of the last four quarters 
Though existing products like Trajenta and Forteo as well as new products like Cyramza and Portrazza among others should boost top line growth  there are challenges in the form of generic competition faced by drugs like Alimta and Cialis in certain territories as well as competition from immuno oncology agents  Moreover  price revisions in Japan  effective Mar 1  will impact sales  Focus should be on the performance of recently launched moderate to severe plaque psoriasis treatment  Taltz  among other things  read more    LILLY ELI   CO Price and EPS Surprise   Pharmacy benefit manager  Express Scripts Holding Company s   NASDAQ ESRX   Zacks Rank  3 increases the predictive power of the ESP  However  it has a 0 00  ESP  which makes it difficult to predict an earnings beat when it reports its Q2 results on Jul 25  after the market closes  Express Scripts  track record has however been decent with the company having comfortably beaten expectations in three of the last four quarters 
For the second quarter  Express Scripts expects earnings in the range of  1 55  1 59 per share while adjusted claims are anticipated to be 312 million to 322 million  The company should continue to benefit from increased generic utilization  a shift toward mail orders  strong specialty growth and an aging population  Focus will remain on the status of Express Scripts  contract with Anthem  Inc    NYSE ANTM    read more    EXPRESS SCRIPTS Price and EPS Surprise   Chemed Corporation   NYSE CHE   purchases  operates and divests subsidiaries engaged in diverse business activities  Currently  the company operates through two wholly owned subsidiaries  VITAS Healthcare and Roto Rooter  This Cincinnati  OH based company has delivered encouraging performance in three of the last four quarters with an average beat of 2 70   However  the company s Zacks Rank  3 with an ESP of 0 00  makes a surprise prediction difficult this quarter 
Chemed is scheduled to release Q2 results on Jul 25  after the market closes CHEMED CORP Price and EPS Surprise  ",2016-07-21,Zacks Investment Research,"https://www.investing.com/analysis/medical-stocks-reporting-early-next-week:--gild,-lly---more-200143529",200143529
130028,351543,BIIB,Pharma Industry Outlook  Fundamentals Remain Strong,opinion,"It s been a rough start to the year for pharma and biotech with several factors weighing on the sector including media and political focus on the high price of drugs  mixed first quarter results  slower than expected new product launches  and increasing competition  Macroeconomic factors have also been playing a role in the sector s performance 
The impact of these issues is more prominent in biotech stocks with the NASDAQ Biotechnology Index declining 14 5  year to date  YTD  
However  the sector s fundamentals remain strong and mergers and acquisitions  M As   product approvals and positive data flow should act as catalysts 
M As to Pick Pace 
With the major price correction that has resulted in reasonable valuations  we could see several M A agreements being announced as the year progresses  So far in 2016  some of the announced completed acquisitions include Shire Baxalta  Bristol Myers  BMY  Padlock  and Pfizer  NYSE PFE   PFE  Anacor among others  Currently  Sanofi  PA SASY   SNY  is looking to acquire cancer focused Medivation   we expect a bidding war as Medivation has signed confidentiality agreements with many firms including Sanofi 
Meanwhile  small bolt on acquisitions will continue  In licensing activities and collaborations for the development of pipeline candidates have also increased significantly  Several pharma companies are focusing on in licensing mid to late stage pipeline candidates that look promising  instead of developing a product from scratch  which involves a lot of funds and time 
Small biotech companies are open to such deals with most of them finding it challenging to raise cash  thereby making it difficult to survive and continue with the development of promising pipeline candidates  Therefore  it makes sense to seek deals with pharma companies sitting on huge piles of cash 
We recommend biotech stocks that have attractive pipeline candidates or technology that can be used for the development of novel therapeutics  Therapeutic areas attracting a lot of interest include central nervous system disorders  hepatitis C virus  HCV  and immunology inflammation 
Another highly lucrative area is immuno oncology as these therapies have the potential to change the treatment paradigm for cancer    they basically use the natural capability of the patient s own immune system to fight the cancer  Major players in this field include Bristol Myers  AstraZeneca  Merck  NYSE MRK  and Roche 
Deals targeting immuno oncology are being inked by companies like Pfizer  Merck KGaA  Bristol Myers  AstraZeneca and Incyte  Companies like Kite are also advancing in this area 
Another trend being witnessed is the divestment of non core business segments  Companies like Pfizer  UCB  Novartis  Glaxo and AstraZeneca have all been a part of this trend  The monetization of non core assets allows these companies to focus on their areas of expertise 
Restructuring activities are also gaining momentum as large pharma companies look to cut costs and streamline operations  Most of these companies are re evaluating their pipelines and discontinuing programs with an unfavorable risk benefit profile  
New Products Should Gain Traction in 2H16
Highly awaited new products that gained approval last year should contribute significantly to revenues  Some of the important new product approvals include Vertex s cystic fibrosis treatment  Orkambi  Amgen s  AMGN  heart failure treatment  Corlanor  Pfizer s cancer treatment  Ibrance  Novartis  psoriasis treatment  Cosentyx  PCSK9 inhibitors   Amgen s Repatha and Sanofi Regeneron s Praluent  Roche s advanced melanoma treatment  Cotellic and Gilead s Genvoya  HIV  
Meanwhile  so far in 2016  the FDA has approved 15 new drugs including Epclusa  HCV  Ocaliva  rare  chronic liver disease   Zinbryta  multiple sclerosis   Tecentriq  urothelial cancer   Venclexta  chronic lymphocytic leukemia in patients with a specific chromosomal abnormality   Taltz  moderate to severe plaque psoriasis   Cinqair  severe asthma  and Zepatier  HCV  among others  The FDA also expanded the label of cancer drugs like Kyprolis  Imbruvica and Xalkori 
Biosimilars Gaining Importance
With the FDA approving the first biosimilar in the U S   Zarxio  a biosimilar version of Amgen s blockbuster drug  Neupogen   the floodgates have opened  While biosimilars have been available in the EU for quite a while  there was no regulatory pathway for biosimilars in the U S 
Biosimilars should cut healthcare costs and provide a large number of patients with access to much needed biologic treatments  According to information provided by Express Scripts  about  250 billion could be saved in the next decade  2014   2024  if biosimilars for 11 products including Neupogen  Avastin  Epogen  Humira  Neulasta  Remicade and Rituxan are approved  According to the company  Neupogen biosimilars alone represent potential savings of about  5 7 billion 
Apart from Novartis  companies like Merck  Amgen  NASDAQ AMGN   Pfizer  Biogen  NASDAQ BIIB   BIIB  and Allergan  NYSE AGN pa  are targeting the highly lucrative biosimilars market 
Drug Pricing to Remain in Focus 
With Presidential candidates  policymakers  the media and the general public focusing on the high price tags for drugs  the drug pricing issue is not likely to die down easily at least not until elections are over 
According to the Oct 2015 Kaiser Health Tracking poll  affordability of prescription drugs remains at the top of the public s priority list for the President and Congress   focus should be on ensuring the affordability of high cost drugs to people who need them and taking steps to lower prescription drug prices 
So  drug companies may find it a bit difficult to justify their high prices by citing the years and funds that go into bringing new treatments to market and the need to invest in R D to bring additional treatments to market 
Earnings Trends
Looking at consensus earnings expectations  the Medical sector  which had performed well in 1Q16  is expected to see earnings growth of 1 7  and revenue growth of 7 7  in Q2  While results will continue to be affected by currency movement  new products should start contributing significantly and increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector  Performance should improve as the year progresses 
Zacks Industry Rank
Within the Zacks Industry classification  pharma and biotech are broadly grouped into the Medical sector  one of 16 Zacks sectors  and further sub divided into four industries at the expanded level  large cap pharma  med biomed gene  med drugs and med generic drugs 
We rank all the 260 plus industries in the 16 Zacks sectors based on the earnings outlook and fundamental strength of the constituent companies in each industry 
As a point of reference  the outlook for industries with Zacks Industry Rank  88 and lower is  Positive   between  89 and  176 is  Neutral  and  177 and higher is  Negative  
The Zacks Industry Rank for large cap pharma is  74   32 for med generic drugs   85 for med biomed gene and  89 for med drugs  Analyzing the Zacks Industry Rank for different medical segments  it is obvious that the outlook is Positive for large cap pharma  med generic drugs and med biomed gene while Neutral for med drugs 
OPPORTUNITIES
While negative currency impact and pricing pressure remain headwinds  many companies which are out of the worst of the genericization phase  should continue to see a sustained improvement in results this year  Cost cutting  share buybacks  and new products should support growth 
Among pharma stocks  companies like Bristol Myers is a Zacks Rank  1  Strong Buy  stock while Johnson   Johnson  NYSE JNJ   JNJ  is a Zacks Rank  2  Buy  stock 
In the biotech space  we are positive on Gilead  Incyte and AVEO   all are Zacks Rank  2 stocks  Within the generic segment  Mylan  NASDAQ MYL   Allergan  Mallinckrodt  NYSE MNK  and Supernus are Zacks Rank  2 stocks 
WEAKNESSES
We recommend avoiding names that offer little growth or opportunity for a take out  These include companies which are developing drugs that are likely to face regulatory hurdles 
Pharma companies that currently carry a Zacks Rank  4  Sell  or Zacks Rank  5  Strong Sell  include Sanofi and Glaxo  Among biotech stocks  companies like Medivation and Lexicon are Zacks Rank  5 stocks  and others like Juno  JUNO  and Epizyme are Zacks Rank  4 stocks ",2016-07-22,Zacks Investment Research,https://www.investing.com/analysis/pharma-industry-outlook:-fundamentals-remain-strong-200143855,200143855
130029,351544,BIIB,Zacks Industry Outlook Highlights  Bristol Myers  Pfizer  Sanofi  Amgen And Biogen,opinion,"For Immediate Release

Chicago  IL   July 25  2016   Today  Zacks Equity Research discusses Pharma  including  Bristol Myers     Pfizer  NYSE PFE      Sanofi  PA SASY      Amgen  NASDAQ AMGN      and Biogen  NASDAQ BIIB     

Industry  Pharma

Link  

It s been a rough start to the year for pharma and biotech with several factors weighing on the sector including media and political focus on the high price of drugs  mixed first quarter results  slower than expected new product launches  and increasing competition  Macroeconomic factors have also been playing a role in the sector s performance 

The impact of these issues is more prominent in biotech stocks with the NASDAQ Biotechnology Index declining 14 5  year to date  YTD  

However  the sector s fundamentals remain strong and mergers and acquisitions  M As   product approvals and positive data flow should act as catalysts 

M As to Pick Pace 

With the major price correction that has resulted in reasonable valuations  we could see several M A agreements being announced as the year progresses  So far in 2016  some of the announced completed acquisitions include Shire Baxalta  Bristol Myers     Padlock  and Pfizer     Anacor among others  Currently  Sanofi     is looking to acquire cancer focused Medivation   we expect a bidding war as Medivation has signed confidentiality agreements with many firms including Sanofi 

Meanwhile  small bolt on acquisitions will continue  In licensing activities and collaborations for the development of pipeline candidates have also increased significantly  Several pharma companies are focusing on in licensing mid to late stage pipeline candidates that look promising  instead of developing a product from scratch  which involves a lot of funds and time 

Small biotech companies are open to such deals with most of them finding it challenging to raise cash  thereby making it difficult to survive and continue with the development of promising pipeline candidates  Therefore  it makes sense to seek deals with pharma companies sitting on huge piles of cash 

We recommend biotech stocks that have attractive pipeline candidates or technology that can be used for the development of novel therapeutics  Therapeutic areas attracting a lot of interest include central nervous system disorders  hepatitis C virus  HCV  and immunology inflammation 

Another highly lucrative area is immuno oncology as these therapies have the potential to change the treatment paradigm for cancer    they basically use the natural capability of the patient s own immune system to fight the cancer  Major players in this field include Bristol Myers  AstraZeneca  Merck  NYSE MRK  and Roche 

Deals targeting immuno oncology are being inked by companies like Pfizer  Merck KGaA  Bristol Myers  AstraZeneca and Incyte  Companies like Kite are also advancing in this area 

Another trend being witnessed is the divestment of non core business segments  Companies like Pfizer  UCB  Novartis  Glaxo and AstraZeneca have all been a part of this trend  The monetization of non core assets allows these companies to focus on their areas of expertise 

Restructuring activities are also gaining momentum as large pharma companies look to cut costs and streamline operations  Most of these companies are re evaluating their pipelines and discontinuing programs with an unfavorable risk benefit profile 

New Products Should Gain Traction in   2H16

Highly awaited new products that gained approval last year should contribute significantly to revenues  Some of the important new product approvals include Vertex s cystic fibrosis treatment  Orkambi  Amgen s    heart failure treatment  Corlanor  Pfizer s cancer treatment  Ibrance  Novartis  psoriasis treatment  Cosentyx  PCSK9 inhibitors   Amgen s Repatha and Sanofi Regeneron s Praluent  Roche s advanced melanoma treatment  Cotellic and Gilead s Genvoya  HIV  

Meanwhile  so far in 2016  the FDA has approved 15 new drugs including Epclusa  HCV  Ocaliva  rare  chronic liver disease   Zinbryta  multiple sclerosis   Tecentriq  urothelial cancer   Venclexta  chronic lymphocytic leukemia in patients with a specific chromosomal abnormality   Taltz  moderate to severe plaque psoriasis   Cinqair  severe asthma  and Zepatier  HCV  among others  The FDA also expanded the label of cancer drugs like Kyprolis  Imbruvica and Xalkori 

Biosimilars Gaining Importance

With the FDA approving the first biosimilar in the U S   Zarxio  a biosimilar version of Amgen s blockbuster drug  Neupogen   the floodgates have opened  While biosimilars have been available in the EU for quite a while  there was no regulatory pathway for biosimilars in the U S 

Biosimilars should cut healthcare costs and provide a large number of patients with access to much needed biologic treatments  According to information provided by Express Scripts  about  250 billion could be saved in the next decade  2014   2024  if biosimilars for 11 products including Neupogen  Avastin  Epogen  Humira  Neulasta  Remicade and Rituxan are approved  According to the company  Neupogen biosimilars alone represent potential savings of about  5 7 billion 

Apart from Novartis  companies like Merck  Amgen  Pfizer  Biogen     and Allergan  NYSE AGN pa  are targeting the highly lucrative biosimilars market 

Want the latest recommendations from Zacks Investment Research  Today  you can download7 Best Stocks for the Next 30 Days   

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact

Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-07-24,Zacks Investment Research,"https://www.investing.com/analysis/zacks-industry-outlook-highlights:-bristol-myers,-pfizer,-sanofi,-amgen-and-biogen-200143930",200143930
130061,351576,BIIB,4 Stocks That Crushed The Biotechnology ETF  IBB  This Week,opinion,"Although biotech has been a strong area of the market for quite some time  the past year has been a brutal stretch for this segment  In fact  the top biotechnology ETF    has seen a loss of roughly 25 5  in the past 52 weeks  making for a massive underperformance when compared to the broad markets in the same time frame 

And while there has been a bit of a comeback lately  the last few trading days have certainly put an end to that  as IBB has lost nearly five percent in the past five trading sessions 

But which stocks in particular have been driving this horrendous return as of late for this popular ETF  The following stocks are definitely the culprits as they have all lost more than the overall ETF with several slumping more than 10  in the time frame  Let s take a quick look at a few of the biggest contributors to IBB s underperformance as of late below 

Biogen  NASDAQ BIIB    

Biogen shares have been in trouble lately thanks to a weak report on its MS drug results  The Phase 2 trial failed to meet both its primary and secondary endpoints and shares of BIIB plunged as a result  see   



The stock remains a Zacks Rank  3  Hold   while it has a VGM Score of  A   so fundamentals are still looking promising for this stock despite the recent drop 

Alexion Pharma   

More poor drug trial news to report back on  as ALXN suffered from a Phrase III letdown in its Soliris drug  as this missed its primary efficacy endpoint  Shares sold off significantly as a result of this release  and it is especially disappointing since it comes in Phase III  see    



The stock is currently a Zacks Rank  4  sell  while it has Value and Growth Style Scores of  D  so there are definitely better prospects out there in the biotechnology world right now 

BioMarin Pharma   

And BioMarin struggled as its main competitor in the Muscular Dystrophy market  Sarepta     saw some somewhat promising news from the FDA  This hope for SRPT along with BioMarin s woes in the space  lead many investors to continue their exodus out of BMRN shares which was to IBB investors  detriment yet again  see    



This stock is also a Zacks Rank  3  hold   but the quarterly Earnings ESP is plunging  coming in at  13 5   This suggests that the most recent estimates have been pretty weak for BMRN and that a downgrade may be on the horizon if this trend continues 

Regeneron   

This was a bit of a surprise addition to the list of biggest losers on the week  as REGN actually reported positive results from a Phase III trial  However  the perception of the broader space has swung negative and REGN was unable to escape the downturn  falling more than 7  on the week  See  for more info  



Arguably shares had run up a bit too high in the preceding month and this was just a bit of a snap back to reality  Still  this remains a decent choice in the space thanks to solid EPS growth projections and a Zacks Rank  3  Hold   And unlike others on the list  it has been seeing some relatively positive news lately 

Bottom Line

The four components listed above make up roughly one fifth of the total exposure in IBB so they are bound to have a big impact on its overall performance  Investors in IBB will definitely need to see a turnaround here before the fund can make a comeback  and return to its storied past 



However  you could easily argue that the boom is starting to fade in the biotech sector  and especially so given the coming political headwinds for the space  Given that  it may be time to look to other  for now  at least until the firestorm dies down in this often volatile corner of the stock market 

Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-06-10,Zacks Investment Research,https://www.investing.com/analysis/4-stocks-that-crushed-the-biotechnology-etf-(ibb)-this-week-200135347,200135347
130062,351577,BIIB,5 Attractive Biotechnology Stocks For Healthy Long Term Returns ,opinion,"Introduction
I am a fervent believer that investors are best served by investing towards a specific investment objective that suits their own unique goals  objectives and risk tolerance  In other words  investing is not always trying to get the highest possible total returns  If that were true  no one would have ever invested in bonds  CDs or other fixed income instruments 
Personally  my primary current investment objective is focused on achieving a reliable and growing dividend income stream  That doesn t mean that I don t expect capital appreciation to go along with my dividends  because I do  However  capital appreciation is secondary to what I need right now  Therefore  I am content to allow it to happen over the long run  This means being willing to accept the ups and downs of short term market volatility that is sure to occur  as long as my dividend income keeps increasing 
On the other hand  I also have discretionary assets that I can invest in or utilize outside of my core portfolio  So even though I favor dependable dividend paying stocks  I still am attracted to examining exciting growth investments with money I am both willing to and can afford to lose  However  even though I m willing to lose with these discretionary assets  I don t expect to  Instead  my objective is to generate significantly higher total returns than my prudent dividend growth portfolio is realistically capable of achieving 
More simply stated  I still appreciate powerful and exciting growth stocks because I understand they are capable of generating significantly higher returns  However  I am also cognizant of the fact that the risk associated with achieving those returns is also significantly higher  Consequently  I am just as adamantly  or even more so  focused on valuation when investing in growth stocks as I am with prudent blue chip dividend paying stocks 
One of the most difficult things for the value oriented investor to accept and embrace is the reality that the best value comes from stocks that are temporarily out of favor  In this regard  the value investor must also recognize that hitting the perfect bottom can only be accomplished with luck  Therefore  the intelligent value investor is willing to assume some short term pain in order to achieve long term gain 
The biotechnology sector contains many exciting growth stocks  But most importantly  as it relates to this article  the sector has recently been out of favor  which I believe has created bargain investment opportunities  Consequently  I offer the following 5 biotechnology stocks as attractive looking research candidates primarily for growth or long term total return  However  2 of these 5 biotech stocks offer attractive dividends in conjunction with above average growth and attractive value 
3 Research Worthy Biotechnology Growth Stock Candidates
These first 3 biotechnology research candidates are offered as pure growth stocks  None of them pay a dividend  and I don t expect any of them to initiate one anytime soon  However  I believe all 3 appeared attractive relative to their long term growth potential 
On each candidate  I present a short business description courtesy of S P Capital IQ  followed by a series of  and FUN Graphs highlighting some important fundamental metrics  Importantly  what I am presenting here is the recommendation that these stocks are worthy of further scrutiny if growth for high total return is your objective 
Biogen Inc  NASDAQ BIIB 

 Biogen Inc  discovers  develops  manufactures  and delivers therapies for the treatment of neurodegenerative diseases  hematologic conditions  and autoimmune disorders  It offers TECFIDERA  AVONEX  and PLEGRIDY to treat relapsing forms of multiple sclerosis  MS   TYSABRI to treat relapsing forms of MS and Crohn s disease  and FAMPYRA to improve walking ability for patients with MS 
The company also provides ELOCTATE to treat adults and children with hemophilia A for control of bleeding episodes  ALPROLIX to treat adults and children with hemophilia B for control of bleeding episodes  RITUXAN for treating non Hodgkin s lymphoma  rheumatoid arthritis  and chronic lymphocytic leukemia  CLL   as well as two forms of ANCA associated vasculitis  GAZYVA for the treatment of patients with previously untreated CLL  and FUMADERM to treat plaque psoriasis 
The company s products in Phase III development stage comprise ZINBRYTA  a monoclonal antibody for the treatment of relapsing remitting MS  Aducanumab for Alzheimer s disease  and ISIS SMNRx for spinal muscular atrophy  Its Phase II clinical trial products include Anti LINGO for optic neuritis and MS  Amiselimod for multiple autoimmune indications  BAN2401 and E2609 for Alzheimer s disease  Raxatrigine for trigeminal neuralgia  rAAV XLRS for X linked juvenile retinoschisis  and BG00011 for idiopathic pulmonary fibrosis  Its Phase I clinical trial products comprise Dapirolizumab pegol for systemic lupus erythematosus  SLE   ISIS   DMPK for myotonic dystrophy  Anti BDCA2 for SLE  Anti alpha synuclein for Parkinson s disease  and BIIB063 for sjogren s syndrome 
The company has a strategic research collaboration with Ionis Pharmaceuticals  Inc  It offers products primarily through its own sales force  marketing groups  and third parties worldwide  The company was formerly known as Biogen Idec Inc  and changed its name to Biogen Inc  in March 2015 
Biogen Inc  was founded in 1978 and is headquartered in Cambridge  Massachusetts  

Biogen has produced an impressive record of earnings growth since fiscal year 2008  However  it should be noted that growth expectations for 2016 and 2017 are below historical norms 

When monthly closing stock prices are brought into the equation we initially see a very high correlation between price and earnings over the long run  However  we also see a significant disconnect where price became significantly ahead of earnings justified valuation for most of 2013  2014  and the first half of 2015  However  it appears that expectations for slower growth took the wind out of the price sails 

Nevertheless  in spite of the drastic correction in stock price  the long term returns that Biogen generated for shareholders has significantly outperformed the average company 

Biogen has produced excellent gross and net profit margins over the last 10 years  Even though growth is expected to slow somewhat  I find it comforting that net profit margins are strong and improving 

I also like the fact that Biogen s return on equity has been increasing at a rapid rate 

Consensus long term earnings estimates and growth rates are currently forecast to be below historical norms  However  Biogen does have an exciting pipeline of potential future blockbuster drugs  but  there is high risk as to whether they will generate future profits or not 

Celgene Corporation  NASDAQ CELG 

 Celgene Corporation discovers  develops  and commercializes therapies to treat cancer and inflammatory diseases worldwide  It markets REVLIMID  an oral immunomodulatory drug for multiple myeloma  myelodysplastic syndromes  MDS   and mantle cell lymphoma  ABRAXANE  a solvent free chemotherapy product to treat breast  non small cell lung  pancreatic  and gastric cancers  POMALYST IMNOVID to treat multiple myeloma  and OTEZLA  a small molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis  psoriasis  ankylosing spondylitis  Beh et s disease  atopic dermatitis  and ulcerative colitis 
The company s products also include VIDAZA  a pyrimidine nucleoside analog to treat intermediate 2 and high risk MDS  and chronic myelomonocytic leukemia  as well as acute myeloid leukemia  AML   THALOMID for the patients with multiple myeloma and erythema nodosum leprosum  ISTODAX to treat cutaneous and peripheral T cell lymphoma  and FOCALIN  FOCALIN XR  and RITALIN products  Its clinical stage products include OTEZLA for the treatment of various immune inflammatory diseases  sotatercept for the treatment of renal anemia  beta thalassemia and MDS  luspatercept for beta thalassemia and MDS  CC 486 to treat MDS  AML  and solid tumors  CC 122 and CC 220 to treat hematological and solid tumor cancers  and inflammation and immunology diseases  PDA 002 for the treat diabetic foot ulcers and peripheral neuropathy  and PNK 007 for hematological malignancies treatment 
The company has collaborative agreements with Novartis Pharma AG  Acceleron Pharma  Agios Pharmaceuticals  Inc   Epizyme Inc   Sutro Biopharma  Inc   bluebird bio  Inc   FORMA Therapeutics Holdings  LLC  Acetylon Pharmaceuticals  Inc   OncoMed Pharmaceuticals  Inc   NantBioScience  Inc   AstraZeneca PLC  Lycera Corp   Juno Therapeutics  Inc   TriNetX  Inc   Triphase Accelerator Corporation  and Nurix  Inc 
The company was founded in 1980 and is headquartered in Summit  New Jersey  

Of the research candidates presented in this article  Celgene  represents my personal favorite  Historical earnings growth has been extremely strong and very consistent since 2008  The only real negative is the company s high debt to capital 

Once again  we see a clear correlation between monthly closing stock prices and earnings over the long run  But most importantly  it is clear that the best times historically to invest in Celgene has been when its price has been below its earnings justified level as it is today 

Celgene represents another example of significant long term performance in spite of its current undervaluation  and the fact that it was moderately overvalued at the beginning of 2008  This clearly illustrates the power of compounding earnings growth at high levels 

Celgene has produced strong gross and net margins historically  However  net profit margins weaken somewhat in 2015  but remain high relative to the average company  On the other hand  net profit margin has improved to almost 32  through the March quarter of 2016  not shown on the graph  

Celgene also produces high returns on equity 

Analysts continue to expect Celgene to grow future long term earnings in excess of 20  per annum 

Jazz Pharmaceuticals  NASDAQ JAZZ 

 Jazz Pharmaceuticals Public Limited Company  a biopharmaceutical company  identifies  develops  and commercializes pharmaceutical products for various medical needs in the United States  Europe  and internationally 
The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology oncology  It markets Xyrem  an oral solution for the treatment of cataplexy and excessive daytime sleepiness  EDS  in patients with narcolepsy  Erwinaze to treat acute lymphoblastic leukemia  ALL   Defitelio for the treatment and prevention of severe hepatic veno occlusive disease  a potentially life threatening complication of hematopoietic stem cell transplantation  and Prialt  an intrathecally administered infusion of ziconotide for the management of severe chronic pain 
The company also develops JZP 110  a late stage investigational compound  which is in phase III clinical trail for the treatment of EDS in narcolepsy and obstructive sleep apnea  and JZP 386  a deuterium modified analog of sodium oxybate that is completed phase I clinical trail for use in patients with narcolepsy  In addition  it sells psychiatry and other products 
The company is headquartered in Dublin  Ireland  

Jazz Pharmaceuticals went from negative earnings in 2009 to positive earnings in 2010  Consequently  long term earnings growth rate has been distorted by aberrantly high earnings growth in 2010 and 2011  Nevertheless  historical earnings growth since 2013 has exceeded 20  per annum 

When monthly stock prices are included  we once again see a high correlation between earnings growth and stock price over the long term  However  in this case  the orange earnings justified valuation line is drawn at a market average P E ratio of only 15 

Nevertheless  Jazz has produced exciting long term returns for its shareholders 

Jazz has produced exceptional gross margins since 2007  However  net profit margins have been a little more erratic  Nevertheless  I consider this an intriguing research candidate at its current valuation 

The return on equity for Jazz is troubling  Therefore  I consider this my least favorite of the 5 research candidates presented  However  it s hard to argue with its past performance 

Consensus estimates for future growth are very strong   approaching 19  per annum  However  there is scant history available to analyze on this company  and analysts don t have a great record of forecasting earnings over the last couple of years 

2 Research Worthy Biotechnology Dividend Growth Stock Candidates
These next 2 biotechnology research candidates offer both above average growth and above average current dividend yield and dividend growth potential  Consequently  I consider both attractive long term total return opportunities with the benefit of a solid and growing dividend yield 
AbbVie Inc  NYSE ABBV 

 AbbVie Inc  discovers  develops  manufactures  and sells pharmaceutical products worldwide  The company offers HUMIRA  a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases  IMBRUVICA an oral therapy for the treatment of chronic lymphocytic leukemia  and VIEKIRA PAK  an interferon free therapy  with or without ribavirin  for adults with genotype 1 chronic hepatitis  including those with compensated cirrhosis 
It also provides Kaletra  an anti HIV 1 medicine used with other anti HIV 1 medications as a treatment that maintains viral suppression in HIV 1 patients  Norvir  a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV 1  and Synagis to prevent respiratory syncytial virus infection in high risk infants 
In addition  the company offers AndroGel  a testosterone replacement therapy for males diagnosed with symptomatic low testosterone  Creon  a pancreatic enzyme therapy for exocrine pancreatic insufficiency  Synthroid to treat hypothyroidism  and Lupron  a product for the palliative treatment of prostate cancer  and endometriosis and central precocious puberty  as well as for the treatment of patients with anemia 
Further  it provides Duopa and Duodopa  a levodopa carbidopa intestinal gel to treat Parkinson s disease  Sevoflurane  an anesthesia product for human use  TriCor  Trilipix  and Niaspan treat metabolic conditions characterized by high cholesterol and or high triglycerides  and Zemplar to treat secondary hyperparathyroidism 
The company sells its products to wholesalers  distributors  government agencies  health care facilities  specialty pharmacies  and independent retailers from its distribution centers and public warehouses  AbbVie Inc  has strategic collaboration with C2N Diagnostics  Calico Life Sciences LLC  Infinity Pharmaceuticals  Inc   Ablynx NV  Galapagos NV  and Alvine Pharmaceuticals  Inc 
The company was incorporated in 2012 and is based in North Chicago  Illinois  

AbbVie has a short history after being spun off of Abbott Labs  However  the company has produced consistent above average earnings growth and its dividend has been increased and grown each year since it was an independent company 

Even though the history is short  AbbVie s stock price has moved in tandem with earnings over the long run  Moreover  periods of both overvaluation and undervaluation are vividly revealed  Currently  I consider this high quality biotechnology company currently undervalued  My only reservation is the company s high debt to capital ratio 

Even though AbbVie s performance history is short  the company has outperformed the S P 500 on both capital appreciation and dividend income  I think this is noteworthy considering how strong the performance of the average company was during this timeframe 

AbbVie has produced strong and attractive gross and net margins since it was an independent company  However  it s also important to recognize that Humira is their flagship drug and it has produced more than 50  of sales and 70  of profits  However  the company s pipeline is interesting  and Humira is expected to be a solid contributor for years to come 

AbbVie s return on equity has been very high stakes in most part due to Humira 

Consensus estimates for AbbVie s future earnings growth is significantly above average  Couple this with an extremely attractive current dividend yield and AbbVie appears to be a very solid investment 

Amgen Inc  NASDAQ AMGN 

 Amgen Inc   a biotechnology company  engages in discovering  developing  manufacturing  and delivering human therapeutics worldwide  It offers products for the treatment of illness in the areas of oncology hematology  cardiovascular  inflammation  bone health  nephrology  and neuroscience 
The company s principal products include Neulasta  a pegylated protein to decrease the incidence of infection associated with chemotherapy induced febrile neutropenia in cancer patients  NEUPOGEN  a recombinant methionyl human granulocyte colony stimulating factor for reducing the incidence of infection for patients with non myeloid malignancies  and Enbrel to treat rheumatoid arthritis  plaque psoriasis  and psoriatic arthritis 
Its principal products also comprise EPOGEN to treat a lower than normal number of red blood cells caused by chronic kidney disease  CKD  in patients on dialysis  Aranesp for treating anemia  XGEVA for the prevention of skeletal related events  Prolia to treat postmenopausal women with osteoporosis  Repatha for the treatment of high cholesterol  and Sensipar Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis 
The company s other marketed products include Kyprolis  a proteasome inhibitor to treat patients with multiple myeloma and small cell lung cancer  Nplate  a thrombopoietic compound  Vectibix  a human monoclonal antibody  and BLINCYTO for the treatment of patients with Philadelphia chromosome negative relapsed or refractory B cell precursor acute lymphoblastic leukemia  It also develops various products that are in various clinical trials 
The company serves pharmaceutical wholesale distributors  and physicians or their clinics  dialysis centers  hospitals  and pharmacies  as well as consumers  It has collaborative agreements with Xencor  Inc   UCB  Novartis AG  and Bayer  DE BAYGN  HealthCare Pharmaceuticals Inc 
Amgen Inc  was founded in 1980 and is headquartered in Thousand Oaks  California  

Amgen is widely considered as the mother of all biotechnology companies  This biotech giant has produced strong and steady earnings growth over its entire history  and the initiation of a dividend in 2011 that has grown significantly is also a plus 

Clearly  Amgen s stock price has closely tracked its earnings achievement  After becoming moderately overvalued in 2015  the recent negativity towards biotechnology in general appears to have brought the stock to attractive valuations again 

Amgen has been a solid performer that has generated higher returns than the S P 500 and a higher level of cumulative dividend income even though it s only paid a dividend since 2011 

Not only have Amgen s gross and net profit margins been high  they have also been very consistent 

Likewise  Amgen has achieved a very attractive and consistently high return on equity historically 

Long term estimates for Amgen s future earnings growth are above average  Adding the additional opportunity of an above average and growing dividend income makes Amgen look very solid at current valuations 

Summary and Conclusions
The best of breed companies in the biotechnology sector have a legacy of producing exceptional long term shareholder returns  However  the sector has recently gone out of favor which I believe has created a significant long term opportunity for investors willing to take the risk 
There are many that believe that biotechnology represents the future and promise of medicine  Some even believe that chemical driven pharmaceuticals have run their course  The 5 research candidates presented in this article appear to be worthy of further research and due diligence for those interested in above average long term returns  and are willing to take the risk associated with investing in biotech 
Considering that the stock market in general appears rather frothy  attractively valued biotechnology stocks appear to be worth a closer look considering the retrenchment in price most have experienced recently  But most importantly  biotechnology stocks today appear to offer something for everyone  If income is your objective  there are 2 here that are worth looking at  If growth is your objective  I believe all 5 of these candidates are worth a closer look 
Disclosure  Long ABBV
Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation ",2016-06-12,Chuck Carnevale,https://www.investing.com/analysis/5-attractive-biotechnology-stocks-for-healthy-long-term-returns-200135418,200135418
130063,351578,BIIB,The Zacks Analyst Blog Highlights  IShares Nasdaq Biotechnology  Biogen  Alexion Pharma  BioMarin Pharma And Regeneron,opinion,"For Immediate Release 

Chicago  IL   June 13  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include iShares Nasdaq Biotechnology     Biogen  NASDAQ BIIB      Alexion Pharma     BioMarin Pharma    and Regeneron     

Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Friday s Analyst Blog  

4 Stocks That Crushed the Biotech ETF  IBB  Last Week

Although biotech has been a strong area of the market for quite some time  the past year has been a brutal stretch for this segment  In fact  the top biotechnology ETF    has seen a loss of roughly 25 5  in the past 52 weeks  making for a massive underperformance when compared to the broad markets in the same time frame 

And while there has been a bit of a comeback lately  the last few trading days have certainly put an end to that  as IBB has lost nearly five percent in the past five trading sessions 

But which stocks in particular have been driving this horrendous return as of late for this popular ETF  The following stocks are definitely the culprits as they have all lost more than the overall ETF with several slumping more than 10  in the time frame  Let s take a quick look at a few of the biggest contributors to IBB s underperformance as of late below 

Biogen     

Biogen shares have been in trouble lately thanks to a weak report on its MS drug results  The Phase 2 trial failed to meet both its primary and secondary endpoints and shares of BIIB plunged as a result  see   

The stock remains a Zacks Rank  3  Hold   while it has a VGM Score of  A   so fundamentals are still looking promising for this stock despite the recent drop 

Alexion Pharma     

More poor drug trial news to report back on  as ALXN suffered from a Phrase III letdown in its Soliris drug  as this missed its primary efficacy endpoint  Shares sold off significantly as a result of this release  and it is especially disappointing since it comes in Phase III  see    

The stock is currently a Zacks Rank  4  sell  while it has Value and Growth Style Scores of  D  so there are definitely better prospects out there in the biotechnology world right now 

BioMarin Pharma     

And BioMarin struggled as its main competitor in the Muscular Dystrophy market  Sarepta  saw some somewhat promising news from the FDA  This hope for SRPT along with BioMarin s woes in the space  lead many investors to continue their exodus out of BMRN shares which was to IBB investors  detriment yet again  see    

This stock is also a Zacks Rank  3  hold   but the quarterly Earnings ESP is plunging  coming in at  13 5   This suggests that the most recent estimates have been pretty weak for BMRN and that a downgrade may be on the horizon if this trend continues 

Regeneron     

This was a bit of a surprise addition to the list of biggest losers on the week  as REGN actually reported positive results from a Phase III trial  However  the perception of the broader space has swung negative and REGN was unable to escape the downturn  falling more than 7  on the week  See  for more info  

Arguably shares had run up a bit too high in the preceding month and this was just a bit of a snap back to reality  Still  this remains a decent choice in the space thanks to solid EPS growth projections and a Zacks Rank  3  Hold   And unlike others on the list  it has been seeing some relatively positive news lately 

Bottom Line

The four components listed above make up roughly one fifth of the total exposure in IBB so they are bound to have a big impact on its overall performance  Investors in IBB will definitely need to see a turnaround here before the fund can make a comeback  and return to its storied past 

However  you could easily argue that the boom is starting to fade in the biotech sector  and especially so given the coming political headwinds for the space  Given that  it may be time to look to other  for now  at least until the firestorm dies down in this often volatile corner of the stock market 

Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days   

Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact
	Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-06-12,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-ishares-nasdaq-biotechnology,-biogen,-alexion-pharma,-biomarin-pharma-and-regeneron-200135619",200135619
130064,351579,BIIB,Stock Market News For June 16  2016,opinion,"Benchmarks ended in the red for the fifth consecutive session on Wednesday after the Fed opted to keep interest rate unchanged and raised concerns about number of hikes this year  Meanwhile  concerns over  Brexit  and decline in crude prices continued to weigh on investor sentiment  While the Dow and S P 500 witnessed a five day losing streak for the first time since early February while the Nasdaq registered identical losses for the first time since early April 
	For a look at the issues currently facing the markets  make sure to read today s  article 

	The Dow Jones Industrial Average  DJI  decreased 0 2  to close at 17 640 17  The S P 500 also fell 0 2  to close at 2 071 50  The tech laden Nasdaq Composite Index closed at 4 834 93  also losing 0 2   However  the fear gauge CBOE Volatility Index  VIX  declined 1 8  to settle at 20 14  A total of around 6 8 billion shares were traded on Wednesday  nearly in line with the last 20 session average  Advancers outpaced declining stocks on the NYSE  For 59  stocks that advanced  38  declined 

	After concluding its two day policy meeting yesterday  the Federal Open Market Committee  FOMC  decided to keep federal funds rate unchanged between 0 25  and 0 5  following concerns regarding weak jobs data  The FOMC stated   The pace of improvement in the labor market has slowed while growth in economic activity appears to have picked up  Although the unemployment rate has declined  job gains have diminished   Also the Fed chairwoman Janet Yellen said that  Brexit  is likely to have  consequences for economic and financial conditions in global financial markets  

	Meanwhile  the Fed s decision to stick with its 2016 rate path also appears to be on shaky ground with just six of the 17 policymakers forecasting one rate hike this year  compared to only one Fed official take a similar view in March  Yellen said   I m not comfortable to say it s in the next meeting or two  but it could be It s not impossible that by July  for example  we would see data that led us to believe that we are in a perfectly fine course  

	Moreover  the central bank expects the key inflation rate to remain  low in the near term   Also  the fed funds rate is now expected to be 3  in the long run  compared to earlier projection of 3 3   Moreover  the Fed forecasted the economy would grow at 2  this year  declining from March s anticipation of 2 2  rise  The expected GDP growth rate for next year was also revised down from 2 1  to 2  

	Separately  concerns regarding  Brexit  continue to drag major benchmarks lower  Most of the recently released polls revealed that Britain may opt for  Brexit  in June 23 s referendum  These concerns dragged down the U S  10 year Treasury yield to its lowest level of 1 59  in over three years  Unchanged rate decision also led the U S  dollar to weaken against major currencies  The ICE U S  Dollar Index  DXY  declined 0 4  to 94 59 

	The Health Care Select Sector SPDR  XLV   which declined 0 7   emerged as the biggest decliner among the S P 500 sectors  Key stocks from the sector including  Allergan  NYSE AGN pa  plc     Medtronic  NYSE MDT  plc     Alexion Pharmaceuticals  NASDAQ ALXN   Inc      Biogen  NASDAQ BIIB  Inc      and Bristol Myers Squibb Company  NYSE BMY     fell 2   1 5   1 3   1 2  and 0 7   respectively 

	Additionally  oil prices declined as concerns over weak demand offset fall in crude inventories  The EIA reported that U S  crude inventories declined by 0 9 million barrels to 531 5 million barrels for the week ending June 10  compared to previous week s decline 3 2 million barrels  While the Energy Select Sector SPDR  XLE  NYSE XLE   declined more than 0 2   two Dow components from the sector   Chevron Corporation  NYSE CVX      and Exxon Mobil Corporation  NYSE XOM       also decreased 0 6  and 0 3   respectively 

	In economic news  industrial production declined 0 4  in May  wider than the consensus estimate of a 0 2  decrease  This also compares unfavorably compared to April s rise of 0 6   Also  capacity utilization decreased from April s 75 3 to 74 9 in May  lower than the consensus estimate of 75 2 

	However  the U S  Bureau of Labor Statistics reported that the Producer Price Index  PPI  rose 0 4  in May  higher than the consensus estimate of 0 3  rise and April s rise of 0 2   Meanwhile  core PPI that excludes prices of foods  energy  and trade services declined 0 1  last month  compared to 0 3  rise in April 

	Separately  the NY Empire State Index   an indicator of economic conditions in New York   came in at 6 1 in June  in contrast to last month s reading of negative 9 02 ",2016-06-15,Zacks Investment Research,"https://www.investing.com/analysis/stock-market-news-for-june-16,-2016-200136379",200136379
130065,351580,BIIB,Biogen  BIIB  Q2 Earnings  Will The Stock Disappoint ,opinion,"Biogen Inc    NASDAQ BIIB    a well known name in the multiple sclerosis  MS  market  will be reporting second quarter 2016 earnings on Jul 21  before the market opens Biogen has consistently surpassed expectations over the last four quarters with an average earnings surprise of  9 54  Let s see how things are shaping up for the second quarter Will Tecfidera s Performance Improve Since the emergence of the first progressive multifocal leukoencephalopathy  PML  related death in a patient on oral MS drug  Tecfidera  investor focus has remained on the performance of the drug Biogen is working on growing Tecfidera sales and had launched a TV campaign to increase patient awareness about MS and Tecfidera  Although the company said that it helped increase awareness  Biogen does not intend to purchase additional TV spots beyond mid 2016  The company will  however  continue with its marketing efforts across other print and digital channels Tecfidera demand is expected to remain relatively stable in the U S  Outside the U S   Tecfidera s performance in Germany will remain in focus While Tysabri should remain on a stable trajectory  the number of patients using Avonex and Plegridy combined will continue to decline as patients move toward oral treatments 
Profit share for Rituxan and Gazyva will also decline given FDA approval for Gazyva for Rituxan refectory indolent non Hodgkin s lymphoma Meanwhile  Biogen intends to spin off its hemophilia business by the end of 2016 or early 2017 Head count reduction and restructuring initiatives announced last year are expected to benefit operating expenses by about  250 million this year Focus on Call  Investor focus on the second quarter call will remain on Tecfidera s scrip trends  news regarding additional PML cases  pipeline progress and plans for acquisitions What Our Model IndicatesOur proven model does not conclusively show that Biogen is likely to beat earnings estimates this quarter  This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to announce an earnings surprise  That is not the case here as you will see below Zacks ESP  The  for Biogen is  2 35  since the Most Accurate estimate stands is  4 58 per share  and the Zacks Consensus Estimate is  4 69 per share Zacks Rank  Biogen carries a Zacks Rank  3  Biogen s Zacks Rank  3 when combined with an ESP of  2 35  makes surprise prediction difficult We caution against stocks with a Zacks Rank  4 and 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions BIOGEN INC Price and EPS Surprise   Stocks That Warrant a LookHere are some health care stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Gilead Sciences Inc    NASDAQ GILD   has an Earnings ESP of  6 91  and carries a Zacks Rank  2  It will be reporting results on Jul 25 The Earnings ESP for Novartis AG   NYSE NVS   is  0 85  and it carries a Zacks Rank  3  The company is scheduled to release results on Jul 19 Eli Lilly and Company   NYSE LLY   has an Earnings ESP of  2 35  and a a Zacks Rank  3  The company is scheduled to release results on Jul 26 Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-07-14,Zacks Investment Research,https://www.investing.com/analysis/biogen-(biib)-q2-earnings:-will-the-stock-disappoint-200142124,200142124
130091,351606,BIIB,Kite  KITE  And Biogen s Drugs Included In PRIME Initiative,opinion,"Kite Pharma  Inc    NASDAQ KITE   announced that its immuno oncology candidate  KTE C19  has been granted access to the Priority Medicines  PRIME  regulatory initiative in Europe by the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  and Committee for Advanced Therapies  CAT  for the treatment of patients with refractory diffuse large B cell lymphoma  DLBCL  
We note that PRIME is a new initiative undertaken by the EMA to provide better scientific guidance and support accelerated review of investigational therapies that address a high unmet medical need  The initiative also offers early and enhanced regulatory support to optimize regulatory applications 
Consequently  Kite Pharma will now work closely with the CHMP and CAT as it progresses with the multi center ZUMA studies on KTE C19  and moves ahead with the marketing authorisation application process 
The candidate was also granted Breakthrough Therapy designation for the treatment of patients with DLBCL  primary mediastinal B cell lymphoma  PMBCL   and transformed follicular lymphoma by the FDA in Dec 2015  Moreover  KTE C19 enjoys orphan drug status in the U S  and the EU for DLBCL  PMBCL  follicular lymphoma  mantle cell lymphoma  chronic lymphocytic leukemia and acute lymphoblastic leukemia 
The news bodes well for Kite Pharma as it should accelerate the development and consequent review of the candidate  We note that Kite Pharma has no marketed products in its portfolio yet 
In addition  Biogen Inc    NASDAQ BIIB   announced that its pipeline candidate  aducanumab  was accepted for the PRIME program for early Alzheimer s disease  AD  primarily based on positive results from the phase Ib placebo controlled study on aducanumab in patients with prodromal or mild AD  Meanwhile  Biogen is evaluating aducanumab in two global phase III studies   ENGAGE and EMERGE   to evaluate its safety and efficacy in slowing cognitive impairment and the progression of disability in patients suffering from AD 
Kite Pharma and Biogen currently carry a Zacks Rank  3  Hold   A couple of better ranked stocks in the healthcare sector are Pfizer Inc    NYSE PFE   and Bristol Myers Squibb Co    NYSE BMY    both sporting a Zacks Rank  1  Strong Buy  ",2016-06-02,Zacks Investment Research,https://www.investing.com/analysis/kite-(kite)-and-biogen's-drugs-included-in-prime-initiative-200133739,200133739
130092,351607,BIIB,5 More Trade Ideas For This Week  AGU  BIIB  BLMN  BMY  CNI,opinion,"Here are the Rest of the Top 10 
Agrium Inc  NYSE AGU 

Agrium  AGU  has trended lower since making a top over 116 to start March 2015  It started rising off of a bottom in February but found resistance as t crossed 90  he pullback from there made a higher low into May and it turned back up  Entering the week it is back at resistance with support to move higher  The RSI is rising in the bullish zone and the MACD is rising  Look for a break of resistance to participate to the upside   
Biogen  NASDAQ BIIB 

Biogen  BIIB  gapped down in July last year and has drifted lower since  A series of lower highs and lower lows morphed into a bottoming pattern from February through March  And now it has seen a higher high following a higher low in May  The RSI is in the bullish zone and rising while the MACD rises  both supporting more upside  Look for a break of the short term resistance last week to participate to the upside   
Bloomin Brands Inc  NASDAQ BLMN 

Bloomin  Brands  BLMN  has been moving through a rounded bottom  making a series of higher highs and higher lows since February  Last week saw the stock push back to the May highs  with support for more upside from the bullish and rising RSI and the MACD about to cross up  Look for a break of the May high to participate to the upside   
Bristol Myers Squibb Company  NYSE BMY 

Bristol Myers Squibb  BMY  recovered from the August 2015 drop  rising into the end of 2015  But it fell back with the market from there to a low in February  Since then it has moved higher to a peak at the end of April  It has consolidated the under resistance for more than a month  As it does  the RSI is rising in the bullish zone and the MACD is about to cross up  Look for a break above resistance to participate to the upside   
Canadian National Railway Company  NYSE CNI 

Canadian National Railway  CNI  ran higher from the February low until peaking in late April  It pulled back from there and found support at the 200 day SMA  It has been consolidating there since  The RSI has started back higher and is moving through the mid line while the MACD is crossed up and rising  Look for a break of resistance to participate to the upside   
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday which heading into the first full week of June sees the Equity Indexes looking solid 
Elsewhere look for Gold to bounce higher in consolidation while Crude Oil consolidates its move higher  holding at the round number 50  The US Dollar Index looks better to the downside short term in its broad consolidation while US Treasuries are strong and look to move higher  The Shanghai Composite has a short term bias higher and may have broken a long term pattern to the upside while Emerging Markets are continue to move up 
Volatility looks to remain subdued keeping the bias higher for the equity index ETF s SPDR S P 500  NYSE SPY   iShares Russell 2000  NYSE IWM  and PowerShares QQQ Trust Series 1  NASDAQ QQQ   There charts show some variation in the short run with the IWM leading to the upside  perhaps catching up  while the QQQ has a short term upward bias in consolidation and the SPY looks to be muddled in consolidation after its move higher  Use this information as you prepare for the coming week and trad em well 
DISCLAIMER  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer ",2016-06-06,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-of-june-6,-2016:-the-rest-200134056",200134056
130093,351608,BIIB,Why Is Biogen  BIIB  Stock Plunging Today ,opinion,"On Tuesday  shares of biopharmaceutical company Biogen  NASDAQ BIIB  are plunging  down over 15  in afternoon trading after the company s Phase 2 study of its treatment for relapsing multiple sclerosis failed to meet its primary and secondary endpoints 
The drug  opicinumab  did not meet the primary objective of the improvement of physical and cognitive function and disability  while the secondary objective was slowing of disability progression 
 Achieving repair of the human central nervous system through remyelination would be a substantial achievement  and while we missed the primary endpoint  the SYNERGY study results suggest evidence of a clinical effect of opicinumab   said Chief Medical Officer Alfred Sandrock   Due to the complex nature of the data set  we continue to analyze the results to inform the design of our next study  
Biogen added that opicinumab was generally well tolerated and showed a linear  well behaved PK profile over the studied dose range 
So far this year  BIIB has underperformed the broader markets  dropping over 5  as of Monday s close ",2016-06-07,Zacks Investment Research,https://www.investing.com/analysis/why-is-biogen-(biib)-stock-plunging-today-200134583,200134583
130094,351609,BIIB,Where s Biotech Headed ,opinion,"Valeant Pharmaceuticals  NYSE VRX  was down 14  and Biogen  NASDAQ BIIB  was off by 12 3   I guess it goes without saying that Bill Ackman had another lousy day  Biotech s weakness kept the NASDAQ from any kind of a rally on Tuesday  despite the Dow  SPX and the Russell all being on solid ground 
So where does that leave biotech going forward  Take a look at  NASDAQ IBB     the iShares Nasdaq Biotechnology Index 
There is a clear level of support underneath  but more importantly is the downtrend that is converging with the base resistance  Break these two levels at around  290 and you ll likely have a rally that could go as high as  340 
Obviously that s huge for biotech stocks and a rally would help the entire market make that run toward new all time highs and beyond 
Here s What I m Looking At ",2016-06-07,Ryan Mallory,https://www.investing.com/analysis/where's-biotech-headed-200134578,200134578
130095,351610,BIIB,Forget Biogen  BIIB   Buy These 5 Biotech Stocks Instead,opinion,Biogen Inc  s   NASDAQ BIIB   shares declined 12 8  yesterday with the company announcing disappointing top line results on one of its most watched experimental multiple sclerosis  MS  treatments  opicinumab  anti LINGO 1   The company said that opicinumab missed the primary as well as secondary efficacy endpoint in a mid stage study  Read more    Biogen is a well known name in the MS market and generates a major part of its revenues from its MS franchise  The company is focused on bringing new MS treatments to market  However  Biogen is currently facing challenges in the MS market with its interferon treatments being impacted by the continuing shift to oral therapies  Tysabri facing competition from oral treatments and Tecfidera facing a slowdown since the emergence of the first progressive multifocal leukoencephalopathy  PML  case Moreover  recently approved Zinbryta is not expected to be a major contributor to the top line given the product label   firstly  it is basically a third line treatment option  approved for use in patients who have not responded adequately to two or more MS drugs   and secondly  it has serious safety risks including liver injury and immune conditions  Zinbryta has a boxed warning and is available only under a Risk Evaluation and Mitigation Strategy  REMS   These two factors are likely to limit the commercial potential of the drug Biogen s sales and promotional practices are also under state and federal government investigation and the company has received related subpoenas  In early Mar 2016  Biogen received a subpoena from the federal government for documents relating to its relationship with non profit organizations that provide assistance to patients taking drugs sold by Biogen Lack of near term pipeline catalysts  the MS franchise s performance  Tecfidera patent challenges and pipeline setbacks will remain an overhang on the shares  In such a scenario  we advise investors to forget Biogen and invest in biotech stocks which sport a strong Zacks Rank and have interesting pipelines products and growth potential Our ChoicesCambridge  MA based Merrimack Pharmaceuticals  Inc    NASDAQ MACK   has transitioned from a development stage company to a commercial stage company following the FDA approval of cancer treatment  Onivyde  in Oct 2015  Onivyde is off to an encouraging start and its addition to the National Comprehensive Cancer Network  NCCN  2016 Clinical Practice Guidelines in Oncology as a category I Treatment Option should also boost sales  This Zacks Rank  2  Buy  stock is working on expanding Onivyde s label and has several interesting candidates in its pipeline for different types of cancer San Diego  CA based Retrophin  Inc    NASDAQ RTRX   has been consistently delivering positive earnings surprises over the last four quarters  This Zacks Rank  1  Strong Buy  stock has three marketed products in its portfolio  The company has an important pipeline event coming up with top line results from the phase II sparsentan study  focal segmental glomerulosclerosis   FSGS  expected in the third quarter Cambridge  MA based Idera Pharmaceuticals  Inc    NASDAQ IDRA   is a clinical stage company focused on the discovery  development and commercialization of novel therapeutics for cancer and rare diseases  This Zacks Rank  2 stock has two distinct proprietary drug discovery technology platforms   toll like receptor  TLR  targeting technology and third generation antisense  3GA  technology  Idera s TLR agonists have the potential to be applied in immuno oncology  a therapeutic area that has been garnering a lot of interest and activity from both large as well as small mid sized pharma and biotech companies  These treatments hold huge commercial potential and have the ability to change the treatment paradigm Ardsley  NY based Acorda Therapeutics  Inc    NASDAQ ACOR   is a commercial stage biopharmaceutical company focused on the development and commercialization of novel treatments that improve neurological function in people suffering from multiple sclerosis  MS   spinal cord injury  SCI  and other nervous system disorders  This Zacks Rank  2 stock has consistently surpassed earnings expectations over the last four quarters  Ampyra continues to perform well and Acorda is progressing with its pipeline La Jolla  CA based Ligand Pharmaceuticals Incorporated   NASDAQ LGND   is a biotechnology company with a focus on drug discovery  reformulation and partnering  The company s Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties  This Zacks Rank  2 stock s earnings performance is pretty impressive with the company delivering positive earnings surprises over the last four quarters  Ligand s raised outlook for 2016 is encouraging  Geographical and label expansion of its key partnered assets  Promacta and Kyprolis  the anticipated approval and launch of up to five new partnered products  and continued development of the partnership portfolio are likely to boost the top line throughout 2016 Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-07,Zacks Investment Research,"https://www.investing.com/analysis/forget-biogen-(biib),-buy-these-5-biotech-stocks-instead-200134851",200134851
130100,351615,BIIB,The Zacks Analyst Blog Highlights  Biogen  Merrimack Pharmaceuticals  Retrophin  Idera Pharmaceuticals And Acorda Therapeutics,opinion,"For Immediate Release

	Chicago  IL   June 9  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Biogen  NASDAQ BIIB  Inc      Merrimack Pharmaceuticals  Inc      Retrophin  Inc      Idera Pharmaceuticals  Inc     and Acorda Therapeutics  Inc      

	Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Wednesday s Analyst Blog  

Forget Biogen  Buy These Biotech Stocks Instead

Biogen Inc  s    shares declined 12 8  yesterday with the company announcing disappointing top line results on one of its most watched experimental multiple sclerosis  MS  treatments  opicinumab  anti LINGO 1   The company said that opicinumab missed the primary as well as secondary efficacy endpoint in a mid stage study  Read more    

	Biogen is a well known name in the MS market and generates a major part of its revenues from its MS franchise  The company is focused on bringing new MS treatments to market  However  Biogen is currently facing challenges in the MS market with its interferon treatments being impacted by the continuing shift to oral therapies  Tysabri facing competition from oral treatments and Tecfidera facing a slowdown since the emergence of the first progressive multifocal leukoencephalopathy  PML  case 
	Moreover  recently approved Zinbryta is not expected to be a major contributor to the top line given the product label   firstly  it is basically a third line treatment option  approved for use in patients who have not responded adequately to two or more MS drugs   and secondly  it has serious safety risks including liver injury and immune conditions  Zinbryta has a boxed warning and is available only under a Risk Evaluation and Mitigation Strategy  REMS   These two factors are likely to limit the commercial potential of the drug 
	Biogen s sales and promotional practices are also under state and federal government investigation and the company has received related subpoenas  In early Mar 2016  Biogen received a subpoena from the federal government for documents relating to its relationship with non profit organizations that provide assistance to patients taking drugs sold by Biogen 
	Lack of near term pipeline catalysts  the MS franchise s performance  Tecfidera patent challenges and pipeline setbacks will remain an overhang on the shares  In such a scenario  we advise investors to forget Biogen and invest in biotech stocks which sport a strong Zacks Rank and have interesting pipelines products and growth potential Our Choices
	Cambridge  MA based Merrimack Pharmaceuticals  Inc     has transitioned from a development stage company to a commercial stage company following the FDA approval of cancer treatment  Onivyde  in Oct 2015  Onivyde is off to an encouraging start and its addition to the National Comprehensive Cancer Network  NCCN  2016 Clinical Practice Guidelines in Oncology as a category I Treatment Option should also boost sales  This Zacks Rank  2  Buy  stock is working on expanding Onivyde s label and has several interesting candidates in its pipeline for different types of cancer 
	San Diego  CA based Retrophin  Inc     has been consistently delivering positive earnings surprises over the last four quarters  This Zacks Rank  1  Strong Buy  stock has three marketed products in its portfolio  The company has an important pipeline event coming up with top line results from the phase II sparsentan study  focal segmental glomerulosclerosis   FSGS  expected in the third quarter 
	Cambridge  MA based Idera Pharmaceuticals  Inc     is a clinical stage company focused on the discovery  development and commercialization of novel therapeutics for cancer and rare diseases  This Zacks Rank  2 stock has two distinct proprietary drug discovery technology platforms   toll like receptor  TLR  targeting technology and third generation antisense  3GA  technology  Idera s TLR agonists have the potential to be applied in immuno oncology  a therapeutic area that has been garnering a lot of interest and activity from both large as well as small mid sized pharma and biotech companies  These treatments hold huge commercial potential and have the ability to change the treatment paradigm 
	Ardsley  NY based Acorda Therapeutics  Inc     is a commercial stage biopharmaceutical company focused on the development and commercialization of novel treatments that improve neurological function in people suffering from multiple sclerosis  MS   spinal cord injury  SCI  and other nervous system disorders  This Zacks Rank  2 stock has consistently surpassed earnings expectations over the last four quarters  Ampyra continues to perform well and Acorda is progressing with its pipeline 
	Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days   

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

	Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

	Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact
	Zacks Investment Research
	800 767 3771 ext  9339

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  

	This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ",2016-06-08,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-biogen,-merrimack-pharmaceuticals,-retrophin,-idera-pharmaceuticals-and-acorda-therapeutics-200134995",200134995
130121,351636,BIIB,The Zacks Analyst Blog Highlights  Horizon Pharma  Incyte  Juno Therapeutics  Halozyme Therapeutics And Kite Pharma,opinion,"For Immediate Release 

Chicago  IL   May 09  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include   Horizon Pharma plc     Incyte Corporation     Juno Therapeutics Inc      Halozyme Therapeutics  Inc      and Kite Pharma  Inc     

Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Friday s Analyst Blog  

Biotech Stocks We re Watching for Earnings Reports

It s nearing the closing bell of the first quarter 2016 earnings season with almost 75  of the S P 500 members having already reported results  With 71 4  of these members beating bottom line estimates and 56 4  surpassing top line expectations  the first quarter earnings season has been  

Notably  the Medical sector is anticipated to be one of the seven sectors to record earnings growth in the first quarter of 2016  as per our   Our Q1 scorecard shows that 75 5  of the Medical sector has reported results with a blended beat of 67 5   the percentage of companies that have beaten both EPS as well as revenue estimates  

Particularly  the earnings picture for the biotech sector looks quite mixed  By now  several biotech companies have reported first quarter results 

Companies like Amgen  NASDAQ AMGN  and Regeneron have topped first quarter earnings and revenues  While Amgen raised the outlook for the year  Regeneron upped the 2016 view for its key eye drug  Eylea  However  heavyweight biotech stock Gilead lagged both earnings and revenue estimates even though it reiterated its outlook for the year  As far as the other biotech stocks are concerned  including the likes of Biogen  NASDAQ BIIB   Celgene  NASDAQ CELG   Alexion  and AbbVie  while some managed to post mixed results  others came up with disappointing performances and outlooks for the year 
	Still  several medium and small sized biotech companies are yet to report first quarter results  Let s see what awaits these six biotech stocks when they report their first quarter 2016 results on May 9 Can these Biotech Stocks Pull a Surprise Horizon Pharma plc    has already provided weaker than expected net sales and adjusted EBITDA expectations for the first quarter of 2016 last month  The company expects a major part of its sales and EBITDA to come in the second half of the year  Focus will be on the results of the company s business units as well as the performance of key products including Actimmune  Horizon Pharma s Zacks Rank  3  Hold  and an  of  13 16  do not conclusively show that the company is likely to beat earnings estimates this quarter  read more     

Oncology focused Incyte Corporation s    Zacks Rank  3 increases the predictive power of the ESP but its ESP of  46 67  makes a surprise prediction difficult this quarter  Incyte s track record has however been pretty good with the company surpassing expectations in three of the last four quarters with an average positive surprise of 85 99  

Juno Therapeutics Inc     is among the major players in the field of T cell based immunotherapy and has pipeline candidates like JCAR015  JCAR017 and JCAR014 which use CAR T cell technology to target CD19  It has collaborations with companies like Celgene for the global development and commercialization of immunotherapies  With no approved products in its portfolio and not generating any product revenues as yet  focus will be on the company s cash burn and pipeline updates 
	Juno has a Zacks Rank  3 which when combined with an ESP 0 00  makes a surprise prediction difficult  read more     

San Diego  CA based Halozyme Therapeutics  Inc       focused on the development and commercialization of oncology therapies  has an impressive track record  The company has beaten estimates in three of the trailing four quarters with an average positive surprise of 60 41   Our model does not show that Halozyme is likely to beat estimates this quarter  Though the company s Zacks Rank  3 enhances the predictive power of the ESP  its 0 00  ESP makes a surprise prediction difficult 

Kite Pharma  Inc   s    performance over the last four quarters is mostly disappointing with the company surpassing expectations in just one quarter  Moreover  Kite Pharma s Zacks Rank  4  Sell  which when combined with an ESP  11 48  does not conclusively show that Kite Pharma is likely to beat estimates this quarter as well 
	This development stage company is looking to transform the paradigm of treating cancer which involves using the body s immune system to recognize and destroy cancer cells  Focus will be on updates on the company s progress with its lead pipeline candidate KTE C19 as well as on collaboration agreements with several companies including Amgen  read more     

Stay tuned  Check later on our full write up on earnings releases of these stocks 

Want the latest recommendations from Zacks Investment Research  Today  you can download7 Best Stocks for the Next 30 Days  

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research    Find out What is happening in the  on zacks com ",2016-05-08,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-horizon-pharma,-incyte,-juno-therapeutics,-halozyme-therapeutics-and-kite-pharma-200128837",200128837
130122,351637,BIIB,Drug Stocks Reporting On May 10  XON  ARIA  CPRX   More,opinion,"now that a large part of the first quarter 2016 earnings season has come through with 87 2   as of May 6  of the S P 500 members having already reported results  This season is likely to finish as the fourth straight quarter of earnings declines for the S P 500 index  Moreover  this trend of earnings declines is expected to continue into the second quarter as well With several pharma and major biotech companies having released their earnings results  our Q1 scorecard shows that 92 5  of the Medical sector has reported results with a blended beat of 65 3   the percentage of companies that have beaten both EPS as well as revenue estimates  Notably  the Medical sector is anticipated to be one of the seven sectors to record earnings growth in the first quarter of 2016  as per our  report The earnings picture for both the pharma and the biotech sector looks pretty mixed with beats and misses  While in the biotech sector  Amgen Inc    NASDAQ AMGN   topped first quarter earnings and revenues and even raised the outlook for the year  another well known biotech name Gilead lagged both earnings and revenue estimates even though it kept its outlook for the year intact  Among the other biotech stocks  Biogen  NASDAQ BIIB   Celgene  NASDAQ CELG   Alexion and AbbVie managed to post mixed results  while some others came up with disappointing results and outlook for the year Pharma giants like Johnson   Johnson   NYSE JNJ    Pfizer  NYSE PFE  and Bristol Myers Squibb surpassed first quarter earnings and revenue expectations and also raised the outlook for the year  Eli Lilly raised its outlook for the year despite an earnings miss while Glaxo expects core earnings growth of 10 12  at constant exchange rate in 2016 
With several medium and small sized drug companies still to report first quarter 2016 results  let s see what awaits these drug stocks when they report their first quarter results on May 10 
What Awaits these Drug Stocks Jazz Pharmaceuticals plc   NASDAQ JAZZ    a biopharmaceutical company  has a portfolio of offerings targeting sleep and hematology oncology disorders  Focus will be on the performance of marketed products including Xyrem  Defitelio and Erwinaze among others along with that of commercialization plans for Defitelio in the U S   and the company s business development plans  Jazz s  of  6 11  and a Zacks Rank  3  Hold  make us confident of an earnings beat this quarter  read more    

Palo Alto  CA based Anacor Pharmaceuticals  Inc    NASDAQ ANAC   is a biopharmaceutical company focused on the discovery  development and commercialization of small molecule therapeutics derived from its boron chemistry platform  Anacor s track record so far has been mixed with the company missing estimates in two of the trailing four quarters with an average negative surprise of 16 68   The company s Zacks Rank  4  Sell  when combined with an ESP  32 35  makes a beat difficult to predict this quarter 
Intrexon Corporation s   NYSE XON   Zacks Rank  3 increases the predictive power of the ESP but its current ESP of  6 90  makes a surprise prediction difficult this quarter  Previously our model had shown that Intrexon is likely to beat estimates this quarter  read more     Intrexon  a leader in the synthetic biology field  follows a business model under which it commercializes its technologies through exclusive channel collaborations and licensing agreements  The company s performance has been mixed over the four trailing quarters with the company beating estimates in two of them 
Oncology focused ARIAD Pharmaceuticals Inc  s   NASDAQ ARIA   performance has been far from impressive with the company missing expectations in each of the last four quarters  ARIAD has a Zacks Rank  5  Strong Sell  which when combined with an ESP of 0 00  makes a surprise prediction difficult  read more     Iclusig  a leukemia drug  is this biotech company s sole marketed product  The drug s sales should be driven by continued demand  new patient additions and launch in additional territories  Meanwhile  the company is also working on achieving cost efficiencies and resource reallocation  which is a part of its ongoing strategic review  Focus will be on the performance of Iclusig and strategic plans 

Being a development stage biopharmaceutical company with a focus on neuromuscular and neurological diseases and disorders  Catalyst Pharmaceuticals  Inc    NASDAQ CPRX   does not have any approved product in its portfolio  Currently  Catalyst has three candidates under development   Firdapse  CPP 115 and CPP 109  In this scenario  investor focus will be on pipeline and regulatory updates  Catalyst has a pretty good track record with the company beating estimates on three occasions  while posting in line results in one  Though Catalyst s Zacks Rank  3 increases the predictive power of the ESP  the company s 0 00  ESP makes a surprise prediction difficult  read more    ",2016-05-08,Zacks Investment Research,"https://www.investing.com/analysis/drug-stocks-reporting-on-may-10:-xon,-aria,-cprx---more-200128808",200128808
130123,351638,BIIB,Perrigo  PRGO  Tops Q1 Earnings  2016 Earnings View Intact,opinion,"Perrigo Company s   NYSE PRGO   first quarter 2016 earnings of  1 75 per share beat the Zacks Consensus Estimate of  1 73  Reported earnings  however  fell 5  from the year ago figure Net sales in the reported quarter soared 32  to  1 38 billion  beating the Zacks Consensus Estimate of  1 35 billion 
Quarter in Detail
Perrigo reports revenues primarily from the following segments  Consumer Healthcare  Branded Consumer Healthcare  created as a result of the Mar 2015 Omega Pharma acquisition   Prescription  Rx  Pharmaceuticals  Specialty Sciences  and Other  which include the active pharmaceutical ingredients business  
We note that Perrigo is currently pursuing the sale of its Vitamins  Minerals and Supplements  VMS  business within the Consumer Healthcare segment  The first quarter of 2016 and 2015 net sales from the VMS business were  47 million and  38 million  respectively 
Excluding net sales contribution from VMS  adjusted net sales in the reported quarter came in at  1 34 billion  an increase of 32  from the year ago period and 33  on a constant currency basis  It benefited from the inclusion of the Branded Consumer Healthcare segment and growth in Consumer Healthcare segment  excluding net sales from VMS   Also  the company benefited from new product sales  partially offset by absence of sales from discontinued products 
Consumer Healthcare  Perrigo reported adjusted Consumer Healthcare net sales in the first quarter of  653 million  up 1  from the year ago period and 2  on a constant currency basis 
Revenues were driven by new product sales and an increase in existing product revenues  primarily in the infant formula and smoking cessation categories  offset partially by decreases in the analgesics and cough   cold categories mainly due to the extremely mild cough cold season   These increases were offset partially by absence of sales from discontinued products absence of sales from discontinued products absence of sales from discontinued products Branded Consumer Healthcare  The company reported net sales of  318 million  which included new product sales as well as contributions from the GlaxoSmithKline plc   NYSE GSK   portfolio and Yokebe acquisitions  Reported sales were however down 2 4  sequentially 
Rx Pharmaceuticals  The Rx Pharmaceuticals segment performed encouragingly during the quarter  with net sales rising 2  to  257 million driven by new product sales and from sales related to recent product acquisitions  partially offset by a decrease in sales of existing products 
Specialty Sciences  Segmental revenues comprised royalties of  88 million received by Perrigo on net sales of Biogen Inc  s   NASDAQ BIIB   multiple sclerosis drug Tysabri  up 7  year over year  Unfavorable foreign currency movements hurt revenues by  1 million 
Others accounted for the remaining revenues 
2016 Earnings Outlook Reaffirmed
Perrigo maintained its earnings guidance for 2016 that was provided late last month  The company continues to expect 2016 earnings in the range of  8 20 to  8 60 per share  representing year over growth of 8 13   The Zacks Consensus Estimate for earnings is  8 45 per share 
Our Take
Perrigo s first quarter results were better than expected with the company beating on both top and bottom line estimates  We are pleased with the performance of the Consumer Healthcare  Branded Consumer Healthcare  Rx Pharmaceuticals and Specialty Sciences segments  We are also positive on the company s focus on acquisition driven growth  Moreover  the company s restructuring plans to boost shareholder value look encouraging 
Perrigo is a Zack Rank  5  Strong Sell   ANI Pharmaceuticals  Inc    NASDAQ ANIP   is a better ranked stock in the health care sector  sporting a Zacks Rank  1  Strong Buy  ",2016-05-11,Zacks Investment Research,"https://www.investing.com/analysis/perrigo-(prgo)-tops-q1-earnings,-2016-earnings-view-intact-200129555",200129555
130124,351639,BIIB,Biotech Stock Roundup  Medivation Buyout Rumors Continue  NewLink Plunges On Late Stage Data ,opinion,"Earnings remained in focus this week as well with several small and mid sized biotech companies reporting results  Meanwhile  Medivation   NASDAQ MDVN   remains in the news as the acquisition saga continues with more companies rumored to be interested in buying the firm Other updates include data presentations as well as label expansions and product approvals Recap of the Week s Most Important Stories1  With first quarter earnings season drawing to a close  several small and mid sized biotech companies reported results over the last five trading days  Most of these are companies like Juno   NASDAQ JUNO    Kite   NASDAQ KITE   and Repros which have no approved products in their portfolios and are still in the development stage  In such a scenario  investors are more focused on the pipelines and cash burn 
Kite and Juno are key names in the immuno oncology space with both looking to bring their lead candidates to market in 2017  While Juno s JCAR015 is in a registrational phase II study  ROCKET  in adult patients with relapsed refractory acute lymphoblastic leukemia  Read more     Kite s KTE C19 is in the pivotal phase of a phase I II study  ZUMA 1  in patients with refractory diffuse large B cell lymphoma including primary mediastinal B cell lymphoma and transformed follicular lymphoma  Read more    2  Medivation  which had rejected an unsolicited offer from French drugmaker Sanofi  PA SASY   continues to be in the news as speculation increases about other companies being interested in acquiring Medivation  The latest rumor is that the company is now interested in selling itself  According to a Reuters article  Pfizer  NYSE PFE  and Amgen   NASDAQ AMGN   are some of the companies that have signed non disclosure agreements with Medivation 3  As part of its ongoing strategic review  ARIAD   NASDAQ ARIA   has decided to divest its European operations and out license Iclusig in Europe and a few other countries to Incyte  This deal will allow ARIAD to focus its efforts in the U S  and it also provides the company with a non dilutive source of funds  Under this agreement  ARIAD stands to receive up to  275 million including an upfront payment of  140 million plus tiered royalties starting from 32  that could go up to 50  4  The FDA expanded the label of AbbVie s   NYSE ABBV   cancer treatment  Imbruvica  The label now includes new data from two late stage studies supporting its expanded use in patients with chronic lymphocytic leukemia  CLL  and small lymphocytic lymphoma  SLL  AbbVie and Bristol Myers also gained EU approval for their blood cancer treatment  Empliciti making it the first and only immunostimulatory antibody approved for multiple myeloma in the EU 5  NewLink Genetics    NASDAQ NLNK   shares plunged more than 30  on disappointing data from a late stage study being conducted on its experimental cancer treatment  algenpantucel L  The study  conducted in patients with resected pancreatic cancer  failed to achieve the primary endpoint  The news comes as a major disappointment considering algenpantucel L is the most advanced candidate in NewLink s pipeline  The company is now evaluating the future of its HyperAcute platform PerformanceIt was a mixed week for biotech stocks with Gilead recording a decline of 1 99  last week while Vertex gained 3 72  during this period  Meanwhile  Regeneron lost 34 35  over the last six months 
The NASDAQ Biotechnology Index was down 0 78  over the last five trading days  See the last biotech stock roundup here    What s Next in the Biotech World Medivation will remain in the news as acquisition rumors continue  Meanwhile  with earnings season drawing to a close  investor focus will be back on the usual pipeline and regulatory updates Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-05-12,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stock-roundup:-medivation-buyout-rumors-continue,-newlink-plunges-on-late-stage-data-200129622",200129622
130125,351640,BIIB,Biogen   AbbVie s Multiple Sclerosis Drug Gets FDA Nod,opinion,Biogen Inc    NASDAQ BIIB   and AbbVie Inc    NYSE ABBV   have gained FDA approval for their multiple sclerosis  MS  treatment  Zinbryta  The once monthly  self administered  subcutaneous treatment has been approved for relapsing forms of multiple sclerosis  RMS  in patients who have had an inadequate response to two or more MS therapies FDA approval makes Zinbryta the first once monthly  self administered MS treatment to be approved  Approval comes with a black box warning regarding the risk of hepatic injury  including autoimmune hepatitis  and other immune mediated disorders  Moreover  only prescribers  pharmacies and patients enrolled in the Zinbryta Risk Evaluation and Mitigation Strategy  REMS  Program  which includes required monthly liver function tests  will have access to the treatment Zinbryta is currently under regulatory review in the EU  Switzerland  Canada and Australia  EU approval should come shortly considering the European Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  issued a positive opinion in late April Zinbryta s approval comes as a boost for Biogen  which already has a strong position in the MS market  However  Biogen has been facing its share of troubles in this market following the emergence of a progressive multifocal leukoencephalopathy  PML  related death of a patient on the company s oral MS treatment  Tecfidera  Biogen s interferon business is also facing challenges with the market shifting towards orals  The company has been working on strengthening its position in the MS market and recently decided to spin off of its hemophilia business so that it can focus on developing and bringing neurology products to market  The company plans to speed up its efforts to bring new treatments for MS  spinal muscular atrophy  SMA   Alzheimer s disease  Parkinson s disease  amyotrophic lateral sclerosis  ALS   and neuropathic pain to market Meanwhile  AbbVie is looking to strengthen its product portfolio and diversify its revenue base  With quite a few companies working on bringing biosimilar versions of Humira  AbbVie s flagship product  to market  AbbVie has been working on reducing its dependence on Humira While Biogen is a Zacks Rank  3  Hold  stock  AbbVie is a Zacks Rank  5  Strong Sell  stock  Some better ranked stocks in the health care sector include Bristol Myers Squibb Company   NYSE BMY   and Pfizer  Inc    NYSE PFE     both Zacks Rank  1  Strong Buy  stocks ,2016-05-29,Zacks Investment Research,https://www.investing.com/analysis/biogen---abbvie's-multiple-sclerosis-drug-gets-fda-nod-200132921,200132921
130126,351641,BIIB,Roche s Subcutaneous Formulation Of MabThera Gets EU Nod,opinion,Roche Holding  SIX ROG  AG   OTC RHHBY   announced that the European Commission  EC  has approved the subcutaneous  SC  formulation of MabThera  rituximab  for the treatment of patients suffering from previously untreated and relapsed refractory chronic lymphocytic leukemia  CLL   The approved dose for this indication is 1600 mg The subcutaneous  SC  formulation of MabThera is intended to save time and ease treatment burden over the intravenous form The approval was based on positive results from the phase Ib study  SAWYER  which demonstrated comparable safety and efficacy of the two formulations  both in combination with chemotherapy We note that MabThera is approved for the treatment of several types of blood cancers   certain forms of non Hodgkin lymphoma  NHL  and CLL In the U S   Roche markets MabThera as Rituxan  in collaboration with Biogen   NASDAQ BIIB   Approval of the SC formulation of MabThera will broaden Roche s hematology portfolio  which currently comprises approved drugs like MabThera Rituxan  Gazyva Gazyvaro  Tecentriq  atezolizumab  and Venclexta  and has an encouraging pipeline including investigational candidates like polatuzumab vedotin RG7596 and a small molecule antagonist of MDM2  idasanutlin RG7388  Last month  the FDA granted accelerated approval to Tecentriq for the treatment of patients suffering from locally advanced or metastatic urothelial carcinoma  who experienced disease progression during or after platinum based chemotherapy  or whose disease has worsened within 12 months of receiving platinum based chemotherapy before or after surgery Moreover  Roche is developing emicizumab  ACE910  for the treatment of hemophilia A We expect investors to focus on new drug approvals at Roche  as the company s top line could be marred by the entry of biosimilars for its key drugs  expected in the second half of 2017 in Europe  like MabThera and Herceptin Roche currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector are Pfizer Inc    NYSE PFE   and Bristol Myers Squibb Company   NYSE BMY    Both stocks sport a Zacks Rank  1  Strong Buy  ,2016-05-30,Zacks Investment Research,https://www.investing.com/analysis/roche's-subcutaneous-formulation-of-mabthera-gets-eu-nod-200133086,200133086
130127,351642,BIIB,The Zacks Analyst Blog Highlights  Sarepta  Biogen  AbbVie  Intercept And Ionis,opinion,"For Immediate Release 

Chicago  IL   June 02  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include   Sarepta     Biogen  NASDAQ BIIB      AbbVie     Intercept     and Ionis    

Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Wednesday s Analyst Blog  

Biotech Stock Roundup

This week  the biotech sector saw quite a few updates on the regulatory and pipeline front  While companies like Sarepta     Biogen     AbbVie    and Intercept    came out with encouraging news  Ionis     suffered a setback 

Recap of the Week s Most Important Stories

1  Sarepta s shares shot up 26 7  on news that the FDA will not be able to deliver a decision regarding the approval status of the company s experimental Duchenne muscular dystrophy  DMD  treatment  eteplirsen  by May 26  The agency informed the company that it continues to review the NDA and will return with a decision in a timely manner  The news has raised hopes among investors as well as the medical community that the agency may very well decide to approve eteplirsen  Read more     

We remind investors that DMD drugs have not really had much success on the regulatory front so far  While PTC Therapeutics had received a  refusal to file  letter from the FDA for its experimental DMD treatment  Translarna  BioMarin s Kyndrisa received a complete response letter  CRL  earlier this year  BioMarin  in fact  announced this week that it does not intend to continue with the development of Kyndrisa  The company withdrew its marketing application in the EU following discussions with the Committee for Medicinal Products for Human Use  CHMP  which indicated the drug would receive a negative opinion from the CHMP 

2  Across the pond  quite a few drugs received positive CHMP opinions including Biogen s Tysabri  label expansion for use in relapsing remitting multiple sclerosis patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy  as well as Gilead s experimental hepatitis C virus  HCV  drug  Epclusa  Read more      Amgen s cancer drug Kyprolis and AbbVie s flagship product Humira also got positive CHMP opinions for label expansions  Read more     

3  The FDA granted approval to Biogen and AbbVie s multiple sclerosis  MS  treatment Zinbryta making it the first once monthly  self administered MS treatment to be approved  However  the label has a black box warning regarding the risk of hepatic injury  including autoimmune hepatitis  and other immune mediated disorders  Moreover  only prescribers  pharmacies and patients enrolled in the Zinbryta Risk Evaluation and Mitigation Strategy  REMS  Program  which includes required monthly liver function tests  will have access to the treatment   Read more     

AbbVie s cancer treatment  Imbruvica  also gained EU approval for the first line treatment of chronic lymphocytic leukemia  CLL  patients  The label expansion was expected as the CHMP had recently issued a positive opinion for this indication  With this label expansion  Imbruvica can now be used across all lines of CLL 

4  Ionis  shares were down 39 4  on news that Glaxo  which has the option to exclusively license Ionis  IONIS TTRRx  has decided against initiating a phase III outcome study in patients with TTR amyloid cardiomyopathy  The study had been placed on clinical hold earlier this year due to safety findings in the ongoing NEURO TTR study   Read more     

5  Intercept s Ocaliva gained accelerated approval in the U S  for the treatment of primary biliary cholangitis  PBC  making it the first new medicine to be approved for PBC in almost two decades  Shares were up on the news though approval was largely expected as an FDA advisory panel had voted unanimously in favor of approving the drug   Read more      Of course  Ocaliva s main potential lies in the nonalcoholic steatohepatitis  NASH  market which represents blockbuster potential 

Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact

Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-06-01,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-sarepta,-biogen,-abbvie,-intercept-and-ionis-200133646",200133646
130151,351666,BIIB,IBB Faces Key Technical Test,opinion,"Those who have followed our blog for some time now know that we are big proponents of technical analysis in   This type of examination can also be applied when we are analyzing individual sectors or industries that have diverged from the conventional path of the market 
Last year s big diverging theme was energy stocks as noted by the  21 50  decline in the Energy Select Sector SPDR  NYSE XLE   versus relatively flat performance in the broad based SPDR S P 500 ETF  NYSE SPY  
This year  the weakest sector has been health care stocks  The Health Care Select Sector SPDR  NYSE XLV  is still down over 8  as SPY begins to peak its head above the flat line 

The biggest contributor to this decline in health care has been the biotechnology industry  The iShares Nasdaq Biotechnology  NASDAQ IBB  has over  5 7 billion dedicated to a market cap weighted index of 190 biotech companies  Top holdings include large cap stocks  Celgene Corp  NASDAQ CELG   Amgen Inc  NASDAQ AMGN   and Biogen Inc  NASDAQ BIIB  
There are a  in varying styles  weights  and construction methodologies  However  IBB is the largest and most watched index of them all because of its tenure and skew towards the largest companies in this group 
The chart below shows that this ETF recently touched a critical level near  240 and has started to bounce intra day  This same level was probed in early February and proved to be a key support line 

It goes without saying that if IBB can mount another rally from these levels  it may be viewed by technicians as a bullish  double bottom  price pattern  I point this out for traders and those with a disciplined investment approach because a breach of those lows could also lead to another wave of selling pressure 
If your style involves watching for turnaround potential using price charts and momentum divergences  then this opportunity should certainly be on your radar  IBB is down  27  on a year to date basis and has shown in the past that rallies can materialize quickly 
I don t currently own any direct sector exposure to a fund like IBB for my growth clients because of the merry go round in leadership  It s difficult to forecast where the next burst of strength will come from at the sector or industry level unless you are betting on short term moves with tight stop losses 
My current mix of stocks is directed towards broad  low volatility or quality focused indexes that I believe offer a more stable platform to participate in further upside momentum  This  without worrying about hitting the nail perfectly on the head 
Nevertheless  I always keep a close eye on how specific areas of the market are trading and whether or not a reversal can morph into a new uptrend 
Disclosure  FMD Capital Management  its executives  and or its clients may hold positions in the ETFs  mutual funds or any investment asset mentioned in this article  The commentary does not constitute individualized investment advice  The opinions offered herein are not personalized recommendations to buy  sell or hold securities ",2016-03-18,David Fabian,https://www.investing.com/analysis/big-biotech-etf-faces-key-technical-test-200122022,200122022
130152,351667,BIIB,This Week s Top 5 Trade Ideas  BIIB  KKR  ON  WEB  ZG,opinion,"5 Trade ideas excerpted from the detailed analysis and plan for premium subscribers
Here are the Rest of the Top 10 
Biogen  NASDAQ BIIB 
Biogen  BIIB  reported earnings Thursday morning and after moved higher to resistance  Friday broke that to the upside making another higher high  This is the second higher high  but still takes place in the long downtrending channel  Positive but with some work left  As it moves up the RSI is in the bullish zone and rising while the MACD is moving higher supporting the upside  Look for continuation Monday to participate to the upside 
KKR   Co LP  NYSE KKR 
KKR  will report earnings before the market opens Monday  Heading into that event the chart looks promising for a break out  it made a higher low and is approaching resistance  a move over that would make for a higher high and confirm a reversal  The RSI is bullish and rising while the MACD is crossed up and rising  also supporting more upside  Look for a positive reaction to participate to the upside 
ON Semiconductor Corporation  NASDAQ ON 
ON Semiconductor  ON  made a bottom in February and has been moving higher since  the last two weeks it has rounded into consolidation and the Bollinger Bands  are squeezing  This is often a precursor to a move in price  The RSI is in the bullish zone and the MACD flattened after a fall and now approaching a positive cross  Look for a push over resistance to participate in the upside 
Web com Group Inc  NASDAQ WEB 
Web com  WEB  is coming out of a bottoming pattern  having back to back higher highs and higher lows  Coming into the week it is at resistance  trying to make another higher high  The RSI is now in the bullish zone and rising with the MACD crossed up and rising  These support more upside 
Zillow Group Inc  NASDAQ ZG 
Zillow Group  ZG  bounced off of a bottom in February  making the familiar  V  shaped recovery  It met resistance at the consolidation zone from November and December before a pullback to a shallower low  Another touch at resistance fell back farther but has also recovered to that resistance  The RSI is in the bullish zone and the MACD crossed and rising as it hits there again on a strong candle Friday  Look for a push through resistance to participate to the upside 
Up Next  Bonus Idea
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday which heading into the last week of April the Equity indexes are showing signs of rotation out of the PowerShares QQQ Trust Series 1  NASDAQ QQQ  and SPDR S P 500  NYSE SPY  and into the iShares Russell 2000  NYSE IWM  
Elsewhere look for Gold to consolidate in a  30 range while Crude Oil continues higher  The US Dollar Index continues to test the bottom of a wide consolidation range while US Treasuries are biased lower  The Shanghai Composite and Emerging Markets are biased to the downside with risk of the Emerging Market longer term uptrend re exerting itself  Volatility looks to remain subdued and with a bias lower keeping the bias higher for the equity index ETF s SPY  IWM and QQQ  despite the moves last week 
Their charts are mixed with the IWM just strong all around and the SPY strong on the weekly timeframe but with cracks on the daily  The QQQ is the weakest on the daily and shows consolidation on the weekly  Perhaps next week rotates back into the QQQ  Use this information as you prepare for the coming week and trad em well 
DISCLAIMER  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2016-04-25,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-of-april-25,-2016:-the-rest-200126255",200126255
130153,351668,BIIB,Biotech ETFs Sink On Mixed Q1 Results ,opinion,"Since the second half of 2015  the biotech sector has been experiencing weakness due to industry specific headwinds  The bear run was triggered by a  price gouging  tweet from Democratic Presidential candidate Hillary Clinton  Additionally  strained balance sheets and macro economic factors are adding to investors  anxiety  read    

To deepen its woes  the sector has failed to gain investor confidence so far in the first quarter as well  Although well known biotech industry player Amgen Inc     NASDAQ AMGN    easily managed to beat estimates on both earnings and revenues  several other companies including Biogen    NASDAQ BIIB     Celgene Corporation    NASDAQ CELG     Gilead    NASDAQ GILD    and Alexion Pharmaceuticals    NASDAQ ALXN    reported disappointing or mixed results 

Quite expectedly  investors will keep an eye on biotech earnings for the rest of this season to assess whether the sector can pull off another turnaround supported by strong pipelines  innovative treatments  growing demand for drugs  especially for rare to treat diseases  an aging population and increased health care spending  read    
Biotech Earnings in Detail

Gilead reported disappointing first quarter results as both earnings and revenues lagged the respective Zacks Consensus Estimate  The biotech giant s first quarter earnings  including stock based compensation expenses  of  2 98 per share missed the Zacks Consensus Estimate of  3 03  Reported earnings were  however  higher than the year ago figure of  2 90 per share 

Quarterly revenues were up 2 6  to  7 79 billion driven by strong product sales  However  the revenue figure fell short the Zacks Consensus Estimate of  8 13 billion  Meanwhile  the company maintained its 2016 product sales guidance  The company expects product sales in the range of  30  31 billion  The stock has fallen 9 1  since reporting earnings  as of April 29  2016  

Another biotech behemoth  Amgen beat both earnings and revenue estimates in the first quarter  The company s first quarter 2016 earnings of  2 90 per share surpassed the Zacks Consensus Estimate of  2 56 and improved from the year ago earnings of  2 48  Also  total revenues grew 10  to  5 527 billion  which beat the Zacks Consensus Estimate of  5 362 billion  Foreign exchange translation negatively impacted first quarter sales by five percentage points 

Based on an improved revenue outlook and a lower tax rate  the company upgraded its outlook for 2016 earnings to  10 85  11 20 per share from  10 60  11 00 per share  The company also pushed up its revenue guidance to  22 2  22 6 billion from  22 0  22 5 billion  However  the stock has lost 1 4  since releasing earnings 

Meanwhile  Biogen managed to beat on earnings  while it missed revenues marginally  The company s earnings per share of  4 79 were well above the Zacks Consensus Estimate of  4 48  Earnings grew about 25  year over year while revenues increased 7   Revenues came in at  2 7 billion  missing the Zacks Consensus Estimate of  2 8 billion  The stock gained 3 4  since it reported earnings 

Similarly  Celgene reported mixed results with earnings of  1 18 per share  including stock based compensation expenses  beating the Zacks Consensus Estimate of  1 05 and revenues of  2 51 billion missing the Zacks Consensus Estimate slightly  However  both earnings and revenues rose year on year in the reported quarter  Net sales of the drug Revlimid  the backbone of Celgene  saw a year over year rise of 17 2   The company has narrowed its 2016 outlook  The company now anticipates earnings in the range of  5 60  5 70 per share as compared to the old guidance   5 50  5 70 per share  The stock is down 2 9  post its earnings release 

On the other hand  Alexion came up with out and out disappointing first quarter results with both earnings and revenues missing estimates  First quarter 2016 earnings  including stock based compensation expense  of 87 cents per share missed the Zacks Consensus Estimate of 91 cents  Earnings were also below the year ago figure of  1 08 per share  Nevertheless  Alexion s revenues climbed 16 8  year over year in the first quarter to  701 million  Revenues  however  missed the Zacks Consensus Estimate of  712 million 

Alexion has revised its outlook for 2016  The company expects adjusted earnings per share and revenues to be at the low end of the previous projections of  5 00  5 20 and  3 05  3 1 billion  respectively  Shares have lost a whopping 7 6  in the last two trading sessions 
ETFs in Focus

Thanks to mixed results  biotech ETFs with considerable exposure to the five stocks above were all in the red in the last 10 trading sessions  as of April 29  2016   This has put the spotlight on biotech ETFs  Below we discuss four of these ETFs having a sizeable exposure to the above stocks  see   
iShares Nasdaq Biotechnology   

This top player in the biotech ETF space tracks the NASDAQ Biotechnology Index  holding 189 securities in the basket  Celgene  Amgen  Gilead Sciences  Biogen and Alexion are placed among the top 10 holdings with a combined exposure of about 36 3  in the fund  The fund has an asset base of more than  7 6 billion and trades in an average volume of nearly 2 3 million shares a day  It has an expense ratio of 0 47  and lost 4 5  in the above mentioned timeframe  IBB currently has a Zacks ETF Rank  3  Hold  with a High risk outlook  read   
Market Vectors Biotech ETF   

This fund follows the Market Vectors U S  Listed Biotech 25 Index and holds 26 securities in its basket  Gilead Sciences  12 5    Amgen  12 2    Celgene  9 6   and Biogen  5 9   take the top four spots in the fund while Alexion  4 3   takes the eleventh place  The fund has amassed nearly  545 8 million in its asset base and trades in moderate volumes of roughly 103 000 shares a day  The product charges an annual fee of 35 bps per year and lost almost 4  in the said timeframe  It currently carries a Zacks ETF Rank  2  Buy  with a High risk outlook 
PowerShares Dynamic Biotech   Genome ETF    

The fund tracks the Dynamic Biotech   Genome Intellidex Index  The top 4 holdings include Amgen  5    Biogen  4 9    Alexion  4 7   and Gilead  4 7    Total assets of the fund are  274 4 million representing 31 holdings  The fund s expense ratio is 0 57   The trading volume is roughly 52 000 shares per day  The fund has lost 4 5  in the past 10 trading sessions  It currently carries a Zacks ETF Rank  4  Sell  with a High risk outlook 
First Trust NYSE Arca Biotech ETF   

FBT tracks the NYSE Arca Biotechnology Index and holds 30 securities in the basket  The fund is well diversified with no stock holding more than 4  weight  Biogen  Amgen  Celgene  Alexion and Gilead have a combined exposure of about 16 5  in the fund  Total assets of the fund are  884 5 million  The fund s expense ratio is 0 58   The trading volume is roughly 443 000 shares per day  It currently carries a Zacks ETF Rank  2 with a High risk outlook  The fund has lost 3 4  in the last 10 trading sessions  read    


Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-05-02,Zacks Investment Research,https://www.investing.com/analysis/biotech-etfs-sink-on-mixed-q1-results-200127401,200127401
130154,351669,BIIB,Drug Stocks Earnings Preview  GERN  RPRX  ICPT  AGIO   More,opinion,"As we approach the end of this earnings season  investors will possibly heave a sigh of relief seeing that the going was not as bad as expected  Of the total S P500 members  88  will have reported results by the end of this week  thus making the picture even clearer  A major reason behind companies posting better than expected results during the quarter is perhaps already lowered expectations since the beginning of the earnings cycle  The recent decline in the U S  dollar also aided matters  As a result  although estimates for the second quarter are still witnessing downward revisions  the decline is not as severe as last quarter Meanwhile  the medical sector started the year on a shaky note due to the sell off witnessed by the biotech sector in the second half of 2015  Nevertheless  things are definitely looking up as the sector is still poised to beat both earnings and revenues estimates on an overall basis  In fact  as per our  report  the medical sector is one of the few sectors slated to record earnings growth this season What to Expect From These Drug Stocks Johnson   Johnson   NYSE JNJ   kick started the season on a positive note  wherein its earnings surpassed expectations and the company raised its outlook for the year  Abbott Laboratories   NYSE ABT   followed suit  Swiss oncology major Novartis   NYSE NVS    however  missed estimates  On the other hand  biotech majors Biogen   NASDAQ BIIB   and Amgen   NASDAQ AMGN   topped expectations  while industry bigwig  Gilead Sciences   NASDAQ GILD   disappointed investors  expectations However  a few key stocks are still yet to report results  Let s see how these stocks are poised ahead of their scheduled announcements tomorrow Geron Corporation   NASDAQ GERN   is scheduled to report first quarter 2016 results on May 5  Being a development stage company  investor focus is expected to remain on the company s pipeline candidate  imetelstat  However  our proven model does not conclusively show that Geron is likely to beat earnings as this Zacks Rank  3  Hold  has an  of 0 00   which makes surprise prediction difficult   Read more    Repros Therapeutics Inc    NASDAQ RPRX   is expected to report first quarter 2016 results on May 5  The company focuses on the development of drugs for the treatment of hormonal and reproductive system disorders  With no approved products in its portfolio  investors are expected to focus on Repros  progress with its pipeline candidates as well as the company s cost projections   Read more    Intercept Pharmaceuticals  Inc    NASDAQ ICPT   is scheduled to report first quarter 2016 results on May 5  Intercept does not have any approved product in its portfolio  which means that investors will watch out for updates on its lead candidate  Ocaliva  The company has a disappointing track record so far  having missed estimates in three of the last four quarters  It currently carries a Zacks Rank  4  Sell  and has an Earnings ESP of  19 83   making it highly unlikely for the stock to post an earnings beat   Read more    Agios Pharmaceuticals  Inc    NASDAQ AGIO   is scheduled to report first quarter 2016 results on May 5  Being a development stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders  investors should look out for pipeline updates  Agios  performance so far has been disappointing  with the company missing expectations in three of the last four quarters  The company currently has a Zacks Rank  3 and an Earnings ESP of 0 00  which makes surprise prediction difficult   Read more    GW Pharmaceuticals plc   NASDAQ GWPH   is scheduled to report second quarter fiscal 2016 results on May 5  GW Pharma s lead drug  Sativex  is approved outside the U S  for the treatment of spasticity associated with multiple sclerosis  Apart from pipeline updates  investor focus is expected to remain on the company s guidance  Although GW Pharma s Zacks Rank  3 enhances the predictive power of the ESP  its 0 00  ESP makes surprise prediction difficult   Read more    Conatus Pharmaceuticals Inc    NASDAQ CNAT   is scheduled to report first quarter 2016 results on May 5  With no approved product in its portfolio at the moment  investor focus is expected to remain on the company s progress with its pipeline candidates  The company currently has a Zacks Rank  3 and an Earnings ESP of 0 00   which makes surprise prediction difficult   Read more  C  AVEO Pharmaceuticals  Inc    NASDAQ AVEO   is expected to report first quarter 2016 results on Mar 5  Being a development stage biopharmaceutical company  investors are expected to focus on pipeline updates  Our proven model does not conclusively show that AVEO is likely to beat earnings this quarter as the Zacks Rank  3 company has an Earnings ESP of 0 00   making surprise prediction difficult   Read more   
Stay tuned and check later on our full write up on earnings releases of these stocks ",2016-05-03,Zacks Investment Research,"https://www.investing.com/analysis/drug-stocks-earnings-preview:-gern,-rprx,-icpt,-agio---more-200127933",200127933
130156,351671,BIIB,Biotech Stock Roundup  Amgen Impresses  Gilead Disappoints In Q1  Biogen To Spin Off Hemophilia ,opinion,"Earnings were the key focus this week with several major biotech companies like Amgen   NASDAQ AMGN    Gilead   NASDAQ GILD   and Celgene   NASDAQ CELG   reporting results  But in the midst of all this  acquisitions and deals continued to garner interest with Medivation   NASDAQ MDVN   confirming it got an unsolicited offer from Sanofi  PA SASY  and Biogen   NASDAQ BIIB   deciding to spin off its hemophilia business    Recap of the Week s Most Important Stories1  Big names in the biotech sector reported earnings over the last five trading days with some hitting the bull s eye and others falling short  Amgen started the year on the right note with not only a beat on all fronts but also a raised outlook  Read more    Meanwhile  pricing pressure and increasing competition is affecting sales of hepatitis C virus  HCV  products with both Gilead  Read more    and AbbVie   NYSE ABBV   recording a slowdown in HCV product sales  Vertex s first quarter results were also disappointing with the company missing estimates on earnings and revenues falling well short of expectations with Orkambi sales and guidance lagging expectations as well  Read more    
Alexion s results also fell short of expectations  Read more    
Celgene s results were mixed with an earnings beat and revenue miss   Read more    2  AbbVie  known for its flagship product Humira  continues to sign deals to expand its pipeline and diversify its revenue base  Along with reporting first quarter results  the company said that it will be acquiring cancer drugmaker Stemcentrx  Rova T  Stemcentrx s lead pipeline candidate  is currently in registrational studies for small cell lung cancer 
According to AbbVie  the candidate has blockbuster potential and could be launched in 2018  AbbVie intends to evaluate Rova T for additional indications and estimates peak sales approaching  5 billion   Read more   3  Medivation confirmed last week that it received an unsolicited offer from French drugmaker Sanofi  However  Medivation s Board of Directors rejected the offer of  52 50 per share as not being in the best interests of the company and its shareholders  According to rumors  Sanofi is not the only company interested in acquiring Medivation  Companies like AstraZeneca  Pfizer  NYSE PFE   Gilead and Amgen are all rumored to be prospective suitors 4  Biogen confirmed that it will be spinning off its hemophilia business into an independent  publicly traded company  There was quite a bit of speculation that the company would sell its hemophilia franchise which consists of Eloctate and Alprolix  Both products brought in total sales of  640 million during the twelve month period ended Mar 31  2016 With the spin off of this business  Biogen will go back to doing what it does best   developing and bringing neurology products to market  The company plans to speed up its efforts to bring new treatments for multiple sclerosis  spinal muscular atrophy  SMA   Alzheimer s disease  Parkinson s disease  amyotrophic lateral sclerosis  ALS   and neuropathic pain to market PerformanceAll the major biotech stocks recorded declines last week with Gilead declining 13 97  during this period  Meanwhile  Vertex has lost 35 99  over the last six months 

The NASDAQ Biotechnology Index was down 5 5  over the last five trading days  See the last biotech stock roundup here    What s Next in the Biotech World While most of the major biotech companies have already reported first quarter results  companies like Regeneron   NASDAQ REGN   will be reporting later this week Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-05-04,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stock-roundup:-amgen-impresses,-gilead-disappoints-in-q1,-biogen-to-spin-off-hemophilia-200127925",200127925
130160,351675,BIIB,The Zacks Analyst Blog Highlights  Amgen  Gilead  Celgene  Medivation And Biogen,opinion,"For Immediate Release 

Chicago  IL   May 05  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include the Amgen    NASDAQ AMGN     Gilead    NASDAQ GILD     Celgene    NASDAQ CELG     Medivation    NASDAQ MDVN    and Biogen     NASDAQ BIIB    

Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Wednesday s Analyst Blog  

Biotech Stock Roundup

Earnings were the key focus this week with several major biotech companies like Amgen    NASDAQ AMGN     Gilead    NASDAQ GILD    and Celgene     NASDAQ CELG    reporting results  But in the midst of all this  acquisitions and deals continued to garner interest with Medivation    NASDAQ MDVN    confirming it got an unsolicited offer from Sanofi  PA SASY  and Biogen    NASDAQ BIIB    deciding to spin off its hemophilia business 

Recap of the Week s Most Important Stories
	1  Big names in the biotech sector reported earnings over the last five trading days with some hitting the bull s eye and others falling short  Amgen started the year on the right note with not only a beat on all fronts but also a raised outlook  Read more     
	Meanwhile  pricing pressure and increasing competition is affecting sales of hepatitis C virus  HCV  products with both Gilead  Read more     and AbbVie recording a slowdown in HCV product sales  Vertex s first quarter results were also disappointing with the company missing estimates on earnings and revenues falling well short of expectations with Orkambi sales and guidance lagging expectations as well  Read more     

Alexion s results also fell short of expectations  Read more     

Celgene s results were mixed with an earnings beat and revenue miss   Read more     
	2  AbbVie  known for its flagship product Humira  continues to sign deals to expand its pipeline and diversify its revenue base  Along with reporting first quarter results  the company said that it will be acquiring cancer drugmaker Stemcentrx  Rova T  Stemcentrx s lead pipeline candidate  is currently in registrational studies for small cell lung cancer 

According to AbbVie  the candidate has blockbuster potential and could be launched in 2018  AbbVie intends to evaluate Rova T for additional indications and estimates peak sales approaching  5 billion   Read more    
	3  Medivation confirmed last week that it received an unsolicited offer from French drugmaker Sanofi  However  Medivation s Board of Directors rejected the offer of  52 50 per share as not being in the best interests of the company and its shareholders  According to rumors  Sanofi is not the only company interested in acquiring Medivation  Companies like AstraZeneca  Pfizer  NYSE PFE   Gilead and Amgen are all rumored to be prospective suitors 
	4  Biogen confirmed that it will be spinning off its hemophilia business into an independent  publicly traded company  There was quite a bit of speculation that the company would sell its hemophilia franchise which consists of Eloctate and Alprolix  Both products brought in total sales of  640 million during the twelve month period ended Mar 31  2016 
	With the spin off of this business  Biogen will go back to doing what it does best   developing and bringing neurology products to market  The company plans to speed up its efforts to bring new treatments for multiple sclerosis  spinal muscular atrophy  SMA   Alzheimer s disease  Parkinson s disease  amyotrophic lateral sclerosis  ALS   and neuropathic pain to market 

Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days   

About Zacks Equity Research 

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research    Find out What is happening in the  on zacks com ",2016-05-04,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-amgen,-gilead,-celgene,-medivation-and-biogen-200128209",200128209
130181,351696,BIIB,Great Start To The New Month,opinion," When I was young I thought that money was the most important thing in life  now that I am old I know that it is   Oscar Wilde

A very solid and strong start to the week as iShares Russell 2000  N IWM  is joining into the party once again and confirming the SPDR S P 500  N SPY  and PowerShares QQQ Trust Series 1  O QQQ  moves with QQQ leading  which is always best 
I bought a few more stocks today like NETGEAR Inc  O NTGR   Biogen Inc  O BIIB   and Supernus Pharmaceuticals Inc  O SUPN  so I m very heavy into stocks now and would love to remain so for months to come if they let me 

SPY is breaking out well although volume isn t spectacular  but the action is great so far  Heavy volume will be ideal and very positive as we move into new highs in the weeks ahead most likely ",2015-11-03,Warren Bevan,https://www.investing.com/analysis/great-start-to-the-new-month-270096,270096
130184,351699,BIIB,Earnings Watch  Healthcare Darling Losing Lustre ,opinion,"Biogen  O BIIB  reports earnings Wednesday morning before the market opens  The stock had been one of the darlings of the healthcare space as it rose over 850  from a base near 50 in 2010 to its peak 480 nearly a year ago  But it has not caused such great excitement recently  After a quick drop to  300  the stock has been moving lower in a channel  as shown in the chart  since August  Now off nearly 50  from the all time high  it is continuing lower into earnings 
The RSI is running flat in bearish territory just above oversold levels  as the MACD continues lower  These support more downside in the price  There is support lower at 255 and then you need to look back to a gap to fill to 253 22 from November 2013  with 230 and 223 followed by 205 as possible support after that  There is resistance above at 275 and 291 before 300  Short interest is low at 1 2  
The reaction to the last 6 earnings reports has been a move of about 9 95  on average or  26 making for an expected range of 234 to 287  The at the money January 29 Expiry Straddles suggest a smaller  17 75 move by Expiry Friday with Implied Volatility at 89  above the February at 43   Open interest is largest at the 275 Strike this week  with most of it on the Put side  There is big activity on the Put side today at the 240 Strike with a block of nearly 1600 trading on the bid  Call open interest is much lighter than both of these but all above the current price 

Trade Idea 1  Buy the January 29 Expiry 262 5 272 5 1 2 Call Spread for  0 50 
Trade Idea 2  Buy the January 29 Expiry 262 5 272 5 282 5 Call Butterfly for  2 50 
Trade Idea 3  Buy the January 29 Expiry 262 5 272 5 282 5 Call Butterfly and sell the January 29 Expiry 240 Put for 45 cents 
Trade Idea 4  Buy the January 29 Expiry 260 240 1 2 Put Spread for  4 00 
Trade Idea 5  Sell the January 29 Expiry 240 285 Strangle for a  3 45 credit 
 1   2 and  3 look for a move higher but not to exceed 280  following options open interest   1 is profitable from 263 to 282  while  2 makes money between 265 and 280   3 adds leverage to the butterfly increasing the profitable range to 262 95 to 282 05   4 follows the chart lower with leverage and is profitable between 256 and 224 Friday   5 looks both ways and uses the big open interest at 240 as well as the historical range to 285 as bounds  It is profitable between 236 55 and 289 45 Friday ",2016-01-26,Gregory W. Harmon,https://www.investing.com/analysis/earnings-watch:-healthcare-darling-losing-lustre-381760,381760
130186,351701,BIIB,Health Care  How To Play The Current Biotech Market Ahead Of Earnings,opinion,"Welcome to the February 1 edition of This Week on Estimize  We are pleased to be joined by Joe McCann  founder of Slingshot Insights  In this episode  Leigh and Joe discuss the current state of the health care industry  and look at quarterly expectations for upcoming biotech and pharma companies such as        and  
To access the Slingshot Insight projects mentioned by Joe on today s podcast  please click below ",2016-02-03,Estimize,https://www.investing.com/analysis/health-care-analyst:-how-to-play-the-current-biotech-market-ahead-of-ear-382921,382921
130207,351722,BIIB,Biogen Or Bluebird  Which Will Lead In Sickle Cell Disease ,opinion,"On April 29   of Piper Jaffray released a report highlighting several biopharmaceutical companies tackling Sickle Cell Disease  or SCD  The hereditary blood disorder is recognized by abnormal hemoglobin in the blood  Schimmer believes that to cure SCD with gene therapy  only  a very small percentage of the cells need to be successfully corrected to essentially stop the disease process   The analyst believes that Bluebird Bio and Biogen  NASDAQ BIIB  have therapies that should  prove successful for patients   but he has unique considerations for each 
Joshua Schimmer has a 58  overall success rate recommending stocks with a  12 9  average return per recommendation 
Bluebird bio Inc  NASDAQ BLUE 
LentiGlobin  Bluebird s pipeline gene therapy for SCD  is currently in Phase 1 2 testing in the United States  France  and Australia  Schimmer notes that BLUE s stock price has increased more than 500  since  the release of the first two beta thal pts treated with LentiGlobin last June   The analyst believes that LentiGlobin will bring in more than  1 billion per year in the United States alone  For now  Schimmer notes the near term investment opportunity in BLUE  However  he notes potential risks such as LentiGlobin s failure to achieve targets in testing Joshua Schimmer maintained an Overweight rating on the stock with a  186 price target  He has only rated the stock once before in February  earning an  18 9  average return on the recommendation 
On average  the top analyst consensus for BLUE on TipRanks is Strong Buy 
Biogen Inc  NASDAQ BIIB 
Schimmer also analyzes the pipeline drug developed in partnership between Biogen and Sangamo BioSciences Inc  NASDAQ SGMO   though he focuses his analysis on Biogen  The two companies are working on a ZFN approach to target BCL11a  meaning the use of artificial enzymes to target a specific protein  Schimmer notes that this approach offers  a viable alternative  to LentiGlobin  If the product is successful  Schimmer believes that  even modest penetration  in the market will deliver over  1 billion 
Joshua Schimmer currently has an Overweight rating on Biogen with a  484 price target  He has rated the stock 6 times since January 2010  earning a 67  success rate recommending the stock with a  6 0  average return per BIIB recommendation 
On average  the top analyst consensus for BIIB on TipRanks is Moderate Buy ",2015-04-30,Sarah Roden,https://www.investing.com/analysis/biogen-or-bluebird:-which-will-lead-in-scd-250221,250221
130208,351723,BIIB, 400 Billion Hidden In Your Medicine Cabinet,opinion,"If you re like most Americans  your medicine cabinet is filled with drugs that treat high blood pressure  pain and high cholesterol   Better watch those hot dogs and chips during today s Fourth of July festivities     You might feel like you re paying an arm and a leg for these prescriptions  But  surprisingly  those types of medications aren t what s costing consumers the most money   
The bulk of out of pocket pharmaceutical spending goes toward specialty drugs  These drugs require special administration and monitoring and are used to treat complex conditions  As a result  they can be extremely costly 
Today s chart looks at the change in spending on traditional and specialty drugs over the past nine years  As you can see  consumers spent 30  more on specialty drugs last year than they did in 2013 
How is this possible  Easy  Just look at the price tags   
Gilead Sciences  NASDAQ GILD    Nasdaq  GILD  Hepatitis C treatment drug Harvoni costs  94 500 for a 12 week treatment  Genentech s cancer treatment drug Avastin costs  5 560 for two vials  Biogen  NASDAQ BIIB  s  Nasdaq  BIIB  multiple sclerosis drug Avonex costs  1 363 for just one injection 
And this high level pricing isn t about to stop  Consumer spending on specialty drugs is expected to reach  400 billion by 2020 
Of course  while specialty drugs are costly for consumers  they can be extremely profitable for the companies that create them   
In 2014  Harvoni and its predecessor Sovaldi made more than  12 4 billion for Gilead  Shares of the company ended the year 25  higher than where they started 
So it s easy to see why more and more companies are racing to develop specialty drugs    and why more and more investors are scrambling to get in on the action ",2015-07-05,Investment U,https://www.investing.com/analysis/$400-billion-hidden-in-your-medicine-cabinet-257176,257176
130209,351724,BIIB,US Dollar  Commodities Eye FRS Meeting,opinion,"Global stock indices retreated on Friday  We assume they were driven down by negative macroeconomic data from the USA and the EU  New Home sales slumped 6 8  in June to their 7 month lowest  Industrial PMI in the EU  Germany and France turned out to be worse than expected  Besides  the Biogen  NASDAQ BIIB  corporation cut the current year earnings forecast  putting additional weight on stocks  As a result  S P 500 showed a weekly decrease of 2 2   Dow Jones contracted 2 9   while Nasdaq lost 2 3   The Friday statistics in the USA appeared to be less bright than in Europe  so US ICE Dollar Index dropped in relation to the euro  The American stocks trade volume was 11  above the monthly average  making 7 3bln shares  Durable Goods Orders in June will be released today at 14 30 CET  the tentative outlook is positive 
European indices have been edging higher at the moment  but have been closing with a minus for 5 consequent days  Ifo Climate Business survey in July outstripped forecasts  underpinning the euro  Analysts suppose that Greek stocks will resume business this week  Some market participants worry that they may open with a negative gap  restraining other European stocks  No important macroeconomic news is published today in the EU 
Nikkei fell to the 2 week lowest today  following other world indices  as Chinese shares plummeted after negative national earnings reports  data for June   Investors anticipate that economic slowdown in China may cut down the demand for Japanese export 
Shanghai SE Composite Index plunged 8 5  this morning  Traders sentiment deteriorated on expectations of economic slowdown in China  which produced pressure on many commodity futures 
Oil futures have been declining on expectations of the growing production in Iran  To be noted  Iraq has already increased export to 3mln barrels daily and became the second largest exporter in OPEC after Saudi Arabia  Despite the drop in prices  the number of rigs in the US rose by 21  the fastest pace since April  2014  the data were announced by Baker Huges  
The USA have been producing about 9 7mln barrels per day for a long time  Most investors estimate that global oil prices will not exceed  70 per barrel till 2017  According to US Commodity Futures Trading Commission  CFTC   the net long oil futures position has been contracting at the fastest speed since 2006 for the last 4 weeks  At the same time the overall number of net long positions has been the lowest for 5 years  China is one of the chief beneficiaries of the current oil market situation  According to National Energy Administration  the power consumption in China increased 0 7  in the first half of the year  Meanwhile  the consumption of non ecological coal contracted 5 8  due to the usage of more clean oil   2 1   and natural gas   4 3   
According to CFTS  the aggregate gold net short position has shaped at Comex for the first time since 2006  The similar copper and silver positions were previously opened by the largest hedge funds  Gold futures have now been rebounding  The price used to drop for 5 straight weeks for the first time since 2012  We believe that market participants will be looking forward to the FRS meeting minutes that are expected on Wednesday  The rate hike data may affect the American currency and precious metals prices ",2015-07-27,IFC Markets,https://www.investing.com/analysis/frs-meeting-may-affect-the-dollar-259614,259614
130237,351752,BIIB,3 Biotech ETFs in Focus As Biogen Soars,opinion,"Biotech stocks and their related ETFs have been quite popular since the start of the year  Last week   shares of Biogen Idec  NASDAQ BIIB    one of the largest U S  biotechnology companies  clocked an all time high after the company reported positive results from an early study of an investigational Alzheimer s disease treatment  read    The drug called aducanumab showed positive results in patients with early and mild forms of Alzheimer s  This encouraged investors as some of the high profile companies like Pfizer Inc  NYSE PFE  and Eli Lilly and Company  NYSE LLY  have met with failures in this field  However  the treatment still requires larger drug trials as it might not be suitable for all patients  Nonetheless  the news pushed Biogen s stock price to  480 18 during market hours  The stock rose 9 8  to  475 98 through the close of regular trading on Friday  Moreover  Biogen is planning to advance to a Phase 3 trial of aducanumab later this year   If they can replicate the Alzheimer s data in Phase III  they could conceivably have the biggest drug on the planet   according to JMP Securities analyst Michael King  If the company indeed succeeds with the drug  it might have great days ahead as roughly 75 million people are expected to develop the disease by 2030 Market Impact The surge in biotech shares also led biotech ETFs having largest exposure to the stock higher in Friday s trading session  Below we have highlighted three such products which have high allocation to Biogen shares  Investors should closely watch these products to enjoy gains if any in these products  The biotech space is currently seeing new fund launches that provide exposure to clinical biotechnology companies  These companies focus on testing their experimental drug candidates in human clinical trials with the ultimate aim of gaining FDA approval  As such  apart from the below mentioned funds  some of the recently launched products like  BioShares Biotechnology Clinical Trials Fund and ALPS Medical Breakthroughs ETF  might also see a surge in activity iShares NASDAQ Biotech  NASDAQ IBB   IBB is one of the most popular funds in the biotech space with an AUM of  7 2 billion and an average trading volume of 1 5 million shares This fund provides exposure to 150 firms by tracking the Nasdaq Biotechnology Index  see   Biogen occupies the top spot with 9 5  allocation  followed by Celgene  NASDAQ CELG  and Amgen  NASDAQ AMGN  with 9 8   7 4  and 6 9  allocations  respectively  The ETF has returned 20 8  in the year to date frame and currently has a Zacks ETF Rank  2 or Buy rating Market Vectors Biotech  NYSE BBH  This fund tracks the Market Vectors US Listed Biotech 25 Index  holding 26 securities in the basket  The product has so far amassed  798 million in its asset base and sees moderate trading volumes of roughly 161 000 shares a day  see all    Biogen scores among the top five holdings with 7 98  exposure  while Gilead Sciences Inc  NASDAQ GILD   Amgen Inc  NASDAQ AMGN  and Celgene Corporation  NASDAQ CELG  take the top three spots  The fund charges 35 basis points as fees and is up 20  this year  BBH currently has a Zacks ETF Rank  21 or Strong Buy ratingPowerSh  Dynamic Biotech   Genome  NYSE PBE  This fund provides exposure to 30 firms by tracking the Dynamic Biotech   Genome Intellidex Index  Biogen takes the fourth spot with 5 4  allocation  The product has amassed  5 7 billion in its asset base while it trades in lower volumes of 77 000 shares per day 
PBE has gained 16 5  in the year to date frame and currently has a Zacks ETF Rank  2 or Buy rating ",2015-03-24,Zacks Investment Research,https://www.investing.com/analysis/3-biotech-etfs-in-focus-as-biogen-soars-245986,245986
130238,351753,BIIB,Can Healthways Surprise This Earnings ,opinion,Healthways Inc   NASDAQ HWAY  is set to report first quarter 2015 earnings results on Apr 23  Last quarter  the company reported earnings of 25 cents per share  which beat the Zacks Consensus Estimate by 31 6   6 cents   Let s see how things are shaping up for this quarter Factors at PlayHealthways has a substantial and active pipeline of potential contracts with new and existing customers in both domestic and international markets  Revenues continue to be driven by new business wins  timing of recognizing performance based fees and expansion of existing contracts Furthermore  Healthways sees increased demand for its population health services which is expected to drive margins and revenues going forward We believe that collaborations with the likes of MedAssets Inc   NASDAQ MDAS   Sul America  SA SULA11  and EmblemHealth  and expansion of its long term relationship with CareFirst BlueCross BlueShield  CareFirst  will boost top line growth Nevertheless  the company expects to report loss in the first quarter of 2015 owing to apprehensions of lower revenues  Moreover  the back end loaded 2015 guidance is a concern Earnings Whispers Our proven model does not conclusively show that Healthways is likely to beat earnings this quarter  That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank  1  2 or 3 for this to happen  That is not the case here as you will see below Zacks ESP  Healthways currently has an Earnings ESP of 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of 3 cents Zacks Rank  Healthways has a Zacks Rank  3 which increases the predictive power of ESP  but when combined with a 0 00  ESP  it makes surprise prediction difficult We caution against stocks with Zacks Rank  4 and 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revision momentum Stocks to ConsiderHere are a few stocks worth considering that  per our model  have the right combination of elements to post an earnings beat this quarter Air Methods Corporation  NASDAQ AIRM  with an Earnings ESP of  5 88  and a Zacks Rank  1  Strong Buy  Biogen Inc   NASDAQ BIIB  with an Earnings ESP of  0 51  and a Zacks Rank  1 ,2015-04-21,Zacks Investment Research,https://www.investing.com/analysis/can-healthways-surprise-this-earnings-249188,249188
130239,351754,BIIB,Amgen Starts Earnings Season On Strong Note  Setbacks For Ampio   Athers,opinion,"Earnings season in the biotech sector started on a positive note with Amgen  NASDAQ AMGN        reporting better than expected first quarter 2015 results  Meanwhile  The Medicines Co        received some good news with an FDA advisory panel backing its antiplatelet agent  However  companies like Athersys       and Ampio suffered setbacks on the pipeline front 
Recap of the Week s Most Important Stories
1  Amgen kicked off 2015 on a strong note with both earnings and revenues surpassing expectations  Earnings were driven by higher revenues and lower operating expenses  The strong first quarter 2015 results led to the company to raise its earnings guidance for the year significantly 
We are positive on the company s restructuring plan  which should make it leaner and more cost efficient  This will be an important year on the pipeline and regulatory front as well  However  the company does have some competitive challenges in store for 2015  including the entry of biosimilar competition for Neupogen 2  The FDA s advisory panel voted in favor of approving The Medicines Co  s intravenous antiplatelet agent  Kengreal  With the panel giving a positive vote  chances of Kengreal getting approved by Jun 23 look high  The product is already approved in the EU  Read more    3  Athersys suffered a pipeline setback with its stem cell treatment failing to fare better than placebo in in a mid stage study conducted in patients who suffered an ischemic stroke  Shares were down on the interim results  Read more    4  Another company that suffered a pipeline setback is Ampio   the company s experimental pain treatment  Ampion  failed to achieve the primary endpoint in a late stage study  STRIDE study AP008   Shares were down significantly on the news  Read more    5  Alnylam       presented promising 12 month data from an ongoing mid stage study on patisiran  Patisiran is being evaluated for the treatment of transthyretin  TTR  mediated amyloidosis  ATTR amyloidosis  in patients with familial amyloidotic polyneuropathy  FAP   Results showed a decrease  2 5 point  in modified Neuropathy Impairment Score as well as a sustained knockdown in mean serum TTR at the 80  target level  According to the company  the results support the hypothesis that neuropathy progression in patients with FAP can be halted with TTR knockdown 


Over the last five trading days  Amgen was the highest gainer  3 62   among major biotechs  while Celgene  NASDAQ CELG  declined 0 83   Biogen  NASDAQ BIIB  was the highest gainer  29 18   over the last six months  Gilead       lost 1 38  during this period 
The NASDAQ Biotechnology Index was up 2 1  over the last five trading days  See the last biotech stock roundup here    
What s Next in the Biotech World 
Later this week  companies like AbbVie       and Biogen       will be reporting first quarter results  Amgen also has an important regulatory event coming up with an FDA advisory panel expected to review its regulatory application for its experimental melanoma talimogene laherparepvec on Apr 29 ",2015-04-23,Zacks Investment Research,"https://www.investing.com/analysis/amgen-starts-earnings-season-on-strong-note,-setbacks-for-ampio---athers-249387",249387
130263,351778,BIIB,Biogen s Alzheimer s Drug Moves to Phase III,opinion,Shares of Biogen Idec Inc  NASDAQ BIIB  increased 6 4  on Tuesday following positive interim results from an early stage study of its Alzheimer s disease treatment called BIIB037 that attacks amyloid plaques in the brain  As a result of the rise in trading volume  Biogen s market value increased by about  4 7 billion Biogen Idec Vice President Doug Williams claimed the treatment had a considerable effect on cognition among patients who participated in the 54 week study during Phase I studies  and saw a decline in amyloid deposits on the brain The company is now planning to move  aggressively  into Phase III  the most advanced stage of studies  This is generally the last step before seeking regulatory approval Williams stated    There are  lots of caveats  obviously  because we re still early in the clinical program  but encouraging enough data to really have us pull the trigger on moving forward aggressively to plan for Phase III    Many major biopharmaceutical companies have attempted to develop a treatment to fight Alzheimer s with little to no success On December 2nd  Deutsche Bank analyst  reiterated a Buy rating on Biogen Idec with a  430 price target following the announcement of the company s interim results of BIIB037  She noted   We see FV of Alzheimer s at  58 sh for BIIB at 100   We believe the street could be assigning 25 50  probability with this first success and see upside of  15  29 sh to stock  We think the today s stock move of  22 sh fairly represents the potential upside at this stage  Karnauskas currently has a 73  success rate recommending stocks with a  14 8  average return per recommendation  She has rated Biogen 8 times since April of this year with 75  success Similarly  BMO Capital analyst  reiterated an Outperform rating for the stock on December 2nd with a  474 price target  He reasoned   Overall  data are better than expected  with statistically significant improvement in cognition not anticipated in such a smaller study  Internal consistency of data  including dose and time dependence of Ab clearing as well as FDG PET improvement in synaptic function in the brain  lend further support for a meaningful biologic and clinical effect that should be reproduced in phase 3  Birchenough has a 63  success rate recommending stocks with a  47 5  average return per recommendation On average  the top analyst consensus for Biogen Idec is Strong Buy ,2014-12-03,Uri Gruenbaum,https://www.investing.com/analysis/biogens-alzheimers-drug-moves-to-phase-iii-234574,234574
130268,351783,BIIB,Pharma Highlights  Regulus Therapeutics Release Promising Data,opinion,It s been a busy week in the pharmaceutical industry with new data emerging on trial drugs and M A between drug companies  Here are some highlights from the latest ratings On March 18  analyst  of Piper Jaffray maintained an Overweight rating on Nektar Therapeutics  NASDAQ NKTR  but lowered his price target from  20 to  15  Nektar announced test results for NKTR 102  a drug that targets metastatic breast cancer  Unfortunately  the topline results did not show statistical significance Schimmer noted that although Nektar considers the NKTR 102 results a  near miss   he sees a potential  viable path forward   He continued   Pending regulatory clarity  we are stripping NKT 102 and associated costs from our model  but with royalties from Movantik and BAX 855 plus some additional partnered and wholly owned shots on goal  we maintain our OW rating  Joshua Schimmer has a 74  overall success rate recommending stocks with a  19 8  average return per recommendation The top analyst consensus for Nektar Therapeutics on  is Strong Buy On March 18  analyst  of BMO Capital reiterated an Outperform rating on Regulus Therapeutics Inc  NASDAQ RGLS  with a  36 price target  New promising data was released on RG 101  a hepatitis C drug  demonstrating that the drug successfully lowers levels of the virus Birchenough noted the success of the RG 101 test and commented   We continue to view a broad opportunity to shorten and simplify  hepatitis C virus  therapy  address patients with treatment failure and provide a novel option for difficult to treat patients with  the hepatitis C virus    He believes the value of the treatment has  been under estimated  and continues  to see significant value in RG 101  Jim Birchenough has an 80  overall success rate recommending stocks with a  57  average return per recommendation On average  the top analyst consensus for Regulus on is Strong Buy On March 18  analyst  of RBC Capital reiterated an Outperform rating on Biogen Idec  NASDAQ BIIB  but did not provide a price target  Biogen will be releasing new data on its experimental Alzheimer s drug  BIIB 037  on March 20 Yee has high expectations for BIIB 037 and expects the drug to prompt  stabilization of cognition levels   The study was performed over the course of one year and Yee expects to see a notable difference in cognition levels between study participants who received BIIB 037 and those who received the placebo  Yee notes that Biogen has strong fundamentals and a robust pipeline Michael Yee has a 73  overall success rate recommending stocks with a  16  average return per recommendation On average  the top analyst consensus for Biogen Idec on is Strong Buy On March 18  analyst  of Jefferies downgraded Salix Pharmaceuticals Ltd  NASDAQ SLXP  from a Buy to a Hold with a  173 price target  Salix recently agreed on a deal to be taken over by Valeant Pharmaceuticals  NYSE VRX  for  173 per share  an increase from the initial offer of  158 per share Steinberg noted that Salix chose Valeant s bid over Endo Health Solutions Inc  NASDAQ ENDP   though Endo rescinded its offer after Valeant raised its bid  He commented   We view the likelihood of a successful tender close on or near April 1 as very high  We thus downgrade SLXP from Buy to Hold  David Steinberg has a 75  overall success rate recommending stocks with a  24 4  average return per recommendation On average  the top analyst consensus for Salix on is Hold ,2015-03-19,Sarah Roden,https://www.investing.com/analysis/this-weeks-pharma-highlights-245587,245587
130269,351784,BIIB,SPX  More Room To Run,opinion," When a resolute young fellow steps up to the great bully  the world  and takes him boldly by the beard  he is often surprised to find it comes off in his hand  and that it was only tied on to scare away the timid adventurers   Ralph Waldo EmersonA great Friday with stocks rocking in the right sectors and markets doing very well also Follow the trend and focus on leading sectors and you ll do great 

Another solid move for SPY that is teetering on all time highs and it does have some room to run still for a couple days before we hit overbought levels There are some awesome stock moves going on and we were lucky enough to be part of theBiogen Idec Inc  NASDAQ BIIB  large move Friday and I m still in and looking for more There are other stocks who are set to make similar moves and I ll look into those later in this letter as always ",2015-03-22,Warren Bevan,https://www.investing.com/analysis/more-room-to-run-245805,245805
130272,351787,BIIB,Biogen s Alzheimer s Drug Shows Promising Test Results,opinion,Biogen  NASDAQ BIIB  presented test results for BIIB037  a drug intended to treat Alzheimer s disease  on March 20  The medical community was excited by the data derived from the Phase 1b study  which demonstrated  an acceptable safety profile  and  positive results on radiologic and clinical measurements in patients with prodromal or mild Alzheimer s disease   There are currently no approved drugs that fight or prevent the neurodegenerative disease Results from the trial showed that BIIB037 treatment stagnates the growth of amyloid plaque  which is considered to be a primary cause of Alzheimer s  Though the preliminary findings are promising  the data shows that the treatment will be most effective if given early on in the progression of the disease  However  the study showed side effects of headaches caused by brain swelling  Experts are cautious to create too much enthusiasm around the drug as it must endure more testing and several similar drugs have proved to be ineffective Biogen executive Alfred Sandrock  M D   Ph D   noted   This is the first time an investigational drug for Alzheimer s disease has demonstrated a statistically significant reduction on amyloid plaque as well as a statistically significant slowing of clinical impairment in patients with prodromal or mild disease  Based on these results  we are advancing the aducanumab clinical program to Phase 3 with plans to initiate enrollment later this year  According to    of J P  Morgan reiterated an Overweight rating on Biogen on March 20 Kasimov was encouraged by the results of BIIB037 and noted that the outcomes met his  relatively high expectations   He was impressed by the  strong efficacy profile in Phase 1  and notes the potential for  meaningful risks heading into Phase 3   Kasimov ultimately believes BIIB037 s  promising results will reinforce investor desire to own a piece of the potential of this asset and further fuel expectations  Cory Kasimov has rated BIIB 5 times since this January  earning an 80  overall success rate recommending the stock and a  25 8  average return per recommendation  Overall  the analyst has a 64  success rate recommending stocks with a  16 7  average return per recommendation Analyst of Cowen   Co  also appeared bullish on Biogen after the BIIB037 results as he reiterated an Outperform rating on the stock and raised his price target from  425 to  500  Schmidt noted that the drug  demonstrated an impressive time and dose dependent reduction in decline of cognition  and that  safety appears acceptable   He raised his price target due to the drug s  impressive profile  Eric Schmidt has rated Biogen 7 times since May 2009 earning an 86  success rate recommending the stock with a  32 2  average return per BIIB rating  Overall  Schmidt has an 89  success rate recommending stocks with a  58 3  average return per recommendation On average  the top analyst consensus for Biogen on is Moderate Buy ,2015-03-23,Sarah Roden,https://www.investing.com/analysis/biogens-alzheimers-drug-shows-promising-test-results-245945,245945
130281,351796,BIIB,Vitae Pharmaceuticals IPO  Neutral Plus Rating,opinion,"Vitae Pharmaceuticals Overview 
Vitae is a clinical stage biotechnology company focused on discovering and developing novel  small molecule drugs for diseases that represent large market opportunities where there are significant unmet medical needs 
Focusing in particular on type 2 diabetes and Alzeimer s  Boehringer Ingelheim GmbH is the collaborator 
Based in Fort Washington  PA  Vitae Pharmaceuticals  VTAE  scheduled a  60 million IPO on the Nasdaq with a market capitalization of  196 million at a price range mid point of  12 for Wednesday  Sept  24  2014 
There are nine new IPOs scheduled for the week of September 22 
Management
Manager  Co Managers  Stifel  BMO Capital Markets  Joint Managers  JMP Securities  Wedbush PacGrow

Valuation   

ConclusionThe rating is neutral plus  Company is currently in Phase 2 trials for type 2 diabetes  In Phase 1 trials for Alzheimer s Stockholders affiliated with Prospect Venture Partners  New Enterprise Associates  Venrock Associates and Atlas Ventures  indicated an interest in purchasing an aggregate of up to  11 million of IPO stock To put the conclusions and observations in context  the following is reorganized  edited and summarized from the full S 1 referenced above 
Business VTAE is a clinical stage biotechnology company focused on discovering and developing novel  small molecule drugs for diseases that represent large market opportunities where there are significant unmet medical needs 
VTAE is developing a robust and growing portfolio of novel product candidates generated by Contour   its proprietary structure based drug discovery platform 
VTAE s team of accomplished scientists utilizes Contour to rapidly discover highly potent and selective product candidates for validated but difficult to drug targets in multiple disease areas 
Clinical trials  VTAE s most advanced product candidates include VTP 34072  which commenced the first Phase 2 clinical trial for the treatment of type 2 diabetes in July 2014  with data expected in the first half of 2015  and VTP 37948  which is in Phase 1 clinical trials for the treatment of Alzheimer s disease  or Alzheimer s  with data expected in the second half of 2014 
Collaborations  Both products are being developed by Boehringer Ingelheim GmbH  or BI  under separate collaborations  Due to the fact that the trials for VTP 34072 and VTP 37948 are being conducted by BI in Germany  no IND  investigational new drug  applications have been submitted in the United States to date 
These collaborations have provided VTAE with an aggregate of  152 million in funding as of June 30  2014  including upfront license fees  research funding and success based milestone payments as well as equity investments 
Preclinical studies  In addition  VTAE has several wholly owned products advancing in preclinical studies  including VTP 43742 for the treatment of autoimmune disorders  with Phase 1 proof of concept expected by the end of 2015  VTP 38443 for the treatment of acute coronary syndrome  and VTP 38543 for the treatment of atopic dermatitis 
VTAE intends to advance and retain rights to these and other programs and product candidates that VTAE believes can be developed and commercialized by us  and to strategically partner where doing so can accelerate a program and generate non dilutive capital for us 
Structured based drug discovery  VTAE is a structure based drug discovery company  and has leveraged its expertise to create a growing portfolio of novel  potent and selective product candidates 
VTAE utilizes Contour to discover and develop product candidates for validated therapeutic targets against which the industry has traditionally struggled to develop drugs due to challenges related to potency  selectivity  pharmacokinetics  or patentability issues 
VTAE refers to these targets as  difficult to drug   Contour s computational software uses artificial intelligence and sophisticated algorithms to model the assembly of molecular fragments  which are chemical structures consisting of one to several atoms  into fully elaborated  drug like structures that precisely fit each target s 3 dimensional binding site  These molecules are then assessed by Contour s state of the art scoring function to identify the most promising and drug like structures 
Together  these functions allow VTAE to rapidly focus on those structures with the highest potential from among hundreds of billions of possibilities for a given biologic target  VTAE chemically synthesizes  comprehensively tests and critically evaluates these novel structures rapidly  iterating each new data set back into the design process until VTAE identifies product candidates with demonstrable first  or best in class potential 
VTAE s experienced scientists are experts in the related disciplines of structural biology  molecular modeling  i e   the design of drugs using computers   medicinal chemistry and biology  VTAE s scientists utilize its platform and approach for each of its product candidates to rapidly overcome discovery obstacles 
VTAE has achieved animal proof of concept with a qualified product candidate in less than 18 months from the initiation of a program 
Dividend Policy No dividends are planned 
Intellectual Property Each of VTAE s most advanced product candidates is the subject of patents and patent applications for composition of matter and methods of treatment in major markets worldwide 
These patents and patent applications  if granted  are expected to provide VTAE with intellectual property protection for all of VTAE s current product candidates until 2030 and beyond 
VTAE intends to continue to expand its intellectual property protections by seeking and maintaining domestic and international patents on inventions that are commercially important to its business  VTAE will also relies on know how and continuing technological innovation to develop and maintain its proprietary position 
Competition If VTAE s product candidates are approved  they will compete with currently marketed drugs and potentially with product candidates currently in development focusing on the same mechanism of action which include 
 11b HSD1  VTAE believes that Bristol Myers Squibb Company  NYSE BMY  or BMS  Eli Lilly and Company  NYSE LLY   and Roche Holding  OTC RHHVF  are studying their 11b HSD1 inhibitors in clinical trials 
 BACE  VTAE believes that Merck   Company Inc  NYSE MRK   Astrazeneca Plc  NYSE AZN  and Eisai Co   Ltd   TOKYO 4523  in collaboration with Biogen Idec Inc  NASDAQ BIIB  are studying BACE inhibitors in clinical trials 
 RORgt  VTAE believes that a number of companies including large pharmaceutical companies and large biotech companies are actively assessing RORgt inhibitors in preclinical studies 
 LXRb  VTAE believes that BMS is studying an LXRb inhibitor in cardiovascular clinical trials and Alexar Therapeutics  Inc  is developing an LXRb inhibitor for dermatologic conditions 
5  Stockholders
Prospect Venture Partners 15 2  
New Enterprise Associates 17 8  
Venrock Associates 15 6  
Atlas Venture 11 2  
Boehringer Ingelheim R D Beteiligungs GmbH 10 8  
Allergan  Inc  5 6  
Peter Barrett  Ph D  11 2  
Bryan Roberts  Ph D  15 6 
Use of Proceeds VTAE intends to use the  53 million in proceeds from its IPO as follows along with cash equivalents 
 14 0 million to fund the costs for progressing its RORgt program through Phase 1 clinical development  which consists of two trials  a single dose trial and a two week multiple dose trial  both for VTP 43742 and to identify backup compounds 
 4 0 million to fund the costs for progressing VTP 38443 through filing an IND in preparation for a Phase 1 clinical trial for the treatment of ACS 
 4 0 million to fund the costs for progressing VTP 38543 through a single dose Phase 1 clinical trial for the treatment of atopic dermatitis 
 20 0 million to fund its continued discovery efforts to identify additional drug candidates for new therapeutic molecular targets  including its immuno oncology efforts 
 9 0 million for debt maintenance  its credit facility bears interest at 8 85  per annum and the final payment is due in October 2015   and
the remainder for working capital and other general corporate purposes 
The full IPO calendar is available at  
Disclaimer  This VTAE IPO report is based on a reading and analysis of VTAE s S 1 filing  which can be found   and a separate  independent analysis by   There are no unattributed direct quotes in this article ",2014-09-24,Francis Gaskins,https://www.investing.com/analysis/vitae-pharmaceuticals-ipo:-neutral-plus-rating-226913,226913
130282,351797,BIIB,Amgen Beats Earnings Estimates  What s Next ,opinion,"Earlier today  the world s largest biotechnology company  Amgen Inc   NASDAQ AMGN  reported its earnings results for fiscal Q3 after the closing bell  and the company posted better than anticipated earnings and revenue  despite the fact that the company s total net income was hit hard by the firm s recent restructuring effort 
AMGN has spent a sizeable amount of money  approximately  376 million  and perhaps  150 million in Q4  trying to restructure itself  AMGN has recently had to deal with approximately 2 900 lay offs  and plant closings  in order to reallocate resources and efforts towards producing a potential best seller cholesterol drug  AMGN spiked higher in after hours despite the fact that the firm missed net income estimates  and many investors are still waiting for more information regarding the company s overall restructuring plans  and tomorrow  Tuesday   in New York  AMGN will carry out a business update  AMGN stock closed on Monday at  148 20 share and the stock is up in after hours trading  by about  1 55 share  or 1 05   edging very close to the  150 share price tag  which will serve as a milestone for the AMGN s stock  Amgen announced that it had earned  2 30 EPS  which exceeded the Zacks Consensus estimate by  0 24 share  This is not bad at all  considering how AMGN has been consistent with positively surprising EPS estimates  and how the company retains an average surprise of 11 11   AMGN has also readjusted its earnings expectations for 2014  raising EPS from  8 20    8 40 to  8 45    8 55 EPS  AMGN s recorded revenue for Q3 was up by 6   to  5 03 billion  beating Wall Street s estimate of  4 96 billion  The company previously forecasted  19 5    19 7 billion in revenue  however now it has also raised this to  19 8    20 0 billion  Lastly  AMGN conceded on net profit  Net income was down from  1 37 billion in Q3 2013  to  1 24 billion Q3 2014  Financials aside  AMGN s prospects do not look too bad for the future either  sales of the white blood cell booster  Neulasta  surged by 5   amounting to about  1 19 billion  Kyprolis  on the other hand  is a multiple myeloma drug that was more or less acquired through AMGN s mammoth acquisition of Onyx Pharmaceuticals last year  and the drug had sales of  94 million  AMGN also sells Prolia  a treatment drug for osteoporosis  and Prolia sales managed to jump 43  to  255 million  however that is not as good as last quarter s revenues of  264 million from the drug  Enbrel  the rheumatoid arthritis drug followed in Prolia s footsteps  and failed to shine as sales fell by about 3   However AMGN was quick to mention that inventory issues hurt the sales for Q3  though as investors  we also have to keep in mind that other biotechnology companies are competing with AMGN  Celgene  NASDAQ CELG  is another large biotech company that is aiming to render Kyprolis obsolete with its own drug  Pomalyst  which accomplished  181 million in sales for the company in Q3 
Bottom LineAMGN seems like a very solid and reputable company without a doubt  but we can expect cutthroat competition and AMGN is going to have to pick up the pace with the needed restructuring process  so as not to fall behind in regards to market share or R D  We can expect AMGN s wide variety of products to contribute to its continued growth and top line revenue  and perhaps when restructuring is finished  the company can march even higher  AMGN has been an excellent investment for investors  and we may see the stock rise on Tuesday  Still  AMGN sports a Zacks Rank  3  Hold   Despite the very high forward P E and PEG ratios when compared to the industry s average  AMGN is performing relatively well compared to other biotechnology giants  such as Gilead Sciences  NASDAQ GILD   Illumina Inc   NASDAQ ILMN   Intercept Pharmaceuticals  NASDAQ ICPT   and Biogen Idec Inc   NASDAQ BIIB   All of the aforementioned stocks maintain a Zacks Rank  1  Strong Buy   or  2  Buy   except for GILD  and that is most likely due to how it fares after it conducts its earnings conference call after the closing bell on Tuesday  The following is a comparison between the aforementioned stocks and the S P 500 Index for those looking at making a biotech investment now ",2014-10-28,Zacks Investment Research,"https://www.investing.com/analysis/amgen-beats-earnings-estimates,-what's-next-230467",230467
130283,351798,BIIB,Gilead Posts Weak Earnings  Stock Falls 4  After Hours,opinion,"Research based biopharmaceutical juggernaut  Gilead Sciences  NASDAQ GILD  announced its financial results for fiscal Q3 2014 after the market closed on Tuesday  The company s total revenues for the third fiscal quarter of 2014 rose to  6 04 billion  as opposed to the Q3 2013s relatively paltry  2 78 billion in total revenue 
Net income for Q3 was  2 73 billion  or  1 67 diluted share  which was considerably better than  788 6 million or 47 cents diluted share for Q3 last year  GILD posted  1 84 EPS for the quarter  which was better than the Zacks Consensus Estimate of  1 64 in EPS  after non recurring items   GILD currently trades at around  108 6 share in after hours trading  which is down by about  4 3  from the market closing price  GILD had previously  during regular trading  made new highs  striking an all time high of  114 13 share 
Details of GILD s Report
Product sales totaled approximately  5 97 billion for Q3  however  sales of GILD s high end Hepatitis C virus treatment slipped below Wall Street s estimates of  2 97 billion  reporting only  2 80 billion in sales  This can be partially blamed on GILD s new combination and improved once a day pill  Harvoni  which has already been approved by the FDA earlier this month  GILD claims that Harvoni will be cheaper than Sovaldi  which is likely true  given that it will truncate the duration of the treatment  which will translate into cheaper costs than Sovaldi  Sovaldi costs about  1 000 pill  or  84 000 for the regular 12 week course of treatment  in conjunction with other drugs  Harvoni will be priced at a hefty  1 125 pill  or  94 500 for a 12 week course treatment  however there will not be a need for patients to use it along with other drugs  and the success rate of Harvoni will be better than Sovaldi s already excellent rate  Many expect that the majority of patients will be able to take Harvoni for only eight weeks  rendering the cost to about  63 000 
Sales by Region        
U S product sales for the third quarter of 2014 increased to  4 21 billion  from  1 67 billion  and Europe product sales increased to  1 44 billion from  823 6 million compared to last year s Q3  The following charts are a quick display of how antiviral products sales have been faring  Antiviral products increased by  5 54 billion for Q3 2014  far better than  2 33 from the same quarter last year  thanks to sales of Sovaldi  Cardiovascular product sales also increased to  278 9 million  up from  250 9 million from last year s Q3 

Many investors blame higher operating costs to be hindering GILD s performance  and GILD s research and development expenses totaled  586 3 million  far higher than Q3 2014 s  488 5 million  However Non GAAP selling  general  and administrative costs were truly disappointing  as they more than doubled year year to  888 3 million in Q3 2014  GILD  however  has witnessed considerable growth in HIV drugs such as Viread  Complera Eviplera  and Stribild  which all managed to hit double digit year year sales increases  with Stribild s revenue jumping 128  from Q3 2013  Higher operating costs will not hold GILD back from growing and beating analysts  expectations  especially when GILD signs blockbuster deals for Harvoni in the international market in 2015  The payment of  337 million   0 21 diluted share  for the branded prescription drug fee imposed by the Affordable Care Act must also be taken into consideration for this quarter s sluggish results  Expansion of clinical studies and the launch of Sovaldi  and the chronic lymphocytic leukemia drug  Zydelig have also run operating costs  and that must be taken into account Round Up Although GILD will tumble off of its 52 week highs in the near term  the stock could have some long term promise thanks to the upcoming international release of Harvoni  Still  it is worth noting that GILD is currently a Zacks Rank  3  Hold   so earnings estimate activity has been mixed as of late  Other biomedical stocks to consider would be Illumina Inc   NASDAQ ILMN   or Biogen Idec  NASDAQ BIIB   Both sport a Zacks Rank  1  Strong Buy   and are likely to pay off very well as growth stocks for the patient investor  The following is a comparison graphic showing GILD s stellar performance versus the S P 500 Index ",2014-10-29,Zacks Investment Research,https://www.investing.com/analysis/gilead-posts-weak-earnings;-stock-falls-4-after-hours-230630,230630
130284,351799,BIIB,Gilead Sciences Releases Impressive Results for Hepatitis C Drug,opinion,Gilead Sciences  NASDAQ GILD  is a research based biopharmaceutical company based in Foster City  California  Gilead develops treatments for life threatening diseases  specifically focusing on therapies for HIV AIDS  liver diseases  and cancers  The biopharmaceutical company released impressive test results for a hepatitis C drug on November 11th  just two weeks after they released a Q3 report that topped analysts  expectations Gilead released third quarter earnings on October 28th  Total revenue for the third quarter was  6 04 billion  an impressive year over year increase from  2 78 billion  Earnings per share on a diluted basis were  1 67  also a large increase from  0 47 in the same quarter of last year Gilead in the NewsOn November 11th  Gilead Sciences released impressive test results for their newest hepatitis C drug  Harvoni  The study reported that 96  of a 500 person patient pool with advanced liver disease  sustained virologic response  from Havarti  meaning they were cured of the infection  Hepatitis C is a chronic disease that can be cured and affects 3 2 million Americans Harvoni was approved by the FDA and Health Canada in October 2014  Gilead touts the drug as the  first and only hepatitis C treatment to provide a complete regimen in a single tablet  taken orally once daily for eight  12  or 24 weeks   Gilead is working to ensure that everyone can afford access to Harvoni by partnering with seven generic pharmaceutical producers based in India  Providing generic versions of the drug will expand the market into 91 countries  which Gilead reports represents  more than half of the global hepatitis C infected population  Merck   Company  NYSE MRK   another American pharmaceutical company based in New Jersey  also developed a drug for hepatitis  The drug is a combination of existing medications and intended to be administered in a four week regimen  However  a study released on November 11th reported that the Merck drug was only successful in 39  of patients participating in the study Shares of Gilead Sciences opened at  107 50 on Tuesday  November 11th  The pharmaceutical company has a 1 year high of  116 83 and a 1 year low of  63 50  The daily moving average is  107 70 and it has a 50 day moving average of  106 41  The market cap for Gilead is  162 95 billion and its P E ratio is 19 24 A Financial Expert s OpinionOn November 11th  Robyn Karnauskas of Deutsche Bank maintained a Buy rating on Gilead Sciences with a price target of  142  Karnauskas compared the hepatitis C drugs produced by both Gilead and Merck  noting that the sustained viral response was higher with Harvoni than it was in Merck s drug  Karnauskas does  not think that  doctors  will be confident in Merck s  drug  Consequently  she continued   Gilead s  Harvoni  will remain dominant LT in the difficult to treat patients  We model 55  mkt share LT in refractory patients  20  for ABBV and 25  for other regimens including Merck s  Karnauskas has rated Gilead Sciences 16 times with a success rate of 94  and an average return of  39 9  per Gilead recommendation Robyn Karnauskas s Past RecommendationsKarnauskas has a history of rating pharmaceutical stocks such as Biogen Idec  NASDAQ BIIB  and Aegerion  NASDAQ AEGR   helping her earn an overall success rate of 75  with an average return of  14 8  per recommendation Karnauskas last rated Biogen Idec with a Buy on October 22nd when shares were  309 07  Now  shares are  324 59  Successful recommendations such as this has helped earned Karnauskas an 86  success rate recommending Biogen with an average return of  18 9  per recommendation However  Karnauskas rated Aegerion a Buy on February 26th when shares were  54 76  Now  shares are down to  21 56  She has rated the stock five times with a negative average return of  43 9  ConclusionGilead Sciences ran a very successful test with its new Harvoni drug for Hepatitis C  Karnauskas sees great potential  but do you trust her latest recommendation based on her history of financial advice To see more recommendations from Robyn Karnauskas  visit TIpRanks today ,2014-11-12,Uri Gruenbaum,https://www.investing.com/analysis/gilead-sciences-releases-impressive-results-for-hepatitis-c-drug-232260,232260
130288,351803,BIIB,Market Can t Sell    ,opinion,Yet  Of course  it can  but it has yet to show any sign of doing  so no matter what s going on around it that says it has to sell  At least some one would think that s the case  We can research one weekly index chart after another  and the degree of negative divergences is huge  Sometimes you look and think  well these aren t that bad  Not the case here  They re really bad  Then we can take a look at the monthly index charts  We get concerned when RSI s approach 70  Well  now they re approaching 80 in some cases  Unheard of on monthly charts  Nice combination for the bears between the weekly divergences and the monthly overbought conditions One would think  but nothing yet for the bears  So now we can focus on the daily charts  but they too are approaching  or at  70 RSI s across the key index charts  Could the bears ask for more  Now that you ask  yes they can  They can say   hey bulls  you re out of control on the sentiment front   and they d be correct in saying so  Another journey to the land of over 40 on the bull bear spread  Add this all up  and  to be kind  the market should be falling apart  Just getting annihilated day after day  No mercy  Straight down with huge volume to top things off  The bulls should be taking a real beating  Nope  No sellers  Not even a hint of it  Seems impossible  but it is what it is I admit I don t understand it  Since this  basically  never happens there is no way to know if  or when  things will turn down  The fact that I can say  if  tells you the power behind the market in terms of not allowing a single  reasonable selling episode  It may not be healthy  but that s what we re dealing with for now  Neither I  nor any one of you  know when this will turn  so you stay with the trend in place and wait for the reversal  As we have discussed  if you re in you ll have to deal with some losing trades at the end of things  and  thus  your choices are playing lightly or staying cash  Shorting makes little to no sense  The unheard of is being heard loud and clear for now  Interesting times It has gotten so bad for the bears that they can t even take out the simplest of support levels on the short term sixty minute charts  204 00 on the S P 500 is the 20 day exponential moving average  and watching for two hours as the bears tried to take this level out with force  was almost comical  It has gotten so bad that it s almost as if the bulls are rubbing it in to the bears   Go ahead and try boys and girls  It s only the 20 day EMA on the short term charts  Anyone can do that  right   Well maybe you can t  Mocking them  Every attempt below met with instant buyers  It s sad to watch The biggest problem with all of this is the bulls are allowing their own frothy behavior to increase the level of bulls to bears  The higher the spread the nastier the damage somewhere down the road  The mocking they re doing now will come back in spades against them in time  But  for now  the very simplest of support levels can t be taken out by the bears  Saddest times for them I can remember in quite a few years  It s as if they ve truly given up on all levels  A bad sign for the bulls  We shall see  but  for now  the bears having absolutely nothing  even when they are up against the easiest of support levels Do not lose touch with what s happening in this phase of the bull market  In normalized bull markets there are few  if any real  slaughters that take place from sector to sector when they get overbought  They gently pull back on price as the oscillators unwind themselves  Not the case here  Since this is a bullied bull market due to rates  the money is rotating  but as it does we are seeing some real nasty days along the way  Today the biotech stocks took a beating  Some true collapses not only today  but for quite a few days  Some stocks just crushed along the way  The point is that you can t just throw a dart and know things are good You need to do some real research on each sector chart before running in as an overbought sector  because it can lead to real nastiness  Stocks such as Biogen Idec Inc   BIIB   Puma Biotechnology  Inc   PBYI   Regeneron Pharmaceuticals  Inc   REGN   Amgen Inc   AMGN   Gilead Sciences Inc   GILD   and Celgene Corporation  CELG  to name a few today that took hits  Some massive  This market is more complicated in terms of where you place your dollars  so be very careful to do your homework before entering  Be sure not to play sectors with 70 RSI s  They can work  but the risk is very high  Look for unwound situations on those short term sixty minute charts for safer entry  Nothing is guaranteed  of course  but the more unwinding you get the lower the risk ,2014-11-15,Jack Steiman,https://www.investing.com/analysis/market-can't-sell....-232558,232558
130290,351805,BIIB,Affymetrix Now a Strong Buy  Raised Guidance Positive,opinion,"On Nov 14  2014  Zacks Investment Research upgraded Affymetrix Inc   NASDAQ AFFX   to a Zacks Rank  1  Strong Buy   Positive estimate revisions owing to impressive third quarter results and a raised guidance primarily drove the upside 
Why the Upgrade  Impressive third quarter results  positive guidance revision  new products  accretive acquisitions and partnerships were the primary reasons justifying the upgrade  In the recently concluded third quarter  both earnings and revenues beat the respective Zacks Consensus Estimate  Most importantly  earnings surged a significant 60  from the year ago quarter  This marked the sixth consecutive earnings beat for the company after a period of persistent losses  Affymetrix s restructuring plan aimed at diversifying revenues by focusing on high growth markets is finally paying off as demonstrated by its stellar bottom line growth  We are encouraged by the company s robust third quarter adjusted performance which prompted a higher revenue and EBITDA guidance for 2014   Despite a tight academic funding environment  new products and acquisitions along with accretive agreements should propel growth going forward Estimate Revisions The Zacks Consensus Estimate for fiscal 2014 have surged approximately 39   7 cents  to 25 cents per share over the last 30 days  This represents year over year growth of 150   Likewise  for fiscal 2015  the Zacks Consensus Estimate jumped 35   7 cents  to 27 cents per share over the same time frame Other Stocks to Consider One may also consider some other players in the industry that look attractive at current levels  These include AMAG Pharmaceuticals  NASDAQ AMAG    ANI Pharmaceuticals  NASDAQ ANIP  and Biogen Idec  NASDAQ BIIB   All the three stocks carry the same Zacks Rank as Affymetrix ",2014-11-16,Zacks Investment Research,"https://www.investing.com/analysis/affymetrix-now-a-strong-buy,-raised-guidance-positive-232629",232629
130292,351807,BIIB,Covered Call Writing With Protective Puts  A Proposed Strategy,opinion,"When protective puts are integrated into our covered call writing strategy it is known as the collar strategy  The covered call aspect of the trade generates cash flow and the protective put leg serves as an insurance policy against catastrophic share depreciation  Recently  one of our members  Gary  shared with me a related strategy he had heard about and I thought I d discuss it with the entire BCI community  On this site we never embrace or reject a strategy approach outright but rather evaluate it from a  pros and cons  perspective and then each of us can make an informed decision as to whether it should be integrated into our portfolios based on our personal risk tolerance  Let s break this down the Blue Collar way 
The proposed strategy
Select a stock or ETF with high implied volatility  like Gilead Sciences Inc  NASDAQ GILD   Biogen Idec Inc  NASDAQ BIIB   iShares NASDAQ Biotech  NASDAQ IBB  
Underlying securities should be large cap so option  is high and bid ask spreads tight
Associated options should have weeklies that generate   1 
Go 1 2 strikes out of the money for weeklies
Buy protective puts 6 months out
Protective puts should be 15   20  out of the money  lower than current market value 
Cost of puts should be no more than 1 month of covered call profits
Theoretical returns
1  per week for 6 months   26 
Cost of put   26  6   4 3 
6 month theoretical return   21 7 
Annualized theoretical return   43 4 
GILD example
Real life price    102 22
 85  6 month put is 17 5  out of the money
Cost of  85 put    4 30  less than 1 month of weekly premiums as shown below 
The  104 weekly call generates  1 25 which meets the 1  system criteria
Theoretical return per contract for GILD example if share price and premiums remain constant
 26 x  125     430  10 222   27 6    55  annualized
Advantages of this strategy
The advantages of this strategy are clear  A huge annualized return can be realized based on certain assumptions like share price and short call premiums remaining constant during the 6 month time frame  We also have protection against catastrophic share loss below the  85 put strike  By selecting a 6 month put  the monthly cost of this protection is decreased compared to buying a put each month  In addition to this  there is opportunity to generate additional profit if share price moves up to the strike of the short call 
Potential pitfalls and possible disadvantages of this strategy
Trading commissions
One of the disadvantages of weeklies is that we have 4   5 times the amount of trading commissions compared to monthlies  Assuming a reasonable fee of  10 per trade  that computes to  260 for the 6 month time frame  assuming 1 contract trades  Let s add  20 in commissions for the purchase of the shares and then put  Therefore  over the 6 month time frame  the short calls must overcome a net debit of  430    280    710 
When do we breakeven  
Based on a weekly premium of  125  we breakeven after 6 weeks  Keep in mind that we paid  102 22 for the shares and we are using a security with high implied volatility as defined by the proposed strategy  If share price declines  we must be prepared for this  we start losing money and we will not break even for 6 weeks 
What about management techniques 
For traditional covered call writing we are managing two positions  the long stocks and the short call  In the proposed strategy  we are also managing the long put position  The investor must be capable of managing all 3 positions   In addition to this  if share price moves above the short call strike  we must roll the option in order to retain share ownership  This will most likely impact our  125 week premium goal as the time value of a short call will decline as the strike moves deeper in the money  Rolling out and up may actually result in a short call debit  Rolling will also result in more trading commissions further eroding the profits from a theoretical trade 
What about earnings reports 
Two times within the 6 month time frame  there will be an earnings announcement  I strongly believe that a short call should not be written in those 2 weeks  thereby decreasing returns from the theoretical stats we archived above  The strategy  however  does require us to retain the shares through these two earnings reports and that may result in a dramatic share decline if the report  s  is disappointing  Now we are protected below  85 because of the long put but there s a lot to lose between  102 22 and  85 
What about dividends 
Of the three securities mentioned by Gary  IBB does distribute a quarterly dividend  Although unlikely  there is the possibility of early exercise  when expiration occurs after the ex dividend date  Should the shares be assigned because of the ex date  new shares would have to be purchased at the current market value and who knows how this would impact our theoretical returns  There are ways to avoid early exercise resulting from ex dates but that would involve sophisticated management skills and would not be guaranteed 
What is the basis for selecting the underlying security 
For traditional covered call writing  according to the BCI methodology  a stock or ETF is chosen based on three factors  fundamental and technical analysis as well as common sense principles like minimum trading volume and avoiding earnings reports  In this proposed strategy  it appears that the main criteria for selection is option returns and liquidity  Quantity seems to take precedence over quality 
What about the 6 month time frame 
We enter a trade today because certain system criteria are met such as those mentioned at the top of this article  By undertaking a 6 month obligation  we are making the assumption that those same positive factors will be in place for half a year  We should at least be prepared that this may not come to fruition as shown in the chart below 

GILD  price movement impacting strike selection
Discussion
There are many ways to make money in the stock and option markets  The proposed strategy may be one of those ways for certain investors  One key point is that there are no free lunches and every strategy has its advantages and disadvantages which must be evaluated before risking our hard earned money 
Market tone
Another positive week of economic reports supported an advancing stock market 
Minutes from the October 28   29 FOMC meeting revealed that the Fed plans to keep interest rates near zero  An improving economy was noted but so were concerns of low inflation
The Conference Board s Index of Leading Economic Indicators rose by 0 9  in October  above expectations  the 13th increase in the last 15 months
Industrial production declined by 0 1  in October  below the   0 2  anticipated
Manufufacturing  in general  was up 0 2  in October
New housing starts declined by 2 8  in October but are still up 7 8  from a year ago
Housing permits were up 4 8  in October  the highest monthly increase since July and higher than a year ago
Sales of existing homes in October increased by 1 5  and for the first time in 2014 was higher year over year and at its highest pace since September  2013
The median price of existing homes in October rose to  208 300  a 5 5  increase from October  2013  This marks 32 consecutive weeks of year over year increases
The Producer Price Index  PPI  increased by 0 2  in October and by 1 5  year over year
The CPI was unchanged in October  Inflation is up 1 7  year over year  below the Fed s 2  target rate
The Conference Board s Index of Leading Economic Indicators rose by 0 9  in October  above expectations  This was the 13th increase in the past 15 months
For the week  the S P 500 rose by 1 2  for a year to date return of 14   including dividends 
Summary
IBD  Confirmed uptrend
GMI 6 6  Buy signal since market close of October 27  2014
BCI  Moderately bullish favoring out of the money strikes 2 to 1
Wishing you the best in investing ",2014-11-23,Dr. Alan Ellman,https://www.investing.com/analysis/covered-call-writing-with-protective-puts:-a-proposed-strategy-233382,233382
130293,351808,BIIB,Dow Jones  Reached All Time High Of 17 877 75,opinion,Dow JonesDow Jones Industrial Average added 100 95 points  or 0 6 percent  to an all time high of 17 877 75  The Russell 2000 Index of small companies jumped 1 3 percent  after dropping 1 6 percent yesterday    The economy seems to be fine and nothing is changing that narrative   James W  Gaul  a portfolio manager at Boston Advisors LLC  which oversees about  2 8 billion  said by phone   The energy sector is up while oil is down  Maybe the thought is the sector fell too far  too fast  Health care is being led by biotechnology stocks  mainly Biogen Idec  NASDAQ BIIB  ,2014-12-03,ICM Brokers,"https://www.investing.com/analysis/dow-jones:-reached-all-time-high-of-17,877.75-234490",234490
130311,351826,BIIB,Leaders Of The Pharmaceutical Pack,opinion,"When it comes to the large cap pharma biotech companies Allergan Inc  NYSE AGN   and Merck   Company Inc  NYSE MRK   may be the canaries in the coal mine  The tell  The leaders of the pack  when it comes to signals of a market sector reversal  Allergan  is not a small company at  38 billion market cap  It is starting to turn the ship around and head higher  The weekly chart below shows the shows the Marubozu candle building this week confirming the Hammer reversal from last week higher  This comes after a retracement of only 23 6  of that major move higher from June 2013  but 61 8  of the last leg in that run from the February 3rd low  The RSI has started to move back higher and you
can measure a positive RSI Reversal to at least 137 36  The MACD is leveling after a brief pullback and staring to kink up  A cross higher confirms the others  When you look at Celgene Corporation  NASDAQ CELG  Biogen IDEC   NASDAQ BIIB   Bristol Myers Squibb  Bristol Myers Squibb Company  NYSE BMY   and Pfizer Inc  NYSE PFE  they are not nearly as far along in reversing  But one other to watch is Merck  The weekly chart on this shows a very shallow  V  recovery and only a thin resistance zone from 57 to 57 70 above before heading for new highs  Keep an eye on these new leaders of the pack  Allergan reports May 7th and Merck April 29th 
Disclosure  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2014-04-16,Gregory W. Harmon,https://www.investing.com/analysis/leaders-of-the-pharmaceutical-pack-209751,209751
130314,351829,BIIB,Top Trade Ideas For The Week Of June 30  2014  Bonus Idea,opinion,"Here is your Bonus Idea with links to the full Top Ten 
Biogen Idec  Ticker  BIIBBiogen Idec  NASDAQ BIIB   has built a Cup and Handle pattern and is testing the top of the pattern for a break out  A move over 322 carries a Measured Move higher to 372  The RSI is in the bullish zone and rising with a MACD that is crossing up and positive as well as the accum dist statistic that has been rising  There is resistance higher at 331 and 347 followed by 355 and then free air higher  Support may come lower at 312 and 304 followed by 288 and 280 
Trade Idea 1  Buy the stock on a move over 322 with a stop at 310 
Trade Idea 2  Buy the July 320 Calls  offered at  6 40 late Friday  on the same trigger 
Trade Idea 3  Buy the July August 325 Call Calendar   6 70  
Trade Idea 4  Buy the August 325 350 Call Spread and sell the August 300 Put   1 60  
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which  sees Monday closing the 2nd Quarter and then we head into July with the equity market still looking strong  Elsewhere look for Gold to continue in its uptrend while Crude Oil may continue to consolidate in its uptrend  The US Dollar Index is in another short term downtrend while US Treasuries are biased higher  but may need a very short pullback first  The Shanghai Composite continues to grind sideways with Emerging Markets pulling back or consolidating in their uptrend  Volatility looks to remain minuscule keeping the bias higher for the equity index ETF s SPY  IWM and QQQ  Their charts show that the SPY and IWM gained some strength to end the week but are still in a range while the QQQ is rising and very strong  Use this information as you prepare for the coming week and trad em well 
Disclosure  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2014-06-30,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-of-june-30,-2014:-bonus-idea-217864",217864
130331,351846,BIIB,5 Top Biotech ETFs,opinion,There are only a handful of effective ETFs focused exclusively on biotechnology  Nevertheless  the sector contains companies that will probably produce more effective medical treatment and healthcare than all the insurance plans and HMOs combined  This is the next big thing for the human race as in the future immunization and cures for disease will allow people to live longer and healthier lives  As an anecdote  a very famous and successful heart surgeon told me a few decades ago that his profession would no doubt be obsolete someday due to advances in biotechnology Biotechnology companies are valued more for their future promise than current earnings and sales  This has always been the case making PEs sometimes very high and confusing more uninformed investors  At the same time  when there are clinical trial failures of new drugs or treatments the related company s shares may plunge significantly  Successful results can lead to dramatic stock gains  One other little known trait is that when earnings from more conventional sectors struggle investors often turn to the biotech sector seeking better performance away from earnings  It may seem an odd pattern but it is something I ve noticed over more than a few decades In fact  since the beginning of 2012  the biotech sector has been one of the better performing areas  This has been due to recent successful clinical trials and a belief that more M A activity will occur  Established pharmaceutical companies may wish to acquire biotech firms as their pipeline of new drugs weakens  It s easier and perhaps even cheaper to acquire these firms than to develop their technology from scratch We feature a technical view of conditions from monthly chart views  Simplistically  we recommend longer term investors stay on the right side of the 12 month simple moving average  When prices are above the moving average  stay long  and when below remain in cash or short  Some more interested in a fundamental approach may not care so much about technical issues preferring instead to buy when prices are perceived as low and sell for other reasons when high  but  this is not our approach For traders and investors wishing to hedge  leveraged and inverse issues are available to utilize from ProShares and where available these are noted   FBT follows the NYSE Arca Biotechnology Index which is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services  The fund was launched in June 2006  The expense ratio is 0 60     AUM equal  259M and average daily trading volume is 70K shares  As of May 2012 the annual dividend yield is negligible and YTD return 38 21   The 1YR return was  0 07     Data as of May 2012 FBT Top Ten Holdings and Weightings    Amylin Pharmaceuticals Inc  AMLN   9 60     Regeneron Pharmaceuticals  Inc   REGN   6 55     Illumina  Inc   ILMN   6 37     Nektar Therapeutics  Inc   NKTR   5 78     Alexion Pharmaceuticals  Inc   ALXN   5 54     Vertex Pharmaceuticals  VRTX   4 97     Incyte Corp Ltd  INCY   4 91     Life Technologies Corp  LIFE   4 73     Myriad Genetics  Inc   MYGN   4 68     Biogen Idec Inc  BIIB   4 68   PBE follows the Dynamic Biotechnology   Genome Intellidex Index which is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria  including fundamental growth  stock valuation  investment timeliness and risk factors The fund was launched in June 2005  The expense ratio is 0 60   AUM equal  134M and average daily trading volume is 13K shares  As of May 2012 the annual dividend yield is1 70  and YTD return 9 67   The 1 YR return was  7 06  Data as of May 2012PBE Top Ten Holdings and Weightings  Alexion Pharmaceuticals  Inc   ALXN   5 38   Biogen Idec Inc  BIIB   5 30   Gilead Sciences Inc  GILD   5 29   Waters Corporation  WAT   5 13   Life Technologies Corp  LIFE   5 02   Sigma Aldrich Corporation  SIAL   4 93   Amgen Inc  AMGN   4 92   Biomarin Pharmaceutical  Inc   BMRN   4 80   Seattle Genetics  Inc   SGEN   3 10   Nektar Therapeutics  Inc   NKTR   3 03  BBH follows the Market Vectors US Listed Biotech 25 Index which is a rules based index intended to track the overall performance of 25 of the largest U S  listed and publicly traded biotech companies  The fund was  relaunched  in December 2011  It is the result of Van Eck taking over control of what previously was the Merrill Lynch HOLDRs which was a trust of securities from 2000  As a trust the previous constituents could not be changed other than if one were assumed by another company or ceased to exist  As a consequence over time some constituents increased dramatically in size and weighting  Frankly BBH was Amgen and little else  The new index keeps much of the previous weightings as Van Eck from a business view most likely did not want to disrupt previous holders who were content with the way things were  But now we move on and we ll see how the index changes over time  The expense ratio is 0 35   AUM equal  106M and average daily trading volume is 42K shares  As May 2012 the annual dividend yield is 1 08  and YTD return 28 33   The 1 YR return was 32 07  with the latter mostly due to an even heavier weighting in Amgen than currently  Data as of May 2012BBH Top Ten Holdings and Weightings  Amgen Inc  AMGN   16 49   Gilead Sciences Inc  GILD   9 40   Celgene Corporation  CELG   8 96   Biogen Idec Inc  BIIB   7 60   Regeneron Pharmaceuticals  Inc   REGN   6 48   Alexion Pharmaceuticals  Inc   ALXN   5 38   Illumina  Inc   ILMN   5 30   Vertex Pharmaceuticals  VRTX   5 03   Life Technologies Corp  LIFE   4 45   Seattle Genetics  Inc   SGEN   3 87 IBB which follows the NASDAQ Biotechnology Index which contains companies classified as either biotechnology cor pharmaceuticals companies  The fund was launched in May 2001  The expense ratio is 0 48   Assets under Management  AUM  equal  1 771M and average daily trading volume is 485K shares  As of May 2012 the annual dividend yield is 0 01  and YTD return 21 16   The 1 YR return was 15 47   ProShares has leveraged long and short ETFs for those wishing to speculate or hedge  Data as of May 2012IBB Top Ten Holdings and Weightings  Regeneron Pharmaceuticals  Inc   REGN   7 63   Amgen Inc  AMGN   7 38   Alexion Pharmaceuticals  Inc   ALXN   7 32   Celgene Corporation  CELG   5 83   Gilead Sciences Inc  GILD   5 70   Biogen Idec Inc  BIIB   5 15   Teva Pharmaceutical Industries Ltd ADR  TEVA   4 61   Perrigo Company  PRGO   4 00   Vertex Pharmaceuticals  VRTX   3 23   Mylan Inc  MYL   2 71 XBI follows the S P Biotechnology Select Industry Index which represents the biotechnology sub industry portion of the S P Total Markets Index  The S P TMI tracks all the U S  common stocks listed on the NYSE  AMEX  NASDAQ National Market and NASDAQ Small Cap exchanges  The Biotech Index is an equal weighted market cap index The fund was launched in January 2006  The expense ratio is 0 35   AUM equal  539M and average daily trading volume is 211K shares  As of May 2012 the annual dividend yield is 0 01  and YTD return 24 37   The 1 YR return was 11 13  Data as of May 2012XBI Top Ten Holdings and Weightings  Human Genome Sciences Inc  HGSI   4 88   Amylin Pharmaceuticals Inc  AMLN   4 48   Incyte Corp Ltd  INCY   3 61   Regeneron Pharmaceuticals  Inc   REGN   3 44   Onyx Pharmaceuticals  Inc   ONXX   3 26   Dendreon Corp  DNDN   3 15   Gilead Sciences Inc  GILD   3 08   Biogen Idec Inc  BIIB   3 03   Ariad Pharmaceuticals  ARIA   3 02   Seattle Genetics  Inc   SGEN   3 01 Biotechnology still remains the hope for the future of health care in our opinion  Exposure to them is important  but their inherent volatility makes technical views equally important  We rank the top 10 ETF by our proprietary stars system as outlined below  However  given that we re sorting these by both short and intermediate issues we have split the rankings as we move from one classification to another Strong established linked indexExcellent consistent performance and index trackingLow fee structureStrong portfolio suitabilityExcellent liquidityEstablished linked index even if  enhanced Good performance or more volatile if  enhanced  indexAverage to higher fee structureGood portfolio suitability or more active management if  enhanced  indexDecent liquidityEnhanced or seasoned indexLess consistent performance and more volatileFees higher than averagePortfolio suitability would need more active tradingAverage to below average liquidityIndex is newIssue is new and needs seasoningFees are highPortfolio suitability also needs seasoningLiquidity below averageIt s also important to remember that ETF sponsors have their own competitive business interests when issuing products which may not necessarily align with your investment needs  New ETFs from highly regarded and substantial new providers are also being issued  These may include Charles Schwab s ETFs and Scottrade s Focus Shares which both are issuing new ETFs with low expense ratios and commission free trading at their respective firms  These may also become popular as they become seasoned Disclosure  The ETF Digest is long IBB and XBI  Source for data is from ETF sponsors and various ETF data providers ,2012-05-16,Dave Fry,https://www.investing.com/analysis/5-top-biotech-etfs-123255,123255
130334,351849,BIIB,Top 10 Trade Ideas   Week Of December 3  2012,opinion,Biogen Idec  BIIB Biogen Idec  BIIB  has been consolidating after a move off the base at 135 140  A break over the consolidation at 150 carries a Measured Move higher to 162  There is resistance at 153 80 and 156 75 along the way and then free air higher  The Relative Strength Index  RSI  is teasing a move into bullish territory with a Moving Average Convergence Divergence indicator  MACD  that is positive but fading  These are positive but caution a possible reversal  As does the bearish engulfing candle on Friday  confirming the Shooting Star reversal candle lower  A fall back below 147 50 finds support lower at 142 and 139 before 135  Long Trade Ideas 1  Buy the stock on a move over 150 with a  3 trailing stop  2  Buy the December 150 Calls  offered at  3 20 late Friday  on the same trigger  3  Sell the December 140 Puts  50 cents  on the same trigger  4  Buy the December 150 160 Call Spread Risk Reversal selling the December 140 Puts   2 10  on the same trigger 5  Buy the December January 155 Call Calendar selling the January 140 Put  40 cents  on the same trigger  Short Trade Ideas 1  Sell the stock short on a break below 147 50 with a stop at 149  2  Buy the December 145 Puts   1 75  on the same trigger  3  Buy the December 145 140 Put Spread   1 25  on the same trigger  4  Buy the December 145 140 135 Put Butterfly   1 05  on the same trigger  5  Buy the December 145 140 1 2 Ratio Put Spread  75 cents  on the same trigger After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Saturday which  heading into December sees the markets are biased higher but cautiously so  Gold looks headed lower in its long term channel while Crude Oil heads higher  The US Dollar Index seems content to move lower while US Treasurys are biased lower but may continue to consolidate  The Shanghai Composite is marching lower while Emerging Markets stagnate in their consolidation zone  Volatility looks to remain low keeping the bias higher for the equity index ETF s SPY  IWM and QQQ  Their charts are starting to show signs of being tired though  so caution is warranted on the long side in the near term  Use this information as you prepare for the coming week and trade m well Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ,2012-12-04,Gregory W. Harmon,"https://www.investing.com/analysis/top-10-trade-ideas:--week-of-december-3,-2012-146011",146011
130335,351850,BIIB,TECFIDERA Raises The Bar For Biogen Idec,opinion,The bar has been raised significantly for Biogen Idec  BIIB  after the FDA approval of TECFIDERA   dimethyl fumarate    Biogen Idec s first line oral treatment for relapsing forms of multiple sclerosis  MS   While the approval wasn t all that surprising to the market judging by the mild  5 4  jump that BIIB saw during last Thursday s trading  many investors who prefer larger pharmaceutical companies are now looking much more favorably upon BIIB  The stock is up 31 6  since the start of the year  beating the broader market by almost 22   Although it s just one more drug in Biogen s already impressive multiple sclerosis product line  Wall Street is expecting particularly high sales for Tecfidera based on its proven efficacy and target indication  Just how high are these expectations  Consider that Biogen s three big MS drugs   AVONEX  approved in 2003   TYSABRI  in 2006   and RITUXAN  in late 2012   bring in the bulk of its   5 billion in annual revenues  These three drugs bring in quarterly revenues of  736 million   275 million  and  288 million respectively as of Q3 2012  and have generally penetrated quite nicely into their target indications  The one exception is Rituxan  which has a lot more room to run  Then consider that the eight BIIB analysts surveyed by  have an average expectation of  3 25 billion in annual revenue for 2017  This implies that Tecfidera will have to outperform Biogen s blockbuster drug Avonex after it fully saturates its target indication  Yeah  the drug has some pretty big shoes to fill  To top it off  the drug will have competition for this indication from Novartis s  NVS  Gilenya and Sanofi s  SNY  Aubagio  as mentioned in the Bloomberg article   but BIIB investors might be encouraged to know that that Novartis  next  promising  oral MS drug BAF312 isn t expected to hit the market any time before 2017  The notion that Tecfidera is going to single handedly boost Biogen Idec s already enormous revenues by 65  within the next few years might be hard to swallow  but the sheer size of the MS indication makes it more than feasible  The degenerative disease affects about 2 1 million worldwide  and roughly 350 000 in the United States alone  With MS treatments costing around  30 000 per patient per year  one can infer that the MS drug market could be as large as  10 billion in the US alone  with a lot more potential in overseas markets that s more difficult to measure  This is huge market  which is why it doesn t make sense to worry about Biogen s valuation given how much more revenue potential it has down the road  Patent expirations are also a non issue for now  Note that in 2009  Biogen Idec was able to move the patent expiration on Avonex all the way to 2026  So while Biogen Idec really was a laggard amongst the big pharma names in past years  its highly profitable multiple sclerosis portfolio is taking the company in a completely new direction  I also think that Wall Street has placed very realistic expectations for Tecfidera that may even be surpassed before 2017  depending on its marketing and market penetration rate  Because of this  I see BIIB as an undiversified but fairly safe pharmaceutical stock that has one of the better risk reward profiles in the big pharma space  I also believe that its lack of yield is outweighed by the stock s lower valuation relative to its top line growth  which should continue quite nicely with the introduction of Tecfidera  Since the analyst expectations for Tecfidera s sales potential will basically be the market s general expectations for the new MS drug for quite some time  I d expect BIIB to either hold its new levels or possibly stage another rally given that the company doesn t release any additional news that could fade the bullish sentiment  We ll have to see ,2013-04-02,Myriad Equity,https://www.investing.com/analysis/tecfidera-raises-the-bar-for-biogen-idec-161190,161190
130336,351851,BIIB,Have The Biotech Stocks Topped Out  ,opinion,The biotech stocks have the been one of the leading stocks sectors throughout 2012 and 2013  The Market Vectors Biotech ETF  BBH  has rallied higher by more than  36 00 since August 10  2011  Today  the BBH is trading lower by 0 41 cents to  64 32 a share  The BBH looks very overbought and extended on the daily and weekly charts  This tells us that a pullback should be expected as it is very overdue  Short term traders should watch for intra day support on the BBH around the  63 70  and  62 30 levels  The daily chart will likely have support around the  60 00 area Some other biotech ETF s that traders can follow include the SPDR S P Biotech  ETF   XBI   and the iShares NASDAQ Biotechnology Index  ETF   IBB   Some of the leading biotech stocks that make up a large part of these ETF s include Amgen Inc  AMGN   Celgene Corporation  CELG   and Biogen Idec Inc  BIIB   All of these stocks have traded very similar chart patterns to the biotech ETF s so they are very susceptible to pullbacks at this time ,2013-04-09,Nicholas Santiago,https://www.investing.com/analysis/have-the-biotech-stocks-topped-out-162141,162141
130337,351852,BIIB,Cowen Questions Sales Growth Of Biogen Idec s MS Drug Tecfidera,opinion,Yesterday  Biogen Idec  BIIB  was the worst performer amongst the larger pharmaceutical companies after Cowen analyst Eric Schmidt pointed that the IMS prescription sales data for new prescriptions  NRx  of the company s recently launched multiple sclerosis   MS drug Tecfidera  dimethyl fumarate  may be flawed due to double counting of patients were prescribed a new dose of the drug  After Biogen launched the drug earlier in the year at a price of  54 900 per year  Wall Street began to create a correlation between the drug s performance and the price of BIIB common stock   This can explain the sensitivity that BIIB shares had to Cowen s bearish note on Tecfidera and the delay of the European launch into the second half of 2013   There has been some skepticism over the drug because of the cheap manufacturing cost of the easily available NF  B inhibitor dimethyl fumarate  the active ingredient of Tecfidera  although Biogen was indeed the first to clinically develop the compound for the relapsed MS indication  and can justify a price premium for its branded drug  Now it seems that the patent protection of Tecfidera is causing the drug some serious issues in Europe  which explains why the company would delay its introduction into Europe   AVONEX   interferon beta 1a   TYSABRI   natalizumab   and RITUXAN   rituximab  are Biogen s other primary drugs in the MS indication  These three brought in the vast majority of the company s  1 4 B in quarterly revenues   736 million   275 million  and  288 million respectively   which represents what should be the lion s share of the   10 15 B US MS drug market  The three drugs also saw in 13   9   and 7  year over year growth respectively   Despite the strength of Biogen s existing pipeline  expectations are very high for Tecfidera  and it s generally agreed that the drug will have to pull more than its own weight in order for the company to meet its 2013 sales growth forecast of 16 18   particularly since none of the company s existing drugs are growing sales at that rate  Expect the market to continue to monitor Tecfidera s performance very closely  and to punish BIIB further in the event that Cowen s theory on the prescription sales is correct ,2013-06-06,Myriad Equity,https://www.investing.com/analysis/cowen-questions-sales-growth-of-biogen-idecs-ms-drug-tecfidera-170046,170046
